0001564590-21-009946.txt : 20210301 0001564590-21-009946.hdr.sgml : 20210301 20210301172301 ACCESSION NUMBER: 0001564590-21-009946 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 142 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210301 DATE AS OF CHANGE: 20210301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kodiak Sciences Inc. CENTRAL INDEX KEY: 0001468748 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270476525 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38682 FILM NUMBER: 21699511 BUSINESS ADDRESS: STREET 1: 1200 PAGE MILL RD CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 650-281-0850 MAIL ADDRESS: STREET 1: 1200 PAGE MILL RD CITY: PALO ALTO STATE: CA ZIP: 94304 FORMER COMPANY: FORMER CONFORMED NAME: Oligasis, LLC DATE OF NAME CHANGE: 20090721 10-K 1 kod-10k_20201231.htm 10-K kod-10k_20201231.htm
false FY 0001468748 --12-31 P5Y P3Y kod:RetirementAndSavingsPlanMember 2018-10-31 2023-10-31 P9Y6M P3Y9M18D P8Y8M23D P8Y25D P6Y P5Y9M10D P6Y21D P5Y6M21D P6Y29D P9Y3M18D P6Y3M21D 0001468748 2020-01-01 2020-12-31 xbrli:shares 0001468748 2021-02-19 iso4217:USD 0001468748 2020-06-30 0001468748 2020-12-31 0001468748 2019-12-31 iso4217:USD xbrli:shares 0001468748 2019-01-01 2019-12-31 0001468748 2018-01-01 2018-12-31 0001468748 us-gaap:RedeemableConvertiblePreferredStockMember 2017-12-31 0001468748 us-gaap:CommonStockMember 2017-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001468748 us-gaap:RetainedEarningsMember 2017-12-31 0001468748 2017-12-31 0001468748 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001468748 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001468748 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001468748 us-gaap:CommonStockMember 2018-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001468748 us-gaap:RetainedEarningsMember 2018-12-31 0001468748 2018-12-31 0001468748 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001468748 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001468748 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001468748 us-gaap:CommonStockMember 2019-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001468748 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001468748 us-gaap:RetainedEarningsMember 2019-12-31 0001468748 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001468748 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001468748 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001468748 us-gaap:CommonStockMember 2020-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001468748 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001468748 us-gaap:RetainedEarningsMember 2020-12-31 0001468748 us-gaap:IPOMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001468748 us-gaap:IPOMember us-gaap:CommonStockMember 2018-12-31 0001468748 us-gaap:CommonStockMember us-gaap:IPOMember 2018-10-08 2018-10-09 0001468748 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember kod:WarrantsExercisedIntoConvertiblePreferredSharesThenConvertedMember us-gaap:IPOMember 2018-10-09 0001468748 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember us-gaap:WarrantMember us-gaap:IPOMember 2018-10-08 2018-10-09 0001468748 us-gaap:CommonStockMember kod:TwoThousandSeventeenConvertibleNotesMember us-gaap:IPOMember 2018-10-08 2018-10-09 0001468748 us-gaap:CommonStockMember kod:TwoThousandEighteenConvertibleNotesMember us-gaap:IPOMember 2018-10-08 2018-10-09 0001468748 kod:FollowOnOfferingMember us-gaap:CommonStockMember 2019-12-01 2019-12-31 0001468748 kod:FollowOnOfferingMember us-gaap:CommonStockMember 2020-11-01 2020-11-30 0001468748 kod:FollowOnOfferingMember us-gaap:CommonStockMember 2019-12-31 0001468748 kod:FollowOnOfferingMember us-gaap:CommonStockMember 2020-11-30 0001468748 kod:FollowOnOfferingMember 2019-12-01 2019-12-31 0001468748 kod:FollowOnOfferingMember 2020-11-01 2020-11-30 0001468748 srt:MaximumMember 2019-01-01 2019-12-31 kod:Segment 0001468748 us-gaap:BankTimeDepositsMember 2020-12-31 0001468748 us-gaap:BankTimeDepositsMember 2019-12-31 0001468748 kod:LaboratoryEquipmentMember 2020-01-01 2020-12-31 0001468748 kod:ComputerEquipmentAndOfficeEquipmentMember 2020-01-01 2020-12-31 0001468748 us-gaap:SoftwareDevelopmentMember 2020-01-01 2020-12-31 0001468748 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2020-01-01 2020-12-31 0001468748 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2020-01-01 2020-12-31 xbrli:pure 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2019-12-01 2019-12-01 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2019-12-01 0001468748 kod:BakerBrosAdvisorsLPMember srt:MinimumMember kod:FundingAgreementMember 2019-12-01 0001468748 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001468748 us-gaap:AccountingStandardsUpdate201613Member 2020-12-31 0001468748 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001468748 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001468748 kod:LaboratoryEquipmentMember 2020-12-31 0001468748 kod:LaboratoryEquipmentMember 2019-12-31 0001468748 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001468748 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001468748 us-gaap:ComputerEquipmentMember 2020-12-31 0001468748 kod:ComputerSoftwareMember 2020-12-31 0001468748 kod:ComputerSoftwareMember 2019-12-31 0001468748 us-gaap:OfficeEquipmentMember 2020-12-31 0001468748 us-gaap:OfficeEquipmentMember 2019-12-31 0001468748 us-gaap:ConstructionInProgressMember 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember kod:RepurchaseAgreementMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember kod:RepurchaseAgreementMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember kod:RepurchaseAgreementMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember kod:RepurchaseAgreementMember 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0001468748 us-gaap:FairValueMeasurementsNonrecurringMember 2019-12-31 0001468748 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember 2020-12-31 0001468748 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001468748 us-gaap:CommercialPaperMember 2019-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember 2019-12-31 0001468748 srt:MaximumMember 2020-12-31 kod:Building 0001468748 kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember stpr:CA 2020-06-01 2020-06-30 utr:sqft 0001468748 kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember kod:BuildingOneMember stpr:CA 2020-06-30 0001468748 kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember kod:BuildingTwoMember stpr:CA 2020-06-30 0001468748 kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember kod:BuildingOneMember stpr:CA 2020-06-01 2020-06-30 0001468748 kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember kod:BuildingTwoMember stpr:CA 2020-06-01 2020-06-30 0001468748 kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember stpr:CA 2020-06-30 0001468748 kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember stpr:CA 2020-07-01 utr:sqm 0001468748 kod:LeaseAgreementOnAprilTwoThousandAndTwentyMember kod:OfficeAndLaboratorySpaceMember country:CH 2020-04-30 0001468748 kod:LeaseAgreementOnAprilTwoThousandAndTwentyMember kod:OfficeAndLaboratorySpaceMember country:CH 2020-04-01 2020-04-30 iso4217:CHF 0001468748 kod:LeaseAgreementOnAprilTwoThousandAndTwentyMember kod:OfficeAndLaboratorySpaceMember country:CH srt:MaximumMember 2020-04-30 0001468748 kod:ManufacturingAgreementMember kod:ClinicalAndCommercialSupplyMember 2020-08-31 0001468748 kod:ManufacturingAgreementMember kod:ClinicalAndCommercialSupplyMember 2020-08-01 2020-08-31 0001468748 kod:ManufacturingAgreementMember kod:ClinicalAndCommercialSupplyMember srt:MaximumMember 2020-08-01 2020-08-31 0001468748 kod:LeaseAgreementOnAprilAndJuneTwoThousandAndTwentyMember 2020-12-31 0001468748 kod:LonzaMember us-gaap:ServiceAgreementsMember 2020-12-31 0001468748 kod:LonzaMember us-gaap:ServiceAgreementsMember 2019-12-31 0001468748 kod:LonzaMember us-gaap:ServiceAgreementsMember 2020-01-01 2020-12-31 0001468748 kod:LonzaMember us-gaap:ServiceAgreementsMember 2019-01-01 2019-12-31 0001468748 kod:LonzaMember us-gaap:ServiceAgreementsMember 2018-01-01 2018-12-31 0001468748 us-gaap:PurchaseCommitmentMember 2020-12-31 0001468748 us-gaap:PurchaseCommitmentMember 2019-12-31 0001468748 srt:MaximumMember us-gaap:LicensingAgreementsMember 2020-01-01 2020-12-31 0001468748 us-gaap:LeaseholdImprovementsMember stpr:CA kod:TenantImprovementAllowanceAgreementMember 2013-05-31 0001468748 us-gaap:LeaseholdImprovementsMember stpr:CA kod:TenantImprovementAllowanceAgreementMember 2013-05-01 2013-05-31 0001468748 us-gaap:LeaseholdImprovementsMember stpr:CA 2016-03-31 0001468748 us-gaap:LeaseholdImprovementsMember stpr:CA 2016-03-01 2016-03-31 0001468748 kod:TenantImprovementAllowancePayableMember srt:MaximumMember 2020-12-31 0001468748 kod:TenantImprovementAllowancePayableMember srt:MaximumMember 2019-12-31 0001468748 kod:TenantImprovementAllowancePayableMember 2020-12-31 0001468748 kod:TenantImprovementAllowancePayableMember 2019-12-31 0001468748 us-gaap:DomesticCountryMember 2020-12-31 0001468748 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001468748 us-gaap:DomesticCountryMember kod:NetOperatingLossNotSubjectToExpirationMember 2020-12-31 0001468748 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001468748 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001468748 us-gaap:CaliforniaFranchiseTaxBoardMember 2020-01-01 2020-12-31 0001468748 srt:MaximumMember 2019-12-31 kod:Vote 0001468748 kod:StockOptionsOutstandingAndReleaseOfRestrictedSharesMember 2020-12-31 0001468748 kod:StockOptionsOutstandingAndReleaseOfRestrictedSharesMember 2019-12-31 0001468748 us-gaap:WarrantMember 2020-12-31 0001468748 us-gaap:WarrantMember 2019-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember 2020-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember 2019-12-31 0001468748 kod:TwoThousandEighteenEmployeeSharePurchasePlanMember 2020-12-31 0001468748 kod:TwoThousandEighteenEmployeeSharePurchasePlanMember 2019-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember kod:IncentiveStockOptionsMember 2020-01-01 2020-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember srt:MinimumMember 2020-01-01 2020-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember kod:IncentiveStockOptionsMember srt:MaximumMember 2020-01-01 2020-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember kod:IncentiveStockOptionsGrantedToGreaterThanTenPercentStockholderMember srt:MaximumMember 2020-01-01 2020-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember 2020-12-31 0001468748 kod:TwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember 2019-12-31 0001468748 kod:TwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001468748 kod:TwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember 2020-12-31 0001468748 kod:TwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember 2019-01-01 2019-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001468748 kod:NonEmployeeStockOptionMember 2020-01-01 2020-12-31 0001468748 kod:NonEmployeeStockOptionMember 2019-01-01 2019-12-31 0001468748 kod:NonEmployeeStockOptionMember 2018-01-01 2018-12-31 0001468748 kod:OptionsGrantedToNonEmployeesMember 2020-01-01 2020-12-31 0001468748 kod:OptionsGrantedToNonEmployeesMember 2019-01-01 2019-12-31 0001468748 kod:OptionsGrantedToNonEmployeesMember 2018-01-01 2018-12-31 0001468748 us-gaap:RestrictedStockMember 2019-12-31 0001468748 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001468748 us-gaap:RestrictedStockMember 2020-12-31 0001468748 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001468748 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001468748 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001468748 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001468748 us-gaap:RestrictedStockUnitsRSUMember srt:MaximumMember 2018-01-01 2018-12-31 0001468748 kod:PerformanceBasedEquityAwardsMember 2020-01-01 2020-12-31 0001468748 kod:PerformanceBasedEquityAwardsMember 2019-01-01 2019-12-31 0001468748 kod:PerformanceBasedStockOptionsMember 2019-01-01 2019-12-31 0001468748 kod:PerformanceBasedStockOptionsMember 2019-12-31 0001468748 kod:PerformanceBasedRestrictedStockUnitMember 2019-12-31 0001468748 kod:TwoThousandEighteenEmployeeSharePurchasePlanMember 2020-12-31 0001468748 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001468748 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001468748 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001468748 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001468748 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001468748 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001468748 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001468748 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001468748 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001468748 us-gaap:InternalRevenueServiceIRSMember 2020-01-01 2020-12-31 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2020-02-04 2020-02-04 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2020-02-29 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2020-12-31 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2020-01-01 2020-12-31 0001468748 2020-01-01 2020-03-31 0001468748 2020-04-01 2020-06-30 0001468748 2020-07-01 2020-09-30 0001468748 2020-10-01 2020-12-31 0001468748 2019-01-01 2019-03-31 0001468748 2019-04-01 2019-06-30 0001468748 2019-07-01 2019-09-30 0001468748 2019-10-01 2019-12-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-K

 

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to _________

Commission File Number: 001-38682

 

KODIAK SCIENCES INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

27-0476525

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

1200 Page Mill Road

Palo Alto, CA

 

94304

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (650) 281-0850

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001

KOD

The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The aggregate market value of the common stock held by non-affiliates of the registrant, based on the closing price of a share of the registrant’s common stock on June 30, 2020 as reported by the Nasdaq Global Market on such date, was approximately $1.6 billion. Shares of common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the registrant, have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.

As of February 19, 2021, the registrant had 51,162,424 shares of common stock, $0.0001 par value per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive Proxy Statement relating to the 2021 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2020.

 

 


Table of Contents

 

Kodiak Sciences Inc.

Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2020

 

 

 

 

Page

PART I.

 

 

Item 1.

Business

1

Item 1A.

Risk Factors

67

Item 1B.

Unresolved Staff Comments

107

Item 2.

Properties

107

Item 3.

Legal Proceedings

107

Item 4.

Mine Safety Disclosures

107

PART II.

 

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholders Matters and Issuer Purchases of Equity Securities

108

Item 6.

Selected Consolidated Financial Data

109

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

110

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

118

Item 8.

Financial Statements and Supplementary Data

119

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

145

Item 9A.

Controls and Procedures

145

Item 9B.

Other Information

145

PART III.

 

 

Item 10.

Directors, Executive Officers and Corporate Governance

146

Item 11.

Executive Compensation

146

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters

146

Item 13.

Certain Relationships and Related Party Transactions, and Director Independence

146

Item 14.

Principal Accounting Fees and Services

146

PART IV.

 

 

Item 15.

Exhibits, Financial Statement Schedules

147

Item 16.

Form 10-K Summary

150

 

Signatures

151

 

i


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made and/or management’s good faith beliefs as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, or similar expressions and comparable terminology intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including those set forth under the section titled “Risk Factors” and elsewhere in this report. Forward-looking statements include, but are not limited to, statements about:

 

the success, cost and timing of our development activities, preclinical studies, clinical trials and regulatory filings;

 

the translation of our preclinical results and data and early clinical trial results in particular relating to safety, efficacy and durability into future clinical trials in humans;

 

the continued durability, efficacy and safety of our product candidates;

 

our ability to achieve our “2022 Vision” of a Biologics License Application of KSI-301 in 2022;

 

the number, size and design of clinical trials that regulatory authorities may require to obtain marketing approval, including the order and number of clinical studies required to support a Biologics License Application, or BLA, in wet age-related macular degeneration, or wet AMD, diabetic macular edema, or DME, retinal vein occlusion, or RVO, and diabetic retinopathy, or DR;

 

the timing or likelihood of regulatory filings and approvals, including the potential to achieve FDA approval of KSI-301 in wet AMD, DME, RVO and DR;

 

our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate;

 

our ability to obtain funding for our operations, including funding necessary to develop, manufacture and commercialize our product candidates;

 

the rate and degree of market acceptance of our product candidates;

 

the success of competing products or platform technologies that are or may become available;

 

our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain approval;

 

our expectation as to the concentration of retinal specialists in the United States and its impact on our sales and marketing plans;

 

our expectations regarding our ability to enter into manufacturing-related commitments, and the timing thereof;

 

future agreements with third parties in connection with the commercialization of our product candidates;

 

the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to serve those markets;

 

existing regulations and regulatory developments in the United States and foreign countries;

 

the expected potential benefits of strategic collaboration agreements and our ability to attract collaborators with development, regulatory and commercialization expertise;

 

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

 

potential claims relating to our intellectual property and third-party intellectual property;

 

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

 

the pricing and reimbursement of our product candidates, if approved;

ii


 

our estimates regarding the impact of the novel coronavirus, or COVID-19, pandemic on our business and operations, the business and operations of our collaborators, and on the global economy;

 

our aspirational goals and objectives related to our human capital resources and workforce objectives;

 

our ability to attract and retain key managerial, scientific and medical personnel;

 

the accuracy of our estimates regarding the sufficiency of our cash resources, expenses, future revenue, capital requirements and needs for additional financing; and

 

our financial performance.

All forward-looking statements are based on information available to us on the date of this Annual Report on Form 10-K and we will not update any of the forward-looking statements after the date of this Annual Report on Form 10-K, except as required by law. Our actual results could differ materially from those discussed in this Annual Report on Form 10-K. The forward-looking statements contained in this Annual Report on Form 10-K, and other written and oral forward-looking statements made by us from time to time, are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, and you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Factors that might cause such a difference include, but are not limited to, those discussed in the following discussion and within Part I, Item 1A “Risk Factors” of this Annual Report on Form 10-K.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

All brand names or trademarks appearing in this report are the property of their respective holders. Unless the context requires otherwise, references in this report to “Kodiak” the “Company,” “we,” “us,” and “our” refer to Kodiak Sciences Inc.

RISK FACTOR SUMMARY

Investing in our securities involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described under “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10‑K.

 

We are in the clinical stage of drug development and have a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.

 

We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur significant and increasing net losses for the foreseeable future.

 

Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We have never generated any revenue from product sales, and we may never generate revenue or be profitable.

 

Our prospects are heavily dependent on our KSI-301 product candidate, which is currently in clinical development for multiple indications.

 

A failure of KSI-301 in clinical development may require us to discontinue development of other product candidates based on our ABC Platform.

 

Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized.

 

We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.

iii


 

We may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected.

 

Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy or durability of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization.

 

We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may retain their market share with existing drugs, or achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.

 

The manufacture of our product candidates is highly complex and requires substantial lead time to produce.

 

We have no experience manufacturing any of our product candidates at a commercial scale. If we or any of our third-party manufacturers encounter difficulties in production, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to establish a commercially viable cost structure.

 

The regulatory approval processes of the FDA, EMA, NMPA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.

 

We plan to conduct clinical trials for our product candidates outside the United States, and the FDA, EMA, NMPA and applicable foreign regulatory authorities may not accept data from such trials.

 

Our business is subject to complex and evolving U.S. and foreign laws and regulations relating to privacy and data protection. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business.

 

If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

 

We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.

 

If we are unable to obtain and maintain patent protection for any product candidates we develop or for our ABC Platform, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.

 

If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.

 

Third-party claims of intellectual property infringement, misappropriation or other violation against us or our collaborators may prevent or delay the development and commercialization of our ABC Platform, product candidates and other technologies.

 

We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.

 

We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.

 

Our business is currently affected and could be materially and adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics, including the ongoing effects of the COVID-19 pandemic. The COVID-19 pandemic continues to impact our business and could materially and adversely affect our operations, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.

 

 

 

iv


PART I

ITEM 1. BUSINESS

Overview

At Kodiak, we are bringing new science to the design and development of next generation retinal medicines. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Our goal is to prevent and treat the major causes of blindness by developing and commercializing next-generation therapeutics for chronic, high-prevalence retinal diseases.

Throughout 2020 and into 2021, we have generated compelling clinical data with our most advanced product candidate, KSI-301, a novel anti-VEGF antibody biopolymer conjugate, which is designed to maintain potent and effective drug levels in ocular tissues for longer periods than the currently-marketed biologic medicines used to treat retinal diseases. We believe that KSI-301, if approved, has the potential to be an important therapy to treat patients with wet age-related macular degeneration, or wet AMD, diabetic macular edema, or DME, macular edema due to retinal vein occlusion, or RVO, and diabetic retinopathy, or DR, as well as other vision-threatening diseases that are less prevalent but also may be responsive to anti-VEGF therapy.

The ABC Platform and KSI-301 were developed at Kodiak, and we own rights to these assets in key geographies including the US, EU, China and other major countries. We have applied our ABC Platform to develop additional product candidates beyond KSI-301, including KSI-501, our bispecific anti-IL-6/VEGF bioconjugate, and we are expanding our early research pipeline to include ABC Platform-based triplet inhibitors for multifactorial retinal diseases such as dry AMD and the neurodegenerative aspects of glaucoma. In October 2020, we announced that we entered a supplemental research agreement with AbCellera to generate additional therapeutic antibody candidates for novel disease targets in ophthalmology in support of our evolving research pipeline. We intend to progress these and other product candidates to address high-prevalence ophthalmic diseases.

Our overall objective is to develop our product candidates, seek FDA and worldwide health authority marketing authorization approvals, and ultimately commercialize our product candidates.

Where Kodiak Stands Today

Growing KSI-301 Clinical Experience: We remain very pleased with the current clinical profile of KSI-301. Approximately 2,000 KSI-301 injections have been administered to approximately 500 patients representing approximately 350 patient-years of exposure. When and if we submit our planned single BLA in wet AMD, DME and RVO, we expect to have durability, efficacy and safety data on KSI-301 treatment in over 1,000 patients across our concurrent pivotal studies.

In our ongoing Phase 1b clinical study, we have administered multiple doses of KSI-301 over 52-weeks or more to treatment-naïve patients with wet AMD, DME or RVO, and we continue to observe promising durability, efficacy and safety data in each of the retinal diseases under study. Some patients have been given KSI-301 injections and followed for as long as two years in the Phase 1b study. KSI-301’s clinical durability continues to be supported with maturing data that demonstrate two in every three patients with wet AMD, DME, or RVO achieving six months or longer treatment-free intervals at Year 1. Additionally, KSI-301 continues to demonstrate an efficacy and safety profile that is tracking with standard of care anti-VEGF agents.

Thoughtfully Designed Pivotal Clinical Trials: Our ongoing registrational study program, designed based on an End of Phase 2 meeting we held in 2019 with the FDA, is assessing KSI-301 in four pivotal studies: two Phase 3 studies in DME (the GLEAM and GLIMMER studies), one Phase 2b/3 study in wet AMD (the DAZZLE study) and one Phase 3 study in RVO (the BEACON study). Each study protocol design has been optimized based on Phase 1b data and experience and will include similar treatment-naïve patient populations as in the Phase 1b, as well as tighter dosing interval ranging, tighter disease control criteria, decreased subjectivity for retreatments, high dose level of 2 mg, and each study has high statistical power for non-inferiority (>90%). The DAZZLE study completed recruitment in late 2020 and top-line results are expected in early 2022. Recruitment is underway for the GLEAM, GLIMMER and BEACON trials. We plan to expand the KSI-301 clinical study program in 2021 with one Phase 3 study (GLOW) in NPDR without DME, and potentially one or more additional clinical studies that could be beneficial for product labeling and/or reimbursement and market access purposes.

1


Investing with Conviction Commensurate with the Opportunity: Kodiak remains focused on thoughtful execution of our KSI-301 pivotal program, the requisite manufacturing efforts, the regulatory strategy and the pre-commercial readiness. As to manufacturing, in line with our 2022 Vision which sees us submitting our initial BLA in 2022 and potentially commercializing KSI-301 in 2023, it is our intent to be able to supply millions of doses in Year 1 from our Lonza-Kodiak Ibex Dedicate facility designed from inception with Flex Up capabilities and capacity for double digit millions of doses per year to supply a growing market demand.

Poised Commercial Opportunity: We are optimistic for the future care of patients with retinal vascular diseases. The competitive landscape of intravitreally-injected anti-VEGF biologic therapies and therapeutic candidates is clearing, due to the incremental durability of competing molecules, and/or safety challenges that, even if only recently appreciated, have been observed from early in the development of these potential competitors. Adjacent surgical and gene therapy solutions may also face challenges with long-term safety, limited accessibility and the complex economics of surgical implantation.

KSI-301, with its powerful combination of design attributes, has the potential to be a Generation 2.0 anti-VEGF – a first-line anti-VEGF “product for everyone” that may achieve a significant market share.

As a company, we remain independent. This independence provides us with the flexibility to adapt both R&D and commercial decision-making within the ever-changing domestic and global landscapes. We remain well capitalized and supported by a high-quality group of long-term stakeholders who understand what is needed to build, invest and execute commensurate with the opportunity.

Recent Developments

KSI-301 Phase 1b Study

Updated Year 1 durability, efficacy and safety data from our ongoing Phase 1b trial of KSI-301 in patients with treatment naïve wet AMD, DME or RVO were presented at the Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition meeting in February 2021. The data show 2 in every 3 patients are on a 6-month or longer treatment-free interval at Year 1 in each of the 3 major retinal vascular diseases after only 3 loading doses. Robust vision gains (particularly notable in the context of very good baseline vision) and robust retinal drying (when baseline anatomical characteristics are considered) were seen across all three diseases being studied. Strong anti-VEGF efficacy (achieving at Year 1 approximately 20/40 eye chart vision on average in wet AMD and approximately 20/32 vision on average in DME and RVO) and an encouraging safety profile continue to be observed across all three diseases. We believe the data continue to support the “anti-VEGF Generation 2.0” profile of KSI-301.

KSI-301 Pivotal Program

We saw robust patient enrollment in our DAZZLE pivotal study in wet AMD through the third quarter of 2020 and completed global patient recruitment in November 2020 – a potential reflection of the enthusiasm for KSI-301 on the part of clinical investigators and patients. With a one-year primary endpoint, we remain on track for DAZZLE top-line data readout in early 2022.

In the third quarter of 2020, we initiated two Phase 3 studies in DME (GLEAM and GLIMMER) and one Phase 3 study in RVO (BEACON). The randomization of treatment-naïve patients into these three studies is a critical step to build the clinical evidence for KSI-301 as a safe, effective and highly durable therapy for patients with retinal diseases. The initiation of the additional Phase 3 studies and the robust patient recruitment into DAZZLE represent strong operational progress towards our 2022 Vision of a single BLA filed for KSI-301 in wet AMD, DME, and RVO in 2022. Clinical trial applications for BEACON, GLEAM, and GLIMMER have been submitted and approved in countries across the EU. To date, we are pleased with progress in site activation, patient screening, and recruitment in these studies. We believe we are also on track to begin recruitment of the GLOW study in NPDR without DME in 2021.

Importantly, to date the data emerging in our Phase 1b study remain consistent and provide support for and confidence in our pivotal study designs.

Follow-on Equity Offering

On November 20, 2020, we completed a follow-on equity offering and issued and sold 5,972,222 shares of the Company’s common stock at a price to the public of $108.00 per share. The gross proceeds from this offering were $645.0 million, resulting in aggregate net proceeds of $612.0 million after deducting underwriting discounts and commissions and other offering costs.

2


Proceeds from the equity offering together with our current cash, cash equivalents and marketable securities are expected to advance the clinical programs for KSI-301 towards achieving our “2022 Vision” of a Biologics License Application, or BLA, of KSI-301 in 2022 for wet AMD, DME, RVO and potentially DR without DME, including the manufacturing activities necessary for BLA submission, as well as to advance our pipeline of drug candidates including KSI-501 and our triplet inhibitor drug candidates and for working capital and general corporate purposes.

Our current cash, cash equivalents and marketable securities which includes the net proceeds from the November 2020 public offering provide the resources for us to advance the KSI-301 program towards achieving our “2022 Vision,” and also to advance our pipeline of drug candidates including KSI-501 and our triplet inhibitor drug candidates, and for working capital and general corporate purposes.

Commercial Manufacturing

We successfully negotiated a long-term agreement with Lonza for the manufacture of KSI-301. This agreement will provide Kodiak with a custom-built bioconjugation facility with a capacity to supply millions of doses per year. With construction targeted for completion in early 2022, the Lonza-Kodiak Ibex facility will provide Kodiak with the facility needed for commercial-scale manufacturing of KSI-301. The scale is designed to support KSI-301’s potential to achieve significant market share as a new first-line agent designed to improve outcomes for patients with common and serious retinal vascular diseases.

COVID-19

We are continuing to monitor the global ongoing COVID-19 pandemic. Since the initial outbreak in early 2020, governments globally have taken preventative and protective actions, including but not limited to, restrictions on non-essential travel, business operations, and gatherings of individuals. The State of California, where our corporate office is located, declared a state of emergency and shelter-in-place order in March 2020. Although certain restrictions have eased, and phased re-openings are underway, it is not certain when such restrictions will be fully lifted, and recent resurgences in number and rates of infections, reactions to increased testing and/or further spreading of the virus may result in the return or implementation of more restrictive measures. Global financial markets have also experienced extreme volatility and as a result, economic uncertainties have arisen which could impact our operations and its financial position. The extent of the impact of the ongoing COVID-19 pandemic will depend on certain evolving developments, including the duration and spread of the outbreak, regulatory and private sector responses, and the impact on our employees, vendors including supply chain and clinical partners, all of which are uncertain and cannot be predicted.

We continue to monitor government responses and may elect to temporarily close our office and/or laboratory space to protect our employees. We continue to assess the potential for supply chain disruptions as the pandemic may impact personnel at third party manufacturing facilities in China, Switzerland and other countries, as well as its impact on the availability and/or cost of materials. We continue to monitor financial markets and the impact on our operations and capital resources.

We and our key clinical and manufacturing partners have been able to continue to advance our operations. Because the diseases under study in the KSI-301 development program are serious, vision-threatening conditions for which patients are still seeking and receiving treatment from retina specialists during the pandemic, we have been able to continue advancing the clinical programs for KSI-301 during the pandemic towards achieving our “2022 Vision.”

During this pandemic, we continue to work closely with our clinical sites towards maximal patient safety and the lowest number of missed visits and study discontinuations. We have taken and continue to take proactive measures to maintain the integrity of our ongoing clinical studies. To date, we are seeing low levels of patient missed visits.

In response to the COVID-19 pandemic with regards to business operations, clinical trials, and manufacturing activities:

 

We have taken steps in line with guidance from the U.S. Centers for Disease Control and Prevention, or CDC, and the State of California to protect the health and safety of our employees and the community. In particular, we have implemented remote work arrangements for certain employees since March 17, 2020.

 

We are working closely with our clinical trial sites to monitor and attempt to minimize the potential impacts of the evolving COVID-19 pandemic on patient enrollment, continued participation of patients already enrolled in our clinical studies, protocol compliance, data quality, and overall study integrity. Some specific actions we have taken in the United States include the use of remote study monitoring, temporarily increasing study site budget overhead rates, providing additional transportation service options for patients to attend study site visits and focusing on new patient enrollment only at study sites with appropriate backup resource plans in place and where the local COVID-19 situation allows. Since the month of March 2020, the rate of missed study visits has remained <5%. As of now, we have not experienced significant delays to our ongoing or planned clinical trials; however, this could change rapidly depending on the dynamics of the pandemic.

3


 

In June 2020, we restarted patient recruitment activities at certain sites in EU countries. DAZZLE study sites in the EU were activated in the first quarter of 2020, but we deferred study patient enrollment until June due to the pandemic.

 

To minimize the potential for disruption of our pivotal studies of KSI-301, we have refined our study designs, including sample size and country selection. We began enrollment of our pivotal DME (GLEAM and GLIMMER) and RVO (BEACON) studies in the third quarter of 2020 in the United States and aim to initiate the pivotal study in non-proliferative DR (GLOW) in the first half of 2021, dependent on the continued evolution of the COVID-19 pandemic. Ex-U.S. clinical trial application submissions are underway for GLEAM, GLIMMER and BEACON, and most have already been approved; recruitment activities are now underway in the EU. We believe we are still on track to achieve our “2022 Vision” objective of filing a single BLA in 2022 for KSI-301 in wet AMD, DME and RVO.

 

Our supply chain and manufacturing activities remain intact, and we do not currently anticipate disruptions to our clinical supply of KSI-301 due to COVID-19.

 

As we work towards commercial scale-up and manufacturing activities to support BLA submission, there is increasing competition with COVID-19 related vaccine and therapeutic programs for manufacturing related (i) materials such as resins, filters, sterile tubesets, pipette tips; (ii) personnel such as facility engineering and construction as well as plant engineers and workers; and (iii) production slots in cGMP facilities. We are carefully monitoring any potential impacts to our manufacturing activities and timelines with the objective to intersect clinical timelines, manufacturing timelines and number of doses available in the first year(s) after commercial launch. We believe we are still on track for a close intersection of these three key elements.

We will continue to monitor the COVID-19 situation closely. The ultimate impact of the ongoing COVID-19 pandemic on our business operations remains highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. See also the section titled “Risk Factors” for additional information on risks and uncertainties related to the evolving COVID-19 pandemic.

Additional Business Highlights

In 2020 and into the first quarter of 2021, additional highlights of our activities included:

 

Completed Lease Agreement for Kodiak’s New U.S. corporate offices: We have leased approximately 82,662 square feet located at 1200 Page Mill Road, Palo Alto, California and approximately 72,812 square feet located at 1250 Page Mill Road, Palo Alto, California. These newly leased buildings will serve as Kodiak’s U.S. corporate offices for office and laboratory space. We also leased approximately 10,750 square feet in Visp, Switzerland, for manufacturing support and supervision.

 

Supplemental Research Agreement with AbCellera: In October 2020, we announced that we entered a supplemental research agreement with AbCellera to generate additional therapeutic antibody candidates for novel disease targets in ophthalmology in support of our evolving research pipeline. We intend to progress these and other product candidates to address high-prevalence ophthalmic diseases.

 

Appointment of Charles Bancroft to Board of Directors: Charles Bancroft, formerly Chief Financial Officer of Bristol Myers Squibb (BMS), joined Kodiak’s Board of Directors as chair of our audit committee and member of our nominating and governance committee in April 2020. Mr. Bancroft recently retired from a successful career at BMS where he held a number of leadership roles in commercial, strategy and finance. Mr. Bancroft brings financial and management experience that will be vital to Kodiak as the company continues to scale and build its manufacturing and commercial capabilities.

 

Kodiak’s 2022 Vision and KSI-301 Accelerated Development Strategy

We believe we remain on track to achieve our “2022 Vision” of a single BLA submission and initial FDA approval for KSI-301 in wet AMD, DME and RVO in 2022 with a total of four pivotal trials - two in DME (GLEAM and GLIMMER), one in wet AMD (DAZZLE) and one in RVO (BEACON). These studies, together with our ongoing pivotal study in wet AMD, will be the basis of our intended BLA and supplemental BLA submissions. We currently expect to submit the wet AMD, DME, and RVO indications in a single initial BLA for KSI-301 and the DR indication (to be studied in the Phase 3 GLOW trial) in a supplemental BLA in the United States. We may also begin one or more additional KSI-301 clinical studies in 2021 that could be beneficial for product labeling and/or reimbursement and market access purposes.

4


We continue to invest in our science and our pipeline, including our bispecific ABC product candidate KSI-501 for retinal vascular diseases with a strong inflammatory component and our new triplet ABC product candidate KSI-601 for the high prevalence multifactorial retinal disease dry AMD.

 

Our 2022 Vision includes the following potential catalysts and milestones in 2021, 2022 and 2023, along with the important milestones achieved in 2019 and 2020 that support the accelerated development program:

 

5


 

Our “2022 Vision” is built on the following concurrent development strategy. This table incorporates our most recent view of the KSI-301 clinical program and its execution, as described above, and we believe the successful prosecution of this program is achievable based on our currently available information and the evolving effects of the COVID-19 pandemic:

 

 

Opportunity for Clinically Meaningful Differentiation

Current intravitreal anti-VEGF agents require frequent eye injections to achieve the best clinical results. When patients do not follow product labeling or miss treatments, improvements in their vision following treatment may be transient or decline over time. Real-world data demonstrate that most patients are not currently receiving their anti-VEGF therapy at the recommended intervals. We believe that our ABC Platform medicines could address this problem by requiring less frequent dosing, and the Year 1 Phase 1b clinical data with KSI-301 support meaningfully differentiated clinical profiles of KSI-301 relative to standard of care in each of the major retinal diseases treated today with anti-VEGF therapy. The current standard of care treatment regimens and the dosing regimens Kodiak intends to test in its pivotal trials with KSI-301 are shown in the below table.

 

 

 

 

 

 

 

 

 

 

 

Retinal disease:

Wet AMD

Diabetic macular
edema

Retinal vein
occlusion

Non-proliferative
diabetic retinopathy

Current standard of care

Aflibercept once every 2 months, after 3 monthly loading doses

 

 

Aflibercept once every 2 months, after 5 monthly loading doses

Aflibercept once monthly (for both Branch and Central RVO)

 Aflibercept once every 2 months, after 5 monthly loading doses

 

 

 

 

 

 

 

Kodiak’s Potential Dosing Regimen for KSI-301 (as studied in ongoing or anticipated pivotal trials)

KSI-301 once every 3, 4 or 5 months, after 3 monthly loading doses

KSI-301 once every 2 to 6 months, after 3 monthly loading doses

KSI-301 once every 2 months or longer, after 2 monthly loading doses

 

KSI-301 once every 6 months, after 3 initiating doses

 

Data From Our Ongoing Phase 1b Trial Continue to Demonstrate KSI-301’s Differentiated Profile

We have continued to make progress with our studies of KSI-301, and the Year 1 durability, efficacy and safety data we observe in the Phase 1b study continue to surpass our expectations. We now have more than 168 patient-years of clinical experience with KSI-301 in the Phase 1b study.

6


The overall study duration was originally nine and then 18 months, and we have now extended the treatment and follow-up period to 36 months total, to continue generating long-term outcomes data in advance of the pivotal studies. Outcomes include vision, measured as change in best corrected visual acuity or BCVA using the standard ETDRS testing protocol, and retinal anatomy, which is measured as change in retinal central subfield thickness, or CST, using optical coherence tomography imaging, or OCT. We also obtain other images such as fluorescein angiography, color fundus photos, and OCT angiography.

The figures below present the most recent data on durability and efficacy outcomes from the ongoing Phase 1b study presented at the Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition meeting, held in February 2021. Across all three diseases under study, improvements in vision and retinal anatomy were observed through Year 1 of patient follow-up, with stability in OCT and BCVA over time in the monthly follow-up intervals following the three mandatory loading doses. Year 1 data show 2 in every 3 patients are on a 6-month or longer treatment-free interval at Year 1 in each of the 3 major retinal vascular diseases after only 3 loading doses. Strong anti-VEGF efficacy (achieving at Year 1 ~20/40 eye chart vision on average in wAMD and ~20/32 vision on average in DME and RVO) and an encouraging safety profile continue to be observed across all three diseases. Vision is measured as change in BCVA, on a standardized eye chart, and retinal anatomy is measured as change in retinal CST using OCT imaging.

The Phase 1b study design, retreatment criteria, and patient baseline characteristics are described below. In the Phase 1b study, treatment-naïve patients with wet AMD, DME or RVO receive three monthly loading doses of KSI-301 at either the 2.5 mg or 5 mg dose levels and are followed thereafter; retreatment with KSI-301 is administered as per the protocol-specified retreatment criteria.

 

7


 

 

 

 

 

 

 

 

 

wet AMD

cohort

 

DME

cohort

 

RVO

cohort

Variable

 

(n=51)

 

(n=35)

 

(n=35)

Age, mean (SD), years

 

77.9 (10.5)

 

59.7 (11.7)

 

63.6 (12.6)

Gender, n (%), female

 

32 (62.7)

 

14 (40.0)

 

13 (37.1)

Race, n (%), White

 

48 (94.1)

 

28 (80.0)

 

31 (88.6)

BCVA, mean (SD), ETDRS letters

 

63.3 (13.3)

 

66.8 (10.2)

 

54.9 (15.4)

Snellen equivalent

 

~20/50

 

~20/50

 

~20/80

BCVA, Snellen 20/40 or better, n (%)

 

20 (39.2)

 

16 (45.7)

 

6 (17.1)

OCT CST, mean (SD), microns

 

450 (182)

 

453 (110)

 

675 (237)

SD = standard deviation; BCVA = best corrected visual acuity; OCT = optical coherence tomography; CST = central subfield thickness

 

8


The Phase 1b data in treatment-naïve patients demonstrate that the observed vision gains of 5.7 letters in wet AMD and 7.6 letters in DME at Year 1 are appropriate for the relatively high baseline vision. After one year of treatment, wet AMD subjects in our Phase 1b study were observed to have an average visual acuity of 69.7 eye chart letters or approximately 20/40 Snellen visual acuity, and DME subjects were observed to have an average visual acuity of 73.9 eye chart letters or approximately Snellen 20/32.

Although out Phase 1b study does not have an active comparator, the chart below places the observed baseline (pre-treatment) and one-year visual acuity outcomes in the context of the starting and one-year visual acuity metrics seen in other recent and historical clinical trials and also demonstrates how post-treatment average visual acuity is dependent on the starting (baseline) visual acuity.

 

 

Wet AMD

The data below are observed from 50 wet AMD patients who received all loading doses and reached Week 12 or later. These patients had good starting vision, approximately 64 letters. They experienced a visual acuity increase after 3 loading doses and maintained a gain of 5.7 letters, to an average BCVA of 69.7 letters (Snellen ~20/40), achieved with a mean of just 2.0 individualized doses. Supporting the extended durability, we see only a very slow fluctuation in the OCT over time, which compares favorably to the OCT fluctuations observed with existing anti-VEGFs given on shorter dosing intervals. The stability in BCVA over this interval is also consistent with the prolonged duration of KSI-301.

In the Phase 1b study, the average retinal thickness or OCT CST data as reported by our clinical investigators includes the height of pigment epithelial detachments or PEDs. PEDs are an anatomic feature in some patients with wet AMD; treatment success in subjects with PEDs does not necessarily imply complete flattening of the PED, but rather eliminating the intraretinal and subretinal fluid, particularly when the PED is very high prior to anti-VEGF treatment. Additionally, comparison across studies of OCT mean CST values is difficult because it is often not clear or not disclosed in presentations and publications whether the data include or exclude the height of the PED, and whether or how the data are corrected for different OCT machine, among other reasons.

9


When comparing subjects with and without very high PED at baseline, which we defined as 500 microns or more total CST, the BCVA and OCT CST curves are similar in shape to those of the full cohort. Excluding give patients with high PEDs, the OCT CST values are lower at baseline and over time, and the standard error of the mean (SEM) error bars are narrower. Thus, those five patients with high PEDs thus pull the overall average CST value up.

Excluding those patients, the average retinal center subfield thickness is 316 microns after initiation of treatment with KSI-301, as measured using the Heidelberg OCT machine employed by the Phase 1b study sites, in which 305 microns is normal for a healthy (no AMD) female and 315 microns is normal for a healthy male.

10


Overall, 66% of our wet AMD patients have achieved a 6-months treatment-free interval at Year 1 and 74% of patients achieved a five months or longer treatment-free interval at Year 1. 80% of patients have received two or fewer retreatments in Year 1. Remarkably, 80% of these wet AMD patients have achieved a 6-month treatment free interval at least once during follow-up. As this is an anti-VEGF treatment naïve population, there is no pre-selection for “anti-VEGF responders” or patients who might require or be predicted to require less frequent dosing.

 

 

11


 

The data generated in wAMD patients in the Phase 1b study form a compelling data package. At Year 1, KSI-301 is achieving remarkable durability, strong efficacy that brings patients to an average ~20/40 vision on the Snellen chart and a favorable safety profile. Together with strong anti-VEGF activity on both vision (BCVA gains) and retinal anatomy (OCT drying) in the DME and RVO cohorts of the Phase 1b, we believe KSI-301 continues to track well towards its “Generation 2.0” profile.

Diabetic Macular Edema (DME)

 

We measure KSI-301 efficacy data in treatment naïve DME as change from baseline in BCVA and OCT CST. Below are data from the 32 DME patients who received all loading doses and reached Week 12 or later. These patients had good starting vision, approximately 66 letters. They experienced a visual acuity increase after three loading doses and maintained a gain of 7.6 letters, to an average BCVA of 73.9 letters (Snellen ~20/32), achieved with a mean of just 1.0 retreatments.

12


Consistent with the extended durability effect of KSI-301, we see again only slight fluctuations in the OCT over time, which compares favorably to the OCT fluctuations observed with existing anti-VEGF agents that are given on shorter dosing intervals.

13


The swim lane plot for DME durability is shown below. At Year 1, 94% of DME patients have achieved a three months or longer treatment-free interval. Of these patients, 84% have gone four months or longer, and 78% five months or longer at Year 1. Further, 69% have gone six-months or longer – as there is no cap to the treatment interval in the DME cohort. Half of patients did not require any retreatment at Year 1. 81% of patients have achieved a six months or longer treatment-free interval at least once during follow-up.

14


Retinal Vein Occlusion (RVO)

KSI-301 efficacy in treatment naïve RVO is also measured as change from baseline in BCVA and OCT CST. The 34 RVO patients that received all loading doses and reached Week 12 or later began with a lower visual acuity baseline of approximately 54 letters, typical of this disease. After three loading doses, their visual acuity substantially improved, with a 22.2 letter improvement at Year 1, to an average vision of 76.6 letters (Snellen ~20/32). The vision gain was maintained with an average of just 1.7 injections. A sustained OCT response with a decrease of 357 microns was also noted.

15


In this swim lane plot of the durability of individual patients with RVO, the disease with arguably the highest VEGF load, the bars in pink and orange now denote retreatment intervals of six months or longer and two months or shorter, respectively. 87% of RVO patients have achieved a three months or longer treatment-free interval at Year 1. Only 3% of patients were on a monthly treatment interval at Year 1. 75% of patients achieved a four months or longer treatment-free interval at Year 1, and 69% achieved a five months or longer interval at Year 1. Remarkably, given that many RVO patients require monthly therapy for the best results with existing medicines, 66% of patients have achieved a six months or longer treatment-free interval at Year 1.

16


Safety of KSI-301 Injections

We believe the safety profile of KSI-301 continues to be very encouraging. Now with 710 injections given in the Phase 1a/1b program (as of January 26, 2021), and with patients followed for as long as 26 months, we are continuing to track with the expectations set by the safety profile of the current standard of care intravitreal medicines.

None of the serious adverse events, or SAEs, observed have been reported as or deemed drug-related, and they are typical of the systemic SAEs expected in these patient populations. The ocular SAE of worsening cataract was in a diabetic patient with pre-existing cataract, was not drug-related, and resolved with routine cataract surgery. The ocular SAE of subretinal hemorrhage in a wAMD patient is often found in wAMD patients and was not drug-related.

There have been only two events (previously described) of intraocular inflammation. The events were mild in nature, both trace to 1+ grade cells in the vitreous, on a standardized scale where 0 is none and 4+ is severe. They resolved completely, and there was no vasculitis or retinitis in either patient. Both patients have done very well with substantial improvements in vision from baseline; each of them had gained 30 letters or 6 lines of vision as of their last visits.

17


KSI-301 Pivotal Study Designs

 

Our pivotal study designs for wet AMD (our ongoing DAZZLE study), DME (our ongoing GLEAM and GLIMMER studies), and RVO (our ongoing BEACON study) have been optimized based on Phase 1b data and experience.

18


Wet AMD DAZZLE Study

DAZZLE (NCT04049266) assesses patients with treatment naïve wet AMD and are randomized 1:1 to receive KSI-301 every 12 to 20 weeks or Eylea every 8 weeks, each after 3 monthly loading doses. The determination of treatment interval for the patients assigned to KSI-301 is based on disease activity assessments where both OCT and BCVA are measured and compared against prior data, similar to other recent and ongoing Phase 3 studies in the field. By default, patients are on an every 20 week regimen. If disease activity criteria are met before 20 weeks, that is, 12 or 16 weeks after the last dose, then the treatment interval is correspondingly shortened.

The primary endpoint is at one year and is a non-inferiority comparison to Eylea, with a four-letter non-inferiority margin. The one-year endpoint is measured as the average of the BCVA change from baseline to weeks 48 and 52. All of the KSI-301 patients are analyzed together as a single group with respect to the primary comparison to Eylea. In the second year of the study, patients whose disease is stable can have their KSI-301 treatment interval extended, and patients originally randomized to Eylea will be re-randomized 1:1 to either continued Eylea or switched to every eight week KSI-301.

19


Disease assessment criteria are used to determine whether the treatment interval is 12, 16 or 20 weeks. These criteria are tightened, and subjectivity has been reduced, compared to the retreatment criteria used in the Phase 1b study. The DAZZLE criteria, and the overall approach to dosing regimen determination in DAZZLE, are very similar to other recent Phase 3 programs in wet AMD. The aim is to customize the dose interval per patient, in a way that is feasible in a large, multicenter, double-masked trial.

Diabetic Macular Edema Paired Studies, GLEAM and GLIMMER

In DME, we are conducting two Phase 3 studies in parallel with identical design. In each of the two studies, called GLEAM (NCT04611152) and GLIMMER (NCT04603937), we will randomize 450 treatment-naïve DME patients to either KSI-301 every 8 to 24 weeks after 3 loading doses, or Eylea every 8 weeks after 5 loading doses. The primary endpoint is the change from baseline in BCVA at one year, again the average of the week 48 and 52 visits. The studies are non-inferiority studies with a margin of 4.5 letters.

At each monthly study visit, patients who have been randomized to KSI-301 will undergo a disease activity assessment, using data from both BCVA and OCT measurements. Depending on their disease activity status, the dosing interval can be shortened, lengthened, or maintained at the same interval. This is different from the DAZZLE wet AMD study design where the interval can only be maintained or shortened in the first year. In DME, patients may experience disease modification (improvement in the severity of the underlying retinopathy) that curtails the need for therapy over time, an event that has been seen in many DME patients treated with KSI-301 allowing for the treatment interval to be potentially further prolonged after the first retreatment. The minimum KSI-301 treatment interval in GLEAM and GLIMMER is every eight weeks, and the maximum interval is every 24 weeks or six months.

20


In the second year of both studies, the same approach is maintained. Eylea will stay on its q8 week regimen, and patients on KSI-301 will continue to be on an 8 to 24 week regimen based on disease activity.

21


To determine the treatment interval for KSI-301 patients, we are employing disease activity assessments and protocol-specified criteria. All patients randomized to KSI-301 are on the longest interval by default. If patients meet any of these disease activity criteria at earlier timepoints, the retreatment interval is shortened. The criteria for shortening the treatment interval are tighter than they are in Phase 1b, and the subjectivity is reduced. Additional anatomic criteria have also been included.

 

Retinal Vein Occlusion BEACON Study Design

 

The Phase 3 BEACON study (NCT04592419) in patients with RVO is a year-long study in which we will randomize 550 patients with treatment-naïve RVO, either branch or central vein type, to either every 8 weeks KSI-301 after two loading doses, or to monthly Eylea, for the first six months. The primary endpoint is at six months, with a non-inferiority margin of 4.5 letters.

In the second six months, patients in both groups will receive treatment on an individualized regimen, again using typical disease activity assessments. This phase of the study will provide a direct, head-to-head comparison of Eylea and KSI-301 on the same criteria-driven regimen. The minimum interval is monthly and there is no upper limit to the retreatment interval in this six-month period.

22


Because the first six months of the study are fixed-interval dosing, the disease activity assessment criteria are only used to determine dosing in the second six months of the RVO study. The criteria are similar to our DME studies, and tighter than they are in Phase 1b, with the OCT and BCVA measured against the best previous measurements; subjectivity is also reduced.

23


Current Standard of Care for Wet AMD, DME/DR, and RVO

Overexpression of vascular endothelial growth factor, or VEGF, in ocular tissues is central to the pathogenesis and clinical manifestations of wet AMD, DME/DR, and RVO. VEGF is a protein produced by cells that stimulates the formation of new blood vessels, a process called neovascularization, and induces vascular permeability. In wet AMD, DME, and RVO fluid that exits from blood vessels causes swelling, or edema, of the retina and loss of vision. This loss of vision can be reversed if treated early with an anti-VEGF agent to suppress VEGF signaling. Delayed treatment or undertreatment can result in permanent retinal damage and blindness. To reach effective ocular tissue concentrations, these agents must be injected into the vitreous humor, the jelly-like substance that fills the area between the lens and retina. These injections must occur at regular intervals in order to maintain anti-VEGF effects.

Lucentis (ranibizumab), marketed by Genentech, Inc., a subsidiary of the Roche Group, in the United States and by Novartis AG outside the United States, and Eylea (aflibercept), marketed by Regeneron Pharmaceuticals, Inc. in the United States and by Bayer HealthCare LLC outside the United States, are anti-VEGF therapies that have become the standard of care for treating wet AMD and severe forms of DR based on pivotal clinical studies in which Lucentis was injected every four weeks and Eylea was injected every eight weeks (after three initial monthly doses in the case of wet AMD and after five initial monthly doses in the case of DR with DME). Beovu (brolucizumab), marketed worldwide by Novartis, was approved in late 2019 in the United States and early 2020 in Europe for the treatment of wet AMD and is injected every eight to 12 weeks after three initial monthly doses. It is not currently approved for diseases other than wet AMD. Avastin (bevacizumab), marketed for non-ocular indications by Genentech in the United States and by Roche outside of the United States, is an anti-VEGF cancer therapy that shares structural characteristics with Lucentis and is commonly used off-label to treat wet AMD, DME, and RVO through intravitreal injection dosed every four weeks.

Annual worldwide sales of branded anti-VEGFs for all indications totaled more than $11.5 billion in 2020. We believe that a substantial majority of these sales were in connection with the treatment of wet AMD and DME. Avastin, which is currently approved and marketed for the treatment of cancer, is also used off-label to treat wet AMD, DME, and RVO. We estimate that off-label Avastin represents approximately 60% of the U.S. wet AMD market by volume. We believe that an improved anti-VEGF therapy could further increase both adoption of approved therapies and extend the duration patients remain on treatment, and thus the total addressable market opportunity in wet AMD, DME/DR, and RVO could be substantial.

Limitations of Current Anti-VEGF Therapies

The limitations of current anti-VEGF therapies include:

 

Existing anti-VEGF therapies block VEGF activity effectively but have limited durability. We believe current anti-VEGF therapies maintain potent and effective drug levels in ocular tissues for three to six weeks after injection on average. But typical treatment intervals in real-world clinical practice are longer. When a patient’s dosing cycle is extended beyond the durability of the anti-VEGF agent, and the amount of drug remaining in the eye falls below therapeutic levels, the disease can progress and cause cumulative and permanent retinal damage. Most wet AMD, DME, RVO and DR patients will require protracted anti-VEGF therapy, possibly for life. Under these circumstances, strict adherence to the manufacturer’s labeled treatment regimen of every four weeks for Lucentis and every eight weeks for Eylea is challenging.

 

Real-world utilization of current anti-VEGFs results in undertreatment, which diminishes effectiveness. A divergence between the efficacy of Lucentis and Eylea in pivotal clinical trials and in the real world is evidenced in multiple studies and is increasingly recognized as an important unmet medical need. A 2017 report by the Angiogenesis Foundation suggested that the burden involved in monthly visits for evaluation and treatment causes patients and physicians to extend treatment intervals, which in turn results in undertreatment and visual outcomes that fall short of the results seen in clinical trials. For example, Lucentis was tested and failed to successfully extend the treatment interval to 12-week dosing, with patients going back to pre-treatment baseline or even losing vision at the end of the first year of treatment, on average. The Lucentis U.S. product labeling refers to this regimen as an option which is “not as effective” as monthly dosing. The FDA allowed an update to Eylea’s labeling to allow 12-week dosing, but only in the second year of treatment (after one full year of intensive treatment). The labeling refers to it as “not as effective as the recommended every 8-week dosing.” Even a small deviation from per label dosing can be devastating for vision. Missing as few as one or two injections in a year from Eylea’s recommended dosing results in almost one line of vision lost.

 

Patients are not sustaining visual acuity gains over the long term. Following exit from tightly controlled clinical trials into the real-world environment, patients, on average, lose all the gains in visual acuity that had been previously achieved.

 

Damage caused by these retinal diseases may be irreversible if anti-VEGF therapy is not initiated early in the disease progression. A study in patients with diabetic macular edema, or DME, a severe form of DR, found that undertreatment in the early course of patients’ disease may reduce the patients’ ability to respond to anti-VEGF therapies.

24


Market Opportunity

Wet AMD

Overview of Wet AMD

AMD is a common eye condition affecting people of age 55 years and older with a reported prevalence of approximately 11 million people in the United States and 170 million people globally. It is a progressive disease affecting the central portion of the retina, known as the macula, which is the region of the eye responsible for sharp, central vision and color perception. The likelihood of AMD progression and associated vision loss increases with age.

Wet AMD is an advanced form of AMD characterized by neovascularization and fluid leakage under the retina. It is the leading cause of severe vision loss in patients over the age of 50 in the United States and the EU, with a reported prevalence of approximately 1.25 million people and an annual incidence of approximately 200,000 people in the United States. The likelihood of disease progression increases with age, so the prevalence and incidence of wet AMD is projected to accelerate in countries with aging populations. It has additionally been observed that approximately 50% of patients presenting with wet AMD in one eye will develop wet AMD in the other eye within five years, leading to a relatively significant number of patients requiring treatment in both eyes. While wet AMD represents only 10% of the number of cases of AMD overall, it is responsible for 90% of AMD-related severe vision loss. In many eyes with wet AMD, the disease can progress quickly with rapid loss of central vision needed for activities such as reading and driving. Untreated or undertreated wet AMD results in blood vessel leakage, fluid in the macula, and ultimately scar tissue formation, which can lead to permanent vision loss, or even blindness, as a result of the scarring and retinal deformation that occur during periods of non-treatment or undertreatment.

Current Therapies for Wet AMD

The standard of care treatments for wet AMD are two anti-VEGF drugs, Lucentis (ranibizumab) and Eylea (aflibercept). Lucentis (ranibizumab), marketed by Genentech, Inc., a subsidiary of the Roche Group, in the United States and by Novartis AG outside the United States, is a recombinant humanized monoclonal antibody fragment that binds to and inhibits VEGF proteins in the eye and was approved in the United States in 2006 and in Europe in 2007. Eylea (aflibercept), marketed by Regeneron Pharmaceuticals, Inc. in the United States and by Bayer HealthCare LLC outside the United States, is a recombinant fusion protein containing portions of the human VEGF receptor that binds to soluble VEGF and was approved in the United States in 2011 and in Europe in 2012. These drugs became the standard of care for treating wet AMD based on pivotal clinical trials in which Lucentis was injected every four weeks and Eylea was injected every eight weeks (after three initial monthly loading doses). Since its approval, Eylea has been widely adopted largely due to a durability advantage compared to Lucentis, but both agents were effective in improving visual acuity in the first months of the treatment period and sustaining this gain throughout the duration of their respective clinical trials. Avastin (bevacizumab), marketed for non-ocular indications by Genentech in the United States and by Roche outside of the United States, is an anti-VEGF cancer therapy that shares structural characteristics with Lucentis and is commonly used off-label as a monthly, intravitreal injection for wet AMD. Beovu (brolucizumab), marketed worldwide by Novartis, was approved in late 2019 in the United States and early 2020 in Europe for the treatment of wet AMD and is injected every eight to 12 weeks after three initial monthly doses. Its competitiveness with Lucentis and Eylea in the commercial marketplace has yet to be observed.

Total Market for Wet AMD

Annual worldwide sales of branded anti-VEGFs for all indications were an estimated $11.5 billion in 2020. We believe a substantial majority of these sales were in connection with the treatment of wet AMD, DME, and RVO. Avastin, which is currently approved and marketed for the treatment of cancer, is also used off-label to treat wet AMD, DME, RVO, and DR. We estimate that off-label Avastin represents approximately 60% of the U.S. wet AMD market by volume. We believe that an improved anti-VEGF therapy could further increase both adoption of approved therapies and extend the duration patients remain on treatment, and thus the total addressable market opportunity in wet AMD and DR could be substantial.

With an improved anti-VEGF therapy, we believe the total addressable market opportunity in wet AMD could be substantially greater than sales of Lucentis and Eylea in wet AMD, DME and RVO. A clinically meaningful durability advantage over existing treatments could increase long-term compliance rates and maintain patients on a consistent and FDA approved treatment regimen for this chronic condition. Furthermore, we believe that an anti-VEGF therapy that is more durable than Avastin may reduce the relative weight of cost as a deciding factor for patients and providers who currently favor Avastin and expand the market for “branded” treatments.

25


Diabetic Retinopathy

Overview of Diabetic Retinopathy

DR is an eye disease resulting from diabetes, in which chronically elevated blood sugar levels cause damage to blood vessels in the retina. There are two major types of DR:

 

Non-proliferative DR, or NPDR. NPDR is an earlier, more typical stage of DR and can progress into more severe forms of DR over time if untreated and if exposure to elevated blood sugar levels persists.

 

Proliferative DR, or PDR. PDR is a more advanced stage of DR than NPDR. It is characterized by retinal neovascularization and, if left untreated, leads to permanent damage and blindness.

DME, which occurs when fluid accumulates in the macula due to leaking blood vessels, can develop at any stage of DR. PDR, together with DME, are the primary causes of vision-threatening DR, or VTDR. VTDR is the leading cause of blindness among people with diabetes and the leading cause of blindness among working age adults in the United States and the EU. Patients with mild or moderate NPDR who have not developed DME are characterized as patients with non-vision threatening DR, or NVTDR.

Current Therapies for DR

PDR has historically been treated with laser therapy. In recent years, use of anti-VEGF therapies has emerged as a complementary first-line treatment for PDR. Lucentis and Eylea are also approved for the treatment of DME with or without PDR. In April 2017, Lucentis’ approval was expanded to include all forms of DR, whether or not the patient also has DME. The approval was based on the demonstration that treatment with Lucentis results in more patients experiencing improvement of their diabetic retinopathy severity (disease regression). In March 2018, Regeneron announced results from its study in which Eylea demonstrated it can reverse disease progression in patients with moderately severe to severe NPDR when administered on average 4.4 times over 24 weeks. In 2019, Eylea received FDA approval as a treatment for DR without DME. For DR without DME, the recommended Lucentis regimen is monthly and the recommend Eylea regimen is every 8 weeks after 5 initial monthly injections.

The first-line interventions for non-vision threatening DR are observation, lifestyle changes and treatment of underlying diabetes. In practice, anti-VEGF therapies are not commonly prescribed for patients with NVTDR. However, results from the RISE and RIDE trials for Lucentis as well as the PANORAMA study for Eylea showed that anti-VEGF therapies can slow disease progression in patients with NPDR as well as induce regression.

 

Figure: Time to disease worsening (DR progression as defined by a composite endpoint)

from baseline in DME patients with NPDR treated with sham procedures vs. Lucentis.

 

26


 

Figure: Proportion of subjects improving or worsening per treatment arm.

Total Market for DR

According to the Center for Disease Control, or CDC, and National Institutes of Health, or NIH, (1) an estimated 30 million people in the United States have diabetes, with approximately 1.5 million additional people in the United States diagnosed with diabetes each year, and (2) 285 million people worldwide have diabetes. We estimate that the number of people in the United States and the EU with DR in 2015 was approximately 28.5 million. According to the NIH, the number of Americans with DR is expected to nearly double from 2010 to 2050. The CDC estimates that approximately 900,000 Americans are affected by VTDR. We believe a substantial majority of the approximately $11.5 billion in global sales of branded anti-VEGFs in 2020 were for the treatment of wet AMD, DME and RVO, with only a small proportion of sales for the treatment of NPDR without DME. Furthermore, we believe that the frequent injections required by current anti-VEGF therapies may dissuade patients with mild or asymptomatic forms of DR from accepting treatment. A more durable agent such as KSI-301 could be attractive for these untreated patients and extend the anti-VEGF market to include patients with NVTDR.

Limitations of Current Anti-VEGF Therapies

The underlying pathophysiologies of wet AMD, DME, DR and RVO are responsive to anti-VEGF drugs. Both conditions suffer from the limitations of current anti-VEGF therapies such as limited on-mechanism durability and frequent dosing intervals. On-mechanism durability is a function of the time that therapeutic levels are sustained in the ocular tissues. Data suggest that the effectiveness of Lucentis and Eylea in clinical practice is inferior to the results seen in well-controlled clinical studies, an observation attributed to insufficiently frequent dosing and resulting undertreatment even, in the case of Eylea, with its labeled eight-week regimen. Other studies show that while patients may benefit from anti-VEGF therapies in the early treatment phase, they may fail to sustain their visual acuity gains over the long term. Clinical studies have also shown that non-treatment or undertreatment with anti-VEGF agents in the months or years after disease onset may reduce the benefit of anti-VEGF therapies once therapy is initiated. These factors contribute to permanent and unnecessary vision loss for many patients.

27


Existing anti-VEGF therapies block VEGF activity effectively but have limited durability.

Wet AMD, DME, and DR are chronic and progressive diseases that require protracted treatment, possibly for life. Currently available anti-VEGF agents have relatively short durability. To maintain effective drug levels in the eye, existing anti-VEGF treatments must be administered on a frequent and sustained schedule. Lucentis was approved based on a monthly dosing interval. For wet AMD and DME, Eylea was approved based on a dosing interval of every eight weeks (following three initial, monthly loading doses for wet AMD, and five for DME). The most accepted sign of disease activity in wet AMD for retina specialists worldwide is recurrent accumulation of fluid in the macula, as determined by evaluating the retinal thickness and anatomic appearance with OCT. As can be seen in the figure below, when Eylea or Lucentis are dosed on a Q4W (once every four weeks) regimen, the retinal thickness remains stable between doses, as measured on OCT. However, when Eylea dosing is shifted to its Q8W (once every eight weeks) labeled regimen, the retina expands and contracts as it begins to swell with fluid before its next retreatment, exhibiting a seesaw pattern that we refer to as OCT flutter. This suggests that, although vision outcomes are comparable on average between fixed-interval 4-weekly and 8-weekly dosing, Eylea’s durability and ability to maintain disease control as measured by OCT is less than the approved 8-week per-label dosing.

 

Figure: Retinal thickness (y-axis), measured in microns, decreases upon treatment with Eylea. Rq4 = Lucentis every four weeks; 0.5q4 = Eylea 0.5mg every four weeks; 2q4 = Eylea 2mg every four weeks; 2q8 = Eylea 2mg every eight weeks.

The clinical implication is that when a patient’s dosing cycle is extended beyond the durability of the anti-VEGF agent and the amount of drug remaining in the eye falls below therapeutic levels, disease activity can recur. At this point, the disease can progress and begin to cause cumulative and possibly permanent retinal damage. To this point, the Eylea product labeling in the United States notes that “some patients may need every 4-week (monthly) dosing after the first 12 weeks (3 months).”

Additional evidence of the recognition of limited durability is seen in the FDA’s evaluation of both Lucentis and Eylea. Lucentis was tested for its potential to reach quarterly dosing in a Phase 3b study; it failed to successfully deliver the same efficacy results as monthly dosing. The FDA did accept dosing every three months after three initial monthly loading doses in the Lucentis product labeling, with the following wording: “Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. In the 9 months after three initial monthly doses, less frequent dosing with 4-5 doses on average is expected to maintain visual acuity while monthly dosing may be expected to result in an additional average 1-2 letter gain. Patients should be assessed regularly.” The loss of one line of vision translates into patients going back to baseline or even losing vision at the end of the first year of treatment, on average. Furthermore, the required wording of regular assessments means that the high burden of frequent office visits remains. For Eylea, recently, the FDA updated the product labeling to allow 12-week dosing but only in the second year of treatment, after one full year of intensive treatment. The labeling refers to it as “not as effective as the recommended every 8-week dosing.” For both Lucentis and Eylea, the recommended fixed interval dosing of monthly and bimonthly, respectively, appear to result in the best and most consistent visual acuity results, with all flexible or less-frequent dosing intervals labeled by FDA as “not as effective.”

Real-world utilization of current anti-VEGF therapies results in undertreatment which diminishes effectiveness.

Extended treatment intervals caused by the burden of frequent treatments causes undertreatment and visual outcomes that fall short of the results seen in pivotal clinical trials.

Compared to Lucentis’ pivotal trials in wet AMD, ANCHOR and MARINA, where initial vision gains are maintained with monthly dosing over two years, a variety of studies have shown that the initial gains (if achieved) are not maintained, on average, after the initial loading phase.

28


This is clearly seen in AURA, a multi-country real-world practice study of Lucentis. The visual acuity improvement seen in AURA falls significantly short of the visual acuity improvement that patients showed in MARINA and ANCHOR. A gradual loss of the initial vision gains can be seen as early as three months after initiation of treatment as depicted in the graph below. A key finding in AURA is that populations that received less frequent anti-VEGF treatment tended to experience less improvement in visual acuity, on average, as illustrated in the table below.

 

Figure: Vision gains seen in the AURA study over time for all patients by country (adapted from Holz et al).

*Last observation carried forward analysis.

 

Country

 

N

 

 

Mean

injections in

full 2 years

 

 

Change in

VA score to

day 90*

 

 

Change in

VA score to

year 1*

 

 

Change in

VA score

to year 2*

 

 

Mean VA

score at

year 2*

 

UK

 

 

410

 

 

 

9.0

 

 

 

5.7

 

 

 

6.0

 

 

 

4.1

 

 

 

59.0

 

The Netherlands

 

 

350

 

 

 

8.7

 

 

 

4.6

 

 

 

3.8

 

 

 

2.6

 

 

 

52.4

 

France

 

 

398

 

 

 

6.3

 

 

 

4.1

 

 

 

0.8

 

 

 

-1.1

 

 

 

54.4

 

Germany

 

 

420

 

 

 

5.6

 

 

 

3.3

 

 

 

1.1

 

 

 

-0.8

 

 

 

51.9

 

Italy

 

 

365

 

 

 

5.2

 

 

 

1.4

 

 

 

0

 

 

 

-2.9

 

 

 

62.7

 

 

Table: Summary of changes in visual acuity (VA) score from baseline and number of injections over two years, per country.

*Last observation carried forward analysis.

Consistent with the AURA study, an observational study following patients who completed the SEVEN UP and HORIZON trials for Lucentis in wet AMD showed a correlation between the number of injections and level of visual acuity benefit. Patients who received 11 or more injections during the period from four to eight years after they exited the pivotal clinical trial were more likely to experience improved vision (average gain of 3.9 letters) than patients who received six to ten injections during the same period (average loss of 6.9 letters).

 

 

 

No

injections

(n=26)

 

 

1-5

injections

(n=11)

 

 

6-10

injections

(n=11)

 

 

11

injections

(n=14)

Letter change:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SEVEN UP vs HORIZON exit

 

 

-8.7

 

 

 

-10.8

 

 

 

-6.9

 

 

+3.9 1

 

1p<0.05

Table: Mean letter change from HORIZON to SEVEN UP by total number of anti-VEGF treatments.

The implication of these data is that in clinical practice and outside of clinical studies, patients are receiving fewer injections than the labeled regimens for Lucentis (12 per year) and Eylea (seven to eight in the first year and six in subsequent years). In 2017, the Angiogenesis Foundation reported that in routine clinical practice, 65% of wet AMD patients receive six or fewer injections during the first year of treatment. Likewise, a recent publication from the American Academy of Ophthalmology’s IRIS (Intelligent Research In Sight) patient registry showed that, in 13,859 U.S. patients with wet AMD, the average number of injections in the first year of treatment was approximately six.

29


As illustrated in the top right of the figure below, data regarding long-term anti-VEGF treatment show that visual acuity outcomes are positively correlated with number of injections, with the greatest benefit seen when therapies are used at 10.5 or more injections per year reflecting high intensity, fixed Q4W or Q8W dosing.

 

Figure: Five-year visual acuity outcomes versus injection frequency for three or more years in AMD.

In real-world practice, even a small deviation from per-labeled dosing can result in significant vision loss. In the PERSEUS Study, the real-world effectiveness of Eylea was evaluated in patients treated per-label (regular treatment) compared to patients treated irregularly. Patients treated regularly received a mean of 7.4 injections compared to 5.2 in the irregular treatment group. The initial vision gains seen after the loading doses started to decrease at month four, with vision returning, on average, to almost baseline in the irregularly treated patients, as shown in the graph below. The difference in vision of 4.6 letters gained between the two groups is statistically significant, and, more importantly, represents almost a line (five eye chart letters) of vision difference on average, which is recognized in the field as clinically meaningful. Additionally, in this study, the majority of patients (70.5%) did not receive regular treatment.

 

Figure: mean change in visual acuity for regularly and irregularly treated patients in the PERSEUS Study (effectiveness set)

Real-world outcomes of anti-VEGF treatment in patients with DME show similar patterns to wet AMD. For instance, a recently published report of electronic health records real-world data from 15,608 DME patient eyes showed that patients on average receive fewer injections over 12 months and have meaningfully worse visual acuity outcomes compared to randomized controlled trials.

30


Patients are not sustaining visual acuity gains over the long term.

Patients treated with anti-VEGF agents can sustain visual acuity gains over time if they adhere to a tighter dose frequency. Results from the VIEW 1 extension study demonstrate that it is possible for patients treated with anti-VEGF agents to sustain visual acuity gains over time, as long as patients adhere to a tighter dose frequency that is closer to the labeled regimen. In the early intensive treatment phase, patients in VIEW 1 achieved a ten-letter visual acuity gain, which they then maintained over two years on a Q8W regimen. At the end of two years, patients shifted into a less-intensive clinical monitoring regimen and into a more flexible dosing regimen in which they were required to maintain at least Q12W dosing. In this hybrid setting, patients showed a slow but steady decrease in average visual acuity from ten letters to seven letters; however, their average visual acuity did not drop to pretreatment levels or below.

 

Figure: Mean visual acuity and 95% confidence interval for 647 patients in the Comparison of Age-Related

Macular Degeneration Treatments Trials Follow-up Study: (A) overall and by drug assigned in the clinical

trial and (B) overall and by dosing regimen assigned in the clinical trial. PRN = “as needed.”

As mentioned above, AURA and many other real-world practice studies show that the vision gains seen in tightly controlled clinical trials are not transferrable to clinical practice. A United Kingdom study of approximately 93,000 Lucentis injections reviewed EMRs of thousands of patients treated outside the context of clinical trials. On average, patients received a median of 5, 4, and 4 injections of Lucentis over years one, two and three, respectively. The study found that although patients showed early improvement, they regressed, on average, to pretreatment levels by the end of year two with continued deterioration below their starting visual acuity by year three, as shown in the chart below.

 

Figure: Mean visual acuity (VA), as measured by letter score, over time comparing patients with follow-up of at least 1, 2 or 3 years.

More importantly, with many patients losing vision, during the study follow-up many patients experienced new sight impairment (29.6%, 41%, 48.7% and 53.7% in years one, two, three and four, respectively) and even new cases of blindness (5.1%, 8.6%, 12% and 15.6% in years one through four, respectively).

31


In the United States, an EMR study of 7,650 eyes treated with Lucentis and Eylea outside of the clinical trial setting showed that these therapies improved patients’ visual acuity less in practice than they do in clinical trials. Further, by the end of the first year of treatment, patients’ average visual acuity had deteriorated below their pretreatment levels.

 

Figure: Mean change in visual acuity (VA) letter score at 3, 6 and 12 months in the first year of treatment.

VA was lower at 12 months than at the beginning of treatment.

When patients leave the tightly controlled clinical trial environment, their eyesight, on average, falls to pretreatment levels. In practice, anti-VEGF therapies are not delivering the level of benefit that their pivotal clinical trials suggested. In the pivotal Lucentis trials MARINA and ANCHOR, patients were able to gain and maintain vision gains with monthly dosing over two years. After exiting the clinical trials, patients were followed in the HORIZON study with as needed dosing (Pro Re Nata or PRN) for three more years. Gradual vision decline can be seen immediately after exiting the trials, returning to pre-treatment baseline vision before the end of the third year of follow-up in HORIZON.

 

Figure: Mean change in visual acuity (VA) letter score in MARINA and ANCHOR

(years one and two) and in HORIZON (years three to five).

VA gradually decreased immediately after the patients exited monthly dosing in a clinical trial setting.

A study funded by the National Eye Institute followed patients who left the tightly controlled clinical trial environment into clinical practice and showed that these patients, on average, lost all the gains in visual acuity that they obtained while enrolled in the trial.

 

32


Undertreatment in the early course of patients’ disease risks the patients’ ability to benefit from anti-VEGF therapies after the passage of time.

After disease onset, how soon patients receive appropriate treatment is important to whether they can respond to treatment. Failure to appropriately treat neovascularization in the early period may reduce patients’ ability to respond to anti-VEGF therapies as the disease progresses, possibly leading to irreversible damage. In the RIDE/RISE clinical studies of Lucentis in DR, patients who received Lucentis saw an increase in visual acuity of 10 to 12 letters at month 24. Patients who received sham treatment (a procedure that is intended to mimic a therapy in a clinical trial as closely as possible without having any actual efficacy) for 24 months saw no benefit. At the 24-month mark, the patient arms were crossed over, such that the patients who had initially received sham treatment now began to receive Lucentis. These patients were only able to improve by four letters by year three. The interpretation is that the unchecked disease progression in the initial period damaged the retina to such an extent that patients were subsequently unable to respond to Lucentis to the same degree as patients treated with Lucentis earlier in their disease process.

 

Figure: At 36 months, patients who received Lucentis 0.5mg experienced a mean BCVA change from

baseline of 11.4 letters and 11.0 letters in RIDE and RISE, respectively. Patients who received sham treatment for

24 months and then crossed over to Lucentis 0.5mg experienced a diminished benefit in mean best corrected visual

acuity change from baseline at 36 months of 4.7 letters and 4.3 letters in RIDE and RISE, respectively.

Conclusions

There is a significant and urgent unmet medical need to find better therapeutic options for patients with neovascular diseases of the retina that can:

 

keep patients on mechanism for longer than currently available anti-VEGF therapies, thereby preventing repeated undertreatment by overextending treatment intervals and thus avoiding latent recurrence of retinal edema;

 

match the required frequency of injections to keep the patient’s disease quiescent with the frequency of visits that patient and physician behavior suggest is achievable in practice;  

 

sustain the strong visual acuity gains of the early intensive treatment phase over the long term and outside of clinical trial contexts; and

 

provide a tolerable treatment regimen even for patients who are early in the course of their disease, so they can achieve the maximal benefit of anti-VEGF therapy.

In the 2018 Preferences and Trends Survey conducted by the American Society of Retina Specialists, retina specialists worldwide cited both reduced treatment burden and long-acting durability as the greatest unmet needs regarding wet AMD treatment, and in the 2019 Survey, the majority of retina specialists believed that wet AMD patients are being undertreated.

Our Lead Product Candidate: KSI-301

Our lead product candidate, KSI-301, is a novel, clinical-stage anti-VEGF biological agent that combines inhibition of a known pathway with a potentially superior on-mechanism durability profile compared to currently marketed drugs for wet AMD, DME, DR and RVO. By addressing the primary causes of undertreatment, KSI-301 has the potential to improve and sustain visual acuity outcomes in patients with retinal vascular and exudative diseases.

33


Components of KSI-301

KSI-301 is a bioconjugate comprised of two novel components. The first component is a recombinant, full-length humanized anti-VEGF monoclonal antibody. The second component is a branched, optically clear phosphorylcholine biopolymer. The antibody is conjugated to the biopolymer in a one-to-one ratio through a stable and site-specific chemical linkage to form the antibody biopolymer conjugate. The molecular weight of KSI-301 is approximately 950,000 Daltons (Dalton is a standard measure of molecular weight), of which approximately 150,000 Daltons are attributable to the antibody component and 800,000 Daltons are attributable to the biopolymer component. It is well-established that substances, when injected intravitreally, with a smaller molecular weight will be cleared from ocular tissues more quickly than larger substances.

 

Figure: Functional structure of the KSI-301 antibody biopolymer conjugate.

Antibody Intermediate

The antibody intermediate of KSI-301 consists of a humanized anti-VEGF antibody. KSI-301 behaves pharmacologically similar to Lucentis by inhibiting VEGF-mediated neovascularization and vascular permeability.

Biopolymer Intermediate

The biopolymer component is a branched, optically clear phosphorylcholine biopolymer. Phosphorylcholine is a naturally occurring phospholipid head group present on the external surface of mammalian cellular membranes. Phosphorylcholine demonstrates physiological inertness that has been attributed to its molecular structure, where a permanent positive charge on the nitrogen group is equally balanced by a negative charge on the phosphate, yielding a net neutral charge over a wide range of conditions. Because of these biophysical properties, phosphorylcholine-based materials demonstrate super-hydrophilic properties in which they bind large amounts of water molecules very tightly, to create what we call “structured water.” Phosphorylcholine is used successfully in marketed medical materials as the key water control monomer, in particular as a hydrogel in certain contact lenses and as a polymeric surface coating in certain cardiac drug-eluting stents. In these applications, phosphorylcholine containing monomers are polymerized via “uncontrolled” free radical polymerization. For an external hydrogel application (contact lens) and an internal surface coating application (drug eluting stent), control of molecular weight and architecture are not important performance attributes. Kodiak’s objective was to incorporate phosphorylcholine into well-controlled biomaterials to use as conjugates for soluble, injectable medicines such as biopharmaceuticals. In such an application, control of molecular weight and architecture are important manufacturing and performance parameters. Therefore, we used controlled “living” polymerization techniques to build precise, star-shaped, high molecular weight, well-characterized phosphorylcholine-based biopolymers that preserve functional chemistry for subsequent conjugation to biologically active proteins and, once conjugated, bring a highly structured water environment into close proximity with the bioactive antibody’s target binding regions. We are also applying these controlled “living” polymerization techniques to develop phosphorylcholine-based biopolymers as copolymers of phosphorylcholine-containing and drug-containing comonomers to build chemistry-based product candidates that we believe may demonstrate high biocompatibility, high drug loading and sustained release of small molecule drugs for ophthalmology applications.

34


Characteristics of KSI-301

We believe that KSI-301 can be a highly differentiated treatment with an improved durability and bioavailability profile compared to current anti-VEGF therapies due to the following design features and resulting performance benefits we have observed with KSI-301 in our preclinical development:

 

Design feature: KSI-301’s ultra-high molecular weight of 950,000 Daltons as compared to 115,000 for Eylea, 48,000 for Lucentis and 27,000 for brolucizumab

 

Associated performance benefits:

 

3x improvement in key ocular pharmacokinetic parameters of KSI-301, as compared to Eylea

 

~1000x ocular concentration advantage at three months post-dosing of KSI-301, as compared to Eylea

 

Design feature: KSI-301’s phosphorylcholine-based ABC Platform

 

Associated performance benefits:

 

4x increase in key target ocular tissue bioavailability, as compared to Eylea

 

Same or increased bioactivity, as compared to the standard of care anti-VEGF agents

 

Increased stability and resistance to degradation of bioconjugates compared to therapeutic proteins

 

Design feature: KSI-301’s increased formulation strength of 50 mg/mL as compared to 40 mg/mL for Eylea and 10 mg/mL for Lucentis, as measured by weight of protein moiety

 

Associated performance benefits:

 

3.5x and 7x higher number of anti-VEGF binding sites per dose, as compared with Eylea and Lucentis, respectively

We believe that the aggregated effects of these properties could afford KSI-301 a longer on-mechanism durability that will more closely match the frequency of physician visits that is realistic for patients in clinical practice.

We also believe that these properties along with KSI-301’s delivery by intravitreal injection position it favorably compared to other therapies being studied in the clinic with the aim of long-interval dosing in retinal vascular disease. For example, both subretinal gene therapy and an implantable drug reservoir require the patient to undergo surgery, which is generally riskier than an intravitreal injection. This need for surgery may reduce the likelihood that those technologies could be useful for or adopted by a broad range of physicians and patients, especially those patients with earlier-stage disease. An implantable drug reservoir also leaves a foreign body permanently in the eye, with an attendant increased risk of infection or other long-term postoperative complications such as implant dislocation. Coated microsphere drug depots that deliver small-molecule receptor tyrosine kinase inhibitor drugs into the eye may leave a foreign residual material, which may cause visual symptoms and/or other safety problems. Additionally, receptor tyrosine kinase inhibitor drugs affect signaling through additional receptors other than VEGF receptor; the effects on the eye of this additional receptor inhibition, either good or bad, are not yet known. Likewise, intravitreally-administered gene therapy vectors have been associated with chronic intraocular inflammation in a high percentage of treated patients, which may limit the efficacy of these treatments, the ability to retreat the first eye or treat the second eye over time, and the overall adoption of these approaches if they are successful. Finally, bispecific antibodies that target VEGF as well as other angiogenic signaling pathways are attempting to increase durability of treatment effect both through high molar doses and the targeting of additional pathways beyond VEGF, but the antibodies being used are the same size as typical monoclonal antibodies (~150 kDa) and we believe they do not have any unique size or half-life extending properties.

35


Trajectories in Field of Medicines Development for Retinal (Intravitreal) Therapies

Since the initial FDA approval of Lucentis in 2006 as a monthly therapy for wet AMD, efforts have been made to improve the durability of intravitreal anti-VEGF therapy. Primarily, two parameters have been varied: size of molecule and amount of injected dose. First, increasing molecular weight, which can increase durability or ocular pharmacokinetics, or PK, in the eye because a larger molecule can lead to a slower exit from the eye. For example, Lucentis has a molecular weight of 48 kDa whereas Eylea, approved in 2011, has a molecular weight of 115 kDa. The second parameter is increasing the formulation strength (concentration) to increase the effective dose of anti-VEGF, given the limited volume of medicine that can be injected intravitreally in a single administration. This increases effective durability by keeping drug concentrations in the eye above a minimal threshold for longer periods of time. For example, Eylea has a 2x molar equivalence to Lucentis. In designing KSI-301, we addressed both parameters: first, increasing the molecular weight to 950 kDa through our ABC approach, and second, increasing the molar strength through a high concentration formulation of 50 mg/mL (by weight of protein). We believe our design decisions for KSI-301 may provide increased durability. The following figure illustrates these concepts.

36


Affinity for and Inhibition of VEGF

The therapeutic activity of KSI-301 is driven by its antibody component, OG1950, which (1) binds to VEGF and (2) prevents VEGF from carrying out its functions that promote neovascularization and increase vascular permeability. Our preclinical tests have demonstrated that OG1950 and KSI-301 bind to VEGF with similar affinity, which indicates that, despite the size and complex architecture of the biopolymer intermediate, the biopolymer does not interfere with antibody binding.

Table: Binding kinetics of OG1950 and KSI-301 to huVEGF-A165 by SPR or KinExA analysis.

 

Molecule

 

Platform (°C)

 

Kon (M)

 

Koff (M)

 

K(pM)

 

OG1950

 

Biacore(25°)

 

5.31x106

 

4.48x10-5

 

 

9.02

 

 

 

KinExA(37°)

 

5.09x105

 

1.75x10-6

 

 

3.43

 

KSI-301

 

Biacore(25°)

 

3.19x106

 

5.33x10-5

 

 

17.0

 

 

 

KinExA(37°)

 

2.69x105

 

1.82x10-6

 

 

6.75

 

°C = degrees Celsius; KD = dissociation constant

We have also tested OG1950 and KSI-301 in vitro alongside other anti-VEGF biologics to test their respective abilities to inhibit VEGF from binding to VEGF receptors. As shown in the figure and table below, while KSI-301 and OG1950 have similar IC50 (the concentration at which binding is reduced by half) compared to Eylea, KSI-301 consistently demonstrates a higher maximal inhibition than Eylea or Lucentis. Of note, KSI-301 improved maximal inhibition more than OG1950, suggesting that the special nature of our antibody biopolymer conjugate synergistically improves the bioactivity of the antibody intermediate acting alone.

 

Figure: Inhibition of VEGF binding to VEGF receptors by anti-VEGF agents.

 

Molecule

 

IC50 (nM)

 

Maximal

inhibition

(%)

KSI-301

 

3.72±0.74

 

93.89±1.41

OG1950

 

3.97±1.19

 

83.72±3.13

Ranibizumab (Lucentis)

 

8.60±1.29

 

70.67±2.36

Aflibercept (Eylea)

 

4.50±0.14

 

74.96±1.84

Bevacizumab (Avastin)

 

10.29±0.70

 

73.08±4.20

 

Table: Average IC50 and maximal inhibition of anti-VEGF agents. IC50 values measured in nanomoles (nM) and

calculated from concentration of anti-VEGF agents. All values shown as average with standard deviation.

37


Inhibition of VEGF-Mediated Processes

Based on its ability to bind and inhibit VEGF, KSI-301 is expected to behave pharmacologically similar to Lucentis, Eylea and Avastin to decrease the leakage of blood proteins and fluid into the retina. In fact, in vitro testing of KSI-301 against Lucentis, Eylea and Avastin in their respective ability to inhibit VEGF-mediated endothelial cell proliferation (a key component of neovascularization) in primary human retina microvascular endothelial cells, or HRMVECs, showed that KSI-301 inhibited proliferation to approximately the same degree as Eylea and with greater potency than Lucentis or Avastin. In addition, KSI-301 displayed a superior maximal inhibition of VEGF-mediated proliferation relative to Eylea and Avastin.

 

Figure: Effects of KSI-301, Lucentis, Eylea and Avastin on HRMVEC proliferation.

 

Molecule

 

IC50 (nM)

 

Maximal

Inhibition

(%)

KSI-301

 

0.96±0.18

 

64.74±2.36

OG1950

 

0.85±0.07

 

58.92±5.30

Ranibizumab (Lucentis)

 

1.25±0.14

 

60.96±2.53

Aflibercept (Eylea)

 

0.74±0.10

 

53.93±4.91

Bevacizumab (Avastin)

 

1.25±0.36

 

38.98±6.18

 

Table: IC50 Values and maximal inhibition of anti-VEGF agents on VEGF-mediated proliferation of HRMVECs. IC50 values were calculated from concentration of anti-VEGF agents. All values shown as average with standard deviation.

To mimic in vivo conditions where endothelial cells and pericytes coexist in blood vessels, a three-dimensional co-culture of HRMVECs and human mesenchymal pericytes, or HMPs, grown on beads was established. This model was then used to test the ability of KSI-301 to inhibit VEGF-mediated vascular sprouting compared to Lucentis and Eylea. The average number of sprouts per bead and the length per sprout were analyzed under each treatment condition.

38


As shown in the figures below, at maximal anti-VEGF inhibition the average sprout length of cultures treated with KSI-301 was substantially less than that of the control (481 compared with 990 microns) and comparable to Lucentis and Eylea (505 and 428 microns respectively). The average number of sprouts per bead for cultures treated with KSI-301 was 11.5, which was comparable to 13.3 and 13.0 sprouts per bead observed for the cultures treated with Lucentis and Eylea, respectively.

 

Figure: Effects of KSI-301 and other anti-VEGF molecules on length and number of vascular sprouts in 3-dimensional culture.

Extended Ocular Half-Life versus Standard of Care Agents

The addition of the biopolymer intermediate increases the size of the biologic, thereby extending the ocular half-life of the molecule beyond that of standard of care anti-VEGF agents. Preclinical studies with KSI-301 in the well-established rabbit ocular pharmacokinetics model have demonstrated that KSI-301 has ocular tissue half-lives of 10+ days in the retina and 12.5+ days in the choroid. This is in comparison to published data for ocular tissue half-lives for Lucentis of 2.9 days and Eylea of 4-5 days.

Enhanced Ocular Tissue Bioavailability versus Eylea

The data also show that KSI-301, despite its large size, penetrates ocular tissues well and has a retina and choroid ocular tissue biodistribution that is more than four-fold higher than Eylea.

 

39


Modeling On-Mechanism Durability and Human Dose Frequency

In order to estimate the impact of high potency and extended ocular half-life on durability of effect, we used a pharmacokinetic and pharmacodynamic model that overlays rabbit ocular tissue pharmacokinetic profiles of intravitreally injected anti-VEGF therapeutics and correlates the drug levels with (1) human OCT data to define a rabbit minimal inhibitory concentration to maintain human on-mechanism durability that corresponds with human OCT outcomes, and (2) human dose frequency to define a rabbit minimal inhibitory concentration to support a dose frequency in humans which corresponds to the ability to maintain visual acuity outcomes over the long-term. Specifically, we overlay the ocular tissue pharmacokinetic profiles of Lucentis at 0.5 mg dose (the marketed dose in wet AMD), Eylea at 2.0mg dose (the marketed dose), and bioconjugate KSI-301 at 5.0 mg dose (our selected dose), as separately tested.

 

Our modeling suggests a single dose of KSI-301 can stay above both on-mechanism and “dosing” minimal inhibitory concentrations for longer than 12 weeks in wet AMD patients. A minimal inhibitory concentration is the minimum concentration of a drug that still has the desired therapeutic effect. The implication is that KSI-301 may on average keep the retina dry for longer than 12 weeks after dosing, allowing patients to be dosed in regular 12-week intervals or less frequently and still maintain anti-VEGF mediated visual acuity gains over the long term. This contrasts with overextending the treatment interval beyond a point where retinal swelling recurs as observed in Eylea’s VIEW 2 Phase 3 clinical trial (as described above).

KSI-301 has demonstrated superior stability compared to typical protein therapeutics

Stability studies have shown that KSI-301 bioconjugate is stable in ex vivo vitreous for at least 4 months at 37°C. Further, forced degradation studies at the extreme condition of 64°C have shown that KSI-301 bioconjugate remains in solution and is optically clear for at least 48 hours whereas the precursor antibody protein precipitated forming an opaque white suspension within several hours.

Toxicology Profile

KSI-301 has demonstrated an attractive safety profile. In all GLP monkey toxicology studies conducted through ocular or systemic administration, KSI-301 has been well tolerated. In ocular studies, KSI-301 was dosed bilaterally via intravitreal injection at 2.5 or 5.0 mg per eye every four weeks up to seven doses and evaluated through 40 weeks. Findings were limited to a dose-related anterior segment and posterior segment mild inflammatory response, which was not associated with other ocular abnormalities. The anterior segment response declined during the interval between doses and generally the finding was not present one-week post dose. The posterior segment response was attributed to a mild immune mediated response typically observed to a humanized therapeutic in monkeys.  No drug related systemic toxicity was observed. Additionally, in a systemic administration study, KSI-301 was well tolerated up to the highest dose of 5 mg/kg when dosed intravenously every four weeks for ten weeks. In summary, the results of the toxicology studies strongly indicate that KSI-301’s well tolerated safety profile in monkeys is favorable compared to that reported for Lucentis and Eylea.

40


KSI-301 Commercialization

We currently have no sales, marketing or commercial product distribution capabilities and have no experience as a company in marketing products. We intend to build our own commercialization capabilities over time.

If KSI-301 receives marketing approval, we plan to commercialize it in the United States with our own focused, specialty sales force. We believe that retinal specialists in the United States, who perform most of the medical procedures involving diseases of the back of the eye, are sufficiently concentrated that we will be able to effectively promote KSI-301 to these specialists with a sales and marketing group of fewer than 200 persons.

We expect to use a variety of types of collaboration, distribution and other marketing arrangements with one or more third parties to commercialize KSI-301 in markets outside the United States.

KSI-301 Manufacturing

We believe it is important to our business and success to have a reliable, high-quality clinical drug supply. As we mature as a company and approach commercial stage operations, securing reliable high-quality commercial drug supply will be critical.

We do not currently own or operate facilities for product manufacturing, storage, distribution or testing.

We rely on third-party contract manufacturers, or CMOs, to manufacture and supply our clinical materials to be used during the development of our product candidates. We have established relationships with several CMOs, including Lonza AG, or Lonza, for the manufacture of KSI-301, as well as certain of our other product candidates.

We currently do not need commercial manufacturing capacity. When and if this becomes relevant, we intend to evaluate both third-party manufacturers as well as building out internal capabilities and capacity. We may choose one or both options, or a combination of the two.

The process for manufacturing KSI-301 consists of conjugating our antibody intermediate with our biopolymer intermediate. Our antibody intermediate is produced in a recombinant GS-CHO (Glutamine Synthetase—Chinese Hamster Ovary) cell line in a protein-free and animal component-free medium. Our biopolymer intermediate is synthesized via a multi-step controlled “living” polymerization process, purified and formulated. Following conjugation of the intermediates, the bioconjugate drug substance is further purified, concentrated, and stored.

To date, we have relied primarily on Lonza for the manufacture of KSI-301. Notably, in the first quarter of 2020, we completed three successful re-supply batches of cGMP-manufactured KSI-301 drug substance. We believe that supply from these new batches, together with previously available KSI-301 supply from prior cGMP drug substance manufacturing, is sufficient to support our ongoing and planned clinical development activities.

The manufacture of KSI-301, like other biologic products, is complex and we have actively worked with Lonza to develop and refine our manufacturing process. As our need for KSI-301 increases in connection with pre-BLA manufacturing and validation activities and, if approved, commercial quantities, we anticipate continued collaboration with Lonza. We have also identified multiple other CMOs that we believe would be capable of implementing, validating and commercializing our manufacturing process for KSI-301 should the need arise.

ABC Platform

We believe that our ABC Platform is well suited to extend the durability of soluble, injectable retinal medicines, while at the same time providing for other useful benefits. We intend to develop additional drug candidates by applying our ABC Platform in other significant areas of unmet medical need in retina and ophthalmic disease.

We believe our ABC Platform differentiates us and has the potential to fuel a pipeline of differentiated product candidates in high-prevalence ophthalmic diseases. In addition to KSI-301, we have leveraged our ABC Platform to build a pipeline of potential product candidates, including KSI-501, a recombinant, mammalian cell expressed dual inhibitor antibody biopolymer conjugate, targeting both VEGF and IL-6 for the treatment of retinal diseases with an inflammatory component. The cGMP master cell bank for KSI-501 has been completed, and KSI-501 is being further developed towards an IND in 2021.

In addition, we have expanded our early research pipeline to include ABC Platform-based triplet inhibitors. In this approach, a bispecific or dual inhibitor antibody is conjugated to a phosphorylcholine biopolymer variant that is embedded with hundreds of copies of a small-molecule drug. As a result, multiple disease-related biologies - both intracellular and extracellular - can be targeted with a single medicine. This approach can be of particular relevance for common vision-threatening diseases that are more complex because of their multifactorial pathophysiology, such as dry AMD and glaucoma. KSI-601 is a triplet inhibitor for dry AMD, and we currently intend to submit an IND in 2022.

41


Overview of KSI-501

In addition to angiogenesis, inflammation has been implicated in the pathogenesis of a number of retinal diseases. Anti-inflammatory therapies such as steroids have been effective in treating both uveitis (a spectrum of diseases with intraocular inflammation as a defining characteristic) and DME. Similarly, genetically inherited variations in the interleukin 6, or IL-6, gene have been associated with higher PDR incidence in patients with type 2 diabetes. Moreover, disease progression in AMD, DR and RVO have been reported to be associated with increased serum and/or ocular levels of IL-6. Additionally, chronic inflammatory cells have been seen on the surface of the basement membrane behind the retina in eyes with wet AMD. Interestingly, IL-6 has been implicated in resistance to anti-VEGF treatments in DME patients. This in part is believed to be an indirect result of IL-6 mediated upregulation of VEGF expression as well as more direct VEGF-independent angiogenic functions mediated by IL-6 signaling that occur in the presence of VEGF inhibitors.

Our KSI-501 product candidate is a dual inhibitor Trap-Antibody-Fusion, or TAF, bioconjugate molecule designed to target concurrent inflammation and abnormal angiogenesis observed in the pathogenesis of retinal vascular diseases. KSI-501 acts through an anti-VEGF mechanism similar to Eylea and an anti-inflammatory mechanism that targets the potent cytokine IL-6. Similar to KSI-301, KSI-501 uses the ABC Platform and is a bioconjugate of the TAF protein conjugated to our phosphorylcholine-based biopolymer. Preclinical binding and functional studies demonstrate that the TAF protein binds specifically and simultaneously to its intended targets. We believe that this dual inhibition may provide a superior treatment option for patients with retinal vascular diseases and in particular those patients with diseases known to have a high inflammatory component such as DME, as well as in ocular inflammatory diseases such as uveitis.

KSI-501 is now in GMP manufacturing, and we are currently working towards IND submission in early 2022.

Components of KSI-501

KSI-501 is a bioconjugate of a dual inhibitor TAF protein and a phosphorylcholine-based biopolymer. The protein portion of KSI-501 has two VEGF binding domains from human VEGF receptors which together act as a trap or soluble receptor decoy to bind the most abundant isoforms of VEGF. The anti-VEGF trap domains are fused to a high-affinity IgG1 antibody that binds with high specificity and affinity to IL-6 and disrupts the ligand’s association with its cognate IL-6 receptor. Moreover, the Fc domain has been engineered to reduce immune effector function and facilitate site-specific conjugation to our phosphorylcholine-based biopolymer.

Notably, this IgG1 antibody sequence is identical to that from KSI-301, except for the six CDR regions that mediate target binding and which are specific for binding to the IL-6 target. Retaining the IgG1 frameworks across ABC Platform-derived product candidates enables “platform capability” which simplify manufacturing and product development. KSI-501, furthermore, uses the same cGMP biopolymer intermediate as KSI-301.

 

Figure: Functional structure of the KSI-501 antibody biopolymer conjugate. CH – constant heavy, CL – constant light, VH – variable heavy, VL – variable light, – Complementarity Determining Regions (CDR).

42


Characteristics of KSI-501

We believe that KSI-501 can be a highly differentiated treatment due to its dual mechanism of action, with an improved durability and bioavailability profile due to the ABC Platform component. In addition, there are currently no IL-6 inhibitors approved for use in the eye.

We incorporated the following design features into KSI-501:

 

Binds with high affinity to the most abundant isoforms of VEGF

 

Engineered to remove a protease hotspot to prevent cleavage in Chinese Hamster Ovary, or CHO, mammalian expression systems, which may improve potency and formulation stability

Design Feature: KSI-501’s anti-IL-6 domain

 

Affinity matured, humanized anti-IL-6 IgG1 that binds with high affinity to IL-6 and inhibits binding of IL-6 to its cognate receptor

 

IgG1 Fc domain engineered to reduce immune effector functions

Design Feature: KSI-501’s phosphorylcholine-based ABC Platform

 

Ultra-high molecular weight of 1,000,000 Daltons for improved ocular pharmacokinetics

 

Same IgG1 framework sequences and same phosphorylcholine-based biopolymer as KSI-301 and other ABC Platform-derived product candidates to simplify manufacturing and product development

 

Other benefits of the ABC Platform such as enhanced tissue access to key ocular tissues and bioconjugate stability

Note that the in vitro data shown below are generated using the TAF (protein) of KSI-501, without conjugation to our ABC biopolymer. Results using KSI-501 may be different, but experience with a structurally similar prior molecule, KSI-201, has shown that these individual components, i.e., trap antibody fusion protein and biopolymer, can function together simultaneously as a dual inhibitor bioconjugate. Prior experiences with bioconjugates KSI-201 and KSI-301 have also demonstrated that the biopolymer portion does not interfere with the bioactivity of the protein portion.

Affinity and concurrent binding to VEGF and IL-6

Preclinical studies indicate that the TAF portion of KSI-501 binds with high affinity to both VEGF and IL-6, as measured by SPR analysis (Table). Importantly, binding of each molecule has no effect on the binding of the other, and KSI-501 can bind to both molecules as shown below. Thus, we believe our dual inhibitor can simultaneously inhibit both of its targets with high potency.

Table: Binding kinetics of TAF portion of KSI-501 to huVEGF-A165 or IL-6 by SPR analysis.

 

Molecule

 

Kon (M)

 

Koff (M)

 

KD (pM)

 

IL-6

 

3.72x106

 

4.06x10-4

 

 

109

 

VEGF-A165

 

1.07x107

 

1.63x10-4

 

 

15.2

 

 

Figure: TAF of KSI-501 simultaneously binds to IL-6 and VEGF by sandwich ELISA, which only shows a signal if a compound binds to both IL-6 and VEGF concurrently.

43


Inhibition of VEGF and IL-6

KSI-501 was designed to inhibit both VEGF and IL-6 mediated signaling that occur after the ligands bind to their respective receptors. The figure below shows that the TAF protein of KSI-501 effectively prevents VEGF from stimulating downstream VEGFR2 signaling in a reporter assay in a comparable manner to Eylea, while anti-IL-6 alone served as a negative control.

 

Figure: VEGF stimulated reporter assay with increasing concentrations of anti-VEGF inhibitors

The figure below shows that the control anti-IL-6 antibody and TAF protein of KSI-501 effectively compete with IL-6R for binding to plate-bound IL-6 and therefore inhibit this specific antigen-receptor interaction. The IC50 values for the control anti-IL-6 monoclonal antibody and the TAF protein are comparable (anti-IL-6 = 0.36 nM, KSI-501 = 0.47 nM), while Eylea had no effect.

 

Figure: ELISA measuring IL-6 binding to IL-6R in the presence of increasing concentrations of anti-IL-6 inhibitors

Together, these data indicate that the TAF protein of KSI-501 inhibits both VEGF and IL-6 from binding their cognate receptors as effectively as the monotherapies. Importantly, these data also demonstrate that the TAF protein of KSI-501 can simultaneously block downstream signaling mediated by both VEGF and IL-6.

44


IL-6 and VEGF mediated proliferation of HUVECs

The ability of the TAF protein of KSI-501 to inhibit IL-6 and VEGF mediated angiogenic functions was tested in a Human Vascular Endothelial Cell, or HUVEC, proliferation assay as shown in the figure below. Importantly, the concentrations of VEGF and IL-6 used to stimulate proliferation were below the saturation point for each individual stimulant and under these conditions VEGF and IL-6 showed some synergy for growth. The presence of TAF protein significantly attenuated proliferation to approximately 50% of maximal growth, while neither Eylea nor control anti-IL-6 alone had quantifiable effects. These data provide supporting evidence that KSI-501 can synergistically abrogate endothelial cell proliferation that is driven by concurrent inflammatory and VEGF mediated signaling.

 

Figure: VEGF/IL-6 mediated HUVEC proliferation in the presence of inhibitors

IL-6 and VEGF mediated tubule formation of HUVECs:

TAF protein of KSI-501 was also tested in an endothelial cell tubule formation assay. Treatment of HUVECs seeded on an extracellular basement membrane matrix (Matrigel) with VEGF and IL-6 together stimulate tubule formation to a higher degree than either treatment alone. The TAF protein of KSI-501 demonstrated superior inhibition of this tubule formation when compared to Eylea or control anti-IL-6 antibody.

Furthermore, quantification of the effects of each inhibitor on twenty parameters of HUVEC tubule formation show that the TAF protein significantly inhibited 17 of 20 angiogenic parameters versus control (compared to 4 of 20 for Eylea and 7 of 20 for control anti-IL-6 antibody). TAF protein was statistically better than Eylea and anti-IL-6 control in 12 of 20 parameters.  

 

Figure: Quantification of IL-6/VEGF mediated HUVEC tubule formation in the presence or absence of inhibitor molecules using the Angiogenesis Analyzer plugin for ImageJ

45


Together, these data show that the TAF protein of KSI-501 can simultaneously bind IL-6 and VEGF to inhibit their downstream angiogenic signaling pathways. We believe that this novel dual inhibitor can provide an alternative option for the treatment of retinal vascular diseases, especially those that have a high inflammatory component and/or that do not respond adequately to anti-VEGF treatments alone.

Competition

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.

Our potential competitors include large pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic or biosimilar drug companies. Many of our competitors have significantly greater financial and human resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring products, product candidates or other technologies complementary to our programs.

The key competitive factors affecting the success of KSI-301, if approved, are likely to be its efficacy, safety, method and frequency of administration, on-mechanism durability of therapeutic effect, convenience, price, the level of generic and biosimilar competition and the availability of coverage and reimbursement from government and other third-party payors. The method of administration of KSI-301, intravitreal injection, is commonly used to administer ophthalmic drugs for the treatment of severe disease and is generally accepted by patients facing the prospect of severe visual loss or blindness. However, a therapy that offers a less invasive method of administration might have a competitive advantage over one administered by intravitreal injection, depending on the relative safety of the other method of administration.

The current standard of care for wet AMD, advanced stages of DR (including DME), and RVO is monotherapy administration of anti-VEGF drugs, principally Avastin, Lucentis and Eylea, which are well-established therapies and are widely accepted by physicians, patients and third-party payors. Physicians, patients and third-party payors may not accept the addition of KSI-301 to their current treatment regimens for a variety of potential reasons, including:

 

if they do not wish to incur the additional cost of KSI-301;

 

if they perceive the addition of KSI-301 to be of limited benefit to patients;

 

if they wish to treat with more than an anti-VEGF drug;

 

if sufficient coverage and reimbursement are not available; and

 

if they do not perceive KSI-301 to have a favorable risk-benefit profile.

We are developing KSI-301 as an alternative to existing anti-VEGF drugs, including Avastin, Lucentis and Eylea. Accordingly, KSI-301 would directly compete with these therapies. While we believe KSI-301 will compete favorably with existing anti-VEGF drugs, future approved standalone or combination therapies with demonstrated improved efficacy over KSI-301 or currently marketed therapies with a favorable safety profile and any of the following characteristics might pose a significant competitive threat to us:

 

a mechanism of action that does not involve VEGF;

 

a duration of action that obviates the need for frequent intravitreal injection;

 

a method of administration that avoids intravitreal injection; and

 

significant cost savings or reimbursement advantages compared to KSI-301 and other anti-VEGF therapies.

Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. A drug with greater convenience than KSI-301 might make such a drug more attractive to physicians and patients. An anti-VEGF gene therapy product might substantially reduce the number and frequency of intravitreal injections when treating wet AMD, DME, RVO, or DR, making KSI-301 unattractive to physicians

46


and patients. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected because in many cases insurers or other third-party payors seek to encourage the use of generic products.

In addition to currently available therapies, we are aware of a number of products in preclinical research and clinical development by third parties to treat wet AMD, DME, RVO and DR. We expect that product candidates currently in clinical development, or that could enter clinical development in the near future, that inhibit the function of VEGF or inhibit the function of both VEGF and other factors, could represent significant competition if approved. These product candidates may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. For example, Novartis has received FDA and EMA approval for Beovu (brolucizumab) for the treatment of wet AMD, and is studying Beovu as a potential treatment option for patients with DME and RVO. Roche is developing faricimab, a bispecific antibody targeting VEGF and another mechanism, in wet AMD, DME, and RVO, and recently presented Phase 3 data demonstrating the non-inferiority of faricimab to Eylea in wet AMD and DME. There are also several companies and research organizations pursuing treatments targeting other molecular targets, potential gene therapy treatments, stem cell transplant treatments and medical devices for the treatment of wet AMD, DME, DR, and RVO.

Because there are a variety of means to treat wet AMD, DME, DR, and RVO, our patents and other proprietary protections for KSI-301 will not prevent development or commercialization of product candidates that are different from KSI-301.

Funding Agreement

On December 1, 2019, we, and our subsidiary, Kodiak Sciences GmbH, entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to BBA for $225,000,000. Under the funding agreement, BBA purchased the right to receive a capped 4.5% royalty on net sales following marketing approval of KSI-301 in exchange for $225,000,000 in committed development funding payable to us. Unless earlier terminated or re-purchased by us, the royalty “caps” or terminates upon the date that BBA has received an aggregate amount equal to 4.5 times the funding amount paid to us. Under the terms of the funding agreement, BBA was required to pay the first $100,000,000 of the funding amount at the closing of the funding transaction and the remaining $125,000,000 of the funding amount, subject to delivery of notice by the Company, payable upon enrollment of 50% of the patients in the RVO clinical program. We have the option, exercisable at any point during the term of the funding agreement, to repurchase from BBA 100% of the royalties due to BBA under the funding agreement for a purchase price equal to the funding amount paid to us as of such time times 4.5, less amounts paid by us to BBA. Under the funding agreement, BBA also received a right to a royalty interest on future net sales following marketing approval of other of our products that employ an anti-VEGF A, or VEGF-A, biology as a sole molecular or chemical biology. In the event we commercialize related products that contain both an anti-VEGF-A biology together with at least one additional molecular or chemical biology(ies), BBA would have the right to receive a fractional royalty of up to 2.25% for one additional molecular or chemical biology or 1.5% for two additional molecular or chemical biologies provided that such other products are being progressed in indications for, or patient populations with, retinal vein occlusion, wet AMD or diabetic macular edema, or indications or patient populations in which KSI-301 or a VEGF-A product has received marketing approval. Total royalty payments under the funding agreement are not to exceed the cap of 4.5 times the funding amount paid to us. The funding agreement was the result of a competitive process overseen by independent and disinterested directors of Kodiak with the assistance of outside counsel.

Government Regulation

Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.

47


U.S. Drug Development

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations, and biologics under the FDCA, the Public Health Service Act, or PHSA, and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA’s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.

Any future product candidates must be approved by the FDA through either a new drug application, or NDA, or a biologics license application, or BLA, process before they may be legally marketed in the United States. The process generally involves the following:

 

completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements;

 

submission to the FDA of an IND, which must become effective before human clinical trials may begin;

 

approval by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each trial may be initiated;

 

performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;

 

submission to the FDA of an NDA or BLA;

 

a determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review;

 

satisfactory completion of a FDA pre-approval inspection of the manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with current good manufacturing practices, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic’s identity, strength, quality and purity;  

 

potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA or BLA;

 

FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug or biologic in the United States; and

 

compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies.

The data required to support an NDA or BLA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all.

Preclinical Studies and IND

The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin.

48


Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.

Clinical Trials

The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor’s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.

A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary.

Clinical trials in the United States generally are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap.

 

Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the drug.

 

Phase 2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified and a preliminary evaluation of efficacy is conducted.

 

Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.

Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA.

Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.

49


Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their shelf life.

NDA/BLA Review Process

Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity and potency for a biologic. The application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product’s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States.

Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA or BLA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for approved human drugs and biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.

The FDA reviews all submitted NDAs and BLAs before it accepts them for filing, and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months, from the filing date, in which to complete its initial review of a new molecular-entity NDA or original BLA and respond to the applicant, and six months from the filing date of a new molecular-entity NDA or original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for additional information or clarification.

Before approving an NDA or BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete Response Letter may require additional clinical data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the

50


applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.

Expedited Development and Review Programs

The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for fast track designation if they are intended to treat a serious or life threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for fast track status any time before receiving NDA or BLA approval, but ideally no later than the pre-NDA or pre-BLA meeting.

Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies.

A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions, as it deems necessary to assure safe use of the product.

Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process.

Abbreviated Licensure Pathway of Biological Products as Biosimilar or Interchangeable

The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products shown to be highly similar to an FDA-licensed reference biological product. An application for licensure of a biosimilar product must include information demonstrating biosimilarity based upon the following, unless the FDA determines otherwise:

 

analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product notwithstanding minor differences in clinically inactive components;

 

animal studies (including the assessment of toxicity); and

 

a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) sufficient to demonstrate safety, purity and potency in one or more conditions for which the reference product is licensed and intended to be used.

In addition, an application must include information demonstrating that:

 

the proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s) of use prescribed, recommended, or suggested in the proposed labeling, but only to the extent the mechanism(s) of action are known for the reference product;

 

the condition or conditions of use prescribed, recommended, or suggested in the labeling for the proposed biosimilar product have been previously approved for the reference product;

51


 

the route of administration, the dosage form, and the strength of the proposed biosimilar product are the same as those for the reference product; and  

 

the facility in which the biological product is manufactured, processed, packed or held meets standards designed to assure that the biological product continues to be safe, pure, and potent.

Biosimilarity means that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product. In addition, the law provides for a designation of “interchangeability” between the reference and biosimilar products, whereby the biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient to show that:

 

the proposed product is biosimilar to the reference product;

 

the proposed product is expected to produce the same clinical result as the reference product in any given patient; and

 

for a product that is administered more than once to an individual, the risk to the patient in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without such alternation or switch.

FDA approval is required before a biosimilar may be marketed in the United States. In addition, as with BLAs, biosimilar product applications will not be approved unless the product is manufactured in facilities designed to assure and preserve the biological product’s safety, purity and potency.

The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar application for twelve years from the date of first licensure of the reference product. Additionally, a biosimilar product sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference product may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for a rare disease or condition (an “orphan drug”) may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference product may be approved until either the end of the twelve-year period provided under the biosimilarity statute or the end of the seven-year orphan drug exclusivity period, whichever occurs later. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and thus block biosimilarity applications from being approved on or after the patent expiration date. In addition, the FDA may under certain circumstances extend the exclusivity period for the reference product by an additional six months if the FDA requests, and the manufacturer undertakes, studies on the effect of its product in children, a so-called pediatric extension.

Post-Approval Requirements

Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping requirements, requirements to report adverse experiences, and comply with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (known as “off-label use”) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of additional data or preclinical studies and clinical trials.

The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.

52


The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

 

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

 

fines, warning letters or holds on post-approval clinical studies;

 

refusal of the FDA to approve pending applications or supplements to approved applications;

 

applications, or suspension or revocation of product license approvals;

 

product seizure or detention, or refusal to permit the import or export of products; or

 

injunctions or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

Other U.S. Regulatory Laws

Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare & Medicaid Services, or CMS, other divisions of the Department of Health and Human Services, or HHS, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety & Health Administration, the Environmental Protection Agency and state and local governments.

For example, in the United States, our business operations, including any sales, marketing and scientific and educational programs, also must comply with state and federal fraud and abuse laws, including the federal Anti-Kickback Statue and false claims laws; federal data privacy and security laws; and federal transparency laws related to payments and/or other transfers of value made to physicians and other healthcare professionals and teaching hospitals. The federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Federal false claims laws, including the False Claims Act, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment of federal funds, and knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government.

The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

Many states have similar laws and regulations that may differ from federal law in significant ways, thus complicating compliance efforts. For example, states have anti-kickback and false claims laws that may be broader in scope than analogous federal laws and may apply regardless of payer. In addition, the federal physician payment transparency requirements, sometimes referred to as the “Physician Payments Sunshine Act,” created under the ACA and its implementing regulations, require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report

53


such information related to payments or other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year.

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses and their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information as well as their covered subcontractors, relating to the privacy, security, and transmission of such individually identifiable health information. In addition, state data privacy laws that protect the security of health information may differ from each other and may not be preempted by federal law.

Moreover, several states and local jurisdictions have enacted legislation requiring pharmaceutical manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales and marketing activities, report information related to drug pricing, require the registration of sales representatives, and prohibit certain other sales and marketing practices.

Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.

The distribution of biologic and pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.

Data Privacy

Privacy laws in the U.S. are also increasingly complex and changing rapidly. For example, the California legislature enacted the California Consumer Privacy Act, or CCPA, which took effect on January 1, 2020. The CCPA requires covered companies to provide new disclosures to California residents, and honor their requests to access, delete and opt-out of certain sharing of their personal information. The CCPA provides for civil penalties for violations. Since the enactment of the CCPA, new privacy and data security laws have been proposed in more than half of the states and in the U.S. Congress, reflecting a trend toward more stringent privacy legislation in the U.S. The CCPA itself will expand substantially as a result of California voters approving a November 2020 ballot measure that adopted the California Privacy Rights Act of 2020, or CPRA, which will, among other things, create a new administrative agency to implement and enforce California’s privacy laws effective January 1, 2023.

In addition, the processing of personal data in connection with clinical trials in the EU must comply with comprehensive data protection requirements imposed by EU’s General Data Protection Regulation, or GDPR. GDPR, which took effect on May 25, 2018, imposes stringent data protection requirements and provides for penalties for noncompliance that can include bans on processing personal data and fines of up to the greater of 20 million euros or four percent of worldwide annual revenues. The GDPR requires organizations to give detailed disclosures about how they collect, use and share personal information; in most cases, obtain explicit consent to process sensitive personal information, such as health or genetic information; contractually require vendors to meet data protection requirements; maintain adequate data security measures; notify regulators and affected individuals of certain data breaches; meet extensive privacy governance and documentation requirements; and honor individuals’ data protection rights, including their rights to access, correct and delete their personal information.

European data protection laws, including the GDPR, also restrict the transfer of personal information from Europe, including the European Economic Area, the United Kingdom and Switzerland, to the U.S. and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. One of the primary safeguards allowing U.S. companies to import personal information from Europe has been certification to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks administered by the U.S. Department of Commerce. However, the Court of Justice of the European Union adopted a decision in July 2020 invalidating the EU-U.S. Privacy Shield. The same decision also raised questions about whether one of the primary alternatives to the EU-U.S. Privacy Shield, namely, the European Commission’s Standard Contractual Clauses, can lawfully be used for personal information transfers from Europe to the U.S. or most other countries. Authorities in Switzerland also have issued guidance raising similar questions about the Swiss-U.S. Privacy Shield and the Standard Contractual Clauses.

54


The failure to comply with any of these laws or regulatory requirements may result in possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in significant penalties, including administrative, civil, and criminal penalties, fines, imprisonment, disgorgement, injunctions, exclusion from participation in federal healthcare programs, integrity oversight and reporting obligations, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.

U.S. Health Care Reform

Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (1) changes to our manufacturing arrangements; (2) additions or modifications to product labeling; (3) the recall or discontinuation of our products; or (4) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. Further, the United States, there have been and continue to be a number of healthcare-related legislative initiatives that have significantly affected the healthcare industry.  For example, there remain judicial challenges to certain aspects of the ACA. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was Tax Cuts and Jobs Act of 2017 (the Tax Act), the remaining provisions of the ACA are invalid as well. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, but it is unknown when a decision will be reached. Although the United States Supreme Court has yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the United States Supreme Court ruling, other such litigation, and the healthcare form measures of the Biden administration will impact the ACA and our business. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Further, on November 20, 2020, CMS issued an interim final rule implementing President Trump’s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.

U.S. Patent-Term Restoration and Marketing Exclusivity

Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent-term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA.

55


Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of a NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

A reference biological product is granted twelve years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. “First licensure” typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the “first licensure” of a biological product is determined on a case-by-case basis with data submitted by the sponsor.

European Union Drug Development

As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained.

Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority, or NCA, and one or more Ethics Committees, or ECs. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred.

The EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. Recently enacted Clinical Trials Regulation EU No 536/2014 ensures that the rules for conducting clinical trials in the EU will be identical. In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all clinical trials performed in the EU.

56


European Union Drug Review and Approval

In the European Economic Area, or EEA, which is comprised of the 27 Member States of the European Union (including Norway and excluding Croatia), Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations.

 

The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.

 

National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State, or RMS. The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics, or SPC, and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling, or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Member States Concerned).

Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.

People’s Republic of China Drug Regulation

China heavily regulates the development, approval, manufacturing and distribution of drugs, including biologics. The legal framework for the administration of pharmaceutical products in China was established by the Drug Administration Law of the PRC (DAL). The DAL applies to entities and individuals engaged in the development, production, trade, clinical use, as well as supervision and administration of pharmaceutical products by regulatory agencies and provides a framework for regulating pharmaceutical manufacturers, pharmaceutical trading companies, medical institutions, and the research, development, manufacturing, distribution, packaging, pricing, and advertisement activities related to pharmaceutical products. The DAL was revised in 2019 (rDAL) and reflects the regulatory trend of strengthening the lifecycle management of drugs, balancing the development of innovative drugs and generic drugs, and enhancing drug review and enforcement. It also represents legislative efforts to address prominent problems of the pharmaceutical industry, such as high drug prices and counterfeit and substandard drugs.

The rDAL contains a dedicated chapter on the Marketing Authorization Holder (MAH) system. Subject to approval by the NMPA, MAHs will be allowed to transfer their marketing authorizations, although it is uncertain whether the transferability of MAH will offer more flexibility in structuring cross-border transactions. In addition, the implementation of the MAH system was accompanied by a range of new requirements for the MAHs, such as establishing a quality assurance system and being responsible for the whole process including all aspects of preclinical research, clinical trials, manufacturing and distribution, post-marketing research, adverse drug reaction monitoring and reporting.

The rDAL also requires MAHs, manufacturers, distributors, and medical institutions to establish and implement drug track and trace systems. A drug pharmacovigilance system will also be established to monitor, identify, evaluate and control adverse drug reactions and other possible drug-related problems. The NMPA will issue related standards and regulations regarding drug track and trace system.

The rDAL no longer requires the certification for good clinical practice (GCP), good supply practice (GSP), and GMP. Drug manufacturers and drug distributors must still comply with current requirements and the NMPA and its local counterparts are directed to strengthen their surveillance, including through regular and continuous site inspections, to ensure their compliance.

57


The rDAL creates an expanded access pathway for investigational drugs under which a company sponsor of a clinical trial in China can apply to establish an expanded access treatment program for patients with life-threatening disease who otherwise do not satisfy the inclusion criteria of a clinical trial. To qualify for expanded access: (1) the drug must be used for life-threatening diseases that lack effective treatment; (2) the drug must have demonstrated its potential efficacy based on medical observations; (3) such use is in line with ethical principles; (4) such expanded use has been reviewed and approved (although the approval pathway not clear), and has obtained patients’ informed consent; and (5) the drug must be used within the clinical trial institution and used on patients with similar conditions.

The rDAL also significantly increases and expands penalties for violations. Depending on various types of violations, the DAL imposes different penalties, including warnings, confiscation of illegal gains, fines of up to 5 million RMB (about $725,000) or up to 30 times of illegal gains, revocation of required business and operating licenses, certificates or approval documents for drugs, suspension of business, temporary (10 years) or permanent debarment of companies, institutions and responsible persons, and criminal liabilities in the case of serious violations.

There are still uncertainties with respect to the interpretation and implementation of the rDAL. We plan to monitor the implementation of the rDAL in China.

Regulatory Authorities and Recent Government Reorganization

In China, the NMPA is the primary regulator for pharmaceutical products and businesses. The agency was formed from the prior China Food and Drug Administration (CFDA) in 2018 as part of a complete government reorganization. The NMPA is no longer an independent agency and its parent agency is now the newly formed State Administration of Market Regulation (SAMR), into which agencies responsible for, among other areas, consumer protection, advertising, anticorruption, antitrust, fair competition and intellectual property have been merged.

Like the CFDA, the NMPA is still the chief drug regulatory agency and implements the same laws, regulations, rules, and guidelines as the CFDA. The agency regulates almost all of the key stages of the lifecycle of pharmaceutical products, including nonclinical studies, clinical trials, marketing approvals, manufacturing, advertising and promotion, distribution, and pharmacovigilance (i.e., post-marketing safety reporting obligations). The Center for Drug Evaluation (CDE), which remains under the NMPA, conducts the technical evaluation of each drug and biologic application for safety and efficacy.

The National Health Commission (NHC), formerly known as Ministry of Health (MOH) and National Health and Family Planning Commission (NHFPC), is China’s chief healthcare regulator. It is primarily responsible for overseeing the operation of medical institutions, which also serve as clinical trial sites, and regulating the licensure of hospitals and other medical personnel. Furthermore, the NHC and its local counterparts also oversee and organize public medical institutions’ centralized bidding and procurement process for pharmaceutical products.. This is the primary way that public hospitals and their internal pharmacies procure drugs and the NHC plays a significant role in drug reimbursement.

Pre-Clinical and Clinical Development

The NMPA requires preclinical data to support registration applications for new drugs, which includes safety assessment studies that meet the GLP standards, issued in 2003 and amended in 2017. The rDAL requires the NMPA to accredit GLP labs, and that nonclinical studies of chemical drug substances and preparations and biologics that are not yet marketed in China be conducted in GLP-certified labs. There are no approvals required from the NMPA to conduct preclinical studies.

Registration Categories

An applicant will need to determine the registration category for its drug candidate, prior to engaging with the NMPA on research and development and approval, which will determine the requirements for its clinical trial and marketing application. There are five categories for small molecule drugs: Category 1 (innovative drugs) refers to drugs that have a new chemical entity that has not been marketed anywhere in the world, Category 2 (improved new drugs) refers to drugs with a new indication, dosage form, route of administration, combination, or certain formulation changes not approved in the world, Categories 3 and 4 are for generics that reference an innovator drug (or certain well-known generic drugs) marketed either abroad or in China, respectively, and Category 5 refers to innovative or generic drugs that have already been marketed abroad but are not yet approved in China (i.e., imported drugs).

The categories are similar for therapeutic biologics, with Category 1 for new and innovative biologics that have not been approved inside or outside of China. Biosimilars are under Category 3. KSI-301 is classified as Category 1 based on the defined registration category by the NMPA.

58


Expedited Programs – Priority Evaluation and Approval Programs to Encourage Innovation

The NMPA has adopted several expedited review and approval mechanisms since 2009 and created additional expedited programs in recent years that are intended to encourage innovation. Applications for these expedited programs can be submitted after the CTA is admitted for review by the CDE. The NMPA’s Drug Registration Rules effective from July 1, 2020 (DRR) provides certain categories of drugs that may be eligible for priority status. If admitted to one of these expedited programs, an applicant will be entitled to more frequent and timely communication with reviewers at the CDE, expedited review and approval, and more agency resources throughout the approval process.

Clinical Trials and Marketing Approval

Upon completion of pre-clinical studies, a sponsor typically needs to conduct clinical trials in China for registering a new drug in China. The materials required for this application and the data requirements are determined by the registration category. The NMPA has taken a number of steps to increase efficiency for approving CTAs, and it has also significantly increased monitoring and enforcement of GCP to ensure data integrity.

Trial Approval

All clinical trials conducted in China for the purpose of seeking marketing approvals must be approved by the NMPA and conducted at hospitals satisfying GCP requirements. In addition to a standalone China trial to support development, imported drug applicants may establish a site in China that is part of an international multicenter trial (IMCT). Domestically manufactured drugs are not subject to foreign approval requirements, and in contrast to prior practice, the NMPA has decided to permit those drugs to conduct development via an IMCT as well.

The rDAL has now also adopted an implied approval system for clinical trials of new drugs. Trials can proceed if after 60 business days, the applicant has not received any objections from the CDE, as opposed to the lengthier previous clinical trial pre-approval process in which the applicant had to wait for affirmative approval. In addition, by abolishing the GCP accreditation system, the rDAL also expanded the number of trial sites and simplified the notification procedure followed by trial sites.

Clinical Trial Register

Clinical trials conducted in China must be registered and published through the Drug Clinical Trial Information Platform (http://www.chinadrugtrials.org.cn). Applicants are required to pre-register the trial information within one month after trial approval to obtain the unique trial registration number and to complete registration of certain information before the first subject is enrolled. If the foregoing pre-registration and registration is not obtained within one year after obtaining the clinical trial approval, the applicant shall submit an explanation, and if the procedure is not completed within three years, the clinical trial approval automatically expires.

Human Genetic Resources Regulation

The Regulation on the Administration of Human Genetic Resources (HGR Regulation) became effective on July 1, 2019. The HGR Regulation applies to all human genetic resources (HGR)-related activities for R&D purposes, including sampling, biobanking, use of HGR materials and associated data in China, and the provision or sharing of such materials or data with foreign parties.

The HGR Regulation applies to foreign parties, including foreign entities and entities established or controlled by foreign entities and individuals. Such foreign parties seeking access to China’s HGRs for scientific research, including clinical trials intended to support marketing approval of drugs and medical devices in China, must engage in collaborations with Chinese parties, such as Chinese hospitals. The HGR Regulation prohibits foreign parties from independently sampling or biobanking any China HGR in China and requires approval for the sampling of certain HGR and biobanking of all HGR by Chinese parties. Any cross-border transfer of the HGR materials, either under an international collaboration or as a direct export, must be on an as-needed basis and requires approval. In addition, providing HGR data to foreign parties requires a record filing.

The HGR Regulation retains the provision in the Interim Measures for the Administration of Human Genetic Resources issued in 1998 (the Interim Measures) that parties should jointly apply for and own the patent rights arising from the results generated from international collaborations that utilize China HGR. Subject to approval, the parties may contractually agree on how to dispose of their patent rights and non-patent proprietary rights arising from the collaboration. As the joint ownership requirement is rather broad, it is unclear how this requirement will be implemented in practice.

59


The HGR Regulation also significantly increases and expands penalties for various violations, including warnings, disgorgement of illegal gains, confiscation of illegal HGR, fines up to 10 million RMB($1,450,000) or 5-10 times of illegal gains in the event such illegal gains exceed 1 million RMB ($145,000), and temporary (1-5 years) or permanent debarment of companies, institutions and responsible persons from future HGR projects regulated by the HGR Regulation.

Clinical Trial Process and Good Clinical Practices

As in other parts of the world, clinical trials in China typically have three phases. Phase 1 refers to the initial clinical pharmacology and human safety evaluation studies. Phase 2 refers to the preliminary evaluation of a drug candidate’s therapeutic efficacy and safety for target indication(s) in patients. Phase 3 (often the pivotal study) refers to clinical trials to further verify the drug candidate’s therapeutic efficacy and safety on patients with target indication(s) and ultimately provide sufficient evidence for the review of a drug registration application. The NMPA requires that the different phases of clinical trials in China receive ethics committee approval and comply with GCP. The NMPA conducts inspections on clinical trials conducted in China to assess GCP compliance and may refuse to approve the drug if it finds substantial issues in the trials. In addition, upon granting the drug registration certificate, NMPA may, at its sole discretion, require a Phase 4 trial to be conducted by MAH within a specified period of time so as to further monitor and obtain safety and efficacy data of the drug.

Pursuant to GCP, sponsors of clinical trials are responsible for proper packaging and labeling of drugs used for clinical trials, including that investigational drugs shall be consistent with the control drug or placebo in appearance, odor, packaging, labeling, and certain other features in double-blinded clinical trials. Pharmaceutical packaging must comply with national and professional standards or obtain approval from the provincial administration for medical products or bureau of standards if these standards are not available and need to be developed and implemented by the sponsors. Changes in such approved packaging standards need to be re-approved. Drugs of which the packaging standards are not approved shall not be released or marketed in China, except for those specifically supplied to the military.

Acceptance of Foreign Clinical Trial Studies

The NMPA may be flexible on the requirements of trials and data generated in China, dependent on the drug and the existing data. The NMPA has granted waivers for all or part of trials and has stated that it will accept data generated abroad (even if not part of a global study), including early phase data, that meets its requirements. In 2018, the NMPA issued the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data (the Guidance Principles), as one of the implementing rules for the Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices (the Innovation Opinion). According to the Guidance Principles, data from foreign clinical trials must meet authenticity, completeness and accuracy requirements and such data must be obtained in compliance with the relevant requirements under the GCP of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Sponsors must be attentive to ethnic differences in the subject population that could be potentially meaningful.

New Drug Application (NDA) and Approval

Upon completion of clinical trials, a sponsor may submit clinical trial data to support marketing approval for the drug. For domestically manufactured drugs, NDA sponsors must submit data derived from the submitted drugs in support of their approval. Under the rDAL, upon approval of the registration application, the NMPA will issue a drug registration certificate to the applicant which is in fact the marketing approval of the drug, and the applicant is no longer required to be equipped with relevant manufacturing capability.

Manufacturing and Distribution

All facilities that manufacture drugs in China must receive a drug manufacturing license with an appropriate “scope of manufacturing” from the local drug regulatory authority. This license must be renewed every five years, and the manufacturing facility is also required to be in compliance with GMP.

New Drug Monitoring Period

Previously, new varieties of domestically produced drugs approved under Categories 1 or 2 in China could be placed under a monitoring period for three to five years. Category 1 innovative drugs were monitored for five years. During the monitoring period, the NMPA would not approve another CTA from another applicant for the same type of drug, except if another sponsor had an approved CTA at the time that the monitoring period was initiated, it could proceed with its trial and once approved become another drug that was part of the monitoring period. The DRR has abolished these new drug monitoring period programs; however, drugs that had been placed under a monitoring period before the DRR took effect are still entitled to exclusivity before the monitoring periods end.

60


Post-Marketing Surveillance

Under the rDAL, the MAH of a drug is ultimately responsible for pharmacovigilance, including quality assurance, adverse reaction reporting and monitoring, and product recalls. Distributors and user entities (e.g., hospitals) are also required to report, in their respective roles, adverse reactions of the products they sell or use, and assist the MAH with any product recalls. An MAH for a drug that is currently under the new drug monitoring period must report all adverse drug reactions (as opposed to just serious adverse reactions) for that period.

Advertising and Promotion of Pharmaceutical Products

China has a strict regime for the advertising of approved medicines. No unapproved medicines may be advertised. The definition of an advertisement is very broad and does not expressly exclude scientific exchange. It can be any media that directly or indirectly introduces the product to end users. There is no clear line between advertising and any other type of promotion.

Regulatory Intellectual Property Protections

In January 2020, the United States and China signed the Economic and Trade Agreement Between the United States of America and the PRC (the Trade Agreement), in which, among other things, China agreed to provide effective protection and enforcement of pharmaceutical-related intellectual property rights, such as patents and undisclosed test or other data submitted as a condition of marketing approval. These provisions of the Trade Agreement will need to be implemented in China. In October 2020, amendments to the PRC Patent Law (the Amended PRC Patent Law) were adopted, effective June 1, 2021, which contains both patent term extension and a mechanism for early resolution of patent disputes, that may be comparable to patent linkage in the United States. There is uncertainty around the scope and implementation of the patent term extension and the early resolution mechanism as the provisions are unclear and/or remain subject to the approval of implementing regulations that are still in draft form or have not yet been proposed.

Regulatory Data Protection

The Innovation Opinion provided a foundation for regulatory data protection to protect innovative drugs and will be available for undisclosed clinical trial data of drugs within the following categories: innovative drugs, innovative therapeutic biologics, drugs that treat orphan diseases, pediatric drugs, and drugs for which there has been a successful patent challenge. According to the Trade Agreement, China has committed to providing for effective protection of undisclosed clinical trial or other data submitted as a condition of marketing approval.

The NMPA has published draft regulations for public comment that would set regulatory data protection for innovative small molecule drugs at six years and for innovative therapeutic biologics at 12 years; pediatric and orphan drugs would receive six years to run concurrently from their approval dates. Full terms of protection would require reliance on local trials or sites of multi-center trials in China and simultaneous submissions of marketing applications in China and other countries. Submissions in China that are up to six years later than those abroad would result in the term being reduced to 1-5 years and submissions over six years later in China may not receive protection.

Patent Linkage

The Innovation Opinion also established the basic elements of a patent linkage system to protect innovators. A follow-on applicant would be required to identify patents that are relevant to its application and notify those relevant patent right holders (including, innovators) within a specified period after filing an application, permitting the patent holders the ability to protect their rights. The system will require that the NMPA continue to review the potentially infringing follow-on application during any lawsuit by the innovator and that the NMPA may not approve the follow-on application pending resolution of the patent litigation in favor of the follow-on application or for a specified period of time, whichever is shorter. Similarly, the Trade Agreement also adopted certain elements of a patent linkage system (notice to the patent right holder of the follow-on application, time and opportunity for that right holder to sue or to seek expeditious remedies, obtain a timely resolution of the patent dispute) but did not explicitly mention a stay of marketing approval of the follow-on application.

The Amended PRC Patent Law provides a cause of action to allow a patent holder to initiate a declarative action during the regulatory review process of a drug to determine whether the drug falls within the patent scope, that may be comparable to the patent linkage system in the United States. There is uncertainty around the scope and implementation of the early resolution mechanism as the provisions are unclear and/or remain subject to the approval of implementing regulations that are still in draft form or have not yet been proposed.

61


Patent Term Extension

In early 2019, pursuant to the Innovation Opinion, the National People’s Congress issued a proposal for patent term extension as part of a proposed amendment to the Patent Law. The Amended PRC Patent Law provides that the China National Intellectual Property Administration shall provide patent term extension, similar to the United States, for the patent term lost during the regulatory review process of a new drug upon the patent holder’s request. The extended term shall not exceed five years, and the total patent term after market entry of the new drug shall not exceed 14 years. The Trade Agreement also provides for patent term extension to compensate for unreasonable delay that occurs during pharmaceutical product marketing approvals. There is uncertainty around the scope and implementation of the patent term extension as the provisions are unclear and/or remain subject to the approval of implementing regulations that are still in draft form or have not yet been proposed.

Other PRC national- and provincial-level laws and regulations

Pharmaceutical companies operating in China are subject to changing regulations under many other laws and regulations administered by governmental authorities at the national, provincial and municipal levels, some of which are or may become applicable to our business. For example, regulations control the confidentiality of patient medical information and the circumstances under which patient medical information may be released for inclusion in our information systems or released by us to third parties. These laws and regulations governing both the disclosure and the use of confidential patient medical information may become more restrictive in the future, including restrictions on transfer of healthcare data. The Cybersecurity Law that took effect in 2017 designates healthcare as a priority area that is part of critical information infrastructure, and China’s cyberspace administration is working to finalize a draft rule on cross-border transfer of personal information.

Coverage and Reimbursement

Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. In the United States no uniform policy of coverage and reimbursement for drug or biological products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.

The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, the ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies’ share of sales to federal health care programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs.

The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of HHS as a condition for states to receive federal matching funds for the manufacturer’s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers’ rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price, or AMP, to 23.1% of AMP and adding a new rebate calculation for “line extensions” (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. CMS has proposed to expand Medicaid rebate liability to the territories of the United States as well.

62


The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.

For a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. In 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although, under the current state of the law, with the exception of children’s hospitals, these newly eligible entities will not be eligible to receive discounted 340B pricing on orphan drugs. In addition, as 340B drug prices are determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase.

As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. An increasing emphasis on cost containment measures in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.

Intellectual Property

We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights. We seek to protect our proprietary position by, among other methods, filing patent applications in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen, and maintain our proprietary position in the field. Although we are not party to any material in-license agreements as of the date of this annual report, we may in the future pursue in-licensing opportunities to strengthen our proprietary position in the field. We additionally rely on data exclusivity, market exclusivity, and patent term extensions when available, and may seek and rely on regulatory protection afforded through orphan drug designations. Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including our patents; and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties.

63


We have prosecuted numerous patents and patent applications and possess know-how and trade secrets relating to the development and commercialization of our ABC Platform and product candidates, including related manufacturing processes and technology. As of December 31, 2020, we were the assignee of record for approximately five U.S. issued patents, and approximately 13 U.S. pending patent applications directed to certain of our proprietary technology, inventions, and improvements and our most advanced product candidates, as well as 28 patents issued in jurisdictions outside of the United States and 66 patent applications pending in jurisdictions outside of the United States that, in many cases, are counterparts to the foregoing U.S. patents and patent applications. We also have one pending PCT application. For example, these patents and patent applications include claims directed to:

 

therapeutic proteins and biologically active agents conjugated to a biopolymer, which comprise our ABC Platform;

 

specific therapeutics, including KSI-301; and

 

components of our therapeutics.

64


The following patents and patent applications (including anticipated 20-year expiration dates, which could be altered by, for example, a disclaimer, patent term adjustment or patent term extension) relate to KSI-301 and/or ABC Platform:

 

Patent and Patent Application Numbers

 

Anticipated U.S.

Expiration Date

 

Description of Representative U.S. Claims

 

 

 

 

 

US 8,846,021, US Appl. No. 16/424265, EP Patent No. 1988910, JP Patent No. 5528710, JP Patent No. 5745009, and foreign applications in certain jurisdictions claiming priority to PCT/US2007/005372

 

2/28/2027

 

Representative claims include conjugates

 

 

 

 

 

US Appl. No. 15/368,376, AU Patent No. 2011239434, AU Patent No. 2017201930, CA Patent No. 2795667, EP Patent No. 2558538, JP Patent No. 6568748, JP Patent No. 6754749, MX Patent No. 365521, and foreign applications in certain jurisdictions claiming priority to PCT/US2011/032768

 

4/15/2031

 

Representative claims include conjugates

 

 

 

 

 

US 8,765,432, US Appl. No. 15/099,234, AU Patent No. 2010330727, CA Patent No. 2783615, EP Patent No. 2512462, EP Patent No. 3254678, CN Patent No. ZL201080062252.7, HK Patent No. 1247828, IN Patent No. 319269, JP Patent No. 5760007, JP Patent No. 5990629, JP Patent No. 6416832, JP Patent No. 6777706, MX Patent No. 346423, MX Patent No. 374020, KR Patent No. 10-1852044, MO Patent No. J/002943, and foreign applications in certain jurisdictions claiming priority to PCT/US2010/061358

 

5/10/2030

 

Representative claims include copolymers and methods of making copolymers (ABC Platform specifically)

 

 

 

 

 

US 10,702,608, US Appl. No. 16/781869, EP Patent No. 3041513, JP Patent No. 6463361, JP Patent No. 6732056, and foreign applications in certain jurisdictions claiming priority to PCT/US2014/054622

 

12/21/2034

 

Representative claims include polymers and method of making polymers

 

 

 

 

 

US Appl. No. 15/394500 and foreign applications in certain jurisdictions claiming priority to PCT/US2016/069336

 

 

12/29/2036

 

Representative claims include antibody and antibody conjugate claims, as well as methods of making and using the conjugates

 

 

 

 

 

US Appl. No. 17/066856 and PCT Application No. PCT/US2020/055074

 

10/9/2040

 

Representative claims include method of treating an eye disorder using the antibody conjugates

 

In the normal course of business, we intend to pursue, when possible, composition, method of use, dosing and formulation patent protection, as well as manufacturing and drug development processes and technology. The patents and patent applications we have filed outside of the United States are in Europe, Japan, and various other jurisdictions.

Individual patents extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the United States are effective for 20 years from the earliest effective filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date.

65


Our issued U.S. patents will expire on dates ranging from 2027 to 2035. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2027 to 2040. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent.

We have filed 34 trademark applications. These include two applications that have matured to registration in the United States. One application has been abandoned in the United States. Sixteen of our applications have matured to registration, of which ten are in China, and one is in each of Canada, the European Union, Japan, Singapore, Switzerland and the United Kingdom. We have eleven pending trademark applications, of which three are in the United States and eight are in China. We also may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets are difficult to protect. We seek to protect our technology and product candidates, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, contractors, consultants, collaborators, and advisors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or may be independently discovered by competitors. To the extent that our employees, contractors, consultants, collaborators, and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For this and more comprehensive risks related to our proprietary technology, inventions, improvements and products, please see the section on “Risk Factors—Risks Related to Intellectual Property.”

We are also a party to an assignment and license agreement with a former collaborator, whereby we were assigned and non-exclusively licensed certain intellectual property relating to KSI-201 and related technology. Under this agreement, we agreed to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize KSI-201, and will owe milestone payments to our former collaborator upon the achievement of certain milestones related to KSI-201, as well as a low single digit percentage royalty on net sales of KSI-201. The assignment and license agreement includes customary termination provisions, including the right of the company to terminate for convenience and the right of either party to terminate for cause.

Human Capital Management

As of February 19, 2021, we had 72 employees worldwide, of whom 8 were based outside of the U.S. Of these employees, 55 employees were engaged in or support research, development and clinical activities, 19 of whom hold a Ph.D. degree or M.D. (or equivalent) degree. None of our employees are subject to a collective bargaining agreement. Given our expanding operations and need to further grow our headcount to support our business, we continually assess employee turnover, recruitment initiatives, compensation and benefits programs, safety in performing critical laboratory work, diversity and other matters relevant to human capital management, and we review results with our Board of Directors on a periodic basis. We aim to offer competitive compensation (including salary, incentive bonus, and equity) and benefits packages in each of our locations and in each of employee groups at each level around the globe as assessed with internal and external benchmarking data. We aim to build a pipeline for talent to create more opportunities for workplace diversity and to support greater representation within the Company.

Legal Proceedings

As of the date of this annual report, we are not a party to any material legal proceedings. In the normal course of business, we may be named as a party to various legal claims, actions and complaints. We cannot predict whether any resulting liability would have a material adverse effect on our financial position, results of operations or cash flows.

Additional Information

We maintain an internet website at the following address: https://kodiak.com. The information on our website is not incorporated by reference in this annual report on Form 10-K or in any other filings we make with the Securities and Exchange Commission, or SEC.

We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Securities Exchange Act of 1934, as amended. These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC. In addition, the SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

66


ITEM 1A. RISK FACTORS

You should consider carefully the following risk factors, together with all the other information in this report, including the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and our consolidated financial statements and notes thereto. The occurrence of any events described in the following risk factors and the risks described elsewhere in this report could harm our business, operating results, financial condition, and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements that we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.

Risks Related to the Discovery, Development and Commercialization of Our Product Candidates

Our prospects are heavily dependent on our KSI-301 product candidate, which is currently in clinical development for multiple indications.

KSI-301 is our only product candidate currently in clinical trials. It may be years before a registrational-type trial is completed, if at all. Further, we cannot be certain that either KSI-301 or any of our product candidates will be successful in clinical trials.

Our early encouraging preclinical and Phase 1/1b clinical trial results for KSI-301 in the respective indications are not necessarily predictive of the results of our ongoing or future discovery programs or any future preclinical or clinical studies. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical studies after achieving positive results in early-stage development, including early-stage clinical studies, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical studies were underway or safety or efficacy observations made in preclinical studies and clinical studies, including previously unreported or unobserved adverse events as more patients are treated with KSI-301 and followed for longer periods of time.

There can be significant variability in safety or efficacy results between different clinical studies of the same product candidate due to numerous factors, including changes in study procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical study protocols and the rate of dropout among clinical study participants. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical studies nonetheless failed to obtain FDA approval.

We may in the future advance product candidates into clinical trials and terminate such trials prior to their completion. While we have certain preclinical programs in development and intend to develop other product candidates, it will take additional investment and time for such programs to reach the same stage of development as KSI-301.

A failure of KSI-301 in clinical development may require us to discontinue development of other product candidates based on our ABC Platform.

If KSI-301 fails in development as a result of any underlying problem with our platform, then we may discontinue development of some or all of our product candidates that are based on our ABC Platform. If we discontinue development of KSI-301, or if KSI-301 were to fail to receive regulatory approval or were to fail to receive regulatory approval in one or more of our four planned key clinical indications or were to fail to achieve sufficient market acceptance, we could be prevented from or significantly delayed in achieving profitability.

Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized.

We are at an early stage of development of our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:

 

our product candidates may not successfully complete preclinical studies or clinical trials;

 

a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;

 

our competitors may develop therapeutics that render our product candidates obsolete or less attractive;

 

our competitors may develop platform technologies that render our ABC Platform obsolete or less attractive;

67


 

the product candidates and ABC Platform that we develop may not be sufficiently covered by intellectual property for which we hold exclusive rights or may be covered by third party patents or other intellectual property or exclusive rights;

 

the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive;

 

a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;  

 

if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and

 

a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable.

If any of these events occur, we may be forced to abandon our development efforts for a product candidate or candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Failure of a product candidate may occur at any stage of preclinical or clinical development, and, because our product candidates and our ABC Platform are in development, there is a relatively higher risk of failure and we may never succeed in developing marketable products or generating product revenue.

We may not be successful in our efforts to further develop our ABC Platform and current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product candidates is in the early stages of development and will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical studies that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates or if we do not meet the clinical endpoints with statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates.

If any of our product candidates successfully completes clinical trials, we generally plan to seek regulatory approval to market our product candidates in the United States, the EU, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing, and distribution of our product candidates. We may also rely on our collaborators or partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product candidates. We cannot be sure that our collaborators or partners will conduct these activities successfully or do so within the timeframe we desire. Even if we (or our collaborators or partners) are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected.

Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. That approval may be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical studies to obtain approval or be subject to additional post-marketing testing requirements to maintain regulatory approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a modified Risk Evaluation and Mitigation Strategy, or REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.

Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates.

68


We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.

Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an IND application or a clinical trial application, or CTA, will result in the FDA, European Medicines Agency, or EMA, China National Medical Products Administration, or NMPA, or any other regulatory authority as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include:

 

inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;

 

delays in reaching a consensus with regulatory agencies on study design or, in the case of China, the registration category for the drug candidate to be studied in the clinical trial;

 

the determination by the reviewing regulatory authority to require more costly or lengthy clinical trials than we currently anticipate;

 

delays in reaching agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;

 

delays in identifying, recruiting and training suitable clinical investigators;

 

delays in obtaining required Institutional Review Board, or IRB, approval at each clinical trial site;

 

imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND or amendment, CTA or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical trial operations or study sites; developments on trials conducted by competitors for related technology that raises FDA, EMA, NMPA or any other regulatory authority concerns about risk to patients of the technology broadly; or if the FDA, EMA, NMPA or any other regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;

 

delays in identifying, recruiting and enrolling suitable patients to participate in our clinical trials, and delays caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up;

 

difficulty collaborating with patient groups and investigators;

 

failure by our CROs, other third parties, or us to adhere to clinical trial requirements;

 

failure to perform in accordance with the FDA’s or any other regulatory authority’s current good clinical practices, or cGCPs, requirements, or applicable EMA, NMPA or other regulatory guidelines in other countries;

 

occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;

 

changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;  

 

changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;

 

the cost of clinical trials of our product candidates being greater than we anticipate;

 

clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates;

 

transfer of manufacturing processes to larger-scale facilities operated by CMOs or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and

 

delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing.

Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.

69


We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA, EMA, NMPA or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, NMPA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

Delays in the commencement or completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.

Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA, NMPA or other comparable foreign regulatory authorities.

During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our product candidates has side effects or causes serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results and financial condition.

Our most advanced product candidate, KSI-301, is an anti-VEGF biologic that we are studying in wet AMD, DME/DR and RVO. There are some potential side effects associated with intravitreal anti-VEGF therapies such as intraocular hemorrhage, intraocular pressure elevation, retinal detachment, inflammation, vasculitis, artery occlusion or infection inside the eye and over-inhibition of VEGF, as well as the potential for potential systemic side effects such as heart attack, stroke, wound healing problems, and high blood pressure. Recent trends in the development of anti-VEGF therapies have favored increased molar dosages, as compared to currently marketed treatments. To date these heightened dosages have not exhibited a safety profile significantly worse than that of current treatments, as attributable to molar dose. However, anti-VEGF product candidates featuring higher molar dosages, including KSI-301, may heighten the risk of adverse effects associated with anti-VEGF treatments generally, both in the eye and in the rest of the body. There are risks inherent in the intravitreal injection procedure of drugs like KSI-301 which can cause injury to the eye and other complications including conjunctival hemorrhage, punctate keratitis, eye pain, conjunctival hyperemia, intra-ocular inflammation, and endophthalmitis.

Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study and/or result in potential product liability claims. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of management’s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates and decreased demand for our product candidates, if approved for commercial sale.

Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to:

 

regulatory authorities may withdraw approvals of such product;

 

regulatory authorities may require additional warnings on the label;

70


 

we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies;

 

we may be required to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;

 

we could be sued and held liable for harm caused to patients; and

 

our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations, and prospects.  

We may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected.

The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:

 

the size and nature of the patient population;

 

the patient eligibility criteria defined in the protocol, including certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have such patient eligibility criteria;

 

the size of the study population required for analysis of the trial’s primary endpoints;

 

the proximity of patients to a trial site;

 

the effects of health epidemics, including the ongoing COVID-19 pandemic and the resulting shelter-in-place, travel or similar restrictions;

 

the design of the trial;

 

our ability to recruit clinical trial investigators with the appropriate competencies and experience;

 

competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility criteria;

 

clinicians’ and patients’ perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates;

 

our ability to obtain and maintain patient consents; and

 

the risk that patients enrolled in clinical trials will not complete such trials, for any reason.

For example, because patients with early stages of DR often lack symptoms, it may be challenging to identify and enroll patients at early stages of disease that may be required for a clinical trial. Our inability to enroll a sufficient number of patients for our clinical trials could result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, delay or halt the development of and approval processes for our product candidates and jeopardize our ability to commence sales of and generate revenues from our product candidates, which may harm our business and results of operation.

Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy or durability of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization.

Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. For those product candidates that are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. This is especially true for anti-VEGF biologic agents where Lucentis and Eylea are established products with accepted safety profiles.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of our product candidates may not be

71


predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety, efficacy or durability results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Product candidates in later stages of clinical trials may fail to show the desired safety, efficacy and durability profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.

We may be unable to design and execute clinical trials that support marketing approval. We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.

In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential.

We may not be successful in our efforts to continue to create a pipeline of product candidates or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates, our commercial opportunity may be limited.

One of our strategies is to identify and pursue clinical development of additional product candidates through our ABC Platform. Our ABC Platform may not produce a pipeline of viable product candidates, or our competitors may develop platform technologies that render our ABC Platform obsolete or less attractive. Our research methodology may be unsuccessful in identifying potential product candidates, or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make them unmarketable or unlikely to receive marketing approval. Identifying, developing, obtaining regulatory approval and commercializing additional product candidates for the treatment of retinal diseases will require substantial additional funding and is prone to the risks of failure inherent in drug development. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunity may be limited.

We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may retain their market share with existing drugs, or achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.

The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.

There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of the retinal disease indications for which we have product candidates, including wet AMD, DME/DR, and RVO. Certain of our competitors have commercially approved products for the treatment of retinal diseases that we are pursuing or may pursue in the future, including Roche, Regeneron and Novartis for the treatment of wet AMD, DME/DR, and RVO. These drugs are well established therapies and are widely accepted by physicians, patients and third-party payors, which may make it difficult to educate these parties on the benefits of switching to KSI-301. Companies that we are aware are developing therapeutics in the retinal disease area include large companies with significant financial resources, such as Roche, Novartis, Bayer and Regeneron, AbbVie/Allergan, Mylan, Momenta, and Samsung Bioepis. In addition to competition from other companies targeting retinal indications, any products we may develop may also face competition from other types of therapies, such as gene-editing therapies and drug delivery devices.

72


Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of retinal disease indications, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA, NMPA or other regulatory approval for their products more rapidly than we may obtain approval for ours. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.

In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors’ products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. For more information regarding potential disputes concerning intellectual property, see the subsection of this report titled “Risks Related to Our Intellectual Property.”

The manufacture of our product candidates is highly complex and requires substantial lead time to produce.

Manufacturing our product candidates involves complex processes, including developing cells or cell systems to produce the biologic, growing large quantities of such cells, and harvesting and purifying the biologic produced by them. These processes require specialized facilities, highly specific raw materials and other production constraints. As a result, the cost to manufacture a biologic is generally far higher than traditional small molecule chemical compounds, and the biologics manufacturing process is less reliable and is difficult to reproduce. Because of the complex nature of our products, we need to oversee the manufacture of multiple components that require a diverse knowledge base and specialized personnel.

Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our product candidates generally cannot be adequately characterized prior to manufacturing the final product. As a result, an assay of the finished product is not sufficient to ensure that the product will perform in the intended manner. Accordingly, we expect to employ multiple steps to attempt to control our manufacturing process to assure that the process works and the product or product candidate is made strictly and consistently in compliance with the process

Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, improper storage or transfer, inconsistency in yields and variability in product characteristics. Even minor deviations from normal manufacturing, distribution or storage processes could result in reduced production yields, product defects and other supply disruptions. Some of the raw materials required in our manufacturing process are derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt commercialization. Production of additional drug substance and drug product for any of our product candidates may require substantial lead time. For example, currently any new large-scale batches of KSI-301 would require at least 12 months to manufacture. In the event of significant product loss and materials shortages, we may be unable to produce adequate amounts of our product candidates or products for our operational needs.

Further, as product candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials.

These challenges are magnified by the international nature of our supply chain, which, for KSI-301, requires drug substance and drug product sourced from single source suppliers from China, Japan, the United Kingdom and Switzerland. For example, the effects of health epidemics, including the ongoing COVID-19 pandemic and the resulting shelter-in-place, travel or similar restrictions may impact the timing of clinical resupply facing and BLA facing manufacturing activities.

73


We have no experience manufacturing any of our product candidates at a commercial scale. If we or any of our third-party manufacturers encounter difficulties in production, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to establish a commercially viable cost structure.

In order to conduct clinical trials of our product candidates, or supply commercial products, if approved, we will need to manufacture them in small and large quantities. Our third-party manufacturer has made only a limited number of lots of KSI-301 to date and has not made any commercial lots. The manufacturing processes for KSI-301 have never been tested at commercial scale and the process validation requirement (the requirement to consistently produce the active pharmaceutical ingredient used in KSI-301 in commercial quantities and of specified quality on a repeated basis and document its ability to do so) has not yet been satisfied. Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our manufacturing partners are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of our product candidates may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. The same risks would apply to any internal manufacturing facilities, should we in the future decide to build internal manufacturing capacity.

In addition, the manufacturing process for any products that we may develop is subject to FDA, EMA, NMPA and foreign regulatory authority approval processes and continuous oversight. We will need to contract with manufacturers who can meet all applicable FDA, EMA, NMPA and foreign regulatory authority requirements, including complying with current good manufacturing practices, or cGMPs, on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA, EMA, NMPA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA, EMA, NMPA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects.  

If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.

We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.

There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.

Factors that may inhibit our efforts to commercialize any approved product on our own include:

 

our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs and other support personnel;

 

the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future approved products;

 

the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors;

 

the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability;

 

restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;

74


 

the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and

 

unforeseen costs and expenses associated with creating an independent commercialization organization.

If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved.

Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.

The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:

 

the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials and published in peer-reviewed journals;

 

the potential and perceived advantages compared to alternative treatments;

 

the ability to offer our products for sale at competitive prices;

 

the ability to offer appropriate patient access programs, such as co-pay assistance;

 

the extent to which physicians recommend our products to their patients;

 

convenience and ease of dosing and administration compared to alternative treatments;

 

the clinical indications for which the product candidate is approved by FDA, EMA, NMPA or other regulatory agencies;

 

product labeling or product insert requirements of the FDA, EMA, NMPA or other comparable foreign regulatory authorities, including any limitations, contraindications or warnings contained in a product’s approved labeling;

 

restrictions on how the product is distributed;

 

the timing of market introduction of competitive products;

 

publicity concerning our products or competing products and treatments;

 

the strength of marketing and distribution support;

 

sufficient third-party coverage or reimbursement; and

 

the prevalence and severity of any side effects.

If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable.

Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.

The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse

75


pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval.

Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid and Veterans Affairs, or VA, hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, that the level of reimbursement will be sufficient.

Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.

There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the medicine is approved by the FDA, EMA, NMPA or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition.

Our product candidates may face competition from biological products that are biosimilar to or interchangeable with our product candidates sooner than anticipated.

The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty.

We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

76


If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.

We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit testing and commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

 

decreased or interrupted demand for our products;

 

injury to our reputation;

 

withdrawal of clinical trial participants and inability to continue clinical trials;

 

initiation of investigations by regulators;

 

costs to defend the related litigation;

 

a diversion of management’s time and our resources;

 

substantial monetary awards to trial participants or patients;

 

product recalls, withdrawals or labeling, marketing or promotional restrictions;

 

loss of revenue;

 

exhaustion of any available insurance and our capital resources;

 

the inability to commercialize any product candidate; and

 

a decline in our share price.

Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.

Risks Related to Regulatory Approval and Other Legal Compliance Matters

The regulatory approval processes of the FDA, EMA, NMPA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.

The time required to obtain approval by the FDA, EMA, NMPA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. We have not submitted for or obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.

Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:

 

the FDA, EMA, NMPA or comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;

 

the FDA, EMA, NMPA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use of our products;

77


 

the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;

 

we may be unable to demonstrate to the FDA, EMA, NMPA or comparable foreign regulatory authorities that a product candidate’s risk-benefit ratio for its proposed indication, when compared to the standard of care, is acceptable;

 

the FDA, EMA, NMPA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

 

the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere;

 

the FDA, EMA, NMPA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and

 

the approval policies or regulations of the FDA, EMA, NMPA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects.

We plan to conduct clinical trials for our product candidates outside the United States, and the FDA, EMA, NMPA and applicable foreign regulatory authorities may not accept data from such trials.

We plan to conduct one or more of our clinical trials outside the United States, including Europe, China and other foreign countries. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA, NMPA or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (1) the data are applicable to the U.S. population and U.S. medical practice and (2) the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations. Additionally, the FDA’s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA, NMPA or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction, including any trials that we may conduct in China. If the FDA, EMA, NMPA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming, would delay aspects of our business plan and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA, EMA or NMPA grants marketing approval of a product candidate, we would not be permitted to manufacture, market or promote the product candidate in other countries unless and until comparable regulatory authorities in foreign jurisdictions had approved the candidate for use in their countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials. There can be no assurance that any clinical trials conducted in one jurisdiction will be accepted by regulatory authorities in other jurisdictions.

Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any collaborator we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

78


Even if we obtain regulatory approval for a product candidate, our products will remain subject to extensive regulatory scrutiny.

If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.

Manufacturers and manufacturers’ facilities are required to comply with extensive requirements imposed by the FDA, EMA, NMPA and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA or marketing authorization application, or MAA. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.

Any regulatory approvals that we receive for our product candidates will be subject to limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval (including the requirement to implement a REMS), or contain requirements for potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA, NMPA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved BLA or MAA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:

 

issue warning letters that would result in adverse publicity;

 

impose civil or criminal penalties;

 

suspend or withdraw regulatory approvals;

 

suspend any of our ongoing clinical trials;

 

refuse to approve pending applications or supplements to approved applications submitted by us;

 

impose restrictions on our operations, including closing our contract manufacturers’ facilities;

 

seize or detain products; or

 

require a product recall.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.

Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.

Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain international jurisdictions, there

79


have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government’s comparative effectiveness research.

Since the ACA’s enactment, there have been, and continue to be, numerous challenges to the ACA. Since January 2017, President Trump has signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA.  While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA’s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. Further, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. In addition, on December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, but it is unknown when a decision will be reached. Although the United States Supreme Court has yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the United States Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the ACA and our business.

In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2021. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

 

the demand for our product candidates, if we obtain regulatory approval;

 

our ability to receive or set a price that we believe is fair for our products;

 

our ability to generate revenue and achieve or maintain profitability;

 

the level of taxes that we are required to pay; and

 

the availability of capital.

80


Moreover, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies. At the federal level, the Trump administration’s budget proposal for fiscal 2021 included a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent “principles” for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. In addition, the Trump administration previously released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. On July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration’s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20, 2020, CMS issued an interim final rule implementing President Trump’s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our product candidates, if approved. Further, it is possible that additional governmental action is taken in response to the ongoing COVID-19 pandemic.

Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements or insider trading violations, which could significantly harm our business.

We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA, EMA, NMPA and other comparable foreign regulatory authorities; provide true, complete and accurate information to the FDA, EMA, NMPA and other comparable foreign regulatory authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. Employee misconduct could also involve the improper use of, including improper trading based upon, information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. 

81


In connection with our IPO, we adopted a code of business conduct and ethics that applies to all our employees, including management, and our directors. However, it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.

If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditions could be adversely affected.

Our current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as, sell, market and distribute any products for which we obtain marketing approval. The laws that may impact our operations include:

 

the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;

 

federal civil and criminal false claims laws, including the False Claims Act, which can be enforced by private citizens on behalf of the government through civil whistleblower or qui tam actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;

 

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;

 

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses and their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information as well as their covered subcontractors, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization;

 

the federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program to report annually to the Centers for Medicare & Medicaid Services under the Open Payments Program, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;

 

Beginning in 2022, applicable manufacturers also will be required to report such information related to payments or other transfers of value made to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year;

 

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.; and  

82


 

analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could, despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.

Our business is subject to complex and evolving U.S. and foreign laws and regulations relating to privacy and data protection. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business.

A wide variety of provincial, state, national, and foreign laws and regulations apply to the collection, use, retention, protection, disclosure and transfer of personal data. These data protection and privacy-related laws and regulations are evolving and may result in ever-increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions. For example, the European Union’s General Data Protection Regulation, or GDPR, which took effect on May 25, 2018, imposes stringent data protection requirements and provides for penalties for noncompliance that can include bans on processing personal data and fines of up to the greater of 20 million euros or four percent of worldwide annual revenues. The GDPR requires organizations to give detailed disclosures about how they collect, use and share personal information; in most cases, obtain explicit consent to process sensitive personal information, such as health or genetic information; contractually require vendors to meet data protection requirements; maintain adequate data security measures; notify regulators and affected individuals of certain data breaches; meet extensive privacy governance and documentation requirements; and honor individuals’ data protection rights, including their rights to access, correct and delete their personal information.

European data protection laws, including the GDPR, also restrict the transfer of personal information from Europe, including the European Economic Area, the United Kingdom and Switzerland, to the U.S. and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. One of the primary safeguards allowing U.S. companies to import personal information from Europe has been certification to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks administered by the U.S. Department of Commerce. However, the Court of Justice of the European Union adopted a decision in July 2020 invalidating the EU-U.S. Privacy Shield. The same decision also raised questions about whether one of the primary alternatives to the EU-U.S. Privacy Shield, namely, the European Commission’s Standard Contractual Clauses, can lawfully be used for personal information transfers from Europe to the U.S. or most other countries. Authorities in Switzerland also have issued guidance raising similar questions about the Swiss-U.S. Privacy Shield and the Standard Contractual Clauses. At present, there are few, if any, viable alternatives to the EU-U.S. Privacy Shield, the Swiss-U.S. Privacy Shield and the Standard Contractual Clauses. Although we and third party service providers rely primarily on individuals’ explicit consent to transfer certain information from Europe to the U.S. and other countries, in certain cases we and third parties we work with have relied on the EU-U.S. Privacy Shield and the Standard Contractual Clauses. If we are unable to rely on explicit consent to transfer individuals’ personal information from Europe, which can be revoked, or implement other valid compliance solutions, we may face increased exposure to fines under European data protection laws as well as bans on processing personal information from Europe. Inability to import personal information from Europe may also impact our operations in the European Economic Area and Switzerland and require us to incur significant costs to increase our data processing capabilities in Europe.

83


In addition, it is unclear whether the transfer of personal information from the EU to the United Kingdom will continue to remain lawful under the GDPR in light of Brexit. Pursuant to a post-Brexit trade deal between the United Kingdom and the EU, transfers of personal information from the European Economic Area to the United Kingdom are not considered restricted transfers under the GDPR for a period of up to six months from January 1, 2021. However, unless the EU Commission makes an adequacy finding with respect to the United Kingdom before the end of that period, the United Kingdom will be considered a “third country” under the GDPR and transfers of European personal information to the United Kingdom will require an approved compliance mechanism to render such transfers lawful under the GDPR. Although the United Kingdom’s primary data protection legislation is designed to be consistent with the GDPR, uncertainty remains regarding how data transfers to and from the United Kingdom will be regulated after Brexit. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.

Privacy laws in the U.S. are also increasingly complex and changing rapidly. For example, the California legislature enacted the California Consumer Privacy Act, or CCPA, which took effect on January 1, 2020. The CCPA requires covered companies to provide new disclosures to California residents, and honor their requests to access, delete and opt-out of certain sharing of their personal information. The CCPA provides for civil penalties for violations. Since the enactment of the CCPA, new privacy and data security laws have been proposed in more than half of the states and in the U.S. Congress, reflecting a trend toward more stringent privacy legislation in the U.S. The CCPA itself will expand substantially as a result of California voters approving a November 2020 ballot measure that adopted the California Privacy Rights Act of 2020, or CPRA, which will, among other things, create a new administrative agency to implement and enforce California’s privacy laws effective January 1, 2023. While certain clinical trial activities are exempt from the CCPA’s requirements, other personal information that we handle may be subject to the CCPA, which may increase our compliance costs, exposure to regulatory enforcement action and other liabilities.

The GDPR, CCPA and many other laws and regulations relating to privacy and data protection are still being tested in courts, and they are subject to new and differing interpretations by courts and regulatory officials. We are working to comply with the privacy and data protection laws and regulations that apply to us, and we anticipate needing to devote significant additional resources to complying with these laws and regulations. It is possible that the GDPR, CCPA or other laws and regulations relating to privacy and data protection may be interpreted and applied in a manner that is inconsistent from jurisdiction to jurisdiction or inconsistent with our current policies and practices.

Our actual or perceived failure to adequately comply with applicable laws and regulations relating to privacy and data protection, or to protect personal data and other data we process or maintain, could result in regulatory fines and bans on processing personal information, investigations and enforcement actions, penalties and other liabilities, claims for damages by affected individuals, and damage to our reputation, any of which could materially affect our business, financial condition, results of operations and growth prospects.

If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We and any contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.

Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

84


Our business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws.

Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate or may operate in the future, including the UK Bribery Act. The FCPA generally prohibits offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There can be no assurance that all of our employees, agents, contractors or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.

Risks Related to Our Reliance on Third Parties

We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.

We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct some aspects of our research, preclinical testing and clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities.

Our reliance on these third parties for research and development activities reduces our control over these activities, but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with cGCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and to post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines.  

We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.

We contract with third parties for the manufacture of materials for our product candidates and preclinical studies and clinical trials and for commercialization of any product candidates that we may develop. This reliance on third parties carries and may increase the risk that we will not have sufficient quantities of such materials, product candidates or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

We do not have any manufacturing facilities. We currently rely exclusively on a third-party manufacturer, Lonza AG, for the manufacture of our materials for preclinical studies and clinical trials and expect to continue to do so for preclinical studies, clinical trials and for commercial supply of any product candidates that we may develop.

85


We may be unable to establish any further agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

 

the possible breach of the manufacturing agreement by the third party or us;

 

the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;

 

the possible early termination of the agreement by us at a time that requires us to pay a cancellation fee;

 

reliance on the third party for regulatory compliance, quality assurance, safety and pharmacovigilance and related reporting; and

 

the inability to produce required volume in a timely manner and to quality standards.

Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in clinical holds on our trials, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations, and prospects.

Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.

Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply for any of our product candidates. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs.

Our current and anticipated future reliance upon others for the manufacture of any product candidates we may develop or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.  

Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Reliance on third parties to conduct clinical trials, assist in research and development and to manufacture our product candidates, will at times require us to share trade secrets with them. We seek to protect our proprietary technology by in part entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.

We rely on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business.

We rely on third-party suppliers for the raw materials required for the production of our product candidates. Our reliance on these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality and delivery schedules. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our competitors who are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.

86


We may depend on collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates.

We may seek third-party collaborators for the research, development and commercialization of certain of the product candidates we may develop. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies and academic institutions. If we enter into any such arrangements with any third parties, we will likely have shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators’ abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.

Collaborations involving our product candidates we may develop, pose the following risks to us:

 

collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations;

 

collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to our product candidates or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property;  

 

collaborators may own or co-own intellectual property covering our product candidates that result from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates;

 

disputes may arise with respect to the ownership of intellectual property developed pursuant to collaborations;

 

we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us;

 

collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;

 

disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;

 

collaborators may decide not to pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator’s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;

 

collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;

 

collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;

 

collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of such product candidates;

 

we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;

 

collaborators may undergo a change of control and the new owners may decide to take the collaboration in a direction which is not in our best interest;

87


 

collaborators may become party to a business combination transaction and the continued pursuit and emphasis on our development or commercialization program by the resulting entity under our existing collaboration could be delayed, diminished or terminated;

 

collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, know-how or intellectual property of the collaborator relating to our products, product candidates;

 

key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators;

 

collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders, or disrupt our management and business;

 

collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or our ABC Platform; and

 

collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. 

We may face significant competition in seeking appropriate collaborations. Recent business combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate or delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.

If we enter into collaborations to develop and potentially commercialize any product candidates, we may not be able to realize the benefit of such transactions if we or our collaborator elect not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator’s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Any collaborator may also be subject to many of the risks relating to product development, regulatory approval, and commercialization described in this “Risk Factors” section, and any negative impact on our collaborators may adversely affect us.

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain patent protection for any product candidates we develop or for our ABC Platform, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.

Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our ABC Platform and any proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by in-licensing intellectual property and filing patent applications in the United States and abroad relating to our ABC Platform, product candidates and other technologies that are important to our business. Given that the development of our technology and product candidates is at an early stage, our intellectual property portfolio directed to certain aspects of our technology and product candidates is also at an early stage. We have filed or intend to file patent applications on core aspects of our technology and product candidates; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in some cases, we only have filed provisional patent applications on certain aspects of our technology and product candidates, and none of these provisional patent applications is eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. Furthermore, in some cases, we may not be able to obtain issued claims covering compositions relating to our ABC Platform and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture for protection of such ABC Platform, product candidates and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third

88


parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our ABC Platform and product candidates could have a material adverse effect on our business, financial condition, results of operations, and prospects.  

If any of our patent applications does not issue as a patent in any jurisdiction, we may not be able to compete effectively.

Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, and obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.

The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. In addition, our own fixed applications may become prior art against our current or future patent applications. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, and in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.

If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our ABC Platform, product candidates or other technologies or that effectively prevent others from commercializing competitive technologies and product candidates.

Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents may be challenged, narrowed, circumvented, rendered unenforceable or invalidated by third parties. Consequently, we do not know whether our ABC Platform, product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review, or interference proceedings or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our ABC Platform, product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions and other challenges in a foreign patent office or administrative tribunal, that challenge our or our licensor’s priority of invention or other features of patentability with respect to our owned or in-licensed patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our ABC Platform, product candidates and other technologies. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.

89


In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

We may not be able to protect our intellectual property and proprietary rights throughout the world.

Filing, prosecuting and defending patents relating to our ABC Platform, product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as U.S. laws. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult, costly or impossible for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. Payment within these late fee windows may be employed in order to simplify the payment of these fees generally. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, while not relevant for KSI-301, if we rely on a different product, its development could involve the use of government funds, which can require additional compliance aspects to make certain all rights are transferred to or remain with us.

Issued patents may be challenged or invalidated, and recent changes in U.S. patent law have diminished and may further diminish the value of patents in general. We rely on patents to protect our products, and any diminishment in the scope or value of our patents would adversely affect our business.

If we initiated legal proceedings against a third party to enforce a patent directed to our ABC Platform, product candidates or other technologies, the defendant could allege that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including obviousness, lack of novelty, lack of written description, or non-enablement. Grounds for an unenforceability challenge include an allegation that someone connected with prosecution of the patent withheld material information from the USPTO with an intent to deceive the USPTO, or made a misleading statement, during prosecution. The filing of a legal proceeding could also result in the third party challenging the patent at the USPTO, such as in post-grant and inter partes review.

90


Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For patent filings beginning in March 2013, the United States employs a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. Under the current patent laws, a third party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (1) file any patent application related to our ABC Platform, product candidates or other technologies or (2) invent any of the inventions claimed in our or our licensor’s patents or patent applications.

Changes to U.S. patent laws since 2011 also include allowing third party submissions of prior art to the USPTO during patent prosecution and additional procedures for attacking the validity of a patent through USPTO administered post-grant proceedings, including re-examination, post-grant review, inter partes review, interference proceedings and derivation proceedings. Some of these changes apply to patents issued prior to 2011. These and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings) could result in the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our ABC Platform, product candidates or other technologies. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standards applied in United States federal courts that apply to actions seeking to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if challenged in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not otherwise have been invalidated if first challenged by the third party as a defendant in a district court action.

As compared to intellectual property-reliant companies generally, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. These rulings have created uncertainty with respect to the validity and enforceability of patents, even once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.

In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.

Any future changes to patent laws could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our ABC Platform, product candidates or other technologies. Increased uncertainty with respect to, or loss of, patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects.

If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.

Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our owned or in-licensed U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. Patent term extension in the United States and/or foreign countries and territories may not be available if, among other things, we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to the expiration of relevant patents, or otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of

91


patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension received is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor or owner or co-owner. For example, we may have inventorship disputes arise from conflicting obligations of employees, collaborators, consultants or others who are involved in developing our ABC Platform, product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our ABC Platform, product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for our ABC Platform, product candidates and other technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information and to maintain our competitive position. Trade secrets and know-how can be difficult to protect. Over time, we expect our trade secrets and know-how to be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel from academic to industry scientific positions.

We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, train our employees not to bring or use proprietary information or technology from former employers to us or in their work and remind former employees when they leave their employment of their confidentiality obligations to us. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to contain such breaches or disclosures or obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed without the protection of a confidentiality agreement found unenforceable by relevant courts or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.

We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.

Many of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have improperly used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.

In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached,

92


and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. Where post-filing date patent assignments are not executed by an inventor, it is our practice to employ and record the assignment provision that can be found in the employee’s employment agreement. This is done when possible, and when the intellectual property is of interest to us.

Third-party claims of intellectual property infringement, misappropriation or other violation against us or our collaborators may prevent or delay the development and commercialization of our ABC Platform, product candidates and other technologies.

The field of discovering treatments for retinal diseases is highly competitive and dynamic. Due to the focused research and development that is taking place in this field by several companies, including us and our competitors, the intellectual property landscape is in flux, and it may remain uncertain in the future. As such, there may be significant intellectual property related litigation and proceedings relating to our owned, and other third party, intellectual property and proprietary rights in the future.

Our commercial success depends in part on our and our collaborators’ ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. As discussed above, due to changes in U.S. law referred to as patent reform, new procedures including inter partes review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future.

Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist relating to ABC technology and in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our ABC Platform, product candidates and other technologies may give rise to claims of infringement of the patent rights of others. We cannot assure you that our ABC Platform, product candidates and other technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued or that a third party, including a competitor in the fields in which we are developing our ABC Platform, product candidates and other technologies, might assert are infringed by our current or future ABC Platform, product candidates or other technologies. Such a dispute may concern claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our ABC Platform, product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our ABC Platform, product candidates or other technologies, could be found to be infringed by our ABC Platform, product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that later result in issued patents that our ABC Platform, product candidates or other technologies may infringe.

Third parties may have patents or obtain patents in the future and claim that the manufacture, use or sale of our ABC Platform, product candidates or other technologies infringes these patents. If a third party alleges that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by our ABC Platform, product candidates or other technologies, even if we believe such claims are without merit. In that event, the successful plaintiff may be able to block our ability to commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or such patents expire or are finally determined to be invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees, royalties or both. Any license granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our ABC Platform, product candidates or other technologies, or our commercialization efforts may be significantly delayed, which could in turn significantly harm our business.

We are aware of a number of patents and applications that are directed to one or more aspects of KSI-301. Our intent is to maintain our development efforts under 35 U.S.C. Section 271(e)(1) (which provides a safe harbor from patent infringement claims related to certain drug development activities) through to at least the launch of any KSI-301 product. As such, we do not intend to launch KSI-301 when any valid patent is still in force. We are aware of at least one pending application with claims that are directed to some aspect of KSI-301, and that could, if issued, result in a patent term beyond our intended launch date of KSI-301. If this were to occur, we may challenge the validity of the claims, obtain a license, modify KSI-301, or delay launch.

93


If we choose to further the pipeline and develop a different product, such a product would be delayed until the expiration of any valid patent that is still in force on such product. Alternatively, our options for addressing any such patents relating to these non-KSI-301 products would include the following: challenge the validity of the claims, obtain a license, or modify the non-KSI-301 product.

Defending against infringement claims, regardless of their merit, would involve substantial litigation expense, would be a substantial diversion of management and other employee resources from our business and may adversely impact our reputation. We may be subject to an injunction that prevents or delays us from commercializing our ABC Platform technology, product candidates or other technologies during ongoing litigation even if we ultimately prevail in the litigation proceedings or the litigation is settled in our favor. We may be subject to an injunction that prevents or delays us from commercializing our ABC Platform, product candidates or other technologies during ongoing litigation even if we ultimately prevail in the litigation proceedings or the litigation is settled in our favor. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing our infringing ABC Platform, product candidates or other technologies. In addition, we may have to pay substantial damages (including treble damages and attorneys’ fees for willful infringement) obtain one or more licenses from third parties, pay royalties and/or redesign our infringing product candidates or technologies, which may be impossible or require substantial time and monetary expenditure. If we were unable to further develop and commercialize our ABC Platform, product candidates or other technologies, it would harm our business significantly.

Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.

We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. If we assert our intellectual property against others, it could increase the likelihood that our patents or the patents of our licensing partners become involved in inventorship, priority or validity disputes. As discussed above, countering or defending against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent owned or in-licensed by us is invalid or unenforceable, the other party’s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. §271(e)(1), or may refuse to stop the other party from using the technology at issue on the grounds that our owned and in-licensed patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated, rendered unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Even if we prevail in asserting our intellectual property, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately or to assert all claims we believe to be viable. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

We rely on trademarks, service marks, tradenames and brand names. We cannot assure you that our trademark applications will be approved. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, any registered or unregistered trademarks or trade names that we currently have or may in the future acquire may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our

94


markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. We own a registered trademark for the mark “KODIAK” and “KODIAK SCIENCES” in the United States. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We engage a third party watching service to monitor use by third parties of names that are identical or similar to our name. We have identified at least two companies that are using names that we continue to monitor. We have sent cease and desist letters to two companies and filed a trademark opposition proceeding against one company. If we deem it appropriate, we may decide to take further action with respect to those companies. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

 

others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we may license or own;

 

we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or own now or in the future;  

 

we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;

 

others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;

 

it is possible that our current or future pending owned or licensed patent applications will not lead to issued patents;

 

issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;

 

our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

 

we may not develop additional proprietary technologies that are patentable;

 

the patents of others may harm our business; and

 

we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.

Risks Related to Our Operations

We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.

Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, particularly our Chief Executive Officer, Dr. Victor Perlroth, and our scientific and medical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business.

We conduct our U.S. operations at our facilities in Palo Alto, California, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and

95


the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region and doing so may be costly and difficult.

To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided restricted stock and stock option grants, including early exercise stock options exercisable for restricted stock that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain “key man” insurance policies on the lives of all of these individuals or the lives of any of our other employees. If we are unable to attract, incentivize and retain quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer.

We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.

As of February 19, 2021, we had 72 employees, all of whom were full-time. As our development plans and strategies develop, and as we continue operating as a public company, we must add a significant number of additional managerial, operational, financial and other personnel. Future growth will impose significant added responsibilities on members of management, including:

 

identifying, recruiting, integrating, retaining and motivating additional employees;

 

managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to contractors and other third parties;

 

expanding our operational, financial and management controls, reporting systems and procedures; and

 

managing increasing operational and managerial complexity.

Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities.

We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all.

If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development, and commercialization goals.

If we engage in acquisitions, in-licensing or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.

We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including:

 

increased operating expenses and cash requirements;

 

the assumption of indebtedness or contingent liabilities;

 

the issuance of our equity securities which would result in dilution to our stockholders;

 

assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel;

 

the diversion of our management’s attention from our existing product candidates and initiatives in pursuing such an acquisition or strategic partnership;

96


 

retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;

 

risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and

 

our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs.

In addition, if we undertake such a transaction, we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.

Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer a cybersecurity incident that could harm our business.

In the course of our business, we collect, store and transmit proprietary, confidential and sensitive information, including personal information. The information and data processed and stored in our technology systems, and those of our research collaborators, CROs, contractors, consultants, and other third parties on which we depend to operate our business, may be vulnerable to security breaches, loss, damage, corruption, unauthorized access, use or disclosure, or misappropriation. Such incidents may also result from errors or malfeasance by our personnel or the personnel of the third parties with which we work, malware, viruses, software vulnerabilities, hacking, denial of service attacks, social engineering (including phishing), ransomware, credential stuffing or other cyberattacks, including attacks by state-sponsored organizations or sophisticated groups of hackers.

While we have developed systems and processes designed to protect the integrity, confidentiality and security of the confidential and personal information under our control, we cannot assure you that our security measures or those of the third parties we depend on will be effective in preventing cybersecurity incidents. There are many different and rapidly evolving cybercrime and hacking techniques, and we may be unable to anticipate attempted security breaches, identify them before our information is exploited, or react in a timely manner.

Additionally, as a result of the ongoing COVID-19 pandemic, certain functional areas of our workforce remain in a remote work environment and outside of our corporate network security protection boundaries, which imposes additional risks to our business, including increased risk of industrial espionage, phishing and other cybersecurity attacks, and unauthorized dissemination of proprietary or confidential information, any of which could have a material adverse effect on our business.

Although to our knowledge, we have not experienced a material system failure or cybersecurity incident to date, if such an event were to occur, it could result in a material disruption of our development programs and our business operations, whether due to a loss of trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third-party research institution collaborators, CROs, other contractors and consultants for many aspects of our business, including research and development activities and manufacturing of our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business.

Cybersecurity incidents and any unauthorized access or disclosure of our information or intellectual property could also compromise our intellectual property, expose sensitive business information, expose the personal information of our employees, require us to incur significant remediation costs, disrupt key business operations and divert attention of management and key information technology resources. Such incidents could also subject us to significant liability, harm our competitive position and delay the further development and commercialization of our product candidates.

We cannot be certain that our insurance coverage will be adequate for cybersecurity liabilities, will continue to be available to us on economically reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. The successful assertion of one or more large claims against us that exceed available insurance coverage, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could adversely affect our reputation, business, financial condition and results of operations.

 

97


Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.

Our operations, and those of our CROs, CMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. For example, in connection to the ongoing COVID-19 pandemic, the various quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could adversely affect our business, financial condition or results of operations by limiting our ability to manufacture product, forcing temporary closure of facilities that we rely upon or increasing the costs associated with obtaining clinical supplies of our product candidates. The extent to which the ongoing COVID-19 pandemic impacts our results will depend on future developments, which are highly uncertain and cannot be accurately predicted, including new information which may emerge concerning the severity of the COVID-19 pandemic and the actions to contain the coronavirus or treat its impact, among others.

Our operations are located at facilities in Palo Alto, California and Switzerland. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may be seriously harmed by such delays and interruption.

We recently implemented a new enterprise resource planning, or ERP, system as well as other systems as part of our ongoing technology and process improvements. Our ERP system is critical to our ability to accurately maintain books and records and prepare our financial statements. If we encounter unforeseen problems with our ERP system or other systems and infrastructure, our business, operations, and financial results could be adversely affected.

Our business is subject to economic, political, regulatory and other risks associated with international operations.

Our business is subject to risks associated with conducting business internationally. Some of our suppliers and collaborative relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:

 

economic weakness, including inflation or political instability in particular non-U.S. economies and markets;

 

differing and changing regulatory requirements, pricing and reimbursement regimes in non-U.S. countries;

 

challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;

 

difficulties in compliance with non-U.S. laws and regulations;

 

changes in non-U.S. regulations and customs, tariffs and trade barriers;

 

changes in non-U.S. currency exchange rates and currency controls;

 

changes in a specific country’s or region’s political or economic environment;

 

trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;

 

negative consequences from changes in tax laws;

 

compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;

 

workforce uncertainty in countries where labor unrest is more common than in the United States;

 

difficulties associated with staffing and managing international operations, including differing labor relations;

 

potential liability under the FCPA or comparable foreign laws; and

 

business interruptions resulting from geo-political actions, including war and terrorism or natural disasters.

Following the result of a referendum in 2016, the United Kingdom, or UK, left the European Union, or EU, on January 31, 2020, commonly referred to as Brexit.  Pursuant to the formal withdrawal arrangements agreed between the UK and the

98


EU, the UK was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply.  A trade and cooperation agreement, or the Trade and Cooperation Agreement, that outlines the future trading relationship between the United Kingdom and the European Union was agreed in December 2020.

Since a significant proportion of the regulatory framework in the UK, is derived from EU directives and regulations, Brexit may have a material impact upon the regulatory regime applicable to our operations, including with respect to our ability to obtain regulatory approvals of our product candidates in the EU. For example, Great Britain is no longer covered by the centralized procedures for obtaining EU-wide marketing authorization from the European Medicines Agency, or EMA, and a separate marketing authorization will be required to market our product candidates in Great Britain.  It is currently unclear whether the Medicines & Healthcare products Regulatory Agency, or MHRA, in the UK is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any marketing approvals, would delay or prevent us from commercializing our product candidates in the UK or the EU and restrict our ability to generate revenue and achieve and sustain profitability.

While the Trade and Cooperation Agreement provides for the tariff-free trade of medicinal products between the UK and the EU there may be additional non-tariff costs to such trade which did not exist prior to the end of the Transition Period.  Further, should the UK diverge from the EU from a regulatory perspective in relation to medicinal products, tariffs could be put into place in the future.  We could therefore, both now and in the future, face significant additional expenses (when compared to the position prior to the end of the Transition Period) to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the UK It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.

These and other risks associated with our planned international operations may materially adversely affect our ability to attain profitable operations.

Our business is currently affected and could be materially and adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics, including the ongoing effects of the COVID-19 pandemic. The COVID-19 pandemic continues to impact our business and could materially and adversely affect our operations, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.

Our business could be materially and adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business operations and could cause significant disruption in the operations of third party manufacturers and CROs upon whom we rely. For example, in March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. In response, we delayed initiation of the next set of KSI-301 pivotal studies by one quarter from June to September 2020 in order to assess how best to minimize the impact of COVID-19 on clinical trial conduct. We implemented and continue to implement various enhancements into our ongoing study execution to help ensure the safety of patients, physicians, study site staff and Kodiak operations team members during the ongoing COVID-19 pandemic, including the use of remote study monitoring. To date, we have observed minimal disruption resulting from the evolving effects of the COVID-19 pandemic, and we and our key clinical and manufacturing partners have been able to continue to advance our operations. during the pandemic towards achieving our “2022 Vision.”

The COVID-19 pandemic continues to unfold and we will continue to monitor our operations in response. We continue to observe government recommendations and may elect to temporarily close our office and/or laboratory space to protect our employees. Quarantines for COVID-19 or other viruses could impact personnel at third party manufacturing facilities, or the availability or cost of materials, which would disrupt our supply chain. While many of these materials may be obtained by more than one supplier, port closures and other restrictions resulting from the coronavirus outbreak in the region may disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products.

In addition, our current and future clinical trials may be materially and adversely affected by the COVID-19 outbreak in the future. Site initiation and patient enrollment may be further delayed due to prioritization of hospital resources toward the COVID-19 outbreak. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may and adversely impact our clinical trial operations. Kodiak staff and/or our CRO partners may not be able to travel to study sites, impacting further site initiations and in-person monitoring of study data quality. Other Kodiak vendors on whom we depend, such as supply chain and logistics partners and our image reading centers may be disrupted, and our operations could be affected. Our clinical studies enroll patients who have underlying risk factors such as advanced age, hypertension and/or diabetes which could lead to higher than expected study discontinuation rates and/or missed visit rates if these patients are adversely affected by the COVID-19

99


outbreak. To date, we are seeing low levels of patient missed visits (<5%). Additionally, the pandemic could result in delayed recruitment in some or all of our clinical studies that are currently recruiting patients, for example if as a consequence of the pandemic patients are not willing to be seen by their physician as frequently as our study protocols require.

The global outbreak of COVID-19 continues to rapidly evolve. The ultimate impact of the COVID-19 outbreak or a similar health epidemic is highly uncertain and subject to change.

The extent to which the risks and evolving effects of the COVID-19 pandemic impact our business and our clinical development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate duration and severity of the pandemic, government actions, such as travel restrictions, quarantines and social distancing requirements in the U.S. and in other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and in other countries to contain and treat the disease, including the effectiveness and timing of vaccine programs in the U.S. and worldwide. The COVID-19 pandemic may also have the effect of heightening many of the other risks described in this “Risk Factors” section.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

As of December 31, 2020, the Company had $50.1 million of federal and $171.0 million of state net operating loss, or NOLs, that may be available to offset future taxable income. A portion of the federal NOL carryforwards begin to expire in 2035 and the state NOL carryforwards begin to expire in 2035, if not utilized. Under Sections 382 and 383 of the United States Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an “ownership change” (generally defined as a greater than 50-percentage-point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our pre-change net operating loss carryforwards and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.

The Tax Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) enacted in March 2020, among other things, includes changes to U.S. federal tax rates and the rules governing NOL carryforwards. Federal NOLs arising in tax years beginning after December 31, 2017 are permitted to be carried forward indefinitely, but carryback of such NOLs is generally permitted to the prior five taxable years only for NOLs arising in taxable years beginning before 2021. In addition, under the Tax Act, as modified by the CARES Act, the deductibility of federal NOLs incurred in taxable years beginning after December 31, 2017 is limited in taxable years beginning after December 31, 2020. For state income tax purposes, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California recently imposed limits on the usability of California state net operating losses to offset taxable income in tax years beginning after 2019 and before 2023. The new limitations on use of NOLs may significantly impact our ability to utilize our NOLs to offset taxable income in the future.

Risks Related to Our Business, Financial Condition and Capital Requirements

We are in the clinical stage of drug development and have a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.

We are a clinical stage biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We commenced operations in June 2009, have no products approved for commercial sale and have not generated any revenue. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. Except for KSI-301, we have not initiated clinical trials for any of our other product candidates. To date, we have not completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product, or conducted sales and marketing activities necessary for successful product commercialization. Our limited operating history as a company and early stage of drug development make any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer.

100


We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur significant and increasing net losses for the foreseeable future.

We have incurred net losses in each reporting period since our inception, including net losses of $133.1 million, $47.4 million and $41.4 million for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, we had an accumulated deficit of $291.2 million.

We have invested significant financial resources in research and development activities, including for our product candidates and our ABC Platform. We do not expect to generate revenue from product sales for several years, if at all. The amount of our future net losses will depend, in part, on the level of our future expenditures and our ability to generate revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.

We expect to continue to incur significant and increasingly higher expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:

 

progress our current and any future product candidates through preclinical and clinical development;

 

work with our contract manufacturers to scale up the manufacturing processes for our product candidates or, in the future, establish and operate a manufacturing facility;

 

continue our research and discovery activities;

 

continue the development of our ABC Platform;

 

initiate and conduct additional preclinical, clinical or other studies for our current and any future product candidates;  

 

change or add additional contract manufacturers or suppliers;

 

seek regulatory approvals and marketing authorizations for our product candidates, including KSI-301;

 

establish sales, marketing and distribution infrastructure to commercialize any products for which we obtain approval;

 

acquire or in-license product candidates, intellectual property and technologies;

 

make milestone, royalty or other payments due under any current or future collaboration or license agreements;

 

obtain, maintain, expand, protect and enforce our intellectual property portfolio;

 

attract, hire and retain qualified personnel;

 

experience any delays or encounter other issues related to our operations;

 

meet the requirements and demands of being a public company; and

 

defend against any product liability claims or other lawsuits related to our products.

Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders’ equity and working capital. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.

Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We have never generated any revenue from product sales, and we may never generate revenue or be profitable.

We have no products approved for commercial sale and have not generated any revenue from product sales. We do not anticipate generating any revenue from product sales until after we have successfully completed clinical development and received regulatory approval for the commercial sale of a product candidate, if ever.

Our ability to generate revenue and achieve profitability depends significantly on many factors, including:

 

successfully completing research and preclinical and clinical development of our product candidates;

 

obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development and clinical trials;

 

developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and any commercial demand for our product candidates;

101


 

identifying, assessing, acquiring and/or developing new product candidates;

 

negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;

 

launching and successfully commercializing product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure;  

 

obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign countries where our products are commercialized;

 

obtaining adequate reimbursement for our product candidates from payors;

 

obtaining market acceptance of our product candidates as viable treatment options;

 

addressing any competing technological and market developments;

 

maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including patents, trade secrets and know-how; and

 

attracting, hiring and retaining qualified personnel.

Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA or foreign regulatory agencies, to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators’ clinical trials or the development of any of our product candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate and ongoing compliance efforts.

Even if we are able to generate revenue from the sale of any approved products, we may not become profitable, and we will need to obtain additional funding through one or more debt or equity financings in order to continue operations. Revenue from the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the commercial rights for that territory. If the number of addressable patients is not as significant as we anticipate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.

Our failure to become and remain profitable could decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations and cause a decline in the value of our common stock, all or any of which may adversely affect our viability.

If we fail to obtain additional financing, we may be unable to complete the development and, if approved, commercialization of our product candidates.

Our operations have required substantial amounts of cash since inception. To date, we have funded our operations primarily through the sale of equity securities. Developing our product candidates is expensive, and we expect to continue to increase our spending as we conduct the Phase 3 clinical trials for our KSI-301 product candidate. Even if we are successful in developing our product candidates, obtaining regulatory approvals and launching and commercializing any product candidate will require substantial additional funding.

As of December 31, 2020, we had cash, cash equivalents and marketable securities of $969.0 million. Our estimate as to how long we expect our existing cash, cash equivalents and marketable securities to be available to fund our operations is based on assumptions that may prove inaccurate, and we could deplete our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate.

We will require additional capital for the further development and, if approved, commercialization of our product candidates. Additional capital may not be available when we need it, on terms acceptable to us or at all. For example, the ongoing COVID-19 pandemic has significantly disrupted world financial markets, negatively impacted US market conditions, increased the volatility of trading prices for biopharmaceutical companies, and may reduce opportunities for us to seek out additional funding when needed. We currently have no committed source of additional capital. If adequate capital is not

102


available to us on a timely basis, we may be required to significantly delay, scale back or discontinue our research and development programs or the commercialization of any product candidates, if approved, or be unable to continue or expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations and cause the price of our common stock to decline.

Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on product candidates that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Due to the significant resources required for the development of our product candidates, we must decide which product candidates and indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain product candidates may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our product candidates or misread trends in the biopharmaceutical industry, in particular for retinal diseases, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights.

 

Risks Related to Ownership of Our Common Stock

The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares.

The market price of our common stock may be volatile. As a result, you may not be able to sell your common stock at or above the price that you paid for such shares. Some of the factors that may cause the market price of our common stock to fluctuate include:

 

the success of existing or new competitive products or technologies;

 

the timing and results of clinical trials for our current product candidates and any future product candidates that we may develop;

 

commencement or termination of collaborations for our product candidates;  

 

failure or discontinuation of any of our product candidates;

 

failure to develop our ABC Platform;

 

results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;

 

regulatory or legal developments in the United States and other countries;

 

developments or disputes concerning patent applications, issued patents or other proprietary rights;

 

the recruitment or departure of key personnel;

 

the commencement of litigation;

 

the level of expenses related to any of our research programs, product candidates that we may develop;

 

the results of our efforts to develop additional product candidates or products;

 

actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

 

announcement or expectation of additional financing efforts;

 

sales of our common stock by us, our insiders, or other stockholders;

 

expiration of market standoff or lock-up agreements;

103


 

variations in our financial results or those of companies that are perceived to be similar to us;

 

changes in estimates or recommendations by securities analysts, if any, that cover our stock;

 

changes in the structure of healthcare payment systems;

 

market conditions in the pharmaceutical and biotechnology sectors;

 

general economic, industry, and market conditions, including fluctuations attributable to the ongoing COVID-19 pandemic and other unforeseeable circumstances; and

 

the other factors described in this “Risk Factors” section.

In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company’s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management’s attention and resources from our business.

Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

We will seek additional capital through one or a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional capital through the sale of equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.

Our principal stockholders own a significant percentage of our common stock, which could limit your ability to affect the outcome of key transactions, including a change of control.

Our directors, executive officers, significant holders of outstanding common stock and their respective affiliates beneficially own a significant amount of our common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock.

Delaware law and provisions in our certificate of incorporation and bylaws might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.

Provisions in our certificate of incorporation and bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our charter documents:

 

provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;

 

eliminate cumulative voting in the election of directors;

 

authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval;

 

provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship;

104


 

permit stockholders to only take actions at a duly called annual or special meeting and not by written consent;

 

prohibit stockholders from calling a special meeting of stockholders;

 

require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;

 

authorize our board of directors, by a majority vote, to amend the bylaws; and

 

require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above.

In addition, Section 203 of the General Corporation Law of the State of Delaware, or DGCL, prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.

Any provision of our certificate of incorporation, bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.

Our bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

Our bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for:

 

any derivative action or proceeding brought on our behalf;

 

any action asserting a claim of breach of fiduciary duty;

 

any action asserting a claim against us arising under the DGCL, our certificate of incorporation, or our bylaws; and

 

any action asserting a claim against us that is governed by the internal-affairs doctrine.

Our bylaws further provide that the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.  

These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either exclusive-forum provision in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. Our bylaws further provide that unless we otherwise consent in writing, the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. 

General Risk Factors

If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.

The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.  

105


Future sales of our common stock in the public market could cause our share price to decline, even if our business is doing well.

Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales, particularly sales by our directors, executive officers and significant stockholders, may have on the prevailing market price of our common stock. All of our outstanding shares of common stock are available for sale in the public market, subject only to the restrictions of Rule 144 under the Securities Act in the case of our affiliates. In addition, the shares of common stock subject to outstanding options under our equity incentive plans and the shares reserved for future issuance under our equity incentive plans, as well as shares issuable upon vesting of restricted stock unit awards, will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. In addition, certain holders of our common stock have the right, subject to various conditions and limitations, to request we include their shares of our common stock in registration statements we may file relating to our securities.  If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.

A failure to maintain an effective system of internal control over financial reporting could result in material misstatements of our financial statements in future periods and may impair our ability to comply with the accounting and reporting requirements applicable to public companies. Furthermore, our business, financial position, and results of operations could be adversely affected.

As a public company, we are subject to reporting and other obligations under the Exchange Act, including the requirements of SOX Section 404, which require annual management assessments of the effectiveness of our internal control over financial reporting.

The rules governing the standards that must be met for management to determine that our internal control over financial reporting is effective are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by SOX. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim consolidated financial statements will not be prevented or detected on a timely basis. Any failure to maintain effective internal controls could also have an adverse effect on our business, financial position and results of operations.

 

106


ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

Our corporate offices are located in Palo Alto, California, where we lease approximately 155,000 square feet of office, research and development, engineering and laboratory space pursuant to lease agreements commending in June 2020. The initial lease term for 1200 Page Mill Road is 6.5 years and 13 years for 1250 Page Mill Road.

We continue to lease office and laboratory space at 2631 Hanover Street in Palo Alto, California, which commenced in January 2013. In March 2016, we executed a third lease amendment agreement that became effective March 31, 2016 and extended the lease term until October 31, 2023. The facilities in Palo Alto, California houses substantially all of our personnel.

In April 2020, we entered into a lease agreement for office and laboratory space at Rottenstrasse 5 in Visp, Switzerland. The space is approximately 1,000 square meters. The initial lease term is 5 years, with automatic renewals every 5 years for a maximum lease term of 15 years.

We are not a party to any material legal proceedings at this time. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

ITEM 4. MINE SAFETY DISCLOSURES

None.

107


PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our common stock trades on the Nasdaq Global Market under the trading symbol “KOD”.

 

Holders of Common Stock

As of February 19, 2021, there were approximately 29 holders of record of our common stock. The approximate number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in “street name” or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.

Dividend Policy

We have never declared or paid any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future.

Recent Sales of Unregistered Securities

None.

Purchases of Equity Securities by the Issuer and Affiliated Purchases

None.

108


ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA

You should read the selected historical financial data below in conjunction with the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. The selected financial data set forth below is derived from our audited consolidated financial statements and may not be indicative of future operating results.

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

 

2017

 

 

2016

 

 

 

(in thousands, except share and per share data)

 

Consolidated Statements of Operations Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

107,389

 

 

$

37,506

 

 

$

18,793

 

 

$

22,022

 

 

$

14,053

 

General and administrative

 

 

28,618

 

 

 

11,684

 

 

 

7,581

 

 

 

3,499

 

 

 

3,098

 

Total operating expenses

 

 

136,007

 

 

 

49,190

 

 

 

26,374

 

 

 

25,521

 

 

 

17,151

 

Loss from operations

 

 

(136,007

)

 

 

(49,190

)

 

 

(26,374

)

 

 

(25,521

)

 

 

(17,151

)

Interest income

 

 

2,902

 

 

 

1,568

 

 

 

617

 

 

 

 

 

 

 

Interest expense

 

 

(25

)

 

 

(8

)

 

 

(5,519

)

 

 

(1,185

)

 

 

(6

)

Other income (expense), net

 

 

34

 

 

 

265

 

 

 

(4,688

)

 

 

(1,230

)

 

 

25

 

Loss on extinguishment of debt

 

 

 

 

 

 

 

 

(5,479

)

 

 

 

 

 

 

Net loss

 

$

(133,096

)

 

$

(47,365

)

 

$

(41,443

)

 

$

(27,936

)

 

$

(17,132

)

Net loss per share attributable to common stockholders,

   basic and diluted

 

$

(2.91

)

 

$

(1.25

)

 

$

(2.77

)

 

$

(3.72

)

 

$

(2.38

)

Weighted-average shares outstanding used in

   computing net loss per share attributable to

   common stockholders, basic and diluted

 

 

45,741,845

 

 

 

37,853,616

 

 

 

14,976,515

 

 

 

7,515,336

 

 

 

7,211,360

 

 

 

 

As of December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

 

2017

 

 

2016

 

 

 

(in thousands)

 

Consolidated Balance Sheet Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash, cash equivalents and marketable securities

 

$

968,974

 

 

$

348,177

 

 

$

88,254

 

 

$

1,395

 

 

$

9,622

 

Working capital

 

 

940,583

 

 

 

327,519

 

 

 

85,623

 

 

 

(7,563

)

 

 

7,682

 

Total assets

 

 

1,067,347

 

 

 

358,866

 

 

 

92,189

 

 

 

3,244

 

 

 

12,114

 

Total liabilities

 

 

206,596

 

 

 

13,507

 

 

 

5,356

 

 

 

21,965

 

 

 

3,180

 

Accumulated deficit

 

 

(291,227

)

 

 

(158,131

)

 

 

(110,766

)

 

 

(69,323

)

 

 

(41,387

)

Total stockholders’ equity (deficit)

 

 

860,751

 

 

 

345,359

 

 

 

86,833

 

 

 

(68,738

)

 

 

(41,083

)

 

109


ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with the section titled “Selected Consolidated Financial Data” and our consolidated financial statements and the related notes included elsewhere in this report. This discussion and analysis and other parts of this report contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the section titled “Risk Factors” and elsewhere in this report.

Overview

Kodiak Sciences (we or the Company) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases in the United States and additional international markets. We are bringing new science to the design and development of next generation retinal medicines. Our ABC PlatformTM uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak’s discovery engine. Our lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate generating compelling data in treatment naïve patients with retinal vascular diseases. Our pivotal program is exploring KSI-301 in wAMD, DME, RVO and non-proliferative diabetic retinopathy. Our hope with KSI-301 is to meaningfully change the treatment paradigm for all patients with retinal vascular diseases. Our pipeline, including product candidates KSI-501 and KSI-601, aims to bring a similar ethos of drug development to other unmet needs in retina such as dry AMD and glaucoma.

Our goal is to prevent and treat the major causes of blindness by developing next-generation therapeutics for chronic, high-prevalence retinal diseases. Our overall objective is to develop our product candidates, seek FDA and worldwide health authority marketing authorization approvals, and ultimately commercialize our product candidates.

Product Candidates

KSI-301

Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients. We continue to observe promising safety, efficacy and clinical durability data through 52-weeks in our ongoing Phase 1b study of KSI-301 in treatment-naïve patients with wet AMD, DME or RVO. Based on the encouraging data from our Phase 1b study, we have expanded the KSI-301 clinical pivotal program in the third quarter of 2020, and we have entered into the manufacturing-related commitments necessary for KSI-301’s commercial scale-up and BLA submission. We successfully recruited patients into both of our paired pivotal studies in DME (GLEAM and GLIMMER) and into our pivotal study in RVO (BEACON) in the third quarter of 2020. The pivotal study for wet AMD (DAZZLE) began recruiting in the third quarter of 2019 and completed patient enrollment in the fourth quarter of 2020. Approximately 2,000 KSI-301 injections have been administered to approximately 500 patients, representing approximately 350 patient-years of exposure. We believe the intersection of these clinical and manufacturing activities remain on track per our “2022 Vision” to submit a single BLA for wet AMD, DME and RVO in calendar year 2022.

We believe that KSI-301, if approved, has the potential to be an important therapy to treat patients with wet age-related macular degeneration, or wet AMD, diabetic retinopathy, or DR, including diabetic macular edema, or DME, and macular edema due to retinal vein occlusion, or RVO.

Our Pre-Clinical Pipeline

Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. The ABC Platform and KSI-301 were developed at Kodiak, and we own worldwide rights to these assets.

Further details of our ongoing KSI-301 Phase 1b trial, our accelerating development strategy, our manufacturing-related commitments, and our pipeline of retinal medicines based on the ABC Platform are described in the “Business” section above.

110


Financial Operations Overview

Since inception in June 2009, we have devoted substantially all of our resources to discovering and developing product candidates and manufacturing processes, building our ABC Platform and assembling our core capabilities in drug development for ophthalmic disease. We plan to continue to use third-party contract research organizations, or CROs, to carry out our preclinical and clinical development. We rely on third-party contract manufacturing organizations, or CMOs, to manufacture and supply our preclinical and clinical materials to be used during the development of our product candidates. We are evaluating investments in commercial manufacturing capacity. We do not have any products approved for sale and have not generated any product revenue since inception.

We have funded our operations primarily through the sale and issuance of equity securities. In October 2018, we completed our initial public offering, or IPO. In December 2019, we completed a follow-on offering. In November 2020, we completed a second follow-on offering.

We have incurred significant operating losses to date and expect that our operating losses will increase significantly as we advance our product candidates, particularly KSI-301, through preclinical and clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization; broaden and improve our platform; acquire, discover, validate and develop additional product candidates; obtain, maintain, protect and enforce our intellectual property portfolio; and hire additional personnel. In addition, we expect to incur additional costs associated with operating as a public company. Our net loss was $133.1 million, $47.4 million and $41.4 million for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, we had an accumulated deficit of $291.2 million.

Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candidates. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of KSI-301 for wet AMD, RVO, DME or NPDR or delay our efforts to advance and expand our product pipeline.

In November 2020, we filed an automatic shelf registration statement (File No. 333-250109), which became effective upon filing. The shelf registration statement allows us to issue certain securities, including shares of our common stock, from time to time. In November 2020, we completed a follow-on offering pursuant to the automatic shelf registration and issued and sold 5,972,222 shares of the Company’s common stock, including the underwriters’ full exercise of their over-allotment option, at a price to the public of $108.00 per share under our shelf registration statement. The gross proceeds from this offering were $645.0 million, resulting in aggregate net proceeds of $612.0 million after deducting underwriting discounts and commissions and other offering costs.

As of December 31, 2020, we had cash, cash equivalents and marketable securities of $969.0 million.

Components of Operating Results

Operating Expenses

Research and Development Expenses

Substantially all of our research and development expenses consist of expenses incurred in connection with the development of our ABC Platform and product candidates. These expenses include certain payroll and personnel expenses, including stock-based compensation, for our research and product development employees; laboratory supplies and facility costs; consulting costs; contract manufacturing and fees paid to CROs to conduct certain research and development activities on our behalf; and allocated overhead, including rent, equipment, depreciation and utilities. We expense both internal and external research and development expenses as they are incurred. Costs of certain activities, such as manufacturing and preclinical and clinical studies, are generally recognized based on an evaluation of the progress to completion of specific tasks. Nonrefundable payments made prior to the receipt of goods or services that will be used or rendered for future research and development activities are deferred and capitalized. The capitalized amounts are recognized as expense as the goods are delivered or the related services are performed.

111


We are focusing substantially all of our resources and development efforts on the development of our product candidates, in particular KSI-301. We expect our research and development expenses to increase substantially during the next few years as we conduct our Phase 3 clinical studies, complete our clinical program, pursue regulatory approval of our drug candidates and prepare for a possible commercial launch. Predicting the timing or the final cost to complete our clinical program or validation of our commercial manufacturing and supply processes is difficult and delays may occur because of many factors, including factors outside of our control. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict when or if our drug candidates will receive regulatory approval with any certainty.

General and Administrative Expenses

General and administrative expenses consist principally of payroll and personnel expenses, including stock-based compensation; professional fees for legal, consulting, accounting and tax services; allocated overhead, including rent, equipment, depreciation and utilities; and other general operating expenses not otherwise classified as research and development expenses.

We anticipate that our general and administrative expenses will increase as a result of increased personnel costs, including stock-based compensation, expanded infrastructure and higher consulting, legal and accounting services associated with maintaining compliance with requirements of the stock exchange listing and Securities and Exchange Commission, or SEC, investor relations costs and director and officer insurance premiums associated with being a public company.

Interest Income

Interest income consists primarily of interest income earned on our cash, cash equivalents and marketable securities.

Other Income (Expense), Net

Other income (expense), net consists primarily of accretion income and amortization expense on marketable debt securities net of amortized issuance costs from the liability related to the future sale of royalties to BBA in 2019.

Results of Operations

The following table summarizes our results of operations for the periods indicated:

 

 

 

Year Ended

December 31,

 

 

2020 vs 2019

Change

 

 

 

2020

 

 

2019

 

 

2018

 

 

Dollar

 

 

Percent

 

 

 

(in thousands, except percentages)

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

107,389

 

 

$

37,506

 

 

$

18,793

 

 

$

69,883

 

 

 

186

%

General and administrative

 

 

28,618

 

 

 

11,684

 

 

 

7,581

 

 

 

16,934

 

 

 

145

%

Loss from operations

 

 

(136,007

)

 

 

(49,190

)

 

 

(26,374

)

 

 

(86,817

)

 

 

176

%

Interest income

 

 

2,902

 

 

 

1,568

 

 

 

617

 

 

 

1,334

 

 

 

85

%

Interest expense (includes $nil, $nil and $3,030

   attributable to related parties for the years ended

   December 31, 2020, 2019 and 2018, respectively)

 

 

(25

)

 

 

(8

)

 

 

(5,519

)

 

 

(17

)

 

*

 

Other income (expense), net (includes $49, $nil, and

   $2,736 expenses attributable to related parties for

   the years ended December 31, 2020, 2019, and

   2018, respectively)

 

 

34

 

 

 

265

 

 

 

(4,688

)

 

 

(231

)

 

*

 

Loss on extinguishment of debt (includes $1,587

   attributable to related parties for the year ended

   December 31, 2018)

 

 

 

 

 

 

 

 

(5,479

)

 

 

-

 

 

*

 

Net loss

 

$

(133,096

)

 

$

(47,365

)

 

$

(41,443

)

 

$

(85,731

)

 

 

181

%

 

*Percentage is not meaningful

112


Research and Development Expenses

Research and development expenses increased $69.9 million, or 186%, from the year ended December 31, 2019 to the year ended December 31, 2020.

The following table summarizes our research and development expenses:

 

 

 

Year Ended

December 31,

 

 

2020 vs 2019

 

 

 

2020

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

ABC Platform external expenses (1)

 

$

7,365

 

 

$

2,218

 

 

$

1,397

 

 

$

5,147

 

KSI-301 program external expenses (2)

 

 

58,563

 

 

 

19,285

 

 

 

8,252

 

 

 

39,278

 

KSI-501 program external expenses (3)

 

 

1,573

 

 

 

1,188

 

 

 

 

 

 

385

 

Payroll and personnel expenses (4)

 

 

30,434

 

 

 

11,978

 

 

 

6,825

 

 

 

18,456

 

Other research and development expenses (5)

 

 

9,454

 

 

 

2,837

 

 

 

2,319

 

 

 

6,617

 

Total research and development expenses

 

$

107,389

 

 

$

37,506

 

 

$

18,793

 

 

$

69,883

 

 

(1)

ABC Platform external expenses primarily relates to manufacturing of biopolymer intermediate drug substance which can be used with multiple product candidates. These expenses are primarily for services provided by CMOs.

(2)

KSI-301 program external expenses relate to development of KSI-301, including manufacturing and clinical trial costs. These expenses are primarily for services provided by CMOs and CROs.

(3)

KSI-501 program external expenses relate to research and development of KSI-501.

(4)

Payroll and personnel expenses includes salaries, benefits and stock-based compensation for our personnel involved in research and development activities. These expenses are separately classified and not allocated to specific programs because these expenses relate to multiple programs.

(5)

Other research and development expenses includes direct costs related to research and development activities other than those listed above.

ABC Platform external expenses increased $5.1 million during the year ended December 31, 2020 as compared to 2019. The increase was primarily driven by manufacturing runs to support our product candidate pipeline.

KSI-301 program external expenses increased $39.3 million during the year ended December 31, 2020 as compared to 2019, primarily due to clinical trial costs to support ongoing trials, as well as manufacturing activities for KSI-301. Our pivotal Phase 2b/3 clinical study in wAMD (DAZZLE) dosed the first patient in October 2019, and patient recruitment completed in the fourth quarter of 2020. We initiated two pivotal Phase 3 clinical studies in DME (GLEAM and GLIMMER) and one pivotal Phase 3 clinical study in RVO (BEACON) in the third quarter of 2020.

KSI-501 program external expenses increased $0.4 million during the year ended December 31, 2020 as compared to 2019, due to ongoing research and development of KSI-501.

Payroll and personnel expenses increased $18.5 million during the year ended December 31, 2020 as compared to 2019, due to increased headcount and stock-based compensation expense.

Other research and development expenses increased $6.6 million during the year ended December 31, 2020 as compared to 2019, primarily due to the allocation of lease costs for Palo Alto and Switzerland. Our other research and development expenses may fluctuate in future periods as we elect to develop other product candidates.

General and Administrative Expenses

General and administrative expenses increased $16.9 million, or 145%, from the year ended December 31, 2020 as compared to 2019. The increase in general and administrative expenses was primarily driven by increased headcount and stock-based compensation expense as well as professional services related to consulting, legal and accounting, as well as the allocation of lease costs for Palo Alto.

113


Interest Income

Interest income increased $1.3 million from the year ended December 31, 2020 as compared to 2019, which was mainly attributable to interest income earned on increased cash balances from our follow-on offering in December 2019 and November 2020.

Other Income (Expense), Net

Other income (expense), net decreased $0.2 million from the year ended December 31, 2020 as compared to 2019, which was mainly attributable to issuance costs from the liability related to the future sale of royalties to BBA in December 2019.

Liquidity and Capital Resources; Plan of Operations

Sources of Liquidity

We have funded our operations primarily through the sale and issuance of common stock, redeemable convertible preferred stock, convertible notes and warrants. As of December 31, 2020, we had cash, cash equivalents and marketable securities of $969.0 million.

IPO

In connection with our IPO in 2018, we sold and issued 9,400,000 shares of common stock at a price to the public of $10.00 per share. The aggregate net proceeds from our IPO, inclusive of the partial over-allotment option exercise, were $83.5 million after deducting underwriting discounts and commissions and other offering costs.

Follow-On Offering

In December 2019, we completed a follow-on offering pursuant to the shelf registration on Form S-3 and issued and sold 6,900,000 shares of common stock at a price to the public of $46.00 per share. The gross proceeds from this offering were $317.4 million, resulting in aggregate net proceeds of $297.6 million after deducting underwriting discounts and commissions and other offering costs payable by us.

In November 2020, we completed a follow-on offering pursuant to the shelf registration on Form S-3 and issued and sold 5,972,222 shares of common stock at a price to the public of $108.00 per share. The gross proceeds from this offering were $645.0 million, resulting in aggregate net proceeds of $612.0 million after deducting underwriting discounts and commissions and other offering costs.

Future Funding Requirements

We have incurred net losses since our inception. For the years ended December 31, 2020, 2019 and 2018, we had net losses of $133.1 million, $47.4 million, and $41.4 million, respectively, and we expect to continue to incur additional losses in future periods. As of December 31, 2020, we had an accumulated deficit of $291.2 million.

We have based these estimates on assumptions that may prove to be wrong, and we could deplete our available capital resources sooner than we expect. Because of the risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors.

To date, we have not generated any product revenue. We do not expect to generate any product revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates or enter into collaborative agreements with third parties, and we do not know when, or if, either will occur. We expect to continue to incur significant losses for the foreseeable future, and we expect our losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Moreover, we expect to continue incurring additional costs associated with operating as a public company.

We have based these estimates on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. The timing and amount of our operating expenditures and capital requirements will depend on many factors, including:

 

the scope, timing, rate of progress and costs of our drug discovery, preclinical development activities, laboratory testing and clinical trials for our product candidates;

114


 

the number and scope of clinical programs we decide to pursue;

 

the scope and costs of manufacturing development and commercial manufacturing activities;

 

the extent to which we acquire or in-license other product candidates and technologies;

 

the cost, timing and outcome of regulatory review of our product candidates;

 

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

 

our ability to establish and maintain collaborations on favorable terms, if at all;

 

our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates;

 

the costs associated with being a public company; and

 

the cost and timing associated with commercializing our product candidates, if they receive marketing approval.

A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license rights to our product candidates in certain territories or indications to others that we would prefer to develop and commercialize ourselves.

The significant uncertainties caused by the evolving effects of the COVID-19 pandemic may also negatively impact our operations and capital resources. We and our key clinical and manufacturing partners have been able to continue to advance our operations, and we continue to monitor the impact of COVID-19 on our ability to continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. This pandemic may ultimately have a material adverse effect on our liquidity and operating plans, although we are unable to make any prediction with certainty given the spread and rapidly changing nature of the pandemic and the evolving global actions taken to contain and treat the novel coronavirus.

Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. See the section titled “Risk Factors” for additional risks associated with our substantial capital requirements.

Summary Statement of Cash Flows

The following table sets forth the primary sources and uses of cash for each of the periods presented below:

 

 

 

Year Ended

December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

 

 

(in thousands)

 

Net cash (used in) provided by:

 

 

 

 

 

 

 

 

 

 

 

 

Operating activities

 

$

(83,428

)

 

$

(39,146

)

 

$

(29,031

)

Investing activities

 

$

104,834

 

 

$

(136,998

)

 

$

(581

)

Financing activities

 

$

717,377

 

 

$

299,687

 

 

$

116,471

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

$

738,783

 

 

$

123,543

 

 

$

86,859

 

 

Cash Flows from Operating Activities

Net cash used in operating activities was $83.4 million for year ended December 31, 2020. Cash used in operating activities was primarily driven by the increase in net loss during this period due to increased payroll and personnel expenses and manufacturing and clinical trial costs to support overall growth. Cash used in operating activities was also driven by changes in operating assets and liabilities.

115


Cash Flows from Investing Activities

Net cash provided by investing activities was $104.8 million for year ended December 31, 2020 and primarily related to purchases of marketable securities, net of maturities, and purchases of property and equipment.

Cash Flows from Financing Activities

Net cash provided by financing activities was $717.4 million for year ended December 31, 2020, which consisted primarily of the net proceeds from our follow-on offering, proceeds from sale of future royalties to BBA, and proceeds from the exercise of stock options.

Contractual Obligations and Commitments

The following table summarizes our contractual obligations as of December 31, 2020 (in thousands):

 

 

 

Payments Due by Period

 

 

 

Less than

1 year

 

 

1 to 3

years

 

 

3 to 5

years

 

 

More than

5 years

 

 

Total

 

Operating lease obligations

 

$

4,288

 

 

$

22,258

 

 

$

30,512

 

 

$

71,462

 

 

$

128,520

 

Manufacturing agreements

 

 

82,576

 

 

 

50,939

 

 

 

36,261

 

 

 

72,523

 

 

 

242,299

 

Tenant improvement obligations

 

 

42

 

 

 

94

 

 

 

110

 

 

 

51

 

 

 

297

 

Other agreements

 

 

470

 

 

 

 

 

 

 

 

 

 

 

 

470

 

Total

 

$

87,376

 

 

$

73,291

 

 

$

66,883

 

 

$

144,036

 

 

$

371,586

 

 

For further information, refer to Note 7 of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.

Critical Accounting Policies, Significant Judgments and Use of Estimates

Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. The impact of the ongoing COVID-19 pandemic continues to evolve. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

Accrued Research and Development

Our accrued research and development costs are estimated based on the level of services performed, including the phase or completion of events, and contracted costs. Accrued clinical trial and related costs are estimated using data such as patient enrollment, clinical site activations or information provided by outside service providers regarding their actual costs incurred. Management determined accrual estimates through reports from and discussions with clinical personnel and outside service providers as to the progress of trials, or the services completed. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other assets until the services are rendered.

Stock-Based Compensation Expense

We measure and recognize compensation expense for all stock‑based awards made to employees, directors and non‑employees, based on estimated fair values of the awards on the grant date and recognized using the straight‑line method over the requisite service period.

The fair value of options is estimated on the grant date using the Black‑Scholes option valuation model. The calculation of stock‑based compensation expense requires that we make certain assumptions and judgments about a number of complex and subjective variables used in the Black‑Scholes model, including the expected term, expected volatility of the underlying common stock and risk‑free interest rate. Our stock-based awards are subject to either service or performance-based vesting

116


conditions. We evaluate whether achievement of the performance conditions is probable and record expense over the appropriate service period based on this assessment.

Changes in these assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop.

Income Taxes

We provide for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating loss, or NOLs, and credit carryforwards, and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.

We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement.

As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (1) the factors underlying the sustainability assertion have changed and (2) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. Our policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service, or IRS, and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on our value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. We have completed a Section 382 study through December 31, 2020 which concluded no such ownership change had occurred through December 31, 2020.

As of December 31, 2020 and 2019, we had unrecognized tax benefits, all of which would affect income tax expense if recognized, before consideration of our valuation allowance. We do not expect that our uncertain tax positions will materially change in the next twelve months.

 

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Recent Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is discussed under Note 2 to our consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.

117


ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK  

We are exposed to market risk related to changes in interest rates. As of December 31, 2020, we had cash, cash equivalents and marketable securities of $969.0 million, primarily invested in money market funds. As of December 31, 2019, we had cash and cash equivalents of $348.2 million, primarily invested in money market funds, overnight repurchase agreements, U.S. treasury securities, commercial paper and corporate notes. Changes in the general level of interest rates can affect the fair value of our investment portfolio. If market interest rates were to increase immediately and uniformly by 100 basis points, or one percentage point, from levels at December 31, 2020, the net fair value of our interest-sensitive marketable securities would have resulted in a hypothetical decline of less than $0.1 million.

We do not believe that other market risks, like foreign currency exchange rate risk, had a significant impact on our results of operations for any periods presented herein.

118


ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

119


Report of Independent Registered Public Accounting Firm

 

To the Board of Directors and Stockholders of Kodiak Sciences Inc.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Kodiak Sciences Inc. and its subsidiaries (the “Company”) as of December 31, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, of redeemable convertible preferred stock and stockholders’ equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2020, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

 

Change in Accounting Principle

 

As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the

120


company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

 

Critical Audit Matters

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Accrued Clinical Trial and Related Costs

 

As described in Notes 2 and 4 to the consolidated financial statements, the Company recorded $11.1 million in accrued clinical trial and related costs as of December 31, 2020. Accrued clinical trial and related costs are estimated using data such as patient enrollment, clinical site activations or information provided by outside service providers regarding their actual costs incurred. Management determined accrual estimates through reports from and discussions with clinical personnel and outside service providers as to the progress of trials, or the services completed.  

 

The principal considerations for our determination that performing procedures relating to accrued clinical trial and related costs is a critical audit matter are the judgment by management in evaluating the data used in developing the accrued clinical trial and related cost estimates, which in turn led to a high degree of auditor judgment and effort in performing procedures to  evaluate audit evidence obtained related to patient enrollment, clinical site activations and services rendered by outside service providers used by management in developing the estimates.

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the completeness and accuracy of clinical trial accruals, including controls relating to the reliability of data used in the development of the estimates. These procedures also included, among others, (1) testing management’s process for developing the estimated accrued clinical trial and related costs, (2) evaluating the appropriateness of the approach used by management to develop the estimates, (3) testing the completeness and accuracy of the data used in developing the estimates, including data related to patient enrollment, clinical site activations and services rendered by outside service providers, (4) confirming clinical costs and contracted fees with the clinical vendors on a test basis, and (5) examining clinical vendor contracts on a test basis to evaluate the completeness of costs considered in the estimates.

 

/s/ PricewaterhouseCoopers LLP

San Jose, California

March 1, 2021

 

We have served as the Company’s auditor since 2016.

 

121


Kodiak Sciences Inc.

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

Assets

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

944,396

 

 

$

211,797

 

 

Marketable securities

 

 

24,578

 

 

 

124,684

 

 

Prepaid expenses and other current assets

 

 

3,031

 

 

 

2,749

 

 

Total current assets

 

 

972,005

 

 

 

339,230

 

 

Marketable securities

 

 

 

 

 

11,696

 

 

Restricted cash

 

 

6,324

 

 

 

140

 

 

Property and equipment, net

 

 

5,136

 

 

 

996

 

 

Operating lease right-of-use asset

 

 

73,672

 

 

 

1,790

 

 

Other assets

 

 

10,210

 

 

 

5,014

 

 

Total assets

 

$

1,067,347

 

 

$

358,866

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

8,646

 

 

$

2,619

 

 

Accrued and other current liabilities

 

 

20,402

 

 

 

8,658

 

 

Operating lease liability

 

 

2,374

 

 

 

434

 

 

Total current liabilities

 

 

31,422

 

 

 

11,711

 

 

Operating lease liability, net of current portion

 

 

75,028

 

 

 

1,501

 

 

Liability related to sale of future royalties

 

 

99,890

 

 

 

 

 

Other liabilities

 

 

256

 

 

 

295

 

 

Total liabilities

 

 

206,596

 

 

 

13,507

 

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value, 10,000,000 shares authorized;

   0 shares issued and outstanding at December 31, 2020 and 2019

 

 

 

 

 

 

 

Common stock, $0.0001 par value, 490,000,000 shares authorized at

   December 31, 2020 and 2019; 51,112,302 and 44,413,404 shares

   issued and outstanding at December 31, 2020 and 2019, respectively

 

 

5

 

 

 

5

 

 

Additional paid-in capital

 

 

1,151,920

 

 

 

503,475

 

 

Accumulated other comprehensive income

 

 

53

 

 

 

10

 

 

Accumulated deficit

 

 

(291,227

)

 

 

(158,131

)

 

Total stockholders’ equity

 

 

860,751

 

 

 

345,359

 

 

Total liabilities and stockholders’ equity

 

$

1,067,347

 

 

$

358,866

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

122


Kodiak Sciences Inc.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

107,389

 

 

$

37,506

 

 

$

18,793

 

General and administrative

 

 

28,618

 

 

 

11,684

 

 

 

7,581

 

Total operating expenses

 

 

136,007

 

 

 

49,190

 

 

 

26,374

 

Loss from operations

 

 

(136,007

)

 

 

(49,190

)

 

 

(26,374

)

Interest income

 

 

2,902

 

 

 

1,568

 

 

 

617

 

Interest expense (includes $nil, $nil and $3,030

   attributable to related parties for the years ended

   December 31, 2020, 2019 and 2018, respectively)

 

 

(25

)

 

 

(8

)

 

 

(5,519

)

Other income (expense), net (includes $49, $nil, and

   $2,736 expenses attributable to related parties for

   the years ended December 31, 2020, 2019, and

   2018, respectively)

 

 

34

 

 

 

265

 

 

 

(4,688

)

Loss on extinguishment of debt (includes $1,587

   attributable to related parties for the year ended

   December 31, 2018)

 

 

 

 

 

 

 

 

(5,479

)

Net loss

 

$

(133,096

)

 

$

(47,365

)

 

$

(41,443

)

Net loss per common share, basic and diluted

 

$

(2.91

)

 

$

(1.25

)

 

$

(2.77

)

Weighted-average common shares outstanding used in

   computing net loss per common share, basic and diluted

 

 

45,741,845

 

 

 

37,853,616

 

 

 

14,976,515

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

Change in unrealized gains related to available-for-sale

   debt securities, net of tax

 

 

43

 

 

 

10

 

 

 

 

Total other comprehensive income

 

 

43

 

 

 

10

 

 

 

 

Comprehensive loss

 

$

(133,053

)

 

$

(47,355

)

 

$

(41,443

)

 

The accompanying notes are an integral part of these consolidated financial statements.

123


Kodiak Sciences Inc.

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands, except share and per share amounts)

 

 

 

Redeemable

Convertible

Preferred Stock

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders’

Equity

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

(Deficit)

 

Balance at December 31, 2017

 

 

12,385,154

 

 

 

50,017

 

 

 

 

7,936,434

 

 

 

1

 

 

 

584

 

 

 

 

 

 

(69,323

)

 

 

(68,738

)

Issuance of common stock upon

   exercise of stock options

 

 

 

 

 

 

 

 

 

47,800

 

 

 

 

 

 

49

 

 

 

 

 

 

 

 

 

49

 

Issuance of restricted stock awards

 

 

 

 

 

 

 

 

 

27,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Conversion of redeemable convertible

   preferred stock into common stock

 

 

(12,385,154

)

 

 

(50,017

)

 

 

 

12,385,154

 

 

 

1

 

 

 

50,016

 

 

 

 

 

 

 

 

 

50,017

 

Conversion of redeemable convertible

   preferred stock warrants into common

   stock warrants

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,000

 

 

 

 

 

 

 

 

 

5,000

 

Issuance of common stock upon

   exercise of common stock warrants

 

 

 

 

 

 

 

 

 

100,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Conversion of 2017 and 2018 convertible

   notes into common stock

 

 

 

 

 

 

 

 

 

6,932,969

 

 

 

1

 

 

 

55,732

 

 

 

 

 

 

 

 

 

55,733

 

Issuance of common stock in conection

   with initial public offering, net of

   offering costs of $10,542

 

 

 

 

 

 

 

 

 

9,400,000

 

 

 

1

 

 

 

83,458

 

 

 

 

 

 

 

 

 

83,459

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,756

 

 

 

 

 

 

 

 

 

2,756

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(41,443

)

 

 

(41,443

)

Balance at December 31, 2018

 

 

 

 

 

 

 

 

 

36,829,857

 

 

 

4

 

 

 

197,595

 

 

 

 

 

 

(110,766

)

 

 

86,833

 

Issuance of common stock upon

   exercise of stock options

 

 

 

 

 

 

 

 

 

662,079

 

 

 

 

 

 

2,287

 

 

 

 

 

 

 

 

 

2,287

 

Vesting of restricted stock units, net of

   taxes withheld

 

 

 

 

 

 

 

 

 

21,467

 

 

 

 

 

 

(132

)

 

 

 

 

 

 

 

 

(132

)

Issuance of common stock upon

   exercise of common stock warrants

 

 

 

 

 

 

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock in connection

   with follow-on offering, net of

   offering costs of $19,784

 

 

 

 

 

 

 

 

 

6,900,000

 

 

 

1

 

 

 

297,615

 

 

 

 

 

 

 

 

 

297,616

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6,110

 

 

 

 

 

 

 

 

 

6,110

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10

 

 

 

 

 

 

10

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(47,365

)

 

 

(47,365

)

Balance at December 31, 2019

 

 

 

 

 

 

 

 

 

44,413,404

 

 

 

5

 

 

 

503,475

 

 

 

10

 

 

 

(158,131

)

 

 

345,359

 

Issuance of common stock upon

   exercise of stock options

 

 

 

 

 

 

 

 

 

704,675

 

 

 

 

 

 

6,248

 

 

 

 

 

 

 

 

 

6,248

 

Issuance of common stock in connection

   with follow-on offering, net of

   offering costs of $32,984

 

 

 

 

 

 

 

 

 

5,972,222

 

 

 

 

 

 

612,016

 

 

 

 

 

 

 

 

 

612,016

 

Vesting of restricted stock units, net of

   taxes withheld

 

 

 

 

 

 

 

 

 

22,001

 

 

 

 

 

 

(487

)

 

 

 

 

 

 

 

 

(487

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

30,668

 

 

 

 

 

 

 

 

 

30,668

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

43

 

 

 

 

 

 

43

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(133,096

)

 

 

(133,096

)

Balance at December 31, 2020

 

 

 

 

$

 

 

 

 

51,112,302

 

 

$

5

 

 

$

1,151,920

 

 

$

53

 

 

$

(291,227

)

 

$

860,751

 

 

The accompanying notes are an integral part of these consolidated financial statements.

124


Kodiak Sciences Inc.

Consolidated Statements of Cash Flows

(in thousands)

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Cash flows from operating activities

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(133,096

)

 

$

(47,365

)

 

$

(41,443

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

477

 

 

 

538

 

 

 

490

 

Non-cash interest expense and amortization of debt discount

   and issuance cost

 

 

 

 

 

 

 

 

5,482

 

Change in fair value of redeemable convertible preferred

   stock warrant liability

 

 

 

 

 

 

 

 

2,700

 

Change in fair value of derivative instrument

 

 

 

 

 

 

 

 

1,988

 

Extinguishment of debt

 

 

 

 

 

 

 

 

5,479

 

Stock-based compensation

 

 

30,668

 

 

 

6,110

 

 

 

2,665

 

Amortization (accretion) of premium (discount) on marketable securities

 

 

(51

)

 

 

(241

)

 

 

 

Amortization of operating lease right-of-use asset

 

 

3,731

 

 

 

373

 

 

 

 

Amortization of issuance costs

 

 

49

 

 

 

 

 

 

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid expense and other current assets

 

 

(218

)

 

 

(168

)

 

 

(1,995

)

Other assets

 

 

(1,814

)

 

 

(4,511

)

 

 

 

Accounts payable

 

 

5,224

 

 

 

1,569

 

 

 

(2,323

)

Accrued and other current liabilities

 

 

11,748

 

 

 

4,932

 

 

 

(2,105

)

Operating lease liability

 

 

(146

)

 

 

(383

)

 

 

 

Other liabilities

 

 

 

 

 

 

 

 

31

 

Net cash used in operating activities

 

 

(83,428

)

 

 

(39,146

)

 

 

(29,031

)

Cash flows from investing activities

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

(3,814

)

 

 

(437

)

 

 

(78

)

Deposits on property and equipment

 

 

(3,184

)

 

 

 

 

 

(503

)

Purchases of marketable securities

 

 

(86,317

)

 

 

(150,961

)

 

 

 

Maturities of marketable securities

 

 

198,149

 

 

 

14,400

 

 

 

 

Net cash provided by (used in) investing activities

 

 

104,834

 

 

 

(136,998

)

 

 

(581

)

Cash flows from financing activities

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock in connection with offering, net of offering costs

 

 

612,016

 

 

 

297,616

 

 

 

83,755

 

Proceeds from issuance of common stock upon option exercise

 

 

6,248

 

 

 

2,287

 

 

 

49

 

Payments for restricted stock units, net of taxes withheld

 

 

(487

)

 

 

(132

)

 

 

 

Proceeds from issuance of convertible notes (includes $9,560 from

   related parties for the years ended December 31, 2018)

 

 

 

 

 

 

 

 

33,000

 

Debt issuance cost

 

 

 

 

 

 

 

 

(140

)

Proceeds from sale of future royalties, net of issuance costs

 

 

99,643

 

 

 

 

 

 

 

Principal payments of capital lease

 

 

(5

)

 

 

(48

)

 

 

(108

)

Principal payments of tenant improvement allowance payable

 

 

(38

)

 

 

(36

)

 

 

(85

)

Net cash provided by financing activities

 

 

717,377

 

 

 

299,687

 

 

 

116,471

 

Net increase in cash, cash equivalents and restricted cash

 

 

738,783

 

 

 

123,543

 

 

 

86,859

 

Cash, cash equivalents and restricted cash, at beginning of year

 

 

211,937

 

 

 

88,394

 

 

 

1,535

 

Cash, cash equivalents and restricted cash, at end of year

 

$

950,720

 

 

$

211,937

 

 

$

88,394

 

Reconciliation of cash, cash equivalents and restricted cash

   to consolidated balance sheets

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

944,396

 

 

$

211,797

 

 

$

88,254

 

Restricted cash

 

 

6,324

 

 

 

140

 

 

 

140

 

Cash, cash equivalents and restricted cash in consolidated balance sheets

 

$

950,720

 

 

$

211,937

 

 

$

88,394

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

25

 

 

$

8

 

 

$

19

 

Supplemental disclosures of non-cash investing and financing information:

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease right-of-use asset obtained in exchange for

   operating lease liability

 

$

75,614

 

 

$

2,163

 

 

$

 

Purchase of property and equipment under accounts payable

 

$

803

 

 

$

 

 

$

 

Unpaid offering costs

 

$

238

 

 

$

459

 

 

$

205

 

Offering costs paid in restricted stock awards

 

$

 

 

$

 

 

$

91

 

Derivative instrument related to convertible notes

 

$

 

 

$

 

 

$

6,603

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

125


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

1. The Company

Kodiak Sciences Inc. (the “Company”) is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high-prevalence ophthalmic diseases. The Company devotes substantially all of its time and efforts to performing research and development, raising capital and recruiting personnel.

Initial Public Offering

In 2018, the Company sold and issued 9,400,000 shares of common stock, including the underwriters’ full exercise of their over-allotment option, at a price to the public of $10.00 per share for gross proceeds of $94.0 million. The aggregate net proceeds to the Company from the IPO, inclusive of the partial over-allotment option exercise, were $83.5 million after deducting underwriting discounts and commissions and other offering costs.

Upon the closing of the IPO, all convertible preferred shares then outstanding automatically converted into 12,385,154 shares of common stock, 500,000 redeemable convertible preferred stock warrants automatically converted into common stock warrants and 100,000 of such warrants were exercised immediately following the closing of the IPO. The 2017 convertible notes converted into 2,637,292 shares of common stock and the 2018 convertible notes converted into 4,295,677 shares of common stock upon closing of the IPO. In connection with the IPO, the Company amended and restated its certificate of incorporation and bylaws.

Follow-On Offering

In December 2019, the Company sold and issued 6,900,000 shares of common stock, including the underwriters’ full exercise of their over-allotment option, at a price to the public of $46.00 per share for gross proceeds of $317.4 million. The aggregate net proceeds to the Company from the follow-on offering were $297.6 million after deducting underwriting discounts and commissions and other offering costs.

In November 2020, the Company sold and issued 5,972,222 shares of common stock, including the underwriters’ full exercise of their over-allotment option, at a price to the public of $108.00 per share for gross proceeds of $645.0 million. The aggregate net proceeds to the Company from the follow-on offering were $612.0 million after deducting underwriting discounts and commissions and other offering costs.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).

Reclassification

Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation.

Principles of Consolidation

The consolidated financial statements include the Company’s accounts and the accounts of Kodiak Sciences Financing Corporation and Kodiak Sciences China, the Company’s direct wholly owned subsidiaries, incorporated in the United States and Cayman Islands, respectively, and Kodiak Sciences GmbH and Kodiak Sciences Valais GmbH, the Company’s indirect wholly owned subsidiaries, both incorporated in Switzerland. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar. The aggregate foreign currency transaction loss included in determining net loss was $0.3 million, less than $0.1 million and $0.3 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Segments

The Company operates and manages its business as one reportable and operating segment, which is the business of research and development of drugs for ophthalmic diseases. The chief operating decision maker reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.

126


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and expenses during the reporting period. The impact of the ongoing COVID-19 pandemic continues to evolve. As a result, certain estimates and assumptions required increased judgment and carried a higher degree of variability and volatility, including but not limited to, the fair value of marketable securities, performance-based equity awards, and research and development accruals. As events continue to unfold and additional information becomes available, these estimates may change materially in future periods. Actual results could differ from those estimates.

Risk and Uncertainties

In March 2020, the World Health Organization declared a pandemic due to the global COVID-19 outbreak. The significant uncertainties caused by the ongoing COVID-19 pandemic may negatively impact the Company’s operations, liquidity, and capital resources and will depend on certain evolving developments, including the duration and spread of the outbreak, regulatory and private sector responses and the impact on employees and vendors including supply chain and clinical partners, all of which are uncertain and cannot be predicted. During this pandemic, the Company continues to work closely with clinical sites towards maximal patient safety and the lowest number of missed visits and study discontinuations. The Company has taken and continues to take proactive measures to maintain the integrity of its ongoing clinical studies. Despite these efforts, the ongoing COVID-19 pandemic could significantly impact clinical trial enrollment and completion of its clinical studies. The Company will continue to monitor the COVID-19 situation and its impact on the ability to continue the development of, and seek regulatory approvals for, the Company’s product candidates, and begin to commercialize any approved products.

The Company’s future results of operations involve a number of risks and uncertainties common to clinical-stage companies in the biotechnology industry. The Company’s product candidates are in development and the Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s potential drug candidates, uncertainty of market acceptance of any of the Company’s product candidates that receive regulatory approval, competition from new technological innovations, substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals, contract manufacturer and research organizations, and other suppliers.

Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that any of the Company’s product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approvals, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. 

The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be on terms acceptable by the Company.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2020 and 2019, cash, cash equivalents and marketable securities were invested primarily in money market funds, overnight repurchase agreements, U.S. treasury securities, commercial paper and corporate notes through highly rated financial institutions. Investments are restricted, in accordance with the Company’s investment policy, to a concentration limit per issuer or sector.

127


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

Cash and Cash Equivalents

The Company considers all highly liquid investments with stated maturities of three months or less at the date of purchase to be cash equivalents.

Marketable Securities

The Company invests excess cash balances in marketable securities. The investments in marketable securities are classified as either held-to-maturity or available-for-sale based on facts and circumstances present at the time of purchase. Marketable securities with a remaining maturity date greater than one year are classified as non-current. The Company’s marketable securities consist of U.S. treasury securities, commercial paper, and corporate bonds. Marketable securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium or discount arising at purchase of marketable debt securities is amortized and/or accreted to other income (expense), net over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense), net.

If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is “other-than-temporary” and, if so, marks the investment to market through a charge to the Company’s statement of operations and comprehensive loss.

Restricted Cash

As of December 31, 2020, and 2019, the Company had $6.3 million and $0.1 million, respectively, of long-term restricted cash deposited with a financial institution. The entire amount is held in separate bank accounts to support letter of credit agreements related to the Company’s U.S. corporate offices.

Fair Value of Financial Instruments

Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company's own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:

Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and inputs to the model.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities and other current liabilities, approximate fair value due to their relatively short maturities.

128


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

Leases

The Company determines if an arrangement is, or contains, a lease at inception and then classifies the lease as operating or financing based on the underlying terms and conditions of the contract. Leases with terms greater than one year are initially recognized on the balance sheet as right-of-use assets and lease liabilities based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term and in a similar economic environment of the applicable country or region. Variable lease payments are excluded from the right of use assets and operating lease liabilities and are recognized in the period in which the obligation for those payments is incurred.

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over the estimated useful lives of assets, which is generally four years for laboratory equipment, three years for computer equipment and office equipment, five years for computer software and five to seven years for furniture and fixtures. Leasehold improvements are stated at cost and amortized over the shorter of the useful life of the assets or the length of the lease. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Impairment of Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the assets. There have been no such impairments of long-lived assets in the years ended December 31, 2020 and 2019.

Research and Development Expenses

Costs related to research, design and development of products are charged to research and development expense as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, including stock-based compensation, laboratory supplies, outside services and allocated overhead, including rent, equipment, depreciation and utilities.

Accrued Research and Development

The Company has entered into various agreements with various third parties, including clinical investigator sites, contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), to provide research and development activities. The Company’s accrued research and development costs are estimated based on the level of services performed, including the phase or completion of events, and contracted costs. Accrued clinical trial and related costs are estimated using data such as patient enrollment, clinical site activations or information provided by outside service providers regarding their actual costs incurred. Management determined accrual estimates through reports from and discussions with clinical personnel and outside service providers as to the progress of trials, or the services completed. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses or other assets until the services are rendered.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, Compensation-Stock Compensation. The Company measures stock-based compensation expense for stock options and restricted stock units granted to its employees, directors and non-employees based on the estimated fair value of the awards on the grant date. The fair value of options is calculated using the Black-Scholes valuation model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The expense is recorded on a straight-line basis over the requisite service period, which is generally the vesting period, for the entire award. The Company accounts for forfeitures as they occur.

129


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

Prior to the adoption of Accounting Standards Update ("ASU") No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"), the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. After adoption of ASU 2018-07 as of January 1, 2019, the measurement date for non-employee awards is the date of grant without changes in the fair value of the award.

The Company has certain stock options and restricted stock units that vest in conjunction with certain performance conditions. At each reporting date, the Company is required to evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon the Company's assessment of accomplishing each performance provision.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses (“NOLs”) and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.

The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Comprehensive Loss

Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists primarily of unrealized gains and losses on debt securities.

Liability related to Sale of Future Royalties

On December 1, 2019, the Company and its subsidiary Kodiak Sciences GmbH entered into a funding agreement with Baker Bros. Advisors, LP (“BBA”), which holds more than 5% of the Company’s stock, pursuant to which BBA purchased the right to receive a capped 4.5% royalty on future net sales of KSI-301, the Company’s anti-VEGF antibody biopolymer conjugate therapy, in exchange for $225.0 million. Under the terms of the funding agreement, there is no obligation to repay any funding amount received, other than through the capped royalty payments on future product revenues. The Company recorded the funding amount paid by BBA as a liability on the consolidated balance sheet net of issuance costs, in accordance with ASC 730, Research and Development. Under ASC 730, the significant related party relationship between the Company and BBA creates an implicit obligation to repay the funding amount paid to the Company. Once royalty payments to BBA are determined to be probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest to accrete the liability on a prospective basis based on such estimates. If and when the Company makes royalty payments under the funding agreement, it would reduce the liability balance at such time. Refer to Note 14.

Credit Losses – Available-for-Sale Debt Securities

For available-for-sale debt securities in an unrealized loss position, the Company will periodically assess its portfolio for impairment. The assessment first considers the intent or requirement to sell the security. If either of these criteria are met, the amortized cost basis will be written down to fair value through earnings.

If not met, the Company will evaluate whether the decline resulted from credit losses or other factors by considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.

130


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

Net Loss per Share Attributable to Common Stockholders

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, the redeemable convertible preferred stock, preferred stock warrants, convertible notes, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. The Company’s participating securities do not have a contractual obligation to share in the Company’s losses. As such, the net loss is attributed entirely to common stockholders. Since the Company has reported net loss for all periods presented, diluted net loss per share is the same as basic net loss per common share for those periods.

Recent accounting pronouncements

From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified effective date, unless otherwise discussed below.

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). In July 2018, the FASB issued ASU 2018-10, Leases (Topic 842), Codification Improvements, and ASU 2018-11, Leases (Topic 842), Targeted Improvements. ASU 2018-10 clarified certain provisions and corrected unintended applications of the guidance such as the application of implicit rate, lessee reassessment of lease classification, and certain transition adjustments that should be recognized to earnings rather than to stockholders' equity. ASU 2018-11 provided an alternative transition method and practical expedient for separating contract components for the adoption of Topic 842. ASU 2016-02, ASU 2018-10, and ASU 2018-11 (collectively, "the new lease standards") superseded the previous leases standard, ASC 840 Leases.

The Company adopted ASC 842 effective January 1, 2019 using the modified retrospective approach to recognize a cumulative-effect adjustment on the effective date and to not adjust financial information and disclosures required under the new lease standards for comparative prior periods. The Company did not elect for the package of practical expedients and assessed all contracts at the transition date. The Company did not utilize the practical expedient which allows the use of hindsight in determining lease term and assessing impairment in right-of-use assets. The Company elected to apply the practical expedient and accounted for each lease component and related non-lease component as one single component. The Company elected the practical expedient not to recognize leases with terms of one year or less on the balance sheet. 

The adoption of the new lease standards on January 1, 2019 resulted in the initial recognition of right-of-use asset of $2.2 million and operating lease liability of $2.3 million and derecognition of noncurrent deferred liabilities of $0.2 million related to the operating lease for the Company’s office and laboratory space in Palo Alto, California on the consolidated balance sheets with no material impact to the consolidated statements of operations, stockholders’ equity or cash flows. Refer to Note 7.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 362): Measurement of Credit Losses on Financial Statements and ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. The Company assessed the impact of ASU 2016-13 on its available-for-sale debt securities and determined there were no credit losses within the portfolio requiring an allowance upon adoption. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB’s disclosure framework project. Among the changes, entities will no longer be required to disclose the amount of and reasons for transfers between Levels 1 and 2 of the fair value hierarchy but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.

131


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which clarifies the accounting for implementation, set-up, and other upfront costs incurred in cloud computing arrangements. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.

New Accounting Pronouncements Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein, and early adoption is permitted. The Company has early adopted ASU 2019-12 in 2020; the effect was not material on the Company’s financial statements.

 

3. Property and Equipment, net

Property and equipment, net consists of the following (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

 

 

 

 

 

 

 

 

Leasehold improvement

 

$

1,285

 

 

$

1,265

 

Laboratory equipment

 

 

3,351

 

 

 

1,125

 

Furniture and fixtures

 

 

214

 

 

 

204

 

Computer hardware

 

 

31

 

 

 

 

Computer software

 

 

89

 

 

 

79

 

Office equipment

 

 

107

 

 

 

94

 

Construction in progress

 

 

2,229

 

 

 

 

Total property and equipment

 

 

7,306

 

 

 

2,767

 

Less: Accumulated depreciation

 

 

(2,170

)

 

 

(1,771

)

Property and equipment, net

 

$

5,136

 

 

$

996

 

 

All property and equipment are maintained in the United States and Switzerland. Depreciation expense, including depreciation of assets under capital leases, was $0.5 million, $0.5 million and $0.5 million for the years ended December 31, 2020, 2019 and 2018, respectively.

4. Accrued Liabilities and Other Current Liabilities

Accrued liabilities and other current liabilities consist of the following (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

Accrued clinical trial and related costs

 

$

11,119

 

 

$

4,056

 

Accrued research and development

 

 

3,082

 

 

 

838

 

Accrued salaries and benefits

 

 

5,094

 

 

 

3,108

 

Accrued legal fees

 

 

252

 

 

 

302

 

Accrued professional fees

 

 

253

 

 

 

195

 

Accrued other liabilities

 

 

602

 

 

 

159

 

Total accrued and other current liabilities

 

$

20,402

 

 

$

8,658

 

 

132


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

5. Fair Value Measurements

The following tables present the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands):

 

 

 

Fair Value Measurements at December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

917,485

 

 

$

 

 

$

 

 

$

917,485

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

 

 

 

10,006

 

 

 

 

 

 

10,006

 

Corporate notes

 

 

 

 

 

14,572

 

 

 

 

 

 

14,572

 

Total

 

$

917,485

 

 

$

24,578

 

 

$

 

 

$

942,063

 

 

 

 

Fair Value Measurements at December 31, 2019

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

155,276

 

 

$

 

 

$

 

 

$

155,276

 

Repurchase agreement

 

 

50,000

 

 

 

 

 

 

 

 

 

50,000

 

Commercial paper

 

 

 

 

 

5,987

 

 

 

 

 

 

5,987

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

 

 

 

50,185

 

 

 

 

 

 

50,185

 

Commercial paper

 

 

 

 

 

34,533

 

 

 

 

 

 

34,533

 

Corporate notes

 

 

 

 

 

51,662

 

 

 

 

 

 

51,662

 

Total

 

$

205,276

 

 

$

142,367

 

 

$

 

 

$

347,643

 

 

As of December 31, 2020, the fair value of the liability related to sale of future royalties is based on our current estimates of future royalties expected to be paid to BBA, which are considered Level 3 inputs. Refer to Note 14. There were no liabilities measured at fair value on a recurring and non-recurring basis as of December 31, 2019. There were no transfers of assets or liabilities between the fair value measurement levels during the years ended December 31, 2020 and 2019.

6. Marketable Securities

The marketable securities are classified as available-for-sale and consist of U.S. treasury securities, corporate notes and commercial paper. The fair value measurement data for marketable securities is obtained from independent pricing services. The Company validates the prices provided by the third-party pricing services by understanding the valuation methods and data sources used and analyzing the pricing data in certain instances.

The following table summarizes the marketable securities (in thousands):

 

 

 

December 31, 2020

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair

Value

 

U.S. treasury securities

 

$

10,003

 

 

$

3

 

 

 

 

 

$

10,006

 

Corporate notes

 

 

14,522

 

 

 

50

 

 

 

 

 

 

14,572

 

Total marketable securities, current

 

$

24,525

 

 

$

53

 

 

$

 

 

$

24,578

 

133


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

 

 

 

December 31, 2019

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair

Value

 

U.S. treasury securities

 

$

50,190

 

 

$

 

 

$

(5

)

 

$

50,185

 

Commercial paper

 

 

34,532

 

 

 

1

 

 

 

 

 

 

34,533

 

Corporate notes

 

 

39,956

 

 

 

13

 

 

 

(3

)

 

 

39,966

 

Total marketable securities, current

 

$

124,678

 

 

$

14

 

 

$

(8

)

 

$

124,684

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate notes

 

$

11,692

 

 

$

4

 

 

$

 

 

$

11,696

 

Total marketable securities, noncurrent

 

$

11,692

 

 

$

4

 

 

$

 

 

$

11,696

 

 

 

All marketable securities held at December 31, 2020 had effective maturities of less than one year. There were no realized gains or losses recognized on the sale or maturity of available-for-sale debt securities during the year ended December 31, 2020 and as a result, the Company did not reclassify any amounts out of accumulated comprehensive loss. No marketable securities with unrealized losses as of December 31, 2020. All marketable securities with unrealized losses as of December 31, 2019 have been in a loss position for less than twelve months and the loss is not material. These marketable securities were not considered to be other-than-temporarily impaired.

7. Commitments and Contingencies

Leases

Palo Alto, California Leases

In June 2020, the Company entered into lease agreements for two buildings at 1200 and 1250 Page Mill Road in Palo Alto, California, which are now the Company’s U.S. corporate offices. The facilities are approximately 82,662 square feet and 72,812 square feet, respectively and include office and laboratory space. For 1200 Page Mill Road, the monthly rent during the initial 6.5-year term will be approximately $0.6 million, with annual year-over-year increases of 3% plus certain operating expenses and taxes and total rent abatement of approximately $7.2 million. The Company has an option to extend the lease term for a period of 6.5 years. For 1250 Page Mill Road, the monthly rent during the initial 13-year term will be approximately $0.5 million, with annual year-over-year increases of 3% plus certain operating expenses and taxes and total rent abatement of approximately $6.3 million. The Landlord will provide a tenant improvement allowance of approximately $1.2 million and $10.6 million for each building, respectively. The Company has two options to extend the lease term for a period of 5 years each. The Company determined that the renewal options were not reasonably certain at lease inception for the two buildings. The Company executed a $10.9 million cash-collateralized letter of credit, which was subsequently reduced to $6.2 million as a result of meeting certain reduction requirements specified therein. The cash collateralizing the letter of credit is classified as restricted cash on the Company’s consolidated balance sheets. Under ASC 842, the Company classified these leases as operating leases and recorded right-of-use assets and lease liabilities on the lease commencement date.

The Company continues to lease office and laboratory space at 2631 Hanover Street in Palo Alto, California. The Company entered into a lease agreement in January 2013 which was amended in March 2016 and extended the lease term until October 2023. The Company classified this lease as an operating lease and recorded a right-of-use asset and lease liability on January 1, 2019 and recognized rent expense on a straight-line basis throughout the remaining lease term.

Switzerland Lease

In April 2020, the Company entered into a lease agreement for office and laboratory space at Rottenstrasse 5 in Visp, Switzerland. The space is approximately 1,000 square meters. The initial lease term is 5 years, with automatic renewals every 5 years for a maximum lease term of 15 years. The monthly rent during the initial 5-year term will be approximately 32 thousand Swiss Francs plus certain operating expenses and taxes. Under ASC 842, the Company classified these leases as operating leases and recorded right-of-use assets and lease liabilities on the lease commencement date.

134


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

The maturities of the operating lease liabilities as of December 31, 2020 were as follows (in thousands):

 

Year ending December 31,

 

As of

December 31, 2020

 

2021

 

$

4,288

 

2022

 

 

7,660

 

2023

 

 

14,598

 

2024

 

 

15,037

 

2025

 

 

15,475

 

Thereafter

 

 

71,462

 

Total undiscounted lease payments

 

 

128,520

 

Less: imputed interest

 

 

(51,118

)

Total operating lease liabilities

 

$

77,402

 

 

The minimum lease payments above do not include any related common area maintenance charges or real estate taxes. The weighted-average remaining lease terms and weighted-average discount rates were as follows:

 

 

 

December 31,

2020

 

 

December 31,

2019

 

Weighted-average remaining lease term (in years)

 

 

9.5

 

 

 

3.8

 

Weighted-average discount rate

 

 

6.7

%

 

 

8.5

%

 

Embedded lease

In August 2020, the Company and its subsidiary Kodiak Sciences GmbH entered into a manufacturing agreement with a contract manufacturing organization for the clinical and commercial supply of drug substance for KSI-301, the Company’s proprietary therapeutic candidate for the treatment and prevention of retinal vascular diseases. A custom-built manufacturing suite is planned to be completed and dedicated to the manufacture of the Company’s drug substance with an estimated capital contribution of 40 million Swiss Francs from the Company. Construction of the manufacturing suite is targeted for completion in 2021. The Company will be required to pay annual suite fees of 12 million Swiss Francs for 2021 and 16 million Swiss Francs for each year thereafter, which covers the manufacturing fees for a specified number of batches, and the Company may pay for additional batches to be manufactured. The manufacturing agreement has an initial term of eight years, and the Company has the right to extend the term up to a total of 16 years.

The Company concluded that this agreement contains an embedded lease as the custom-built manufacturing suite will be dedicated for the Company’s use. As of December 31, 2020, the Company did not have control of this manufacturing space and therefore, did not record a right-of-use asset and corresponding lease liability. These commitments are not included in the above table.

Manufacturing Agreement

The Company has entered into service agreements with Lonza AG and its affiliates (“Lonza”), pursuant to which Lonza agreed to perform activities in connection with the manufacturing process of certain compounds. Such agreements, and related amendments, state that planned activities that are included in the signed work orders are, in some cases, binding and, hence, obligate the Company to pay the full price of the work order upon satisfactory delivery of products and services or obligate the Company to the binding amount regardless of whether such planned activities are in fact performed. Per the terms of the agreements, the Company has the option to cancel signed orders at any time upon written notice, which may or may not be subject to payment of a cancellation fee. The level of cancellation fees may be dependent on the timing of the written notice in relation to the commencement date of the work, with the maximum cancellation amount dependent on the agreement or the work order. Under these agreements, the total amount of contractual obligations, over a period of ten years, are cancellable and subject to varying levels of cancellation fees, were $242.3 million and $4.7 million, including accrued amounts, as of December 31, 2020 and 2019, respectively. Purchases under this agreement for the years ended December 31, 2020, 2019 and 2018 were $16.8 million, $7.9 million and $2.8 million, respectively. As of December 31, 2020, the Company had not incurred any cancellation fees for the work performed by Lonza.

Other Funding Commitments

135


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

In the normal course of business, the Company enters into agreements with third-parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company. As of December 31, 2020 and 2019, the total amount of noncancellable purchase commitments, including potential cancellation fees were $0.5 million and $0.7 million, respectively.

The Company is also party to a cancellable assignment and license agreement that would require the Company to make milestone payments of up to $33.2 million and royalty payments on net sales of products utilizing KSI-201 and related technology. Such milestones and royalties are dependent on future activity or product sales and are not estimable.

The Company has also entered into various cancellable license agreements for certain technology. The Company may be obligated to make payments on future sales of specified products associated with such license agreements. Such payments are dependent on future product sales and are not estimable.

Tenant Improvement Allowance Payable

In May 2013, the Company entered into a tenant improvement allowance agreement with its landlord. The agreement allowed the Company to draw down $0.3 million for tenant improvements related to the office lease over the period from the execution of the agreement to October 2018. The interest rate is 8% per year over the lease period. This tenant improvement allowance was repaid in October 2018.

In March 2016, the Company entered into a lease amendment, under which the Company is allowed to draw down an additional allowance of $0.4 million for tenant improvements related to the office lease over the period from the execution of the agreement to October 2023. The interest rate is 8% per year over 10 years. Principal and interest are payable on the first day of every month.

As of December 31, 2020 and 2019, the current portion of the tenant improvement allowance payable in accrued and other current liabilities was less than $0.1 million and less than $0.1 million, respectively. As of December 31, 2020 and 2019, the non-current portion of the tenant improvement allowance payable in other liabilities was $0.3 million and $0.3 million, respectively.

Legal Proceedings

From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. Management is currently not aware of any matters that could have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount.

Indemnification

To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company’s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not specified in the agreements; however, the Company has director and officer insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.

8. Income Taxes

The provision (benefit) for income taxes consists of the following (in thousands):

 

136


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Current:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

 

 

$

 

 

$

 

State

 

 

 

 

 

 

 

 

 

Foreign

 

 

14

 

 

 

 

 

 

 

Total current

 

$

14

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

 

 

$

 

 

$

 

State

 

 

 

 

 

 

 

 

 

Foreign

 

 

 

 

 

 

 

 

 

Total deferred

 

$

 

 

$

 

 

$

 

Provision (Benefit) for income taxes

 

$

14

 

 

$

 

 

$

 

 

The components of loss before income taxes were as follows (in thousands):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

United States

 

$

(17,273

)

 

$

2,633

 

 

$

(17,273

)

Foreign

 

 

(115,809

)

 

 

(49,998

)

 

 

(24,170

)

Total loss before income taxes

 

$

(133,082

)

 

$

(47,365

)

 

$

(41,443

)

 

The tax effects of temporary differences that give rise to significant components of the net deferred tax assets are as follows (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

December 31,

2018

 

Deferred tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

28,451

 

 

$

18,523

 

 

$

11,044

 

Intangible assets

 

 

12,088

 

 

 

12,112

 

 

 

7,588

 

Research and development tax credits

 

 

10,527

 

 

 

4,037

 

 

 

1,559

 

Stock-based compensation

 

 

8,405

 

 

 

1,539

 

 

 

394

 

Accruals

 

 

1,367

 

 

 

885

 

 

 

700

 

Operating lease liability

 

 

22,276

 

 

 

577

 

 

 

-

 

Property and equipment

 

 

127

 

 

 

143

 

 

 

109

 

Total deferred tax assets

 

 

83,241

 

 

 

37,816

 

 

 

21,394

 

Valuation allowance

 

 

(62,005

)

 

 

(37,249

)

 

 

(21,394

)

Net deferred tax assets

 

 

21,236

 

 

 

567

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease right-of-use asset

 

 

(21,234

)

 

 

(534

)

 

 

 

Capitalized legal fees

 

 

(2

)

 

 

(33

)

 

 

 

Total deferred tax liabilities

 

 

(21,236

)

 

 

(567

)

 

 

 

Total net deferred tax assets

 

$

 

 

$

 

 

$

 

 

The Company has recorded a full valuation allowance against its net deferred tax assets due to the uncertainty as to whether such assets will be realized. The net change in the total valuation allowance for the years ended December 31, 2020, 2019 and 2018 was an increase of approximately $24.8 million, $15.9 million and $8.2 million, respectively.

137


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

NOLs and tax credit carry-forwards are subject to review and possible adjustment by the Internal Revenue Service (“IRS”) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company’s value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed a Section 382 study through December 31, 2020 which concluded no such ownership change had occurred through December 31, 2020.

As of December 31, 2020, the Company had $50.1 million of federal and $171.0 million of state net operating loss available to offset future taxable income. A portion of the federal net operating loss carryforwards begin to expire in 2035 and the state net operating loss carryforwards begin to expire in 2035, if not utilized. $32.0 million of the federal net operating loss are not subject to expiration.

As of December 31, 2020, the Company also had federal and state research and development credit carryforwards of $10.2 million and $4.9 million, respectively. The federal research and development credit carryforwards expire beginning 2035. The California tax credit can be carried forward indefinitely.

A reconciliation of the Company’s effective tax rate to the statutory U.S. federal rate is as follows:

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

December 31,

2018

 

Federal statutory income tax rate

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

State taxes

 

 

4.3

 

 

 

11.0

 

 

 

5.6

 

Foreign tax rate differential

 

 

(7.9

)

 

 

(12.4

)

 

 

(3.8

)

Change in valuation allowance

 

 

(17.3

)

 

 

(30.5

)

 

 

(18.3

)

Stock-based compensation

 

 

6.7

 

 

 

7.7

 

 

 

(0.6

)

Research tax credit

 

 

3.8

 

 

 

3.3

 

 

 

1.3

 

Other

 

 

 

 

 

(0.1

)

 

 

(0.1

)

Sale of future royalties

 

 

(9.4

)

 

 

 

 

 

 

Section 162(m)

 

 

(1.2

)

 

 

 

 

 

 

Fair value adjustments

 

 

 

 

 

 

 

 

(2.4

)

Extinguishment of convertible note

 

 

 

 

 

 

 

 

(2.7

)

Provision for income taxes

 

 

0.0

%

 

 

0.0

%

 

 

0.0

%

 

The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. As of December 31, 2020, 2019 and 2018, none of the unrecognized tax benefits would affect income tax expense with consideration of the valuation allowance. The Company does not anticipate the uncertain tax positions will materially change in the next 12 months. It is the Company's policy to include penalties and interest expense related to income taxes as a component of other expense, net as necessary.

The beginning and ending unrecognized tax benefits amounts are as follows (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

December 31,

2018

 

Unrecognized tax benefits at beginning of period

 

$

1,838

 

 

$

398

 

 

$

357

 

Increases related to prior year tax positions

 

 

 

 

 

 

 

 

-

 

Increases related to current year tax positions

 

 

2,812

 

 

 

1,440

 

 

 

41

 

Unrecognized tax benefits at end of period

 

$

4,650

 

 

$

1,838

 

 

$

398

 

 

The Company files income tax returns in the United States and Switzerland. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits.

138


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

9. Preferred Stock

As of December 31, 2020 and 2019, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue up to 10,000,000 shares of preferred stock at the par value of $0.0001 per share. As of December 31, 2020, there are no holders of the Company’s preferred stock.

10. Common Stock

As of December 31, 2020 and 2019, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 490,000,000 shares of common stock at the par value of $0.0001 per share. Each share of common stock is entitled to one vote. The board of directors may declare and pay dividends to holders of common stock. The Company has never declared or paid any dividends on common stock.

 

The Company had reserved common stock for future issuances as follows:

 

 

 

December 31,

2020

 

 

December 31,

2019

 

Exercise of options outstanding and release of restricted shares

 

 

7,257,221

 

 

 

6,830,442

 

Exercise of common stock warrants outstanding

 

 

399,999

 

 

 

399,999

 

Issuance of common stock under the 2018 Equity Incentive Plan

 

 

2,742,183

 

 

 

2,118,877

 

Issuance of common stock under the 2018 Employee Share Purchase Plan

 

 

460,000

 

 

 

460,000

 

Total

 

 

10,859,403

 

 

 

9,809,318

 

 

 

11. Stock-Based Compensation

2018 Equity Incentive Plan

In August 2018, the Company adopted the 2018 Equity Incentive Plan (“2018 Plan”), which became effective on the business day prior to the effectiveness of the registration statement relating to the IPO. The 2018 Plan initially reserved 4,300,000 shares of common stock for the issuance of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock, restricted stock units (“RSUs”), stock appreciation rights, performance units and performance shares to employees, directors and consultants of the Company. The number of shares available for issuance will increase annually on the first day of each fiscal year beginning in 2019 equal to the least of (1) 4,300,000 shares, and (2) 4% of outstanding shares of common stock as of the last day of the immediately preceding year, and (3) such other amount as determined by the board of directors. The exercise price of options must be equal to at least the fair market value of the common stock on the grant date. For ISOs, the term may not exceed ten years, except in respect to any participant with more than 10% of voting power of all classes or stock, then the term may not exceed five years and the exercise price must be equal to at least 110% of the fair market value of the common stock on the grant date. Options granted generally vest over four years.

The number of shares available for issuance increased by 1,776,761 shares in 2020 and there were 2,742,183 shares available for grant under the 2018 Plan as of December 31, 2020.

Shares Subject to Repurchase

The Company has a right of repurchase with respect to unvested shares issued upon early exercise of options at an amount equal to the lower of (1) the exercise price of each restricted share being repurchased and (2) the fair market value of such restricted share at the time the Company’s right of repurchase is exercised. The Company’s right to repurchase these shares lapses as those shares vest over the requisite service period.

Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as accrued liabilities and other current liabilities on the consolidated balance sheet and is reclassified to common stock and additional paid-in capital as such shares vest. At December 31, 2020 and 2019, there are no early exercised stock options that remained subject to the Company’s right of repurchase.

139


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

Stock Options

Stock option activity under the 2018 Plan and 2015 Plan is summarized as follows:

 

 

 

Number

of

Options

 

 

Weighted

Average

Exercise

Price

 

 

Weighted

Average

Remaining

Contractual

Term

(in years)

 

 

Aggregate

Intrinsic

Value

(in thousands)

 

Outstanding at December 31, 2019

 

 

6,671,542

 

 

$

17.90

 

 

 

8.73

 

 

$

362,081

 

Granted

 

 

1,068,335

 

 

$

55.27

 

 

 

 

 

 

 

 

 

Exercised

 

 

(704,675

)

 

$

8.89

 

 

 

 

 

 

 

 

 

Forfeited or canceled

 

 

(137,926

)

 

$

25.07

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

6,897,276

 

 

$

24.52

 

 

 

8.07

 

 

$

841,704

 

Shares exercisable December 31, 2020

 

 

3,769,990

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested and expected to vest December 31, 2020

 

 

6,897,276

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The weighted-average grant date fair value of the stock options granted for 2020, 2019 and 2018 was $32.44, $34.11 and $4.36 per share, respectively. The aggregate intrinsic value represents the value of the Company’s closing stock price on the last trading day of the period in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable.

Employee Stock Options

Prior to the Company’s IPO, the fair value of the shares of common stock underlying the stock options was determined by the board of directors with assistance from management and external appraisers as there has been no historical public market for the Company’s common stock. Subsequent to the Company’s IPO, the fair value of the Company’s common stock is determined based on its closing market price.

The Company estimated the fair value of employee stock options using the Black-Scholes valuation model. The fair value of employee stock options was estimated using the following weighted-average assumptions:

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

 

Expected volatility

 

 

66

%

 

 

68

%

 

 

59

%

 

Risk-free interest rate

 

 

0.39

%

 

 

1.65

%

 

 

2.82

%

 

Dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

 

Expected term

 

 

6.00

 

 

 

5.78

 

 

 

6.06

 

 

 

Expected Term. The expected term is calculated using the simplified method, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.

Expected Volatility. As the Company does not have sufficient trading history for its common stock, our approach to estimating expected volatility is to phase in our own common stock trading history and supplement the remaining historical information with an average historical stock price volatility of a peer group of publicly traded companies to be representative of its expected future stock price volatility. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, the Company measured historical volatility over a period equivalent to the expected term. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

Risk-Free Interest Rate. The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.

140


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

Expected Dividend Rate. The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be zero.

The total fair value of employee options vested during the years ended December 31, 2020, 2019 and 2018 was $19.7 million, $4.6 million and $1.2 million, respectively. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for options granted to employees was $20.8 million, $5.7 million and $2.0 million, respectively.

Non-Employee Stock Options

The Company granted 41,500, 15,000 and 215,000 stock options to non-employees during the years ended December 31, 2020, 2019 and 2018, respectively.

Subsequent to the adoption of ASU 2018-07 effective January 1, 2019, existing stock options granted to non-employees will no longer be revalued, and the estimated fair value of new stock options granted to non-employees will be calculated on the date of grant and not remeasured, similar to stock options granted to employees. The fair value of non-employee stock options was estimated using the following weighted-average assumptions:

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Expected volatility

 

 

67

%

 

 

73

%

 

 

68

%

Risk-free interest rate

 

 

0.36

%

 

 

1.61

%

 

 

2.71

%

Dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

Expected term

 

 

5.56

 

 

 

6.08

 

 

 

9.30

 

 

Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for options granted to non-employees was $0.7 million, $0.1 million and $0.4 million, respectively.

Restricted Shares

Restricted share activity, including restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and performance-based restricted stock units (“PSUs”), under the 2018 Plan and 2015 Plan is summarized as follows:

 

 

 

 

Number of

Restricted

Shares

 

 

Weighted

Average

Grant Date

Fair Value

 

Unvested at December 31, 2019

 

 

160,747

 

 

$

60.81

 

Granted

 

 

236,045

 

 

$

52.18

 

Vested

 

 

(23,848

)

 

$

9.21

 

Shares withheld related to net share settlement of RSUs

 

 

(7,999

)

 

$

9.90

 

Canceled

 

 

(5,000

)

 

$

72.46

 

Unvested at December 31, 2020

 

 

359,945

 

 

$

59.54

 

 

Restricted Stock Awards

Under the terms of the restricted stock agreements, the awards vest over four years, which is the requisite service period. Recipients of restricted stock awards generally have voting and dividend rights with respect to such shares upon grant without regard to vesting. Shares of restricted stock that do not vest are subject to forfeiture. The Company recognizes stock-based compensation expense for RSAs on a straight-line basis over the requisite service period for the entire award.

The Company did not grant any RSA to employees in 2020. The total fair value of RSAs vested during the years ended December 31, 2020, 2019 and 2018 was $nil million, less than $0.1 million and $0.2 million, respectively. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for RSAs was $nil million, less than $0.1 million and $0.2 million, respectively.

141


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

Restricted Stock Units

RSUs will vest in four equal annual installments over four years, which is the requisite service period after that date.

The Company granted 236,045 RSUs to employees in 2020. The total fair value of RSUs vested during the year ended December 31, 2020 and 2019 was $0.3 million and $0.3 million, respectively. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for RSUs was $1.9 million, $0.3 million, and less than $0.1 million, respectively.

Performance-Based Stock Options and Restricted Stock Units

These performance-based equity awards will vest one-quarter upon the achievement of specific clinical development milestones. The remaining shares will then vest in three equal annual installments after that date. Performance-based stock options are recorded as expense beginning when vesting events are determined to be probable.

The Company did not grant performance-based equity awards to employees in 2020. None of these performance-based equity awards vested during 2020 or 2019. The Company believes that the achievement of the requisite performance condition continues to be probable. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for the performance-based equity awards was $7.2 million, less than $0.1 million and $nil million, respectively.

The fair value of performance-based stock options was estimated using the following weighted-average assumptions:

 

 

 

 

 

Year Ended

December 31,

2019

 

Expected volatility

 

 

 

 

72

%

Risk-free interest rate

 

 

 

 

1.67

%

Dividend yield

 

 

 

 

0

%

Expected term

 

 

 

 

6.31

 

 

 

The weighted-average grant date fair value was $47.89 per share for performance-based stock options and $73.51 per share for performance-based restricted stock units.

2018 Employee Share Purchase Plan

In August 2018, the Company adopted the 2018 Employee Share Purchase Plan (“ESPP”), which became effective on the business day prior to the effectiveness of the registration statement relating to the IPO. A total of 460,000 shares of common stock were initially reserved for issuance under the ESPP. The initial offering period of the ESPP was authorized by the Company’s board of directors and commenced on January 4, 2021.

Stock-Based Compensation Expense

Stock-based compensation is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

 

Research and development

 

$

16,957

 

 

$

3,496

 

 

$

1,535

 

 

General and administrative

 

 

13,711

 

 

 

2,614

 

 

 

1,073

 

 

Total stock-based compensation

 

$

30,668

 

 

$

6,110

 

 

$

2,608

 

 

 

As of December 31, 2020, the Company had $91.4 million of unrecognized compensation expense related to unvested stock options and unvested restricted stock awards and units that is expected to be recognized over a weighted-average period of 2.9 years.

142


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

12. Net Loss per Share Attributable to Common Stockholders

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share data):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$

(133,096

)

 

$

(47,365

)

 

$

(41,443

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding

 

 

45,741,845

 

 

 

37,869,291

 

 

 

15,136,197

 

Less: weighted-average unvested restricted shares

   and shares subject to repurchase

 

 

 

 

 

(15,675

)

 

 

(159,682

)

Weighted-average shares outstanding used in

   computing net loss per share attributable to

   common stockholders, basic and diluted

 

 

45,741,845

 

 

 

37,853,616

 

 

 

14,976,515

 

Net loss per share attributable to common stockholders,

   basic and diluted

 

$

(2.91

)

 

$

(1.25

)

 

$

(2.77

)

 

The following potentially dilutive securities, presented on an as-converted to common stock basis, were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive:

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Exercise of options outstanding

 

 

6,897,276

 

 

 

6,671,542

 

 

 

5,135,267

 

Unvested restricted shares

 

 

359,945

 

 

 

160,747

 

 

 

50,450

 

Total

 

 

7,257,221

 

 

 

6,832,289

 

 

 

5,185,717

 

 

13. 401(k) Plan

In 2011, the Company adopted a 401(k) retirement and savings plan covering all employees. The 401(k) plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The 401(k) plan was amended to include an employer matching provision in 2019. The Company will make matching contributions of 100% of employee contributions up to a maximum of 50% of the individual maximum contribution limit allowed under the IRS rules. For the year ended December 31, 2020 and 2019, the expense related to the matching contributions was $0.6 million and $0.3 million, respectively.

14. Liability related to Sale of Future Royalties

On December 1, 2019, the Company and its subsidiary Kodiak Sciences GmbH entered into a funding agreement with BBA, which holds more than 5% of the Company’s stock, pursuant to which BBA purchased the right to receive a capped 4.5% royalty on future net sales of KSI-301, the Company’s anti-VEGF antibody biopolymer conjugate therapy, in exchange for $225.0 million. The royalty terminates upon the date that BBA has received an aggregate amount equal to 4.5 times the funding amount paid to the Company, unless earlier terminated or repurchased by the Company. Under the terms of the funding agreement, there is no obligation to repay any funding amount received, other than through the capped royalty payments on future product revenues. The Company has the option, exercisable at any point during the term of the funding agreement, to repurchase 100% of the royalties due to BBA for a purchase price equal to 4.5 times the funding amount paid to the Company as of such time, less amounts paid by the Company to BBA.

The closing of the funding agreement was subject to certain conditions and occurred in February 2020. The Company received $100.0 million of the funding on February 4, 2020. The remaining $125.0 million, subject to delivery of notice by the Company, payable upon enrollment of 50% of the patients in the RVO clinical program.

143


Kodiak Sciences Inc.

Notes to Consolidated Financial Statements

(in thousands, except share and per share data)

 

The Company recorded the initial $100.0 million payment as a liability on the consolidated balance sheet net of issuance costs. Once royalty payments to BBA are determined to be probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest to accrete the liability on a prospective basis based on such estimates. If and when the Company makes royalty payments under the funding agreement, it would reduce the liability balance at such time. As of December 31, 2020, royalty payments are not probable and estimable.

For the year ended December 31, 2020, no interest expense was recognized for the liability related to the sale of future royalties.

 

 

15. Selected Quarterly Financial Data (unaudited)

The following table provides the selected quarterly financial information for the years, 2020 and 2019 (in thousands, except per share data):

 

 

 

Three Months Ended

 

 

 

March 31,

2020

 

 

June 30,

2020

 

 

September 30,

2020

 

 

December 31,

2020

 

Loss from operations

 

$

(25,723

)

 

$

(26,779

)

 

$

(36,663

)

 

$

(46,842

)

Net loss

 

$

(24,392

)

 

$

(25,999

)

 

$

(36,122

)

 

$

(46,583

)

Net loss per share attributable to common

   stockholders, basic and diluted

 

$

(0.54

)

 

$

(0.58

)

 

$

(0.80

)

 

$

(0.97

)

 

 

 

Three Months Ended

 

 

 

March 31,

2019

 

 

June 30,

2019

 

 

September 30,

2019

 

 

December 31,

2019

 

Loss from operations

 

$

(8,460

)

 

$

(11,814

)

 

$

(12,732

)

 

$

(16,184

)

Net loss

 

$

(7,984

)

 

$

(11,385

)

 

$

(12,380

)

 

$

(15,616

)

Net loss per share attributable to common

   stockholders, basic and diluted

 

$

(0.21

)

 

$

(0.31

)

 

$

(0.33

)

 

$

(0.40

)

 

 

 

 

144


ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES

None.

 

 

ITEM 9A. CONTROLS AND PROCEDURES

Management’s Evaluation of our Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of December 31, 2020. Based upon such evaluation, our principal executive officer and principal financial officer concluded that the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level as of December 31, 2020.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in “Internal Control—Integrated Framework” (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2020.

Our independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of our  internal control over financial reporting as of December 31, 2020, as stated in their report included in Item 8 of this Annual Report on Form 10-K.

Limitations on the Effectiveness of Controls

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements and projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended December 31, 2020, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

ITEM 9B. OTHER INFORMATION

We are currently party to an Investors’ Rights Agreement, dated September 8, 2015, as amended (the “Investors’ Rights Agreement”) which provides registration rights to entities affiliated with Felix Baker, a member of our board of directors, and Dr. Perlroth, our board chair and chief executive officer. The Investors’ Rights Agreement expires this year, and on March 1, 2021, we entered into a registration rights agreement (the “Registration Rights Agreement”) with 667, L.P., Baker Brothers Life Sciences, L.P. (collectively, the “Baker Entities”) and Victor Perlroth (together with the Baker Entities, the “Investors”) which is intended to supersede the expiring Investors’ Rights Agreement and pursuant to which the Investors are entitled to certain resale registration rights with respect to shares of common stock of the Company held by the Investors.  The rights of the Investors under the Registration Rights Agreement will continue in effect for up to ten years.

The foregoing is only a brief description of the terms of the Registration Rights Agreement and the transactions contemplated thereby, and is qualified in its entirety by reference to the Registration Rights Agreement that is filed as Exhibit 4.7.

 

145


 

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this item will be contained in our definitive proxy statement to be filed with the SEC in connection with the Annual Meeting of Stockholders within 120 days after December 31, 2020, or the Proxy Statement, under the caption “Executive Officers” and “Board of Directors and Corporate Governance”, and is incorporated in this Annual Report on Form 10-K by reference.

ITEM 11. EXECUTIVE COMPENSATION

The information required by this item will be contained in the Proxy Statement under the caption “Executive Compensation” and is incorporated in this Annual Report on Form 10-K by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this item will be contained in the Proxy Statement under the caption “Security Ownership of Certain Beneficial Owners and Management” and is incorporated in this Annual Report on Form 10-K by reference.

The information required by this item will be contained in the Proxy Statement under the caption “Related Person Transactions” and is incorporated in this Annual Report on Form 10-K by reference.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by this item will be contained in the Proxy Statement under the caption “Ratification of Appointment of Independent Registered Public Accounting Firm” and is incorporated in this Annual Report on Form 10-K by reference.

146


 

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a) The following documents are filed as part of this report:

(1) FINANCIAL STATEMENTS

The consolidated financial statements are filed as part of this report under Item 8.

(2) FINANCIAL STATEMENT SCHEDULES

All schedules to the consolidated financial statements are omitted as the required information is either inapplicable or presented in the consolidated financial statements.

(3) EXHIBITS

147


 

EXHIBIT INDEX

 

 

 

 

 

Incorporated by Reference

Exhibit

Number

 

Description

 

Form

 

File No.

 

Exhibit

 

Filing Date

 

 

 

 

 

 

 

 

 

 

 

    3.1

 

Amended and Restated Certificate of Incorporation of Kodiak Sciences Inc.

 

10-Q

 

001-38682

 

3.1

 

11/16/2018

 

 

 

 

 

 

 

 

 

 

 

    3.2

 

Amended and Restated Bylaws of Kodiak Sciences Inc.

 

10-Q

 

001-38682

 

3.2

 

11/16/2018

 

 

 

 

 

 

 

 

 

 

 

    4.1

 

Form of Common Stock Certificate

 

S-1/A

 

333-227237

 

4.1

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

    4.2

 

Investors’ Rights Agreement, dated September 8, 2015, as amended, by and among the registrant and the investors and founders named therein

 

S-1/A

 

333-227237

 

4.2

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

    4.5

 

Form of Class B Share Warrant

 

S-1/A

 

333-227237

 

4.5

 

9/7/2018

 

 

 

 

 

 

 

 

 

 

 

    4.6

 

Description of Securities

 

10-K

 

001-38682

 

4.6

 

3/16/2020

 

 

 

 

 

 

 

 

 

 

 

    4.7*

 

Registration Rights Agreement, dated March 1, 2021, by and among the registrant and the investors named therein

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  10.1+

 

Form of Director and Officer Indemnification Agreement

 

S-1/A

 

333-227237

 

10.1

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.2+

 

2009 Options and Profits Interest Plan

 

S-1

 

333-227237

 

10.2

 

9/7/2018

 

 

 

 

 

 

 

 

 

 

 

  10.3+

 

2015 Share Incentive Plan

 

S-1

 

333-227237

 

10.3

 

9/7/2018

 

 

 

 

 

 

 

 

 

 

 

  10.4+

 

Form of Notice of Stock Option Grant and Stock Option Agreement under the 2009 Option and Profits Interest Plan

 

S-1

 

333-227237

 

10.4

 

9/7/2018

 

 

 

 

 

 

 

 

 

 

 

  10.5+

 

Form of Notice of Stock Option Grant and Stock Option Agreement under the 2015 Share Incentive Plan

 

S-1

 

333-227237

 

10.5

 

9/7/2018

 

 

 

 

 

 

 

 

 

 

 

  10.6+

 

2018 Equity Incentive Plan

 

S-1/A

 

333-227237

 

10.6

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.7+

 

Form of Notice of Stock Option Grant and Stock Option Agreement under the 2018 Equity Incentive Plan

 

S-1/A

 

333-227237

 

10.7

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.8+

 

Form of Notice of Restricted Stock Unit Grant and Terms and Conditions of Restricted Stock Unit Grant under the 2018 Equity Incentive Plan

 

S-1/A

 

333-227237

 

10.8

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.9+

 

2018 Employee Stock Purchase Plan

 

S-1/A

 

333-227237

 

10.9

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.10+

 

Form of Subscription Agreement under the 2018 Employee Stock Purchase Plan

 

S-1/A

 

333-227237

 

10.10

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.11+

 

Executive Employment Agreement, effective as of September 6, 2018, between the Registrant and Victor Perlroth

 

S-1/A

 

333-227237

 

10.11

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.12+

 

Amended Executive Employment Agreement, effective as of September 6, 2018, between the Registrant and John Borgeson

 

S-1/A

 

333-227237

 

10.12

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.13+

 

Executive Employment Agreement, effective as of September 6, 2018, between the Registrant and Jason Ehrlich

 

S-1/A

 

333-227237

 

10.13

 

9/24/2018

148


 

 

 

 

 

 

 

 

 

 

 

 

  10.14+

 

Amended Executive Employment Agreement, effective as of September 6, 2018, between the Registrant and Hong Liang

 

S-1/A

 

333-227237

 

10.14

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.15+

 

Executive Incentive Compensation Plan

 

S-1/A

 

333-227237

 

10.15

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.16+

 

Outside Director Compensation Policy

 

S-1/A

 

333-227237

 

10.16

 

9/24/2018

 

 

 

 

 

 

 

 

 

 

 

  10.17

 

Funding Agreement, dated as of December 1, 2019, between Kodiak Sciences Inc., Kodiak Sciences GmbH and Baker Bros. Advisors, LP

 

8-K

 

001-38682

 

10.1

 

12/2/2019

 

 

 

 

 

 

 

 

 

 

 

  10.18

 

Lease Agreement for 1200 Page Mill Road, Building 3, by and between the Registrant and 1050 Page Mill Road Property, LLC, dated June 19, 2020

 

10-Q

 

001-38682

 

10.1

 

8/10/2020

  10.19

 

Lease Agreement for 1250 Page Mill Road, Building 4, by and between the Registrant and 1050 Page Mill Road Property, LLC, dated June 19, 2020

 

10-Q

 

001-38682

 

10.2

 

8/10/2020

  23.1*

 

Consent of Independent Registered Public Accounting Firm

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  24.1*

 

Power of Attorney (included in signature page)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  31.1*

 

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  31.2*

 

Certification of Principal Financial and Accounting Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  32.1*

 

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  32.2*

 

Certification of Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

Inline XBRL Instance Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

149


 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*

Filed herewith.

+

Indicates management contract or compensatory plan.

The certifications attached as Exhibits 32.1 and 32.2 are deemed “furnished” and not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Kodiak Sciences Inc. under the Securities Exchange Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof irrespective of any general incorporation by reference language contained in any such filing, except to the extent that the registrant specifically incorporates it by reference.

ITEM 16. FORM 10-K SUMMARY

None.

150


 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

KODIAK SCIENCES INC.

 

 

 

 

Date: March 1, 2021

 

 

By:

/s/ Victor Perlroth

 

 

 

Victor Perlroth, M.D.

 

 

 

Chairman and Chief Executive Officer

 

 

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Victor Perlroth and John Borgeson, jointly and severally, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Victor Perlroth

 

Chairman and Chief Executive Officer

(Principal Executive Officer)

 

March 1, 2021

Victor Perlroth, M.D.

 

 

 

 

 

 

 

/s/ John Borgeson

 

Senior Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

 

March 1, 2021

 

John Borgeson

 

 

 

 

 

 

 

/s/ Felix J. Baker

 

Director

 

March 1, 2021

 

Felix J. Baker, Ph.D.

 

 

 

 

 

 

 

/s/ Charles Bancroft

 

Director

 

March 1, 2021

 

Charles Bancroft

 

 

 

 

 

 

 

/s/ Bassil I. Dahiyat

 

Director

 

March 1, 2021

 

Bassil I. Dahiyat, Ph.D.

 

 

 

 

 

 

 

/s/ Richard S. Levy

 

Director

 

March 1, 2021

 

Richard S. Levy, M.D.

 

 

 

 

 

 

 

/s/ Robert A. Profusek

 

Director

 

March 1, 2021

 

Robert A. Profusek, J.D.

 

 

 

 

 

 

 

/s/ Taiyin Yang

 

Director

 

March 1, 2021

 

Taiyin Yang, Ph.D.

 

 

 

 

151

EX-4.7 2 kod-ex47_8.htm EX-4.7 kod-ex47_8.htm

Exhibit 4.7

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this Agreement) is made as of March 1, 2021 by and among Kodiak Sciences Inc., a Delaware corporation (the Company), and the persons listed on the attached Schedule A who are signatories to this Agreement (each, an “Investor,” and collectively, the Investors).  Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.

RECITALS

WHEREAS, the Company and the Investors wish to provide for certain arrangements with respect to the registration of the Registrable Securities (as defined below) by the Company under the Securities Act (as defined below).

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, and other consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

Section 1.
Definitions

1.1

Certain Definitions.  In addition to the terms defined elsewhere in this Agreement, as used in this Agreement, the following terms have the respective meanings set forth below:

(a)BBA Investors” shall mean 667, L.P. and Baker Brothers Life Sciences, L.P.

(b)Block Trade” shall mean an offering of Registrable Securities which requires one or more of the Investors and the Company to enter into a sale agreement and is limited in scope of selling efforts as compared to an Underwritten Offering.

(c)Board” shall mean the Board of Directors of the Company.

(d)Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

(e)Common Stock” shall mean the common stock of the Company, par value $0.0001 per share.

(f)Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time.

(g)Immediate Family” shall mean, with respect to a natural person, child, stepchild, grandchild, parent, stepparent, grandparent, spouse, life partner or similar statutorily-recognized domestic partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships of a natural person referred to herein.

(h)Investors’ Rights Agreement” shall mean that certain Investors’ Rights Agreement, dated September 8, 2015, as amended, by and among the Company and the investors party thereto.  

(i)Governmental Entity” shall mean any federal, state, local or foreign government, or any department, agency, or instrumentality of any government; any public international organization, any transnational governmental organization; any court of competent jurisdiction, arbitral, administrative agency, commission, or other governmental regulatory authority or quasi-governmental authority, any political party; and any national securities exchange or national quotation system.


(j)Other Securities” shall mean securities of the Company, other than Registrable Securities (as defined below).  

(k)Perlroth Investor” means D. Victor Perlroth, M.D.

(l)Person” shall mean any individual, partnership, corporation, company, association, trust, joint venture, limited liability company, unincorporated organization, entity or division, or any government, governmental department or agency or political subdivision thereof.

(m)Registrable Securities” shall mean the shares of Common Stock and any Common Stock issued or issuable upon the exercise or conversion of any other securities (whether equity, debt or otherwise) of the Company now owned or hereafter acquired by any of the Investors. Registrable Securities shall cease to be Registrable Securities upon the earliest to occur of the following events: (i) such Registrable Securities have been sold by the applicable Investor(s) pursuant to an effective Registration Statement; (ii) such Registrable Securities have been sold by the applicable Investor(s) pursuant to Rule 144 (or other similar rule), (iii) at any time after an Investor becomes an affiliate of the Company, (solely with respect to such Investor) such Registrable Securities may be resold by such Investor holding such Registrable Securities without limitations as to volume or manner of sale pursuant to Rule 144; or (iv) ten (10) years after the date of this Agreement.  For purposes of this definition, in order to determine whether an Investor is an “affiliate” (as such term is defined and used in Rule 144, and including for determining whether volume or manner of sale limitations of Rule 144 apply) the parties will assume that all convertible securities (whether equity, debt or otherwise) have been converted into Common Stock.

(n)The terms “register,” “registered” and “registration” shall refer to a registration effected by preparing and filing a Registration Statement in compliance with the Securities Act, and such Registration Statement becoming effective under the Securities Act.

(o)Registration Expenses” shall mean all expenses incurred by the Company in effecting any registration pursuant to this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, up to $50,000 of reasonable legal expenses of one special counsel for Investors (if different from the Company’s counsel and if such counsel is reasonably approved by the Company) in connection with the preparation and filing of the Resale Registration Shelf (as defined below), and up to $50,000 of reasonable legal expenses of one special counsel for the Investors (if different from the Company’s counsel and if such counsel is reasonably approved by the Company) per Underwritten Offering, blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such registration, but shall not include Selling Expenses.

(p)Registration Statement” means any registration statement of the Company filed with, or to be filed with, the Commission under the Securities Act, including the related prospectus, amendments and supplements to such registration statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws other than a registration statement (and related prospectus) filed on Form S-4 or Form S-8 or any successor forms thereto.

(q)Rule 144” shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission.

(r)Securities Act” shall mean the Securities Act of 1933, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time.

(s)Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities, the fees and expenses of any legal or special counsel and any other advisors any of the Participating Investors engage and all similar fees and commissions relating to the Investors’ disposition of the Registrable Securities.

(t)Underwritten Offering” shall mean a public offering of Registrable Securities pursuant to an effective registration statement under the Securities Act (other than pursuant to a registration statement on Form S-4 or S-8 or


any similar or successor form) which requires (i) any of the Participating Investors and (ii) the Company to enter into an underwriting agreement.  

 

Section 2.
Resale Registration Rights

2.1

Resale Registration Rights.

(a)Following written demand by one or more Investors (the Investors initiating any demand pursuant to Section 2, the “Initiating Investors”), the Company shall use commercially reasonable efforts to file with the Commission a Registration Statement on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance with the Securities Act) covering the resale of the Registrable Securities by the Initiating Investors (the “Resale Registration Shelf”), and the Company shall file such Resale Registration Shelf as promptly as reasonably practicable following such demand, and in any event within sixty (60) days of such demand.  Upon receipt of such written demand: (i) the Company shall give written notice thereof to all Investors within five (5) days of receipt and (ii) the Company shall afford such Investors the opportunity to include any Registrable Securities owned by them in such Resale Registration Shelf (the Initiating Investors and other Investors electing to participate in any registration pursuant to Section 2 are referred to herein as the “Participating Investors”).  Such Resale Registration Shelf shall include a “final” prospectus, including the information required by Item 507 of Regulation S-K of the Securities Act, as provided by the Participating Investors in accordance with Section 2.7.  Notwithstanding the foregoing, before filing the Resale Registration Shelf, the Company shall furnish to the Participating Investors a copy of the Resale Registration Shelf and afford the Participating Investors an opportunity to review and comment on the Resale Registration Shelf.  The Company’s obligation pursuant to this Section 2.1(a) is conditioned upon the Participating Investors providing the information contemplated in Section 2.7.  

(b)The Company shall use its commercially reasonable efforts to cause the Resale Registration Shelf and related prospectuses to become effective as promptly as practicable after filing.  The Company shall use its commercially reasonable efforts to cause such Registration Statement to remain effective under the Securities Act until the earlier of the date (i) all Registrable Securities covered by the Resale Registration Shelf have been sold or may be sold freely without limitations or restrictions as to volume or manner of sale pursuant to Rule 144 or (ii) all Registrable Securities covered by the Resale Registration Shelf otherwise cease to be Registrable Securities pursuant to the definition of Registrable Securities.  The Company shall promptly, and within two (2) business days after the Company confirms effectiveness of the Resale Registration Shelf with the Commission, notify the Participating Investors of the effectiveness of the Resale Registration Shelf.

(c)Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to effect, or to take any action to effect, a registration pursuant to Section 2.1(a):

(i) if the Company has and maintains an effective Registration Statement on Form S-3ASR that provides for the resale of an unlimited number of securities by selling stockholders (a “Company Registration Shelf”);

(ii) during the period forty-five (45) days prior to the Company’s good faith estimate of the date of filing of a Company Registration Shelf; or

(iii) if the Company has caused a Registration Statement to become effective pursuant to this Section 2.1 during the prior twelve (12) month period.

(d)If the Company has a Company Registration Shelf in place at any time in which any Initiating Investors make a demand pursuant to Section 2.1(a), the Company shall file with the Commission, as promptly as practicable, and in any event within fifteen (15) business days after such demand, a “final” prospectus supplement to its Company Registration Shelf covering the resale of the Registrable Securities by such Initiating Investors (the “Prospectus”); provided, however, that the Company shall not be obligated to file more than one Prospectus pursuant to this Section 2.1(d) in any six month period to add additional Registrable Securities to the Company


Registration Shelf that were acquired by such Initiating Investors other than directly from the Company or in an underwritten public offering by the Company.  The Prospectus shall include the information required under Item 507 of Regulation S-K of the Securities Act, which information shall be provided by the Investors in accordance with Section 2.7.  Notwithstanding the foregoing, before filing the Prospectus, the Company shall furnish to the Investors a copy of the Prospectus and afford such Initiating Investors an opportunity to review and comment on the Prospectus.

(e)Deferral and Suspension.  At any time after being obligated pursuant to this Agreement to file a Resale Registration Shelf or Prospectus, or after any Resale Registration Shelf has become effective or a Prospectus is filed with the Commission, the Company may defer the filing of or suspend the use of any such Resale Registration Shelf or Prospectus, upon giving written notice of such action to the Investors with Registrable Securities included (or to be included) in such Resale Registration Shelf or Prospectus (“Impacted Investors”) with a certificate signed by the Principal Executive Officer or Principal Financial Officer of the Company stating that in the good faith judgment of the Board, the filing or use of any such Resale Registration Shelf or Prospectus covering the Registrable Securities would be seriously detrimental to the Company or its stockholders at such time and that the Board concludes, as a result, that it is in the best interests of the Company and its stockholders to defer the filing or suspend the use of such Resale Registration Shelf or Prospectus at such time.  The Company shall have the right to defer the filing of or suspend the use of such Resale Registration Shelf or Prospectus for a period of not more than one hundred twenty (120) days from the date the Company notifies the Impacted Investors of such deferral or suspension; provided that the Company shall not exercise the right contained in this Section 2.1(e) more than once in any twelve month period.  In the case of the suspension of use of any effective Resale Registration Shelf or Prospectus, the Impacted Investors, immediately upon receipt of notice thereof from the Company, shall discontinue any offers or sales of Registrable Securities pursuant to such Resale Registration Shelf or Prospectus until advised in writing by the Company that the use of such Resale Registration Shelf or Prospectus may be resumed.  In the case of a deferred Prospectus or Resale Registration Shelf filing, the Company shall provide prompt written notice to the Impacted Investors of (i) the Company’s decision to file or seek effectiveness of the Prospectus or Resale Registration Shelf, as the case may be, following such deferral and (ii) in the case of a Resale Registration Shelf, the effectiveness of such Resale Registration Shelf.  In the case of either a suspension of use of, or deferred filing of, any Resale Registration Shelf or Prospectus, the Company shall not, during the pendency of such suspension or deferral, be required to take any action hereunder (including any action pursuant to Section 2.2 hereof) with respect to the registration or sale of any Registrable Securities pursuant to any such Resale Registration Shelf, Company Registration Shelf or Prospectus.

(f)Other Securities.  Subject to Section 2.2(e) below, any Resale Registration Shelf or Prospectus may include Other Securities, and may include securities of the Company being sold for the account of the Company; provided such Other Securities are excluded first from such Registration Statement in order to comply with any applicable laws or request from any Government Entity, Nasdaq or any applicable listing agency.  For the avoidance of doubt, no Other Securities may be included in an Underwritten Offering pursuant to Section 2.2 without the consent of (x) with respect to an Underwritten Offering initiated by the BBA Investor, the BBA Investors, and (y) with respect to an Underwritten Offering initiated by the Perlroth Investor, the Perlroth Investor.

2.2

Sales and Underwritten Offerings of the Registrable Securities.

(a)Notwithstanding any provision contained herein to the contrary, the BBA Investors, on the one hand, and the Perlroth Investor, on the other hand, shall, subject to the limitations set forth in this Section 2.2, each be permitted (i) one Underwritten Offering per calendar year, but no more than three Underwritten Offerings in total, and (ii) no more than two Underwritten Offerings or Block Trades in any twelve month period, to effect the sale or distribution of Registrable Securities.

(b)If any of the Investors intend to effect an Underwritten Offering or Block Trade pursuant to a Resale Registration Shelf or Company Registration Shelf to sell or otherwise distribute Registrable Securities, they shall so advise the Company and provide as much notice to the Company as reasonably practicable (and, in either case, not less than fifteen (15) business days prior to such Investors’ request that the Company file a prospectus supplement to a Resale Registration Shelf or Company Registration Shelf).  The Company shall give written notice of such Underwritten Offering to all Investors within five (5) days of receipt thereof, and such other Investors shall be entitled to participate in such Underwritten Offering, subject to the limitations set forth in this Section 2.2.  For the avoidance of doubt, no Investor shall have any right to participate in any other Investor’s Block Trade.    


(c)In connection with any offering initiated by any of the Investors pursuant to this Section 2.2 involving an underwriting of shares of Registrable Securities, (x) to the extent the BBA Investors initiated the offer, the BBA Investors and (y) to the extent the Perlroth Investor initiated the offer, the Perlroth Investor shall be entitled to select the underwriter or underwriters for such offering, subject to the consent of the Company, such consent not to be unreasonably withheld, conditioned or delayed.

(d)In connection with any offering initiated by the Investors pursuant to this Section 2.2 involving an Underwritten Offering of Registrable Securities, the Company shall not be required to include any of an Investor’s Registrable Securities in such underwriting unless such Investor (i) enters into an underwriting agreement in customary form with the underwriter or underwriters, (ii) accepts customary terms in such underwriting agreement with regard to representations and warranties relating to ownership of the Registrable Securities and authority and power to enter into such underwriting agreement and (iii) completes and executes all questionnaires, powers of attorney, custody agreements, indemnities and other documents as may be requested by such underwriter or underwriters.  Further, the Company shall not be required to include any of an Investor’s Registrable Securities in such underwriting if (Y) the underwriting agreement proposed by the underwriter or underwriters contains representations, warranties or conditions that are not reasonable in light of the Company’s then-current business or (Z) the underwriter, underwriters or such Investor require the Company to participate in any marketing, road show or comparable activity that may be required to complete the orderly sale of shares by the underwriter or underwriters.

(e)If the total amount of securities to be sold in any offering initiated by the Investors pursuant to this Section 2.2 involving an underwriting of shares of Registrable Securities exceeds the amount that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities (subject in each case to the cutback provisions set forth in this Section 2.2(e)), that the underwriters and the Company determine in their sole discretion shall not jeopardize the success of the offering.  If the Underwritten Offering has been requested pursuant to Section 2.2(a) hereof, the number of shares that are entitled to be included in the registration and underwriting shall be allocated in the following manner: (a) first, shares of Company equity securities that the Company desires to include in such registration shall be excluded, (b) second, Registrable Securities requested to be included in such registration by the Participating Investors shall be excluded, pro rata in accordance with the number of Registrable Securities held by each such Participating Investor at the time of such Underwritten Offering.  To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round down the number of shares allocated to any of the Investors to the nearest 100 shares.

2.3

Fees and Expenses.  All Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company.  All Selling Expenses relating to securities registered on behalf of any Participating Investors shall be borne by such Participating Investors on a pro rata basis, in accordance with the number of Registrable Securities that are registered and/or sold pursuant to such registration.

2.4

Registration Procedures.  In the case of each registration of Registrable Securities effected by the Company pursuant to Section 2.1 hereof, the Company shall keep the Participating Investors advised as to the initiation of each such registration and as to the status thereof.  The Company shall use its commercially reasonable efforts, within the limits set forth in this Section 2.4, to:

(a)prepare and file with the Commission such amendments and supplements to such Registration Statement and the prospectuses used in connection with such Registration Statement as may be necessary to keep such Registration Statement effective and current and comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Registration Statement;

(b)furnish to the Participating Investors such numbers of copies of a prospectus, including preliminary prospectuses, in conformity with the requirements of the Securities Act, and such other documents as the Participating Investors may reasonably request in order to facilitate the disposition of Registrable Securities;

(c)use its commercially reasonable efforts to register and qualify the Registrable Securities covered by such Registration Statement under such other securities or blue sky laws of such jurisdictions in the United States as shall be reasonably requested by the Participating Investors, provided that the Company shall not be required in


connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions;

(d)in the event of an Underwritten Offering or Block Trade, and subject to Section 2.2(d), enter into and perform its obligations under an underwriting agreement or Block Trade sale agreement, in usual and customary form (including any “lock-ups” on behalf of the Company and its directors and officers), with the managing underwriter of such offering and take such other usual and customary action as the Participating Investors may reasonably request in order to facilitate the disposition of such Registrable Securities;

(e)notify the Participating Investors at any time when a prospectus relating to a Registration Statement covering any Registrable Securities is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing.  The Company shall use its commercially reasonable efforts to amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing;

(f)provide a transfer agent and registrar for all Registrable Securities registered pursuant to such Registration Statement and, if required, a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;

(g)if requested by a Participating Investor, use commercially reasonable efforts to cause the Company’s transfer agent to remove any restrictive legend from any Registrable Securities, within two business days following such request;

(h)cause to be furnished, at the request of any Participating Investor, on the date that Registrable Securities are delivered to underwriters for sale in connection with an Underwritten Offering or Block Trade, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, and (ii) a letter or letters from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters; and

(i)cause all such Registrable Securities included in a Registration Statement pursuant to this Agreement to be listed on each securities exchange or other securities trading markets on which Common Stock is then listed.

2.5

The Investors’ Obligations.

(a)Discontinuance of Distribution.  Each Investor agrees that, upon receipt of any notice from the Company of the occurrence of any event of the kind described in Section 2.4(e) hereof, such Investor shall immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until such Investor’s receipt of the copies of the supplemented or amended prospectus contemplated by  Section 2.4(e) hereof or receipt of notice that no supplement or amendment is required and that such Investor’s disposition of the Registrable Securities may be resumed.  The Company may provide appropriate stop orders to enforce the provisions of this Section 2.5(a).

(b)Compliance with Prospectus Delivery Requirements.  Each Investor covenants and agrees that such Investor shall comply with the prospectus delivery requirements of the Securities Act as applicable to them or an exemption therefrom in connection with sales of Registrable Securities pursuant to any Registration Statement filed by the Company pursuant to this Agreement.

(c)Notification of Sale of Registrable Securities.  Each Investor covenants and agrees that such Investor shall notify the Company following its sale of Registrable Securities to a third party as promptly as reasonably practicable, and in any event within thirty (30) days, following the sale of such Registrable Securities.


2.6

Indemnification.

(a)To the extent permitted by law, the Company shall indemnify each of the Investors, and, as applicable, their respective officers, directors, and constituent partners, legal counsel for each Investor and each Person controlling the Investors, with respect to which registration, related qualification, or related compliance of Registrable Securities has been effected pursuant to this Agreement, and each underwriter, if any, and each Person who controls any underwriter within the meaning of the Securities Act against all claims, losses, damages, or liabilities (or actions in respect thereof) (collectively, “Investor Indemnified Persons”) to the extent such claims, losses, damages, or liabilities arise out of or are based upon (i) any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such registration, qualification, or compliance, or (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law applicable to the Company and relating to action or inaction required of the Company in connection with any such registration, qualification, or compliance; and the Company shall pay as incurred to the applicable Investor Indemnified Persons, any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action; provided, however, that the indemnity contained in this Section 2.6(a) shall not apply to amounts paid in settlement of any such claim, loss, damage, liability, or action if settlement is effected without the consent of the Company (which consent shall not unreasonably be withheld); and provided, further, that the Company shall not be liable to an Investor Indemnified Person in any such case to the extent that any such claim, loss, damage, liability, or expense arises out of or is based upon any violation by such Investor of the obligations set forth in Section 2.5 hereof or any untrue statement or omission contained in such prospectus or other document based upon written information furnished to the Company by such Investor Indemnified Person and stated to be for use therein.

(b)To the extent permitted by law, each Investor (severally and not jointly) shall, if Registrable Securities held by such Investor are included for sale in the registration and related qualification and compliance effected pursuant to this Agreement, indemnify the Company, each of its directors, each officer of the Company who signs the applicable Registration Statement, each legal counsel and each underwriter of the Company’s securities covered by such a Registration Statement, each Person who controls the Company or such underwriter within the meaning of the Securities Act against all claims, losses, damages, and liabilities (or actions in respect thereof) arising out of or based upon (i) any untrue statement (or alleged untrue statement) of a material fact contained in any such Registration Statement, or related document, or (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by such Investor of Section 2.5 hereof, the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law applicable to such Investor and relating to action or inaction required of such Investor in connection with any such registration and related qualification and compliance, and shall pay as incurred to such persons, any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action, in each case only to the extent that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in (and such violation pertains to) such Registration Statement or related document in reliance upon and in conformity with written information furnished to the Company by such Investor and stated to be specifically for use therein; provided, however, that the indemnity contained in this Section 2.6(b) shall not apply to amounts paid in settlement of any such claim, loss, damage, liability, or action if settlement is effected without the consent of such Investor (which consent shall not unreasonably be withheld); provided, further, that such Investor’s liability under this Section 2.6(b) (when combined with any amounts such Investor is liable for under Section 2.6(d)) shall not exceed such Investor’s net proceeds from the offering of securities made in connection with such registration.

(c)Promptly after receipt by an indemnified Person under this Section 2.6 of notice of the commencement of any action, such indemnified Person shall, if a claim in respect thereof is to be made against an indemnifying party under this Section 2.6, notify the indemnifying party in writing of the commencement thereof and generally summarize such action.  The indemnifying party shall have the right to participate in and to assume the defense of such claim; provided, however, that the indemnifying party shall be entitled to select counsel for the defense of such claim with the approval of any parties entitled to indemnification, which approval shall not be unreasonably


withheld; provided further, however, that if either party reasonably determines that there may be a conflict between the position of the Company and the Investors in conducting the defense of such action, suit, or proceeding by reason of recognized claims for indemnity under this Section 2.6, then counsel for such party shall be entitled to conduct the defense to the extent reasonably determined by such counsel to be necessary to protect the interest of such party.  The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to defend such action, shall relieve such indemnifying party, to the extent so prejudiced, of any liability to the indemnified Person under this Section 2.6, but the omission so to notify the indemnifying party shall not relieve such party of any liability that such party may have to any indemnified Person otherwise than under this Section 2.6.

(d)If the indemnification provided for in this Section 2.6 is held by a court of competent jurisdiction to be unavailable to an indemnified Person with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified Person hereunder, shall contribute to the amount paid or payable by such indemnified Person as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified Person on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations.  The relative fault of the indemnifying party and of the indemnified Person shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified Person and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission.  In no event, however, shall (i) any amount due for contribution hereunder be in excess of the amount that would otherwise be due under Section 2.6(a) or Section 2.6(b), as applicable, based on the limitations of such provisions and (ii) a Person guilty of fraudulent misrepresentation (within the meaning of the Securities Act) be entitled to contribution from a Person who was not guilty of such fraudulent misrepresentation.

(e)Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with an Underwritten Offering, or the Block Trade sale agreement, are in conflict with the foregoing provisions, the provisions in the underwriting agreement or Block Trade sale agreement shall control; provided, however, that the failure of the underwriting agreement to provide for or address a matter provided for or addressed by the foregoing provisions shall not be a conflict between the underwriting agreement or the Block Trade sale agreement and the foregoing provisions.  

(f)The obligations of the Company and the Investors under this Section 2.6 shall survive the completion of any offering of Registrable Securities in a Registration Statement under this Agreement or otherwise.

2.7

Information.  Each Participating Investor shall furnish to the Company such information regarding such Investor and the distribution proposed by the Investor as the Company may reasonably request and as shall be reasonably required in connection with any registration referred to in this Agreement that such Investor is participating in.  Each Participating Investor agrees to, as promptly as practicable (and in any event prior to any sales made pursuant to a prospectus), furnish to the Company all information required to be disclosed in order to make the information previously furnished to the Company by such Investor not misleading.  Each Investoragrees to keep confidential the receipt of any notice received pursuant to Section 2.4(e) and the contents thereof, except as required pursuant to applicable law.  Notwithstanding anything to the contrary herein, the Company shall be under no obligation to name any Investor in any Registration Statement if such Investor has not provided the information required by this Section 2.7 with respect to such Investor as a selling securityholder in such Registration Statement or any related prospectus.

2.8

Rule 144 Requirements.  With a view to making available to the Investors the benefits of Rule 144 and any other rule or regulation of the Commission that may at any time permit the Investors to sell Registrable Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to:

(a)make and keep public information available, as those terms are understood and defined in Rule 144 at all times after the date hereof;


(b)file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act;

(c)prior to the filing of the Registration Statement or any amendment thereto (whether pre‑effective or post‑effective), and prior to the filing of any prospectus or prospectus supplement related thereto, to provide each Investor with copies of all of the pages thereof (if any) that reference such Investor; and

(d)furnish to any Investor, so long as the Investor owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested by an Investor in availing itself of any rule or regulation of the Commission which permits an Investor to sell any such securities without registration.

2.9

Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company which would provide to such holder rights with respect to the registration of such securities under the Securities Act or the Exchange Act that would conflict with or adversely affect any of the rights provided to the Investors in this Section 2 in any material respect; it being understood and agreed that any subsequent agreement of the Company with any holder or prospective holder of any securities of the Company of the same class (or convertible into or exchange for securities of the same class) as the Registrable Securities granting such Person rights under this Section 2 equivalent to the rights of the Investors under this Section 2 will not be prohibited by the terms of this Section 2.9.

Section 3.
Miscellaneous

3.1

Amendment.  With respect to the rights and obligations of the BBA Investors, no amendment, alteration, waiver or modification of any of the provisions of this Agreement shall be binding unless made in writing and signed by each of the Company and the BBA Investors. With respect to the rights and obligations of the Perlroth Investor, no amendment, alteration, waiver or modification of any of the provisions of this Agreement shall be binding unless made in writing and signed by each of the Company and the Perlroth Investor.

3.2

Prior Agreement.  The Investors’ Rights Agreement is hereby terminated, effective as of the date hereof, and is superseded by this Agreement.

3.3

Injunctive Relief.  It is hereby agreed and acknowledged that it shall be impossible to measure in money the damages that would be suffered if the parties fail to comply with any of the obligations herein imposed on them and that in the event of any such failure, an aggrieved Person shall be irreparably damaged and shall not have an adequate remedy at law.  Any such Person shall, therefore, be entitled (in addition to any other remedy to which it may be entitled in law or in equity) to injunctive relief, including, without limitation, specific performance, to enforce such obligations, and if any action should be brought in equity to enforce any of the provisions of this Agreement, none of the parties hereto shall raise the defense that there is an adequate remedy at law.

3.4

Notices.  All notices required or permitted under this Agreement must be in writing and sent to the address or email address identified below.  Notices must be given: (a) by personal delivery, with receipt acknowledged; (b) by email followed by hard copy delivered by the methods under clause (c) or (d); (c) by prepaid certified or registered mail, return receipt requested; or (d) by prepaid reputable overnight delivery service.  Notices shall be effective upon receipt.  Any Investor may change its notice address by providing the Company written notice of such change and the Company may change its notice address by providing the Investors written notice of such change.  Notices shall be delivered as follows:

If to an Investor:

At such Investor’s address as set forth on Schedule A hereto


If to the Company:

 

Kodiak Sciences Inc.

Attention: John Borgeson, Chief Financial Officer

E-mail: [Omitted]

with a copy to:

 

Cooley LLP

Attention: Dave Peinsipp

E-mail: [Omitted]

 

3.5

Governing Law; Jurisdiction; Venue; Jury Trial.

(a)This Agreement shall be governed by, and construed in accordance with, the law of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York.

(b)Each of the Company and the Investors irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of the courts of the State of New York sitting in the Borough of Manhattan, New York and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement and the transactions contemplated herein, or for recognition or enforcement of any judgment, and each of the Company and the Investors irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York state court or, to the fullest extent permitted by applicable law, in such federal court.  Each of the Company and the Investors hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.

(c)Each of the Company and the Investors irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement and the transactions contemplated herein in any court referred to in Section 3.4(b) hereof.  Each of the Company and the Investors hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.

(d)EACH OF THE COMPANY AND THE INVESTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).  EACH OF THE COMPANY AND THE INVESTORS (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT EACH OF THE COMPANY AND THE INVESTORS HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

3.6

Successors, Assigns and Transferees.  Any and all rights, duties and obligations hereunder shall not be assigned, transferred, delegated or sublicensed by any party hereto without the prior written consent of the other party; provided, however, that the Investors (a) shall be entitled to transfer Registrable Securities to (i) one or more of their respective affiliates (ii) any member or members of such Investor’s Immediate Family or a trust for the benefit of any member or members of such Investor’s Immediate Family, (iii) a trust in respect of which such Investor serves as trustee, or (iv) a limited partnership or limited liability company, all partners or members of which are members of such Investor’s Immediate Family, and (b), solely in connection therewith, may assign their rights hereunder in respect of such transferred Registrable Securities, in each case, so long as such Investor is not relieved of any liability or obligations hereunder, without the prior consent of the Company.  Any transfer or assignment made other than as provided in the first sentence of this Section 3.5 shall be null and void.  Subject to the foregoing and except as otherwise provided herein, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of


the parties hereto.  The Company shall not consummate any recapitalization, merger, consolidation, reorganization or other similar transaction whereby stockholders of the Company receive (either directly, through an exchange, via dividend from the Company or otherwise) equity (the “Other Equity”) in any other entity (the “Other Entity”) with respect to Registrable Securities hereunder, unless prior to the consummation thereof, the Other Entity assumes, by written instrument, the obligations under this Agreement with respect to such Other Equity as if such Other Equity were Registrable Securities hereunder.

3.7

Entire Agreement.  This Agreement, together with any exhibits hereto, constitute the entire agreement between the parties relating to the subject matter hereof and all previous agreements or arrangements between the parties, written or oral, relating to the subject matter hereof are superseded.

3.8

Waiver.  No failure on the part of either party hereto to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of either party hereto in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver thereof; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.

3.9

Severability.  If any part of this Agreement is declared invalid or unenforceable by any court of competent jurisdiction, such declaration shall not affect the remainder of the Agreement and the invalidated provision shall be revised in a manner that shall render such provision valid while preserving the parties’ original intent to the maximum extent possible.

3.10

Titles and Subtitles.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.  All references in this Agreement to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits attached hereto.

3.11

Counterparts.  This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties that execute such counterparts (including by facsimile or other electronic means), and all of which together shall constitute one instrument.

3.12

Term and Termination.  Each Investor’s rights to demand the registration of the Registrable Securities under this Agreement, as well as the Company’s obligations hereunder other than pursuant to Section 2.6 hereof, shall terminate automatically once all of such Investor’s Registrable Securities cease to be Registrable Securities pursuant to the terms of this Agreement.

3.13

Relationship of the Parties. The rights and obligations hereunder of the BBA Investors, on the one hand, and the Perlroth Investor, on the other hand, shall be several and not joint.

[Remainder of Page Intentionally Left Blank; Signature Page Follows]

 

 


IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement effective as of the day, month and year first above written.

Kodiak sciences inc.

By:/s/ John Borgeson                                    

Name:John Borgeson

 

Title:

Chief Financial Officer

 

 


IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement effective as of the day, month and year first above written.

INVESTORS:

667, L.P.

 

By:

BAKER BROS. ADVISORS LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner

By:/s/ Scott L. Lessing                                 

Scott L. Lessing

President

BAKER BROTHERS LIFE SCIENCES, L.P.

 

By:

BAKER BROS. ADVISORS LP, management company and investment adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to BAKER BROTHERS LIFE SCIENCES, L.P., and not as the general partner

By:/s/ Scott L. Lessing                                

Scott L. Lessing

President

 

 


IN WITNESS WHEREOF, the parties hereto have executed this Registration Rights Agreement effective as of the day, month and year first above written.

INVESTORS:

By:/s/ Victor Perlroth                                  

D. Victor Perlroth, M.D.

 

 


 

Schedule A

The Investors

667, L.P.

BAKER BROTHERS LIFE SCIENCES, L.P.

To the above Investors:

Baker Brothers Investments
860 Washington Street
New York, NY 10014

Attn: Scott Lessing

Email: [Omitted]

 

With a copy to:

 

Akin Gump Strauss Hauer & Feld LLP
Attn: Jeffrey Kochian
Email: [Omitted]

One Bryant Park
New York, NY 10036-6745

 

 

 

D. Victor Perlroth, M.D.

c/o Kodiak Sciences Inc.

1200 Page Mill Road

Palo Alto, CA 94304

Email: [Omitted]

 

 

EX-23.1 3 kod-ex231_11.htm AUDITOR'S CONSENT kod-ex231_11.htm

 

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos.333-250109 and 333-234443) and Form S-8 (Nos. 333-231503 and 333-227755) of Kodiak Sciences Inc. of our report dated March 1, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
San Jose, California
March 1, 2021

 

EX-31.1 4 kod-ex311_10.htm 302 CERTIFICATION kod-ex311_10.htm

 

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Victor Perlroth, M.D., certify that:

1.

I have reviewed this Annual Report on Form 10-K of Kodiak Sciences Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: March 1, 2021

 

By:

/s/ Victor Perlroth

 

 

 

Victor Perlroth, M.D.

 

 

 

Chairman and Chief Executive Officer

(Principal Executive Officer)

 

 

EX-31.2 5 kod-ex312_9.htm 302 CERTIFICATION kod-ex312_9.htm

 

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Borgeson, certify that:

1.

I have reviewed this Annual Report on Form 10-K of Kodiak Sciences Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: March 1, 2021

 

By:

/s/ John Borgeson

 

 

 

John Borgeson

 

 

 

Senior Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

EX-32.1 6 kod-ex321_6.htm 906 CERTIFICATION kod-ex321_6.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Kodiak Sciences Inc. (the “Company”) on Form 10-K for the fiscal year ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 1, 2021

 

By:

/s/ Victor Perlroth

 

 

 

Victor Perlroth, M.D.

 

 

 

Chairman and Chief Executive Officer

(Principal Executive Officer)

 

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Kodiak Sciences Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

 

EX-32.2 7 kod-ex322_7.htm 906 CERTIFICATION kod-ex322_7.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Kodiak Sciences Inc. (the “Company”) on Form 10-K for the fiscal year ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 1, 2021

 

By:

/s/ John Borgeson

 

 

 

John Borgeson

 

 

 

Senior Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

 

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Kodiak Sciences Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

 

GRAPHIC 8 gexyhn0lyczh000047.jpg GRAPHIC begin 644 gexyhn0lyczh000047.jpg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end GRAPHIC 9 gexyhn0lyczh000017.jpg GRAPHIC begin 644 gexyhn0lyczh000017.jpg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gexyhn0lyczh000007.jpg GRAPHIC begin 644 gexyhn0lyczh000007.jpg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�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gexyhn0lyczh000030.jpg GRAPHIC begin 644 gexyhn0lyczh000030.jpg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end GRAPHIC 12 gexyhn0lyczh000043.jpg GRAPHIC begin 644 gexyhn0lyczh000043.jpg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

+>2Q R:1Q\NU RHN2K!%;>E1*DSVD<\MQ#YB?(IW # M(!/X5K_9+;:5^SQ;6.2-@P:&M+9BI:WB)0;5R@^4>@H P(=8THX$NFA+E1AD M2%6PNP9ZY_G3C!" MSEVB0N1@L5&2* ,5=2TQM*,D%H@M3.JNC1A1\V#NQT/!!J/^V]*D6#RK(N\9 M_9 KG)F4'8V23ZY.<]. M*Z)[6WD;<\$3-SRR GD8/Z4T65HI!%K""!@$1C@4 9$.IZ3+)"BV!5I'7&85 M&TN,@GZCT_&D75=,AN7"V>Q8TPLB1J#MRP8^H (^O/2M233+.6YAN&A'F0G* M8X /TJ3[':EBQMH=Q;>3Y8R6]?K[T 8MGJ.B;[:TAM-K F-%,(RG;GN,_P#Z MZ;TJW1@;3RF;JL40(;=@@9XY*E3_^JI(M1L[ZRN9; M:SMVDMI-JK*-HSDE>V<\YZ=3CUK9:TMFW;K>([@%.4'('04-:VSHR-;Q,KC# M*4&&'7F@#$M;NSN_M$DFG6IMU@25FC ,=JVTM+:)G:.WB1G&&*H 6'OZT?9+8E2;>+*C .P<<8_E0! M0T^YMM0E:0V:1RL@?+ %F&67D_\ 3^=45OH[26[DO[.&)06@!MF+?(JEVR" M!C@]LY-;L=K!%*TB1*K'N!]?RZG\Z>88FSNB0YR3E1W&#^E '.?VKHL*000Z M>&8+M2,Q*"!G:1S]2??\:E_MO28PLQL9(RP C/DKEONL ,'T8&MG[#:?\^L' M P/W8Z>E.:UMW38T$3+Z% 1V_P !^5 &3:ZEIT][;I;6.'D8A9#$JX !Y'?^ M''K5=M:TP0*7L 4+_.?+7;T!9AZXR.U;_P!G@!4B&/*G*G:./I^9H^RV^,&" M+ .<;!_GL/RH QXM:TQ8QLM'2/(_Y9 /R%&/4[<#\*+*_TJ]G>.&TB"0H[, MQC7Y?NYQ[$,*V%MH$4*L$:J"" $ QR*([6WB!$<$2 C!VH!F@#'M-1M+Y9E ML-/1S#'N4,%4$\J5[]N_3FHX=9TR)H97LA"S1;X2L0RL9SMR?X2<'C\ZW(K: M" YB@CCXQ\B <4C6EL^W=;Q-M7:,H#@>GTH S;"ZL+N&6:QL!^[&X'RU7+>F M?7CK4,]QIEO8P7-S9X-Q"SDHH8HK8+#=UP2^./6MN.&*%=L4:(OHJ@"@PQ,H M5HT*A=H!48QZ?2@#G)-?L#=9GL!Y(QY3F,%V? XQVP#Z]JE;4M)01O'IH:+Y MB&6%>,#!('7MC\/2MLVEL4V&WB*XQ@H,8_R!^5(;*U8L6MH3N.3F,::]Q9YL6EBV"X5XR /F;H#SC9FK U'2KVWN;J&R6G1 .G2@#$&M:-/C9:&0*>* .?&O:/MQ) M9$!/F3$(/ R5/MGFIKC6=*4(DMKEXGV!&C7]V^0,>W.WIZBM?[':YS]FASZ^ M6/I2M:V[MN>WB8YW9* \\<_H/RH RY-0TZULX%GMB4: .0%#[5;G!SUR1^?6 MHCJ>DES&; [RPB8&%>'&<*>>O'';WK::V@@J!]+LI+O[2\ M"M)M*\],'KQT[F@#+_MG2I-XDM-T?&X^4" !R WON)Z9J634M*M[5IY;01K/ M*89%,:Y)4X.[GD _7K6HUI;M&R>2@5EVG:N.*CATVS@MT@6WC,:$LH==V"3D MGGO0!ERZC;+::>?[*#+-\Z1X0^6=RCCW^;/%.@OM,NDG%G8H\D$;2*IA"AN. M0#Z]JV/LT'R?N8_DY3Y!\OT]*5((8F9HXHT9@ 2J@$XH YQ==TYMF^QC,$;; MH"JALH2%5E&.-S9'X9I7U[1,Q0I9AHY)1&=T R+;M";=@QM'0?3VH^R6V6/V>'+#!.P<\8_E0!AW>IBUO[A%L;4&W7,#R-M+ MDXW 84X.6 QU)-6[C4;.VF2.2UVW#%9BNP$C(VELCJ?X<_A6A)8VDK,TEK [ M/C<6C!+8Z9^E/,$1()B0D#:,J.GI0!C6=]IUY=P006$>UT8@E%'E]<@CWQVJ M"?6=*$:B6R1IA$[PQF('Y2,]>VX9_)O2M]+6WC*F.")"OW=J 8^GYFFI96R M 01\9QE/4[LU)%JNFW$=Q/:VP:2 MUC:4,T>W/4G!^N!-^V&-=XPV% W#WH Q#K>D M(9PEM\SL4DQ&H#GKR>G.>_K2M?:9$(?-T]%$MNDFU8E.Q3DX/L,=JV!96@.1 M:P@YW?ZL=?6G?9X, >3'@+M VC@>GTH PH=;TMP8A8,)9=J/$L2G<2!\I/0X M!%#ZSI'EK%#:1N)/NJ8U"MS@_P CV[5N+:6R-N6WB5O4( :/L=MN#?9H=RC M.P<"@#)NM6T^SG:"YM/]2XBAVQA@>$; ],9'MP*ABUC32EQOL-J%RH"QJ=X/ M(R/5MIX]AFMQ[2VD9V>WB9G #ED!+8Z9]:#:VY8,;>(L 0#L&1F@#*_M&PN[ M.Z\JS606B_,DL8 V@D''TVG\JJ)KM@6WS6" *V]"B!F(/,;#C^)=Q]L5T2P0 MJ9"L2#S/OX4?-]?6FFTMF4JUO$5( (*#&!T_*@#"76](DN+>"*T4K++L4F$ M;AD CCV(YQ^M))J@MKB\@CTZU79,IC0MM,W8D84@MD8 _/%;_P!EM\L?(BRQ MR3L')ICV-G(S,]I S,P9BT8))'?ZT 9NIWUMHJ1*ME'Y$BR>85 4(J@G)&.1 MDX/IG-5!K-HEM,;?3$1HE7S5D 174Y)"D [N_4#UKH3!$R[6B0@ @ J.AZ_G M1);PRQK')#&Z*055E! (Z8% &;I_V:^DN-]C:;8I<))'APQ[\X'S#OC(SWXJ M^+*U5"JVT(5AM("#!'7%.AMX+?=Y,,<>XY;8H&3ZG%2T 0I:6T;!DMXE9>A5 = ".U3444 %%%% !1110 4444 %%%% !1110!_]D! end GRAPHIC 15 gexyhn0lyczh000005.jpg GRAPHIC begin 644 gexyhn0lyczh000005.jpg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end GRAPHIC 16 gexyhn0lyczh000037.jpg GRAPHIC begin 644 gexyhn0lyczh000037.jpg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gexyhn0lyczh000036.jpg GRAPHIC begin 644 gexyhn0lyczh000036.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ JO M??:_L4HL3$MR5_=M*"5!]2!5BCJ* /.8[_Q+J/A#09+:YN))Y#,U[/;M&CLJ M[@,!P1R0.QKJ++6)Y_#>GWVG6MQJ/G(,^:ZI(.N2W;.1CBI)O"ND36%M9&W9 M(;8L8?+D963=G<,@YPC?E1]NB]&_*LZB@#1^W1>C?E1]NB]&_*LZB@#1^W1>C?E1] MNB]&_*LZB@"_)J,,<;.0^%&3@4HOX2 46,N@7NL6D-IHSPB601O=I>MYT6H Y7PYJ,L6M)I\KZ!<,EVX:X0L)F8@GCY I?& 3GM7HM>4>' MK=IM7TVX2TUI;-KA6CM[B%4CAV[MI,G5L9.!UY]J]7H **** .-L/^1K\0?[ M\7_H)K8K'L/^1K\0?[\7_H)K8IB"BBB@ HHHH **** "BBB@!DQ A7ZBDI5^ M\OU% &S1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 <5XROHM.\0:1/_:5G871AG6.2^3= PRF1PP(;H0?K6MX M>T^R;PK':PWJWEO-O9[BW;8K,S$MLVGY1DG&#Q5.]\)ZC/KCWUKXCN;:W?>3 M;M!'*%9MOW=P/'R_X5L1V-U_89LX]6?[3C O4AC# Y_N@;?;I0!YIX:?2X=; MT^%;9I%2[5;>.34Y9)(R0V&:,G;D8.1CC(KUZN6T_P )SV6MKJ,FM-/-G,H- ME K2#T+*H/Y5U- !1110!QMA_P C7X@_WXO_ $$UL5CV'_(U^(/]^+_T$UL4 MQ!1110 4444 %%%86H^+=+TO5X]-N&D\Y\995RJ9Z9H%*2BKLW:**:[I'&SR M,J(HR68X % SEM6L;N+5M5N;=9Y1+I\?5LKD2G6;RPSI-!@@M&V:L _*,=,#% 7,'P;!=VO MAR."\ADBE2608D?R#70CBN97 MMKF.V"+'@RR.,J$W8STZG K9K&N] ^TW5Q>,BMRZM$ MO/AX]MX?MY;>,HH6 YB(=.DU/6;K^S]'BL[J !GU>2[\ M@J,?> 7EAQU(QQ5_6-/U/_A7,EF;F;5[PI'ODA #3KYBE@,>JY% &'8:1?'6 M],U22SDM[JXOMXE><%8+15*K 3G#,W!P,],UZ-<7$-I;R7%Q*D4,8W.[G 4> MYKS7PK8PQ^)6DE\/ZJD*7!^P+(08;)2.3C/!)S^=>ES0QW$+12QI(C#E'4$' M\#0!B/XRT==(L]22666"]W&!8XRSN%SN.WT !-;5KF:Z'3?#L\7A73=,FO[JU MFMXQYCVDFW+7#[G/RGO704Q!1110 45B1>+M"FFN(EOT#0 ERPP#CK@]ZQ=8\=1S:>X\/+ M+<7(Y=_))$2]R12NC-U8)7N=K7!'18O&6K:EJ>3#%%^XM)$_B=?XSZC/%9]Y M<>-]:TBTECA=(WRI\@;6?W8=A7?Z-8C3-&M+,(J&*)0P7IN[_KFEN1=579K0 MYFU\=106KV5_%*VL0$Q&.)-PE<< @^]9>GVGBOQ*+RQU.YEM;-AER\0Y/91[ M5UD/A/2X->;6$23[06+[=WRACU.*W,YHL^H*G.7QO^O,\[?PUKWAC3MFEZ@9 M8YY +A8XN4_VAG]:BU+4_',%I9-]G9 %)W0KEI,?WQVX[5Z/)O\ +;RSA\<$ M^M.4D 9/..:+![!6M%M%+2=3@U;3(;R&16#)\_;:P^\".W->XT;1 MK*5KN7='',T@"@#JWX57U#P3J%SXKDG@E6'2YWWR>7*4(!ZC:.YKK=/\/:3I M5P9[*QCBE*[=XZXHU8?O):;?KZ'&Z.FI^!':765,NGW)VL\4F_RV'0X]Z[G2 M]3M=9LEO+%S)"21RN"".Q%)JNE6NLZ>]E=JQB<@Y4X((Z$5Q.M>"M0L(H$\. M3W'E,R.IL]4L-0DECL[N*=XCB0(V2M5]=URW\/Z=]MN$>0;P MJQH<%C7(R>#+_P .6]SJ.B:A-)=*,"((/F3N/AKR_0OAT=9\/1RZR]S;W."MO$,*(E[9'OUK>\.>+;:S" M>']:E2VU.T;[/R,(X ^4@]!D8H3[E4ZDO^7FESM:*QH/%>B7.KG2X;^-[H#@ M \'O@'IFM"TU&SO_ #/LEU%/Y9VOY; [3[TS=23V99HHHH&%%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '$3O^$) Q^%8V MN:+?S^)I[B?PU>:C$;\2/(LZ;);818$>TL.CX;!':M232M1'PN;3_):TNO-3 MRHY&#&%?/4J.N#@8XSVQ0!2L[>TAUW1WT'PSK&FR"Y"W,TL#I&T)5MV\DX/. MWK7I5^*89X/,VM#]B5#(<'Y0VXX/^%='0 4444 <;8?\C7X@ M_P!^+_T$UL5CV'_(U^(/]^+_ -!-;%,052U;48=*TJXO9^5C0X7^\>P_&KO M!)X ZFO-[C5;[Q'XR@LUC-QI,%UE0B_(P7^(GZTFS.I/E7FS1T'P)8MI_P!J MU2)GN;I"QCS@1;N>/>N@\/\ ARS\.0S):-(S2MEW<\G'05KT4601I0C:R"BB MBF:!1110 R4 PN&;:".6]*8AZ&K?B'X MC:;H=W;V\2?;?,7>[0N,(O\ C5_Q7X.M/%2VYFGD@D@)VN@!R#U&*EMO!7AZ MVMH81ID#^200[C+$^I/>C4FU9>ZG\SF+;XE2W?BZWT^*QVV$[B-7D!5SG^+! M_E7HU8WB+0K+5])N(YH0LBINCF11O0KR"#7#^'_B+J]W:260T>2^O((N)(SC M..,N.U%[;@INF[3=[GJ-%>4V'Q'U^WTN[NM0THSJCA4E5#&B,>S5W/A+Q$/$ MVB+?&(0R!RDD8;."*$RX5H3=D;M%>?;WK M11 MB22,?PJ>F?SZ44 87BSQ%<:-?:?:Q7VFV"7*R,UQ?AF7*[<* ".3GKGM46LR MSZK\/I)EOM/NIF:-Q/$_E0.5E4XR2<=,=>M:&KZ/]H(>77KJS5I25 :,#) M4;A[Q[2#)*%.\'UP,4 <+;VFN_:X;C4+"RM+ :M_:4E MR;Y6"+M88Z#/7KFO18Y$FC62-@R,,JP/!%<58Q> I-:\NUL;3[4)O+1O(.PR M=?E)&WL>1Z5VP P!@"@!:*** .-L/\ D:_$'^_%_P"@FMBL>P_Y&OQ!_OQ? M^@FJ'C77;_0M.@DL(U+2R;&D9../4_P!*")R45S,Q/&#:OK.O?V7HTLKQ MPQ 7"1/M568G[Q[\=J[JPLXK"P@M88TC2- -JCC/>LGP?9?9= BFDC=;JZ)F MG:3[S,?6MZA+J13C]M[L****9J%%%% !1110 V0L(V*+N8#@>M*,[1GKCFDD M#&-@K;6(X/I2C[HSR<4 +1110 4444 %%%% !2K]Y?J*2E7[R_44 ;-%%%(8 M4444 %%%% !4$%E:VKR/;VT,32'+M&@4L??'6IZ* (YH(;B%H9HDDC;AD=00 M?J*\\\7^#]46_ANO"J-;B7BXCMY?*&1T;&0*]'HI-7(G34U9G*Z5X$TBVCAN M+^V%[J.-TT\[%]SD<\'@CTXK$U'X>?V=J5SKVD7XMI(-UQ% 8LJI R1UZ=>, M5Z+1U$NC!JUCS.S^+2O83R7.D2F>)1@PME"?]H_PC\Z63XMQKID,ZZ1, M9WE0PW$,6G6R1W'^N41##_7UIK:#I#V4=FVFVIMHV MW)$8AM4^H%&I')6M\0:-K-IK>F0WUK(I60#*;@2C?W3[U7N/%>AVNK-ID^H1 M1W2C+*V0!QG!/3-6V MNX6,Z[DC\P;_ *8ZY%.YHJD6[)FC11106%9?]G7"ZQ>ZD)(WD>W2&V5P<1XR M6S]3M_[YK/\ %OC"W\*16YDMGN))V(5%8+@#JHV%SHBVEK<^;-$3)(GE-&$#L2 H;G M:.0/I47C#SSJFG+IJ:A_:ABEV-:.BCRLKN#;^#SMQWHT_3QX>T2;5V6X@NO* M2-TNV\\HH3CMD<+^M6%O;?3M?\27=W((X(VB+- M_P !-5/!\T>J7.K:T&#-<3^6@[K&H^7Z4>1E-IM1.JHHHIF@4444 %%%% !1 M110 R8*87#G"XY-.7&U<=,<4V4A87)7< .5]:_AOQM8^)WU2&]6\$0W!I)2HE7'W"HZ56M/%WC;5[/4K>WT MUO.4?+(D>PP\\@9ZFO6:0 #. !GDT6)]A;X9-'GWA3PK+JUI)J'BVWENKMCL MB2Z;.U![=LU+XK^',>M7EM<:9)!9% $E41\$#H1CN*[VBBQ7L8 MRUN^"Y4E\+VQ18@JLZCR2Q0X8C*EN2#V)K'\4:G>S:S#910Z]#8Q(_GRV%H& MWL<;?F92"N-V<5TOA\!=$ME4WFT @?;$"2XSW _*@#@])36(?&$%M<7#"5 MY_-DG;4 R3JN0X6/.>?EXQQBO3Z\DT*+3!XDLUB>^F47B>3<-9!$V ,47>3W M)8EOXJ];H **Y;QB=9;[!#I$DR*7=[DV\T<_M5JQU^'_A&M/U!( M=1NTG0 %8?,ESSDL%&.H//2@#D/$1@V^+_/7#6?%$]BD,\(N[Z%GCGC*-L123P?PKT:CJ9))U& M^P4444S0**** "BBB@ HHHH ;)O\MO+QOQ\N?6E&<#/7'--E&Z)ANVY'WO2G M#[HYSQUH 6BBB@ HHHH **** "E7[R_44E*OWE^HH V:***0PHHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#AYKV/2- M9UQ-9L=4N1?L%A>WADEC>'9@(-OW2"6STZYS5S3KV[\-^ 4NKZWFDFA&(K>1 M\R ,^V-&;U&Y035OQ#K]WI=[9V=G!9M+7/DH NW@'!R3NZ>U6#:Q^( MO#9M]82 QS@>:MK<$IPV1M<8/4"@#B=/9#XBT^6?0OL=O!?&RPE^S[;C#.#M MQAD!W >F>E>GUR]CX&\/6-_#>0+<-/%-YZ[[R1QYF"-Q!;!.":ZB@#/U31-/ MUE8Q?0%S$249)&1ER,'#*0<$=1WJW;6\-G;1VUO&L4,2A411@*!VJ6B@#R:& M]L9?B]=REV)(,,1QQY@&#_6N_KF[+2;%O'&M7AMU\^%T\MO[I93DX]3724(S MA&2OS!1113+"BBB@ HHHH **** &3;?)??G9CG'I3EQM7'3'%-E)$3$+N('W M?6G#[HXQQTH 6BBB@ HHHH **** "E7[R_44E*OWE^HH V:***0PHHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/'\ M5Y/)9+;VT+Q(DDCRR68N"N"N0 >GR[C[[<5=T"R@UCP*MEJ,8:VG#QMB'R Z M[CM8+QMSP1WK*\?7Y^TV8MKZ)_LSAI;5;Y8'#[D(8@GYAM##'^U5^%)Y/AS* M);1=:=D8I:).]= M#7E?A:7RO$MI!/KTND2,3MT%RY\S@\?O,_7Y3VKU2@ HHHH XVP_Y&OQ!_OQ M?^@FMBL>P_Y&OQ!_OQ?^@FMBF(**** "BBB@ HHHH **** &R!S&P0X?'!/K M2C.T9ZXYILP5H7#-M4CEO2G+]U<'(QUH 6BBB@ HHHH **** "E7[R_44E*O MWE^HH V:***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@#R/Q7<:./%%\EGI+6VIAAYVH2H#$YP.J[6+#'H!7337/ ME?#-9))HI]QCC>2UC-JIW2JI*CJO6NVK&\6",^%[X2PQ3)L&4EC:1#\PZJOS M'UXH Y>PDTC3;V 6&F6@F_M?[!YKR&63;M8EP6)(/%>@UYMX5T2"XU.UU"SC M\,RQ12;F>T\SS5.". 3P>>]>DT %%%% '&V'_(U^(/\ ?B_]!-;%8]A_R-?B M#_?B_P#036Q3$%%%% !1110 4444 <[?_:[KQ+/;+JMU96T%DDQ$&.268$G( M] *ADCBBB@E?Q??K'.GF1-O7#KP,CCI\P_.KT7_([W?'_,/B_P#0WK(7PG>K M;:A"TD3*-L-@,_ZN$2^80??M]%% QVZUGDEMD\6ZC)(A970%>HZC.W%3-%%' M)-"WBZ_62W">:F],IO\ NYX[U#8Z!J%L]]#- 7@N9)SO6Z.W;)G^#UYJOI_@ M_48KC2[FZEB:42E[_!/SJIS&H]<9H UI=.DANH;63Q3J"W$V?+B+IN; R<#' M:I-#:ZBU;5[&XOI[M+OV.M[;=)-/5(XK=FW>:I M&)"[?WAGY?<'UH J+>:8_GX\;W_[@9EY7Y.G7Y?4PQ M!F5=[XS@97KBK.J^'KZ[L_$,<1C+7\\,D(W[>$" Y/8_*:JS>%KO58+.&]C: M!()7D#M!(O&=Z[3Q M--$!(F71?O$?+V[U.X@\4:G)%(NY'5DP1Z_=K%?P/J$[O=--!!?& M*>6%XR2()Y'#;1ZI@8/KFNOT*SFT_0K&TN-OG0PJC[#D9 YQ0!G^&)+H2ZQ: M75Y+=_9;WRHY)<;MOEHV#@>K&N@KG_#O_(5\1_\ 81_]HQUT% !1110 4444 M %%%% !1110 56U#[;]@E_LX0&\Q^[\\G9G/?'/3-6:* .3LO!F==@UW5[[[ M3J4))3[/"L$8R,8('S-_P(FNLHHH **S-8UZRT18?M7FL\Q(CCAC+NP RQP. MP')J[:74%]:0W5M()()D#QN.A!Y% ')V'_(U^(/]^+_T$UL5D6 _XJOQ!_OQ M?^@FMC!]*8A**7!HP: $HI<&C!]* $HI<&C!H R;[08KW4/MPO+RVG,0B8V\ M@4,H)(SD'U-0_P#".'_H-:K_ -_E_P#B:W,&C!H PQX?=#O76=3)'(#RC'X\ M4?\ ".L>?[:U7GGB9?\ XFMB8+Y+[\A<+2Y+F5+BXGEN2IDDG<,?E! [#UK2P:,&@!**7!HP: $HI<&C M!H 2E7[R_448-"@[EX[T ;-%%%(84444 %%%% !6%/X7BDO[F\AU'4+5[A@T MBP2@*2!C."#6[10!@?\ ",-_T'=7_P"_Z_\ Q-'_ C#?]!W5_\ O^O_ ,36 M_10!@?\ ",-_T'=7_P"_Z_\ Q-'_ C#?]!W5_\ O^O_ ,36_10!@?\ ",-_ MT'=7_P"_Z_\ Q-'_ C#?]!W5_\ O^O_ ,36_10!@?\ ",-_T'=7_P"_Z_\ MQ-'_ C#?]!W5_\ O^O_ ,36_10!G:1HT.CQW BGGG>XE\Z62=PS,V /0=@* MT:** "BBB@ HHHH **** "BBB@ HHHH **** .8\3:?J#:KI^J:?:B[-O'-" M\.\*<.N P)]#U]JFTWPS$OA;3=+U'<[VR MYXT=;:&Y"RWZQS;9G/[O MRW)SSP,A:U_^$)T/_GA-_P!_W_QJM::WKM[?:[:+96T-Q:"/[+'))D$,,[G( M_/ ^E6?"VK7NI?VA'=20W"6LXBCNX%*I-\H+8'^R'?"6G7-C.]W#VBC9Y9 M;@%BS?PHJCU/%95WXTNTO]"LX[:*.6XDA&HAV_X]_,&0@_VOY"@#5_X0G0_^ M>$W_ '_?_&C_ (0G0_\ GA-_W_?_ !KH:* .>_X0G0_^>$W_ '_?_&C_ (0G M0_\ GA-_W_?_ !KH:* .-UWPAI=MH%_/:0W N(X&:,I,Y.['&!FK=IX+T9[. M!Y()][1J6S.^#]+M]#O9K6&X$Z0L8RDSDY[8YKL:X35O&EYIFOSQR_9 MX[2WNHK]3_\(;H_ M_/.X_P# A_\ &LGPMXMN]'X&3Z9KM: ,#_A M#='_ .>=Q_X$/_C1_P (;H__ #SN/_ A_P#&M^B@# _X0W1_^>=Q_P"!#_XT M?\(;H_\ SSN/_ A_\:WZ* ,#_A#='_YYW'_@0_\ C1_PANC_ //.X_\ A_\ M:WZ* ,#_ (0W1_\ GG=Q_X$/_ (USN1]Q M<=,]Z]#'(S0!@?\ "&Z/_P \[C_P(?\ QH_X0W1_^>=Q_P"!#_XUOT4 8'_" M&Z/_ ,\[C_P(?_&C_A#='_YYW'_@0_\ C6_10!@?\(;H_P#SSN/_ (?_&C_ M (0W1_\ GGYB7 C$ MH4>6 ,8&!6K10!@Z_P"&%UZ\LKEM1NK9K,EHEB(V[C_$01R1V]*AN_ ^C7T] MK^%;;4-86^N+FX>-723[,2-A9>G;..^,X)K>K%U3Q#'I6II:3PG MRWM9;A9<\$Q\E?KB@"#2_"-II>H17,=Q<21V_F"U@D8%(-YRV/\ Z_2NAKD] M+\-IPX3;]O:7+J?]G)>1F[!P8P>< MXSCZXYQ0!I4444 %%%% !1110 5S_P#PBJ0Z99V=EJ5[:&TWA)(GY8-U##H? M;TKH** .5?P#IFR.&WFN;>V\J.&>%'XG5#E=WOGJ>XKJ0 H P , 4M% !11 M10 4444 %%%% !1110!B>(_#B>(H;6*6]N+=;>43 0D8=ATW \$#KBI9-#2X ML]/ANKN>=[.=+A9G(W.RG(SBM:B@#FX/"1MM7VOR M_;=D.I0>5"BK_J&)!<_B57I55_A_*DU9;J&", MS>=,L!<>;\N-K(3MZ\[L9HHH Z^BBB@ HHHH **** "BBB@ HHHH **** "B 5BB@ HHHH **** "BBB@ HHHH __9 end GRAPHIC 18 gexyhn0lyczh000034.jpg GRAPHIC begin 644 gexyhn0lyczh000034.jpg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gexyhn0lyczh000011.jpg GRAPHIC begin 644 gexyhn0lyczh000011.jpg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end GRAPHIC 20 gexyhn0lyczh000024.jpg GRAPHIC begin 644 gexyhn0lyczh000024.jpg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end GRAPHIC 21 gexyhn0lyczh000021.jpg GRAPHIC begin 644 gexyhn0lyczh000021.jpg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gexyhn0lyczh000009.jpg GRAPHIC begin 644 gexyhn0lyczh000009.jpg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end GRAPHIC 23 gexyhn0lyczh000023.jpg GRAPHIC begin 644 gexyhn0lyczh000023.jpg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gexyhn0lyczh000032.jpg GRAPHIC begin 644 gexyhn0lyczh000032.jpg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end GRAPHIC 25 gexyhn0lyczh000055.jpg GRAPHIC begin 644 gexyhn0lyczh000055.jpg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end GRAPHIC 26 gexyhn0lyczh000008.jpg GRAPHIC begin 644 gexyhn0lyczh000008.jpg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gexyhn0lyczh000004.jpg GRAPHIC begin 644 gexyhn0lyczh000004.jpg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end GRAPHIC 28 gexyhn0lyczh000010.jpg GRAPHIC begin 644 gexyhn0lyczh000010.jpg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gexyhn0lyczh000026.jpg GRAPHIC begin 644 gexyhn0lyczh000026.jpg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end GRAPHIC 30 gexyhn0lyczh000031.jpg GRAPHIC begin 644 gexyhn0lyczh000031.jpg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end GRAPHIC 31 gexyhn0lyczh000018.jpg GRAPHIC begin 644 gexyhn0lyczh000018.jpg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end GRAPHIC 32 gexyhn0lyczh000035.jpg GRAPHIC begin 644 gexyhn0lyczh000035.jpg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gexyhn0lyczh000003.jpg GRAPHIC begin 644 gexyhn0lyczh000003.jpg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�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gexyhn0lyczh000050.jpg GRAPHIC begin 644 gexyhn0lyczh000050.jpg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gexyhn0lyczh000013.jpg GRAPHIC begin 644 gexyhn0lyczh000013.jpg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end GRAPHIC 36 gexyhn0lyczh000027.jpg GRAPHIC begin 644 gexyhn0lyczh000027.jpg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end GRAPHIC 37 gexyhn0lyczh000049.jpg GRAPHIC begin 644 gexyhn0lyczh000049.jpg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end GRAPHIC 38 gexyhn0lyczh000028.jpg GRAPHIC begin 644 gexyhn0lyczh000028.jpg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gexyhn0lyczh000042.jpg GRAPHIC begin 644 gexyhn0lyczh000042.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH ***S-<\0:7X$?=W'YG/HHZD_2A*X&G67K/B/1O#\'FZMJ-O M:J1D*[?,WT4^.[5?'^HL#PT=OO"D=Q]\#]*&^"6FW*;;_Q M!K-R!T!E7 _,&O4:*/:2#DB>6I\#-#MSOL]9UBWE[.LJ?T44I^$VK6HW:9X[ MU>W8<[7+$$^^''\C7J-%'M)=PY(GEG]B?%C1>;+7['5HATCN% 8_B1[_ -[M M3?\ A9_B/03M\6^#[F",?>N;3)0?GD?^/5ZK2$!@00"#P0:.=/=!R]F)=J6&IQBX;_ )=YOW1<6>(SGU M(^Z?Q&:Y5K;XA?#O+V\O_"2Z(G6-\^=&OZL/PW#V%'+&7PL5VMSURBN6\)^/ M]#\7Q[+.Y[;L<\\ _4]_0=E5.2CI$E* M^LAL<<<,2Q1(J1H,*JC ] *=116984444 %%%% !1110 4444 %%%% '#^+ MOAGIGB.3^T+%CI>LH=Z7=N-NYNVX#K]1S]>E8F@^/]4\.:HGASQ]$()B,6^I M#_5RCU8]/^!?F!UKU.LGQ%XEI;$N/5 M&JK*ZAE(92,@@Y!%+7D&D:UJOPLUF+P]XCE:Y\/3G%CJ&#^Z'H?8=QVZCBO7 MD=9$5T8,C#*LIR"/6IE'E&G<6BBBI&%%%% !1169X@URT\.:%=:K>MB&W3=M M!Y=N@4>Y.!0E<#F?B+XUE\/6L.DZ2AGU[43Y=M$HR8P>-^/7/ ]_H:G^'_@: M+PEIK3W3?:-9N_GN[ACN.3SM!],]3W//IC!^&F@W>K7UQX\UY=U_?$_8T/2& M+ID#MD<#V^M>H5I)\JY40E?WF%%%%9ED5S /7-:I)13:O*10RLIX(-25E>'AG3GD4%8 M);B62!2,8C+$C\#R1[$5JU$X\LFBX2YHIA2,RHI9B%4#))/ %+69XA!.@7G& M5"!I!GJ@(+#_ +YS1%W?]_+\C;HHHK W"BB MB@ HHHH S=>T*Q\1Z//IFHQ"2"8=?XD;LRGL17G'@O6;_P $>(_^$&\12E[= MSG2[QONLIZ)]#V'8\="*]9KE/'_@Z+QAX>>!,)J%OF6SFS@J_P#=)]#T_(]J MN$E\+V)DNJ.KHKA_AIXNE\1Z+)9:EN36M-;R+M'X9LO!!]P?45W%3)-. MS&G=7"BBBD,*\D\7M)X^^(]EX0@8_P!EZ:?M.HLIX+?W?R(4>['TKT?Q'K,7 MA[P[?ZM+@K;0EPI_B;HH_$D#\:X[X/Z++:^&YM=OAQQI#$D42*D:*%55& .@%.HKG?&.L2Z5I:+;L5FG;:&'50. MI'OT_.L*E14X.;Z&]&E*K-0CNS>:XA1]CS1JQ_A+ &I.HR*\:AD=F+,[%B2PFC9R1&PV@GIG/^%G:N_$5W0H M*:OV/.PV'6(KNF[=_P CN/#%PD_A^U*R!]JD 9Y503@'Z# K7KQB.]N+&Y6> MWE:.13P5->MZ5?#4M*MKS !E3+ = >A_7-EF=F)P#PL(M.ZV+E8> MNRF[WZ6DL<"^6LMS<2_=B3=P,=R2#UXP#6Y7*7ODS^*YI38W&H+!#&HBB4&- M9 6)+;B!N (P.>M>A17O7['FUW[MNY*FK26J-=1:O;ZK9QG_ $A5""2)<\N- MO! [@CIWK0TAUN;W4;V$?Z--(JQMVDVK@L/;/&?]FLO63IVKZ)?RHC6U[9Q, M3O3RY8^#P?56&1W!S73Q +"BJFQ0H 7T'I55&E';5Z?DR*:;EOHM?S0^BBD9 ME12S$!5&23V%F MQOXHTN"ADCDB)V2J.#C/((R,CWK,T'6;*UTV&TNY1:L@)B:X_=B:/)*NI/'( M[=14\-];ZSK\)LY%DAL49GE4\,SC: OJ.&)/3@5TRA9M-:+K_7_X@9^J#UKU>*6 M.>&.:)P\C?L0M)6[GH=%%%9EGE_P 8;B74!H/A M2V8B75+Q2^.R @#/MEL_\!KTNUMHK*TAM8%"0PQK&BCLH& *\P4?V[^T&Q/S M0Z+8\>@8C_&7]*]4K2>B2)CJVPKC/B%;N]G9S@$K&[*WMD#'\C79U!>V<-_9 MR6MPNZ.08/M[CWKEKT_:TW#N=.&K>QJQF^AY!:JSG"JS$#) &>*[?P5* US% MW90P_#_]=8\^E:EX8OOM$!W0GY1(%RK _P +"G:)?_8M26?:%1B0RKT /8?Y M[5Y-#]S47-HSV\3^_I/DU3V.TUN$OIYN$=4EM&^TQLPXRH.0?8C(_&N"U:YD MU+4'G$#QR2!?W7WB.!QQUKO]4N;==)F:0AXI8RH /WLBO/8KZ;3YGFM\"4J4 M5V&2ON/?M7?CJL7"--][_(\[+J4E4E47:WS,*?J17J_A>W>U\-V4;@ABA?!_ MVB6'\ZY'2O"%YJ >[NB8!@M$KKDNW8D'^'^==UIEW]NTRVNB@0RQABHZ*>X_ M.L\!AI1O5EZ&N98N$[48ZVU+=1V%B(_/9/,DED!*Q)G .!U).<#V-9J0W_AJT\UKA+VQ1B]P/ M*V2*"O8A%#.3YKK9;O[B.1K/7=>LP(KB.2"-S=0R M*4(4%2BN.XW2WEJ6*D$'N/E.2/Z448MRNE>P5IJ,;-VN7[/5M.GLD@O MF@M[B !9K>X(4HP';/4>A'454BU-&U:74HK.Y?3E@6!)XH\JV"26 ^]M' R M>]1Z_J.BW0T\M63 M1O"7-%,****DH*\I4?\ "*_'DJ/DL_$%OG';S/\ 'Z=?KR/0_-_-!^=:4][=R9[7/4:*;'(LL22() MA^)'%8UZ49QUZ&^'K3IS7+U.$8R21I&"3Z"M>/P_+86)U(NGVN#]\(W7]6MCKQU2<8\D7:Y MA_:=;U.V$45G'8K*HS!D9Z$GM4\3ZGIEZ-(LT@NHDA\V%IY"C(FKRMYL7 MV^W9"]\%.VV/411+_%P=WY>W%)-WMR_U9G@2;:5K\W]71LOX:L^989;J M*\Q@70G8R?CDX(]B,53_ +4GU/2I-,5-^IOOMIRB'RXB"59R>@&.0.O.*DO] M3U;2 JW7V*6*5MB79)B6(X)_>#GTXP>3QQ45I?,D%KI>FBX\ZI)/ Z*Q D^81(3@(N>F!UQU.:RY$_?D[HT4VGR15F5-16YO-*AU& M^N)([6::(O;(V$CA9AG=W8X(SGCK6UK%O/):0RVB!Y;699EB&!O R"H]"03C MWQ6?#>2:7;QZ1J=E-*33?#L7V!4O?/ 9F5QQ]@F;\0I(_E50=I(4MC%\->+[1?"ND+-, MHE%E"'^0]=@S17@%MXTU*UM8;>-8MD2!%RO8#%%=#H:F*J'L_P #$-OX8U6T M?_6P:DZN/^ (/Z&O4J\N^$Q^RZ]XSTQLAH-1+#=U(+.,_P#CH_.O4:PJ?$S6 M'PA1114%!6#XHN?*LHX <&5LGW _^N16]7&^*9_,U5(L\1H!^)Y_J*Y\5+EI M/S.K!PYJJ\M3,=72)'*,%;[I(X-=WIMQ]JTZ"8G+,OS'W'!_6N.O-2FN=.@M M75 D6,$#DX&!6OX9U"-=.DBDW?NWZA"0 1W('UKFPK2J\L=;HZL8FZ/-+2S- M:_L'N7AN;:807<&?+?7K6Y]OML;M[;?[^QMOYXQ52U23R5NH LC2#$T;'&XY//L17L1;46 MI+0\.5G).#U_KH9NH:K8:EJ>FVL;F>U6ZS-(JYBWA3L4MT)W8X'H*OZV);;R M=6AVDV063[S$#G@+TYQS7/W&FZ MCJUC--8W]T^GQ',5O.VXW.P\C. 0IP0,DYK2,4[/9+]3.4VKK=_Y?H:-QJ4& MK:CI,$EO=16[2EW6Y@**SA"44D\'GG STJZ;'4-.DF;3);9K:1S(;>YRHC8\ MDJPSP3DX(J1[K2=:TIFDGC-N?F8L^QHF'//=6!_*L73I8=6N)K2XUBZEM-^V MWBD C-PH R=P4%USGH>0.:23:VLENM_Z8VTGO=O9[?TC5T1);X1ZQ>2*\TB% M841<)&A/49Y); .3[5M5'OAAB;YHTCB'/( 0#^59;^)+)G6*T$MU<2'$4:1L MHD]PQ&W ZDYK)J51W2_X!LG&FK-_\$V*1W6-"[L%51DDG %8]QJNH:= UUJ& MGQ?95&7:VF+LGU!49_"JB"[U36X;?5(XTMQ!]I2U'.3N &\_Q$=<8QDCK0J3 MW>P.JMEN;=OJ-C>.4MKRWF8#)6.56./P-17VH_9GB@MX3LK6[R :9-;*4FN+E&BAA4Y+LPQT]!U)["M&",Q6\4;-N*(%)]<"H MFERIVL:0;YG&]R2L+QL0/ NO$G'_ !+Y_P#T UNUR7Q.N5M?AOK3M_%"(QSW M9@O]:F/Q(M['RPNGWCJ'6UE*L,@A3R**]_\ #OA">X\,:3-Y^WS+.%]IC/&4 M!HKJ=9&'LV.T/_B2_'K7+(_+%JEJ)XQZMA6/\I*]3KRKXGYT#QEX5\6J,1PS M?9;AO]@\_P#H+25ZH"" 000>A%<\]4F;1ZH6BBBLR@KA_$B,NN2,1PX4CZ8 M_H:[BJ&IZ5#J48#G;(OW7 _G6&)I.I"R.G"U52J7EL<,_P#JQ6OX=0_9)B^1 M#+A&#Q^9 JVOA:0L!).@0'MDFK=PEAI-LMK)>/'%(.(0F]F]2 3^-8X M/#S552:V-L;BH.BX1=[E^V>.*]90:T/&9*=[QMK?R_S#4-&TRWU/28X[*"&* M2=A(57&\A"RJWKD@'GTJYJ4BV&M6-]/Q:>6]NSG[L3,5()] =N,_2H[RTU35 MX/LEU!:VL)96::.8NXPO)'MY#?$7:?OJ?;KP16U:Z5I]E)YEK8V\+XQNCC ./K5O )SCI4*I& M*LOZ_,T=.4G=_P!?D0/QY'XU3^%_B$>(? UD\C M[KJT'V6?/7*C@_BN#]26S?\*\^+DML_[O1/$7S1GHLGX,2/HX]*T MC[T7$AZ.YZW115*^U**R:.+RY)KB7/EP0C+-CJ>> !ZD@5"3;LBFTE=EVL^^ MU:*TD:WBBENKL)N$$*Y(]-QZ*#[UG7.HW=Q?V]C<1W&EPR_\MLJQE;LBL,A3 MC)YY/04ES8/X?BEU*QGG>-6\RZ@F?S/,7H6#'D,![XXQ6T::37-N]O\ AS&5 M1M/EV6__ PS3+>SU;?]ODN)=24!I8I2\1BSTV+D87T(SGUJQI%L+'7+^UE= MYY6CCEBGE;<_E\KL)]BI^N?6C69"FJ:3-:0^?>;WPBL%+1%#NR3VSL_'%.CT MB]EN)-0EOGM[Z0!=L.&C1!T7##YN23GCK5MWC=NR?^?Y$*-I:*[7^7YCM9\J M#4=*NU94N#<>3NZ;XV4[E/MP#]14=I;Q:IJU_=7B"7[+-]G@BD&5C 526 Z9 M)/7T IE_;6.GV\EYK$O]H3%"L:3*I#=]J(!C)P/4^]4-'TW3;X3!+^:&[D : M:WM7:W5.,<)@9 Z9.UO.UQZV,^K73:AI,=M86S!H_,9"3=+ MTR4! ST)Y_ T_3M6.CWMYI^L1B!FE:YCGC!:-U8\\XX(8]_44Z'4KC1_P#B M1 )/>IL2RW?*)(R#AFQ_=VG..N!ZU:;2=52XCOQJ:SWD<;((WA"Q,"02O'(^ MZ.'&@NDO=01EDFGN9%:3'.U3A%^FW!_'/> MH(+>XUN^.J17)LH$WPPM"JF290<$L6!&,C@8]^]6(+<:E&NJ6-Q-8W$PQ*H M92R_*0RG@D$$9&.E16%P^@VXT^^CF:.,GRKF.%G5U))YV@[2,X_E4O=N._8M M;)2V[_D);ZCJ<=YJ-Q@L.#\H[\XJR/$%M!(T&I#[#< M;A'(P(<>J$?>_G[5%X8N(VL9;N>N89KSQ&W]FLMJ]NFVZN=N[?N&53;T)'!R>F?6[_-@(2#]WJ3C!XQWJ/9KN6JK[>7D:E]J(M9(X(H7N+J4$I# M'@<#JQ)X YZU0;5]2^UI8#3$2[D4NI,X:-$'!9L 'J>!CGUJ.RM[/1O$L\*Q M1V\=Y!&+73JMO

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end GRAPHIC 40 gexyhn0lyczh000051.jpg GRAPHIC begin 644 gexyhn0lyczh000051.jpg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end GRAPHIC 41 gexyhn0lyczh000012.jpg GRAPHIC begin 644 gexyhn0lyczh000012.jpg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end GRAPHIC 42 gexyhn0lyczh000045.jpg GRAPHIC begin 644 gexyhn0lyczh000045.jpg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gexyhn0lyczh000014.jpg GRAPHIC begin 644 gexyhn0lyczh000014.jpg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end GRAPHIC 44 gexyhn0lyczh000002.jpg GRAPHIC begin 644 gexyhn0lyczh000002.jpg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ⅅ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gexyhn0lyczh000048.jpg GRAPHIC begin 644 gexyhn0lyczh000048.jpg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end GRAPHIC 46 gexyhn0lyczh000025.jpg GRAPHIC begin 644 gexyhn0lyczh000025.jpg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end GRAPHIC 47 gexyhn0lyczh000015.jpg GRAPHIC begin 644 gexyhn0lyczh000015.jpg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end GRAPHIC 48 gexyhn0lyczh000039.jpg GRAPHIC begin 644 gexyhn0lyczh000039.jpg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end GRAPHIC 49 gexyhn0lyczh000040.jpg GRAPHIC begin 644 gexyhn0lyczh000040.jpg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end GRAPHIC 50 gexyhn0lyczh000029.jpg GRAPHIC begin 644 gexyhn0lyczh000029.jpg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end GRAPHIC 51 gexyhn0lyczh000041.jpg GRAPHIC begin 644 gexyhn0lyczh000041.jpg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gexyhn0lyczh000019.jpg GRAPHIC begin 644 gexyhn0lyczh000019.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#CW_UC?4TV MG/\ ZQOJ:;7U1\H%+110(2EHHH&%)2TE "8I"*=012"Y'MI<4ZD) ZFD.X 4 MN*C\WTI=^:+H+,=4+IN/7O4A8 >]1YI.Q4;@L)_O#%3JH4<5&C8-2TXI=!2; M"@GBBH6:A;W,QVQ&1V7+=@"PQGZURRQ,8R<6GH=4<-*45)-:GF8'O3 M2=IP*VO%/ANZ\+Z^^FRDS*0'@D5?]8AZ<>O4$5C2(X;8\;H_]UE(/Y5K&<9* MZ,I0E%VD(')ZTUQQQ3S;RHZH\4BLW160@GZ"I5M+IED*6L["(9DQ$QV#WXX_ M&G=6U%9WT*1YHRPXR:LV]E=WA86EK/<$?>$,3/C\A49BDAN5AFB>-PP#(ZE2 M.?0U%T:),>O"^]0R @\]Z[[X@>$;+0=7T^ST6WN7-Q TC)EI6)!QQWKB)H7C MD:*5'CD4_,KJ01]0:(5(U(*2%.$J<^5D0;BEQFNI\0V'AI=0TN+01=^7*P6Y M^T!P>64#&X#U/2M/QKX9T3PUXNTJRA6==/F17N 7+MC>0<=^@[5"K)V36_Z% MNB]7?:WXG"@'%.'%=+J&BZ7J7C"UTOPVUPEK8N.:L26=TEN)I;.X2 M!NDCPLJG\2,4]%U%KV*8-.S71>"?#R?L_:=#DE%+73^ M M#LO$7B86&H+(T!@=\(Y4Y&,<_C3X/!T^K>.-0T73%9+6VN71YG^811@XR3W/ MH.]4Z\(R<7T5R51G**DNKL-]/\,:+.-+T9)Y[Z,CSYWG+*A_NXZ%CW M]/Y;TWA?P?X0TVQ?Q.;J[OKM-WEQ%MHQC. ".!D5.SUV+6&ES-76 MFYYE25W_ (G\)Z$?"Z>)?#5R_P!E)'F02OD@9VG&>00>HYJM<>%],C^%,'B) M$E_M!W +&0[?]85^[]*:Q,&D^[M\P>&FFUV5_D<302 *CKN=!\-^&H/"H\0> M);V5DE?9%:VK_,.<#('.3@GM@5=2JJ:NR*=)U'9'#$YH!/:NT\:>$=-TG2;# M7M#N))=+O, +*#TK4MO"'AC0?#NGZAXMN+K[1J!!CBA) C!&> M<<\ C)]ZR^LPY5)=?O-?JT^9Q?3[CSK=ZTC. .*ZGQQX27PMJL"6LKSV-VF^ MW9N6'JI(Z]1S[UT_@WX6FZ@DN_$D,D2.O[FU#E7]V;'3Z?G3EBJ<::FWN3'# M5)5'!+5'E9.:<#2.NV9U'0,0/SK;\+0:+/J^S7OM'V/RF/[@,6W\8^Z"<=:T M*M7L$;:E=)I\E6MI\+KRZCMDFU*-Y6"*TC.!DG Y["-+T7X MAV&CZA)+/IE^A\A]^QT;H 2.O(Q^-9_6HWLTU\C3ZK+=--;'GA%"UT7C;P^G MAKQ/<6$(;[*566 N^% M&:MUX6C+N2J$VY1['"-C'-(#Q7HFC>!]$TSPW%XA\9W4L<&/ OC&.:#PY<7%CJ$:;ECF+88>I5LY'T/%9O%POL[=^AHL).RU M5WTZGE4F<@U(HXJ>_L9]/OI[*Z39/ YCD7T(_I42H0!70M=40#I31@C:35AIC14PD('K45&:$[ U_P"/'Q#G M^XG\GKS"WWFY@$1/F^:NS'7=D8_6NS^'GB[2O#$.IIJBW#+=! ODINX&[.>1 MCK6A:^(OAII%PE]8Z)?RW4)W1"0$@-V/S.0/K7$Y2IU)OE;O8[%&-2G!()8U#6 M\J-!!G*HJG(7/OSD^]=5KWBOP+K%_;Z_-9ZA-JD*J!:_<1BIR-YZ$ ^AY]*S MC3G2<7:^C-95(55+6VJ-CQUG_A;'A/V,?_HPU#\1_&FHZ)K5SI&G16\44]KF MXE*9=F<%<@YXP ,5A>(_&VE:QXWT/6;=;@6UCL\X/'AN'R<#/-8?CS7+/Q+X MEDU"Q$H@:%(_WJ[6R,YX_&BE0;<.=;+]15JZ2GR/=_H=IH-QXNC\'V$6EV^E MZ!81@'[;=2#,PQ]XJP/7KGOVXIOQ:C272/#5\[0373OM>YA&%D&T'C_9SR/K M5._\5>$/$_AS38-?348+FP0 16J\.< '!Z8.!UP16=XR\8Z-XB\/:1:6$%Q: MRV,@_<.H*J@&,!L\D #M41IS]HI1V/Q.\7ZCX: MN].ATD10W$\3-):+XHD@CBOW*)(5'W@P((^F M1D>E+XA\:>"?%EQ;6^J6FH+;PKNCNHUVNC'JI SE2 /RK!\:>,+'6K&QT70[ M=X-)LL%?,&"Y P./0#/7DYIT:4DX)1LUNPK58M3;E=/9'1?%;)UCPO\ Y_C2 MI?B%_P E3\+GWA_]'&N<\<>+]-\0ZEHLUD+@)9?ZWS8]I^\IXYYZ&I/%7B[3 M-;\:Z+K%I]H%K9&/S0\8#<2;C@9]*J%*=H:=&14JPO+7=HZ76M3NM.^-]@MN MRA;N"&VEW+G*%B3CT/ JGXZ\9:CI/Q!M;?>OV'3Y(IPBKAB&7#@GN,,:YSQ' MXPL;WXBV/B&SCF>WMO*+)(NUFVDYQSZ&I/'^M>&/$4J:CI)O&U25E642(0@0 M*1C'KTZ>E*%'WH\T>EASK>[/EEUN=1XA\*1:G\5='NXD#V=^BW,C ?*?*P3^ M8V?G7%_$O6O[9\:W01MT%G_HT?/&5^\?^^B?RKT;PYK\VG?"5=6OH"D]E"\5 ML\@Y<9VIC/8G _"O#7+.Q=V+.Q)8GN3U-7AHR^SH1B914;1^UJ>@_"31; M34M"$S6\J>7/$#@E**U-NOF:WAL/X=^*.H>& M[$HNF3J;KR]N2IV @ ^@KAO'NN7^K>);JUNW1HK&XEB@"I@A=W?UZ"IO#_C% M(/'TOB/6!(1*CAEA7=MR % 'H ,5S^N7D6HZ_J%]!N\FXN'E3<,'!.1D5K1H MN-;FDNBU\S*M64J/+%]7IY'4_";_ )'A?^O63_V6O3+?5/#T'B&]\,V.?#TS,L8V2R0 EU'&[:V"#QU%9'C M/Q?H?BO2+.:..YM]7=GIGD'V]ZT9/&7A/Q9IEM%XMLKB*^MUP M)X 2#ZX*\@'T(I3YJD(\\'IO;?Y#@HTYRY)K7:^WS&^(/"7AW4_"T_B/PK,R M1V^6E@RQ4@8W##C DE/D_UA;KGT/I4J%5J-T_BZ[V\ MRG.DG*S7P]-K^1:L/A)JNH:9;7T>IV:)<0K*JLK9 89P:XS2I+"TUB*;5+-K MNSC9O,A0[3)P<#/UQ57S[A1A;B8 < "0X_G7=:'XL\/WOA2/PYXIM9A% V8; MFW'/&<9QR",D9YR*WE[6"?-[R?;='/'V4VN7W6N_4T_'@&O>!M+UW2YO*T6W MPAL#&%\HYV9R.N#QCWS3OC'M^QZ!Y?\ JO*DVXZ=$Q^E8OBSQ?I=UX=M_#/A MVVEBTN(@O)+PTF#G '7KR2:T+;QAX8U[P]8:?XM@NA<:?CRY802) !CG'/(Q MD'TZUS0A.'+.VB;TZV9TSG";E"^K2]+HN_%$E/#OA9F_URKGGU")_7%2_"_6 M-1UOQ1JMUJ5W)<2_9% W=%&[H . *XWQSXO'BG586M8&AL;5/+@1_O'/5B!T MZ#CVJ?X=^*;#POJ=]<:B)RD\ C3R4W'(;//(JW1?U:UO>_X)*K+ZSS7]W_@' M(,,SR'U<_P Z[WX1C'C;_MTD_FM<'UE9AT+$UU'@37[/PWXD^WWPE,/D/'^Z M7<"_&>HZIXUFT: M1+>/2]LJPV\<041A#QSWR,Y^M<]X4\8:9HGC#6M5NUN#;7A?RMD>6Y?<,C/' M%97A#7[/0O&/]K78E-M^]XC7+?-TXKEG0,BND^'_ (LT[PPFJ#4!.?M2((_*3=TW9SS[BMZ\)2P_*EKH<]"<8XB[ M>FIU?AG0? >L/)=Z/;7-Q=69$GV:>9E)(Z'!.",_AZUP?C3Q-?ZWXG^TS6S6 M,MB?+B@8_-&5.?F/KG^E9N@ZU<^']:@U*U/S1M\Z9XD0]5/U_GBMWQ[K>@^( M[Z'4M+2XCNRNRX66(*' Z-G/4=/ICTJ(T90K:W::W[%RK1G1M&R:>W'=#DTW5%N&"3%X#$F["GD@\C'.?SK@]6OY-6U>\U";[]S*T MA'H">!^ P*FA0FJEI;1O;YEUZ\'3O'>5K_(]'^,BN]KH+1_\>F)-N.F<+C], MURGPW28^/M,\G.07+X_N;#G^E;>B>.]+NO#\>@^++)[JVB 6*=!N( Z9'4$> MHJY;^,/!OA2WFD\,Z=//?2KM$LX8 #T);G'L!S2BIPI.CRMO\!R=.=55N9)= MNISGQ+\H^/\ 4?*QTCWX_O;!G^EY-05W4HL^'KGPCKD5[=R>#[ M:RT^RC+SW4C @'LH ')_SWKEM(N_"-SXFU#4=4M%M=/1-UG8*I*N0,8;'?C. M.F6]JYHXENZY7H=,L,E9\RU./HKT75[/2M?^'DGB.+1X-'NHK@11B'A9EW!? M09ZGGU4UJW^B:786NLZ5)I%NFG:=I:R_VBT7[V2X89!$G?Z4OK:737^O\Q_5 M)/KH>2TA%==8VEMX7\/#6=4MHI]2OXRNGV@SV/UI>UI\W+?4/9SY>:VAA<"EQ7K_P#PC@\(> TNI=#T MR^U %I+TW;!@J<_=/?\ A&!ZUY596<^J:E#96D:M<7$FR-,X&3V]A44J\:EV MMD75H2IV3W95/2HI2" N:[(?#3Q0YF7[+;K)&,B(W"[G'JH]/,-JH(>8-,-D$0R3M_ MO,0!^=9NO326NY:H5&VK;'G)V9P#2;@IKL?$6GW5IH'A_2#X?M[>\G =)X76 M2:ZR.X R.6Z$G]*AN?AIXGMK*6Z:U@8Q)ODMXYPTJKZE1_C25>-KO0;H2O9* MYRPDRN*%PPZUK:'X4U?Q#9W5SI=J)X[8@2#< Q)&0 .YJWJ_@77-!TQ=2O(8 M6M68(S0S"383P <>_'&>:OVL+\K>I'LIVYDM#GAA3R:4D/TKT.[^&TFF^ ;G M5+E%;5?]8RM, D$0.21_>8@?K6-IWPX\17D$,XAMH#.N^**XN DCCU"_XU,< M33?70MX>HNFIRJJ0:?FK%]97.FWTUE>0M#-NH/]1[UH:5X5UC7+"XO- M.MA/% XC8!@&+'& !WZBMG.,5=O0Q492=DM3%8_*:C3YJZ@^ ]?_ +<.CI;Q M2WBQ":7RY04B4]-[= >.E5]=\(:OX=MX;F]BB:UF.U)X)!(F?0GL>OY5'M8- MI)E^RFDW8P33E) ..]=/I7P]\1:Q8QWD%M%%!+_JFN)1&9/3:.O-97_".:Q_ M;QT06,IU$-@PC'IG.>FW'.>E"JPNTGL)TIV3:W,O--+$'@UU&K^ M>T;39+^ MXA@D@B.)C;S"0Q'_ &AVJUI=C+!X N[A]$M)EOK@00ZA-*H>)B0H"J1GKGG/ MOVJ76C:\7HJYJ?A_4] M&UI-)N[?_39-FR.-MV[<<#!'O5J?P9KD&O1Z)]E274)$\SRH90VQ?5CT7\:; MG!K5[DJ$T]%L3>(O'&M>*(([>_DB2VC;<(8$VJ6[$\DFN=[UT6K^!M42",],-Z<\4[0_ VN:[8?;K6WB2V)VI)/*$#GIA?7GBB$Z4( M>ZTD.<:LIVDFV<^HP*=7H&K:'%X>^%T(OK"*/5[J\*EW0&1%#'@'TPO;UKDO M#T>E2Z[;+K<[0Z<"6E903G'1>.0">]7"LI1J6T/ASQ M;I7B!+;08+"VTV,M:WT7REL D9X'IG!SP:\H\SC/M12K*=TU9H=6BX6:=TQ] M%=58?#GQ-?V<=TMI#"LHS&D\P1W'L/\ '%8]OX?U6Y\0_P!ABT*:CDJ8I"%Q M@9Z],8YS35:F[VEL2Z-16NMS- Q^-%;VI^#]9T;3&U#4(8H(1-Y*@R#<[9/* MCN.#SZ%I/$>N1O)$CZ?;2*;H,^"1@D#'4Y(YH=:"@YWT0*C-S4+:LY M7(]:#7H_C'1K[5/$*Z#I?AW3X&C)FBEM=H8P_=!D(X7D'BN6UKP=K&@V:7EW M%"]J[;/.MY1(JMZ'TJ:>(A-*[LV74P\XMV5TNIS^*;6Y>^%=7LM:M-'E@3[9 M=A6A1'#!@20#GMT-.'@[6CXD/A\6R'4%3>4$@VA<9SNZ4_:P[D^RGV,-1D4I M7TK>TOP=K.JS7:6D4)BM9#'-8 M;3QG /<^WN*P-.L+C5-0M[&T0/<3MLC4G )^M.-2$DVF*5.<79K]N[>..**40@>9EI7) 0#[W)_G5K_ (5OXF^RF7[)#Y@3S/LWGKYV MW_=_^O4^WI6OS(KV%6]N5G)T5VW@+P/_ ,)+08^4]P.> M36Y+HU$FVMC#HKJ=.^'WB'4K.&ZC@@A2<9A6XF"-(,9X7K3-!\% MZCJWB:32)XVMS:L/M9)&8U]1V)/;\Z3KTTGKL-4*C:5MSF:*[;7? =Z?&,ND M:-:H(Q )80\X)*#"EF/8EL\52?X>>)DL#=BQ23:P5H8Y0TJD^JCZCW%)8BDT MG?<;P]5-JVQR]%;^K^"]:T/2TU&\B@-L7",T4P?8QXP<>_'&:ETOP'K^KV45 MY#;PPPS?ZDW$PC,O^Z.IJO;4^7FYM"?8U.;EY=3FZ2M:'PYJL_B#^PA:[-1R M08G8#&!G.>F,)GCG;[)"'A!/E&<;W [J/0XXSC-$JU..\@C1J2VB MSDJ*[KP'X%'B 2:CJ"M_9\60D:R!3+(#RK=P*Q[/P5K>H7%XL<%O%':S&*6: M28+$KCJH;OCVJ?K%/F<;[%?5ZG*I6W.=HK7UWPSJOAR6)=1@55F&8I8W#H^/ M0^M)X:LIM0\26,$%FEXWF;S;NX59 O)!)Z# K3VD>3G3T(]G+GY&M3)HKK+W M0=2\3^)]672])M[4V>%EM89!LCP,84@ ,20>@JM?^!=?TW1WU2YMXOL\?^M5 M)@SQ?[P'Z\\5"KPT3=FRG0GJTKHYLFD#T$D'(ZCI7HOB+0;?Q+X3T37?#^G1 M1W,CBVN;>W0*-Y.,D#T;OZ-14JJFU?9A3I.HG;H><[N:45W_ (KM-+\+Z+:> M%[*T@O-X)/ '8?6LL_#;Q.EJTYM(3(J>8ULLZF8+_ +O_ M ->HCB8-7>E]BY8>:=EK;J^(I94TZW#+",RRR-L2/ZD]_:I->\ M+:KXN,UK[6'-RWU,O93Y>:VAAFHW%=>GPZ\2.1NMH M8XS!Y[2R3 (B^Y['V]JY6*%[FXB@B :25PB>A).!252$[\KN4Z6NL7]C;MYB* T,#;20,=V]S^0KR5<[1GK6=&LJ MC:70NM1=-)RZCB149?%/(J,K6SN9*Q;M?O\ _ :*2T;+?1:*8AI.9&^IHIIS MYC<]S2@^M-":%I0"Q"J"S$X '@/XY_[Y%4? 7@L^)[N2ZN]ZZ9;-^\V_>F;KL']?K7+7U_ M>:G=&YOKF2XG("F20Y) Z"K5AXBUG2[;[/8:GZMD=-\0;W6[H013Z1-I>AP-Y=I RA0QQP2 >N,X':HM">Z MNM*.J^([ZZF\/Z/2]9UC3$U2_UZ^,"1LS".UMUR"% Z8 [UY]KUG;6'B'4;2S8M;07# MQQDG/ /KW]*M:?XHUS2=/>QL-1E@MG))10.">NTD97\*QSR^NO@WHL&A02SQO)_IB6ZEG)RV<@V,@?4XKA]-UW5M&#C3=1N+57.66-OE)]<'C-5; MG4[^ZU!=0N;R>:\5@RS.^6!!R,>F*Q^KS3WTO?S-?K$+;:VMY'<_%J=8-4TG M1HF_=V-D./<\#]$%4_A/8_:_',4S#*6D#S'/8XVC_P!"KD;N^N]3NWNKZYDN M+A@ 9)#DD#I76>"=>TWP]I6O2W$S+J%S;^5:H$)R<-W P.2/RIRIRAA^1:O_ M #"-6,\1SO1'2:'HVNR?%R\U;4(9X+>WDE=[A\B,QX(103P1C'Y5';:=97NG M:[XH5-5OH+R_DC2PTZ5HPZ;L9?;R0<_D?>N!D\1ZY/IBZ=-JUW)9A0OE-)P0 M.Q[D>QINFZ]J^D121:=J-Q:QRG+K$^ 3Z^Q]Q2>&J/6ZZ+Y(:Q--:6=M7\V= M]X]@BTOX;:+I-MIQTW[5<>:;5I#(8R 3@L>^6%/^(.F7;3^$=!A@E^R(L<#2 MA3MWL57&?7"DUYM>:OJ.H00VUY?3W$,&?*25]P3/I5V3Q1KTZ6R2ZM=.MJX> M#<^2C 8!!]0">M*.&G&UGJK_ (A+$PE>ZT=OP/5GO+6X^.%O:RE,66GF* 'M M(1N./?:36;IEQ_9OB+5];M_">LBZ@\S[7-=7JK&P)R<;L CC(QT%>47%Y?76 MH-?2W,TEV6#FV2W]%_.N#FU34+G3X+">\FDL[?F&!F^5/H/Q-.N]5O[^TM[:\O M)IH+9=L$;ME8QC' ^@JU0=_G?_(S==6LNUO\STGX@Z5J)TSPEH-A;2,J1*GF M'Y8S*0JJ"QX!Z\'UK8CB3Q/K=OI?BCPS?6FM6T>(]3LV;RU Y#!QTY^O->0W MGB'6M0T^*QO-2N9[2$AHXW;(4C@'/7BK9\9^)S:?9FUV^,)7:1YG./3=U_6L M_J\^5+L:K$0YF]=;%;78#;>(=0MFO'O/(G:,7#-DR8.,DUZ!!>3^&_@I'+;R MF*ZU2Y(5U.&"DD$@_P"ZGZUY:K_PU=GU74+NUM[*YO)I;6W&(87;Y8^W ^E= M$Z?,HKL:=I=_>QNKWETK,HWJ6^3[P& >W?WKSW3M6U#1[@SZ;>3VLI&&: M)L9'H>QI-0U74-7N!/J5Y-=2@8#2MG ] .@K-X9\[=]+W-/K*Y$NMK'J/CW0 M?$.O^.+"VTV"1;*"!#;SC*PQ$$DL2. >![]*=X$FN?[<\4#4;HZEK,%N(D:* M7+.J[LJC8_O8'3KBO.4\5>((M/%C'K-XMJ%V",2=%],]E6<\.A^$=H7/\ -_TKC=5U_5M8C5=2U&XN MMG*K(WRK[X'&:J:AJM_JKQ-J%Y-S26=N!)$V"*E85\CC?4MXIU7/'^D:K?67ANPT:TFFTX6JB/R%)42$#!8CIQSD^]>>:CK.J:PR- MJ>H3W9C^X)&X7Z#I4\'B77+;3Q80:M=QV@&!$LF !Z#N![5I'#334E:YG+$P M:<7>QVOQ9N)(ET+299/,D@MS)*V?O-@+G]&_.N2\)^&;CQ5K*V43^5"@WSS8 MSL3V]ST%9E_J-[JES]HO[J6YFVA=\AR<#H/UIUEK>IZ,)#IM]/:F7&\Q-C=C MIG\ZUA2E3H\D7J8SJQJ5N>2T/0/'0U33="DT/1M%N;+P_:_\?%TP \\Y').< MX)Q]?I7 ^&UM_P#A)]*%[M^S?:X_,W=,;AU]J==^*-=U*U>UO=6N[BW?&Z.2 M3(.#D?K69P:5*DXP<9;E5JJE-2CL>H^,-"\2:U\4;<0V]T+1&B,%PN?+B08+ M'/0'.>.O2NAMI;.^^+6J:G&5:+2M.$?89'X5Y/'XK\11V7V1=:O M1;A=H02]!Z9Z_K5.SU74+"&XAL[R:".Y&V98VQY@YZ_F?SK#ZI-QLVM%8V^M MP4KI/5W':KJMWK6HSWUW,\CS.6 9N%'8 =@!Q7:_"J-;:[UK69!\EC9G!/J< ML?T2O/![5;M]4O[.SN+2VO)8K:X&)HT; DXQS755I6I[26IZ- MX"FAD\#>))OL]Q=7LDF9X;9]LS1D#[IZ]W_6J>IW,>D_#>\M+;P[?6-CJ,@\ MM[RZ5BKY'(0_-SM]/>N L]6O=(N?M&GW4UM-C&^)L''H?44W4]T:A<6VF:-8>-Y2CS0Z0EO:Q^L MS]_PY_#-'BRZC\-V>I>(D=3J6K00VMKCJ@VY8_U_ 5XS+J]_=V$%A<7DTMI; M_P"JA9OE3C' J6]U?4-36%;Z]FN5@7;$)&R$'H/R%1'!NZ;?_#=BY8Q6:2_X M?JSTXK8O\*-#A.E7VI6K-^_CL)-K"3)SOP"3SG\<4^5)+O7O!_A^71Y[%+23 M[2@N+A97,:KG!QR.0!SZ5YGIFOZMHRNNFZC<6JN:5Y97+R.Q9F)Y)/)- M6+'5+_3#*;&[EMC,NR0QMCTEWN=EX:UG^W?BO;WN MHSEXWFD^SJ[?*A /E@#I_P#7KI8OW/CG4-4@\+:N^H6S.TD\MX$A9,8X+87& M.0,_RKQX$J5*DJ5.00<$5JW?B?7;ZR-G=ZO=S6Y&#&TG##W[G\:RJ85R?N[6 ML:TL4HQM+>]SO/#'GR^#?&.LV-J[3WTSI#%$-S 'L,=<;S^55X+J?PU\&4DM MY&ANM3N64.IPP4D@X/KM3]:X;3M>U;2(Y(].U&>VCEY=8VX)]?K[U#<:G?7= MG;V=Q=RRVUO_ *F)FRJ?04?5FY:[73^X/K*4=-[-?>>C^#GM_P#A5^L$6MU? M3-<$7<5M)MF9/EQ@]<8S^M0WJB/P;9Z##H5WIEGJE['Y$MYO/\ 3M4U#29S/IUY-:RD8+1-C(]#V-&H:KJ&JW(N-0O)[F91A7D?.WZ> MGX4/"RYW*^E[A]:7LU&VMK'KUGX?L[?QG9V!TC5[\V($@U.]NF,4?&1L'0\X M&/\ "J/AEO[4^+VOZD066T1U0#OC"#]%->>OXN\1.T+-K5Z6A_U9\WIQC\>/ M6J=IK.IV&H27]I?30W@^"WN=- MM/&/B*\CDANHT("RJ0RNKB9=>U:>"Z@EU"=XKM_,N$+<2MQR?R'Y5%)JE_+IL>FR7> M0/Q/YU?U:3=W;=?SNM2$.E?"7P]8SC:M_=K/,/\ 8W%C^FVN MC\86UK?>)-+A_L#5+_;$ALYK2XV0KSGTPN..3VQ7D5WJE_J$%O#>7DT\5NNV M%';(C' P/R'Y5:MO%&O65D+*UU>[BM@,"-9.%'H.X_"I>%ENGKK^)2Q4=FM- M/P/4-&NSJ?Q,U75[JR-FVF:?YO4_G38-4O[2QN+*WN MY8K6X_UT2MA9/K3>%=FN]E\EN"Q2NGVN_FST'PU;W47PDU^\MX99KJ^E,>V- M2S;>%)P/JQIVBM=Z9X0MM-U_PS)JFB7DGG026C>8ZD\C(7\QR.]<%8>(=6TN MUEM++4;BWMY<[XT;Y3D8/T_"IM/\2ZUH]M]GT_5+FWAZB-'^4?0'I^%$L/)\ MVVKN*.(BN7?16-_XB:)!H.H6,%I=W3VTL'F):W$A8VXSC ST'^!JW\)H477= M0U24?NK&S9B?0D_X*:X6ZO+F_N7N;N>2>=_O22,68U+:ZKJ%A;W$%G>3017* M[9DC; D&",'\S^=:.C)T?9WU,U5BJWM+:'H'AF^FTSX;>)O$2N8[J^N"D;CJ M"3C(_%S^50V).E?!/4)V)\S4[O8I)ZC(!_16K@6U6_\ [,73#=RFQ5]XM]WR M!NN<4]]6OKC3H=/EO)7LX3NC@+?*AYY _$_G4?5VW\[_ "1?UA):=K?-E8UZ MA\,]1N-(\'>)-19LV]M\\2,./,"'/Y_+7E]64U:_@TR73H[V9+*8[I( WRN> M.H_ ?E6V(I^TARF6'J>SGS'2?#RZ%]\2K2[U.423S-(^^3^*4JKV_A75VO[8R&:>>\5(F4\<;L C'(&> *\9$K1N&0E64Y5@<$'U%;-WX MIUW4K+[)>:O=S6Y',;R<-]?7\:YZF'%Z].ON*T/&5E&+'P=X9@M/LBW%PKM;!R_E#C( MW'KC>W/M7FMCK^L:9:26MCJ5S;6\A):.-\#)ZGV_"FR:[J\DUI,^I7#2V8Q; M.SY,0QC@T?5JG/S7_KH'UFGR0YP.*GN;BXOKN2ZNIGFGD.YY'.2Q]ZB*UO2I\D%$QJU.>;D>B0?\ M$E^!4C8VR:M>8'NN['\D/YUY\K CBK$^IW]S806$]Y-):6_,,+-\J?0?C5+& M.E*E!T[WZL=6HIVMT1-2$4R,DG!-28(ZULM3#8DME_>G_=HI]O\ ZS_@-%%A MW/H?_A7OA/.?[$M^?=O\:/\ A7OA/_H"6_YM_C7345\Y[6I_,_O/I/8T_P"5 M?<UJ?S/[P]C3_E7W',_ M\*]\*?\ 0$M_S;_&C_A7OA/_ * EO^;?XUTU%'M:G\S^\/8T_P"5?<UJ?S/[P]C3_E7W',_\*]\)_\ M0$M_S;_&C_A7OA/_ * EO^;?XUTU%'M:G\S^\/8T_P"5?<UJ?S/[P]E3_E7W',#X>>$A_S!+?\ -O\ M&E_X5[X3_P"@);_FW^-=-11[6I_,_O#V5/\ E7W',_\ "O?"?_0$M_S;_&C_ M (5[X3_Z EO^;?XUTU%'M:G\S^\/8T_Y5]QS'_"N_"6<_P!B6_YM_C1_PKSP MG_T!+?\ -O\ &NGHH]K4_F?WA[*G_*ON.9_X5[X3_P"@);_FW^-(?AYX388. MB6Y_%O\ &NGHH]K4_F?WA[&G_*ON.6_X5SX1_P"@%;_]]-_C1_PKGPCC']AV M_P#WTW^-=312]K/NP]E#^5'+_P#"NO".,?V';_FW^-)_PKGPA_T K?\ [Z;_ M !KJ:*/:S[L/90_E1RW_ KCPAG/]A6__?3?XTO_ KKPCG/]AV__?3?XUU% M%'M9]V/V4/Y4RI_P J^XY; M_A7/A#_H!6__ 'TW^-*/AUX1!XT.W_[Z;_&NHHH]K/NP]E3_ )5]QS/_ KW MPG_T!+?\V_QH_P"%>^$_^@);_FW^-=-13]K4_F?WA[&G_*ON.9_X5[X3_P"@ M);_FW^-(?AYX2/71+?\ -O\ &NGHH]K4_F?WA[&G_*ON.8_X5WX2_P"@';_F MW^-'_"O/"?\ T!+?\V_QKIZ*/:U/YG]X>RI_RK[CF?\ A7OA/_H"6_YM_C1_ MPKWPG_T!+?\ -O\ &NFHH]K4_F?WA[&G_*ON.9_X5[X3_P"@);_FW^-'_"O? M"?\ T!+?\V_QKIJ*/:U/YG]X>QI_RK[CES\.O")ZZ';_ /?3?XTG_"N/"'_0 M"M_^^F_QKJ:*7M9]V'LH?RHY?_A7/A$?\P.W_P"^F_QI?^%=^$O^@';_ )M_ MC73T4>UGW8>RI_RK[CF/^%>>$O\ H"6_YM_C2_\ "O?"?_0$M_S;_&NFHI^U MJ?S/[P]E3_E7W',_\*]\)_\ 0$M_S;_&C_A7OA/_ * EO^;?XUTU%'M:G\S^ M\/8T_P"5?<UJ?S/[P]C M3_E7W',_\*]\)_\ 0$M_S;_&C_A7OA/_ * EO^;?XUTU%'M:G\S^\/8T_P"5 M?<UJ?S/[P]C3_E7W',_ M\*]\)_\ 0$M_S;_&C_A7OA/_ * EO^;?XUTU%'M:G\S^\/8T_P"5?<UJ?S/[P]C3_E7W',_\*^\*?\ M0$M_S;_&C_A7OA/_ * EO^;?XUTU%'M:G\S^\/8T_P"5?< M>$_^@);_ )M_C7344>UJ?S/[P]C3_E7W','X=^$C_P P.W_-O\:3_A77A'_H M!V__ 'TW^-=112]K/^9A[*G_ "K[CF/^%=^$O^@);_\ ?3?XTG_"NO"/_0#M M_P#OIO\ &NHHH]K/^9A[*G_*ON.7_P"%<^$?^@';_P#?3?XTH^'?A(?\P.W_ M #;_ !KIZ*/:S_F8>RI_RK[CF?\ A7GA/_H"6_YM_C1_PKSPG_T!+?\ -O\ M&NFHI^UJ?S/[P]C3_E7W',?\*\\)?] 2W_-O\:/^%>>$_P#H"6_YM_C73T4> MUJ?S/[P]E3_E7W',?\*[\)?] 2W_ #;_ !H_X5WX2_Z =O\ FW^-=/12]K/^ M9A[*G_*ON.8'PZ\) _\ (#M_^^F_QI?^%>^$_P#H"6_YM_C7344_:U/YG]X> MRI_RK[CFA\/O"BG*Z+;C\6_QHKI:*/:U/YG]X>QI_P J^X****S- HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHI"0H)) Y)/:@!:*:74 $L "< D]:4LJD L!DX&3UH 6B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BJ&KZSIV@Z?)?ZI=Q6MK']Z20]_0#J3["N33Q M)XM\2?-X;T.+3[!ONW^LY4N/5(5^;'N2*I1;U$V=W17$#PMXQN1NO/'LT;'J MEII\2*/H3DT?\(5XA_Z*!K'_ 'XA_P#B:?*NXKOL=O17$?\ "%>(?^B@:Q_W MXA_^)H_X0KQ#_P!% UC_ +\0_P#Q-'+'N.[[';T5Q'_"%>(?^B@:Q_WXA_\ MB:/^$*\0_P#10-8_[\0__$TX7?8[>BN(_X0KQ#_T4#6/^_$/_ ,31_P ( M5XA_Z*!K'_?B'_XFCECW"[[';T5Q'_"%>(?^B@:Q_P!^(?\ XFC_ (0KQ#_T M4#6/^_$/_P 31RQ[A=]CMZ*XC_A"O$/_ $4#6/\ OQ#_ /$T?\(5XA_Z*!K' M_?B'_P")HY8]PN^QV]%<1_PA7B'_ **!K'_?B'_XFC_A"O$/_10-8_[\0_\ MQ-'+'N%WV.WHKB/^$*\0_P#10-8_[\0__$T?\(5XA_Z*!K'_ 'XA_P#B:.6/ M<+OL=O17$?\ "%>(?^B@:Q_WXA_^)H_X0KQ#_P!% UC_ +\0_P#Q-'+'N%WV M.WHKB/\ A"O$/_10-8_[\0__ !-'_"%>(AR/B!J^>V;>$C_T&CECW"[[';T5 MQ#:+X_T_Y['Q79:ECGR=1L!'N]M\9R/RI;7QZ]A>1:?XOTN30[F5MD5R7\RT MF/H)1]T^S8HY'TU%S=SMJ*0$, 0<@]#2U!04444 %<+\6]/N+WX?:I)'J5Q: MP6]M)++##@?:,#Y59NH7/4#KTKNJ@O;*VU&RFL[R!)[:92DD3C*LIZ@T >.^ M+(+34M7TRQU<@Z=;^$IKN .Y55N %&\<_>"XQZ5@:M(=8L&N->E=KFR\%P7M MD\DI5DN"?]8O/WR0HS7N6J>%]#UJWMK?4]*M+N*U(,"RQAA'CL/;@<=.*-3\ M,:'K,UK+J6DV=U):',#2Q ^7[#V]NE $^BRSSZ!ITUUG[1):Q-+GKN*@G]:@ MAU>X.KQZ?=:=);^:DCPR^:KAPA&>!R/O UK5C7O_ "->D?\ 7O<_^TJ -FBB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ K.US6K+P_HUSJE_)LM[=-S8Y+'LH'GWVH10W=Z0+:)LYDR<#&!ZFGRM]!71K444 M4AA1145Q<0VEK+BJ!DG\J ):*K6%_:ZI807UE,LUK.@>*1>C* M>AJ._P!7T_2Y+2.^ND@>\F%O;AL_O)#T4>]%@+M%%% !16?>:WIEA!>S7-]" MD=B@>Z.[)A!Z;@.1FKEO/%=6\5Q X>*5 Z,.C*1D'\J+ 256OK"TU.REL[ZV MBN+:5=LD4J[E8?2K-% 'GEE)<_#G6;72KJ>2X\+7TGE6-Q,VYK"4](G;NA_A M)Z=*]#K-U[1;7Q#H5YI-XN8;F,H3W4]F'N#@CZ5C_#[5[K5/"ZPZBV=2TZ9[ M"\)[R1G&[\1@_C5OWES=25H['54445!045RFL2:O;#[5=^(8=-A>39#!:V/V MAFZD9)R6.!D[5&,'ZUM:++>SV"RWES:70_\C7I'_7O<_P#M*@#9HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XG MP(/M&N^,]08YDEUAK?/^S$BJ!^IKMJXKX=?>\5?]A^Y_]EJX_"R7NCM:***@ MH***R_$.O6?AK0[K5K]]L$"9P#R[=E'N3Q32;=D!R'Q2^(9\&:=#;:>8GU>Z M.Z-7&Y8HP>7(]^@_'TK>\ ZU>>(O!&FZMJ!C-U<(QD,:[5X=@,#Z 5XAJ.BW MVO>"/$/Q"UY3]JNVC6PB/2./S%&X>V/E'XGO7K_PE_Y)?HG_ %SD_P#1C5TU M*<8TM-[ZF49-S\CI==N+VTT&_N--A\Z^BMW>WBV[M[@':,=\FO'CXY^+P7+> M%% R2;%^/\ Q^O<:\O^-7B>?2_#UOH6GLWV[5V\HA#\PBX! _WB0OXFLZ.L MN6R=RI[7N0?"WX@>)?&>MWD.I6MJ+&V@RTL$3+B0D84DL>HW''M7J]<]X)\+ MP>$?"UGI<2KYJKON''\9?%S3$UJY\+Z6_2 M[O)8A]3"V/UQ7G5I>S^)=8\-Z[=JRM9:CIVD+N_OJ&:4_B<5]$76G6=[/;3W M5M%-+:OYD#NN3&V,97T.*J)X9T2.-(TTJT5$NOMBJ(@ )_\ GI_O>]7"MRQY M290N[GD%]XD\3W.L:WJ$&H3V\]AJOV6""2_@AM50, $>-SN8N,_-ZGCI4GC? MQ)J4=YKNHZ3K&K(^EW$4)'VF*&V@D^7,8BY:8GGD@=^PKUJX\,:%=:NFK7&D M64NH)C;7>B6$]S.FR662!2SCW/\ 6A58W3L' M(^YY]K-QK&I>)/&D*>(-1LK;2].AN[>*UD" 2>46Y.,[EA[J06%N'NXA#<-L&94 VA6]0!Q4T6G M6<.FC3HK:)+)8O)$"KA F,;<>F*AS32T&HM'DVEW^LZW?>"--;7;^UAU#19) MKMK9U5Y&&.M2Z/X:CGU.>9U\4M8/*Y!>6%2)[W4AJHU">.:^ACM?+#[?)$+$ M/OQR&ZDUJQ:Q-J%]KVK:GXUN=$FT[5S:PV8P8EB5@%#18RY?/6O2?^$8T(ZS M_;']D67]I9S]J\E=^?7/K[]:+CPQH5WJ\>K7&D64NH1X*W+PJ7!'0Y]1ZT.I M'L'*SR:?SM)O/BC>6VKW:W=NBM&C2*=VY V\C')7[H/85JR:G>ZUXDL]'O\ MQ+))!*L+7,K ;F+$W&DV5H@6D MC.,JQ[C@?E1J/AC0M7M[>WU'2;.ZBMP!"LL(;RP.,#T'M1[5/=#Y&>6:?XD\ M0Z]9^!89=7NK4ZC<7EM<7%N%5KF.,?*XR" 2!UQUYI7U/Q GAC6--M_$+F:R M\0FQAEN[M89[B' /E+*1@.?4^AKUM]'TUYK*5K&W+V.?LI\L?N,C!V>G''%0 M2^'-%GMKNVFTNTD@O)3-<1M$")9#_$WJ?>CVL>W]7#E9R_PUU>6\CU;3;J;5 M3>6$ZB6'494F:$,N0JRI]\<'KS4WA@?9/B1XSLEXCD:UO /0O&58_B5KI]+T M73-#M3;:78V]G"6W%(8PH)]3CJ:YG1?^2M>*?^O&R_\ :E0VFY-!9JQVM%%% M9EGG$.E7VKZG=6Z6+Z?%&[S+%()O)#ABHY^7#.I)W0MC&<@YKOM/A^SZ?;P> M1%!Y<:KY43;D3 Z X&1^%<_JNDZ3IQFN'\1WFBPD>9*B7RI$,MC=B0$+DG'R MXY-;>EZ;::;;%;5I)!*=[S2RM*\AQ]XLQ)/'X4 ,U;7](T%(GU;4[2Q69ML9 MN)0FX^V:;?>(M%TV:UAOM5L[:2[(^SK+,JF7/3;D\CI7F7Q:=%\368>^M])S MH]VOV^[B$L6S@TR[34[(VTE]X1M(=)MYE+OO!QY M:$C);=M/KS0!]&UC7O\ R->D?]>]S_[2J[I23QZ/9).O!\?C?08]+DO7LU2X M6?S%C#DX!&,$C^]73T4TW%W0FDU9GSSXU^$2^%/"-WJP\0W5T+?8! \6U3E@ MO]X],^E=-\(O#PT+PI)XN^W2W'VJRD/V,C"IL9CP<]]OIWKU]D5UVNH9?0C- M($14VA0%] .*VEB)2ARLA4TI71QGP[\?CQ[97UP-.-E]ED5-IEW[MPSZ#%<% MK9_M_P#:1TZRD(:&P";5/3Y$,O\ Z$17MZ11Q_<15SUVC%'E1A]_EKO_ +V. M:F-11DVEN-Q;5F/HHHK(LXKQM=QVWB'P?&]N93/J>Q6\YT\L[3SA3AOH>*YZ MX^)?B-1U@:3IQTS3=4:QGS,XED&\*"@Q@$9&<^O3BN\UOPW;:YJ&CWD\T MT;Z7=?:8E3&';&,-D=/I6/-\.=-G\-ZIHC7EV(-1OS?2."NY7+!L#C&,KWK: M,H65R&I7T-?Q5H">)_#ESIIGDMY)%W03QL5:*0E8FB>%[/0VUYU?6-,2:UL!8ZG.T,45O*[7-MUV-*"- MN#CL>,BI4^)6I1^+;'3;F+1I+>\O_L?E6=RTLT&B]L[5C' MLB;<20?ERV(?$VJ7SR:?I\&D6=Y/:-*LC&5V0_+A M>@'3.?PK'^,T>M+X:>ZM]26VTN)H1)!$I$LTAD Y?/" $' ZGK7;>'?#EMX: MMKV"VFEE6[O);QS+C(9R"0, <<4GBGPW;>*]"DTF[FFAAD='+PXW95@PZ@CM M4J<5--;#LW&QL+]T?2G4@& !Z4M9%A1110 4444 %<5HO_)6O%/_ %XV7_M2 MNUKBM%_Y*UXI_P"O&R_]J54=F)]#M:***D9XAX[U/PQ?^/+E;K59X)K*W19K M:729)TDE3S?+ (_A#/N((VMA<'KCUCPM%'!X1T:&$7 B2RA5!OOF@"S+#%,H66-)%!R Z@@'UH>&*1D9XT9D.5+*"5/J/2G MT4 %8U[_ ,C7I'_7O<_^TJV:QKW_ )&O2/\ KWN?_:5 &S1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%>;:YX@\2>(/'EQX2\,7D.FQ6$*RWU M^\0D8%L$*H/'DT5YIIFO>)O"OCFP\->)K^+5;/5$;['?+"(W5 MQ_"P''_ZQS6I=_%CPI9FZ5[FZ>2UG:&=([5V*%3@L<#A<\9[TW!]!_2.1E0$2Q';QR,CJ?0UTVG>+M(U2'598)W4:5(\= MX)8RAC*@D\'J.#S[4N5VN.Z-VBLW0MK45Y3K MGC/7KU?"<%M>P>'8-9M#<7&H3Q!UC?;D1C=P,^_J*K0^._$;?#C4;V2YA:>W MU1;"/5HX0$>$NJF8*?EXR>>E/D8N9'K]%>56?C35HO#.LVT-ZNIZB-6;2M(N MRJ_OV8##';\IV98D@8^6O3;&"6VL+>">X>YFCC59)W !D8#ECCCDTG%H:=RQ M16-XC\4Z1X5LX[G5KKRA*VR*-%+O*WHJCDUE6OQ&\/W^AZCJ=I<3-_9Z[KBW M:!A-'G@93&<9]*7*[7"Z.NHKR_X2^)=4\3F]O-3UJ>YF ^:R^R".*'+':5<# MYC@'C/%=5KGCW0/#NJ?V;J-Q*EV8!.D:0LYD!) "X'+$@\4W%IV$I)JYTU%< MWIGCOP[JN@7>M07X2SL\_:C,I1H2.S*><^GK5/1OB9X;US4H]/MY;N*XF0R0 M"XMGC$R@9.PD<\ FERL=T=A17EWAWXG?\))<>)K -+UC6]:-\USE(YTMBCW+;B,+$!G/&/P]Z;@T)23.X MHKF;#Q[H&I:'?ZM;W,GDZ>I:[B>%EEAP,\H>:H0?%7PG<7ME;)>S?Z856*9K M=Q%O/1"Y&-W(!].]+E?8=T=K17G*?$I6^*LOAET*6,:^0C+"Q>2X)7J>R#GG MI[UH3?%;PK;W;PO/O%Y\$^'EU460O-UPD/EF39]X$YS@^E=37F'QX_P"2?1_] M?\7\GITHJ4TF$VU%M'-_\-#R?]"RO_@9_P#84?\ #0TG_0M+_P"!O_V%>(T5 MZGU2CV./VT^Y[=_PT-)_T+2_^!G_ -A1_P -#2?]"TO_ (&__85XC4OV6X^Q M_:_(D^S>9Y7G;3LWXSMSTSCG%'U6CV#VT^Y[3_PT-)_T+2_^!O\ ]A1_PT-) M_P!"TO\ X&__ &%>.VFD:GJ$32V6FWES&IVL\$#. ?0D#K5:6&6WF>&:-XI4 M.UT=2K*?0@]*/JM&]K#]K,]K_P"&AI/^A:7_ ,#/_L*/^&AI/^A:7_P,_P#L M*\1HH^J4>PO;3[GU!\//B8WCN_OK9M*%E]EB63<)_,W9)&/NC%>@UX!^SW_R M'=;_ .O:/_T(U[_7FXB"A4<8G53DY1NPHKB[[QXND^*M3TV]M9)8(&LXK86L M>^626<2<$$@8^3]>:K:C\3[&/0'N]-L+ZXO39W-R+IK$T.]HKB--^(-N;UX-598@2BI)'$1'&WV5;AE=B>I!8C [8ZU';_$FU>[E M!M;N83?9196<-M_I#F:)I/FRVWA5+=1@=1SW,6QIMLB*K)R?D(8GD ]/6NTH **** "N*T7_DK7BG M_KQLO_:E=K7%:+_R5KQ3_P!>-E_[4JH[,3Z':T445(SQ+XC:AIE]XGMKZ#6] M$E"0F$0ZC--'Y!5I$D*;%.=V<-T/[L8->M>'(Q%X8TJ,7IO0EG$HNCG]]A!\ M_///7\:\S\8ZAJ^B^,+N)?&6JHEU K1V=EHRW/V=27(R> #A6P?O$*<]!7IO MAUE?PUI;I/<7"M:1$37./-D&T?,^/XCU/O0!I45A>(O%VC^%Q -2GE$EQN,4 M,$+2R,JC+-M4$[0.IJEJ/Q&\,:6;+[1J)9+R!;E)(H7=4A8X61R!\BDG&3B@ M#JJQKW_D:](_Z][G_P!I5L*0RA@001D$=ZQ[[_D:](_Z][G_ -I4 ;-%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 5Y/J9O_ #\3=1\1OI=W?Z' MK$*+-):1^8\$B@=1Z<'\_:O6**<7835SR6WFOOB-\1]%U>WTN\LM"T4-()[R M+RVFD/91^"_D?44SPEIUQ'H/Q(\VRF62XNKKRP\)!E78V-N1\PR>,>M>NT57 M/T%RGA2Z???\(I\+$-E=;X-0!F7R6S$-_5ACY1]:=\1[/4=%\97MEI*'R_&, M$=N0#C;*KJK'\5/_ (\:]SKDH/ 5FOC#_A);W4;^_N(F+7='UQ_#.GRGR M+*ULW/VJ13C?(3CY>N!Z?4U[5:ZUIM[J=YIMM>12WEGM^T0J?FCW=,_6KU1& M7*[L;5T>/^+[B.^U[PQK>K:+?W'A V;%K,6Y;R)CG:9(AZ# _ UL?"RPN&TS M71-83V^@75ZS:;97B?=A.PLYKNZE6*WA0R22-T51R2 M:;G=6#EUN>7ZA%=ZC+XAUC0+00V_A^TFLM'B@B"@W)&9I44<9'W1^-6_AC?7 M-SJVK16]]?WVBI;VS1S7C.Y%PRYE4%N>O4= :]#L;ZUU.QAOK*=9[6=0\4B= M&4]Q5FARTL%M;GFGC^WN],\=>&O%;:=<:AI=@LD5Q';Q^8T);I)M_'_QVJ6@ MI<^)?B+K/BVST^[LM)_LTVJM<1&-KJ3'7:><#'7V%>L44*>E@Y=3@O@[;SVO MPWL8;F"6"42S925"K#YSV/-<_P"*-4CT7XZV&H365Q=0PZ0?,%O%YCQJ6<;P MHY..^.QKUVL*3PM9R>-(O%!FG%Y':FT$8(\O:23G&,YY]:%+5MARZ)(\MLGU MTVGCWQ?HVC3"._:,65MN*JZ<]UJ/CGP;J(FU_4(HY M&2XN;VT,4,+E/N1J% 4#N>G3FO>:BN+F"TA,US-'#&, O(P4<\#DT_:>0N0\ M?T.:6QU3XC:-<6-ZMU?/=7%NWV=BCIL;'S=,G(QZU@OHVK6W@WX?ZOY.I0V^ MG> M#K>*QG,\5W:L\2PL73AMQ(QD=>:]IHHYPY#RN>>31/CW/=W5E=M;ZE81VUO+ M% SH7)4?,1P -IR>U<3<_:]%DO(O#9\3:5J?VDE-"FM/M-O*2W4-C9M[\YZ# MGO7T561J7BK0-&NOLNI:S96DY4/YT]KEM.M6O$5+H MPH9D3HKX&X#VSFK-5[*^M=2LXKRRN([BVE&8Y8F#*P]B*L5F6%%%% !1110 M4444 %%%% !7%?#KKXJ_[#]S_P"RUVM<5\.NOBK_ +#]S_[+5Q^%DO=':UYA M\>/^2?1_]?\ %_)Z]/KS#X\?\D^C_P"O^+^355#^+$53X6?-M%%%>X>>%>@: MEJ=QJOP9M!)#!$EMK:VT,=O$$4 09YQU8DDDGDDUY_3O-D\KRO,?R]V[9N.W M/KCU]ZB<.:S[%1E8[WP2VL^&[_69[N:^LX=$M6NYK#S619)SA8E=0<$$D$^H M%<-=75Q?7Q?L]_\AW6_^O:/_P!"->_UX!^SW_R'=;_Z]H__ $(U[_7C MXO\ BL[J/P(YS4/".C7&LMK5TTJ7!GMIRQEVIOAW"/\ #]X&[E@EDS+R&B18UP>WRK@^N34M_X$TB_P!0 MGO\ ?=V]Y++#*LUM-L:)HD9%V<< JS COFO/(]7\;'0(E8:L(5OPMS>[)-[1 MF(D; 8?,5?, #?(V"< XS6E_:7C.'7] ^TG4;D206HN((;=H5W$GS&)*,AXP M65BA7M0!T3 M4M]X)9)9)C'YWR!WB,3G&,\J?7CMBNNHH XJ?X7Z%,D*I<:E!Y)MRAAN<NGHHH **** "N*T7_ )*U MXI_Z\;+_ -J5VM<5HO\ R5KQ3_UXV7_M2JCLQ/H=K1114C/*_B(\4WB&YMH- M.M?M,6G1W%Q=W&J-9L8UD^%[BQN/"^EMIT7D6HM(A' M;EPS0KL&$;W P#7 ZCXP^&NM:[<0^)-)1-1M%,3M?6!D8!7==H(!/;=Z88=\ MX] \/:;HFGZ6C:#96UK970$ZB"+RP^X##$8'.,=: //_ (D:;=)XSTW6636_ ML']FSVADT;<94E)W(&V\[3^60,\5S>J6/B6&SOAJND7UYJ6N^'+>S1H(-X6Y M#$%'*\(<$,2<#K7O-% %33+:2STFSM96#20P)&Q'"YV(\:*(^8^A4 GTYS72UC7O\ R->D?]>]S_[2H V:*** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ KRC0=?\8Z[XBUQO[7M;?2-%U)UF3[,IDEB M4G]V#VPJ]>N37J]E:[^U+JUXURR-'M$8;/R]3GKUXJHM),EI MMGE:_%77Y;!_$$>M6>X3_)H LF):'=C_ %H'WL<]?\*[&^\2>(O$GCI?#WAR M_ATJVM[!+V>XEMQ*[[P"J[3V^8?K3[7X9ZIIL?\ 9FF^,+VST'[1YXM8H5$R M C;7*+_:\ M\27F8E/F!E0G']W[QZ5A^!_"BZKIWC[P]?3W1CN-0,7VJ1?G'1;B-[:/[*J((UQ\IP!TH?+<%S6,^3Q%J%GK MWQ(>V%K%+IMJDMO*EL@?=L)R[8R_XYJJGC'QAI/P_;QCJ=_9W*7EO''9626X M4)*S8$CL.O )P..<5UDWP^$U]XMN?[2(_P"$A@$)7R?]1A2N>OS=?:K,G@.S MNOAW!X0O+EY(H8%C6Y1=K!E.5<#GOVI:[;Z[::BC M+*\-DT!M)0,@9P RGI_AWI2ZWXO\8>"?$GB&+4;.#24$\"::;8$O$J_,3)G( M;!X[9%=SH7A'7;+5[>]UCQ;=ZC%:Q&*&V2(0HPZ9D /SGZUCM\*KJ*+5-,T_ MQ/GZ0)_/^QPB M+S=NW?COC)Q6+I_@86,_BV7^T"__ D+,2/*QY&58>OS?>]NE2FKME-.R.$D M\;^,[?PUX>\7W%_9&RO[J.W?3H[;&Y22"Y/-3\. M^'=1M]*M=*B5I[F2W$SRR,,@ '@#_ U:N_AF+KP)HOAC^U64:9<)-]H\C/F; M2QQMW]>U3ZUX#NYO$TWB'P]KTNCZA+_"FAV9U/5K%[_6 MKI%@E6V_=V$6T%^!RY&1Z]*V)OA1:OX&N_#L>IS?:+VY6ZNK^6,.\L@8$G;D M8''K6YXJ\&Q>)M*L8!>RV=[I\JS6EY$H)C=1C.#U!]/I1S1N%I'->!/&E]?^ M*[K0+S5(M9M_L_VBVU&.T,&2" R,N,9YSG_(I?'"&^>U\/-!=I' =11!&8\G MS3]Q\^@P>.^:[+PWX]'CGPA_PF M.CV]HEZ;*XMKE+F&8)O 9<]1D>M)-*=QV?+8X77;;7O^%N^&K6#4;<:N='=) M;YX,H#E]SB/.,^@SCFM;PWXH\0M;^+],U+4-/FO]$D"0W]RODQ$,#@R!>@&, M\?3WKPXK7TCP.-*'B@#4#+_; MLLDI_=8\C<&&.OS8W>W2ARCT$DRWX$UVY\2>"-+U>\5%N;B(F38, D,5R!VS MC-<%XG\,>)9O&VN^(ET'1M0L5M46!-2;>&1%!.Q1T8G/7'ZUZ+X1\/?\(MX6 ML=$%R;G[*K+YQ39NRQ;IDXZ^MDP:S MX22UN'D1!=(^4(SD!O7ZUV]/[27KUP'P^_X_[W_KDO\S7?UXN+ M_C,]7"MNDFPHHHKF.@**** "BBB@ HHHH **** "BBB@ KBM%_Y*UXI_Z\;+ M_P!J5VM<5HO_ "5KQ3_UXV7_ +4JH[,3Z':T445(SS'Q_-JEOXD+I+KUI:FQ M!LY=$M1(TUR&;Y)CM)V@%<*<+\SC+*#M/TSB@"]1110 5C7O_(UZ1_U[W/_ +2K9K&OO^1KTC_K MWN?_ &E0!LT444 %%%% !1110 4444 %%%% !1110 4444 ,FFBMX7FFD2.* M-2SNYP% ZDGL*YGP9XWL?&5M>36X2!H)WC$+2AI#&,8D('0$YQ_.NEG@BN8) M()XTEAD4HZ.,JP/4$=Q7SWH)@/PE\76VD"$:\D\OFI"H$XM0ZY''.W&[CZU< M8IHF3:9[G9>)=#U*^>RL=7L;FZ3[T,4ZLP_ &LBR\>Z;?>.KSPS&T2M;1 B= MIEQ+*2,QH.Y SGOQTKRK5Y/"=SH/A"'P8MO_ ,)&MU 4^R+B9>/WGF$<]?7W M[5T-C_8>F?'C7ENH+6.5K:.2SC* ,TQ4%C'_ +9^;IR>:KD1/,STAO%?AY-4 M_LQM;T\7V[;Y!N%W[O3&>OM64/%=V?B@WA7[-#]E&G_:_.R=^[.,>F*\*UV_ MTW4? LMY9V_A_2T>]+1V$*M)?9WO(H< M$@YFV=EXJUC4='@L'T]=/9I[M(9?MUP(@$.<[QVOB+Q%-:^&%U;09M+NM\B".2ZNEC@92<' MY\XS[9K2U+7M*T6&*35=2M+(2\)Y\P3 I@;@G( ;.[]:?LT+G9[6U_9K8_;FNH M!:;=_GF0>7M]=W3%9T'BO0;O3[J^M-7LKBWM5+3/%.I" >O/'XUX?>6WV;X3 M:61??;]!&OB2=H89(T2#NN&YVALX/3D=Z[BT;X>:GXEO;70+"*YO)-+<2R6< M?^B^7_=< [=V=O8]J3@D/F;-*T^(CZYX#NM=T>+3XKV*3;]EOKM46-=^T&1L MC:2 2/ZUUMUK=AI>FPWFK7UI9HZC+R3!5+$=%)ZUX%92Z4W[.VJI;M;?VDLB M?;=@'F8\_P"3?WZ9QFNGUA]+A^*&AR^+1%_8O]C*+(W0S )OXLYXSCU]O:J< M%<2D['K<6L:;-IAU*+4+5[$+N-RLJF,#W;.*KIXET.74(M/CUBQ>\E4/' MP MI=@1D$#/<$?9]HQ$9)]"T:X2WU/6+&TFDY6.>=58 M_@36G'*DT2R1.KQN RLIR&!Z$&O#/%4-M#XX\27&GZUHOVB2-3>Z=KUOL# + MC$4C#D$<_*1U'M7I7PVU"/4_ .EW,6F+IL11E2W3.P ,1E<\[3UYJ91LKE*5 MW8MVFN7C>*-8LKPZ;'IME$DD9,D(%SS@GC\#7H<9)B4DY)45X]XR\/Z9<_'/PW'+ M;@I?QF:YCS\LK1[MI([]!GUQ4P2>C'*ZV/0- U^[;PC!K7BD66EO*OF,N\JL M:'[H8L?O$ZMN8?X,9Z^U>#V\]HWB;P#-;R^'X0UU&5M=*C.^W5L<2R$DLW;![ MYKL_ ^@Z7J?Q&\<7M]907,]KJ2>0TBAO*.2V1Z'('/M3<$M04FSTK6=8L= T MF?4]2G$%I 7<@G&3@# ZDD@5R?@KQS>^-%\0F.Q6T%E($M%D4[SN4D&121S MP. 1UZ]Z[>:"&XC\N>))4R&VNH89!R#@^AKSSX<'/C/X@<_\Q1?Y-4*W*QN] MSJO"A\0MI;'Q*L"W@D;:(1QLZC)!(/7';IWZG=HHJ2@HHHH **** "BBB@ K MBOAUU\5?]A^Y_P#9:[6N*^'77Q5_V'[G_P!EJX_"R7NCM:Y?QY_R+Z_]=T_D M:ZBN7\>?\B^O_7=/Y&KP_P#%CZD5_P"%(\WHHHKWCQ HHHH **** "BBB@#L M?A[_ ,?][_UR7^9KOZX#X>_\?][_ -1K9+H;,D&)R0C@]"#M/Y M4 :%%5+'4[+4S="SG64VL[6T^ 1LD7&5Y],BB]U2RTY[1+N=8FNYQ;P @G?( M02%X]@?RH MT45'//%;6\EQ,X6*)"[MZ*!DG\J )**H:;K-AJZEK"?SE$<)-=;FRN2C% M#C9W&<]1BNG^']UK]QIM[%KS7,DEO<".*:YA6.1AY:,X.T ,%@>%BQ\):.7FBF;[ M%#F6)RZ.=@Y#'D@^IH K^+_%=AX,\/S:OJ&YE0[8X4^_*YZ*/P!)] ":Q=9^ M)ECH\L2_V9?706RCO[QH I%I Y #-DC\2RS7^EZG!B+3I; M:&PFM@^YG!WE7+ (S#"[L<#/K6!JG@SQ?!!=0PVD.IRZSHD.FW$ZR)"+:1"1 MN92>5"'^'.2.G- 'LD4J3PI+$P:-U#*PZ$'D&LF]_P"1KTC_ *][G_VE6AI] MK]ATVUM-V[R(4BW>NT 9_2L5]/BL_&.FR1RW+M+!'--71[F--7A,KSS$!8CY1D"#'WV&,'' ]:?XN\5WOAB:Q=-+CN;*>5(7D:Y M".SNX4)&F#N;&6Y*C /.: .KHHHH **** "BBB@ HHHH **** "JEOI>GVEU M-=6UC;0W$W^MECB56?ZD#)JW10!2MM&TNRNGNK73;2"X?[\L4"JS?4@9ITNE MZ?/?1WTUC;27<0Q'.\2F1/HV,BK=%%P,[^P-&WSO_9-ANN/]F7=CI MFB^;YUY#';@/(X((88&,_P">:[&\TG3M1ACBO[&VNTC^X+B)9,?3(JY13YF* MR(?LEM]E^R_9XOL^W9Y.P;-OICICVJ*QTO3],1DT^QMK17.6$$2H&^N!5NBD M,SUT'1TCN(UTJQ6.X(:91;IB0@Y!88YY]:GN].L;^V%M>6=O<0#I'+$KJ/P( MQ5FBBX%9=.L4L?L*V=N+,C;Y B7R\>FW&,4DFFV$MO#;R65L\,)#11M$I6,C MH5&,#'M3;V_%G=6$!C+&\G,((.-N$9\^_P!S'XUQIK:5ISV263V%JUHA!2 PJ47'3"XP*MT4 '08%026-I+=QWW;.8HH ME53GKP!BK5% &=%H&C0(J0Z181HLGFA4MD #]FZ=?>K4-G:VTLTL%M#%).VZ M5XT"F0^K$=3]:GHH *@AL[6VEFE@MH8I)VW2O&@4R'U8CJ?K4]% !1110 44 M44 %%%% !1110 5Q7PZZ^*O^P_<_^RUVM<5\.NOBK_L/W/\ [+5Q^%DO=':U MR_CS_D7U_P"NZ?R-=17+^//^1?7_ *[I_(U>'_BQ]2*_\*1YO1117O'B!VXK M;FL]/E\/2WMM;RQM$Z(KF7<7)^\64<*/0UB5JRZT'LY88K"W@DG55GDCS^\" M] %Z+GOBL:BDVN4TIN*OS$^D6%B]@EU>Q/-Y]XMJBK(5V9&2W'4\]*RKVW^Q MW]Q;9W>3*R9]<'%:-IKJVID4:?"T!F%Q%"7;$3@8!![CV-94TKSSR32',DC% MV/J2_P#7)?YFN_K@/A[_ ,?][_UR M7^9KOZ\3&?QF>OA/X2/*O%_@'6];\7WFI60CCAN3:VKR&0 M:E76X&/H4QZU MD_\ "N_$L>FVUJ+&.25;7R;*87WEC2I1/(YE 'WLJR'CGY=IXKK_ !CXZNM* M?4+'2+&26XL7M!BS8S7%R;>* 74."0F\EFW83 XPV#G@9ZU;B^)FG3ZMI5C'97*+J,,4L M*ZVB@#QNT M\#^*+;3+N.+2X(2]A%:W<#WQE&I3B52]QU&#M#8W$9W8/ IG_" ^(1HMK9W& MEI>V\+7Z16;WHC$!E*F&4;?E^4;EP.F>!7L]% 'DMKX!UR0Z?;7\"O9)/IIN M(Q<\&.*S:*48!Z;R..]H.!5BBB@ KBM%_Y*UXI_P"O&R_] MJ5VM<5HO_)6O%/\ UXV7_M2JCLQ/H=K1114C/$_']IX=M?'\T4\7A;3Y9K-+ MF2XU6V>8SN7<'"JP"D;>3U.?:O7=#9&T#3VCDMI(S;1E7M4V1,-HP47LOH/2 MN!^(5YXDL_$=H]E;:I)IIA 7^S;:.7,AWA_-WHHHH *QK[_D:](_Z][G_VG6S6-??\C7I' M_7O<_P#M.@#9K(U_1I]9MHX[?5KO3G0G+V^U@ZLI4JRL"&&#QQP<&O+_ (G? M$SQ%X3\7_P!F:8UH+?[,DO[V''(''T%9U,/.FKR*C4C)V1U%%%(Y 1B6"@#[Q[5@:"T5XE M:ZO->Z7XB?1O&K"S*0VT=WJ5_P#.TWG8DG 4$PQD'8N 3SQUK9B\3SP?"G6 MFLKR0ZO;+=K#(UX;II1$P5YHG;YF09R#CCI0!ZI17%_#Z[:<:[;PZC-J.FVM M^([*ZEG\XLIBC9AYG\0#LWTZ5VE !1110 4444 %%%% !45Q<0VEO)<3R+'% M&I9W;H *EK*\0?/96\)4,LUY C ^GF*3^@H D_MRP_OS_P#@-)_\31_;EC_> MG_\ :3_ .)K1HH SO[XL5N'@L+@W%R1;/]PJ8\#(Y/[PMQDX4UM_ MVY8_WYO_ &D_P#B:T:*=Q6,[^W+'^_/_P" TG_Q-']N6/\ >G_\!I/_ (FM M&BD,SO[)M/D51A[>>-CWZHP_D:8C5HHHI#"BBB@ HHHH **** M "BBB@ HHHH *XKX=?>\5?\ 8?N?_9:[6N)^'ORW'BV(GYDU^X)'L0A%7'X6 M2]T=M7+^//\ D7U_Z^%_D:UKS2&N[@RC4]0MP0!Y<$H5?R*FJ%YX1AU"#R;K M5M5ECSNVFX Y_!:=*2A-2?052+G!Q1YA17H'_"N-(_Y_-3_\"?\ ZU'_ KC M2/\ G\U/_P "?_K5Z/U^GV9Y_P!2GW1Y_17H'_"N-(_Y_-3_ / G_P"M1_PK MC2/^?S4__ G_ .M1]?I]F'U*?='G]%>@?\*XTC_G\U/_ ,"?_K4?\*XTC_G\ MU/\ \"?_ *U'U^GV8?4I]T>?T5Z!_P *XTC_ )_-3_\ G_ZU'_"N-(_Y_-3 M_P# G_ZU'U^GV8?4I]T4/A]_Q_WO_7)?YFN_KF;+P39Z<[O9ZEJL3.,,1< Y M'XK5^+0WBF23^V-4?8P;8\RE6QV/R]*X*]15*CDCNHTW3@HLJZMX*T+6M1:_ MOK61IW$8DV3NBR>6VY"RJ0&*GH2.,TQ? GAU=1N+[["QDG\W*&9S&AD&)&1, MX1F[E0#7245B:G+#X>^'EMVC$%SYS3+-]J^UR_: ZJ4!$N[=PI*XST-6)?!& M@S7-K,]K*?LHB"1&XD\L^7_JRR[L,5[$\^N:Z&B@ HHHH **** "BBB@ HHH MH *XK1?^2M>*?^O&R_\ :E=K7%:%^\^*_BUUY6.ULHV/^UM<_P B*J.S$^AV MM%%%2,\P\907%SXUO;:RN-'>:[T9;::#6'>-(XFD;+1E>&R?O+P?E3FO0-$L MSI^@Z=9-=&[-O;1Q&X)R9=J@;OQQFO+_ (HW5I;>+++^T-)TUK=H%5+J[TIK MMIV/F?(&'W0AV';U;?Q7IOAXR'PUI9FL4L93:1%[1%PL!VC* =@.F/:@#2HK ME?%VO:_H_P VD:3:SVT5M)W'E11A/X!@$EC[\5S5_\ %2_^RQW>F:)' M+!;Z3#JVH+<3E'CCD/")@D?]>]S_P"TZ / /CG_ ,E%/_7E%_-J\VKTGXY_ M\E%/_7E%_-J\VKV\/_"B<%3XV%%%%;&85]3_ =_Y)AI7UE_]&-7RQ7U/\'? M^28:5]9?_1C5Q8[^&O4Z,/\ $=C?ZA9Z79R7E_BHL:%$"S( JGJ!Z#V MKY'HP*W^HQ[F7UA]CZZM_&O@JTA6&VU[1X8E^ZD,O\ -*BI@XP@Y7V*A7*?$E_H>I:';6VGK+;W]_%;3W4C@+&')& >/KK1+J"WM+)9I8;4S03++=;%!)1R/+;DG@'.!F@#N**X1O'EP_P 09-"C MCLXK&"YCM)'G$@>21X_,&QP-@/0!6.6YQTY[N@ IDD4_P!TUW-%_$UGXHTA;RV#13(WEW5M)Q);RC[R,/4'\ZVZEIIV8P MKC+WXCZ78)K'GV]R9M.O%L8X(P&DNYF4,%C Z]>]=G7C]_\ #+4;W7/%/B& M/;:VM\EUHLQF&P[54G*@X&XC:=WM2 ZS4?'L]EJ%KI5OXETCPCXK2^\(RZI.[7 M%E87T-S>>*CX;6$1Z/J&I22))*RVJ#;'&@ MRS,S$ >PSDUCZE\4=+L[>SGM+"_OXY]/_M27R%4&WM<@>8P8COG@9/!JIKVC M^(;3PY_8]S:R^,K*[+BZ,DR6TZ'Y3&!@A2H(Y[USEUX0\96%BF+%-5N]0\.? MV-$K[^QO!EC80)/)I6HV3W4@(7,4*%2W/7'IUYKOJ "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@!'941G=@JJ,DD\ 5Q/PXW:C#K M?B9@=NLZ@\D&>\$?[N/]%)_&H_&.ISZ]?CP1HDI%S+.V/4$_WW' M'OFNSL;.WTZQM[*UC$=O;QK%$@Z*H& *OX8^I.[+%%%%04>*:?JOB'1_&0U. MYTGQE=[KN\6_C2W:2W>$DB#RE)QP O(QU/6O9;2X^UV<%SY,L/FQJ_E3+M=, MC.&'8CN*FHH X3X@>%_$GBBYL(-.N-,_LB ^;M M9>O> ?$NJ3W$]M=Z3;OJ^FQZ?JB!9-D>UOOPCO\ *2N&Q7I]% $-I;)9V4%K M'GRX8UC7/7"C _E6"^F6-CXQTV6TM(89)H+DR,B@%N8SS725C7W_ "->D?\ M7O<_^TJ / /CG_R44_\ 7E%_-J\VKTGXY_\ )13_ ->47\VKS:O;P_\ "B<% M3XV%%%%;&85]3_!W_DF&E?67_P!&-7RQ7U/\'?\ DF&E?67_ -&-7%COX:]3 MHP_Q!\8?^27:O_VR_P#1J5\L5]3_ !A_Y)=J_P#VR_\ 1J5\L48'^&_4,1\0 M4445VG.%>E_ O_DHA_Z\9?YI7FE>E_ O_DHA_P"O&7^:5CB/X4C2E\:/I:BB MOEOQOXO\2V?CK7+:UU_4H8(KQUCCCN6"J,] ,\"O*HT75=D=DYJ"NSZ4U71K M36?L7VOS/]#NX[R+8V/WB9VY]1STK*D\$V$NL2:F][J;3'S3"ANB4M7E7:[Q M \JV,XYP,G %?,/_ G'BS_H9=5_\"G_ ,:/^$X\6?\ 0RZK_P"!3_XUT?49 M]S+ZQ'L?3G_"!Z2=;AU5Y;UY8WBF>)IR8YIHTV)*X[N!WSS@$CBNGKX\_P"$ MX\6?]#+JO_@4_P#C0WCCQ9M/_%2ZKT_Y^G_QH^HS[C^L+L?8=%9^A223>'], MEE=GD>TB9W8Y+$H,D^]37NI6.FHKWU[;6J.=JM/*J!CZ#)KBMK8W'7R7;V,R M6,L45TR$122H756]2H(S],BO)'UVYC^&-A=:EXGOTOGO;N"+R)4BEO91*ZQ@ MN>$12 3V &#Z'TW_ (2GP]_T'M+_ / R/_&J$][X(N84AN+KP]+$A9DCDDA9 M5+'+$ ]"3U]:.5]A71C>(+[4Y/ NG6EKXAT^/69&M([FZ6\6$,6 )VL <%]I MV\<@\"MKP%J/]J^#+"[+73LWF(S7,PE=F61E)W@ ,,C@X'&*'O\ P3);R6[W M?A]H)$5)(S)"595X4$9P0.P[5:A\1^&;>%(8-9TF**-0J(EU&JJ!T / HY7 MV"Z-JBJEEJFGZEO^P7]K=^7C?Y$ROMSTS@\5;I#"BBLK7?$%GX>M8IKI9Y7G ME$,%O;1&269\$[54=> 3]!0!JT5D7?B.RM- BU@QW8';N4JP()5E(/0@@@_2@"_1110 444V1=\; M+DC<",@X- $5O>VMVTJVUS#,T+[)1'(&V-Z''0^QI_VB'[0+?SH_/*;Q'N&X MKG&<=<9[UY+X"TW4/#VLW5^^E7RV%OIL-B433S#-/*)CAF7<1(P5LM(#C!X[ MUH>']+\4P_%RXU;5],4Q7-E-$UW'<[XXXQ(IB11M&#@#(SR69L]J /3J*** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D->\'W#ZJ?$'AJ\73=>RF6UD/JLJ]/H<8KN:8\:2H MR2(KHW!5AD'\*M2NK2U%;L9EKXGT"]B$EKK>G3*>A2Y0_P!:L_VSI?\ T$K/ M_O\ K_C67=>!/"=XYDN/#FENYZM]E0']!5?_ (5MX+_Z%G3?^_(H]SS#4W/[ M9TO_ *"5G_W_ %_QH_MG2_\ H)6?_?\ 7_&L/_A6W@O_ *%G3?\ OR*/^%;> M"_\ H6=-_P"_(H]SS#4W/[9TO_H)6?\ W_7_ !H_MG2_^@E9_P#?]?\ &L/_ M (5MX+_Z%G3?^_(H_P"%;>"_^A9TW_OR*/<\PU-S^V=+_P"@E9_]_P!?\:/[ M9TO_ *"5G_W_ %_QK#_X5MX+_P"A9TW_ +\BC_A6W@O_ *%G3?\ OR*/<\PU M-S^V=+_Z"5G_ -_U_P :/[9TO_H)6?\ W_7_ !K#_P"%;>"_^A9TW_OR*/\ MA6W@O_H6=-_[\BCW/,-3<_MG2_\ H)6?_?\ 7_&C^V=+_P"@E9_]_P!?\:P_ M^%;>"_\ H6=-_P"_(H_X5MX+_P"A9TW_ +\BCW/,-3<_MG2_^@E9_P#?]?\ M&C^V=+_Z"5G_ -_U_P :P_\ A6W@O_H6=-_[\BC_ (5MX+_Z%G3?^_(H]SS# M4W/[9TO_ *"5G_W_ %_QH_MG2_\ H)6?_?\ 7_&L/_A6W@O_ *%G3?\ OR*/ M^%;>"_\ H6=-_P"_(H]SS#4W/[9TO_H)6?\ W_7_ !H_MG2_^@E9_P#?]?\ M&L/_ (5MX+_Z%G3?^_(H_P"%;>"_^A9TW_OR*/<\PU-S^V=+_P"@E9_]_P!? M\:3^V=+'74K/_O\ K_C6)_PK;P7_ -"SIO\ WY% ^&_@P'/_ C.F_\ ?@4> MYYAJ3ZEX[\*Z2N;O7K -VCCE$CGZ*N36')KWB;Q>/L_AK3YM'TY^'U?48]LA M7_IC">2?]IL"NHT_PQH.DMNT_1K"U8<[H;=%/Y@9K6HO%;(5F]S&\-^&M/\ M#&G&UL5=GD;S+BXF;=+<2'J[MW-;-%%2VV[LH****0!1110 4444 %8U]_R- M>D?]>]S_ .TZV:QK[_D:](_Z][G_ -IT > ?'/\ Y**?^O*+^;5YM7I/QS_Y M**?^O*+^;5YM7MX?^%$X*GQL****V,PKZG^#O_),-*^LO_HQJ^6*^I_@[_R3 M#2OK+_Z,:N+'?PUZG1A_B#XP_P#)+M7_ .V7_HU*^6*^I_C#_P DNU?_ +9? M^C4KY8HP/\-^H8CX@HHHKM.<*]+^!?\ R40_]>,O\TKS2O2_@7_R40_]>,O\ MTK'$?PI&E+XT?2U?(7Q _P"2A^(/^OZ3^=?7M?(7Q _Y*'X@_P"OZ3^=<.!^ M-^AT8CX3FZ***]0XPI&^XWTI:1ON-]*!H^S_ ]_R+.E?]>(L#'SV_\GKVZ MO$?V>/\ 4>(O]^W_ )/7M+B?XK.ZE\"'UR?CGPM-XEATN2WC MM)Y;"Z,WV:\9EBG4HR,I*@D?>R.#TKR(_'[Q'DC^R]+X/I)_\51_PO\ \1_] M O2_RD_^*J_J=7L+VT#UFST7Q-IWA.'1DN=/O'@M8HC)=-)^_.3YJ$CE5VX" MMR?45H^#=$N?#WAFVTR[EB>2)G*K#DI$K.66-2>2%! R>3BO%?\ A?\ XC_Z M!>E_E)_\51_PO_Q)_P! O2_RD_\ BJ/J=7L'MH'T317@6E?'3Q#?ZS8V4FF: M:J7%Q'$S*'R S ''S=>:]]K&I2E3=I%QFI;''>*OB7H/@[5(]/U1;PSR1"8> M3"&&TDCKD<\&L/\ X7OX/_N:G_X##_XJO/?CW_R/5I_UX)_Z&]>6UVT<+3G! M29SSK2C)I'TI_P +V\'_ -S4_P#P&'_Q5)_PO;P?_+=&75=-$PMFD:,>L>Q]P)*[3T&#EA5WXB:Y?VT^GVFGZNVFH MUK?74LT.PMYD$:LD9+ C&6)(ZD#M0!Z'16?H5Y-J/A[3+ZX0)/F5Q7BOX>CQ'JLM];ZQ/ MIWVRS%A?I'"K_:(-V[ )^XW49YX/2@#K-.O%U#2[2]52JW$*2A?3< IJKZ]+L+ZNNY\0^3-_SPE_[]G_"OI7X4:WI5A\.-,M[S M4;6WG0R[HII51AF1CR#S7I-)M!/('Y5E6Q+JQLT7"DH.Z/-_BMK>E7_PWU6V ML]1M;B=_*VQ0RJ[-B12< <]*^:O)F_YX2_\ ?L_X5]N[5'0#\J6BCB72C9() MTE-W9\0^3-_SPE_[]G_"CR9O^>$O_?L_X5]O5''/#,TBQ2QNT;;7"L"5;T/H M:U^O2[$?5UW/B7R9O^>$O_?L_P"%>A_!>YAT[QZ9[Z1;6'[%*OF3_(N25XR> M]?3=)@'J :F>,E.+C;/-=G MMU:6&2\D9)(U+*PSU!'45]>[%_NC\J, =*QHUG2=TBYP4U9GQ%Y,W_/"7_OV M?\*/)F_YX2_]^S_A7V]4$EY:PW$=O+3CI7MFU?[H_ M*@ #H /PKDA-QFI&THWC8^(O)F_YX2_]^S_A1Y,W_/"7_OV?\*^WJ9++%!$T MLTB1QH,L[D >Y-=?UZ78Q^KKN?$GDS?\\)?^_9_PH\F;_GA+_W[/^%?;<,T M5Q"LL$B2Q.,JZ,&4CV(I]'UZ78/JZ[GA'P'U&RTJ'7AJ%U%:&1X-GVAA'NP' MSC/7K7KMQXFT$VTH&LV!)0X'VA?3ZULE0>H!_"C8O]T?E7)4GSS56/B M,PS;C^XEZG_EF?\ "D\F;_GA+_W[/^%?;U%=?UZ78Q^KKN?$/DS?\\)?^_9_ MPH\F;_GA+_W[/^%?;33PI-'"\L:RR E$+ ,V.N!WQ4E'UZ78/JZ[GQEX?5X? M$NE221R)&EY"S,R$!0'&23Z5])989$DC895T8$'Z$57UZ78GZNNY\2>3-_ MSPE_[]G_ KZ)^#>L:9IWP^AM[Z_MK:87,Q,5HN%)0=S+_X2?0?^@UI__@0G^-'_ D^@_\ 0:T__P "$_QK4VK_ '1^ M5&U?[H_*N8U.=O;_ ,':E/;SWUUHUS+;-O@>9XW,;>JD].@_(5#!KV)XK MI]"FC>07(3 F<5:I .@ I: "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** /)/B6FGS^-H8==%N=.7P]>R6PN2-GV@ M$YD\ >'WNRYN&T^$N9,[B=@ZY[UJZAI.FZM'''J5A:WB1 MMO1;B%9 K>HR.#5L 8 P!V% "T444 %%%% $%[ ]U8SV\=Q);O+&R+-%C?& M2,;ESD9'7FN ^%-C'IDWC"RBDFD2#7)$$DSEW?")RS'J3U)KT:H+>SM;1YGM M[>*%IW,DIC0*9'/\38ZGCJ: )Z*** "BBB@ KQCQ_;^&-2\9R:-!)9PZY=26 M\]]JMY08>*5 RL/0@\&@#@OA!Y<.@ZO8J8F:VU:=7>U/^BD MG#8@'\* $#;V.?6O0Z@L[&TTZU2UL;6&VMXQA(H8PBK] .*GH **** "BBB@ M#PO3];OK[XT:)JFJZ9K-O<7#75M#:RVC*D$ 5"I/WNK,[=!N'I7NE0O:6TM MU#=26\3W$(812L@+(&ZX/49P,U-0 4444 %%%% 'F_Q0TRWUG4O#UI<:QI-B ML;SSK#J<)DCG8(!TR%^4$GDCJ.M;WPWU :I\/M(O%T^"P5XV M[=2L:X=AE0 M>BG&X?6M[4=*T[5[<6^IV%M>PAMPCN(ED4'UP1UJU'&D,:QQ(J1H JJHP% Z M "@!U%%% !1110!XY\4D:Y\?6$%W)I2V*Z-<2Q#5T+0-*&^8* P^?;CG/ R1 MSBDNM4\9W.F^"+C0+"QM=-G: P0O<3E@?);*3'G,7H>3PN:]8U#2=-U>)(M2 MT^UO(T;>BW$*R!6]0".#5M5"J%4 *!@ =!0!#9FY-E;F]6);HQKYRPDE ^/F MVD\XSG&:GHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "N!^*WBC6_"NBZ7: ,2S^()U?Q/X>>PF']C:AI5Q>31[ M 75XSRN?53D8K=@\?:+<:1H6II]I^SZW="UM,Q?-O)8#<,\#Y3S7+V?PON-, M^)USK5E<1IH=S;SC[/N.Z"648;:N,;21GK[=JS])\!>,H+'PKI%VNDKI_A_5 M%N?.CF-9W-T+-C#!(# MCYF'KVQD^U0:O\2X+GPGXEGT>.\LM6TFW$ODW]J8V ;[K[6Z@CU_*LV?X<:W M)X.UO21)9_:+[Q"VI1$R':(BZM@G'WL*>/UJ]XD\":OJVJ>,;FW>U$>L:;#: MVV^0@ATZ[N.!^= &IX;^)&DZQ/9Z?.M[:WDUH+B.6[M6ABN0%!=HR>H')[<# MBIM&^)&A:YJL%C;QW\(N]_V*YN;5HX;S9][RG/WL8]JYV+P-XEUK6-'/B)]/ M@L]%L)K6&2R=F>X:6+RRQ! V@#G'K['BIX0^&^L:1JVD)J-EIK6NDEV6\%Y< M2O,>=A2(L$B([\$>U '9>%_'^D^+[IH=*MM1,:1L[7$MJ4B!# %-W0MR#@=C M4.N_$K0M!U2XT^6+4+N6T027KV5JTJ6BGD&1A]WCGO3_ (<>&[WPGX-ATK4& MA:Y2:61C"Q9<,Y(Y('8US^H^$O%>FZSXE;PZ-,N++Q& 96O)&5[1RI5C@ [U MY) _R0"+7_'NH7?C_P /Z'H%S<0Z?>1+^2\?V?S/.&TG;G/R?6L'1_ %WHGB?POO=:USPQ>6K1"+3+\W$X=B"5VD?+QR>: ,R3XN M^&HIG5H]3\F&[:SN+D6;&&"0-M^=^@R>F,GVI?%OQ)T[1#JVFVJ7LVHV=HTD MDUO:-+#:N4)C\UATR<>WK6+=_#G6IOAYKNA(]F+R_P!9:_C)D.SRS*K#)QUP MO3%6-6\'^*H=:\5#1#IDEAXDA EENG97M6$90X !W @\>G?IR +I/CN[+:%/ MJ-^SB?P\=3N;.&R!:5@,EE;/!X^[BNG7QSHTXT%;:265]=C:2S"1Y(55W,S\ M_*!W]ZYWP_X%U33/$7AF^NFM6@TW0?[.N%5R29,]ACE?\XIG@OX;WGAOQ+J- M[=W4WDE8131SL M\1)<3Z;_ &G?ZM'JD"Q,WE$K@E"2,CN >^.>M 'H-SXPTJTU;4]-F,XGTVS% MY<%8BP\L_P!W&23[ 5@O\2K/4-,UJ&QM=1T_5K73);^"+4;0Q&1%4XD4$\KG M%9;^$O&U]JGB+66NM/TS4=3TR.VMOLLSMY#JV<%BHZ@'YATSQTS69I?PU\0) MJ=]J$UK86C7>A3ZRALMS3, 265@>#QPH'/XUJ:9\4-#U+69-+:UU6QN8K=KF7[=:&(11*,EFR> M!CO6)9>!O$>F7WA^_M'L#>P DD;:;C!VGIRF<9/6J7ASP%XMAL=8TW6 MX])?^VXIEU#58[B22Z9F5@F 5"[02/EX&,T ==H?Q(T+7;Y+6)+^T,T+3VLM M[;-#'=1KRSQL?O #GMQ7,ZK\5TOKWP]#X>2]CAO=7BMFN+FR*Q7,!)#F)SP< M''H:A\,?#75;>[M8]7L=.AAL;.6U6[BO)YY92\9CWHKG;$-IY&/H!VCM/ GC M1K'POH]Y_9 L/#VI13K-'*_F7,:DX.-N%(!Z=S].0#T'Q-XMTWPK#:F]2YGG MNY?*MK6TA,LTS=2%4>E,'Y'R <@7=OJ+W*WVFRZ=;_:KB MVU"U:*41=G"\Y!.!QZCUJ;1_'^EZL)VDL]3TZ.*V-WYFH6IB1X1U=6Y!'MG/ MM7/IX0\3Z[K.HZ_KL6D6UX^EMIMI9#=/"06W,TO0D$Y&!T!]1SD:%\,=:4ZI M:S)!HFEWFG2VDEG:WTES'+,PXE57 V >F2>U '8Z1\2] U>>I]J .R\0:W+I_B_PQIR:A]G3 M4))U>W^S>9Y^U00-^?DQG/0YK+A^+GAN:6W BU-;>:Z^QF[:S80QS9P%9^F3 MUXSQUQ5_Q+X:OM6\;>$]8MFA%MI,MP]P'8AB'0*-HQSR/:N57X<:V/AY'H7F M6?VQ=:^WD^8=GE^9NZXZX[8H ['QW<>(;#PW)J7AQD:[LF$\ML\887$0^^@[ M@XY&/3'>N4T_XE-X@U>75[*Z6S\'Z39K-J%Q+#EI9G&1$O&?ER,X[\=Q7J-> M8V?PUOG^%.K>%+J>W@NKRZEGCDB)*#,@=-W /\(!H Z'2OB)HNIK>AX=1L9K M2V^UO!>VC1R/!_ST1>2R_3FHM.^)>C7\EW%)9:K8S6]D]^([VS,330+U=.>1 M^5W%S(')!+;W)V(<< D9S]:FE_#?Q"F MI7%_/:Z?;-<:)<:=(/MTMQ(\SCB1W<=SV'0>M 'H/A;QGI_C"*:;3+:_6WC5 M&6>YMC&DN[/W"?O8((/O7.:SXRU^#XDZ#HL.G-9Z/,%LX!8=AD_I1/>06\!FDD_=@@94%NO3@@%"7]K)]HVS*?LQQ-_L?7\J +-%017EO-;QSK(!%)] MQG^7/YU(LT3L%61&)&X ,#QZ_2@!]%01WEM*6$<\;;25.&'4,[/O?-PO0\_F/SH GHJ%KNW1 MPC3QJS$@ L,Y R?TYIDM_:021I+<1HT@R@+=1ZT 6:*B-S )5C,R>8S;57<, MDXSC\N:7SXLX\U,C.1N';K0!)147VB'_ )Z+S@\'/!Z'Z4K3PINW2H-HRV6' M ]Z )**@^UVX@68S((V3S%.>JXSG\J8VHVBP"8RY0@D%5))P<' '/6@"U15= M;^U>-9%F4HS*H([EL;?SR*D%Q"0")8SD%A\PY [T 245!%>6TZJT4R,&)"G/ MWL>GK2O=V\:,1#^/<,4 345'YT6<>8F2VW&X=?3ZT+-$Q4+(A+#(PP.1 M0!)148GA) $J$DD ;AR1U%-2[MY$9TF0HK;"V[C/IF@":BJRW]HUQ]G%Q'YW M/R9Y[=OQ%2B:)B LB$G.,,.<=: )**B6YA=MJRH3MW\'MTS2BXA(R)8\<<[A MWZ?G0!)14?GQ;MH=2>>A].M-DN[>)-SS(%W!,[OXB<8^O- $U%-$B%R@92R] M1GD5%'>6TP8QSQMM)!PWIU_*@">BHC<0JC,95VJN\X.<+Z_2F/?6L=L;AKB, M0A"^_=QM'4T 6**B%Q"5W>:F/=@/K4=SJ%I9QF2XG5$"&3<>FT$#/ZC\Z +- M%0I=0.6"RH=A(;GICK^5(;VV6.:0S)LA!,AS]T _P B* )Z*J0ZG:3SI#'* M3(Z;U4HPR/Q'7VZU/]HAP3YJ8&>C>G7\J )**@AN[>?9Y,JOO3>NT]5]?U%, M.HV8CED-Q'LB.';/ /IGUH M45&T\2E@TJ J,MEAP/>D6Y@=2RRH0'V$[APW MI]: ):*C\^$@'S4P06'S#H.IH$\1#'S%PO4Y]LT 244SS8\*=Z_/]WG[WT]: M8UW;I+Y3S(LFW<5+=!P,_J* )J*9YT6<>8F=VW&X=?3ZTC3Q(6#2HI7KE@,4 M 245$+F%IWA$JF1 "RYY /3/Y4[SH@0/,3GI\PYH ?13$ECD^XZMC&=IS3Z M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+SROL-QY[[( M?+;>^?NKCDU@R:1H[)"!5R ,2J 22!GW)..] #H]#TORD"RAD!/\2D-P!SZXV?SHFTW35L M%L_M(1))<)@JWT@V#:D88L(%<%0VS@8/J">/QQ22Z)ITUQEICNF8R[ R_.Y!FM?D5-J+SMSCIG&&Z MXZ>E116.GV37F7EZ]V]WB0@DE95P M !GVQCK56+2-&B<[=0&Y"0V9$ZD[_3GKG\: +1T73EM([.27(B+''RC!?V P MOM@"HX](M[:_:9[J%+9XY%5<@,=V,\^@QQBGW6E:;/UTA;*UEDN$:WMP(HF8@@[6''3DY4#B@"$^']- 8/=Y!(W@E!R1A>W''; MOWS4$>B:-/Y@2_\ ,95PQ+J=N"!GZ<8JQ'H6E HHN=X4.B*74X.TANW)&<\] M*670],^QM*TQ,62PD&T]?H.1F@ OM)LFD,]U>!($MD49*[B$W'<3CD8;H.#W MJ.+2-(NH/-6]+1,"Y(95YSACTR!D8QT'UJ2]T_2IUM6FOF*Q+Y$8$BG<<%?3 MD_-S^%-_L?1X)?M+W'R@>8=S+M W9].G;WH +;2M,L[Z*.*^VW*'(4E22<$# MJ..&Z#K5J\T[3[J5KF:;_6D1@JPP"".A['Y:;/QH 0Z;IJ65O8&\.-S21X*DD$$' M QC&">>U,ET+3Y85C@N0K/\ *I#C)^;+$8ZM21Z#I4<8"WI*G:1+L6C8*X.T #(PN<9(%9PI<$*%Z\=@-WZT 1SZ;HH/EM<;"'$6-H.69G '3DY M)&?]FK/]F:9AJQ'I>GV]I@IUO8V4*7*-J)F2YCX$DB$H@&!AL9P/?- $7]BZ:MP\LEPSN? MO DQ'(-1W.G:9J<6UKL MC;._*2 $.3T_ @$>X%))I%E]EE6"Z1!.Z*A8J57:^[:/4YSUS0 /I^GK;/;S MW@\M_*5<2#<0H^7\3S49T'3VD61KUMP;&,H!N.>V,=^G_P!>HHM(TAU2Z2]D MV.A\MG90N,C.,CU''UXJ>/0])B$G[['#,=[KE1DY//OGF@!D6AZ9/:L8;H2; MH\J^Y> 2#GCH..V.*?#HL/V%;>YNX_-:9WS&% RV00 1C\<9IUE8Z5!+<&.Z M#AD^SR*64+V&#@=<8%0Q>'M(4QA;IG99, F522W!(^N1N]2 M(PLN]>!M ;]%%12:+I3;F%SA9 &PK+CN 1QP.3['O0 )X>TV)Y4>XD:29A]] M@#GY?N\=?E'2GG2=.N;3[$;K=MD,Y*[1URO0#&.M37>FZ==7$LT\XWE,-\ZC M: 5Y]ONCFJZZ3I\L<#+>O^\0",Y5=Z8/ &/0T )'HVDO-(B7.Y@=A&YEN--TLZ>L,VHXB,GG;E=!NS\O88QG% #TT^PL+2027H^S&.2$LS#. M7(+?^@\#ZTBZ'IC3&XAN<&5O,3#*1@YS@$'CGCT[4[^R],6QEMC=[8WD$IRZ MC:2..,<9%5KG1](DS)'=*DDY>&,[AM#C<./0C)_$4 2MH&E6D0,ERZJ[ *2X MRO0@@9QS42:)IL,C,MV5(^8C>N .A/3]>M $LECIZW=W?2WO^OA>-P9 M %P-V/IC\*K1Z!ILH8?:RYDRQ'R#/4 @8X')Z<'BG_V+I2PR@SE]D>6(*DJ@ M QP!Z ?6HX[+1S(R)>$3)*"7X!5L;QSC&,'/IVH EBT;3+$3RM=GF$I(SR#Y M58 9_(#%0MH6DHJS2W?#1CEBJ@@_*I"XP.OIS0^A:1$>;M@[X 8LK$$KC/3' M('?BG7NGZ7]K5YKJ?S;:%,1HN_ Z X .5;L. MO3W(/-6I+#35M;!))OW-NQ\L@C:^%)(/MQG_ ("*2XT_3;R1KB6<8N4#K\P& M1A3D=^B#]:8FFZ4+"/3%N8]Q(FT9QN8J2O3C'R@'MG&:MV.D:9IU\MQ%.!P .E6+32=/LI&*W 9RA@^9ER,@ M#''? 'N:5;.U>\CN([]@L,C2-'E2C,_.>1Z'@CUJ :-IDEU-<&Z:1I/F)+J0 M,DX(X_VB,T $%II]A!,QO%-O:QLDS<#:2JC^$8'RJ.GR"Y! M:X#*\?&?]K RWZ^U #[K2["XN9)FGV3&0N2-IR0JC&"/F "CCGO1;Z;IMS8 MBUBG$L(=G 5AGD%#T],GGUJC!INCW$\*0W%QYC(=I*D;OE"MDE>O&2.OM6E; M:%#9W0N+>:1'Q@C P1NR0>.?2@"H/#VG*C0?:F!8;6&Y/9]J.-A/$@Y& -WX8/YFK4_AVRGN/.??N+,QQCG<<^GK5<>%;;YD>:1HL+ ML' ((SSG'3GITH =R@>\V+;L"@5ERQ)W#\]O;WI;O2;"2X>[DNMC, M"X'R'L,GD?-P.ASBG#PU:+"8EDE"=0/EX.,$YQZ?EVI#X8L#() 9006[C@'H M!QP!VH C7PSISD2+/(5#!P PQCW_ ,:=>:7IIOFO;JZ/SG[K%=H/ Z>N*N6 M&EBR\X!@4F=V9,<RB7"O-G(8,S D$?A^- "6FEZ:+:7R; MPO'=0^6K;UR ,MD'&206)YZ<5''X;TLS&&.=V>)3N3>"55LXX[=\?2K!\-V1 M 4&15VA2HQR !VXZ9XZU:L-,CL)9I$EDD>8Y@!++1[:PO)[F' M=NEZJ>BY.<#\:T*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** (+U8GL;A9V*PM&P<@=%QS^E88T[2%NH9XY9E:\;?$P3*_-DD9*\9R< M9_"NCJIY&.E0KX6L%C6,/.8U0J%+#OC)Z?[(H =#I]@UUI\BWN^6VB58E61<. M%!7./Q/2H&TK1;JX9A=+YBY0X=?O>GXU/%HD<.M_:$E(C.Z4Q[1RS9 M!Y],'I3AX M:4Q1P"+:2"6P<@ECS0!4CT'1XV!$^2ZE5W.N3N4KQ[\G\JFGT[3)X4LFO0#$ M6&T2)NP3N(/Y=>O%2#PY:"=)?-N-R,"GS#Y0"3@<9QDFGRZ!93&0N'S(Q8D$ M#DL6]/4F@"@VB:-*%#7N05QQ,H)0C:!D=L#\>^:LQ1Z9 DFCB\PS8S$C))!![8YW'^F*L3Z+:W%S)<.TF^10#@CC!7D M&K$G?' +EGEEB.U=P;*C/(XX')]JG>RTB]MTA-X'\E1$KF0$_(0W M4]<<9[59@\/V=O(&0R8VN"N0 2P 8\#T Z<5'_PC5F4*M).RL06!*\X&%[=O MU[YH K2:%HK*I-R J+N7]ZN-O3/TYQFK\&C6T0^21V1HVB X^XV.,@>W6J__ M BU@0.&K"-I#'YB;]V,$? M+N!!QQ_M'%5CX4B:95:=C;+EPN!NW^N?3VKHJ* ,U]$M)(((6#;(8S&O3H2I M/;_9'2H5\.6@'SO+(V0=S[<\*5 Z>AK8HH Q#X6L6*%WE8QD[PY'-:5% &9)H=K*ENCERL"%%''0@CTZ\ MU5A\,6RD2R.WG@YW+C .<@\@]/R/I6[10!C-X;M&=G\R;<&#R2O&YAE2.<F<,"".GN>>M:=% &&OA73U0H#+M/!&1TR#C.,]L?0FD_X133N.9&+$1+'NF.V/8" MS _Q[\GCDY_3BMJB@#"_X1+3<8'F@9####@C'/3U ..G%7K_ $L7T;J;F>%G M01EXB,[E/AT6W@OEN MT9PP=GV<;F>A/%:5% &,/#-@EQ'+&9D\N7S0N_<,X7CYLD?='0@]1T.* MDF\/VDSR.QDW22>82".#\WMT^8\5JT4 9$GAZUE;+2SA K;HH SH]'@CL&LM[F%F#$<==VX]NYJ*+P[8 M0-OC642J7, GRAPHIC 54 gexyhn0lyczh000053.jpg GRAPHIC begin 644 gexyhn0lyczh000053.jpg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end GRAPHIC 55 gexyhn0lyczh000054.jpg GRAPHIC begin 644 gexyhn0lyczh000054.jpg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end GRAPHIC 56 gexyhn0lyczh000052.jpg GRAPHIC begin 644 gexyhn0lyczh000052.jpg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end GRAPHIC 57 gexyhn0lyczh000001.jpg GRAPHIC begin 644 gexyhn0lyczh000001.jpg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gexyhn0lyczh000022.jpg GRAPHIC begin 644 gexyhn0lyczh000022.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#C:***^J/D MPHHHH **** "BBB@8F*0J*=12"Y'M%+MI20!DFF;R?NCCUI:(K4?BCBHB6'4 MTH.>]%PL2<5$RAB>3UH,AZ"FYJ6TQI-#EB']_P#2IE4+TJ%6P:FW@TXV%*XM M(2 .:6J[9#;<53=A)7) V3@B@@>E* .HI&SBD/J)QZTA.WI3>>M .XX)S4W' M84/GK0R\<=:,!?2ESD4#(3D_A1\W0&G$'TIN#GK46*N3K]W%12*0>NWK^E.#-WYIV0M1@-. )[5)QUQ132)N(!B MEHHJA!1110(***C)R>:0TA^1ZTFX8IM(:5QV%+$T FFC[U28H&PW>U!8XX%& M*,4Q:$>XFG#Z4W&7-2#I4H;#--+J.].QFF[*;N)6&9!.:>.:3:*>*20V)BDI M](15"0TB@9%.I.<4AB,RCKUH!&*C$9!J14I*[&[(9(#P:>H&*=MS2A0!BG;4 M3EH)BEQ2T51(@&*6BB@ HHHH$%%%% !1110 4444 %%%% !1110 444F:!BT M4F:* L+11FB@ HHHH$%%%% !1110,;S323ZU)2'%)@F5V!)I0& QDU+CGI3L M5/*7S$.PGKFG!:DQ1BGRBYB,IZBF.FW![&IS@5#(P;"CI2DE8<6[C*=GBD R M<;@/K2LBH<,2?I4E";L=Z4$9II*YX7 I-^#Q2N%B8GYE*0#185QOF8[4 MA9CTXIVVEQ1J%T,48-2444TA-A@48HHI@)CG-+110 4F!2T4 )BEQ110 444 M4 %%%% @HHHH **** "BBB@844F:3<1UI7"PZC-,W4H/-%PL.YHHHI@)G%-\ MP=#Q2FHV%2[C21(#3JK*^TXJ8'BA2N-JPZDII:HRY[4-@D3#K10OW113)%ZG MBEJ-@BF,M2VQI( M>)0>E&\FF1J.:DVT*X.PG--*8Y'-/Q3J=@O8KLK=@:E?;M7?G..U'\1%+C<, M&DD-L@QS00HZT\HV<*,^],92OWEJ;6*3N"CU.:4'YN13.:<.!DT@8I(R,$4XGVJ%6'W:<"=V#^%4F2T28-(>G2DY'>C<:8 M@P3CC%!I>M)Z#0XD@D9_*E!J/I3T7 M)P#20V2"I ,#%(J8ZG-.K1(S;"BBFNVT>],0K':,U'N)YH!SS3J6Y6PS>:M#!#!UIXJ/> >E2 M @TDRF.!I#M M2\,,P$T%S'>6Y;LI.'_3/_?5=;+#9^.[EK")8UBT'5$1<'[UL%PWZJ?R%<4L M4XR::VW].AVQPJE%-/?;]3R"]L;S39Q!>V\EO*4#A)!@[3T-5PMRB2"]FC8W4<-K) M!"W/RNBN 1GD''I6L,1>2@UJ93P]H\Z>ARW%%>E>$M+ACTW14U'3M&>+4W8+ MYEK+-<3+GKN4;4Q[U''::1X>T3Q1HZ7I>EVWAO1KT6-A/\ VB6>Z:>REN&))_U<90$) MCD#/I7%W%AI:S^M>WZ.@M?&.IZ;#X6@LK2SMI%AO4B8, MPP.K'AMW]*Q-(T?2;'PQH5P+.PNOMZ[KJ2XLI;AW.<;$* A".1SW%8_7-=5V M-OJFFC[GE@XIVX=Z]#A\/Z7XBL]8T;1(46\L;U9;65XRDC0,0&1L\_(2>OH* MT;32= N]8UYK2RLW&BP1V]O') TB.PSOE=$^9SD8_"K>+2Z$K"M]3S?3--NM M9OX['3XO.N9 2J!@,X&3R>.E5&^1BI^\#@_6O6-$M])3Q[XO8=/I52+3+'5+;PSJM[H=MIMW<:H+:2V2 M(HEQ%S\VP_3_ #Q0\7&VB_JUP6$E?5_U>QYM?VDMA>3V<^WSH'*/L;<,CT(Z MU4_>%2#R.U>H&'2M)T/Q1J+:)8W/:CZRK7:_JUP^K/9/\ J]CR$@YY_2K=GIU] MJCRI96DD[11F201C.U!U8^U>DZE8&Y^'^N:CJ7A.TTB^BDC6%XX=A*[AG /3 M&<9'6LWX4+%)K6KI.YCA;3)!(XZJNYY*26PU1_>1BWN<7;Z;>W.G3 MWT-M+):6^/-G ^1,^IJU'X5\0/9?;5T6]-J5W^9Y1Z>N.N/?%=9XQ7?XOYGD\NFWEO8V]]+:R):W!(AF8?+(1UQ4VG:)JNL^9_9FG MSW?E8\SRESMSTS^1KLM6AMYOAOX,AN[H6MNUQ.KS["X09;G Y-8MA:KI^N"; M2[C4M8T>$HUY)I\:DN_#VMV$]O!>:7=02W+!(%>/'F,>@'O[5ZTL(E^(VE MZO+<3[]0TZ9K&TNT"/;, ,+CZ$^^LXXF3M\OQ_P C26&BK_/\/\SB-2T?4M'>--3LIK5Y 2@E7&X#KBJC MPS1PI*T4BQR9V.RD*^.N#T-=GX]=Y]$\(/)([R/IF6=CEB?EY)/6M;7KQ;KX M8^&E72;413;XGF2-C]DPX!=3T4G!SFM%6ERQ;6[,W0CS22>R/-.6ZU/96%SJ MNH06%E$9;J9MJ)D#)QGJ>*];_L/3_P#A+#X5_P"$4@&C"VW?VGL;S?N9\SS> MG7C'_P"JN$\!JJ?$72D1MZ)&;?2HM.CEGMK]8V5RX)(W,?O[ MNOX_2K[Z#H&FFPT^2PLY].GM!)+*+&>6YE)7)=94!5<=AY!&9)76.-2SL=J@#))K1DT;488YGFC6/R4\QP9%SCZ9J31!';>*84B"S MPF8I%(XYVYX;V./YU>G$-TOB&5[2%'@CPC*O.=Q^;ZFN+&YA7HXA4XKW;)M^ MLK=T=&%P5&K181[TC.'& /I72:I]@MI=-M/[-C87$<4DKQK M^\(ST4#U[^M.OHX5B6]MK:P>UAN$!'V=HG4$X .>M+^VKJ/[MKFO:[7I^+*_ MLFSE[Z]W??U_ YDJT;%75D8=588-7(=.NIDMW6,!+AS'&S, "PZ_2M+Q:Y;6 M70VRIMQ^^"G,G ZGOBK-K&DNDZ#'(H9&O7#*1P13GF=182EB$K<_SM[K?Z$Q MR^'UFI1;OR_+JE^I@3(;>XDMY"!)&VU@#D9^M-KHWBL[2SU6Y-A;S-#>;(U= M>%'^'M4R:;8W>J:?*;=(UGM#,T"\*SCH/U_2DL]C&-ZD'9==-6HJ6WH-Y1*4 MK0DKOIKLW;X.X=15[2K*UE^'>M7P)'*5^902N0#^)KOH8[V]'VJB MUK;4Y*N$]C5]FW?2^AQ[#-(D+2.J(K.['"JHR2?85[1/;:"WQ"'A7_A&].%M MXAC:22-L(55>N=V/7I50F16"(-(\3>#X;]]*L])D@U.&U,EH-H\IRH.< M]2 >I]*F.(=]5II^)4L.K:/77\#SP''85(#FO6-;TC0;1M3TVZL+2"TMX"8) M+>PG\^)@!AVEQM8$]>U<-X+TG3]6UZ--6NX+:RA7S9!-($\W!&$!/J>OMFM* M>)4H.=MC.IAW&:A?XN;:2*&Y7="[C D'J/:JU>D>,O#\FH:+- MXEGU:Q>=)3''#!G7%]HUMIOAS5AX7TQKC6&\J="A\M%#;257H" M<]?:HSH=OI&N^)9X++2O[/LYXT5[^"2?RBP!VJBL2^'=(A\>QQI80?9[G1G MNF@,9\M9.F55N1].U9=A9P:7X8\/3V7AN#6I-4)^US31&0H<@;%Q]T]>?:DL M6F]NWZC>%:TO_6AYW17J;:1H6A2>,Y!IMO?PZ>8'@BFY\MF&2N>N 3^0Q7(^ M$TM]6\?V(N+2#[/<7#LUN$_=@%6.T ]A6D<0I1D:-:Z/KWB/6"FCV5NFE0N+6U",ZRD.1OD5>7QCH M/6K5FVD6_B3PW=165H-1N+AH9/*LI;>%E[2(K@8<$8_X%42Q=G;EU+CA;Z\V MAYYINB7VJRW45LB*]K$995F<1D =>O?VK.R",UZ<+>WU/QAXL^VZ/;P_9["X M:,>41O8,<2\_Q'U%0QSZ3I&C^#PWA[3[N;4H56XEF3+8+*"1_M<]326)=]OZ MM<'AE;?^KV/-STJWIVE7NK2S16,!F>&)II!N P@ZGGZUWXT.WT?6/$<\5GI7 M]GVERD2/?P27!C+ -M5$R0 M..E*6,7V45'"._O/J>/Y'7UI#70>"9-/_P"$BM[75+>*:TO%-LQD4'RV;[K# M/0YP,^]='/X870[?2=!DL[2ZUO4=0+DS]! AP 2.0&QDX]ZVJ5U"7*T90H.< M>9,\Y-,W'.*]4U[2M,NO"&K7+V>G+=Z;H'1+'2X+2TB1I4N+"2"[MAD;CO;ACUK#ZVG;0V^J-=3S!7[&GA@:])\ M06,6CWLNA:;X)AU"P6S$BWNQC+(2N3)Y@]#VJM<^'1=P^!)M.TH317$2?:Y( M8JCBE:[1,L*[V3.,@TB^O-,N]1@@WVEGM\^3,CAN2<5/Y:%U8Z;'J=]8JGV>TD M4LOS=6*CKC^E:*LE!R:\OT,G1;FHWZ7_ %.=M/#.J7:Z>\<"B/4)&BMI))%5 M7936D^T2PR&-]K!AD'!P1UKUBXACO[/P*EWI$5DD]](9+ M+80G(/\ ">@/7'O5/2[/1TDU&WCL+./4'U26**2^L))X&0-@1H5X0CBLHXIJ M[:_JYK+#)V2?]6/+\XI,UZEI_AZUT_3=8O[BSTPZE#J)@9)+:2Y@MTP" L:< M\YZFH/['TT>(KZ\TNRT\6UM8I-=1W]K,8[>0GJD6-S @9 QCFK^MQN[(CZI+ M2[/-0!BEP*]3O]*T"#7?#VH7&F(]O>6LLD\5I:R>667&U_*^\%YY&/2G)X;M M-5\0Z&]Y#I/]FW!FV-8V[VQN&49".CGO1]4XII6O3-7M M-$EL-U[80QW,5[''&NFZ?/!YB%OFB;>,%L9P?:F^*].MKGP_?7>D6>E)8VDB M!@+&2WNH 3C!+?>YZTXXI2:5MQ/#-)N^QYJJ?-FI***ZTK'(W<****8B/%1E M,'BI\"C&:GE+N3V&K7NESFXL;F:VG*E"\38)'I19:OJ&GO,UE=S6QG7;*8WP M7'H:K[1Z4;:EP3W&I-;$UE?WFFW"W%C=36TRC >)BIQZ?2GW^I7VJSB?4+R> MZE VAYG+$#T'I5;%(:?*KWMJ',[6OH:-KXCUK3[,6MGJMW!;JVX11RD*#G/' MXU6EU?4;B&XAEO9I([J7SIT+<22?WC[U6Q2;/2IY(WO8KGE:US4T[7-7TB!H M=/U.ZMHW.62*0@$^N/6J4CO+(TDCL[L2S,QR6/J3ZU &8=Z>'!Z\&J2BG=(A MN35FS5/BSQ"(TC&MWVR,;5'G'@8Q_*JEAX@UC2(6AT[4[JUB8Y*12$ GUQ51 MUR,BH2I-0Z<=K&BJ2WN6[36-1T^\:\M+VX@NG!#3(YW-GDY/>EL-2O;&[^U6 M=W-!.,_O8V*MSU^M4MIJ< !1BA138G)]#2?7]9DU&/47U6[:\C4JDYD)90>H M'H*9I^M:MI0D&GZE=6HE.7$4A 8^I'K[U1!(I]S?T/Q//HU MOK/^ODNM1A""Y$I#QN"3OSU)YK/N-=U>[O8+VYU*YENH#F&5Y"3&?;TK/)H- M)4H)MV'[2;25RW)JNH2V]Q;R7LS0W,OG3(6XDD_O'WJS9:TR7]E+JB2ZA;6B M&.* SF,HN.-K#D8ZCZ5DY ZD4!E['--PBU8%.2=SK]<\907VAS:5IUE@S7,65]>:<\CV5U+;M+&8Y#&V-R'JI]JKF@5,*4(KE2*E M5G)\S99MM0O+*TGM+:[FAM[C'FQ(^%?'3(JW-XG\0S6;6DNMWTENR[6C:8\C MT)ZFLPTWM3=.#=VA*I-:)CYM0O;BRM[*6YE>TMR3#"S?+&3UP.U2Z;K6IZ,[ MMIVH7%H9/O\ DN0&^HZ&J)--XJ'%6M8M2=[W+UUJFH7M\+ZZOKB:[4@K.\AW MKCI@]OPJ34=*%&.F@G*7PN8[FTE>">,Y2 M1#@J?:JFS8V0H'I^%974TZCDC:UA<\KWN212O#*LL3E)%.5 M8=0:?]JG F F?$_^MY^_]:KEJ;OHE"$G>23!2FE9,GGN+B62*9IY#)" L;;N M5 Z8]*2YU"]O4"75W-,JG(#MD"H3N9>*%4D9K-T*3:?*M-M-B_;5$FN9Z^9/ M-=W=S'''/7E5O0EU MJC?-S.Y,UUU04F1Z MTXTH0CRQ22"52<]<_6D)7'45&0">F*=DMA7;W-F3Q-KGO8+ 'Y68="1Z\53*&DV4E%+9%7;W9JR^)M9ET_[!)JUX]I MMV^2925(]/I[5E[MW&.*4+3@M"C;9"X)6*)NVWO@Y/XUA:?KFK:3 T.GZE=6T3\LD4A )]<>M4** MA48*^FY3K3=M=BRFHWL=O=6Z7_;(+F6*ZW%O.1R&R>IS4U[K.J:E<13WNH7-Q M+%S&\DA)3OQZ?A5&BERQO>P1X3 S-)R8SU7Z54DU M*]D2U22ZE9;08MP6_P!4,Y^7TZ#\JJDU&S5/+%;(KFD]V:\/B36H+NXNH-5N MX[BXQYTBR8,F.!FFMK^L-I>W5]<374> DS.=ZXY&#VJK1BFXIZB4FC3G\3Z[> MH\-WJ]Y-%(%#(\I(.#D?KS27_B#6=2L_LM]JU[<6_&8I)25..F?7\:RV7--V MD'DD_6I]G%="^>3ZFG'KVLQZ9_9RZK>"SV[?($QVX]/I[46FO:SI]I]DLM5N M[>VW;O*CE(4'V]*H=J,4_9PML+VD[[EJ36-4E2\22_G9;U@UT"W^N(Z%O6KH M\4^(# L)UF],:H8PIE.-I&,>_%9&*=1[./87M)=R>:]NKFWM[>>XDD@ME*PQ ML>(P>H%.L=0O=+N/M%A=36TV,;XGVG'H:K457*K6L3S.][FE+XAUJXE@EFU2 MZDD@D,L3O)DHYZD>E/MO$VNV:R"VU>\B$KF1PDI 9CU/U-95%+V<+6L/VD[W MN7K/6=4TZXDN++4+F":7_6.DAR_U]?QI\6O:Q#J$FH1ZG=+>2#:\XE.YAZ'V MK.HHY(OH"G)=34/B37&N8;AM7O#/"&$ES2N_$6M7XB%WJMY-Y+!X]\I^5AT(]_>B_U M_6-4@6"_U2ZN8E.0DLA(SZXK-HH5."V0.I)]0HHHJR HHHH ]P_X4]X=_P"? MC4?^_P O_P 31_PI[P[_ ,_&H_\ ?U?_ (FO0:*^<^M5OYF?2?5:/\J//O\ MA3WAW_GXU'_OZO\ \31_PIWP[_S\:C_W^7_XFN[NOM/V67[)Y7VC:?+\[.S= MVSCG%<;IOC+4QI-[J>JVEHT,%V]DD=I(%9G1RI),K*N#CCG--8FL_M">&H+[ M)5_X4[X=_P"?G4?^_P O_P 31_PISPY_S\:C_P!_E_\ B:TD^(VE2+;RQVUZ MUO)8-J$DP1=L$2EE;?SG(*D8&PH M?RHS/^%-^'/^?G4?^_R__$T?\*:\.?\ /SJ/_?Y?_B:L+XYNHM2E6XAA-I#< M:@KF-3O,=NBLN,G&3N.?PZ5*OQ)L^3+HNK1(BPRRN\:8CBE.$D.'Z$]ASP>* M?MZ_\S#V%#^5%+_A37AS_GYU'_O\O_Q- ^#GAT=+G4?IYR__ !-7G^)NBH][ MB&Z:*V29UE4*1+Y7WP!NR.AQN SCBFW7Q$\J-1#H6H&Y%W;P/;2[%<)-DHX^ M8@YP0!GKUQ1[>O\ S,/84/Y45?\ A3OAW_GXU'_O\O\ \32?\*=\._\ /QJ/ M_?U?_B:V_$'CC3O#MY':74-Q),8/M$BQ!:;;ZC> M6<\%U&UE"US<.4&Q( NY9V"1W4BRQ1S2$(H,"NQ5=RDY)R#D*#@#-'MZ[ M^TP]A0_E1G?\*9\-_P#/SJ/_ '^7_P")IW_"FO#G_/QJ/_?Y?_B:MW/Q!C_M M2R2WLYETQ[N>":_F0>6XBC=GV8;.0R8Y'.#BGV_Q+TNZ@W165\UP[1+;VZJA M>?S,[<$-M'W3D,01WH]M7[L/8T.R*/\ PISPY_S\:C_W^7_XFE_X4YX<_P"? MC4?^_P O_P 371^$]=N=?L+ZXNK;[,T-_-;+$1AE5#@!N3\WKCBM^D\367VF M-8:BU?E//?\ A3GAS_GYU'_OZO\ \32?\*;\.?\ /SJ/_?Y?_B:]#HH^LUOY MF/ZK1_E1YT?@QX;)S]IU+_O\O_Q-)_PI?PW_ ,_.I?\ ?Y?_ (FO1J*7UBK_ M ##^K4OY3SK_ (4OX;Q_Q\ZE_P!_E_\ B:!\&/#8Z7.I?]_E_P#B:]%HH^L5 M?YA?5J7\IYY_PIOPY_S\ZC_W^7_XFC_A3?AS_GYU'_O\O_Q->AT4_K-;^9A] M6H_RH\\_X4WX<_Y^-1_[_+_\31_PIOPY_P _.H_]_E_^)KT.BCZS6_F8?5J/ M\J///^%.>'/^?G4?^_R__$TO_"G/#G_/QJ/_ '^7_P")KT*BCZS6_F8?5:/\ MJ///^%.>'/\ GXU'_O\ +_\ $TG_ IKPW_S\:C_ -_E_P#B:]$HH^LU?YF' MU:C_ "H\]_X4YX'/^?C4?^_R__$UZ%6-XKUB;0/"V MHZM;Q)--:PF1(Y"0K'T.*/K-;^9A]5H_RHY;_A3GAW_GYU'_ +_+_P#$T?\ M"G?#O_/SJ/\ W^7_ .)J2U^)MM+6'?^?C4?^_R__$UT&B^+K+7T9K"*;Y;-+IS( MH'EEBP$;<\.-AR.UXABNM533S:M8R7DQL)&>2TVX^613W;.!SUH^M M5OYF+ZK1_E1*VN+8V]R]M+%< !E=,9Z$COZT?6:W\S%]5H_RHY/ M_A3OAS_GXU'_ +_+_P#$TO\ PI[P[_S\:C_W^7_XFO0:*/K5;^9A]5H_RH\] M_P"%.^'?^?C4?^_R_P#Q-+_PI[P[_P _&H?]_5_^)KT&BCZU6_F8?5:/\J// MO^%/>'?^?C4?^_J__$T?\*>\._\ /QJ/_?U?_B:]!HH^M5OYF'U6C_*CS[_A M3WAW_GXU'_O\O_Q-'_"GO#O_ #\:C_W^7_XFO0:*/K5;^9A]5H_RH\^_X4]X M=_Y^-1_[_+_\31_PI[P[_P _&H_]_E_^)KT&BCZU6_F8?5:/\J//O^%/>'?^ M?C4/^_J__$T?\*>\._\ /QJ/_?U?_B:]!HH^M5OYF'U6C_*CSP_!OPX?^7G4 M?^_R_P#Q-)_PIGPW_P _.H_]_E_^)KT2BCZS5_F8_JU'^4\\_P"%-^',?\?& MH_\ ?Y?_ (FE_P"%.>'?^?G4?^_R_P#Q->A44?6:W\S#ZK1_E1Y[_P *=\._ M\_.H_P#?Y?\ XFE_X4[X=_Y^-1_[_+_\37H-F.!1]9K?S,7U6C_ "HQ_P#A3OAW_GXU'_OZO_Q-'_"G?#G_ M #\:C_W]7_XFKL_Q BTP"+4+"ZFDAMH;F[N+6'$4*2,0K$.0XZ=,9]JL2>/K M1)[N%=,U"1X+W^SXMB)BXG_N)ENP!))P */K-;^9A]5H_P J,K_A3GAW_GYU M'_O\O_Q-+_PI[P[_ ,_&H_\ ?U?_ (FH]7^(UQ'#/-IMJBB'3;N>2*[0B2*X MAD1"C8.,?,>GM@UIW'Q"M[:]>T.CZG.R70LO-AC0H]P4#A%RP/(/4\#N:/K5 M;^9A]5H_RHH?\*>\._\ /QJ/_?U?_B:/^%/>'?\ GXU'_O\ +_\ $U:F^*&C M0VUM+]FO&>2-Y980J!X%1RC;@6Y(8$87).#BK*?$"RDU(VL>FZ@T?VMK)+H( MGE/.$WJ@^;/S#H2,>N*/K5;^9A]5H_RHS/\ A3WAW_GXU'_OZO\ \31_PI[P M[_S\:C_W^7_XFK]OXRU*_P# '_"0V>@S&Z8@):D[\KN +C;DLH&3@#)P>*@T M_P =W$][I%G]EAU!KZ>:%Y[$LBP[ #ADDPP8 Y(/0=,]*/K5;^9A]5H_RHK_ M /"GO#O_ #\:C_W]7_XFC_A3WAW_ )^-1_[_ "__ !-7#\2]+2/43)9W@DL4 M20QH8Y#(C2",%=KD9W$<$@UH:)XIN-7\0:CI MV6XBNYX+=9F>-&5&PK/QE3CDC%'UJM_,P^JT?Y48_P#PI[P[_P _&H_]_E_^ M)H_X4]X=_P"?C4?^_P O_P 319^-==U%+.SM++3GOKNZN(H+IG<6LT4*@M(G M&XY+;1VX)R13D\<:M\._P#/QJ/_ '^7_P")H_X4]X=_Y^-1_P"_R_\ Q-='X6UB M]UBVU#[?%;QW%E?RVC?9RVQMF.1GGO6]1]:K?S,/JM'^5'GW_"GO#O\ S\:C M_P!_E_\ B:/^%/>'?^?C4?\ OZO_ ,37H-%'UJM_,P^JT?Y4>??\*>\._P#/ MQJ/_ '^7_P")HKT&BCZU6_F8?5:/\J"BBH+J\MK)%>ZGCA5C@%VP":P.@GK$ MD\)Z-+9BU-JPC%VUZI25U9)F))<,#D9W'\ZM?V]I'_02M?\ OZ*/[>TC_H)6 MO_?T4!:Y3MO".D6$+)96JQ$VC6:ER9 (V8M@JQP?F8GGZ5BZ/\-M/L1>C4)( M[P7,<46R*(PK&(R64K\Q(;)SD$8P,8KIO[>TC_H)6O\ W]%']O:1_P!!*U_[ M^BGS,GE16'A720NG_NIB^GR-);RFYD+J6^]EBV6![@Y%0ZAI6C6VM1:Q+;7' MVYV!)MWD ?T]JEO?#WAC5KB.:YCBE> M!%A.V=E#JK#:K@'#@,1PV>32(GAR*9YHM3BCF9MX=9URAYSCZY.14DDOA^0Q M_P#$TC78Q8[9Q\V7WX/MNYHN*Q6;3?"D_P!HDDV*6>;S=\S+\UP@\SOCE0.G M3VJ=M%\-7,,D1$;)=PQ6K 3M\R0G*+UXP3U[YI5?P\HQ_:410# 0SC ^383_ M -\TV4>&IKI+E[^ R+C_ );#! !'_ 0:+A8@70?"=Q-:5X8O3="XVMYZQ^;(LS+M,)PF&!^5@7X(Y.:LQW.@ MPRQ21:G"K1@ 8G&" H7!_ #\JBWZ!LC7^UU_=<0G[0,Q#C 7Z8'7-.X6':AI MGAW4[B&ZN9 9K95C6:.Z=&*GD*S*1N'?!SZTQ=!\-76M7#"!)K^02/<,9&8N MK@(R/SRN, *>!C@"H7M?#$@ ;4H\+C:/M P."#]2M7;6ZT&SN#-%J.:1?!.@II\E@+67[. MSHZJ;F4F(I]SRR6RF,G&W%:']O:1_P!!*U_[^BC^WM(_Z"5K_P!_11=ARH71 M]%L-"LWM=.A,4+RM*P:1G)=NIRQ)YK0K._M[2/\ H)6O_?T5+;ZK87.13AE:0 BH_[>TC_ *"5K_W]% &C16=_ M;VD?]!*U_P"_HH_M[2/^@E:_]_10!HT5G?V]I'_02M?^_HH_M[2/^@E:_P#? MT4 :-,FF2W@DFD)"1J78@9X R:H_V]I'_02M?^_HJ.?6-&N+>2"34;8I(I1@ M)1T(P: )TU:U8*96,&[&T384G..\M(]B[55)%"CAATZ?QM4*-H45I<01:P@\^%H6+S@]<\X]MQZ8% & MS_:MAY0E^UQ%#NP0V>@R:(M5LI@C)<)B0@(2<;L@$8_,?G6(8_#KS1RRZLLD MB-N+- ZD?2L&- ET 6JV_P#:L9"Q/$'^T#=AB">?J!0!K#5+!G5!>0[F3>!O'W>N?T/Y M'TJC?3:)KVFW&G7XJG&GAF.V-O]OA*'DYG&3PP_\ M9C28\/,6+ZNKF0YE+7 _>=, ^PP.F* &7.E>$M1N+RZDCM;B:[MEAN"DG,D: M$,O0]0<$-UX'--3P[X1ET]=-,<4L2WJW!$L[L[7"X(9F8[F.,#D]"!5II?#K M1>6=0@V\?\MAV38/TJ!H_#23C.<_H/ZU3A\/>$HM/7[/;126T-L;#9&[/YD3$8C8 _/ MS@C.3SQ5F&3P_#'(G]JQN)#'DO< D!#E0/84_P _P^(#"NHP*-L:AA.-R[/N MD'U% %%O#OAS^QY+::"\$5N?MF9;B;SHC@KE7+;EX4C /3ZU8MM)\.B![863 M>7J5N+5XY2S"2.,, " [CD\=?F/3%+ MGPZS*\NI0R2IC9(TR@I@Y&,8 Y]J *FD^'?":2VK6$4CRSLE]&SSRNS-$"JL MQ8D\;R,'^E(OASPS% J)87#)*;GRX8Y)'PDOR2E5S\JD>F.O')K0AG\/6Q+6 M^H6\4A0KO$PST S^@_'/K2SW&@S0Q1C58HO+C,0:.< E"!E3[' H S->\/:+ M=Z;))&8X)-B6_FRPM, MON8#;D$$8;Y@0?>K'A>TTOPIIO\ 9J7WGR3SB=Y! M&54O,3MP!G:#MXY/N>:L"70<,IU9&C+,RQF=<(6!!QW_ (CWI2_AG:RB[M0C M'/Y5X!4@-U]":DMM5M;F)Y 7C5$$ MA\U"ORG.&^AP?RK)5_#TA;TZ'KZ5 MCJOAQ59/[3B,+A0\1F7#;0 ,GK_".,XIZ/X>A)$.IQ1QMD/$LXVN,DX(].3T M]: -'^W;$&,2/)%YCJJ>9&R[MV=IZ=#CK]/6KT$\=S"LL1)1LX)&.AQ6"C^' MPRF35(I]HVKYLX;"X(V_3!/OT]*M6>IZ)8V<5K#J4'EQ+M7?.&./;YGV8[OMHO\ /F-_KPNP-U_N\8Z5-_;VD?\ 02M?^_HH_M[2/^@E M:_\ ?T4 9S^!] 980+.2,Q/(RO%<2(QWOO=2RL"5+'.#Q4G H @31_#5II,NDI+Y-G)<%O+6[D4I)D'Y#NRH!YP"!44?A[PI#'&L94/9 MW1N/.%TYE\X_*Q9]VYLXVD$D<8[5+"OAN%IF&I1LTP8.7N >&&#^E+<+X:N8 ME1]0A&TDJ1.,@EBQ_P#0C^= %6V\)>$5N7L+>#=(T(0QBXD8)&DBR!1\WR@- MM( K?31;&/7)-8CB9+V6(12.LC!74=-RYVDCL<9JA;7.@6ER)HM3A 565(S. M-B!B"<#W(%7O[>TC_H)6O_?T4 0Q>&M*AU!;Z.V*W"W,EV'\QO\ 6R($=L9Q MRHQCI0?#.E?V1?:6(&6SOI));A%E8%V'W MO;:[6UFAFM85@A-O=2Q!(U.0H"L!CU]>]:?]O:1_T$K7_OZ*/[>TC_H)6O\ MW]% $MAIEKIOVG[+'L^TSMTC_ M *"5K_W]% &C16=_;VD?]!*U_P"_HJ>UU&RO79+6ZAF91EA&X.!0!:HHHH * MHZE]G\I/M%M'<+NX6100#CKS5ZL_5O\ 4Q_[W]* ,_\ XEO_ $";7_OVO^%& M--_Z!%K_ -^U_P *AHH FQIO_0(M?^_:_P"%&--_Z!%K_P!^U_PJ&B@";&F_ M] BU_P"_:_X48TW_ *!%K_W[7_"H:* )L:;_ - BU_[]K_A1C3?^@1:_]^U_ MPK-U+4[?2H(I[HN(I)T@#*N0K.<*3Z#/&?>J!\6:2&U!5DD=[&ZCLY45,DRN M<*%]1G(S[&@#H<:;_P! BU_[]K_A1C3?^@1:_P#?M?\ "L>Z\0Z/9QWKS:C; M?Z$I:X1) S(![#G.>/K4KZM8KHS:N+A7L5B,WFIR"H]/?MCUH T\:;_T"+7_ M +]K_A1C3?\ H$6O_?M?\*YY?%>DFSTJZ:9TAU27R;=G3&'Y^5_[IR,?6FWW MB[2K"XOK=VGEFL7ACF2&/<0\IPJCU.>H[9H Z/&F_P#0(M?^_:_X48TW_H$6 MO_?M?\*R-,UJTU62XAB6>&YMB!-;W,1CD3/0X/8^HK1H FQIO_0(M?\ OVO^ M%&--_P"@1:_]^U_PJ&B@";&F_P#0(M?^_:_X48TW_H$6O_?M?\*AHH FQIO_ M $"+7_OVO^%6]/%E]I_<6$$#A3\Z( <>G K.J[I?_'V?]PT %W]A^UR>;IMO M+)GEV0$G]*@QIO\ T"+7_OVO^%.O?^/V7Z_TJO0!-C3?^@1:_P#?M?\ "C&F M_P#0(M?^_:_X5G:IJ5OH^F7&H76_R(%W/L7%PTBA>ORYZTMMX@TB[L'O8M2M3;QJIE;SEQ%D9 ;G@T M ;&--_Z!%K_W[7_"C&F_] BU_P"_:_X5B/XDTA;NVM5OX))KJ)IK=4<$2*OH M>F3V^A]*=;Z_ITL%BT]U;VL][&LD-O+.A=L],8.#]10!LXTW_H$6O_?M?\*, M:;_T"+7_ +]K_A6.NNZ%)]10!NXTW_H$6O_?M?\*,:;_T"+7_ +]K_A65)K>E M17$]O)J=HDUNI>:-IE#1J.I8=J;>:W96=Q;P-)YDLUQ';[(R"4:0$J6'8$ T M :^--_Z!%K_W[7_"C&F_] BU_P"_:_X5DIKND20SRIJEFT*@O_$EC8_8 J7%X;\,;<6V\MU#_K(4D!=/7(H T,:;_T"+7_ +]K M_A1C3?\ H$6O_?M?\*AHH T$L]->S:X_LRU& ?E\I>WX55QIO_0(M?\ OVO^ M%7H/^0-)]&K+H FQIO\ T"+7_OVO^%&--_Z!%K_W[7_"H:.V?2@";&F_] BU M_P"_:_X48TW_ *!%K_W[7_"N*MT..M M33>*="@AMIFU2U:*XF\B-TD#+OQG!(Z?7W'K0!NXTW_H$6O_ '[7_"C&F_\ M0(M?^_:_X5A+XDTQ(7DO;JWL0LTD*^?<)\^PX)&#[].H[U<_M73OML-D;^U% MU, T<)E&YP>A [YH T<:;_T"+7_OVO\ A1C3?^@1:_\ ?M?\*P(O$]A+IMA? MLLT=O>W/V:-F3[K[BHW<\ E< ^XJ4^(=+CDO%GNX[=;286\DL[!$,A7=M4GJ M0",^E &UC3?^@1:_]^U_PHQIO_0(M?\ OVO^%8SZ]8PW=S%2&1+FQE2'[1LOHC#NB_OC/&!W[CO4Y\0 M:*MFEX=6L1:N^Q9C.NUF[@'/6@#8QIO_ $"+7_OVO^%&--_Z!%K_ -^U_P * MR+36[&[N[BV60)+%1B@#5QIO\ T"+7_OVO^%&--_Z!%K_W[7_"L2V\1:=+9V4]S=6]F]X#Y,,U MPFYN<<$'!_"K"ZQICZ@=/74;4WH)4VXE'F9'4;>N10!IXTW_ *!%K_W[7_"C M&F_] BU_[]K_ (5#10!8C&G>:FW2K4-N&"$7C]*NZG]FW1BXLXKC@[?,4''Y MBLV+_71_[P_G5[5_OQ?0_P!* *F--_Z!%K_W[7_"C&F_] BU_P"_:_X5#10! M-C3?^@1:_P#?M?\ "C&F_P#0(M?^_:_X5#10!*6TH;LZ79C;][*K\OUXXI?^ M)81D:3:D?[B_X5YKXF\.Z]=:MXDO]+1\SV<5NL#$;+M"C!P/1U."#]1WJVEM MXGCU>W5!?J$FMQ$1(OV1+4(!(LB]?,SN]\XP<4 =_C3?^@1:_P#?M?\ "F&3 M2!((SIMB)#T0A,G\,5PVA67BBW?3Y9[J]:6>VN1=+?-YD4,@<>3\HY'&>AYJ MMJGA+5-;U_43/%IZ+/:6T?V]X6+(Z[MQ@YRI''4^E 'HN--_Z!%K_P!^U_PJ M&XN]#M$9[FQT^%50NQDV+A1U;D=!ZUQ-U8>(E74YX[G5'4ZBJ+#',H8V8"[C M#G@.3GG.>N*S+O2_$UQ:^>UM=R3I87\5LTI5ID5V3RD<]"Y /YE)<:+) M,88["P>4('**$+!3T.,9P?6I<:;_ - BU_[]K_A7F'XX(.!@5 M?7!H ] QIO\ T"+7_OVO^%107&C72LUOI]C*J.8V,:HP5AU4X'4>E>9QZ;XE MN8(GOHM7>&SU.">)%EQ,8BA$F,L2=K8ZGC)JV+/Q;!%(;07(:\N[JV=68#[/ M&\@,=P![+N'KR* /1L:;_P! BU_[]K_A1C3?^@1:_P#?M?\ "N%TZV\3Q^,& M%S/=_84F?#M\\,EOMP@^]P^<'.,YSGBNTH FQIO_ $"+7_OVO^%&--_Z!%K_ M -^U_P *AHH FQIO_0(M?^_:_P"%7M-%KYLGV>RAMVP,F-0,_D*RZT=)_P!; M+_NB@#5HHHH *S]6_P!3'_O?TK0KFO&6OV?A^QMIKQ92DLI1?+4$YP3ZTXQ< MG9"E)15V)17(?\+)T+^Y=_\ ?L?XT?\ "R="_N7?_?L?XUM]6J_RF/UFE_,= M?17(?\+)T+^Y=_\ ?L?XT?\ "R="_N7?_?L?XT?5JO\ *'UFE_,=?17(?\+) MT+^Y=_\ ?L?XT?\ "R=#_N7?_?L?XT?5JO\ *'UFE_,=#K.F)K.BW>G2/L$\ M>T.!DHW56_ @&L"R\#16>I:->F]:0V*9N5*?\?^9;S0S MQ0$QMYD7G'+');:?^^1FM6\\/7.I:!8Z3=Z@JI#(C7+VT7EF94Y55Y.WD*2> M>E9__"R="_N7?_?L?XT?\+)T+^Y=_P#?L?XT?5JO\H?6:7\PC^ XI9/)FOY) M]/\ M5&D:Y(55R>Y)R36O7(?\ "R=#_N7?_?L?XT?\+)T+ M^Y=_]^Q_C1]6J_RA]9I?S'7T5R'_ LG0O[EW_W['^-'_"R="_N7?_?L?XT? M5JO\H?6:7\QU]%E)V3-J]_X_9?K_2J]5M4UFUM]4N(7$FY&P< >@JG_ &_9^DO_ M 'R/\:\V68X6+<935T=\<'7DKJ+'Z_I9UO0;S35F$#7"!1(5W;<$'IWZ5B7_ M (/N]8CN9=3U9)KR2%+>)HK;9'$@D60X7<222HY)K9_M^S])?^^1_C1_;]GZ M2_\ ?(_QI?VGA/\ GXA_4L1_(S N_ UQ>:C=W4VKE_/BNHDW1'.W>"V\I%6$DKO4-EB#WLVT^6WNX$FMQ<+/^X++*)B" MQ&6)4Y PX^U6UPQCMO+&(590H&X]=W6M?^ MW[/TE_[Y'^-']OV?I+_WR/\ &C^T\)_S\0?4L1_(SFE^'T[BZ^U:LL[7$$<+ M,\))8),),MEB.0,8&!STK7\3^%_^$@GTZ6.2TC6S,A$5Q;F6-@P Z!EQC%7O M[?L_27_OD?XT?V_9^DO_ 'R/\:/[3PG_ #\0?4L1_(S!O/!%U="54U*UB6Y2 MW%PHLLC="1M\LELHN!C'-(W@%#=7[B^4PW N6A#QL7A>8$,<[]I R?XA'J*Y+_A8VB?W+ MO_OV/\:/^%C:)_E3P^"98;12+Z#^T$O(KI9_L[,C>6I4*RLY)X)Z$=O2G_P#" MQM$_N7?_ '['^-'_ L;1/[EW_W['^-'+(/K%+^8E@\'K'>I<2W,9#I_V4JC1'K#Z8; W>X)'8XJQ_PL;1/[EW M_P!^Q_C1_P +&T3^Y=_]^Q_C1RR#ZQ2_F+L?A>/_ (0Z3P_-<;PPJDC\JSY_ IDTK388]1(OK1I7DN)$8K#;K6Q))K>L"XN%@\BW>"V$:QY96+ M,N3N)*C(Z8S4D_A?4)Y[>^.IV0U&(2QEO[/7R2DF,CR]WWAM'S$GT/%1_P#" MQM$_N7?_ '['^-'_ L;1/[EW_W['^-'+(/K%+^8E?PG<+=&\M=22*[6_-Y$ M[6X9!F(1,I7([#(QC%5+/P+/9/I;0ZJL;6:JDLL$4CN1,MPF\:N-2#&+YL!-OEYSG\?TJO_P + M&T3^Y=_]^Q_C1_PL;1/[EW_W['^-'+(/K%+^8ZVBN2_X6-HG]R[_ ._8_P : M/^%C:)_ M%$NMTDJHN8QU) ]:Z;Q7KUGH\UJER)29%8KL4'H1[TXTY2?*EJ/VU/E>#=,N M1ER1S+G8Y!8IGKMW,=N?:CZK6_E#ZU1_F18L_'4,-AH[7D4MP;Q(S),K1 MJR;W* F,'IGT_6DT[QQ)% TFLVO>0Z4RW#ERS%-V2^=YP6QDY.3 MCIQ1]5K?RA]:H_S(DE\?O+IXGL='F:;S[=/+ED4*R2M@$-TW=L=B1GBKJ>*9 M8K^ZL1:7%]>M?2006J>7&55(U=OF)P0-W4\DUG)?>#TTZ?3UTV;[).5:2(Y( MROW<9;*X[8QBB>_\'W,#P3:;*Z/+YQR#NW[0NX-NR#M '!YH^JUOY0^M4?YD M7_$GB:YTFXTE%FL].CO(99)9+]&<1%0I"G8>O)'>JT'Q"B6WLA>:9$ M ;0C3I@;10D)&054'(4G=\P!Z Y H^JUOY0^M4?YD6X?%%]HQWI(/B!:M9"\NM,O+6"2T:[@9F1_.57"$ \'&Z%T MZ*N3,P4KAF+;NAX.>,#%3R7'@J6"*!M)?RXHS$JJ"ORD[B#AOF^;GG//-'U6 MM_*'UJC_ #(N77BW5$2],>EA3:ZQ%8)AU8S*Q&0.>&P0<].1[U8_X3JSBA:2 M\LKBU"BX5@[*<30XW1 C@L0001UJF^K^%7O9+QK";[1+)'*[@$;G3[K$;L9' MK^=5+R\\.WEU;,?M,=I%=_;I+40*1+/G.\L3D>X'!H^JUOY0^M4?YD=[ [RV M\4DD1B=T#-&QR4)'0^XJ2NH' M4_6E+#U8J\HZ%1Q%*3Y8RU.JHHHK$V"JUY#%,BB6*.0 Y =0V/SJS4-Q]U?K M0!1^Q6?_ #YVW_?E?\*/L5G_ ,^=M_WY7_"IZ*?,QAZ??W%G=7$\;VSJD\OV:0Q1%@"-T@&T<$=31S,.5=C7^Q6?\ SYVW M_?E?\*/L5G_SYVW_ 'Y7_"JL^NZ;;:W9Z/+=*M]>HTD$>"0RCWZ#H<>N#BJ, MGC+2(M273I!?K=-YFQ#82_O-@RQ4[?F''4>WK1S,.5=C8^Q6?_/G;?\ ?E?\ M*/L5G_SYVW_?E?\ "L./QUH+R3QF6[BD@:)94FLY(RIE8*@(([D_ES5W4_$F MG:1J$=A >?2E@\0Z1<7$ MENE_"L\4*3212'8R(W*E@V,?3J.^*.9ARKL6_L5G_P ^=M_WY7_"C[%9_P#/ MG;?]^5_PHDO;2%9&ENX(UB($A>55"9Z;LGC/O533=>TW5K62YM;E?+C:17WD M*0$8J6Z_=R#@]*.9ARKL6_L5G_SYVW_?E?\ "C[%9_\ /G;?]^5_PJ965U#* M0RL,@@Y!%+1S,.5=B#[%9_\ /G;?]^5_PH^Q6?\ SYVW_?E?\*GHHYF'*NQ! M]BL_^?.V_P"_*_X5/:VUO%,6BMXHVQC*1@']**D@_P!9^%%V%D1S0Q-,Q:*, MDGDE14?D0_\ /&+_ +X%3R_ZQJPI?%>D0ZLVF>=/)<)(L4AAMI)(XG;HKNH* MJ>1P3WJ.2/8KF?,7_ 'P*S6\2:4FAW.LF=OL-L[QR MR"-LAD;8PQU/S<<4UO%&F1:1=ZK:US:21-STVJP!;J!Q1R0[#YI M=S4\B'_GC%_WP*/(A_YXQ?\ ? JB-?TLW6F6XNU,FJ1M+9\'$J@ G!]<'I4E MEK%AJ-S?V]I<++)82^3,7_? H\B'_GC% M_P!\"H5U+3W@,Z7]HT(;89!.I4-Z9SC/M22ZI8060O)+VV%NP)23S5VO[*B[F!# 8P#FCDAV#FEW M-3R(?^>,7_? H\B'_GC%_P!\"LNZ\4Z-97,UO07UX(Y;.W6YN%"%O+C9@H)Q[D<>G-')#L'-+N:OD0_\\8O M^^!1Y$/_ #QB_P"^!5"\\0:587,%O<7:B6XMY+J)5!;=$B[F;CMCIZ]JHCQK MHW]FG4&^WI:YC5'DL)5\PR'"; 5^;/M[4)M(N-)O-3%T8[6R+"Z,T;1M"0,D,K#(.".W.:CB\5Z.\<3S7$MG MYTP@C6]@>!G311)*ZVQ5P%:3R_O9QD'J. MN*.2'8.:7BBXK(@^QVG_/I;_P#?I?\ "C[':?\ /I;_ /?I?\*GHHN'*B#[':?\ M^EO_ -^E_P */L=I_P ^EO\ ]^E_PK*U#Q?HVEWMQ:7Q^9I9Q>;LJ(N"2"(3-+<6TD2M&3@,I91N!. ,=<23P11S/@?+L?.TANAS@]*+A9$OV.T_Y]+?\ []+_ M (4?8[3_ )]+?_OTO^%8\7C30I;6XN_M,T=G AD:[EMI$A90VW*.1AN>.*UU MO[)HS(MY;E JL6$JX ;[I//?MZT7"R%^QVG_ #Z6_P#WZ7_"C[':?\^EO_WZ M7_"J=[X@TO3[ZWL[B[C$\\AC"AP?+(4OE^?E&%/)K06:)I/+66-I-H?:&!.T M]#CT]Z+A9$?V.T_Y]+?_ +]+_A1]CM/^?2W_ ._2_P"%3T47"R(/L=I_SZ6_ M_?I?\*/L=I_SZ6__ 'Z7_"IZ*+A9$2V=J'4BU@!!&"(E_P *L7<,4C*9(D? MXW*#C\Z:OWA]:EN.JT[L+(J?9;;_ )]H?^_8_P */LMM_P ^T/\ W['^%2T4 M5%N"+A2S.QZ*JCEB?04CF?<.5=C7^RVW_/ MM#_W['^%'V6V_P"?:'_OV/\ "LBZ\7Z%96M[@Z]3D8'?-',^XP D.<_*>1C/6M(2QM*\2R(9$ +(&&5!Z9 M';-',^X>S9M]CH"=>/A^739K_2GGDNXKU[ORI3)/,L@W)Q5[3=5\3R7FIZ>\6GWES:M;R+*RM;H8Y$+% M?XLD$8!]\GI6%KNKZC:^+;![N9F^TR.SN+N: M#,_G)G$@/<,<;@>3M'-^M9YG6VB,X#+Y3J D@0G M&W/"FM.PU"Z^W6$MGJ%]=Z756&03TQ0!HS>!]7O+ MF;4+R^TR6^>]@NQ$;=S;-Y<1CVNI.3P<@]B*S)/ M_$^DZ3&IV,\ZZC>6\82 M![220R-" 3N#9"@#'1CS7J%% %4*H& !T HHHH **** "I(/]9^%1U)! M_K/PH 23_6M]:XYO#&M6UU>0Z7K$%MIM[?B_ES&WVB-MRLZJP(!5MN.>@)%= MC+_K&IE '"R>#M=D\.:KH'V_3!8WLDTJ/Y4GF(9)/, /.,#IQ3D\$ZC+:6EC M+>VEC9P7?VQA8"1W=U7"?ZXL, \XZ<"NXHH \_'PXG9+&VEU=6GPVNPKB^O+*:.2XLII8UA.Q_(+;LCIE@>F,#I4TWP\N%D,EK/II47%XT= MM&..<@_*H(PZX^G)H\1:QJ=AXDUB:QE'GVMM80VT4BLT8$TQ$CE0>3P! MGMBM/3-6\33KJ-L+6QO;G3[Y[=Y7+6RS($5EVC#8;+$9Z<4 .;PI=)X8T"QM MKZ)-1T0QR03O&6B=U4H0R]=I#'H37 26.0P(L MD2Q^6@SNP,$_4U5U?Q!X@L/%-@]UHFH-81/%;JEFP\NXFD'SL22"57HJD $Y M)(XKGAKFKQIKL=E?7=_=-#+,+JVGF<6L?G+E3$Z@*X0G;MS]TT =/>>!+C5I MKI]4N+21+R^MKJXBC1@I6.$QLHSR,DY![57D^&S^7>*NI_:)+NT2&XN+M"SS M.LZR;FQQC8H0#VJUX9U*[&G^))M/EN]6T^U;=IZGGM@3);QI/'; ^2\F=R.A8!0,?>)XZ$4 :0^',=O>BXM;]FQ# M@)I#W5C;J)K64SVAG\QO*;)/SL0I( MZ;0 #4%KXXUBZ@TI[J:UTM9H&D:>6RDF6YE68IY:A3E?E ;N?FXX%&DW^LQW MAM+F?S=+U+5K^S9&C<2PJ [!Q)G@#& , 8YH Z+3_"LVGZ+K6GM<0WLM_,\ M@GOE:4R*0 !,,C=@#;QC@#O6-'X OQ:1^9=V+R07T=U;6DBR2VT*JI5D&\EP M&SDCID#BNC\%W<]]X)T6YNI&DGDM5WR-U?' )]R #6[0!PJ^!+\7^PZG;KIB MW-YIP.F*Z'PIHEWH M.F2VMW=QSEIB\8C3 C7 7<1ENG4\]NU;M% $Z_\>Y_&H*G7_CW/XU!0 444 M4 %%%% '!^(_ -YK>MZE>Q75E&EZD*J\HE,D!08W*%8*QSR-P-26O@S5-/\ M$U]K%O/ILLEQ"16G<>'-?U;17TS5=5L-L(B:TEM;5@1+&P97<,V M"/E *C\ZM^,Y9$TFRA29X4NM3M+>9XVVL(VD&X9[9QC\:Q=,\1^)9M1M6G6T MFMKR\O;6.W$#1LABWF-B^3P=N#QWS0!)J7@O5=?>YN]7O[%KV2.&WC2WA80K M$DRRMG<26+$8]!6EX;\(CPUK&K7%O=&2RNUC6VMW!)ME7<=@/=06X'8<5D>+ M;W6X])M_[0NK+2&6Z4[H+R95N5",67>B;DR<8!]/I6)#K]VVM:+<[[YEFBM8 MUT@WDZSQL2(6UE')Y+RE@R MRM&[$*1CHF.IJ:^\#ZK=-<>3>:7;QWL5HEW$EN^U3 ^0(N>%(]1Q7.6NHZE= MVMU'+JFIO=-IE])K$HKU+1KB:[T+3KFX&)IK6*23C^ M(H"?UH XUO D]MJBWLGV*[LX+NYNS&EL?M=RLRL#&SDX;&[ ]<#IBM+P%H-Y MI.F2W&IB3[9/MAC$V/,BMH\K"C8)&<9)YZFNMHH **** "BBB@!5^\/K4MQU M6HE^\/K4MQU6@"&BBB@ HHHH *QO$6BSZO#92V=REM?6%RMU;/*F^,L 5*L. M#@ACTY%;-% '&2>&_$LEY9ZF^K6$NH6]Y+'Y[.[O$O;^X=Y)[EH_EW''6L-M;,7C^2*QU#4;F6VCE-U9R3, M8[J8I\L$"D *1G?QZ9- #_^%=7LNFWUI)>6$,4JQ&WLX$E:V25) _F;78[< M@;<+@8)ZU=F\%:I)J;31WMA%9S7UK?SPK VY9(552J'. IVC&1D5@#Q%XB_L MC5+2^M-7L[M)[:>_O ?L\,CCS$B )VA4'!&2?F)P:MZ1J-Z=4T62*]O+FR? M6KBTM);AV+7%H82Q+9^\%=>&//% #U^'TM@JM=):W]C;6UU 8K2VQ=W2S=W8 MG#,/_KUT?@G1[[2]#,VKL7U:\8273MC< JA(U...$49]R:Z6B@ HHHH **** M "IK?[S?2H:FM_O-]* )Z*** "H;C[J_6IJAN/NK]: (**** "BBB@ HHHH M*@DLK:6]@O7A4W5NK+%+_$@;&X?0X'Y5/10 4N3ZTE% "Y/J:KSV5MB@ HHHH **** "BBB@ J2#_6?A4=20?ZS\* $ ME_UC4RGR_P"L:F4 %%%% !1110!!]BMO[0^W^2OVORO)\WOLSG;],\U/110 M4N3ZFDHH ,TN3ZFDHH 7)]34 MWC6.&) D:*,!5 P /PJ2BB@ HHHH **** )U_P"/<_C4%3K_ ,>Y_&H* "BB MB@ HHHH **** *][8VNHVCVMY LT#D%D;H2""#]00#5C)/4T44 &:7)]3244 M 0WMI;ZC936=Y$)K:9=LD;9PX]#[5* % 4 8 ':EHH **** "BBB@ HHHH M 5?O#ZU+<=5J)?O#ZU+<=5H AHHHH **** "BBB@ J!+*VCOY;Y(56ZFC6*2 M4=7522H/TR?SJ>B@ I.#Z'D?F* )J*JG4[!;T M6;7D NB0!$7&[)Y QZ^W6IXYHI8S)'(KH"064Y&0<'\B#0 ^BJ=OJ^FW4C1P M7UO(Z(9&4.,A1U8^WO31K6E-:M=+J-L8%8(T@D!4$\@$]J +U%%% !1110 4 M444 %20?ZS\*CJ2#_6?A0 DO^L:F4^7_ %C4R@ HHHH **** "BBF2S1P0O- M-(L<:#+.QP%'N: 'T5%+4D1R MF0;6(ZX/?&.?2@"]14"7UI)=?94N8FN-GF>6&R=O'/TY'/O4] !1110 4444 M %%%% $Z_P#'N?QJ"IU_X]S^-04 %%%% !1110 4444 %%<]KVJWVG:K"EC: MS7;O92L(4&54AT^=AWP">!R>@ZU'-#=S16,UI=7>IV)MR[FVNA%-(['(D'0$ M8R N1CT- '2T5SUEJZR7TUQ"UY=69TZVEB18R\A+/("VWU.!GZ4FK;X;VPU( M27L=AYR&[*7)!0DJJ(8R<8)8;L<^W)H Z*BN4AFN6LM.U)K^Y:YO+W[/-;^; MA-K.RLBK_"4 SD<_*<]:UO#[.=/F62667R[R>-6E,>M $U%5$U.PDO&M([V!KE208E<%@1U'U'<=JF%S MUJ+I94:W*;Q*#E2O7.?2@"6BJ46KZ;/'-)%?V[) H:5O,&(P>A/H.#0-7TUH M8I1?VYCE?RT82##/_=^O(XH NT444 %%%% !1110 5-;_>;Z5#4UO]YOI0!/ M1110 5#6N=RSFV^T>0WD>'[FVDN/,NX(5MOM2-/;,GFQ[@N4_O'<0,#N:DNO'.D6-O% M)=PZA;R2%\6\MHRRA4 +,5/\(R.0: .EHK#U/Q?H^E6EEQF:W%O'O M9XP Q?'H 1^=1IXTT252T=P[CS88DQ&?WGFKN1E]5*Y)/;:?2@#H*Y Z?J4> MK7^HO$;BQAU)IEL1'\TH,:#SA_>92/E7IP>^,2+\1O#CVMQX\N!%E_P!0 M1=R_+_=VY.>V#Z4 5 M]\]EJS+IJWC"XO!)-:SV9,1W$;Y%EP-O'S:LWZRZHVK7=I9W,<3:6UL!)"T;329) "GD[ M1D9_VL"M6?Q!86N@1:Q/<));2! C6V9?,=C@*F.6)/ JBOC;2'>UB5+XW-S< M/;+;_96\U)$ +*Z_PX# YZ8YH Z%?N+]!2UR^J^+6T[Q9#HGDVBK(D3?:+JX M:(,78C:GRD%AC."1U%6M;\8:3X?O6M+T7AD2W%S(8;=I%CBW;=[$= ".: -Z MBN:7QUHS12$+?"=)D@6T-JPGD9U+)M3J05!.?0&HYOB#H,444B_;I@\#W#"& MT9C$B-MD+C^$J0<@T =317&ZC\0(K:+6FMM/GD_LS[.?-=2(YEE*\J0,YPV0 M.^*MR>/M$CC4NM\L[7#6WV5K8K,'50Q!4XQ\I!Z\YH Z>I(/]9^%1*VY%;!& MX X(P1]:E@_UGX4 )+_K&IE/E_UC4R@ HK+UCQ!9:(UO'<)LR7Q_H,4B 274L30PSM<16S-%''*<(S-_"">.>E '3T5S[>, M]'1[TNUT+:S\SSKS[,WV?,=SP*DLO%VCWVF7^H+.\,.GC=="=-K M1#;N!(YZCIB@#J6FKQ3WS7J^:;VTC^9@"/W>.=NP\J.A&>ISEIEU&^AEC<3W4"7- MJT=Q+:&"1L3 N"O&0H .[ ')JQ:>-='O+M;=/M<8>YDM5GFMRD1E0,67>>,X M4TFH>)9U\,Q:[I5G#/:/$T[R7L_V<)$!D'H22W;ZB@"[?37<-I3][GT('6L?3#/IT]K>7NGW#6RVCVL AM270"0E2T8R5+KMS[K MSC-6KSQT\7:3>ZLNGPO<;Y)) M(89VA80S2)]]4?HQ&#^1H AT>QNK5]%6:!HQ%:W 9>HAW.A5"?4#C_@-=%7) MR^-8_P#A,6T&&.T589D@FEN;DQLSLN[$:A2#@$=2,G@5:U;QKH^B:A/97@O- M]NL;SO%;,Z1+(<(68=,GCZT =%17-CQQI#0@K%J#71G:W^PBT;[0'50S93T" MD'/N*BE^(7A^+RV$EW+$UNERTT5LS)'$[%0SG^'!!!STH ZFBN-O/'R0"]*: M7=XL]4BL)"\9_>!R,L@'5N>%^A[U<_X3S13]E11>M/<221BW^SD2HT9"N&4X MP02..>M '34444 3K_Q[G\:@J=?^/<_C4% !1110 4444 %(S*BEG954=2QP M*6N;\6>'[G6VTZ6".SNELY'=[&^+""?3VS7"S?#2ZET^:*:XM; MF[32HK2TN)"V89ED9]PZD !@ >N!5Y_!.H27VJL7L-U]YS)JI+_:X?,CVA!V MVJ??IVSS0!VT,%LK^;!'$&*"+=&!]UI(/).* .Z33]-CU WJ6ULM MY(2/- &YCW_'U[U/$MO#F.'RD+,SE5(R6)R3CUSUKSNZ^&MV;JP,-W'+"D$< MZTC3[N]T^T:?Q%/K#WEE<6\)?:"?E M64\;5VLP/;F@#T<$,,@@CIPKN>68^Y8D_C5^ M@ HHHH **** %7[P^M2W'5:B7[P^M2W'5: (:*** "BCK7._\)OHOVN6#?QH Z*BN8A\?:'-:RW'^FQ!(XI4CEM65YEE.V,Q MKU;<>!2WGCO1=/BB:\6^@=T:1HI;5EDB16VEW4]%SW&<]LT =..HKD-,L=2L MKN&_NXC/:I=3I';+&=UL'E;$V/XBZM"HMU.YBRR\ _-T'S$ANM6-$74+'P_I8>)?)@LD$MN(F-QO"]!SC\ M,537XB>'WLY+D/=XC>)?*^SDR,)21&RJ.2"01Z^U:%OXITVZN(K9/M"W,EVU MGY#Q$.DBIO.X=E"X.?<4 8[0W,US=316UW=V(NX+R4W%N8Y78,=R*" 75%VD M#'; S5FXAGO5U:\@M9TAN9;,1H\11Y"CC?)M/(&,#D9^2F6WC6.\\7RZ)"EH MD4-PUL\DUR5EDD52!Q5K5/&VD:/J,]E=K?%[=Y9(?L:6C&X5HP"^Y.P (Y]Q3) MO'^@0R(/,NI(6AAG:XBMF:*..4X1G;^$9XYZ4 =/17$W'Q"6,%H](O,1ZP-, MD#QL2V0?F0#JW'W?<5HIX[T65K*.(7DDUX7"0BW(="C['#@XP0W&.30!TM%' M0XHH *FM_O-]*AJ:W^\WTH GHHHH *AN/NK]:FJ&X^ZOUH @K!/A#2CJS:@? MM66G-S]F\\^1YY&TR[.F['X=\5O44 T7Q'%;@R2![ M#'-;2;7C MX 9;QS)XEO'MV:* P6L<*," ?XI"3@L 2!@#@FI]8AN[F\LQ;6DK/!*LJ2EH_) M]&\P$[N!G&!U--U?2[F\GO9H9;E'$$8M3'.4VN&;<< XS@CDT -O?"=K?:D; MZ6\U%Y59I8(7N6,,,I4J'5.Q )QSBIV\-:==Z396.JVZ:F;2$1K-=+O!K:9(?[ M4:Z>19R!)&ROC&&R.6 (X_&JUW#>:63?2.P:WBV6P>;+3E9G98NY):,@<]R/ M2@#4U/PO9ZQ?)<7ES?O$KHYLQZ MM#ITYCDP @8DCV8$GFDN;*^_LJT1Q+<-YWFWL44NUY 0Q*JVB>.*.X4/9RV4A,I)9)6W.Q)ZN22=U4Y- M/UO?>+%YK/( 7N))-I;YE)2/#XP1N R$(X&>:!8:LBVLD<-U*5D8QV\T@5(@ M2OWB)"PZ''+]<8H M3>"M)F:8E[Q4GB@BEC2?"/Y)7RV(Q]X;0,^E)J?@K2M M5^W>?)>(M]/Y]PLCW\QV7MO*L N+>94:8_*R[O, M(^=CC[O?GKBF'2-0M[&*WM[:<0Q7$[2QI+DR[FS&ZGS%X /0D<\X.* +3>!M M';P_M^%[#7K.SM;A[J"WLW5XDM9?+ *C"Y&"#C'&>E4(_# M]R+:,/+>&3^SSOS=MS=#&UNO4<^U2K::JUY')+'.;DO&XN1.!$D85=\93/)) MW=N<@YXH NWWAZVU#2[2RN;F])M)5FANA/B<.N<-OQR<$CIWJK8>$]'M-8-[ M;&X:2WE>1+9IRT-O+(,LRI_"S!L_CQC-4Y= O#I"0$7$TDEFOVE'N2=\RNC# MDG@X#C(P.E7#I5Q]LN+^".>*8W%LT*& M/3YC^-4-.@NX;JUTD2$(4$MXJR9,&QB0..GF J./[K58U?3[VZO)\6UQ/OFA M:"5+@)'%&K(75ER,G(8]#G(Y&* );OP;IMW=S7>^]M[R:Y-R+FWG*2(Y01L% M..%*J 1S4?\ P@VABSNK..&:."XLDL9$24_ZM6+#D_Q98DGOFH'T[5660;;Q M)BLGVF9+@,+C+93RU+#''^[@9&>P:3NNW MC+XP10!HOX1TUK^6\+W8,UU%>-$)OW?G1XVN%QP3@ ^N*KW_ (%T?48Y8IWO M/)FN9+J6)9\*[N06SQTX'3!'K5O2+:]M]2O//BE\E\D33/\ ,[;B0 Q!7!Z MX4\ 8K:H .@&!1110!.O_'N?QJ"IU_X]S^-04 %%%% .M<+X4UC^T/& MVH6UIXCDU'3XHV21+F2,L\X;DPJH!$:C@GH3T]:[.ZO+>RB$EQ)L0G (4M^@ M!-9$FOZ59ZDT0A5558\W$4).3(?E VKR#USG\Z .;@\7^)KV^MX;:'1TCO+N M\M8&D64F/R,G3SCK7>G4=,CF>(S0K)$&=LI@+@9;G&,XY(Z^M!NHY+2WN;"S%ZI/[GR]J M!1Z@MC ^G6@#D!XOUV343$L&G+;3ZE=:9!\KF19(T9E=N<$?+@@5BZ=XI\27 MD>BW5OJ-AG7%%MJNC7#L+:YM6.QI&*K@%?XCG&#COZ=Z .7TOQU#QRN,=^:=+XVO8_%CZ8(;/RUU!;$69+? M:W0KN^T#MY8^G0'G-=(-7T94^TK<0+\PA#",A\D9"@8W<@9 [XXIDVOZ6C22 M1D33)9O=*R1GYHUSD;\8'(/!- ',7'B#6;_X3WFO3R06ES*BO;M9E@8U\Q5Y M)/4\].QI?^$ZOO\ A(9;+R++8MW-:_8\M]JC6.,L)VYQY9(].A'.:Z==$R& 2,^!GRCT)/\ =X- 'G\7 MCW7H]*2ZN;"PEDN=,CU" 6XDQ"K2*C>8.20H;<=OH1[U$_Q'U*.&8#^S)E2^ M6U6_C5Q;A3%YFXAV')/RCY@.O)KK9]5T/4OM-@[XMA;)(\T9:(A6?"JI&&Y( MR,=>U.TJ+P]IUO\ 9;%ED6\?>_F%YGE;.W,A;)Z@#YL8QB@#.T'Q+K&LZ[;V MDEK96]N-.BO+D!B[Y'UJ6XZK42_>'UJ6XZK0!#111 M0 =#FN7/@_P^+F[N#+-Y:>Y+2R*S;BKD@ MY&>P QVQ4,^C7EO+J0L()56>YBF+"8GS8@BAD&7!#9!/49'&>:N:5IMXE]!/ M=OQ\N?3BGQPW3^)1="TF MBC$312O*T;(5ZKY>#N!)Y;..GL*KMI-YR].P MH BL?!>BV]O]DADNI$AN89@'GR8VB^9%!QT&1P>OK3M+\/?\59?>*)YK:66Y MB$%N+=&"J@/WFR3ER JDC PM-BTV_;5;2^OK>2U3WGA?3K^:]DG6??>R6\LVV3',)RF/3W]:RH](U& M[2TBGMS''=HS"?[S-CRV4Y/OC.,'-2ZC:MITS;I)!I)FC9HI+IE,A*,#AR> M&VG!(!_F 3W/@O2[B>6=9+VWNI+F2Y-Q;W!216D"JZ@_W2%''M33X.T*6VOM M/B21(IK>"SFBCE^XD7S(!Z'G)/?-+8I>W/A("+SO->9V"M.=[1>:3M$AYY3@ M'Z?6JL.F7<<]Q*=/O/L$EQO-F+H>:R^4JJ<[^@8-\N[N#VQ0!>/A#3/[0:]# M78+7R:AY7G?NEG4$;@N.,YY'?BJ]UX"T>]B6"9KTP"XDN6A$^%=W?><\9Z^F M#CC-0C3]=63"-*;IK8H+B:7*0ML(&TAOF.<9RG)RV:C.FZI]A.V*^.) 5M6D M&TG:1DGS=V"2.0W49Q0!V%%-BW^3'Y@"OM&X Y ..1GO]:=0 5-;_>;Z5#4U MO]YOI0!/1110 5#[S$ ^X>1@'O@].*OT4 4C8%_P"SVEE!>RD\Q2D816.QDQCL M,-V]*J2^';>>UAMI)9/+B,_W0 3YN<_EFMBB@#*CT=C?QW]U>-<72.IWB((- MJJX P/\ KHQS_(4R;01+YP6[=%G@G@E&P'Y_&H*G7_CW/XU!0 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 J_>'UJ6XZK42_ M>'UJ6XZK0!#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4 MUO\ >;Z5#4UO]YOI0!/1110 5#S:DT\]O+9B6,&*2)0S98G:058 M$$4 =C17#K\3+3^S9=0DT>_BMQ8-J%N79,SQJRJV #\I!8=>HJT_CM(5NH[K M2)[6]@6&06T]S$N^.7(5@^<=005ZT ==17)V'CRWU6;3(['2[N7[=!).S%T4 M6ZQOL?>2>Q].M9=Y\30-,OIK'26>[M3 WEM<(\;1R2;-P9#C.>,>I';- 'H% M%.(;.\FBFTN[%O:2PP7UR'0K;2RXVJ1G+8W+DKQSWK0\/>(#X@2[E33K MBV@MYW@665E(F9&*MM .< COZ^U &U1110 4444 %20?ZS\*CJ2#_6?A0 DO M^L:F4^7_ %C4R@ HHHH **** "BN;U?5M6?Q-;^']&^QPW#VC7DMQ>(SJ$#; M0JJI&3GJ<\"JU[XS?1S-#?Z=)+0;Z=#?MIT4R2QA99P,A0"00".YZ4)\0!<_8X['0;ZYNKB*>1H!+ M&IB\E]D@))P>>F.O% '945QR_$73'N=+6.WE:VU'R=DXE3"?R MS2CQZK:3)J(T:=81=U24 %%%% !1110!.O_ M ![G\:@J=?\ CW/XU!0 4444 %%%% !12@9(%'3Y+NYT:^@4V0O[569";F':/=E<9R =APQXJJGQ,LFL[F7^R[EYX);>/R(9HY M/,\XE4*L#M/(P10!W%%!R!@\D^U ';45S&D^-(-UU6&VU/4+Z?RK&+3T,._"%FW^8Q"X ZYYJC)\1K

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gexyhn0lyczh000006.jpg GRAPHIC begin 644 gexyhn0lyczh000006.jpg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end GRAPHIC 60 gexyhn0lyczh000044.jpg GRAPHIC begin 644 gexyhn0lyczh000044.jpg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gexyhn0lyczh000033.jpg GRAPHIC begin 644 gexyhn0lyczh000033.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^JNH79L; M&2Y$?F,F J%PFXD@ 9/ Y-.1VD^R/:=JV_5/A_*[ZC!N*I*;J>%H4^1U;)4\@?+C% %A;WQ4&,KZ9IDL0/S0PW;> M8/8$K@GVXKH8V+QJQ0H2 2K=1[5P^@SZQI^MK!>7FD%-5E:["()0[*1T3/'I MP>:[J@#%/B2U'B<:%Y4GV@KNWY&/NENFG;.*3Q+_ ,@^W_Z_;?\ M]&+0 RBBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ [UMK]T M?2L3O6VOW1]*0Q:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** .,\80W5UK6FPZ6;A=3\F5E:.Y$"^7E=V3@YYQ MQ4VR+7OAX5EO)(04#M/=L'V/&X;YB.&&Y?Q%8_B_5=.U#6[>R*:5>K;"59[: M]NQ;.C_+AE8\]#T[UO7&GMKG@,65E%9VS/&ABBAE$D/R,&"[AU4[<'ZT 86E M:Q+XLUS3X;N]TN-;&7[3&EL)-\[ $ KO ^7GG&>U>B5Q$TFI:EJVB_VGI-OH M\5K=AED:X61I7VL!'&%' /).?2NWH *QO$O_ "#[?_K]M_\ T8M9:Z_?'QPV MG2,$M%<1+$ I9R4+;L?>Q[]*N>)Y;H):1+:AKB6%QJ3]/- \N$?5VZ_@*I1; Z"BL 3>+(QO:RTJ<'GRHYF1E]LG@T?\ M)%=V_P#Q_P#A[485'5X0LR_IBCD?0#?HK$A\7:%*=K7RV[_W+A&C/ZC%37OB M32+%%+WLB_CFG+X2L)7$FI3W>IR#O=3$K_P!\CBGRI;L"Q+XIT&&1 MHWU6VW+U"MNQ^(S3/^$N\/\ _05@_)O\*TH;&SMXA'#:6\:#HJQC%2?9X/\ MGA#_ -^Q2]P"M::QIE\!]EU"UFSV24$_EUJ\01U%9EWX?T>^)-SIEJ['^+RP M#^8JE_PB=O;\Z;J&HV#>D4Y9/^^6XHM%]0-_O6VOW1]*X7R_%5D?DGL-33TE M4P2?F./TK5C\906A6+7-/N]*?IOE3?$?HZ\?GBCD;VU Z:BH;:[MKR 3VMQ% M-$>CQN&'YBJMWKND6()NM3M(L=FF7/Y9S4V8S0HK.L->TG4^++4;:=LXVK(- MWY=:T:&FMP"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 *QO&\>FW.IZ;;:FRVL)CDD6\,S1D,I4A 1QUPW/] MWBMOPC(DOA:Q:.W6!-F JDD'D_,">2#UYYYH X]-46[U*Q:\\42ZBUI.)UL8 M-**2.X! 'M]ZO28W,D2N59=P!VMU'UKCV\?VVGZD]CJUOY;KD^=:/YZ!1W?; MRGXUU\4L<\*2Q,'C=0RL#P0>AH 3[/"9Q/Y,?G 8$FT;L>F>M97B7_D'V_\ MU^V__HQ:V"0" 2 3T'K6/XE_Y!]O_P!?MO\ ^C%H 91113$%%%1W$\5K;R7$ M[B.&)2[N>@ ZT 9FOZG-8VL5M9 /J5XWE6J>A[N?91S4-KX/T2"UCBFL8KJ8 M#]Y/*"6D;NQY[FH]!ADO;B;Q'?J8WG3;:QO_ ,L+<<_FW4T6MUKNMP"ZM)+6 MPLY"?+8H9)64'&['09K6S2LG;N*YFZD=MO=+YHZQ2?(X^JGFDX22N%T:%%'3K14C# MO6R462+8ZAE(P589!K&[UMK]T?2@9@7'@GP]<7!F;3UC+'+K"[1J_P!0I -6 MK3PQH=CS;Z5:(?4Q G\S6M13YY=P,F^\,Z)J7-UIEN[#HX3:P_$8-9__ B, MMKQI>OZG9I_SS:03(/H&Z5TU%"G)=0LKVEPDH/X<&E'CC2HF"WT-]IYZ M$W=JR ?4\BNEIKHLB,CJ&5A@JPR"*.:/5 )%+'/$LL4BR1N,JZG((]C3ZY:7 MP[>Z+*UUX8F6-"=TFFS$^2_KL/\ RS/TXIT?CK2XU\O4H[K3[M>)+>:%B5/L M0""/<4BN:_X3WP[_P _K_\ ?A_\*/\ A.-,&M:*^K0!?T)H_P"$JNO^A9UC_OT/\:.207.EHK#L M/%NDWT_V9YFL[P<&VNT,3C\#U_"MSJ,BI::W **0D 9)P*-RYQD9],T@%HI M01D$$>HI: "BBB@ HHHH X[QI]J>]T^(C4VT]E?S!I\:,WF9&W)8'CKP*WM* MF2#0H)9Y+I8U3+/?$"0#_:Q@5R_CRU:\U;2HHIK+SU!FCAOI&CC.R2-BRL 1 MNXQ@]B:Z30-/%KX>@LYY8;I=IW;#NCP23M&>JCIS0!R?AC7Q&;73VMM'>WO) MVC\ZVN$W39W$%HP.I YKT)$6-%1%"JHP% P *\V\+&)=8M@TBVTXE=3:1:-L M1>O EQT]\\UZ50!RTVEZT_CJTU-_L\FGQJ\:XD8-&I7NN,$D]_:K'B>*Z*6D MBW*+;B[MPT)BR2?,'.[/'Y5T-8WB7_D'V_\ U^V__HQ: &444V21(8GED8*B M*68GL!UIB"22.&)Y975(T&YG8X"CU-@4"M/A]0,7 MQ=>R6GA^2&V4MI+<''X46?AXBQ@BO;VY7,"C?D:K8\16WS"2QO5_NE3"WX'D5#<:K M$\?EZSHMQ$G0L8A,@_%V_DW5O%/$1RDB!A^1HO# MJAZDRL&4,I!4]"#39)HH1F65$'JS 5@GP=IZ,1:7.H6<)^]!;W+*A_ YQ^&* M?'X-T)2&ELOM+_WKF5Y2?^^B12M#O^ :FO#>6UP,PW$4@_V'!J>L2;PCH$S; MCI<$;?WH08C_ ..XJ'_A$XXO^//5]6M?0+<[Q_X^#1:#ZAJ=#17/?V'K4?\ MJ?$]P?\ KM;(_P#+%!T#5;KC4/$5RT?]RTB6#/U/)_*CEC_-^87?8W);JW@8 M":>*,L< .X&:E!R,CD5A1>#]!16\S3TN'88:2Y8RL?Q8G'X5$?#,]B=VAZK< M68ZBWF/G0_3#*2.0?HU+V;_IH+G0T5S__ E07_7:)K,?J?LC-_+-)_PEUM)\MMIN MK3R=T6R=([_ M /X_-7AL4/\ RSL8LM_WV_\ A1R6W87->_TNPU6#R;^TAN(^PD0''T]/PJGI M7A^'1KB1K2[O/LS+@6LLI>-#ZKGD?G5"/5;[P](MMKK>=9$[8M25< >@E'\) M_P!KH?:NE5E= Z,&5AD$'((H:E%6Z M3/UZVGN]#NX+89F9/D .,D$'&?PKE M;S2M;U6[>XM1-8>;,NUI/O*HBVG(SP">,_C7=T41FXC*6DADTJV1K4VK*@5H M2<[2/?O]:NT45# **** "BBB@#@OB!*#/IQ:TBGMDD_>2?81=,#O0,G0[1M+ M'IS@5TOA<2CP[:":U2V;:<1K#Y6%R<'9_"2,'%<'K5B\/C.XN9+"?RY/,Q): M:N;=7)V=06&&]0.O!KT/0@J/Q/;%H[2X^T3 +>6X\H-\A_>#J M* ):P?%8=/B%K;)V: MXDY/Y+M_6M*:O(3.AN;VRTJWC21P@ "1QJ,LV.@ '-8^J7;R6#WFK*+'28CO M:)CF6?'13Z ^E7HK2RT2T>^NWW3*N9KF0[F)]!_0"N>U6WGUVZL8[U2CW/ ]LUK3C&]_Q_R);+_A7170-K-_\UY=L9D0](5;H /7&*ZB MD "@*HPH& /05!-?6MOQ+.BM_=SD_E64I2G*X](HL450_M/=\T5GP/)JQ;WEO= ^3("PZJ>&'U%)Q:!23)Z***D91N]&TZ^.ZXLXF?_ )Z ;7_[ MZ'-5/[%N[;_D'ZQ0Q:=JUW9W ZVMU\Q'_ 6Y_(UTU5;W3;/48]EW;I+C[K$?,OT/ M45:J='_7R%8I&[U6P^:\MTNX.\MJ"'7W*'K^!K0M+VVOH?-MIED7O@\CV([5 MFC2]4L^+#5BT0^[%=Q^9CVW @_GFL^[L=8\[[0-/@%S_ ,_%C/L8_P"\K##? MB:?+&74+LZFBN9L-;U&60P%(;B=/OP/F"8?@XBFM)VX5 M)UP&/H#T-1*G)#33-+O6VOW1]*Q.];:_='TK,H6BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH ;)&DL;1R(KHPPRL,@CWK+TO1!H]S*+2ZD&GN,K9 ML-RQ-GJAZ@?[-:U%-2:5@L9VO02W.B74$'F>9(NT>6<-U'0UR[?\)/9FY54D M=A(B>>O/F (-K 8/4]>/Q%=S15QJ++'),XX!4Y"[5 M&1T/-2Q7'B>>[>.17A5ID5RJ B-2W)7(]/<_A7844_:^2%RG&"37[2X@A@BN M&03DNS+D.I;DGCL/=^+;1[; M7(GO+VV@TZX#R"232UG"2#: N0".S^U%HK>3D$A/X3R<9Z9KJZ\J2 MPBUG5X;_ %2+4E%W*T%AJ$+K"$8YVG8F#V."Q/2O4+>-X;:*)Y6E=$"M(W5B M!U/UH EK&\2_\@^W_P"OVW_]&+3CXAMQK@TSRI>7\OS\#9YFW=M]>E1^)G5; M"W!8#_3+?J?^F@H KWEU'8V-Q=S'$<$;2,?8#-4LQX, MKG+'\!A1]*D^(FIQQZ-!IJ2#=?3!9-K#(C7EOZ#\:HV-_9R+;RW=W8PPP "W MAEF!2$#^(J/O/[FNNG3?L^;N9RDD[&S<7*2QMKNKJT5A;_-:6C#YI&[,P[L> MP[4[1(=3G:;4I85CO+O[TDP/[M/X45?0=SW-0:3!'K>K?VQ3;V'8?G75>=%_SU3_ +Z%3.2C[J_KR!)O4I_VB?]]"L7)LI12'U7N+&WN2&D3# MCHZG##\14OFQ?\]$_P"^A1YL7_/1/^^A23:V&U?J?\ ?0H\Z/\ YZI_WT*+Q[!9]RI_:D?_ #[7 M7_?JC^UK4??\Y/\ >A;_ JYYT?_ #U3_OH4GFQG_EJG_?0HO'L%I=R&+4+2 M=]D=PA;^Z3@_K5FJ\T=G<)ME$#CW(JK]E,'_ !YW_EC_ )YR,'7]>11:+VT# MWD3W^F6FI1A;F(,R\I(IPZ'U##D5E7&F:N;=K,RVFH6I^Z;M2)%_%>I]^M7_ M +7>Q_?AMI1ZQ38/Y&C^V8$XGBFA/?*@C\Q5QYUMJ)M=3&\SQ-HMFOF+;7<* MMR^69HE]^Y _.NAM-;UJ6W6:/3;*^A(^_9W?]&'7\:;!JEA<']U=PM[;L?SJ MW)H9,M96-[>Q+R\L46% ]1NQ MN_"M.QU"UU*W$]I,LB=#CJI]".H/L:>+BW P)H@!V#"LJ^TRTFN#>V5XEE?? M\]HV&']G7HPI>Z]-@U-NBN>7Q#^W.1^M7K+Q#I&H9% MMJ$#,.J,VUA^!YI.$D%S3HJ'[7;?\_$7_?8I1+_OL4 2T5%]JM_^>\7_ 'V*/M-O_P ]XO\ OL4 2T5% M]IM_^>\7_?8H^U6__/>+_OL4 2T4BNKKN1@R^H.:6@ HHHH **** "BBB@#S MWQI!##/+/K>FZ9>6).8GCF\B[3Z?WSGIBNETF&RUKPE!$3?36=Q&,?;"RS%< MY&[OFJ>J#POH6K"^O[9'U&[)96,33.0,9('.T#CICK70V5Y#J%G'=0;_ "I! ME=ZE3^1H X[1['P-!KD2:<5^VP3%8OGD*^9CD#/!.,UW->:>'M*>XURVN[>S MU5M(6;=;B::,1Q[=P5L??(&3@'UKTN@#(/A^V_MP:GYDN0WF>3GY/,V[=WUQ M5;Q-IMG=1V1_=JHFE>'["S6.1+0)#B)GE<=<="3WKPV=LAAEO_M"Q MI*%8@P["DRSP2FSC!A)( '#9&.?7K6M10!G_P!A:7_SX0?]\U%;^&]) MMXR@LXV!=GRPR>23CZ(O#NHZMJDCVL$5N/)=/M(D'[P,!P5QD-QC.<8K.3PGK#%-T$06 M0>6N^56>T'F!]V0/F) (XP:I2:$XIF^+>SMOEU#0E4C_ ):0)O0_U%)!;^%_ MM4LH6!6E"@I*I4#&>@/UKIJCDABE&)(D?_>4&G>+W0K274S)?#^C7UHR+;0[ M'&-\?]"*G_L+2Q_RXP?]\TR31+<.9+1Y+.4]X6P#]5Z&F[M:MSL,=O>+V<-Y M9_$=/RHY4]F',UNBK=^#-"O9)7FL4!DC"$I\I&"3D$F M(C:%W ''IG&36WOUM^D-E'_O.S?RH\O7/^?BR_[]M_C5)R2M<5T^ABCX"-$L9$D?5KFU+?NT\ZY&#WP-W6NA\O7!S]HLC[&-O\ M:Y_Q+INNZBUO+'I\4EQ;AC#)%8E_&HV@\#YE((S3;:W@L;.&*_\*++$L:@7-IMG#@#@GH>?QK$?3=5@U6] MO-0A27SI892LJE1,4+<$\@ C';BN]\.(EOH5G:_:(I9(H@K>6^0#Z#V'3\* M.:2U:_KY K/9G.&7PC]HCDFTV>WV @K):.%.<=< ],?K3;M/ MXBXFCMW4Y5 MX0Z,#^5=U3##$3DQ(3[J*?M%Y_>.S/.8;C2=*C\N"ZT[4H%.=LZ-'+_WT!@_ MB*FMM3TW4[F-H_"EZQA)(,2?(V1[XR*[_P B'_GE'_WR*DI.<']D+/N>?7.M MVMC+_I?@J[BAS_K H;]!4FF:WX,<.OD-$7HP:SKO0=+OL M^?91%C_$HVG\Q34J;WC;T"S[F0Z>$+V%2+C3T5)%]2 MVATFS@MH[8QI=6DY4ERI 9E;D 9)PO4FIDH;Q8U?J=O;OIFE:;=7=G(LEL7+ MD0N&&[@;5Q[X_.DCU^**.5M11;0QL%QYHDSGH..0>#QBLS3=-_L[1]5DU6U2 MW@G92;>!MVT+&J9&,(M*4,?M:D+C)521DC('3TH_X2+2O(,_VL>6" 6VMQD9';IBH([#2$CBB6 MX&'D$B#S>2<%?ZFJ\^CZ+,#F\90NV-ML_HNT _A3Y8>8>\:*Z]IC2M&+M=P. M#P<=0.N,=Q5V"XBN8O-A<.F2N1Z@X/Z@UDW'AVW?3I(+8_,T;HID8E<-C)X^ MG%:EG;)9V<-LA)6) N3U/N?"TU!GE,T8^O2LKX@WWV-[ M2PP"U<[99Y;?^$9LA]E2V4)A41"H*YX;!Y&1S MSZT <1X?AM/^$KMY8;.TCW3,X*6]TK<@\_,=N?K7ITL@AA>0J[!1G:BY)^@[ MUYEH\6HP>,K>VGOH1(\YF:?^T=_VE5!5P(L\9XXP -M>H4 VM MKI/):/?/:2Q!'A4K\N23G<3_ XZ5;\0WULCV%HTH%P][;E4P>1Y@K5^P6?V MO[7]D@^T_P#/;RQO_/K5+7_^/:S_ .OZW_\ 1BT :M%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4UW6-&=V"JHR68X IU8?C)'E\%ZS&B%W:SD M4#))VF@#5M[VUO-WV:YAGV]?*D#8_*IZ\PCGLTN[/4/#ME)&+33)?MTEI;; MQ*KL7& &8-D^U16?B'6K33]2U(WUQ=6>G207!4D.9HF0^8H;:,D''3H>] 'J ME%>7ZAJVOV#:9-/?W4DDL*S-:Q+L9F9\[5RN'PI VY!%>H4 %%%% !1110 4 M444 ! (P1D50GT:PN&WFW5)/[\1V-^E7Z*:;6PFD]S*^R:G:L$A _(\4>ZP]XTZ*RO M)U>UYBN8KQ!_!,NQOS'%*NMQ1,$OH);-NF9!E#]&'%'(^FH.^M) M?N7,+?1Q4ZNK?=8'Z&ILT5=%>_M%O[&6U=BJR#!(&:I3Z##(7,+^06@$*[4! MVX;<3SZ]*T;B=;:W>9P2JC)Q4$>J6<@&)E7+F,!N,D'%5%RMH)M=3,A\+01Q MNIG)+# (0#;\^_CT]*;+X62:*.-[D$1,WE_N1C!!!!]3SUK7M[^WN8D=7 +D M *3R">@JU3CVI(1$&?R% 'F>@C3?\ A(;-88-4 M>'[6AAN)4B5-H5O+&<[L9W'IDGZ5ZS7E&C:EIU[XBTB[0Z-(9;EXX;*VD;SK M?.X[S\VUL<_P\;N*]4E,BQ.8D#R ?*I. 3]: 'UE:_\ \>UG_P!?UO\ ^C%K M&67Q#+XST^2ZLIH;$1NA$,H:+.W[S=\YP!D5KZNEUK0+!?0^;$KA]F]@"1R,X/(]CQ5RB@ Z4444 %%%% !1110 4444 M%%%% !1110 4444 %(5#*58 @]0:6B@"I)I6GR_?L;<_]LQ2VVFV=G(9+>!8 MV88.TGI]*M44^9VM<7*B*X@6YMWABB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9 end GRAPHIC 62 gexyhn0lyczh000038.jpg GRAPHIC begin 644 gexyhn0lyczh000038.jpg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kod-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - The Company link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Property and Equipment, Net link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Accrued Liabilities and Other Current Liabilities link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Marketable Securities link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Preferred Stock link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Common Stock link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Net Loss per Share Attributable to Common Stockholders link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - 401(k) Plan link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Liability Related to Sale of Future Royalties link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Selected Quarterly Financial Data (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Property and Equipment, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Accrued Liabilities and Other Current Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Marketable Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Common Stock (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - The Company - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Accrued Liabilities and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Fair Value Measurements - Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Marketable Securities - Summary of Marketable Securities Held (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Marketable Securities - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Details)2 link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Commitments and Contingencies - Summary of Lessee, Weighted Average Remaining Lease Term and Weighted Average Discount Rates (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Income Taxes - Components of Loss before Income Taxes (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate to Statutory U.S. Federal Rate (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Income Taxes - Summary of Unrecognized Tax Benefits Amounts (Details) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Preferred Stock - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Common Stock - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity Under 2018 Plan and 2015 Plan (Details) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Stock-Based Compensation - Fair Value of Employee Stock Options Estimated Using Weighted-average Assumptions (Details) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Stock-Based Compensation - Fair Value of Non-employee Stock Options Estimated Using Weighted-average Assumptions (Details) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Stock-Based Compensation - Summary of Restricted Shares (Details) link:calculationLink link:presentationLink link:definitionLink 100620 - Disclosure - Stock-Based Compensation - Fair Value of Performance-based Stock Options Estimated Using Weighted-average Assumptions (Details) link:calculationLink link:presentationLink link:definitionLink 100630 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Classified in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) link:calculationLink link:presentationLink link:definitionLink 100640 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) link:calculationLink link:presentationLink link:definitionLink 100650 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100660 - Disclosure - 401(k) Plan - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100670 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100680 - Disclosure - Selected Quarterly Financial Data - Schedule of Quarterly Financial Information (Unaudited) (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 64 kod-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 65 kod-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 66 kod-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Available for sale debt securities accumulated gross unrealized gain before tax, current. Available for sale debt securities accumulated gross unrealized loss before tax current. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Interactive Data Current Entity Interactive Data Current Document Annual Report Document Annual Report Document Transition Report Document Transition Report Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Public Float Entity Public Float Liability related to sale of future royalties. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Marketable securities Marketable Securities Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Marketable securities Marketable Securities Noncurrent Restricted cash Restricted Cash Noncurrent Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use asset Operating Lease Right Of Use Asset Other assets Other Assets Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued and other current liabilities Accrued Liabilities Current Operating lease liability Operating Lease Liability Current Total current liabilities Liabilities Current Operating lease liability, net of current portion Operating Lease Liability Noncurrent Liability related to sale of future royalties Liability Related To Sale Of Future Royalties Other liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 7) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2020 and 2019 Preferred Stock Value Common stock, $0.0001 par value, 490,000,000 shares authorized at December 31, 2020 and 2019; 51,112,302 and 44,413,404 shares issued and outstanding at December 31, 2020 and 2019, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive income Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred Stock, shares issued Preferred Stock Shares Issued Preferred Stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Operating expenses Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Interest income Investment Income Interest Interest expense (includes $nil, $nil and $3,030 attributable to related parties for the years ended December 31, 2020, 2019 and 2018, respectively) Interest Expense Other income (expense), net (includes $49, $nil, and $2,736 expenses attributable to related parties for the years ended December 31, 2020, 2019, and 2018, respectively) Other Nonoperating Income Expense Loss on extinguishment of debt (includes $1,587 attributable to related parties for the year ended December 31, 2018) Gains Losses On Extinguishment Of Debt Net loss Net Income Loss Net loss per common share, basic and diluted Earnings Per Share Basic And Diluted Weighted-average common shares outstanding used in computing net loss per common share, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Other comprehensive income Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract] Change in unrealized gains related to available-for-sale debt securities, net of tax Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent Total other comprehensive income Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Comprehensive loss Comprehensive Income Net Of Tax Amount of income (expense) related to non operating activities, classified as other attributable to related parties. Loss on extinguishment of debt attributable to related parties. Interest expense attributable to related parties Interest Expense Related Party Other income (expense) attributable to related parties Other Non Operating Income Expense Attributable To Related Parties Loss on extinguishment of debt attributable to related parties Loss On Extinguishment Of Debt Attributable To Related Parties Common stock issued upon conversion of preferred stock, shares. Common stock issued upon conversion of preferred stock, value. Conversion of redeemable convertible preferred stock warrant into common stock Warrants. Issuance of common stock upon exercise of common stock warrants. Issuance of common stock upon exercise of common stock warrants, shares. Common stock issued upon conversion of convertible notes, value. Common stock issued upon conversion of convertible notes, shares. Vesting of restricted stock units, net of taxes withheld. Vesting of restricted stock units net of taxes withheld shares. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Redeemable Convertible Preferred Stock Redeemable Convertible Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Beginning Balance Redeemable convertible preferred stock, shares outstanding, beginning balance Temporary Equity Shares Outstanding Redeemable convertible preferred stock, beginning balance Temporary Equity Carrying Amount Attributable To Parent Beginning balance, shares Shares Outstanding Issuance of common stock upon exercise of stock options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon exercise of stock options, shares Stock Issued During Period Shares Stock Options Exercised Issuance of restricted stock awards Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures Issuance of restricted stock awards, shares Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Vesting of restricted stock units, net of taxes withheld Vesting Of Restricted Stock Units Net Of Taxes Withheld Vesting of restricted stock units, net of taxes withheld, shares Vesting Of Restricted Stock Units Net Of Taxes Withheld Shares Conversion of redeemable convertible preferred stock into common stock Stock Issued During Period Value Conversion Of Convertible Securities Conversion of redeemable convertible preferred stock into common stock, shares Common Stock Issued Upon Conversion Of Preferred Stock Shares Conversion of redeemable convertible preferred stock into common stock Common Stock Issued Upon Conversion Of Preferred Stock Value Conversion of redeemable convertible preferred stock into common stock, shares Stock Issued During Period Shares Conversion Of Convertible Securities Conversion of redeemable convertible preferred stock warrants into common stock warrants Conversion Of Redeemable Convertible Preferred Stock Warrant Into Common Stock Warrants Issuance of common stock upon exercise of common stock warrants Issuance Of Common Stock Upon Exercise Of Common Stock Warrants Issuance of common stock upon exercise of common stock warrants, shares Issuance Of Common Stock Upon Exercise Of Common Stock Warrants Shares Conversion of 2017 and 2018 convertible notes into common stock Common Stock Issued Upon Conversion Of Convertible Notes Value Conversion of 2017 and 2018 convertible notes into common stock, shares Common Stock Issued Upon Conversion Of Convertible Notes Shares Issuance of common stock in connection with initial public offering/follow-on offering, net of offering costs Stock Issued During Period Value New Issues Issuance of common stock in connection with initial public offering/follow-on offering, net of offering costs, shares Stock Issued During Period Shares New Issues Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Other comprehensive income Net loss Ending Balance Redeemable convertible preferred stock, shares outstanding, ending balance Redeemable convertible preferred stock, ending balance Ending balance, shares Payments of offering costs on issuance of common stock in connection with initial public offering or follow on offering. Offering costs with respect to issuance of common stock in connection with initial public offering/follow-on offering Payments Of Offering Costs On Issuance Of Common Stock In Connection With Initial Public Offering Or Follow On Offering Change in fair value of redeemable convertible preferred stock warrant liability. Change in fair value of embedded derivative liability. Operating lease right of use asset amortization. Amortization of issuance costs. Increase decrease in operating lease liability. Deposits on property and equipment. Proceeds from sale of future royalties, net of issuance costs. Principal payments of tenant improvement allowance payable. Unpaid offering costs. Issuance of embedded derivative in connection to convertible notes. Statement Of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation Non-cash interest expense and amortization of debt discount and issuance cost Amortization Of Financing Costs And Discounts Change in fair value of redeemable convertible preferred stock warrant liability Change In Fair Value Of Redeemable Convertible Preferred Stock Warrant Liability Change in fair value of derivative instrument Change In Fair Value Of Embedded Derivative Liability Extinguishment of debt Stock-based compensation Share Based Compensation Amortization (accretion) of premium (discount) on marketable securities Accretion Amortization Of Discounts And Premiums Investments Amortization of operating lease right-of-use asset Operating Lease Right Of Use Asset Amortization Amortization of issuance costs Amortization Of Issuance Costs Changes in assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid expense and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Other assets Increase Decrease In Other Operating Assets Accounts payable Increase Decrease In Accounts Payable Accrued and other current liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Operating lease liability Increase Decrease In Operating Lease Liability Other liabilities Increase Decrease In Other Operating Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities Net Cash Provided By Used In Investing Activities [Abstract] Purchase of property and equipment Payments To Acquire Property Plant And Equipment Deposits on property and equipment Deposits On Property And Equipment Purchases of marketable securities Payments To Acquire Marketable Securities Maturities of marketable securities Proceeds From Sale And Maturity Of Marketable Securities Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock in connection with offering, net of offering costs Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock upon option exercise Proceeds From Stock Options Exercised Payments for restricted stock units, net of taxes withheld Payments Related To Tax Withholding For Share Based Compensation Proceeds from issuance of convertible notes (includes $9,560 from related parties for the years ended December 31, 2018) Proceeds From Notes Payable Debt issuance cost Payments Of Debt Issuance Costs Proceeds from sale of future royalties, net of issuance costs Proceeds From Sale Of Future Royalties Net Of Issuance Costs Principal payments of capital lease Repayments Of Debt And Capital Lease Obligations Principal payments of tenant improvement allowance payable Principal Payments Of Tenant Improvement Allowance Payable Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Cash, cash equivalents and restricted cash, at beginning of year Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents and restricted cash, at end of year Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Supplemental disclosures of non-cash investing and financing information: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Operating lease right-of-use asset obtained in exchange for operating lease liability Right Of Use Asset Obtained In Exchange For Operating Lease Liability Purchase of property and equipment under accounts payable Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 Unpaid offering costs Unpaid Offering Costs Offering costs paid in restricted stock awards Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction Derivative instrument related to convertible notes Issuance Of Embedded Derivative The cash inflow from issuance of convertible notes to related parties. Proceeds from issuance of convertible notes Proceeds From Issuance Of Convertible Notes To Related Parties Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] The entire disclosure for the company. Organization Consolidation And Presentation Of Financial Statements [Abstract] The Company The Company [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Property Plant And Equipment [Abstract] Property and Equipment, net Property Plant And Equipment Disclosure [Text Block] Accounts Payable And Accrued Liabilities Current [Abstract] Accrued Liabilities and Other Current Liabilities Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Investments Debt And Equity Securities [Abstract] Marketable Securities Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Equity [Abstract] Preferred Stock Preferred Stock [Text Block] Common Stock Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Earnings Per Share [Abstract] Net Loss per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Compensation And Retirement Disclosure [Abstract] 401(k) plan Pension And Other Postretirement Benefits Disclosure [Text Block] Liability related to sale of future royalties. Liability related to sale of future royalties. Liability Related To Sale Of Future Royalties [Abstract] Liability related to Sale of Future Royalties Liability Related To Sale Of Future Royalties [Text Block] Quarterly Financial Information Disclosure [Abstract] Selected Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Reclassification Prior Period Reclassification Adjustment Description Principles of Consolidation Consolidation Policy [Text Block] Segments Segment Reporting Policy Policy [Text Block] Use of Estimates Use Of Estimates Risk and uncertainties. Risk and Uncertainties Risk And Uncertainties Policy [Text Block] Concentration of Credit Risk Concentration Risk Credit Risk Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Marketable Securities Marketable Securities Policy Restricted Cash Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Fair Value Measurements Fair Value Of Financial Instruments Policy Leases Lessee Leases Policy [Text Block] Property and Equipment, Net Property Plant And Equipment Policy [Text Block] Impairment of Long-Lived Assets Impairment Or Disposal Of Long Lived Assets Policy [Text Block] Research and Development Expenses Research And Development Expense Policy Accrued research and development. Accrued Research And Development Accrued Research And Development Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Income Taxes Income Tax Policy [Text Block] Comprehensive Loss Comprehensive Income Policy Policy [Text Block] Liability related to sale of future royalties. Liability related to Sale of Future Royalties Liability Related To Sale Of Future Royalties Policy [Text Block] Credit Losses – Available-for-Sale Debt Securities Credit Loss Financial Instrument Policy [Text Block] Net Loss per Share Attributable to Common Stockholders Earnings Per Share Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Summary of Property and Equipment, net Property Plant And Equipment [Text Block] Schedule of accrued liabilities and other current liabilities. Schedule of Accrued Liabilities and Other Current Liabilities Schedule Of Accrued Liabilities And Other Current Liabilities Table [Text Block] Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Summary of Marketable Securities Held Marketable Securities [Text Block] Summary of Maturities of Operating Lease Liabilities Lessee Operating Lease Liability Maturity Table [Text Block] Summary of Lessee, Weighted Average Remaining Lease Term and Weighted Average Discount Rates Lease Cost Table [Text Block] Schedule of Provision (Benefit) for Income Taxes Schedule Of Components Of Income Tax Expense Benefit Table [Text Block] Components of Loss before Income Taxes Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block] Components of Deferred Tax Assets Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Schedule of Reconciliation of Effective Tax Rate to Statutory U.S. Federal Rate Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Summary of Unrecognized Tax Benefits Amounts Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block] Schedule of common stock reserved for future issuance. Schedule of Common Stock Reserved for Future Issuances Schedule Of Common Stock Reserved For Future Issuance Table [Text Block] Summary of Stock Options Activity Under 2018 Plan and 2015 Plan Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Schedule of share-based payment award, employee stock options, valuation assumptions. Fair Value of Employee Stock Options Estimated Using Weighted-average Assumptions Schedule Of Share Based Payment Award Employee Stock Options Valuation Assumptions Table [Text Block] Schedule of share-based payment award, non-employee stock options, valuation assumptions. Fair Value of Non-Employee Stock Options Estimated Using Weighted-average Assumptions Schedule Of Share Based Payment Award Non Employee Stock Options Valuation Assumptions Table [Text Block] Summary of Restricted Shares Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block] Schedule of share-based payment award, performance based awards and RSUs, valuation assumptions. Fair Value of Performance Based Awards and RSUs Estimated Using Weighted-average Assumptions Schedule Of Share Based Payment Award Performance Based Awards And R S Us Valuation Assumptions Table [Text Block] Summary of Stock-based Compensation Classified in Condensed Consolidated Statements of Operations and Comprehensive Loss Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block] Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Summary of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule of Quarterly Financial Information Schedule Of Quarterly Financial Information Table [Text Block] Gross proceeds from initial public offering. Organization consolidation and presentation of financial statements. Organization consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Initial Public Offering I P O [Member] Class of Warrant or Right Class Of Warrant Or Right [Axis] Class of Warrant or Right Class Of Warrant Or Right [Domain] Warrant Warrant [Member] Stock Conversion Description Conversion Of Stock By Unique Description [Axis] Conversion of Stock, Name Conversion Of Stock Name [Domain] Warrants exercised into convertible preferred shares then Converted. Warrants Exercised Into Convertible Preferred Shares Then Converted Warrants Exercised Into Convertible Preferred Shares Then Converted [Member] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] 2017 convertible notes. 2017 Convertible Notes Two Thousand Seventeen Convertible Notes [Member] 2018 convertible notes. 2018 Convertible Notes Two Thousand Eighteen Convertible Notes [Member] Follow-On Offering. Follow-On Offering Follow On Offering [Member] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Stock issued during period Share issued price, per share Shares Issued Price Per Share Gross proceeds from initial public offering Gross Proceeds From Initial Public Offering Net proceeds from initial public offering Proceeds From Issuance Initial Public Offering The number of shares of common stock issued from warrants exercised. Conversion of redeemable convertible preferred stock warrants into common stock warrants shares. Warrants exercised into common stock shares Warrants Exercised Conversion of preferred stock warrants into common stock warrants, shares Conversion Of Redeemable Convertible Preferred Stock Warrants Into Common Stock Warrants Shares Gross proceeds from issuance of common stock. Gross proceeds from issuance of common stock Gross Proceeds From Issuance Of Common Stock Net proceeds from issuance of common stock Summary of significant accounting policies. Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum Maximum [Member] Minimum Minimum [Member] Restricted Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Deposited with Financial Institution Bank Time Deposits [Member] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Laboratory equipment. Laboratory Equipment Laboratory Equipment [Member] Computer equipment and office equipment. Computer Equipment and Office Equipment Computer Equipment And Office Equipment [Member] Computer Software Software Development [Member] Furniture and Fixtures Furniture And Fixtures [Member] Minimum Related Party Transaction Related Party Transaction [Axis] Related Party Transaction Related Party Transaction [Domain] Baker bros advisors LP. Baker Bros. Advisors LP Baker Bros Advisors L P [Member] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Funding agreement. Funding Agreement Funding Agreement [Member] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] Accounting Standards Update 2016-02 Accounting Standards Update201602 [Member] ASU 2016-13 Accounting Standards Update201613 [Member] Summary of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Foreign currency transaction loss Foreign Currency Transaction Gain Loss Realized Number of reportable segments Number Of Reportable Segments Number of operating segments Number Of Operating Segments Long-term restricted cash Property and equipment estimated useful lives of assets Property Plant And Equipment Useful Life Impairment of long-lived assets Impairment Of Long Lived Assets Held For Use Unrecognized tax benefits, interest and penalties charged Unrecognized Tax Benefits Income Tax Penalties And Interest Expense Capped percentage of royalty on future net sales. Related party transaction ownership percentage threshold. Capped percentage of royalty on future net sales Capped Percentage Of Royalty On Future Net Sales Contractual obligation under funding agreement Contractual Obligation Ownership percentage threshold Related Party Transaction Ownership Percentage Threshold Derecognition of noncurrent deferred liabilities. Operating lease liability Operating Lease Liability Derecognition of noncurrent deferred liabilities Derecognition Of Noncurrent Deferred Liabilities Allowance for credit losses for available-for-sale debt securities Debt Securities Available For Sale Allowance For Credit Loss Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Leasehold Improvement Leasehold Improvements [Member] Computer Hardware Computer Equipment [Member] Computer software. Computer Software Computer Software [Member] Office Equipment Office Equipment [Member] Construction in Progress Construction In Progress [Member] Property Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Total property and equipment Property Plant And Equipment Gross Less: Accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Accrued clinical trial and related costs current. Accrued research and development current. Accrued legal fees current. Accrued clinical trial and related costs Accrued Clinical Trial And Related Costs Current Accrued research and development Accrued Research And Development Current Accrued salaries and benefits Employee Related Liabilities Current Accrued legal fees Accrued Legal Fees Current Accrued professional fees Accrued Professional Fees Current Accrued other liabilities Other Accrued Liabilities Current Total accrued and other current liabilities Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value Measurements Recurring [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Quoted Price in Active Markets (Level 1) Fair Value Inputs Level1 [Member] Significant Observable Inputs (Level 2) Fair Value Inputs Level2 [Member] Significant Unobservable Inputs (Level 3) Fair Value Inputs Level3 [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Money Market Funds Money Market Funds [Member] U.S. Treasury Securities U S Treasury Securities [Member] Corporate Notes Corporate Note Securities [Member] Significant Unobservable Inputs (Level 3) Repurchase agreement. Repurchase Agreement Repurchase Agreement [Member] Commercial Paper Commercial Paper [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Cash equivalents Cash And Cash Equivalents Fair Value Disclosure Marketable securities Available For Sale Securities Debt Securities Total Assets Fair Value Disclosure Transfers between hierarchy levels. Recurring Nonrecurring Fair Value Measurements Nonrecurring [Member] Liability measured at fair value Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Transfers of assets or liabilities between the fair value measurement levels Transfers Between Hierarchy Levels Available for sale debt securities amortized cost basis current. Available for sale securities amortized cost basis noncurrent. Available for sale debt securities accumulated gross unrealized gain before tax non current. Available for sale debt securities accumulated gross unrealized loss before tax non current. Marketable Securities [Table] Marketable Securities [Table] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Marketable Securities [Line Items] Marketable Securities [Line Items] Amortized Cost, current Available For Sale Debt Securities Amortized Cost Basis Current Unrealized Gains, current Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current Unrealized Losses, current Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current Fair Value, current Available For Sale Securities Debt Securities Current Amortized Cost, noncurrent Available For Sale Debt Securities Amortized Cost Basis Noncurrent Unrealized Gains, noncurrent Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Non Current Unrealized Losses, noncurrent Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current Fair Value, noncurrent Available For Sale Securities Debt Securities Noncurrent Marketable securities, contractual maturities Debt Securities Available For Sale Term Realized gains or losses recognized on sale or maturity of available-for-sale debt securities Debt Securities Available For Sale Realized Gain Loss Marketable securities with unrealized losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Number of leased buildings. Lessee operating lease initial term of contract. Lessee operating lease monthly rent expense. Annual rent year over year increase percentage. Lessee operating lease rent abatement. Tenant improvement allowance. Cash-collateralized letter of credit. Number of options to extend lease term. Commitments and contingencies disclosure. Commitments and contingencies disclosure. Commitments And Contingencies Disclosure [Table] Commitments And Contingencies Disclosure [Table] Lease Contractual Term Lease Contractual Term [Axis] Lease Contractual Term Lease Contractual Term [Domain] Lease Agreement on June two thousand and twenty Lease Agreement on June 2020 Lease Agreement On June Two Thousand And Twenty [Member] Building one. 1200 Page Mill Road in Palo Alto Building One [Member] Building two. 1250 Page Mill Road in Palo Alto Building Two [Member] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] California CALIFORNIA Lease agreement on April two thousand and twenty. Lease Agreement on April 2020 Lease Agreement On April Two Thousand And Twenty [Member] Office and laboratory space. Rottenstrasse 5 in Visp Office And Laboratory Space [Member] Switzerland SWITZERLAND Manufacturing agreement. Manufacturing Agreement Manufacturing Agreement [Member] Clinical and commercial supply. Clinical and Commercial Supply of Drug Substance Clinical And Commercial Supply [Member] Lease agreement on April and June two thousand and twenty Lease Agreement on April and June 2020 Lease Agreement On April And June Two Thousand And Twenty [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Lonza. Lonza Lonza [Member] Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] Service Agreements Service Agreements [Member] Purchase Commitment, Excluding Long-term Commitment Purchase Commitment Excluding Longterm Commitment [Axis] Purchase Commitment, Excluding Long-term Commitment Purchase Commitment Excluding Longterm Commitment [Domain] Purchase Commitments Purchase Commitment [Member] Cancellable Assignment and License Agreement Licensing Agreements [Member] Tenant improvement allowance agreement. Tenant Improvement Allowance Agreement Tenant Improvement Allowance Agreement [Member] Leasehold Improvements Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Tenant improvement allowance payable. Tenant Improvement Allowance Payable Tenant Improvement Allowance Payable [Member] Commitments And Contingencies Disclosure [Line Items] Commitments And Contingencies Disclosure [Line Items] Number of buildings leased Number Of Leased Buildings Lease area Area Of Land Initial lease term Lessee Operating Lease Initial Term Of Contract Monthly rent expense Lessee Operating Lease Monthly Rent Expense Annual rent year-over-year increase percentage Annual Rent Year Over Year Increase Percentage Total rent abatement Lessee Operating Lease Rent Abatement Lessee operating lease option to extend Lessee Operating Lease Option To Extend Tenant improvement allowance Tenant Improvement Allowance Number of options to extend lease term Number Of Options To Extend Lease Term Cash-collateralized letter of credit Cash Collateralized Letter Of Credit Automatic renewal interval. Automatic renewal interval Automatic Renewal Interval Lessee, operating lease, term of contract Lessee Operating Lease Term Of Contract Operating Lease Operating Lease Liabilities Payments Due [Abstract] 2021 Lessee Operating Lease Liability Payments Due Next Twelve Months 2022 Lessee Operating Lease Liability Payments Due Year Two 2023 Lessee Operating Lease Liability Payments Due Year Three 2024 Lessee Operating Lease Liability Payments Due Year Four 2025 Lessee Operating Lease Liability Payments Due Year Five Thereafter Lessee Operating Lease Liability Payments Due After Year Five Total undiscounted lease payments Lessee Operating Lease Liability Payments Due Less: imputed interest Lessee Operating Lease Liability Undiscounted Excess Amount Total operating lease liabilities Weighted-average remaining lease term (in years) Operating Lease Weighted Average Remaining Lease Term1 Weighted-average discount rate Operating Lease Weighted Average Discount Rate Percent Estimated capital contributions. Contractual obligation due in second year and after. Manufacturing agreement initial term. Manufacturing agreement term that can be extended. Estimated capital contribution Estimated Capital Contributions Annual suite fees payment for 2021 Contractual Obligation Due In Next Twelve Months Annual suite fees payment each year after 2021 Contractual Obligation Due In Second Year And After Manufacturing agreement initial term Manufacturing Agreement Initial Term Manufacturing agreement term that can be extended Manufacturing Agreement Term That Can Be Extended Lease liabilities Unrecorded unconditional purchase obligation cancellation fees. Contractual obligation period. Cancelable and/ or non-cancelable contractual obligations, total Unrecorded Unconditional Purchase Obligation Balance Sheet Amount Contractual obligation period Contractual Obligation Period Unrecorded unconditional purchase obligation, expenses recognized Unrecorded Unconditional Purchase Obligation Purchases Unrecorded unconditional purchase obligation, cancellation fees Unrecorded Unconditional Purchase Obligation Cancellation Fees Noncancellable purchase commitments, including potential cancellation fees. Noncancellable purchase commitments, including potential cancellation fees Noncancellable Purchase Commitments Including Potential Cancellation Fees Milestone payments and royalties on net sales that are not estimable. Milestone payments Unrecorded Milestone And Royalty Payments Improvements allowance payable to be drawn Debt Instrument Face Amount Interest rate Debt Instrument Interest Rate Stated Percentage Lease term Lease Expiration Date1 Debt instrument term Debt Instrument Term Current portion of tenant improvement allowance payable Other liabilities, non-current portion of tenant Improvement allowance payable Current: Current Income Tax Expense Benefit Continuing Operations [Abstract] Federal Current Federal Tax Expense Benefit State Current State And Local Tax Expense Benefit Foreign Current Foreign Tax Expense Benefit Total current Current Income Tax Expense Benefit Deferred: Deferred Income Tax Expense Benefit Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense Benefit State Deferred State And Local Income Tax Expense Benefit Foreign Deferred Foreign Income Tax Expense Benefit Total deferred Deferred Income Tax Expense Benefit Provision (Benefit) for income taxes Income Tax Expense Benefit United States Income Loss From Continuing Operations Before Income Taxes Domestic Foreign Income Loss From Continuing Operations Before Income Taxes Foreign Total loss before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Deferred tax assets tax operating lease liability. Deferred tax liabilities operating lease right-of-use asset. Deferred tax liabilities capitalized legal fees. Deferred tax assets: Deferred Tax Assets Net [Abstract] Net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Intangible assets Deferred Tax Assets Goodwill And Intangible Assets Research and development tax credits Deferred Tax Assets Tax Credit Carryforwards Research Stock-based compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Accruals Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Operating lease liability Deferred Tax Assets Tax Operating Lease Liability Property and equipment Deferred Tax Assets Property Plant And Equipment Total deferred tax assets Deferred Tax Assets Gross Valuation allowance Deferred Tax Assets Valuation Allowance Net deferred tax assets Deferred Tax Assets Net Deferred tax liabilities: Deferred Tax Liabilities Net [Abstract] Operating lease right-of-use asset Deferred Tax Liabilities Operating Lease Right Of Use Asset Capitalized legal fees Deferred Tax Liabilities Capitalized Legal Fees Total deferred tax liabilities Deferred Income Tax Liabilities Total net deferred tax assets Deferred Tax Assets Liabilities Net Income taxes. Income taxes. Income Taxes [Table] Income Taxes [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Federal Domestic Country [Member] State State And Local Jurisdiction [Member] Tax Credit Carryforward Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name Tax Credit Carryforward Name [Domain] Net operating loss not subject to expiration. Net Operating Loss Not Subject to Expiration Net Operating Loss Not Subject To Expiration [Member] California California Franchise Tax Board [Member] Income Taxes [Line Items] Income Taxes [Line Items] Increase in valuation allowance Valuation Allowance Deferred Tax Asset Change In Amount Operating loss carryforwards, expiration start year. Net operating loss Operating Loss Carryforwards Net operating loss carryforwards expiration start year Operating Loss Carryforwards Expiration Start Year Research and development credit carryforwards expiration start year. Research and development credit carryforwards expiration year description. Research and development credit carryforwards Tax credit carryforwards expiration start year Research And Development Credit Carryforwards Expiration Start Year Tax credit carryforward, expiration year Research And Development Credit Carryforwards Expiration Year Description Effective income tax rate reconciliation, sale of future royalties. Effective income tax rate reconciliation fair value adjustments. Effective income tax rate reconciliation extinguishment of convertible note. Federal statutory income tax rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate State taxes Effective Income Tax Rate Reconciliation State And Local Income Taxes Foreign tax rate differential Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential Change in valuation allowance Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Stock-based compensation Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost Research tax credit Effective Income Tax Rate Reconciliation Tax Credits Research Other Effective Income Tax Rate Reconciliation Other Adjustments Sale of future royalties Effective Income Tax Rate Reconciliation Sale Of Future Royalties Section 162(m) Effective Income Tax Rate Reconciliation Deductions Fair value adjustments Effective Income Tax Rate Reconciliation Fair Value Adjustments Extinguishment of convertible note Effective Income Tax Rate Reconciliation Extinguishment Of Convertible Note Provision for income taxes Effective Income Tax Rate Continuing Operations Unrecognized tax benefits at beginning of period Unrecognized Tax Benefits Increases related to prior year tax positions Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions Increases related to current year tax positions Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Unrecognized tax benefits at end of period Income tax examination, number of periods open for examination. Number of periods open for examination Income Tax Examination Number Of Periods Open For Examination Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Class Of Stock [Line Items] Class Of Stock [Line Items] Common stock, number of votes per share. Common stock, number of vote per share Common Stock Number Of Votes Per Share Warrant Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Stock options outstanding and release of restricted shares. Stock Options Outstanding and Release of Restricted Shares Stock Options Outstanding And Release Of Restricted Shares [Member] Two thousand eighteen equity incentive plan. 2018 Equity Incentive Plan Two Thousand Eighteen Equity Incentive Plan [Member] Two thousand eighteen employee share purchase plan. 2018 Employee Share Purchase Plan Two Thousand Eighteen Employee Share Purchase Plan [Member] Common stock reserved for future issuances Common Stock Capital Shares Reserved For Future Issuance Share based compensation arrangement by share based payment award options outstanding period increase decrease percentage. Exercise price must be equal to at least 110% of the fair market value of the common stock on the grant date. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Incentive stock options. Incentive Stock Options Incentive Stock Options [Member] Incentive stock options granted to a greater than 10% stockholder. ISO Granted to a Greater than 10% Stockholder Incentive Stock Options Granted To Greater Than Ten Percent Stockholder [Member] Employee Stock Options Employee Stock Option [Member] Non-employee stock option. Non-employee Stock Options Non Employee Stock Option [Member] Options granted to non employees. Options Granted to Non-employees Options Granted To Non Employees [Member] Restricted Stock Awards (RSAs) Restricted Stock [Member] Restricted Stock Units (RSUs) Restricted Stock Units R S U [Member] Performance based equity awards. Performance Based Equity Awards Performance Based Equity Awards [Member] Performance-based stock options. Performance-based Stock Options Performance Based Stock Options [Member] Performance-based restricted stock unit. Performance Based Restricted Stock Units Performance Based Restricted Stock Unit [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Common stock, shares reserved for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Number of shares increases annually Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Percentage of outstanding stock Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Percentage Options, periods granted Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Options exercise price, percentage of estimated fair value of shares on grant date Share Based Compensation Arrangement By Share Based Payment Award Exercise Price Awards vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 Number of shares available for grant Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Two thousand eighteen and two thousand fifteen equity incentive plan. 2018 Plan and 2015 Equity Incentive Plan Two Thousand Eighteen And Two Thousand Fifteen Equity Incentive Plan [Member] Number of Options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Exercised Forfeited or canceled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Ending balance Shares exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Forfeited or canceled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Ending balance Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term. Weighted Average Remaining Contractual Term (in years) Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Weighted Average Remaining Contractual Term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Share-based compensation arrangement by share-based payment award, options, aggregate intrinsic value. Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Stock options, weighted-average grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Expected term Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Dividends paid Payments Of Dividends Expected dividend payment Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments Total fair value of employee options vested Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 Stock-based compensation expense recognized Allocated Share Based Compensation Expense Stock options, granted Number of Restricted Shares Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward Unvested, beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Shares withheld related to net share settlement of RSUs Shares Paid For Tax Withholding For Share Based Compensation Canceled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Unvested, ending balance Shares withheld related to net share settlement of RSUs weighted average grant date fair value Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward Unvested, beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Shares withheld related to net share settlement of RSUs Shares Withheld Related To Net Share Settlement Of R S Us Weighted Average Grant Date Fair Value Canceled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Unvested, ending balance Stock-based compensation of total fair value vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value Stock units, granted Share-based compensation arrangement by share-based payment award, award vesting description. Vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Description Awards vested Weighted-average grant date fair value Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Weighted-average grant date fair value Common stock, shares reserved for issuance Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Research And Development Expense [Member] General and Administrative General And Administrative Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Total stock-based compensation Unrecognized stock-based compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Unrecognized stock-based compensation weighted-average period expected for recognition Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Weighted average number of shares outstanding adjustment. Earnings Per Share Basic And Diluted [Abstract] Numerator: Net Income Loss Available To Common Stockholders Basic [Abstract] Denominator: Weighted Average Number Of Shares Outstanding [Abstract] Weighted-average shares outstanding Weighted Average Number Of Shares Issued Basic Less: weighted-average unvested restricted shares and shares subject to repurchase Weighted Average Number Of Shares Outstanding Adjustment Net loss per share attributable to common stockholders, basic and diluted Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Unvested Restricted Shares Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Anti-dilutive securities excluded from the computation of diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Defined contribution plan, employer matching contribution cap on employee contribution limit. Defined Contribution Plan [Table] Defined Contribution Plan [Table] Income Tax Authority, Name Income Tax Authority Name [Axis] Income Tax Authority, Name Income Tax Authority Name [Domain] IRS Internal Revenue Service I R S [Member] Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Plan name Description Of Defined Contribution Pension And Other Postretirement Plans Defined Contribution Plan, Plan Name [Extensible List] Defined Contribution Plan Plan Name Extensible List Employer matching contribution, percent of match Defined Contribution Plan Employer Matching Contribution Percent Of Match Defined contribution plan, employer matching contribution cap on employee contribution limit Defined Contribution Plan Employer Matching Contribution Cap On Employee Contribution Limit Expense related to matching contributions Defined Contribution Plan Cost Recognized Related party transaction ownership percentage. Percentage of repurchase of royalties. Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Capped percentage of royalty on future net sales Ownership percentage Related Party Transaction Ownership Percentage Percentage of repurchase of royalties Percentage Of Repurchase Of Royalties Funds payable upon enrollment of patients. Percentage of patients to be enrolled. Proceeds from sale of future royalties Funds to be payable upon enrollment of patients Funds Payable Upon Enrollment Of Patients Percentage of patients to be enrolled Percentage Of Patients To Be Enrolled Interest expense, liability related to sale of future royalties. Liability related to sale of future royalties Interest expense, liability related to sale of future royalties Interest Expense Liability Related To Sale Of Future Royalties EX-101.PRE 67 kod-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 68 kod-10k_20201231_htm.xml IDEA: XBRL DOCUMENT 0001468748 2020-01-01 2020-12-31 0001468748 2021-02-19 0001468748 2020-06-30 0001468748 2020-12-31 0001468748 2019-12-31 0001468748 2019-01-01 2019-12-31 0001468748 2018-01-01 2018-12-31 0001468748 us-gaap:RedeemableConvertiblePreferredStockMember 2017-12-31 0001468748 us-gaap:CommonStockMember 2017-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001468748 us-gaap:RetainedEarningsMember 2017-12-31 0001468748 2017-12-31 0001468748 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001468748 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001468748 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001468748 us-gaap:CommonStockMember 2018-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001468748 us-gaap:RetainedEarningsMember 2018-12-31 0001468748 2018-12-31 0001468748 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001468748 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001468748 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001468748 us-gaap:CommonStockMember 2019-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001468748 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001468748 us-gaap:RetainedEarningsMember 2019-12-31 0001468748 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001468748 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001468748 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001468748 us-gaap:CommonStockMember 2020-12-31 0001468748 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001468748 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001468748 us-gaap:RetainedEarningsMember 2020-12-31 0001468748 us-gaap:CommonStockMember us-gaap:IPOMember 2018-01-01 2018-12-31 0001468748 us-gaap:CommonStockMember us-gaap:IPOMember 2018-12-31 0001468748 us-gaap:CommonStockMember us-gaap:IPOMember 2018-10-08 2018-10-09 0001468748 kod:WarrantsExercisedIntoConvertiblePreferredSharesThenConvertedMember us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember us-gaap:IPOMember 2018-10-09 0001468748 us-gaap:WarrantMember us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember us-gaap:IPOMember 2018-10-08 2018-10-09 0001468748 kod:TwoThousandSeventeenConvertibleNotesMember us-gaap:CommonStockMember us-gaap:IPOMember 2018-10-08 2018-10-09 0001468748 kod:TwoThousandEighteenConvertibleNotesMember us-gaap:CommonStockMember us-gaap:IPOMember 2018-10-08 2018-10-09 0001468748 us-gaap:CommonStockMember kod:FollowOnOfferingMember 2019-12-01 2019-12-31 0001468748 us-gaap:CommonStockMember kod:FollowOnOfferingMember 2020-11-01 2020-11-30 0001468748 us-gaap:CommonStockMember kod:FollowOnOfferingMember 2019-12-31 0001468748 us-gaap:CommonStockMember kod:FollowOnOfferingMember 2020-11-30 0001468748 kod:FollowOnOfferingMember 2019-12-01 2019-12-31 0001468748 kod:FollowOnOfferingMember 2020-11-01 2020-11-30 0001468748 srt:MaximumMember 2019-01-01 2019-12-31 0001468748 us-gaap:BankTimeDepositsMember 2020-12-31 0001468748 us-gaap:BankTimeDepositsMember 2019-12-31 0001468748 kod:LaboratoryEquipmentMember 2020-01-01 2020-12-31 0001468748 kod:ComputerEquipmentAndOfficeEquipmentMember 2020-01-01 2020-12-31 0001468748 us-gaap:SoftwareDevelopmentMember 2020-01-01 2020-12-31 0001468748 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001468748 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2019-12-01 2019-12-01 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2019-12-01 0001468748 srt:MinimumMember kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2019-12-01 0001468748 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001468748 us-gaap:AccountingStandardsUpdate201613Member 2020-12-31 0001468748 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001468748 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001468748 kod:LaboratoryEquipmentMember 2020-12-31 0001468748 kod:LaboratoryEquipmentMember 2019-12-31 0001468748 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001468748 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001468748 us-gaap:ComputerEquipmentMember 2020-12-31 0001468748 kod:ComputerSoftwareMember 2020-12-31 0001468748 kod:ComputerSoftwareMember 2019-12-31 0001468748 us-gaap:OfficeEquipmentMember 2020-12-31 0001468748 us-gaap:OfficeEquipmentMember 2019-12-31 0001468748 us-gaap:ConstructionInProgressMember 2020-12-31 0001468748 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001468748 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 kod:RepurchaseAgreementMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 kod:RepurchaseAgreementMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 kod:RepurchaseAgreementMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 kod:RepurchaseAgreementMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001468748 us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0001468748 us-gaap:FairValueMeasurementsNonrecurringMember 2019-12-31 0001468748 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember 2020-12-31 0001468748 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001468748 us-gaap:CommercialPaperMember 2019-12-31 0001468748 us-gaap:CorporateNoteSecuritiesMember 2019-12-31 0001468748 srt:MaximumMember 2020-12-31 0001468748 stpr:CA kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember 2020-06-01 2020-06-30 0001468748 stpr:CA kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember kod:BuildingOneMember 2020-06-30 0001468748 stpr:CA kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember kod:BuildingTwoMember 2020-06-30 0001468748 stpr:CA kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember kod:BuildingOneMember 2020-06-01 2020-06-30 0001468748 stpr:CA kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember kod:BuildingTwoMember 2020-06-01 2020-06-30 0001468748 stpr:CA kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember 2020-06-30 0001468748 stpr:CA kod:LeaseAgreementOnJuneTwoThousandAndTwentyMember 2020-07-01 0001468748 country:CH kod:LeaseAgreementOnAprilTwoThousandAndTwentyMember kod:OfficeAndLaboratorySpaceMember 2020-04-30 0001468748 country:CH kod:LeaseAgreementOnAprilTwoThousandAndTwentyMember kod:OfficeAndLaboratorySpaceMember 2020-04-01 2020-04-30 0001468748 srt:MaximumMember country:CH kod:LeaseAgreementOnAprilTwoThousandAndTwentyMember kod:OfficeAndLaboratorySpaceMember 2020-04-30 0001468748 kod:ClinicalAndCommercialSupplyMember kod:ManufacturingAgreementMember 2020-08-31 0001468748 kod:ClinicalAndCommercialSupplyMember kod:ManufacturingAgreementMember 2020-08-01 2020-08-31 0001468748 srt:MaximumMember kod:ClinicalAndCommercialSupplyMember kod:ManufacturingAgreementMember 2020-08-01 2020-08-31 0001468748 kod:LeaseAgreementOnAprilAndJuneTwoThousandAndTwentyMember 2020-12-31 0001468748 kod:LonzaMember us-gaap:ServiceAgreementsMember 2020-12-31 0001468748 kod:LonzaMember us-gaap:ServiceAgreementsMember 2019-12-31 0001468748 kod:LonzaMember us-gaap:ServiceAgreementsMember 2020-01-01 2020-12-31 0001468748 kod:LonzaMember us-gaap:ServiceAgreementsMember 2019-01-01 2019-12-31 0001468748 kod:LonzaMember us-gaap:ServiceAgreementsMember 2018-01-01 2018-12-31 0001468748 us-gaap:PurchaseCommitmentMember 2020-12-31 0001468748 us-gaap:PurchaseCommitmentMember 2019-12-31 0001468748 srt:MaximumMember us-gaap:LicensingAgreementsMember 2020-01-01 2020-12-31 0001468748 stpr:CA kod:TenantImprovementAllowanceAgreementMember us-gaap:LeaseholdImprovementsMember 2013-05-31 0001468748 stpr:CA kod:TenantImprovementAllowanceAgreementMember us-gaap:LeaseholdImprovementsMember 2013-05-01 2013-05-31 0001468748 stpr:CA us-gaap:LeaseholdImprovementsMember 2016-03-31 0001468748 stpr:CA us-gaap:LeaseholdImprovementsMember 2016-03-01 2016-03-31 0001468748 srt:MaximumMember kod:TenantImprovementAllowancePayableMember 2020-12-31 0001468748 srt:MaximumMember kod:TenantImprovementAllowancePayableMember 2019-12-31 0001468748 kod:TenantImprovementAllowancePayableMember 2020-12-31 0001468748 kod:TenantImprovementAllowancePayableMember 2019-12-31 0001468748 us-gaap:DomesticCountryMember 2020-12-31 0001468748 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001468748 us-gaap:DomesticCountryMember kod:NetOperatingLossNotSubjectToExpirationMember 2020-12-31 0001468748 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001468748 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001468748 us-gaap:CaliforniaFranchiseTaxBoardMember 2020-01-01 2020-12-31 0001468748 srt:MaximumMember 2019-12-31 0001468748 kod:StockOptionsOutstandingAndReleaseOfRestrictedSharesMember 2020-12-31 0001468748 kod:StockOptionsOutstandingAndReleaseOfRestrictedSharesMember 2019-12-31 0001468748 us-gaap:WarrantMember 2020-12-31 0001468748 us-gaap:WarrantMember 2019-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember 2020-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember 2019-12-31 0001468748 kod:TwoThousandEighteenEmployeeSharePurchasePlanMember 2020-12-31 0001468748 kod:TwoThousandEighteenEmployeeSharePurchasePlanMember 2019-12-31 0001468748 kod:IncentiveStockOptionsMember kod:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001468748 srt:MinimumMember kod:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001468748 srt:MaximumMember kod:IncentiveStockOptionsMember kod:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001468748 srt:MaximumMember kod:IncentiveStockOptionsGrantedToGreaterThanTenPercentStockholderMember kod:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001468748 kod:TwoThousandEighteenEquityIncentivePlanMember 2020-12-31 0001468748 kod:TwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember 2019-12-31 0001468748 kod:TwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001468748 kod:TwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember 2020-12-31 0001468748 kod:TwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember 2019-01-01 2019-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001468748 kod:NonEmployeeStockOptionMember 2020-01-01 2020-12-31 0001468748 kod:NonEmployeeStockOptionMember 2019-01-01 2019-12-31 0001468748 kod:NonEmployeeStockOptionMember 2018-01-01 2018-12-31 0001468748 kod:OptionsGrantedToNonEmployeesMember 2020-01-01 2020-12-31 0001468748 kod:OptionsGrantedToNonEmployeesMember 2019-01-01 2019-12-31 0001468748 kod:OptionsGrantedToNonEmployeesMember 2018-01-01 2018-12-31 0001468748 us-gaap:RestrictedStockMember 2019-12-31 0001468748 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001468748 us-gaap:RestrictedStockMember 2020-12-31 0001468748 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001468748 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001468748 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001468748 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001468748 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001468748 kod:PerformanceBasedEquityAwardsMember 2020-01-01 2020-12-31 0001468748 kod:PerformanceBasedEquityAwardsMember 2019-01-01 2019-12-31 0001468748 kod:PerformanceBasedStockOptionsMember 2019-01-01 2019-12-31 0001468748 kod:PerformanceBasedStockOptionsMember 2019-12-31 0001468748 kod:PerformanceBasedRestrictedStockUnitMember 2019-12-31 0001468748 kod:TwoThousandEighteenEmployeeSharePurchasePlanMember 2020-12-31 0001468748 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001468748 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001468748 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001468748 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001468748 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001468748 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001468748 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001468748 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001468748 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001468748 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001468748 us-gaap:InternalRevenueServiceIRSMember 2020-01-01 2020-12-31 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2020-02-04 2020-02-04 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2020-02-29 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2020-12-31 0001468748 kod:BakerBrosAdvisorsLPMember kod:FundingAgreementMember 2020-01-01 2020-12-31 0001468748 2020-01-01 2020-03-31 0001468748 2020-04-01 2020-06-30 0001468748 2020-07-01 2020-09-30 0001468748 2020-10-01 2020-12-31 0001468748 2019-01-01 2019-03-31 0001468748 2019-04-01 2019-06-30 0001468748 2019-07-01 2019-09-30 0001468748 2019-10-01 2019-12-31 shares iso4217:USD iso4217:USD shares kod:Segment pure kod:Building utr:sqft utr:sqm iso4217:CHF kod:Vote false FY 0001468748 --12-31 P5Y P3Y kod:RetirementAndSavingsPlanMember 2018-10-31 2023-10-31 P9Y6M P3Y9M18D P8Y8M23D P8Y25D P6Y P5Y9M10D P6Y21D P5Y6M21D P6Y29D P9Y3M18D P6Y3M21D 10-K true 2020-12-31 2020 false 001-38682 KODIAK SCIENCES INC. DE 27-0476525 1200 Page Mill Road Palo Alto CA 94304 650 281-0850 Common stock, par value $0.0001 KOD NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 1600000000 51162424 <p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:3.57%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions<span style="color:#000000;"> of the registrant’s definitive Proxy Statement relating to the 2021 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2020.</span></p> 944396000 211797000 24578000 124684000 3031000 2749000 972005000 339230000 11696000 6324000 140000 5136000 996000 73672000 1790000 10210000 5014000 1067347000 358866000 8646000 2619000 20402000 8658000 2374000 434000 31422000 11711000 75028000 1501000 99890000 256000 295000 206596000 13507000 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 490000000 490000000 51112302 51112302 44413404 44413404 5000 5000 1151920000 503475000 53000 10000 -291227000 -158131000 860751000 345359000 1067347000 358866000 107389000 37506000 18793000 28618000 11684000 7581000 136007000 49190000 26374000 -136007000 -49190000 -26374000 2902000 1568000 617000 3030000 25000 8000 5519000 49000 2736000 34000 265000 -4688000 1587000 -5479000 -133096000 -47365000 -41443000 -2.91 -1.25 -2.77 45741845 37853616 14976515 43000 10000 43000 10000 -133053000 -47355000 -41443000 12385154 50017000 7936434 1000 584000 -69323000 -68738000 47800 49000 49000 27500 -12385154 -50017000 12385154 1000 50016000 50017000 5000000 5000000 100000 6932969 1000 55732000 55733000 10542000 9400000 1000 83458000 83459000 2756000 2756000 -41443000 -41443000 36829857 4000 197595000 -110766000 86833000 662079 2287000 2287000 21467 -132000 -132000 1 19784000 6900000 1000 297615000 297616000 6110000 6110000 10000 10000 -47365000 -47365000 44413404 5000 503475000 10000 -158131000 345359000 704675 6248000 6248000 32984000 5972222 612016000 612016000 22001 -487000 -487000 30668000 30668000 43000 43000 -133096000 -133096000 51112302 5000 1151920000 53000 -291227000 860751000 -133096000 -47365000 -41443000 477000 538000 490000 0 0 5482000 0 0 2700000 0 0 1988000 -5479000 30668000 6110000 2665000 51000 241000 3731000 373000 49000 0 0 218000 168000 1995000 1814000 4511000 0 5224000 1569000 -2323000 11748000 4932000 -2105000 -146000 -383000 0 0 31000 -83428000 -39146000 -29031000 3814000 437000 78000 3184000 503000 86317000 150961000 198149000 14400000 104834000 -136998000 -581000 612016000 297616000 83755000 6248000 2287000 49000 487000 132000 9560000 33000000 0 0 140000 99643000 0 0 5000 48000 108000 38000 36000 85000 717377000 299687000 116471000 738783000 123543000 86859000 211937000 88394000 1535000 950720000 211937000 88394000 944396000 211797000 88254000 6324000 140000 140000 950720000 211937000 88394000 25000 8000 19000 75614000 2163000 803000 0 0 238000 459000 205000 0 0 91000 0 0 6603000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kodiak Sciences Inc. (the “Company”) is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high-prevalence ophthalmic diseases. The Company devotes substantially all of its time and efforts to performing research and development, raising capital and recruiting personnel. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial Public Offering </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company sold and issued 9,400,000 shares of common stock, including the underwriters’ full exercise of their over-allotment option, at a price to the public of $10.00 per share for gross proceeds of $94.0 million. The aggregate net proceeds to the Company from the IPO, inclusive of the partial over-allotment option exercise, were $83.5 million after deducting underwriting discounts and commissions and other offering costs. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO, all convertible preferred shares then outstanding automatically converted into 12,385,154 shares of common stock, 500,000 redeemable convertible preferred stock warrants automatically converted into common stock warrants and 100,000 of such warrants were exercised immediately following the closing of the IPO. The 2017 convertible notes converted into 2,637,292 shares of common stock and the 2018 convertible notes converted into 4,295,677 shares of common stock upon closing of the IPO. In connection with the IPO, the Company amended and restated its certificate of incorporation and bylaws. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Follow-On Offering </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company sold and issued 6,900,000 shares of common stock, including the underwriters’ full exercise of their over-allotment option, at a price to the public of $46.00 per share for gross proceeds of $317.4 million. The aggregate net proceeds to the Company from the follow-on offering were $297.6 million after deducting underwriting discounts and commissions and other offering costs.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company sold and issued 5,972,222 shares of common stock, including the underwriters’ full exercise of their over-allotment option, at a price to the public of $108.00 per share for gross proceeds of $645.0 million. The aggregate net proceeds to the Company from the follow-on offering were $612.0 million after deducting underwriting discounts and commissions and other offering costs.</p> 9400000 10.00 94000000.0 83500000 12385154 500000 100000 2637292 4295677 6900000 46.00 317400000 297600000 5972222 108.00 645000000.0 612000000.0 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The consolidated financial statements include the Company’s accounts and the accounts of Kodiak Sciences Financing Corporation and Kodiak Sciences China, the Company’s direct wholly owned subsidiaries, incorporated in the United States and Cayman Islands, respectively, and Kodiak Sciences GmbH and Kodiak Sciences Valais GmbH, the Company’s indirect wholly owned subsidiaries, both incorporated in Switzerland. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar. The aggregate foreign currency transaction loss included in determining net loss was $0.3 million, less than $0.1 million and $0.3 million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates and manages its business as one reportable and operating segment, which is the business of research and development of drugs for ophthalmic diseases. The chief operating decision maker reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and expenses during the reporting period. The impact of the ongoing COVID-19 pandemic continues to evolve. As a result, certain estimates and assumptions required increased judgment and carried a higher degree of variability and volatility, including but not limited to, the fair value of marketable securities, performance-based equity awards, and research and development accruals. As events continue to unfold and additional information becomes available, these estimates may change materially in future periods. Actual results could differ from those estimates.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risk and Uncertainties</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared a pandemic due to the global COVID-19 outbreak. The significant uncertainties caused by the ongoing COVID-19 pandemic may negatively impact the Company’s operations, liquidity, and capital resources and will depend on certain evolving developments, including the duration and spread of the outbreak, regulatory and private sector responses and the impact on employees and vendors including supply chain and clinical partners, all of which are uncertain and cannot be predicted. During this pandemic, the Company continues to work closely with clinical sites towards maximal patient safety and the lowest number of missed visits and study discontinuations. The Company has taken and continues to take proactive measures to maintain the integrity of its ongoing clinical studies. Despite these efforts, the ongoing COVID-19 pandemic could significantly impact clinical trial enrollment and completion of its clinical studies. The Company will continue to monitor the COVID-19 situation and its impact on the ability to continue the development of, and seek regulatory approvals for, the Company’s product candidates, and begin to commercialize any approved products.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s future results of operations involve a number of risks and uncertainties common to clinical-stage companies in the biotechnology industry. <span style="Background-color:#FFFFFF;color:#000000;">The Company’s product candidates are in development and the Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. </span>Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s potential drug candidates, uncertainty of market acceptance of any of the Company’s product candidates that receive regulatory approval, competition from new technological innovations, substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals, contract manufacturer and research organizations, and other suppliers.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that any of the Company’s product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approvals, it could have a materially adverse impact on the Company.<span style="Background-color:#FFFFFF;color:#000000;"> Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be on terms acceptable by the Company.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2020 and 2019, cash, cash equivalents and marketable securities were invested primarily in money market funds, <span style="color:#000000;">overnight repurchase agreements, U.S. treasury securities, commercial paper and corporate notes through highly rated financial institutions. Investments are restricted, in accordance with the Company’s investment policy, to a concentration limit per issuer or sector.</span><span style="font-size:12pt;color:#000000;"> </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with stated maturities of three months or less at the date of purchase to be cash equivalents. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests excess cash balances in marketable securities. The investments in marketable securities are classified as either held-to-maturity or available-for-sale based on facts and circumstances present at the time of purchase. Marketable securities with a remaining maturity date greater than one year are classified as non-current. The Company’s marketable securities consist of U.S. treasury securities, commercial paper, and corporate bonds. Marketable securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium or discount arising at purchase of marketable debt securities is amortized and/or accreted to other income (expense), net over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense), net.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is “other-than-temporary” and, if so, marks the investment to market through a charge to the Company’s statement of operations and comprehensive loss.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, and 2019, the Company had $6.3 million and $0.1 million, respectively, of long-term restricted cash deposited with a financial institution. The entire amount is held in separate bank accounts to support letter of credit agreements related to the Company’s U.S. corporate offices. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounting Standards Codification (“ASC”) 820, <span style="font-style:italic;">Fair Value Measurement</span>, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company's own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;">—Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;">—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;">—Unobservable inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and inputs to the model. </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities and other current liabilities, approximate fair value due to their relatively short maturities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is, or contains, a lease at inception and then classifies the lease as operating or financing based on the underlying terms and conditions of the contract. Leases with terms greater than one year are initially recognized on the balance sheet as right-of-use assets and lease liabilities based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term and in a similar economic environment of the applicable country or region. Variable lease payments are excluded from the right of use assets and operating lease liabilities and are recognized in the period in which the obligation for those payments is incurred.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment, Net</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over the estimated useful lives of assets, which is generally four years for laboratory equipment, three years for computer equipment and office equipment, five years for computer software and five to seven years for furniture and fixtures. Leasehold improvements are stated at cost and amortized over the shorter of the useful life of the assets or the length of the lease. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the assets. There have been no such impairments of long-lived assets in the years ended December 31, 2020 and 2019.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to research, design and development of products are charged to research and development expense as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, including stock-based compensation, laboratory supplies, outside services and allocated overhead, including rent, equipment, depreciation and utilities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Research and Development </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various agreements with various third parties, including clinical investigator sites, contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), to provide research and development activities. The Company’s accrued research and development costs are estimated based on the level of services performed, including the phase or completion of events, and contracted costs. Accrued clinical trial and related costs are estimated using data such as patient enrollment, clinical site activations or information provided by outside service providers regarding their actual costs incurred. Management determined accrual estimates through reports from and discussions with clinical personnel and outside service providers as to the progress of trials, or the services completed. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses or other assets until the services are rendered. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, <span style="font-style:italic;">Compensation-Stock </span>Compensation. The Company measures stock-based compensation expense for stock options and restricted stock units granted to its employees, directors and non-employees based on the estimated fair value of the awards on the grant date. The fair value of options is calculated using the Black-Scholes valuation model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The expense is recorded on a straight-line basis over the requisite service period, which is generally the vesting period, for the entire award.<span style="color:#000000;"> The Company accounts for forfeitures as they occur.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the adoption of Accounting Standards Update ("ASU") No. 2018-07, </span><span style="font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ("ASU 2018-07"), the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. After adoption of ASU 2018-07</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as of January 1, 2019</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the measurement date for non-employee awards is the date of grant without changes in the fair value of the award.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has certain stock options and restricted stock units that vest in conjunction with certain performance conditions. At each reporting date, the Company is required to evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon the Company's assessment of accomplishing each performance provision.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses (“NOLs”) and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists primarily of unrealized gains and losses on debt securities.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liability related to Sale of Future Royalties</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On </span><span style="color:#000000;">December 1, 2019, the Company and its subsidiary Kodiak Sciences GmbH entered into a funding agreement with Baker Bros. Advisors, LP (“BBA”), which holds more than 5% of the Company’s stock, pursuant to which BBA purchased the right to receive a capped 4.5% royalty on future net sales of KSI-301, the Company’s anti-VEGF antibody biopolymer conjugate therapy, in exchange for $225.0 million. Under the terms of the funding agreement, there is no obligation to repay any funding amount received, other than through the capped royalty payments on future product revenues. The Company recorded the funding amount paid by BBA as a </span><span style="Background-color:#FFFFFF;">liability on the consolidated balance sheet net of issuance costs</span><span style="color:#000000;">, in accordance with ASC 730, </span><span style="font-style:italic;color:#000000;">Research and Development</span><span style="color:#000000;">. Under ASC 730, the significant related party relationship between the Company and BBA creates an implicit obligation to repay the funding amount paid to the Company. Once royalty payments to BBA are determined to be probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest to accrete the liability on a prospective basis based on such estimates. If and when the Company makes royalty payments under the funding agreement, it would reduce the liability balance at such time. Refer to Note 14.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Credit Losses – Available-for-Sale Debt Securities</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For available-for-sale debt securities in an unrealized loss position, the Company will periodically assess its portfolio for impairment. The assessment first considers the intent or requirement to sell the security. If either of these criteria are met, the amortized cost basis will be written down to fair value through earnings. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If not met, the Company will evaluate whether the decline resulted from credit losses or other factors by considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share Attributable to Common Stockholders </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, the redeemable convertible preferred stock, preferred stock warrants, convertible notes, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. The Company’s participating securities do not have a contractual obligation to share in the Company’s losses. As such, the net loss is attributed entirely to common stockholders. Since the Company has reported net loss for all periods presented, diluted net loss per share is the same as basic net loss per common share for those periods. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent <span style="text-transform:uppercase;">a</span>ccounting <span style="text-transform:uppercase;">p</span>ronouncements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified effective date, unless otherwise discussed below. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, <span style="font-style:italic;">Leases</span> <span style="font-style:italic;">(Topic 842)</span>, which set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (<span style="font-style:italic;">i.e.,</span> lessees and lessors). In July 2018, the FASB issued ASU 2018-10, <span style="font-style:italic;">Leases (Topic 842), Codification Improvements</span>, and ASU 2018-11,<span style="font-style:italic;"> Leases (Topic 842), Targeted Improvements</span>. ASU 2018-10 clarified certain provisions and corrected unintended applications of the guidance such as the application of implicit rate, lessee reassessment of lease classification, and certain transition adjustments that should be recognized to earnings rather than to stockholders' equity. ASU 2018-11 provided an alternative transition method and practical expedient for separating contract components for the adoption of Topic 842. ASU 2016-02, ASU 2018-10, and ASU 2018-11 (collectively, "the new lease standards") superseded the previous leases standard, ASC 840 <span style="font-style:italic;">Leases</span>. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC 842 effective January 1, 2019 using the modified retrospective approach to recognize a cumulative-effect adjustment on the effective date and to not adjust financial information and disclosures required under the new lease standards for comparative prior periods. The Company did not elect for the package of practical expedients and assessed all contracts at the transition date. The Company did not utilize the practical expedient which allows the use of hindsight in determining lease term and assessing impairment in right-of-use assets. The Company elected to apply the practical expedient and accounted for each lease component and related non-lease component as one single component. The Company elected the practical expedient not to recognize leases with terms of one year or less on the balance sheet. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adoption of the new lease standards on January 1, 2019 resulted in the initial recognition of right-of-use asset of $2.2 million and operating lease liability of $2.3 million and derecognition of noncurrent deferred liabilities of $0.2 million related to the operating lease for the Company’s office and laboratory space in Palo Alto, California on the consolidated balance sheets with no material impact to the consolidated statements of operations, stockholders’ equity or cash flows. Refer to Note 7.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 362): Measurement of Credit Losses on Financial Statements</span> and ASU 2018-19, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments—Credit Losses</span>, <span style="Background-color:#FFFFFF;">which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. The Company assessed the </span>impact of ASU 2016-13 on its available-for-sale debt securities and determined there were no credit losses within the portfolio requiring an allowance upon adoption. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, <span style="font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements</span>, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB’s disclosure framework project. <span style="letter-spacing:-0.15pt;">Among the changes, entities will no longer be required to disclose the amount of and reasons for transfers between Levels 1 and 2 of the fair value hierarchy but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. </span>The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15, </span><span style="font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which clarifies the accounting for implementation, set-up, and other upfront costs incurred in cloud computing arrangements. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">New Accounting Pronouncements Not Yet Adopted </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </span>("ASU 2019-12"), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein, and early adoption is permitted. The Company has early adopted ASU 2019-12 in 2020; the effect was not material on the Company’s financial statements. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The consolidated financial statements include the Company’s accounts and the accounts of Kodiak Sciences Financing Corporation and Kodiak Sciences China, the Company’s direct wholly owned subsidiaries, incorporated in the United States and Cayman Islands, respectively, and Kodiak Sciences GmbH and Kodiak Sciences Valais GmbH, the Company’s indirect wholly owned subsidiaries, both incorporated in Switzerland. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar. The aggregate foreign currency transaction loss included in determining net loss was $0.3 million, less than $0.1 million and $0.3 million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></p> -300000 -100000 -300000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates and manages its business as one reportable and operating segment, which is the business of research and development of drugs for ophthalmic diseases. The chief operating decision maker reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</p> 1 1 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and expenses during the reporting period. The impact of the ongoing COVID-19 pandemic continues to evolve. As a result, certain estimates and assumptions required increased judgment and carried a higher degree of variability and volatility, including but not limited to, the fair value of marketable securities, performance-based equity awards, and research and development accruals. As events continue to unfold and additional information becomes available, these estimates may change materially in future periods. Actual results could differ from those estimates.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risk and Uncertainties</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared a pandemic due to the global COVID-19 outbreak. The significant uncertainties caused by the ongoing COVID-19 pandemic may negatively impact the Company’s operations, liquidity, and capital resources and will depend on certain evolving developments, including the duration and spread of the outbreak, regulatory and private sector responses and the impact on employees and vendors including supply chain and clinical partners, all of which are uncertain and cannot be predicted. During this pandemic, the Company continues to work closely with clinical sites towards maximal patient safety and the lowest number of missed visits and study discontinuations. The Company has taken and continues to take proactive measures to maintain the integrity of its ongoing clinical studies. Despite these efforts, the ongoing COVID-19 pandemic could significantly impact clinical trial enrollment and completion of its clinical studies. The Company will continue to monitor the COVID-19 situation and its impact on the ability to continue the development of, and seek regulatory approvals for, the Company’s product candidates, and begin to commercialize any approved products.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s future results of operations involve a number of risks and uncertainties common to clinical-stage companies in the biotechnology industry. <span style="Background-color:#FFFFFF;color:#000000;">The Company’s product candidates are in development and the Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. </span>Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s potential drug candidates, uncertainty of market acceptance of any of the Company’s product candidates that receive regulatory approval, competition from new technological innovations, substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals, contract manufacturer and research organizations, and other suppliers.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that any of the Company’s product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approvals, it could have a materially adverse impact on the Company.<span style="Background-color:#FFFFFF;color:#000000;"> Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be on terms acceptable by the Company.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2020 and 2019, cash, cash equivalents and marketable securities were invested primarily in money market funds, <span style="color:#000000;">overnight repurchase agreements, U.S. treasury securities, commercial paper and corporate notes through highly rated financial institutions. Investments are restricted, in accordance with the Company’s investment policy, to a concentration limit per issuer or sector.</span><span style="font-size:12pt;color:#000000;"> </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with stated maturities of three months or less at the date of purchase to be cash equivalents. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests excess cash balances in marketable securities. The investments in marketable securities are classified as either held-to-maturity or available-for-sale based on facts and circumstances present at the time of purchase. Marketable securities with a remaining maturity date greater than one year are classified as non-current. The Company’s marketable securities consist of U.S. treasury securities, commercial paper, and corporate bonds. Marketable securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium or discount arising at purchase of marketable debt securities is amortized and/or accreted to other income (expense), net over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense), net.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is “other-than-temporary” and, if so, marks the investment to market through a charge to the Company’s statement of operations and comprehensive loss.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, and 2019, the Company had $6.3 million and $0.1 million, respectively, of long-term restricted cash deposited with a financial institution. The entire amount is held in separate bank accounts to support letter of credit agreements related to the Company’s U.S. corporate offices. </p> 6300000 100000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounting Standards Codification (“ASC”) 820, <span style="font-style:italic;">Fair Value Measurement</span>, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company's own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;">—Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;">—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;">—Unobservable inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and inputs to the model. </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities and other current liabilities, approximate fair value due to their relatively short maturities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is, or contains, a lease at inception and then classifies the lease as operating or financing based on the underlying terms and conditions of the contract. Leases with terms greater than one year are initially recognized on the balance sheet as right-of-use assets and lease liabilities based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term and in a similar economic environment of the applicable country or region. Variable lease payments are excluded from the right of use assets and operating lease liabilities and are recognized in the period in which the obligation for those payments is incurred.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment, Net</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over the estimated useful lives of assets, which is generally four years for laboratory equipment, three years for computer equipment and office equipment, five years for computer software and five to seven years for furniture and fixtures. Leasehold improvements are stated at cost and amortized over the shorter of the useful life of the assets or the length of the lease. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.</p> P4Y P3Y P5Y P7Y <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the assets. There have been no such impairments of long-lived assets in the years ended December 31, 2020 and 2019.</p> 0 0 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to research, design and development of products are charged to research and development expense as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, including stock-based compensation, laboratory supplies, outside services and allocated overhead, including rent, equipment, depreciation and utilities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Research and Development </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various agreements with various third parties, including clinical investigator sites, contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), to provide research and development activities. The Company’s accrued research and development costs are estimated based on the level of services performed, including the phase or completion of events, and contracted costs. Accrued clinical trial and related costs are estimated using data such as patient enrollment, clinical site activations or information provided by outside service providers regarding their actual costs incurred. Management determined accrual estimates through reports from and discussions with clinical personnel and outside service providers as to the progress of trials, or the services completed. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses or other assets until the services are rendered. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, <span style="font-style:italic;">Compensation-Stock </span>Compensation. The Company measures stock-based compensation expense for stock options and restricted stock units granted to its employees, directors and non-employees based on the estimated fair value of the awards on the grant date. The fair value of options is calculated using the Black-Scholes valuation model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The expense is recorded on a straight-line basis over the requisite service period, which is generally the vesting period, for the entire award.<span style="color:#000000;"> The Company accounts for forfeitures as they occur.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the adoption of Accounting Standards Update ("ASU") No. 2018-07, </span><span style="font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ("ASU 2018-07"), the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. After adoption of ASU 2018-07</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as of January 1, 2019</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the measurement date for non-employee awards is the date of grant without changes in the fair value of the award.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has certain stock options and restricted stock units that vest in conjunction with certain performance conditions. At each reporting date, the Company is required to evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon the Company's assessment of accomplishing each performance provision.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses (“NOLs”) and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. </p> 0 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists primarily of unrealized gains and losses on debt securities.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liability related to Sale of Future Royalties</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On </span><span style="color:#000000;">December 1, 2019, the Company and its subsidiary Kodiak Sciences GmbH entered into a funding agreement with Baker Bros. Advisors, LP (“BBA”), which holds more than 5% of the Company’s stock, pursuant to which BBA purchased the right to receive a capped 4.5% royalty on future net sales of KSI-301, the Company’s anti-VEGF antibody biopolymer conjugate therapy, in exchange for $225.0 million. Under the terms of the funding agreement, there is no obligation to repay any funding amount received, other than through the capped royalty payments on future product revenues. The Company recorded the funding amount paid by BBA as a </span><span style="Background-color:#FFFFFF;">liability on the consolidated balance sheet net of issuance costs</span><span style="color:#000000;">, in accordance with ASC 730, </span><span style="font-style:italic;color:#000000;">Research and Development</span><span style="color:#000000;">. Under ASC 730, the significant related party relationship between the Company and BBA creates an implicit obligation to repay the funding amount paid to the Company. Once royalty payments to BBA are determined to be probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest to accrete the liability on a prospective basis based on such estimates. If and when the Company makes royalty payments under the funding agreement, it would reduce the liability balance at such time. Refer to Note 14.</span></p> 0.05 0.045 225000000.0 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Credit Losses – Available-for-Sale Debt Securities</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For available-for-sale debt securities in an unrealized loss position, the Company will periodically assess its portfolio for impairment. The assessment first considers the intent or requirement to sell the security. If either of these criteria are met, the amortized cost basis will be written down to fair value through earnings. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If not met, the Company will evaluate whether the decline resulted from credit losses or other factors by considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share Attributable to Common Stockholders </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, the redeemable convertible preferred stock, preferred stock warrants, convertible notes, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. The Company’s participating securities do not have a contractual obligation to share in the Company’s losses. As such, the net loss is attributed entirely to common stockholders. Since the Company has reported net loss for all periods presented, diluted net loss per share is the same as basic net loss per common share for those periods. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent <span style="text-transform:uppercase;">a</span>ccounting <span style="text-transform:uppercase;">p</span>ronouncements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified effective date, unless otherwise discussed below. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, <span style="font-style:italic;">Leases</span> <span style="font-style:italic;">(Topic 842)</span>, which set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (<span style="font-style:italic;">i.e.,</span> lessees and lessors). In July 2018, the FASB issued ASU 2018-10, <span style="font-style:italic;">Leases (Topic 842), Codification Improvements</span>, and ASU 2018-11,<span style="font-style:italic;"> Leases (Topic 842), Targeted Improvements</span>. ASU 2018-10 clarified certain provisions and corrected unintended applications of the guidance such as the application of implicit rate, lessee reassessment of lease classification, and certain transition adjustments that should be recognized to earnings rather than to stockholders' equity. ASU 2018-11 provided an alternative transition method and practical expedient for separating contract components for the adoption of Topic 842. ASU 2016-02, ASU 2018-10, and ASU 2018-11 (collectively, "the new lease standards") superseded the previous leases standard, ASC 840 <span style="font-style:italic;">Leases</span>. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC 842 effective January 1, 2019 using the modified retrospective approach to recognize a cumulative-effect adjustment on the effective date and to not adjust financial information and disclosures required under the new lease standards for comparative prior periods. The Company did not elect for the package of practical expedients and assessed all contracts at the transition date. The Company did not utilize the practical expedient which allows the use of hindsight in determining lease term and assessing impairment in right-of-use assets. The Company elected to apply the practical expedient and accounted for each lease component and related non-lease component as one single component. The Company elected the practical expedient not to recognize leases with terms of one year or less on the balance sheet. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adoption of the new lease standards on January 1, 2019 resulted in the initial recognition of right-of-use asset of $2.2 million and operating lease liability of $2.3 million and derecognition of noncurrent deferred liabilities of $0.2 million related to the operating lease for the Company’s office and laboratory space in Palo Alto, California on the consolidated balance sheets with no material impact to the consolidated statements of operations, stockholders’ equity or cash flows. Refer to Note 7.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 362): Measurement of Credit Losses on Financial Statements</span> and ASU 2018-19, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments—Credit Losses</span>, <span style="Background-color:#FFFFFF;">which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. The Company assessed the </span>impact of ASU 2016-13 on its available-for-sale debt securities and determined there were no credit losses within the portfolio requiring an allowance upon adoption. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, <span style="font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements</span>, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB’s disclosure framework project. <span style="letter-spacing:-0.15pt;">Among the changes, entities will no longer be required to disclose the amount of and reasons for transfers between Levels 1 and 2 of the fair value hierarchy but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. </span>The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15, </span><span style="font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which clarifies the accounting for implementation, set-up, and other upfront costs incurred in cloud computing arrangements. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">New Accounting Pronouncements Not Yet Adopted </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </span>("ASU 2019-12"), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein, and early adoption is permitted. The Company has early adopted ASU 2019-12 in 2020; the effect was not material on the Company’s financial statements. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"> </p> 2200000 2300000 200000 0 <p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Property and Equipment, net </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvement</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,285</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,125</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,229</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,306</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,170</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,771</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,136</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All property and equipment are maintained in the United States and Switzerland. Depreciation expense, including depreciation of assets under capital leases, was $0.5 million, $0.5 million and $0.5 million for the years ended December 31, 2020, 2019 and 2018, respectively.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvement</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,285</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,125</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,229</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,306</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,170</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,771</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,136</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1285000 1265000 3351000 1125000 214000 204000 31000 89000 79000 107000 94000 2229000 7306000 2767000 2170000 1771000 5136000 996000 500000 500000 500000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Accrued Liabilities and Other Current Liabilities </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities and other current liabilities consist of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial and related costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,119</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,056</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,082</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued salaries and benefits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,094</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,108</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued legal fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">253</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued and other current liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,658</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities and other current liabilities consist of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial and related costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,119</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,056</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,082</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued salaries and benefits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,094</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,108</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued legal fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">253</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued and other current liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,658</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> 11119000 4056000 3082000 838000 5094000 3108000 252000 302000 253000 195000 602000 159000 20402000 8658000 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Fair Value Measurements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917,485</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917,485</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,572</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,572</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917,485</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,578</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942,063</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,276</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,276</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreement</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,987</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,987</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,185</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,185</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,533</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,533</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,662</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,662</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,276</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,367</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">347,643</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2020, the fair value of the liability related to sale of future royalties is based on our current estimates of future royalties expected to be paid to BBA, which are considered Level 3 inputs. Refer to Note 14.</span><span style="font-size:12pt;color:#000000;"> </span><span style="Background-color:#FFFFFF;">There were no liabilities measured at fair value on a recurring and non-recurring basis as of December 31, 2019. </span><span style="color:#000000;">There were no transfers of assets or liabilities between the fair value measurement levels during the years ended December 31,</span><span style="Background-color:#FFFFFF;"> 2020 and 2019.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917,485</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917,485</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,572</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,572</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917,485</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,578</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942,063</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,276</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,276</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreement</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,987</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,987</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,185</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,185</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,533</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,533</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,662</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,662</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,276</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,367</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">347,643</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> 917485000 0 0 917485000 0 10006000 0 10006000 0 14572000 0 14572000 917485000 24578000 0 942063000 155276000 0 0 155276000 50000000 0 0 50000000 0 5987000 0 5987000 0 50185000 0 50185000 0 34533000 0 34533000 0 51662000 0 51662000 205276000 142367000 0 347643000 0 0 0 0 0 0 0 0 0 0 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Marketable Securities </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketable securities are classified as available-for-sale and consist of U.S. treasury securities, corporate notes and commercial paper. The fair value measurement data for marketable securities is obtained from independent pricing services. The Company validates the prices provided by the third-party pricing services by understanding the valuation methods and data sources used and analyzing the pricing data in certain instances. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the marketable securities (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,003</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,522</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,572</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, current</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,525</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,578</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,190</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,532</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,533</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,956</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,966</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, current</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,678</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,684</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,692</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,696</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, noncurrent</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,692</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All marketable securities held at December 31<span style="Background-color:#FFFFFF;">, 2020</span> had effective maturities of less than one year. There were no realized gains or losses recognized on the sale or maturity of available-for-sale debt securities during the year ended December 31<span style="Background-color:#FFFFFF;">, 2020</span> and as a result, the Company did not reclassify any amounts out of accumulated comprehensive loss. No marketable securities with unrealized losses as of December 31<span style="Background-color:#FFFFFF;">, 2020</span>. All marketable securities with unrealized losses as of December 31, 2019 have been in a loss position for less than twelve months and the loss is not material. These marketable securities were not considered to be other-than-temporarily impaired.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the marketable securities (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,003</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,006</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,522</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,572</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, current</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,525</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,578</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,190</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,532</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,533</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,956</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,966</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, current</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,678</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,684</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,692</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,696</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities, noncurrent</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,692</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> 10003000 3000 10006000 14522000 50000 14572000 24525000 53000 24578000 50190000 5000 50185000 34532000 1000 34533000 39956000 13000 3000 39966000 124678000 14000 8000 124684000 11692000 4000 11696000 11692000 4000 11696000 P1Y 0 0 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Commitments and Contingencies </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Palo Alto, California Leases</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, the Company entered into lease agreements for two buildings at 1200 and 1250 Page Mill Road in Palo Alto, California, which are now the Company’s U.S. corporate offices. The facilities are approximately <span style="color:#000000;">82,662</span> square feet and 72,812 square feet, respectively and include office and laboratory space. For 1200 Page Mill Road, the monthly rent during the initial 6.5-year term will be approximately $0.6 million, with annual year-over-year increases of 3% plus certain operating expenses and taxes and total rent abatement of approximately $7.2 million. The Company has an option to extend the lease term for a period of 6.5 years. For 1250 Page Mill Road, the monthly rent during the initial 13-year term will be approximately $0.5 million, with annual year-over-year increases of 3% plus certain operating expenses and taxes and total rent abatement of approximately $6.3 million. The Landlord will provide a tenant improvement allowance of approximately $1.2 million and $10.6 million for each building, respectively. The Company has two options to extend the lease term for a period of 5 years each. The Company determined that the renewal options were not reasonably certain at lease inception for the two buildings. The Company executed a $10.9 million cash-collateralized letter of credit, which was subsequently reduced to $6.2 million as a result of meeting certain reduction requirements specified therein. The cash collateralizing the letter of credit is classified as restricted cash on the Company’s consolidated balance sheets. Under ASC 842, the Company classified these leases as operating leases and recorded right-of-use assets and lease liabilities on the lease commencement date. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to lease office and laboratory space at 2631 Hanover <span style="color:#000000;">Street</span> in Palo Alto, California. The Company entered into a lease agreement in January 2013 which was amended in March 2016 and extended the lease term until October 2023. The Company classified this lease as an operating lease and recorded a right-of-use asset and lease liability on January 1, 2019 and recognized rent expense on a straight-line basis throughout the remaining lease term. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Switzerland Lease</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company entered into a lease agreement for office and laboratory space at Rottenstrasse 5 in Visp, Switzerland. The space is approximately 1,000 square meters. The initial lease term is 5 years, with automatic renewals every 5 years for a maximum lease term of 15 years. The monthly rent during the initial 5-year term will be approximately 32 thousand Swiss Francs plus certain operating expenses and taxes.<span style="color:#000000;"> Under ASC 842, the Company classified these leases as operating leases and recorded right-of-use assets and lease liabilities on the lease commencement date.</span> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturities of the operating lease liabilities as of December 31, 2020 were as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,288</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,660</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,598</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,037</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,475</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,462</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,520</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,118</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.96%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The minimum lease payments above do not include any related common area maintenance charges or real estate taxes. The weighted-average remaining lease terms and weighted-average discount rates were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000597">9.5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000598">3.8</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Embedded lease</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company and its subsidiary Kodiak Sciences GmbH entered into a manufacturing agreement with a contract manufacturing organization for the clinical and commercial supply of drug substance for KSI-301, the Company’s proprietary therapeutic candidate for the treatment and prevention of retinal vascular diseases. A custom-built manufacturing suite is planned to be completed and dedicated to the manufacture of the Company’s drug substance with an estimated capital contribution of 40 million Swiss Francs from the Company. Construction of the manufacturing suite is targeted for completion in 2021. The Company will be required to pay annual suite fees of 12 million Swiss Francs for 2021 and 16 million Swiss Francs for each year thereafter, which covers the manufacturing fees for a specified number of batches, and the Company may pay for additional batches to be manufactured. The manufacturing agreement has an initial term of eight years, and the Company has the right to extend the term up to a total of 16 years. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company concluded that this agreement contains an embedded lease as the custom-built manufacturing suite will be dedicated for the Company’s use. As of December 31, 2020, the Company did not have control of this manufacturing space and therefore, did not record a right-of-use asset and corresponding lease liability. These commitments are not included in the above table. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Manufacturing Agreement</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into service agreements with Lonza AG and its affiliates (“Lonza”), pursuant to which Lonza agreed to perform activities in connection with the manufacturing process of certain compounds.<span style="Background-color:#FFFFFF;color:#000000;"> </span>Such agreements, and related amendments, state that planned activities that are included in the signed work orders are, in some cases, binding and, hence, obligate the Company to pay the full price of the work order upon satisfactory delivery of products and services or obligate the Company to the binding amount regardless of whether such planned activities are in fact performed. Per the terms of the agreements, the Company has the option to cancel signed orders at any time upon written notice, which may or may not be subject to payment of a cancellation fee. The level of cancellation fees may be dependent on the timing of the written notice in relation to the commencement date of the work, with the maximum cancellation amount dependent on the agreement or the work order. Under these agreements, the total amount of contractual obligations, over a period of ten years, are cancellable and subject to varying levels of cancellation fees, were $242.3 million and $4.7 million, including accrued amounts, as of December 31, 2020 and 2019, respectively. Purchases under this agreement for the years ended December 31, 2020, 2019 and 2018 were $16.8 million, $7.9 million and $2.8 million, respectively. As of December 31,<span style="Background-color:#FFFFFF;color:#000000;"> 2020</span>, the Company had not incurred any cancellation fees for the work performed by Lonza. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Funding Commitments</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In the normal course of business, the Company enters into agreements with third-parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company. As of </span><span style="color:#000000;">December 31, 2020 and 2019, the total amount of noncancellable purchase commitments, including potential cancellation fees were </span><span style="Background-color:#FFFFFF;">$0.5 million and $0.7 million, respectively. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is also party to a cancellable assignment and license agreement that would require the Company to make milestone payments of up to $33.2 million and royalty payments on net sales of products utilizing KSI-201 and related technology. Such milestones and royalties are dependent on future activity or product sales and are not estimable. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has also entered into various cancellable license agreements for certain technology. The Company may be obligated to make payments on future sales of specified products associated with such license agreements. <span style="Background-color:#FFFFFF;">Such payments are dependent on future product sales and are not estimable. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Tenant Improvement Allowance Payable </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2013, the Company entered into a tenant improvement allowance agreement with its landlord. The agreement allowed the Company to draw down $0.3 million for tenant improvements related to the office lease over the period from the execution of the agreement to <span style="-sec-ix-hidden:F_000620">October 2018</span>. The interest rate is 8% per year over the lease period. This tenant improvement allowance was repaid in October 2018.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the Company entered into a lease amendment, under which the Company is allowed to draw down an additional allowance of $0.4 million for tenant improvements related to the office lease over the period from the execution of the agreement to <span style="-sec-ix-hidden:F_000624">October 2023</span>. The interest rate is 8% per year over 10 years. Principal and interest are payable on the first day of every month. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,<span style="Background-color:#FFFFFF;color:#000000;"> 2020 and 2019</span>, the current portion of the tenant improvement allowance payable in accrued and other current liabilities was less than $<span style="color:#000000;">0.1</span> million and less than $0.1 million, respectively. As of December 31,<span style="Background-color:#FFFFFF;color:#000000;"> 2020 and 2019</span>, the non-current portion of the tenant improvement allowance payable in other liabilities was $0.3 million and $0.3 million, respectively.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Legal Proceedings </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. Management is currently not aware of any matters that could have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indemnification </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company’s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not specified in the agreements; however, the Company has director and officer insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal. </p> 2 82662000000 72812000000 P6Y6M 600000 0.03 7200000 6.5 years P13Y 500000 0.03 6300000 1200000 10600000 2 5 years 2 10900000 6200000 1000 P5Y P5Y P15Y P5Y 32000 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturities of the operating lease liabilities as of December 31, 2020 were as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,288</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,660</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,598</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,037</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,475</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,462</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,520</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,118</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.96%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 4288000 7660000 14598000 15037000 15475000 71462000 128520000 51118000 77402000 The weighted-average remaining lease terms and weighted-average discount rates were as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000597">9.5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000598">3.8</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> 0.067 0.085 40000000 12000000 16000000 P8Y P16Y 0 0 P10Y 242300000 4700000 16800000 7900000 2800000 0 500000 700000 33200000 300000 0.08 400000 0.08 P10Y 100000 100000 300000 300000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Income Taxes</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision (benefit) for income taxes consists of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision (Benefit) for income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss before income taxes were as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,633</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115,809</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,998</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,170</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loss before income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133,082</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,365</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,443</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that give rise to significant components of the net deferred tax assets are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,451</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,523</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,044</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,088</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,112</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,588</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,527</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,037</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,559</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,405</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,539</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,367</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">885</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,276</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,241</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,816</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,394</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,005</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,394</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,236</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">567</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use asset</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,234</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(534</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized legal fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,236</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(567</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has recorded a full valuation allowance against its net deferred tax assets due to the uncertainty as to whether such assets will be realized. The net change in the total valuation allowance for the years ended December 31, 2020, 2019 and 2018 was an increase of approximately $24.8 million, $15.9 million and $8.2 million, respectively. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOLs and tax credit carry-forwards are subject to review and possible adjustment by the Internal Revenue Service (“IRS”) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company’s value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed a Section 382 study through December 31, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> which concluded no such ownership change had occurred through December 31, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had $50.1 million of federal and $171.0 million of state net operating loss available to offset future taxable income. A portion of the federal net operating loss carryforwards begin to expire in 2035 and the state net operating loss carryforwards begin to expire in 2035, if not utilized. $32.0 million of the federal net operating loss are not subject to expiration.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company also had federal and state research and development credit carryforwards of $10.2 million and $4.9 million, respectively. The federal research and development credit carryforwards expire beginning 2035. The California tax credit can be carried forward indefinitely. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company’s effective tax rate to the statutory U.S. federal rate is as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign tax rate differential</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research tax credit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sale of future royalties</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 162(m)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of convertible note</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:10pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. As of December 31, 2020, 2019 and 2018, none of the unrecognized tax benefits would affect income tax expense with consideration of the valuation allowance. The Company does not anticipate the uncertain tax positions will materially change in the next 12 months. It is the Company's policy to include penalties and interest expense related to income taxes as a component of other expense, net as necessary.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The beginning and ending unrecognized tax benefits amounts are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at beginning of period</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,838</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to prior year tax positions</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to current year tax positions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,812</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at end of period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,838</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States and Switzerland. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision (benefit) for income taxes consists of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision (Benefit) for income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 14000 14000 14000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss before income taxes were as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,633</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115,809</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,998</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,170</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loss before income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133,082</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,365</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,443</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> -17273000 2633000 -17273000 -115809000 -49998000 -24170000 -133082000 -47365000 -41443000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that give rise to significant components of the net deferred tax assets are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,451</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,523</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,044</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,088</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,112</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,588</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,527</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,037</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,559</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,405</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,539</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,367</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">885</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,276</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,241</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,816</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,394</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,005</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,394</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,236</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">567</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use asset</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,234</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(534</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized legal fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,236</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(567</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 28451000 18523000 11044000 12088000 12112000 7588000 10527000 4037000 1559000 8405000 1539000 394000 1367000 885000 700000 22276000 577000 0 127000 143000 109000 83241000 37816000 21394000 62005000 37249000 21394000 21236000 567000 0 21234000 534000 0 2000 33000 0 21236000 567000 0 0 0 24800000 15900000 8200000 50100000 171000000.0 2035 2035 32000000.0 10200000 4900000 2035 indefinitely <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company’s effective tax rate to the statutory U.S. federal rate is as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign tax rate differential</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research tax credit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sale of future royalties</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 162(m)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of convertible note</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> 0.210 0.210 0.210 0.043 0.110 0.056 -0.079 -0.124 -0.038 -0.173 -0.305 -0.183 0.067 0.077 -0.006 0.038 0.033 0.013 -0.001 -0.001 -0.094 -0.012 -0.024 -0.027 0.000 0.000 0.000 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The beginning and ending unrecognized tax benefits amounts are as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at beginning of period</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,838</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to prior year tax positions</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to current year tax positions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,812</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits at end of period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,650</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,838</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1838000 398000 357000 0 0 0 2812000 1440000 41000 4650000 1838000 398000 P4Y <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Preferred Stock </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,<span style="Background-color:#FFFFFF;color:#000000;"> 2020 and 2019</span>, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue up to 10,000,000 shares of preferred stock at the par value of $0.0001 per share. As of December 31, 2020, there are no holders of the Company’s preferred stock.</p> 10000000 10000000 0.0001 0.0001 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Common Stock </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,<span style="Background-color:#FFFFFF;color:#000000;"> 2020 and 2019</span>, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 490,000,000 shares of common stock at the par value of $0.0001 per share. Each share of common stock is entitled to one vote. The board of directors may declare and pay dividends to holders of common stock. The Company has never declared or paid any dividends on common stock. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved common stock for future issuances as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of options outstanding and release of restricted shares</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257,221</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,830,442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of common stock warrants outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under the 2018 Equity Incentive Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,742,183</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,118,877</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under the 2018 Employee Share Purchase Plan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,859,403</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,809,318</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 490000000 490000000 0.0001 0.0001 1 1 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved common stock for future issuances as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of options outstanding and release of restricted shares</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257,221</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,830,442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of common stock warrants outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under the 2018 Equity Incentive Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,742,183</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,118,877</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under the 2018 Employee Share Purchase Plan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,859,403</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,809,318</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 7257221 6830442 399999 399999 2742183 2118877 460000 460000 10859403 9809318 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Stock-Based Compensation </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2018 Equity Incentive Plan</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company adopted the <span style="Background-color:#FFFFFF;color:#000000;">2018 Equity Incentive Plan (“2018 Plan”), which became effective on the business day prior to the effectiveness of the registration statement relating to the IPO. The 2018 Plan initially reserved 4,300,000 shares of common stock for the issuance of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock, restricted stock units (“RSUs”), stock appreciation rights, performance units and performance shares to employees, directors and consultants of the Company.</span><span style="font-size:12pt;"> </span><span style="Background-color:#FFFFFF;color:#000000;">The number of shares available for issuance will increase annually on the first day of each fiscal year beginning in 2019 equal to the least of (1) 4,300,000 shares, and (2) 4% of outstanding shares of common stock as of the last day of the immediately preceding year, and (3) such other amount as determined by the board of directors. The exercise price of options must be equal to at least the fair market value of the common stock on the grant date. For ISOs, the term may not exceed</span> ten years, except in respect to any participant with more than 10% of voting power of all classes or stock, then the term may not exceed five years and the exercise price must be equal to at least 110% of the fair market value of the common stock on the grant date. Options granted generally vest over four years.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The number of shares available for issuance increased by 1,776,761 shares in 2020 and there were 2,742,183 shares available for grant under the 2018 Plan as of December 31, 2020.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shares Subject to Repurchase </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a right of repurchase with respect to unvested shares issued upon early exercise of options at an amount equal to the lower of (1) the exercise price of each restricted share being repurchased and (2) the fair market value of such restricted share at the time the Company’s right of repurchase is exercised. The Company’s right to repurchase these shares lapses as those shares vest over the requisite service period. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as accrued liabilities and other current liabilities on the consolidated balance sheet and is reclassified to common stock and additional paid-in capital as such shares vest. At December 31, 2020 and 2019, there are no early exercised stock options that remained subject to the Company’s right of repurchase.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Options </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity under the 2018 Plan and 2015 Plan is summarized as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,671,542</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.90</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000776">8.73</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,081</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,335</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.27</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(704,675</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or canceled</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(137,926</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.07</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,897,276</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.52</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000777">8.07</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841,704</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares exercisable December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,769,990</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,897,276</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of the stock options granted for 2020, 2019 and 2018 was $32.44, $34.11 and $4.36 per share, respectively.<span style="color:#000000;"> The aggregate intrinsic value represents the value of the Company’s closing stock price on the last trading day of the period in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Stock Options </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company’s IPO, the fair value of the shares of common stock underlying the stock options was determined by the board of directors with assistance from management and external appraisers as there has been no historical public market for the Company’s common stock. Subsequent to the Company’s IPO, the fair value of the Company’s common stock is determined based on its closing market price.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of employee stock options using the Black-Scholes valuation model. The fair value of employee stock options was estimated using the following weighted-average assumptions:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.39</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.65</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.82</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000792">6.00</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000793">5.78</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000794">6.06</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term<span style="font-style:normal;">. The expected term is calculated using the simplified method, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility<span style="font-style:normal;">. As the Company does not have sufficient trading history for its common stock,</span><span style="color:#000000;font-style:normal;"> our approach to estimating expected volatility is to phase in our own common stock trading history and supplement the remaining historical information with </span><span style="font-style:normal;">an average historical stock price volatility of a peer group of publicly traded companies to be representative of its expected future stock price volatility. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, the Company measured historical volatility over a period equivalent to the expected term. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate<span style="font-style:normal;">. The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend Rate<span style="font-style:normal;">. The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be zero. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total fair value of employee options vested during the years ended December 31, 2020, 2019 and 2018 was $19.7 million, $4.6 million and $1.2 million, respectively. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for options granted to employees was $20.8 million, $5.7 million and $2.0 million, respectively.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Non-Employee Stock Options </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted 41,500, 15,000 and 215,000 stock options to non-employees during the years ended December 31, 2020, 2019 and 2018, respectively. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to the adoption of ASU 2018-07 effective January 1, 2019, existing stock options granted to non-employees will no longer be revalued, and the estimated fair value of new stock options granted to non-employees will be calculated on the date of grant and not remeasured, similar to stock options granted to employees. The fair value of non-employee stock options was estimated using the following weighted-average assumptions: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.61</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.71</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000816">5.56</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000817">6.08</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000818">9.30</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for options granted to non-employees was $0.7 million, $0.1 million and $0.4 million, respectively.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Shares</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted share activity, including restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and performance-based restricted stock units (“PSUs”), under the 2018 Plan and 2015 Plan is summarized as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,747</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60.81</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,045</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.18</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,848</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares withheld related to net share settlement of RSUs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.90</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359,945</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.54</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Stock Awards </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the restricted stock agreements, the awards vest over four years, which is the requisite service period. Recipients of restricted stock awards generally have voting and dividend rights with respect to such shares upon grant without regard to vesting. Shares of restricted stock that do not vest are subject to forfeiture. The Company recognizes stock-based compensation expense for RSAs on a straight-line basis over the requisite service period for the entire award. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not grant any RSA to employees in 2020. The total fair value of RSAs vested during the years ended December 31, 2020, 2019 and 2018 was $nil million, less than $0.1 million and $0.2 million, respectively. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for RSAs was $nil million, less than $0.1 million and $0.2 million, respectively.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Stock Units </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs will vest in four equal annual installments over four years, which is the requisite service period after that date.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted 236,045 RSUs to employees in 2020. The total fair value of RSUs vested during the year ended December 31, 2020 and 2019 was $0.3 million and $0.3 million, respectively. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for RSUs was $1.9 million, $0.3 million, and less than $0.1 million, respectively. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Performance-Based Stock Options and Restricted Stock Units</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These performance-based equity awards will vest one-quarter upon the achievement of specific clinical development milestones. The remaining shares will then vest in three equal annual installments after that date. Performance-based stock options are recorded as expense beginning when vesting events are determined to be probable.<span style="color:#000000;"> </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not grant performance-based equity awards to employees in 2020. <span style="color:#000000;">None</span> of these performance-based equity awards vested during 2020 or 2019. The Company believes that the achievement of the requisite performance condition continues to be probable. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for the performance-based equity awards was $7.2 million, less than $0.1 million and $nil million, respectively.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of performance-based stock options was estimated using the following weighted-average assumptions:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.67</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000855">6.31</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value was $47.89 per share for performance-based stock options and $73.51 per share for performance-based restricted stock units.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2018 </span><span style="color:#000000;">Employee</span><span style="Background-color:#FFFFFF;"> Share Purchase Plan</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In August 2018, the Company adopted the 2018 Employee Share Purchase Plan (“ESPP”), which became effective on the business day prior to the effectiveness of the registration statement relating to the IPO. A total of 460,000 shares of common stock were initially reserved for issuance under the ESPP. The initial offering period of the ESPP was authorized by the Company’s board of directors and commenced on January 4, 2021. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Stock-Based Compensation Expense</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,957</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,496</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,535</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.44%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,711</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,614</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.44%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,668</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,608</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had $91.4 million of unrecognized compensation expense related to unvested stock options and unvested restricted stock awards and units that is expected to be recognized over a weighted-average period of 2.9 years<span style="color:#000000;">. </span></p> 4300000 4300000 0.04 P10Y P5Y 1.10 P4Y 1776761 2742183 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity under the 2018 Plan and 2015 Plan is summarized as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,671,542</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.90</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000776">8.73</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,081</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,335</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.27</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(704,675</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or canceled</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(137,926</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.07</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,897,276</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.52</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000777">8.07</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.4%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841,704</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares exercisable December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,769,990</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,897,276</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> 6671542 17.90 362081000 1068335 55.27 704675 8.89 137926 25.07 6897276 24.52 841704000 3769990 6897276 32.44 34.11 4.36 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of employee stock options using the Black-Scholes valuation model. The fair value of employee stock options was estimated using the following weighted-average assumptions:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.39</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.65</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.82</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000792">6.00</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000793">5.78</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000794">6.06</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0.66 0.68 0.59 0.0039 0.0165 0.0282 0 0 0 0 0 0 19700000 4600000 1200000 20800000 5700000 2000000.0 41500 15000 215000 The fair value of non-employee stock options was estimated using the following weighted-average assumptions: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.61</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.71</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000816">5.56</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000817">6.08</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000818">9.30</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> 0.67 0.73 0.68 0.0036 0.0161 0.0271 0 0 0 700000 100000 400000 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted share activity, including restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and performance-based restricted stock units (“PSUs”), under the 2018 Plan and 2015 Plan is summarized as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,747</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60.81</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,045</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.18</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,848</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares withheld related to net share settlement of RSUs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.90</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359,945</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.54</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> 160747 60.81 236045 52.18 23848 9.21 7999 9.90 5000 72.46 359945 59.54 P4Y 100000 200000 100000 200000 P4Y 236045 300000 300000 1900000 300000 100000 These performance-based equity awards will vest one-quarter upon the achievement of specific clinical development milestones. The remaining shares will then vest in three equal annual installments after that date. 0 0 0 7200000 100000 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of performance-based stock options was estimated using the following weighted-average assumptions:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.67</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000855">6.31</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"> </p> 0.72 0.0167 0 47.89 73.51 460000 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,957</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,496</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,535</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.44%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,711</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,614</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.44%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,668</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,608</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 16957000 3496000 1535000 13711000 2614000 1073000 30668000 6110000 2608000 91400000 P2Y10M24D <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Net Loss per Share Attributable to Common Stockholders </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share data): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133,096</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,365</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,741,845</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,869,291</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,136,197</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted-average unvested restricted shares</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and shares subject to repurchase</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,675</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159,682</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding used in</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   computing net loss per share attributable to</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   common stockholders, basic and diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,741,845</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,853,616</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,976,515</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders,</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.91</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.25</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.77</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities, presented on an as-converted to common stock basis, were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of options outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,897,276</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,671,542</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,135,267</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359,945</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,747</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,450</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257,221</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,832,289</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,185,717</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share data): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133,096</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,365</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,741,845</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,869,291</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,136,197</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted-average unvested restricted shares</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and shares subject to repurchase</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,675</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159,682</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding used in</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   computing net loss per share attributable to</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   common stockholders, basic and diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,741,845</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,853,616</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,976,515</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders,</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.91</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.25</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.77</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> -133096000 -47365000 -41443000 45741845 37869291 15136197 0 15675 159682 45741845 37853616 14976515 -2.91 -1.25 -2.77 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities, presented on an as-converted to common stock basis, were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of options outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,897,276</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,671,542</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,135,267</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359,945</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,747</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,450</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257,221</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,832,289</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,185,717</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> 6897276 6671542 5135267 359945 160747 50450 7257221 6832289 5185717 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. 401(k) Plan </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2011, the Company adopted a 401(k) retirement and savings plan covering all employees. The 401(k) plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The 401(k) plan was amended to include an employer matching provision in 2019. The Company will make matching contributions of 100% of employee contributions up to a maximum of 50% of the individual maximum contribution limit allowed under the IRS rules. For the year ended December 31, 2020 and 2019, the expense related to the matching contributions was $0.6 million and $0.3 million, respectively.</p> 401(k) 1 0.50 600000 300000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Liability related to Sale of Future Royalties</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On </span><span style="color:#000000;">December 1, 2019, the Company and its subsidiary Kodiak Sciences GmbH entered into a funding agreement with BBA, which holds more than 5% of the Company’s stock, pursuant to which BBA purchased the right to receive a capped 4.5% royalty on future net sales of KSI-301, the Company’s anti-VEGF antibody biopolymer conjugate therapy, in exchange for $225.0 million. The royalty terminates upon the date that BBA has received an aggregate amount equal to 4.5 times the funding amount paid to the Company, unless earlier terminated or repurchased by the Company. Under the terms of the funding agreement, there is no obligation to repay any funding amount received, other than through the capped royalty payments on future product revenues. The Company has the option, exercisable at any point during the term of the funding agreement, to repurchase 100% of the royalties due to BBA for a purchase price equal to 4.5 times the funding amount paid to the Company as of such time, less amounts paid by the Company to BBA. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The closing of the funding agreement was subject to certain conditions and occurred in February 2020. The Company received $100.0 million of the funding on February 4, 2020. The remaining $125.0 million, subject to delivery of notice by the Company, payable upon enrollment of 50% of the patients in the RVO clinical program.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company recorded the initial $100.0 million payment as a liability on the consolidated balance sheet net of issuance costs.</span><span style="color:#000000;"> Once royalty payments to BBA are determined to be probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest to accrete the liability on a prospective basis based on such estimates. If and when the Company makes royalty payments under the funding agreement, it would reduce the liability balance at such time. As of December 31, 2020, royalty payments are not probable and estimable. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, no interest expense was recognized for the liability related to the sale of future royalties.</p> 0.05 0.045 225000000.0 1 100000000.0 125000000.0 0.50 100000000.0 0 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.<span style="font-weight:normal;"> </span><span style="color:#000000;">Selected Quarterly Financial Data (unaudited)</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides the selected quarterly financial information for the years<span style="color:#000000;">, 2020 and 2019</span> (in thousands, except per share data):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,723</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,779</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,663</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,842</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,392</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,122</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,583</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   stockholders, basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.54</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.58</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.80</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.97</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,460</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,814</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,732</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,184</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,984</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,385</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,616</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   stockholders, basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.31</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.33</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.40</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides the selected quarterly financial information for the years<span style="color:#000000;">, 2020 and 2019</span> (in thousands, except per share data):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,723</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,779</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,663</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,842</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,392</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,122</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,583</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   stockholders, basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.54</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.58</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.80</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.97</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,460</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,814</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,732</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,184</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,984</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,385</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,616</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   stockholders, basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.31</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.33</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.40</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> -25723000 -26779000 -36663000 -46842000 -24392000 -25999000 -36122000 -46583000 -0.54 -0.58 -0.80 -0.97 -8460000 -11814000 -12732000 -16184000 -7984000 -11385000 -12380000 -15616000 -0.21 -0.31 -0.33 -0.40 XML 69 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information - USD ($)
$ in Billions
12 Months Ended
Dec. 31, 2020
Feb. 19, 2021
Jun. 30, 2020
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2020    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2020    
Trading Symbol KOD    
Entity Registrant Name KODIAK SCIENCES INC.    
Entity Central Index Key 0001468748    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity File Number 001-38682    
Entity Tax Identification Number 27-0476525    
Entity Address, Address Line One 1200 Page Mill Road    
Entity Address, City or Town Palo Alto    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94304    
City Area Code 650    
Local Phone Number 281-0850    
Entity Incorporation, State or Country Code DE    
Entity Interactive Data Current Yes    
Document Annual Report true    
Document Transition Report false    
Title of 12(b) Security Common stock, par value $0.0001    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
ICFR Auditor Attestation Flag true    
Entity Common Stock, Shares Outstanding   51,162,424  
Entity Public Float     $ 1.6
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive Proxy Statement relating to the 2021 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2020.

   

XML 70 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 944,396 $ 211,797
Marketable securities 24,578 124,684
Prepaid expenses and other current assets 3,031 2,749
Total current assets 972,005 339,230
Marketable securities   11,696
Restricted cash 6,324 140
Property and equipment, net 5,136 996
Operating lease right-of-use asset 73,672 1,790
Other assets 10,210 5,014
Total assets 1,067,347 358,866
Current liabilities:    
Accounts payable 8,646 2,619
Accrued and other current liabilities 20,402 8,658
Operating lease liability 2,374 434
Total current liabilities 31,422 11,711
Operating lease liability, net of current portion 75,028 1,501
Liability related to sale of future royalties 99,890  
Other liabilities 256 295
Total liabilities 206,596 13,507
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2020 and 2019
Common stock, $0.0001 par value, 490,000,000 shares authorized at December 31, 2020 and 2019; 51,112,302 and 44,413,404 shares issued and outstanding at December 31, 2020 and 2019, respectively 5 5
Additional paid-in capital 1,151,920 503,475
Accumulated other comprehensive income 53 10
Accumulated deficit (291,227) (158,131)
Total stockholders’ equity 860,751 345,359
Total liabilities and stockholders’ equity $ 1,067,347 $ 358,866
XML 71 R3.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2020
Dec. 31, 2019
Statement Of Financial Position [Abstract]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred Stock, shares issued 0 0
Preferred Stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 490,000,000 490,000,000
Common stock, shares issued 51,112,302 44,413,404
Common stock, shares outstanding 51,112,302 44,413,404
XML 72 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Operating expenses      
Research and development $ 107,389 $ 37,506 $ 18,793
General and administrative 28,618 11,684 7,581
Total operating expenses 136,007 49,190 26,374
Loss from operations (136,007) (49,190) (26,374)
Interest income 2,902 1,568 617
Interest expense (includes $nil, $nil and $3,030 attributable to related parties for the years ended December 31, 2020, 2019 and 2018, respectively) (25) (8) (5,519)
Other income (expense), net (includes $49, $nil, and $2,736 expenses attributable to related parties for the years ended December 31, 2020, 2019, and 2018, respectively) 34 265 (4,688)
Loss on extinguishment of debt (includes $1,587 attributable to related parties for the year ended December 31, 2018)     (5,479)
Net loss $ (133,096) $ (47,365) $ (41,443)
Net loss per common share, basic and diluted $ (2.91) $ (1.25) $ (2.77)
Weighted-average common shares outstanding used in computing net loss per common share, basic and diluted 45,741,845 37,853,616 14,976,515
Other comprehensive income      
Change in unrealized gains related to available-for-sale debt securities, net of tax $ 43 $ 10  
Total other comprehensive income 43 10  
Comprehensive loss $ (133,053) $ (47,355) $ (41,443)
XML 73 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2018
Income Statement [Abstract]    
Interest expense attributable to related parties   $ 3,030
Other income (expense) attributable to related parties $ 49 2,736
Loss on extinguishment of debt attributable to related parties   $ 1,587
XML 74 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Redeemable Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Beginning Balance at Dec. 31, 2017 $ (68,738)   $ 1 $ 584   $ (69,323)
Redeemable convertible preferred stock, shares outstanding, beginning balance at Dec. 31, 2017   12,385,154        
Redeemable convertible preferred stock, beginning balance at Dec. 31, 2017   $ 50,017        
Beginning balance, shares at Dec. 31, 2017     7,936,434      
Issuance of common stock upon exercise of stock options 49     49    
Issuance of common stock upon exercise of stock options, shares     47,800      
Issuance of restricted stock awards, shares     27,500      
Conversion of redeemable convertible preferred stock into common stock 50,017   $ 1 50,016    
Conversion of redeemable convertible preferred stock into common stock, shares   (12,385,154)        
Conversion of redeemable convertible preferred stock into common stock   $ (50,017)        
Conversion of redeemable convertible preferred stock into common stock, shares     12,385,154      
Conversion of redeemable convertible preferred stock warrants into common stock warrants 5,000     5,000    
Issuance of common stock upon exercise of common stock warrants, shares     100,000      
Conversion of 2017 and 2018 convertible notes into common stock 55,733   $ 1 55,732    
Conversion of 2017 and 2018 convertible notes into common stock, shares     6,932,969      
Issuance of common stock in connection with initial public offering/follow-on offering, net of offering costs 83,459   $ 1 83,458    
Issuance of common stock in connection with initial public offering/follow-on offering, net of offering costs, shares     9,400,000      
Stock-based compensation expense 2,756     2,756    
Net loss (41,443)         (41,443)
Ending Balance at Dec. 31, 2018 86,833   $ 4 197,595   (110,766)
Ending balance, shares at Dec. 31, 2018     36,829,857      
Issuance of common stock upon exercise of stock options 2,287     2,287    
Issuance of common stock upon exercise of stock options, shares     662,079      
Vesting of restricted stock units, net of taxes withheld (132)     (132)    
Vesting of restricted stock units, net of taxes withheld, shares     21,467      
Issuance of common stock upon exercise of common stock warrants, shares     1      
Issuance of common stock in connection with initial public offering/follow-on offering, net of offering costs 297,616   $ 1 297,615    
Issuance of common stock in connection with initial public offering/follow-on offering, net of offering costs, shares     6,900,000      
Stock-based compensation expense 6,110     6,110    
Other comprehensive income 10       $ 10  
Net loss (47,365)         (47,365)
Ending Balance at Dec. 31, 2019 345,359   $ 5 503,475 10 (158,131)
Ending balance, shares at Dec. 31, 2019     44,413,404      
Issuance of common stock upon exercise of stock options 6,248     6,248    
Issuance of common stock upon exercise of stock options, shares     704,675      
Vesting of restricted stock units, net of taxes withheld (487)     (487)    
Vesting of restricted stock units, net of taxes withheld, shares     22,001      
Issuance of common stock in connection with initial public offering/follow-on offering, net of offering costs 612,016     612,016    
Issuance of common stock in connection with initial public offering/follow-on offering, net of offering costs, shares     5,972,222      
Stock-based compensation expense 30,668     30,668    
Other comprehensive income 43       43  
Net loss (133,096)         (133,096)
Ending Balance at Dec. 31, 2020 $ 860,751   $ 5 $ 1,151,920 $ 53 $ (291,227)
Ending balance, shares at Dec. 31, 2020     51,112,302      
XML 75 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Statement Of Stockholders Equity [Abstract]      
Offering costs with respect to issuance of common stock in connection with initial public offering/follow-on offering $ 32,984 $ 19,784 $ 10,542
XML 76 R8.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities      
Net loss $ (133,096) $ (47,365) $ (41,443)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 477 538 490
Non-cash interest expense and amortization of debt discount and issuance cost 0 0 5,482
Change in fair value of redeemable convertible preferred stock warrant liability 0 0 2,700
Change in fair value of derivative instrument 0 0 1,988
Extinguishment of debt     5,479
Stock-based compensation 30,668 6,110 2,665
Amortization (accretion) of premium (discount) on marketable securities (51) (241)  
Amortization of operating lease right-of-use asset 3,731 373  
Amortization of issuance costs 49 0 0
Changes in assets and liabilities:      
Prepaid expense and other current assets (218) (168) (1,995)
Other assets (1,814) (4,511) 0
Accounts payable 5,224 1,569 (2,323)
Accrued and other current liabilities 11,748 4,932 (2,105)
Operating lease liability (146) (383)  
Other liabilities 0 0 31
Net cash used in operating activities (83,428) (39,146) (29,031)
Cash flows from investing activities      
Purchase of property and equipment (3,814) (437) (78)
Deposits on property and equipment (3,184)   (503)
Purchases of marketable securities (86,317) (150,961)  
Maturities of marketable securities 198,149 14,400  
Net cash provided by (used in) investing activities 104,834 (136,998) (581)
Cash flows from financing activities      
Proceeds from issuance of common stock in connection with offering, net of offering costs 612,016 297,616 83,755
Proceeds from issuance of common stock upon option exercise 6,248 2,287 49
Payments for restricted stock units, net of taxes withheld (487) (132)  
Proceeds from issuance of convertible notes (includes $9,560 from related parties for the years ended December 31, 2018)     33,000
Debt issuance cost 0 0 (140)
Proceeds from sale of future royalties, net of issuance costs 99,643 0 0
Principal payments of capital lease (5) (48) (108)
Principal payments of tenant improvement allowance payable (38) (36) (85)
Net cash provided by financing activities 717,377 299,687 116,471
Net increase in cash, cash equivalents and restricted cash 738,783 123,543 86,859
Cash, cash equivalents and restricted cash, at beginning of year 211,937 88,394 1,535
Cash, cash equivalents and restricted cash, at end of year 950,720 211,937 88,394
Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets      
Cash and cash equivalents 944,396 211,797 88,254
Restricted cash 6,324 140 140
Cash, cash equivalents and restricted cash, at end of year 950,720 211,937 88,394
Supplemental cash flow information:      
Cash paid for interest 25 8 19
Supplemental disclosures of non-cash investing and financing information:      
Operating lease right-of-use asset obtained in exchange for operating lease liability 75,614 2,163  
Purchase of property and equipment under accounts payable 803 0 0
Unpaid offering costs 238 459 205
Offering costs paid in restricted stock awards 0 0 91
Derivative instrument related to convertible notes $ 0 $ 0 $ 6,603
XML 77 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows (Parenthetical)
$ in Thousands
12 Months Ended
Dec. 31, 2018
USD ($)
Statement Of Cash Flows [Abstract]  
Proceeds from issuance of convertible notes $ 9,560
XML 78 R10.htm IDEA: XBRL DOCUMENT v3.20.4
The Company
12 Months Ended
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
The Company

1. The Company

Kodiak Sciences Inc. (the “Company”) is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high-prevalence ophthalmic diseases. The Company devotes substantially all of its time and efforts to performing research and development, raising capital and recruiting personnel.

Initial Public Offering

In 2018, the Company sold and issued 9,400,000 shares of common stock, including the underwriters’ full exercise of their over-allotment option, at a price to the public of $10.00 per share for gross proceeds of $94.0 million. The aggregate net proceeds to the Company from the IPO, inclusive of the partial over-allotment option exercise, were $83.5 million after deducting underwriting discounts and commissions and other offering costs.

Upon the closing of the IPO, all convertible preferred shares then outstanding automatically converted into 12,385,154 shares of common stock, 500,000 redeemable convertible preferred stock warrants automatically converted into common stock warrants and 100,000 of such warrants were exercised immediately following the closing of the IPO. The 2017 convertible notes converted into 2,637,292 shares of common stock and the 2018 convertible notes converted into 4,295,677 shares of common stock upon closing of the IPO. In connection with the IPO, the Company amended and restated its certificate of incorporation and bylaws.

Follow-On Offering

In December 2019, the Company sold and issued 6,900,000 shares of common stock, including the underwriters’ full exercise of their over-allotment option, at a price to the public of $46.00 per share for gross proceeds of $317.4 million. The aggregate net proceeds to the Company from the follow-on offering were $297.6 million after deducting underwriting discounts and commissions and other offering costs.

In November 2020, the Company sold and issued 5,972,222 shares of common stock, including the underwriters’ full exercise of their over-allotment option, at a price to the public of $108.00 per share for gross proceeds of $645.0 million. The aggregate net proceeds to the Company from the follow-on offering were $612.0 million after deducting underwriting discounts and commissions and other offering costs.

XML 79 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).

Reclassification

Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation.

Principles of Consolidation

The consolidated financial statements include the Company’s accounts and the accounts of Kodiak Sciences Financing Corporation and Kodiak Sciences China, the Company’s direct wholly owned subsidiaries, incorporated in the United States and Cayman Islands, respectively, and Kodiak Sciences GmbH and Kodiak Sciences Valais GmbH, the Company’s indirect wholly owned subsidiaries, both incorporated in Switzerland. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar. The aggregate foreign currency transaction loss included in determining net loss was $0.3 million, less than $0.1 million and $0.3 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Segments

The Company operates and manages its business as one reportable and operating segment, which is the business of research and development of drugs for ophthalmic diseases. The chief operating decision maker reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and expenses during the reporting period. The impact of the ongoing COVID-19 pandemic continues to evolve. As a result, certain estimates and assumptions required increased judgment and carried a higher degree of variability and volatility, including but not limited to, the fair value of marketable securities, performance-based equity awards, and research and development accruals. As events continue to unfold and additional information becomes available, these estimates may change materially in future periods. Actual results could differ from those estimates.

Risk and Uncertainties

In March 2020, the World Health Organization declared a pandemic due to the global COVID-19 outbreak. The significant uncertainties caused by the ongoing COVID-19 pandemic may negatively impact the Company’s operations, liquidity, and capital resources and will depend on certain evolving developments, including the duration and spread of the outbreak, regulatory and private sector responses and the impact on employees and vendors including supply chain and clinical partners, all of which are uncertain and cannot be predicted. During this pandemic, the Company continues to work closely with clinical sites towards maximal patient safety and the lowest number of missed visits and study discontinuations. The Company has taken and continues to take proactive measures to maintain the integrity of its ongoing clinical studies. Despite these efforts, the ongoing COVID-19 pandemic could significantly impact clinical trial enrollment and completion of its clinical studies. The Company will continue to monitor the COVID-19 situation and its impact on the ability to continue the development of, and seek regulatory approvals for, the Company’s product candidates, and begin to commercialize any approved products.

The Company’s future results of operations involve a number of risks and uncertainties common to clinical-stage companies in the biotechnology industry. The Company’s product candidates are in development and the Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s potential drug candidates, uncertainty of market acceptance of any of the Company’s product candidates that receive regulatory approval, competition from new technological innovations, substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals, contract manufacturer and research organizations, and other suppliers.

Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that any of the Company’s product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approvals, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. 

The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be on terms acceptable by the Company.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2020 and 2019, cash, cash equivalents and marketable securities were invested primarily in money market funds, overnight repurchase agreements, U.S. treasury securities, commercial paper and corporate notes through highly rated financial institutions. Investments are restricted, in accordance with the Company’s investment policy, to a concentration limit per issuer or sector.

Cash and Cash Equivalents

The Company considers all highly liquid investments with stated maturities of three months or less at the date of purchase to be cash equivalents.

Marketable Securities

The Company invests excess cash balances in marketable securities. The investments in marketable securities are classified as either held-to-maturity or available-for-sale based on facts and circumstances present at the time of purchase. Marketable securities with a remaining maturity date greater than one year are classified as non-current. The Company’s marketable securities consist of U.S. treasury securities, commercial paper, and corporate bonds. Marketable securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium or discount arising at purchase of marketable debt securities is amortized and/or accreted to other income (expense), net over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense), net.

If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is “other-than-temporary” and, if so, marks the investment to market through a charge to the Company’s statement of operations and comprehensive loss.

Restricted Cash

As of December 31, 2020, and 2019, the Company had $6.3 million and $0.1 million, respectively, of long-term restricted cash deposited with a financial institution. The entire amount is held in separate bank accounts to support letter of credit agreements related to the Company’s U.S. corporate offices.

Fair Value of Financial Instruments

Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company's own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:

Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and inputs to the model.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities and other current liabilities, approximate fair value due to their relatively short maturities.

Leases

The Company determines if an arrangement is, or contains, a lease at inception and then classifies the lease as operating or financing based on the underlying terms and conditions of the contract. Leases with terms greater than one year are initially recognized on the balance sheet as right-of-use assets and lease liabilities based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term and in a similar economic environment of the applicable country or region. Variable lease payments are excluded from the right of use assets and operating lease liabilities and are recognized in the period in which the obligation for those payments is incurred.

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over the estimated useful lives of assets, which is generally four years for laboratory equipment, three years for computer equipment and office equipment, five years for computer software and five to seven years for furniture and fixtures. Leasehold improvements are stated at cost and amortized over the shorter of the useful life of the assets or the length of the lease. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Impairment of Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the assets. There have been no such impairments of long-lived assets in the years ended December 31, 2020 and 2019.

Research and Development Expenses

Costs related to research, design and development of products are charged to research and development expense as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, including stock-based compensation, laboratory supplies, outside services and allocated overhead, including rent, equipment, depreciation and utilities.

Accrued Research and Development

The Company has entered into various agreements with various third parties, including clinical investigator sites, contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), to provide research and development activities. The Company’s accrued research and development costs are estimated based on the level of services performed, including the phase or completion of events, and contracted costs. Accrued clinical trial and related costs are estimated using data such as patient enrollment, clinical site activations or information provided by outside service providers regarding their actual costs incurred. Management determined accrual estimates through reports from and discussions with clinical personnel and outside service providers as to the progress of trials, or the services completed. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses or other assets until the services are rendered.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, Compensation-Stock Compensation. The Company measures stock-based compensation expense for stock options and restricted stock units granted to its employees, directors and non-employees based on the estimated fair value of the awards on the grant date. The fair value of options is calculated using the Black-Scholes valuation model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The expense is recorded on a straight-line basis over the requisite service period, which is generally the vesting period, for the entire award. The Company accounts for forfeitures as they occur.

Prior to the adoption of Accounting Standards Update ("ASU") No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"), the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. After adoption of ASU 2018-07 as of January 1, 2019, the measurement date for non-employee awards is the date of grant without changes in the fair value of the award.

The Company has certain stock options and restricted stock units that vest in conjunction with certain performance conditions. At each reporting date, the Company is required to evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon the Company's assessment of accomplishing each performance provision.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses (“NOLs”) and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.

The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Comprehensive Loss

Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists primarily of unrealized gains and losses on debt securities.

Liability related to Sale of Future Royalties

On December 1, 2019, the Company and its subsidiary Kodiak Sciences GmbH entered into a funding agreement with Baker Bros. Advisors, LP (“BBA”), which holds more than 5% of the Company’s stock, pursuant to which BBA purchased the right to receive a capped 4.5% royalty on future net sales of KSI-301, the Company’s anti-VEGF antibody biopolymer conjugate therapy, in exchange for $225.0 million. Under the terms of the funding agreement, there is no obligation to repay any funding amount received, other than through the capped royalty payments on future product revenues. The Company recorded the funding amount paid by BBA as a liability on the consolidated balance sheet net of issuance costs, in accordance with ASC 730, Research and Development. Under ASC 730, the significant related party relationship between the Company and BBA creates an implicit obligation to repay the funding amount paid to the Company. Once royalty payments to BBA are determined to be probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest to accrete the liability on a prospective basis based on such estimates. If and when the Company makes royalty payments under the funding agreement, it would reduce the liability balance at such time. Refer to Note 14.

Credit Losses – Available-for-Sale Debt Securities

For available-for-sale debt securities in an unrealized loss position, the Company will periodically assess its portfolio for impairment. The assessment first considers the intent or requirement to sell the security. If either of these criteria are met, the amortized cost basis will be written down to fair value through earnings.

If not met, the Company will evaluate whether the decline resulted from credit losses or other factors by considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.

Net Loss per Share Attributable to Common Stockholders

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, the redeemable convertible preferred stock, preferred stock warrants, convertible notes, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. The Company’s participating securities do not have a contractual obligation to share in the Company’s losses. As such, the net loss is attributed entirely to common stockholders. Since the Company has reported net loss for all periods presented, diluted net loss per share is the same as basic net loss per common share for those periods.

Recent accounting pronouncements

From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified effective date, unless otherwise discussed below.

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). In July 2018, the FASB issued ASU 2018-10, Leases (Topic 842), Codification Improvements, and ASU 2018-11, Leases (Topic 842), Targeted Improvements. ASU 2018-10 clarified certain provisions and corrected unintended applications of the guidance such as the application of implicit rate, lessee reassessment of lease classification, and certain transition adjustments that should be recognized to earnings rather than to stockholders' equity. ASU 2018-11 provided an alternative transition method and practical expedient for separating contract components for the adoption of Topic 842. ASU 2016-02, ASU 2018-10, and ASU 2018-11 (collectively, "the new lease standards") superseded the previous leases standard, ASC 840 Leases.

The Company adopted ASC 842 effective January 1, 2019 using the modified retrospective approach to recognize a cumulative-effect adjustment on the effective date and to not adjust financial information and disclosures required under the new lease standards for comparative prior periods. The Company did not elect for the package of practical expedients and assessed all contracts at the transition date. The Company did not utilize the practical expedient which allows the use of hindsight in determining lease term and assessing impairment in right-of-use assets. The Company elected to apply the practical expedient and accounted for each lease component and related non-lease component as one single component. The Company elected the practical expedient not to recognize leases with terms of one year or less on the balance sheet. 

The adoption of the new lease standards on January 1, 2019 resulted in the initial recognition of right-of-use asset of $2.2 million and operating lease liability of $2.3 million and derecognition of noncurrent deferred liabilities of $0.2 million related to the operating lease for the Company’s office and laboratory space in Palo Alto, California on the consolidated balance sheets with no material impact to the consolidated statements of operations, stockholders’ equity or cash flows. Refer to Note 7.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 362): Measurement of Credit Losses on Financial Statements and ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. The Company assessed the impact of ASU 2016-13 on its available-for-sale debt securities and determined there were no credit losses within the portfolio requiring an allowance upon adoption. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB’s disclosure framework project. Among the changes, entities will no longer be required to disclose the amount of and reasons for transfers between Levels 1 and 2 of the fair value hierarchy but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.

In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which clarifies the accounting for implementation, set-up, and other upfront costs incurred in cloud computing arrangements. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.

New Accounting Pronouncements Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein, and early adoption is permitted. The Company has early adopted ASU 2019-12 in 2020; the effect was not material on the Company’s financial statements.

 

XML 80 R12.htm IDEA: XBRL DOCUMENT v3.20.4
Property and Equipment, Net
12 Months Ended
Dec. 31, 2020
Property Plant And Equipment [Abstract]  
Property and Equipment, net

3. Property and Equipment, net

Property and equipment, net consists of the following (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

 

 

 

 

 

 

 

 

Leasehold improvement

 

$

1,285

 

 

$

1,265

 

Laboratory equipment

 

 

3,351

 

 

 

1,125

 

Furniture and fixtures

 

 

214

 

 

 

204

 

Computer hardware

 

 

31

 

 

 

 

Computer software

 

 

89

 

 

 

79

 

Office equipment

 

 

107

 

 

 

94

 

Construction in progress

 

 

2,229

 

 

 

 

Total property and equipment

 

 

7,306

 

 

 

2,767

 

Less: Accumulated depreciation

 

 

(2,170

)

 

 

(1,771

)

Property and equipment, net

 

$

5,136

 

 

$

996

 

 

All property and equipment are maintained in the United States and Switzerland. Depreciation expense, including depreciation of assets under capital leases, was $0.5 million, $0.5 million and $0.5 million for the years ended December 31, 2020, 2019 and 2018, respectively.

XML 81 R13.htm IDEA: XBRL DOCUMENT v3.20.4
Accrued Liabilities and Other Current Liabilities
12 Months Ended
Dec. 31, 2019
Accounts Payable And Accrued Liabilities Current [Abstract]  
Accrued Liabilities and Other Current Liabilities

4. Accrued Liabilities and Other Current Liabilities

Accrued liabilities and other current liabilities consist of the following (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

Accrued clinical trial and related costs

 

$

11,119

 

 

$

4,056

 

Accrued research and development

 

 

3,082

 

 

 

838

 

Accrued salaries and benefits

 

 

5,094

 

 

 

3,108

 

Accrued legal fees

 

 

252

 

 

 

302

 

Accrued professional fees

 

 

253

 

 

 

195

 

Accrued other liabilities

 

 

602

 

 

 

159

 

Total accrued and other current liabilities

 

$

20,402

 

 

$

8,658

 

 

XML 82 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements
12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements

5. Fair Value Measurements

The following tables present the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands):

 

 

 

Fair Value Measurements at December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

917,485

 

 

$

 

 

$

 

 

$

917,485

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

 

 

 

10,006

 

 

 

 

 

 

10,006

 

Corporate notes

 

 

 

 

 

14,572

 

 

 

 

 

 

14,572

 

Total

 

$

917,485

 

 

$

24,578

 

 

$

 

 

$

942,063

 

 

 

 

Fair Value Measurements at December 31, 2019

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

155,276

 

 

$

 

 

$

 

 

$

155,276

 

Repurchase agreement

 

 

50,000

 

 

 

 

 

 

 

 

 

50,000

 

Commercial paper

 

 

 

 

 

5,987

 

 

 

 

 

 

5,987

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

 

 

 

50,185

 

 

 

 

 

 

50,185

 

Commercial paper

 

 

 

 

 

34,533

 

 

 

 

 

 

34,533

 

Corporate notes

 

 

 

 

 

51,662

 

 

 

 

 

 

51,662

 

Total

 

$

205,276

 

 

$

142,367

 

 

$

 

 

$

347,643

 

 

As of December 31, 2020, the fair value of the liability related to sale of future royalties is based on our current estimates of future royalties expected to be paid to BBA, which are considered Level 3 inputs. Refer to Note 14. There were no liabilities measured at fair value on a recurring and non-recurring basis as of December 31, 2019. There were no transfers of assets or liabilities between the fair value measurement levels during the years ended December 31, 2020 and 2019.

XML 83 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Marketable Securities
12 Months Ended
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]  
Marketable Securities

6. Marketable Securities

The marketable securities are classified as available-for-sale and consist of U.S. treasury securities, corporate notes and commercial paper. The fair value measurement data for marketable securities is obtained from independent pricing services. The Company validates the prices provided by the third-party pricing services by understanding the valuation methods and data sources used and analyzing the pricing data in certain instances.

The following table summarizes the marketable securities (in thousands):

 

 

 

December 31, 2020

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair

Value

 

U.S. treasury securities

 

$

10,003

 

 

$

3

 

 

 

 

 

$

10,006

 

Corporate notes

 

 

14,522

 

 

 

50

 

 

 

 

 

 

14,572

 

Total marketable securities, current

 

$

24,525

 

 

$

53

 

 

$

 

 

$

24,578

 

 

 

 

December 31, 2019

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair

Value

 

U.S. treasury securities

 

$

50,190

 

 

$

 

 

$

(5

)

 

$

50,185

 

Commercial paper

 

 

34,532

 

 

 

1

 

 

 

 

 

 

34,533

 

Corporate notes

 

 

39,956

 

 

 

13

 

 

 

(3

)

 

 

39,966

 

Total marketable securities, current

 

$

124,678

 

 

$

14

 

 

$

(8

)

 

$

124,684

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate notes

 

$

11,692

 

 

$

4

 

 

$

 

 

$

11,696

 

Total marketable securities, noncurrent

 

$

11,692

 

 

$

4

 

 

$

 

 

$

11,696

 

 

 

All marketable securities held at December 31, 2020 had effective maturities of less than one year. There were no realized gains or losses recognized on the sale or maturity of available-for-sale debt securities during the year ended December 31, 2020 and as a result, the Company did not reclassify any amounts out of accumulated comprehensive loss. No marketable securities with unrealized losses as of December 31, 2020. All marketable securities with unrealized losses as of December 31, 2019 have been in a loss position for less than twelve months and the loss is not material. These marketable securities were not considered to be other-than-temporarily impaired.

XML 84 R16.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies
12 Months Ended
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

7. Commitments and Contingencies

Leases

Palo Alto, California Leases

In June 2020, the Company entered into lease agreements for two buildings at 1200 and 1250 Page Mill Road in Palo Alto, California, which are now the Company’s U.S. corporate offices. The facilities are approximately 82,662 square feet and 72,812 square feet, respectively and include office and laboratory space. For 1200 Page Mill Road, the monthly rent during the initial 6.5-year term will be approximately $0.6 million, with annual year-over-year increases of 3% plus certain operating expenses and taxes and total rent abatement of approximately $7.2 million. The Company has an option to extend the lease term for a period of 6.5 years. For 1250 Page Mill Road, the monthly rent during the initial 13-year term will be approximately $0.5 million, with annual year-over-year increases of 3% plus certain operating expenses and taxes and total rent abatement of approximately $6.3 million. The Landlord will provide a tenant improvement allowance of approximately $1.2 million and $10.6 million for each building, respectively. The Company has two options to extend the lease term for a period of 5 years each. The Company determined that the renewal options were not reasonably certain at lease inception for the two buildings. The Company executed a $10.9 million cash-collateralized letter of credit, which was subsequently reduced to $6.2 million as a result of meeting certain reduction requirements specified therein. The cash collateralizing the letter of credit is classified as restricted cash on the Company’s consolidated balance sheets. Under ASC 842, the Company classified these leases as operating leases and recorded right-of-use assets and lease liabilities on the lease commencement date.

The Company continues to lease office and laboratory space at 2631 Hanover Street in Palo Alto, California. The Company entered into a lease agreement in January 2013 which was amended in March 2016 and extended the lease term until October 2023. The Company classified this lease as an operating lease and recorded a right-of-use asset and lease liability on January 1, 2019 and recognized rent expense on a straight-line basis throughout the remaining lease term.

Switzerland Lease

In April 2020, the Company entered into a lease agreement for office and laboratory space at Rottenstrasse 5 in Visp, Switzerland. The space is approximately 1,000 square meters. The initial lease term is 5 years, with automatic renewals every 5 years for a maximum lease term of 15 years. The monthly rent during the initial 5-year term will be approximately 32 thousand Swiss Francs plus certain operating expenses and taxes. Under ASC 842, the Company classified these leases as operating leases and recorded right-of-use assets and lease liabilities on the lease commencement date.

The maturities of the operating lease liabilities as of December 31, 2020 were as follows (in thousands):

 

Year ending December 31,

 

As of

December 31, 2020

 

2021

 

$

4,288

 

2022

 

 

7,660

 

2023

 

 

14,598

 

2024

 

 

15,037

 

2025

 

 

15,475

 

Thereafter

 

 

71,462

 

Total undiscounted lease payments

 

 

128,520

 

Less: imputed interest

 

 

(51,118

)

Total operating lease liabilities

 

$

77,402

 

 

The minimum lease payments above do not include any related common area maintenance charges or real estate taxes. The weighted-average remaining lease terms and weighted-average discount rates were as follows:

 

 

 

December 31,

2020

 

 

December 31,

2019

 

Weighted-average remaining lease term (in years)

 

 

9.5

 

 

 

3.8

 

Weighted-average discount rate

 

 

6.7

%

 

 

8.5

%

 

Embedded lease

In August 2020, the Company and its subsidiary Kodiak Sciences GmbH entered into a manufacturing agreement with a contract manufacturing organization for the clinical and commercial supply of drug substance for KSI-301, the Company’s proprietary therapeutic candidate for the treatment and prevention of retinal vascular diseases. A custom-built manufacturing suite is planned to be completed and dedicated to the manufacture of the Company’s drug substance with an estimated capital contribution of 40 million Swiss Francs from the Company. Construction of the manufacturing suite is targeted for completion in 2021. The Company will be required to pay annual suite fees of 12 million Swiss Francs for 2021 and 16 million Swiss Francs for each year thereafter, which covers the manufacturing fees for a specified number of batches, and the Company may pay for additional batches to be manufactured. The manufacturing agreement has an initial term of eight years, and the Company has the right to extend the term up to a total of 16 years.

The Company concluded that this agreement contains an embedded lease as the custom-built manufacturing suite will be dedicated for the Company’s use. As of December 31, 2020, the Company did not have control of this manufacturing space and therefore, did not record a right-of-use asset and corresponding lease liability. These commitments are not included in the above table.

Manufacturing Agreement

The Company has entered into service agreements with Lonza AG and its affiliates (“Lonza”), pursuant to which Lonza agreed to perform activities in connection with the manufacturing process of certain compounds. Such agreements, and related amendments, state that planned activities that are included in the signed work orders are, in some cases, binding and, hence, obligate the Company to pay the full price of the work order upon satisfactory delivery of products and services or obligate the Company to the binding amount regardless of whether such planned activities are in fact performed. Per the terms of the agreements, the Company has the option to cancel signed orders at any time upon written notice, which may or may not be subject to payment of a cancellation fee. The level of cancellation fees may be dependent on the timing of the written notice in relation to the commencement date of the work, with the maximum cancellation amount dependent on the agreement or the work order. Under these agreements, the total amount of contractual obligations, over a period of ten years, are cancellable and subject to varying levels of cancellation fees, were $242.3 million and $4.7 million, including accrued amounts, as of December 31, 2020 and 2019, respectively. Purchases under this agreement for the years ended December 31, 2020, 2019 and 2018 were $16.8 million, $7.9 million and $2.8 million, respectively. As of December 31, 2020, the Company had not incurred any cancellation fees for the work performed by Lonza.

Other Funding Commitments

In the normal course of business, the Company enters into agreements with third-parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company. As of December 31, 2020 and 2019, the total amount of noncancellable purchase commitments, including potential cancellation fees were $0.5 million and $0.7 million, respectively.

The Company is also party to a cancellable assignment and license agreement that would require the Company to make milestone payments of up to $33.2 million and royalty payments on net sales of products utilizing KSI-201 and related technology. Such milestones and royalties are dependent on future activity or product sales and are not estimable.

The Company has also entered into various cancellable license agreements for certain technology. The Company may be obligated to make payments on future sales of specified products associated with such license agreements. Such payments are dependent on future product sales and are not estimable.

Tenant Improvement Allowance Payable

In May 2013, the Company entered into a tenant improvement allowance agreement with its landlord. The agreement allowed the Company to draw down $0.3 million for tenant improvements related to the office lease over the period from the execution of the agreement to October 2018. The interest rate is 8% per year over the lease period. This tenant improvement allowance was repaid in October 2018.

In March 2016, the Company entered into a lease amendment, under which the Company is allowed to draw down an additional allowance of $0.4 million for tenant improvements related to the office lease over the period from the execution of the agreement to October 2023. The interest rate is 8% per year over 10 years. Principal and interest are payable on the first day of every month.

As of December 31, 2020 and 2019, the current portion of the tenant improvement allowance payable in accrued and other current liabilities was less than $0.1 million and less than $0.1 million, respectively. As of December 31, 2020 and 2019, the non-current portion of the tenant improvement allowance payable in other liabilities was $0.3 million and $0.3 million, respectively.

Legal Proceedings

From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. Management is currently not aware of any matters that could have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount.

Indemnification

To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company’s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not specified in the agreements; however, the Company has director and officer insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.

XML 85 R17.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes
12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes

8. Income Taxes

The provision (benefit) for income taxes consists of the following (in thousands):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Current:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

 

 

$

 

 

$

 

State

 

 

 

 

 

 

 

 

 

Foreign

 

 

14

 

 

 

 

 

 

 

Total current

 

$

14

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

 

 

$

 

 

$

 

State

 

 

 

 

 

 

 

 

 

Foreign

 

 

 

 

 

 

 

 

 

Total deferred

 

$

 

 

$

 

 

$

 

Provision (Benefit) for income taxes

 

$

14

 

 

$

 

 

$

 

 

The components of loss before income taxes were as follows (in thousands):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

United States

 

$

(17,273

)

 

$

2,633

 

 

$

(17,273

)

Foreign

 

 

(115,809

)

 

 

(49,998

)

 

 

(24,170

)

Total loss before income taxes

 

$

(133,082

)

 

$

(47,365

)

 

$

(41,443

)

 

The tax effects of temporary differences that give rise to significant components of the net deferred tax assets are as follows (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

December 31,

2018

 

Deferred tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

28,451

 

 

$

18,523

 

 

$

11,044

 

Intangible assets

 

 

12,088

 

 

 

12,112

 

 

 

7,588

 

Research and development tax credits

 

 

10,527

 

 

 

4,037

 

 

 

1,559

 

Stock-based compensation

 

 

8,405

 

 

 

1,539

 

 

 

394

 

Accruals

 

 

1,367

 

 

 

885

 

 

 

700

 

Operating lease liability

 

 

22,276

 

 

 

577

 

 

 

-

 

Property and equipment

 

 

127

 

 

 

143

 

 

 

109

 

Total deferred tax assets

 

 

83,241

 

 

 

37,816

 

 

 

21,394

 

Valuation allowance

 

 

(62,005

)

 

 

(37,249

)

 

 

(21,394

)

Net deferred tax assets

 

 

21,236

 

 

 

567

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease right-of-use asset

 

 

(21,234

)

 

 

(534

)

 

 

 

Capitalized legal fees

 

 

(2

)

 

 

(33

)

 

 

 

Total deferred tax liabilities

 

 

(21,236

)

 

 

(567

)

 

 

 

Total net deferred tax assets

 

$

 

 

$

 

 

$

 

 

The Company has recorded a full valuation allowance against its net deferred tax assets due to the uncertainty as to whether such assets will be realized. The net change in the total valuation allowance for the years ended December 31, 2020, 2019 and 2018 was an increase of approximately $24.8 million, $15.9 million and $8.2 million, respectively.

NOLs and tax credit carry-forwards are subject to review and possible adjustment by the Internal Revenue Service (“IRS”) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company’s value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed a Section 382 study through December 31, 2020 which concluded no such ownership change had occurred through December 31, 2020.

As of December 31, 2020, the Company had $50.1 million of federal and $171.0 million of state net operating loss available to offset future taxable income. A portion of the federal net operating loss carryforwards begin to expire in 2035 and the state net operating loss carryforwards begin to expire in 2035, if not utilized. $32.0 million of the federal net operating loss are not subject to expiration.

As of December 31, 2020, the Company also had federal and state research and development credit carryforwards of $10.2 million and $4.9 million, respectively. The federal research and development credit carryforwards expire beginning 2035. The California tax credit can be carried forward indefinitely.

A reconciliation of the Company’s effective tax rate to the statutory U.S. federal rate is as follows:

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

December 31,

2018

 

Federal statutory income tax rate

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

State taxes

 

 

4.3

 

 

 

11.0

 

 

 

5.6

 

Foreign tax rate differential

 

 

(7.9

)

 

 

(12.4

)

 

 

(3.8

)

Change in valuation allowance

 

 

(17.3

)

 

 

(30.5

)

 

 

(18.3

)

Stock-based compensation

 

 

6.7

 

 

 

7.7

 

 

 

(0.6

)

Research tax credit

 

 

3.8

 

 

 

3.3

 

 

 

1.3

 

Other

 

 

 

 

 

(0.1

)

 

 

(0.1

)

Sale of future royalties

 

 

(9.4

)

 

 

 

 

 

 

Section 162(m)

 

 

(1.2

)

 

 

 

 

 

 

Fair value adjustments

 

 

 

 

 

 

 

 

(2.4

)

Extinguishment of convertible note

 

 

 

 

 

 

 

 

(2.7

)

Provision for income taxes

 

 

0.0

%

 

 

0.0

%

 

 

0.0

%

 

The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. As of December 31, 2020, 2019 and 2018, none of the unrecognized tax benefits would affect income tax expense with consideration of the valuation allowance. The Company does not anticipate the uncertain tax positions will materially change in the next 12 months. It is the Company's policy to include penalties and interest expense related to income taxes as a component of other expense, net as necessary.

The beginning and ending unrecognized tax benefits amounts are as follows (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

December 31,

2018

 

Unrecognized tax benefits at beginning of period

 

$

1,838

 

 

$

398

 

 

$

357

 

Increases related to prior year tax positions

 

 

 

 

 

 

 

 

-

 

Increases related to current year tax positions

 

 

2,812

 

 

 

1,440

 

 

 

41

 

Unrecognized tax benefits at end of period

 

$

4,650

 

 

$

1,838

 

 

$

398

 

 

The Company files income tax returns in the United States and Switzerland. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits.

XML 86 R18.htm IDEA: XBRL DOCUMENT v3.20.4
Preferred Stock
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Preferred Stock

9. Preferred Stock

As of December 31, 2020 and 2019, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue up to 10,000,000 shares of preferred stock at the par value of $0.0001 per share. As of December 31, 2020, there are no holders of the Company’s preferred stock.

XML 87 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Common Stock
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Common Stock

10. Common Stock

As of December 31, 2020 and 2019, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue 490,000,000 shares of common stock at the par value of $0.0001 per share. Each share of common stock is entitled to one vote. The board of directors may declare and pay dividends to holders of common stock. The Company has never declared or paid any dividends on common stock.

 

The Company had reserved common stock for future issuances as follows:

 

 

 

December 31,

2020

 

 

December 31,

2019

 

Exercise of options outstanding and release of restricted shares

 

 

7,257,221

 

 

 

6,830,442

 

Exercise of common stock warrants outstanding

 

 

399,999

 

 

 

399,999

 

Issuance of common stock under the 2018 Equity Incentive Plan

 

 

2,742,183

 

 

 

2,118,877

 

Issuance of common stock under the 2018 Employee Share Purchase Plan

 

 

460,000

 

 

 

460,000

 

Total

 

 

10,859,403

 

 

 

9,809,318

 

XML 88 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation
12 Months Ended
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-Based Compensation

11. Stock-Based Compensation

2018 Equity Incentive Plan

In August 2018, the Company adopted the 2018 Equity Incentive Plan (“2018 Plan”), which became effective on the business day prior to the effectiveness of the registration statement relating to the IPO. The 2018 Plan initially reserved 4,300,000 shares of common stock for the issuance of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock, restricted stock units (“RSUs”), stock appreciation rights, performance units and performance shares to employees, directors and consultants of the Company. The number of shares available for issuance will increase annually on the first day of each fiscal year beginning in 2019 equal to the least of (1) 4,300,000 shares, and (2) 4% of outstanding shares of common stock as of the last day of the immediately preceding year, and (3) such other amount as determined by the board of directors. The exercise price of options must be equal to at least the fair market value of the common stock on the grant date. For ISOs, the term may not exceed ten years, except in respect to any participant with more than 10% of voting power of all classes or stock, then the term may not exceed five years and the exercise price must be equal to at least 110% of the fair market value of the common stock on the grant date. Options granted generally vest over four years.

The number of shares available for issuance increased by 1,776,761 shares in 2020 and there were 2,742,183 shares available for grant under the 2018 Plan as of December 31, 2020.

Shares Subject to Repurchase

The Company has a right of repurchase with respect to unvested shares issued upon early exercise of options at an amount equal to the lower of (1) the exercise price of each restricted share being repurchased and (2) the fair market value of such restricted share at the time the Company’s right of repurchase is exercised. The Company’s right to repurchase these shares lapses as those shares vest over the requisite service period.

Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as accrued liabilities and other current liabilities on the consolidated balance sheet and is reclassified to common stock and additional paid-in capital as such shares vest. At December 31, 2020 and 2019, there are no early exercised stock options that remained subject to the Company’s right of repurchase.

Stock Options

Stock option activity under the 2018 Plan and 2015 Plan is summarized as follows:

 

 

 

Number

of

Options

 

 

Weighted

Average

Exercise

Price

 

 

Weighted

Average

Remaining

Contractual

Term

(in years)

 

 

Aggregate

Intrinsic

Value

(in thousands)

 

Outstanding at December 31, 2019

 

 

6,671,542

 

 

$

17.90

 

 

 

8.73

 

 

$

362,081

 

Granted

 

 

1,068,335

 

 

$

55.27

 

 

 

 

 

 

 

 

 

Exercised

 

 

(704,675

)

 

$

8.89

 

 

 

 

 

 

 

 

 

Forfeited or canceled

 

 

(137,926

)

 

$

25.07

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

6,897,276

 

 

$

24.52

 

 

 

8.07

 

 

$

841,704

 

Shares exercisable December 31, 2020

 

 

3,769,990

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested and expected to vest December 31, 2020

 

 

6,897,276

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The weighted-average grant date fair value of the stock options granted for 2020, 2019 and 2018 was $32.44, $34.11 and $4.36 per share, respectively. The aggregate intrinsic value represents the value of the Company’s closing stock price on the last trading day of the period in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable.

Employee Stock Options

Prior to the Company’s IPO, the fair value of the shares of common stock underlying the stock options was determined by the board of directors with assistance from management and external appraisers as there has been no historical public market for the Company’s common stock. Subsequent to the Company’s IPO, the fair value of the Company’s common stock is determined based on its closing market price.

The Company estimated the fair value of employee stock options using the Black-Scholes valuation model. The fair value of employee stock options was estimated using the following weighted-average assumptions:

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

 

Expected volatility

 

 

66

%

 

 

68

%

 

 

59

%

 

Risk-free interest rate

 

 

0.39

%

 

 

1.65

%

 

 

2.82

%

 

Dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

 

Expected term

 

 

6.00

 

 

 

5.78

 

 

 

6.06

 

 

 

Expected Term. The expected term is calculated using the simplified method, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.

Expected Volatility. As the Company does not have sufficient trading history for its common stock, our approach to estimating expected volatility is to phase in our own common stock trading history and supplement the remaining historical information with an average historical stock price volatility of a peer group of publicly traded companies to be representative of its expected future stock price volatility. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, the Company measured historical volatility over a period equivalent to the expected term. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

Risk-Free Interest Rate. The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.

Expected Dividend Rate. The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be zero.

The total fair value of employee options vested during the years ended December 31, 2020, 2019 and 2018 was $19.7 million, $4.6 million and $1.2 million, respectively. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for options granted to employees was $20.8 million, $5.7 million and $2.0 million, respectively.

Non-Employee Stock Options

The Company granted 41,500, 15,000 and 215,000 stock options to non-employees during the years ended December 31, 2020, 2019 and 2018, respectively.

Subsequent to the adoption of ASU 2018-07 effective January 1, 2019, existing stock options granted to non-employees will no longer be revalued, and the estimated fair value of new stock options granted to non-employees will be calculated on the date of grant and not remeasured, similar to stock options granted to employees. The fair value of non-employee stock options was estimated using the following weighted-average assumptions:

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Expected volatility

 

 

67

%

 

 

73

%

 

 

68

%

Risk-free interest rate

 

 

0.36

%

 

 

1.61

%

 

 

2.71

%

Dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

Expected term

 

 

5.56

 

 

 

6.08

 

 

 

9.30

 

 

Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for options granted to non-employees was $0.7 million, $0.1 million and $0.4 million, respectively.

Restricted Shares

Restricted share activity, including restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and performance-based restricted stock units (“PSUs”), under the 2018 Plan and 2015 Plan is summarized as follows:

 

 

 

 

Number of

Restricted

Shares

 

 

Weighted

Average

Grant Date

Fair Value

 

Unvested at December 31, 2019

 

 

160,747

 

 

$

60.81

 

Granted

 

 

236,045

 

 

$

52.18

 

Vested

 

 

(23,848

)

 

$

9.21

 

Shares withheld related to net share settlement of RSUs

 

 

(7,999

)

 

$

9.90

 

Canceled

 

 

(5,000

)

 

$

72.46

 

Unvested at December 31, 2020

 

 

359,945

 

 

$

59.54

 

 

Restricted Stock Awards

Under the terms of the restricted stock agreements, the awards vest over four years, which is the requisite service period. Recipients of restricted stock awards generally have voting and dividend rights with respect to such shares upon grant without regard to vesting. Shares of restricted stock that do not vest are subject to forfeiture. The Company recognizes stock-based compensation expense for RSAs on a straight-line basis over the requisite service period for the entire award.

The Company did not grant any RSA to employees in 2020. The total fair value of RSAs vested during the years ended December 31, 2020, 2019 and 2018 was $nil million, less than $0.1 million and $0.2 million, respectively. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for RSAs was $nil million, less than $0.1 million and $0.2 million, respectively.

Restricted Stock Units

RSUs will vest in four equal annual installments over four years, which is the requisite service period after that date.

The Company granted 236,045 RSUs to employees in 2020. The total fair value of RSUs vested during the year ended December 31, 2020 and 2019 was $0.3 million and $0.3 million, respectively. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for RSUs was $1.9 million, $0.3 million, and less than $0.1 million, respectively.

Performance-Based Stock Options and Restricted Stock Units

These performance-based equity awards will vest one-quarter upon the achievement of specific clinical development milestones. The remaining shares will then vest in three equal annual installments after that date. Performance-based stock options are recorded as expense beginning when vesting events are determined to be probable.

The Company did not grant performance-based equity awards to employees in 2020. None of these performance-based equity awards vested during 2020 or 2019. The Company believes that the achievement of the requisite performance condition continues to be probable. Stock-based compensation expense recognized during the years ended December 31, 2020, 2019 and 2018 for the performance-based equity awards was $7.2 million, less than $0.1 million and $nil million, respectively.

The fair value of performance-based stock options was estimated using the following weighted-average assumptions:

 

 

 

 

 

Year Ended

December 31,

2019

 

Expected volatility

 

 

 

 

72

%

Risk-free interest rate

 

 

 

 

1.67

%

Dividend yield

 

 

 

 

0

%

Expected term

 

 

 

 

6.31

 

 

 

The weighted-average grant date fair value was $47.89 per share for performance-based stock options and $73.51 per share for performance-based restricted stock units.

2018 Employee Share Purchase Plan

In August 2018, the Company adopted the 2018 Employee Share Purchase Plan (“ESPP”), which became effective on the business day prior to the effectiveness of the registration statement relating to the IPO. A total of 460,000 shares of common stock were initially reserved for issuance under the ESPP. The initial offering period of the ESPP was authorized by the Company’s board of directors and commenced on January 4, 2021.

Stock-Based Compensation Expense

Stock-based compensation is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

 

Research and development

 

$

16,957

 

 

$

3,496

 

 

$

1,535

 

 

General and administrative

 

 

13,711

 

 

 

2,614

 

 

 

1,073

 

 

Total stock-based compensation

 

$

30,668

 

 

$

6,110

 

 

$

2,608

 

 

 

As of December 31, 2020, the Company had $91.4 million of unrecognized compensation expense related to unvested stock options and unvested restricted stock awards and units that is expected to be recognized over a weighted-average period of 2.9 years.

XML 89 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Net Loss per Share Attributable to Common Stockholders
12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Net Loss per Share Attributable to Common Stockholders

12. Net Loss per Share Attributable to Common Stockholders

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share data):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$

(133,096

)

 

$

(47,365

)

 

$

(41,443

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding

 

 

45,741,845

 

 

 

37,869,291

 

 

 

15,136,197

 

Less: weighted-average unvested restricted shares

   and shares subject to repurchase

 

 

 

 

 

(15,675

)

 

 

(159,682

)

Weighted-average shares outstanding used in

   computing net loss per share attributable to

   common stockholders, basic and diluted

 

 

45,741,845

 

 

 

37,853,616

 

 

 

14,976,515

 

Net loss per share attributable to common stockholders,

   basic and diluted

 

$

(2.91

)

 

$

(1.25

)

 

$

(2.77

)

 

The following potentially dilutive securities, presented on an as-converted to common stock basis, were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive:

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Exercise of options outstanding

 

 

6,897,276

 

 

 

6,671,542

 

 

 

5,135,267

 

Unvested restricted shares

 

 

359,945

 

 

 

160,747

 

 

 

50,450

 

Total

 

 

7,257,221

 

 

 

6,832,289

 

 

 

5,185,717

 

 

XML 90 R22.htm IDEA: XBRL DOCUMENT v3.20.4
401(k) Plan
12 Months Ended
Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]  
401(k) plan

13. 401(k) Plan

In 2011, the Company adopted a 401(k) retirement and savings plan covering all employees. The 401(k) plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The 401(k) plan was amended to include an employer matching provision in 2019. The Company will make matching contributions of 100% of employee contributions up to a maximum of 50% of the individual maximum contribution limit allowed under the IRS rules. For the year ended December 31, 2020 and 2019, the expense related to the matching contributions was $0.6 million and $0.3 million, respectively.

XML 91 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Liability Related to Sale of Future Royalties
12 Months Ended
Dec. 31, 2020
Liability Related To Sale Of Future Royalties [Abstract]  
Liability related to Sale of Future Royalties

14. Liability related to Sale of Future Royalties

On December 1, 2019, the Company and its subsidiary Kodiak Sciences GmbH entered into a funding agreement with BBA, which holds more than 5% of the Company’s stock, pursuant to which BBA purchased the right to receive a capped 4.5% royalty on future net sales of KSI-301, the Company’s anti-VEGF antibody biopolymer conjugate therapy, in exchange for $225.0 million. The royalty terminates upon the date that BBA has received an aggregate amount equal to 4.5 times the funding amount paid to the Company, unless earlier terminated or repurchased by the Company. Under the terms of the funding agreement, there is no obligation to repay any funding amount received, other than through the capped royalty payments on future product revenues. The Company has the option, exercisable at any point during the term of the funding agreement, to repurchase 100% of the royalties due to BBA for a purchase price equal to 4.5 times the funding amount paid to the Company as of such time, less amounts paid by the Company to BBA.

The closing of the funding agreement was subject to certain conditions and occurred in February 2020. The Company received $100.0 million of the funding on February 4, 2020. The remaining $125.0 million, subject to delivery of notice by the Company, payable upon enrollment of 50% of the patients in the RVO clinical program.

The Company recorded the initial $100.0 million payment as a liability on the consolidated balance sheet net of issuance costs. Once royalty payments to BBA are determined to be probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest to accrete the liability on a prospective basis based on such estimates. If and when the Company makes royalty payments under the funding agreement, it would reduce the liability balance at such time. As of December 31, 2020, royalty payments are not probable and estimable.

For the year ended December 31, 2020, no interest expense was recognized for the liability related to the sale of future royalties.

XML 92 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Selected Quarterly Financial Data (Unaudited)
12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Selected Quarterly Financial Data (Unaudited)

15. Selected Quarterly Financial Data (unaudited)

The following table provides the selected quarterly financial information for the years, 2020 and 2019 (in thousands, except per share data):

 

 

 

Three Months Ended

 

 

 

March 31,

2020

 

 

June 30,

2020

 

 

September 30,

2020

 

 

December 31,

2020

 

Loss from operations

 

$

(25,723

)

 

$

(26,779

)

 

$

(36,663

)

 

$

(46,842

)

Net loss

 

$

(24,392

)

 

$

(25,999

)

 

$

(36,122

)

 

$

(46,583

)

Net loss per share attributable to common

   stockholders, basic and diluted

 

$

(0.54

)

 

$

(0.58

)

 

$

(0.80

)

 

$

(0.97

)

 

 

 

Three Months Ended

 

 

 

March 31,

2019

 

 

June 30,

2019

 

 

September 30,

2019

 

 

December 31,

2019

 

Loss from operations

 

$

(8,460

)

 

$

(11,814

)

 

$

(12,732

)

 

$

(16,184

)

Net loss

 

$

(7,984

)

 

$

(11,385

)

 

$

(12,380

)

 

$

(15,616

)

Net loss per share attributable to common

   stockholders, basic and diluted

 

$

(0.21

)

 

$

(0.31

)

 

$

(0.33

)

 

$

(0.40

)

 

XML 93 R25.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).

Reclassification

Reclassification

Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation.

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the Company’s accounts and the accounts of Kodiak Sciences Financing Corporation and Kodiak Sciences China, the Company’s direct wholly owned subsidiaries, incorporated in the United States and Cayman Islands, respectively, and Kodiak Sciences GmbH and Kodiak Sciences Valais GmbH, the Company’s indirect wholly owned subsidiaries, both incorporated in Switzerland. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar. The aggregate foreign currency transaction loss included in determining net loss was $0.3 million, less than $0.1 million and $0.3 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Segments

Segments

The Company operates and manages its business as one reportable and operating segment, which is the business of research and development of drugs for ophthalmic diseases. The chief operating decision maker reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.

Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and expenses during the reporting period. The impact of the ongoing COVID-19 pandemic continues to evolve. As a result, certain estimates and assumptions required increased judgment and carried a higher degree of variability and volatility, including but not limited to, the fair value of marketable securities, performance-based equity awards, and research and development accruals. As events continue to unfold and additional information becomes available, these estimates may change materially in future periods. Actual results could differ from those estimates.

Risk and Uncertainties

Risk and Uncertainties

In March 2020, the World Health Organization declared a pandemic due to the global COVID-19 outbreak. The significant uncertainties caused by the ongoing COVID-19 pandemic may negatively impact the Company’s operations, liquidity, and capital resources and will depend on certain evolving developments, including the duration and spread of the outbreak, regulatory and private sector responses and the impact on employees and vendors including supply chain and clinical partners, all of which are uncertain and cannot be predicted. During this pandemic, the Company continues to work closely with clinical sites towards maximal patient safety and the lowest number of missed visits and study discontinuations. The Company has taken and continues to take proactive measures to maintain the integrity of its ongoing clinical studies. Despite these efforts, the ongoing COVID-19 pandemic could significantly impact clinical trial enrollment and completion of its clinical studies. The Company will continue to monitor the COVID-19 situation and its impact on the ability to continue the development of, and seek regulatory approvals for, the Company’s product candidates, and begin to commercialize any approved products.

The Company’s future results of operations involve a number of risks and uncertainties common to clinical-stage companies in the biotechnology industry. The Company’s product candidates are in development and the Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s potential drug candidates, uncertainty of market acceptance of any of the Company’s product candidates that receive regulatory approval, competition from new technological innovations, substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals, contract manufacturer and research organizations, and other suppliers.

Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that any of the Company’s product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approvals, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. 

The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be on terms acceptable by the Company.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2020 and 2019, cash, cash equivalents and marketable securities were invested primarily in money market funds, overnight repurchase agreements, U.S. treasury securities, commercial paper and corporate notes through highly rated financial institutions. Investments are restricted, in accordance with the Company’s investment policy, to a concentration limit per issuer or sector.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with stated maturities of three months or less at the date of purchase to be cash equivalents.

Marketable Securities

Marketable Securities

The Company invests excess cash balances in marketable securities. The investments in marketable securities are classified as either held-to-maturity or available-for-sale based on facts and circumstances present at the time of purchase. Marketable securities with a remaining maturity date greater than one year are classified as non-current. The Company’s marketable securities consist of U.S. treasury securities, commercial paper, and corporate bonds. Marketable securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium or discount arising at purchase of marketable debt securities is amortized and/or accreted to other income (expense), net over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense), net.

If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is “other-than-temporary” and, if so, marks the investment to market through a charge to the Company’s statement of operations and comprehensive loss.

Restricted Cash

Restricted Cash

As of December 31, 2020, and 2019, the Company had $6.3 million and $0.1 million, respectively, of long-term restricted cash deposited with a financial institution. The entire amount is held in separate bank accounts to support letter of credit agreements related to the Company’s U.S. corporate offices.

Fair Value Measurements

Fair Value of Financial Instruments

Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company's own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:

Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and inputs to the model.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities and other current liabilities, approximate fair value due to their relatively short maturities.

Leases

Leases

The Company determines if an arrangement is, or contains, a lease at inception and then classifies the lease as operating or financing based on the underlying terms and conditions of the contract. Leases with terms greater than one year are initially recognized on the balance sheet as right-of-use assets and lease liabilities based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term and in a similar economic environment of the applicable country or region. Variable lease payments are excluded from the right of use assets and operating lease liabilities and are recognized in the period in which the obligation for those payments is incurred.

Property and Equipment, Net

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over the estimated useful lives of assets, which is generally four years for laboratory equipment, three years for computer equipment and office equipment, five years for computer software and five to seven years for furniture and fixtures. Leasehold improvements are stated at cost and amortized over the shorter of the useful life of the assets or the length of the lease. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the assets. There have been no such impairments of long-lived assets in the years ended December 31, 2020 and 2019.

Research and Development Expenses

Research and Development Expenses

Costs related to research, design and development of products are charged to research and development expense as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, including stock-based compensation, laboratory supplies, outside services and allocated overhead, including rent, equipment, depreciation and utilities.

Accrued Research And Development

Accrued Research and Development

The Company has entered into various agreements with various third parties, including clinical investigator sites, contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), to provide research and development activities. The Company’s accrued research and development costs are estimated based on the level of services performed, including the phase or completion of events, and contracted costs. Accrued clinical trial and related costs are estimated using data such as patient enrollment, clinical site activations or information provided by outside service providers regarding their actual costs incurred. Management determined accrual estimates through reports from and discussions with clinical personnel and outside service providers as to the progress of trials, or the services completed. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses or other assets until the services are rendered.

Stock-Based Compensation

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, Compensation-Stock Compensation. The Company measures stock-based compensation expense for stock options and restricted stock units granted to its employees, directors and non-employees based on the estimated fair value of the awards on the grant date. The fair value of options is calculated using the Black-Scholes valuation model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. The expense is recorded on a straight-line basis over the requisite service period, which is generally the vesting period, for the entire award. The Company accounts for forfeitures as they occur.

Prior to the adoption of Accounting Standards Update ("ASU") No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"), the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. After adoption of ASU 2018-07 as of January 1, 2019, the measurement date for non-employee awards is the date of grant without changes in the fair value of the award.

The Company has certain stock options and restricted stock units that vest in conjunction with certain performance conditions. At each reporting date, the Company is required to evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon the Company's assessment of accomplishing each performance provision.

Income Taxes

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses (“NOLs”) and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.

The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Comprehensive Loss

Comprehensive Loss

Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists primarily of unrealized gains and losses on debt securities.

Liability related to Sale of Future Royalties

Liability related to Sale of Future Royalties

On December 1, 2019, the Company and its subsidiary Kodiak Sciences GmbH entered into a funding agreement with Baker Bros. Advisors, LP (“BBA”), which holds more than 5% of the Company’s stock, pursuant to which BBA purchased the right to receive a capped 4.5% royalty on future net sales of KSI-301, the Company’s anti-VEGF antibody biopolymer conjugate therapy, in exchange for $225.0 million. Under the terms of the funding agreement, there is no obligation to repay any funding amount received, other than through the capped royalty payments on future product revenues. The Company recorded the funding amount paid by BBA as a liability on the consolidated balance sheet net of issuance costs, in accordance with ASC 730, Research and Development. Under ASC 730, the significant related party relationship between the Company and BBA creates an implicit obligation to repay the funding amount paid to the Company. Once royalty payments to BBA are determined to be probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest to accrete the liability on a prospective basis based on such estimates. If and when the Company makes royalty payments under the funding agreement, it would reduce the liability balance at such time. Refer to Note 14.

Credit Losses – Available-for-Sale Debt Securities

Credit Losses – Available-for-Sale Debt Securities

For available-for-sale debt securities in an unrealized loss position, the Company will periodically assess its portfolio for impairment. The assessment first considers the intent or requirement to sell the security. If either of these criteria are met, the amortized cost basis will be written down to fair value through earnings.

If not met, the Company will evaluate whether the decline resulted from credit losses or other factors by considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses will be recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.

Net Loss per Share Attributable to Common Stockholders

Net Loss per Share Attributable to Common Stockholders

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, the redeemable convertible preferred stock, preferred stock warrants, convertible notes, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. The Company’s participating securities do not have a contractual obligation to share in the Company’s losses. As such, the net loss is attributed entirely to common stockholders. Since the Company has reported net loss for all periods presented, diluted net loss per share is the same as basic net loss per common share for those periods.

Recent Accounting Pronouncements

Recent accounting pronouncements

From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified effective date, unless otherwise discussed below.

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). In July 2018, the FASB issued ASU 2018-10, Leases (Topic 842), Codification Improvements, and ASU 2018-11, Leases (Topic 842), Targeted Improvements. ASU 2018-10 clarified certain provisions and corrected unintended applications of the guidance such as the application of implicit rate, lessee reassessment of lease classification, and certain transition adjustments that should be recognized to earnings rather than to stockholders' equity. ASU 2018-11 provided an alternative transition method and practical expedient for separating contract components for the adoption of Topic 842. ASU 2016-02, ASU 2018-10, and ASU 2018-11 (collectively, "the new lease standards") superseded the previous leases standard, ASC 840 Leases.

The Company adopted ASC 842 effective January 1, 2019 using the modified retrospective approach to recognize a cumulative-effect adjustment on the effective date and to not adjust financial information and disclosures required under the new lease standards for comparative prior periods. The Company did not elect for the package of practical expedients and assessed all contracts at the transition date. The Company did not utilize the practical expedient which allows the use of hindsight in determining lease term and assessing impairment in right-of-use assets. The Company elected to apply the practical expedient and accounted for each lease component and related non-lease component as one single component. The Company elected the practical expedient not to recognize leases with terms of one year or less on the balance sheet. 

The adoption of the new lease standards on January 1, 2019 resulted in the initial recognition of right-of-use asset of $2.2 million and operating lease liability of $2.3 million and derecognition of noncurrent deferred liabilities of $0.2 million related to the operating lease for the Company’s office and laboratory space in Palo Alto, California on the consolidated balance sheets with no material impact to the consolidated statements of operations, stockholders’ equity or cash flows. Refer to Note 7.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 362): Measurement of Credit Losses on Financial Statements and ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. The Company assessed the impact of ASU 2016-13 on its available-for-sale debt securities and determined there were no credit losses within the portfolio requiring an allowance upon adoption. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB’s disclosure framework project. Among the changes, entities will no longer be required to disclose the amount of and reasons for transfers between Levels 1 and 2 of the fair value hierarchy but will be required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.

In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which clarifies the accounting for implementation, set-up, and other upfront costs incurred in cloud computing arrangements. The Company adopted this new guidance as of January 1, 2020, which did not impact its consolidated financial statements and related disclosures.

New Accounting Pronouncements Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein, and early adoption is permitted. The Company has early adopted ASU 2019-12 in 2020; the effect was not material on the Company’s financial statements.

 

XML 94 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Property and Equipment, Net (Tables)
12 Months Ended
Dec. 31, 2020
Property Plant And Equipment [Abstract]  
Summary of Property and Equipment, net

Property and equipment, net consists of the following (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

 

 

 

 

 

 

 

 

Leasehold improvement

 

$

1,285

 

 

$

1,265

 

Laboratory equipment

 

 

3,351

 

 

 

1,125

 

Furniture and fixtures

 

 

214

 

 

 

204

 

Computer hardware

 

 

31

 

 

 

 

Computer software

 

 

89

 

 

 

79

 

Office equipment

 

 

107

 

 

 

94

 

Construction in progress

 

 

2,229

 

 

 

 

Total property and equipment

 

 

7,306

 

 

 

2,767

 

Less: Accumulated depreciation

 

 

(2,170

)

 

 

(1,771

)

Property and equipment, net

 

$

5,136

 

 

$

996

 

XML 95 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Accrued Liabilities and Other Current Liabilities (Tables)
12 Months Ended
Dec. 31, 2019
Accounts Payable And Accrued Liabilities Current [Abstract]  
Schedule of Accrued Liabilities and Other Current Liabilities

Accrued liabilities and other current liabilities consist of the following (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

Accrued clinical trial and related costs

 

$

11,119

 

 

$

4,056

 

Accrued research and development

 

 

3,082

 

 

 

838

 

Accrued salaries and benefits

 

 

5,094

 

 

 

3,108

 

Accrued legal fees

 

 

252

 

 

 

302

 

Accrued professional fees

 

 

253

 

 

 

195

 

Accrued other liabilities

 

 

602

 

 

 

159

 

Total accrued and other current liabilities

 

$

20,402

 

 

$

8,658

 

 

XML 96 R28.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis

The following tables present the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands):

 

 

 

Fair Value Measurements at December 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

917,485

 

 

$

 

 

$

 

 

$

917,485

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

 

 

 

10,006

 

 

 

 

 

 

10,006

 

Corporate notes

 

 

 

 

 

14,572

 

 

 

 

 

 

14,572

 

Total

 

$

917,485

 

 

$

24,578

 

 

$

 

 

$

942,063

 

 

 

 

Fair Value Measurements at December 31, 2019

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

155,276

 

 

$

 

 

$

 

 

$

155,276

 

Repurchase agreement

 

 

50,000

 

 

 

 

 

 

 

 

 

50,000

 

Commercial paper

 

 

 

 

 

5,987

 

 

 

 

 

 

5,987

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

 

 

 

 

50,185

 

 

 

 

 

 

50,185

 

Commercial paper

 

 

 

 

 

34,533

 

 

 

 

 

 

34,533

 

Corporate notes

 

 

 

 

 

51,662

 

 

 

 

 

 

51,662

 

Total

 

$

205,276

 

 

$

142,367

 

 

$

 

 

$

347,643

 

 

XML 97 R29.htm IDEA: XBRL DOCUMENT v3.20.4
Marketable Securities (Tables)
12 Months Ended
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]  
Summary of Marketable Securities Held

The following table summarizes the marketable securities (in thousands):

 

 

 

December 31, 2020

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair

Value

 

U.S. treasury securities

 

$

10,003

 

 

$

3

 

 

 

 

 

$

10,006

 

Corporate notes

 

 

14,522

 

 

 

50

 

 

 

 

 

 

14,572

 

Total marketable securities, current

 

$

24,525

 

 

$

53

 

 

$

 

 

$

24,578

 

 

 

 

December 31, 2019

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair

Value

 

U.S. treasury securities

 

$

50,190

 

 

$

 

 

$

(5

)

 

$

50,185

 

Commercial paper

 

 

34,532

 

 

 

1

 

 

 

 

 

 

34,533

 

Corporate notes

 

 

39,956

 

 

 

13

 

 

 

(3

)

 

 

39,966

 

Total marketable securities, current

 

$

124,678

 

 

$

14

 

 

$

(8

)

 

$

124,684

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate notes

 

$

11,692

 

 

$

4

 

 

$

 

 

$

11,696

 

Total marketable securities, noncurrent

 

$

11,692

 

 

$

4

 

 

$

 

 

$

11,696

 

 

 

XML 98 R30.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]  
Summary of Maturities of Operating Lease Liabilities

The maturities of the operating lease liabilities as of December 31, 2020 were as follows (in thousands):

 

Year ending December 31,

 

As of

December 31, 2020

 

2021

 

$

4,288

 

2022

 

 

7,660

 

2023

 

 

14,598

 

2024

 

 

15,037

 

2025

 

 

15,475

 

Thereafter

 

 

71,462

 

Total undiscounted lease payments

 

 

128,520

 

Less: imputed interest

 

 

(51,118

)

Total operating lease liabilities

 

$

77,402

 

Summary of Lessee, Weighted Average Remaining Lease Term and Weighted Average Discount Rates The weighted-average remaining lease terms and weighted-average discount rates were as follows:

 

 

December 31,

2020

 

 

December 31,

2019

 

Weighted-average remaining lease term (in years)

 

 

9.5

 

 

 

3.8

 

Weighted-average discount rate

 

 

6.7

%

 

 

8.5

%

 

XML 99 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Schedule of Provision (Benefit) for Income Taxes

The provision (benefit) for income taxes consists of the following (in thousands):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Current:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

 

 

$

 

 

$

 

State

 

 

 

 

 

 

 

 

 

Foreign

 

 

14

 

 

 

 

 

 

 

Total current

 

$

14

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

 

 

$

 

 

$

 

State

 

 

 

 

 

 

 

 

 

Foreign

 

 

 

 

 

 

 

 

 

Total deferred

 

$

 

 

$

 

 

$

 

Provision (Benefit) for income taxes

 

$

14

 

 

$

 

 

$

 

Components of Loss before Income Taxes

 

The components of loss before income taxes were as follows (in thousands):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

United States

 

$

(17,273

)

 

$

2,633

 

 

$

(17,273

)

Foreign

 

 

(115,809

)

 

 

(49,998

)

 

 

(24,170

)

Total loss before income taxes

 

$

(133,082

)

 

$

(47,365

)

 

$

(41,443

)

Components of Deferred Tax Assets

The tax effects of temporary differences that give rise to significant components of the net deferred tax assets are as follows (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

December 31,

2018

 

Deferred tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

28,451

 

 

$

18,523

 

 

$

11,044

 

Intangible assets

 

 

12,088

 

 

 

12,112

 

 

 

7,588

 

Research and development tax credits

 

 

10,527

 

 

 

4,037

 

 

 

1,559

 

Stock-based compensation

 

 

8,405

 

 

 

1,539

 

 

 

394

 

Accruals

 

 

1,367

 

 

 

885

 

 

 

700

 

Operating lease liability

 

 

22,276

 

 

 

577

 

 

 

-

 

Property and equipment

 

 

127

 

 

 

143

 

 

 

109

 

Total deferred tax assets

 

 

83,241

 

 

 

37,816

 

 

 

21,394

 

Valuation allowance

 

 

(62,005

)

 

 

(37,249

)

 

 

(21,394

)

Net deferred tax assets

 

 

21,236

 

 

 

567

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease right-of-use asset

 

 

(21,234

)

 

 

(534

)

 

 

 

Capitalized legal fees

 

 

(2

)

 

 

(33

)

 

 

 

Total deferred tax liabilities

 

 

(21,236

)

 

 

(567

)

 

 

 

Total net deferred tax assets

 

$

 

 

$

 

 

$

 

Schedule of Reconciliation of Effective Tax Rate to Statutory U.S. Federal Rate

A reconciliation of the Company’s effective tax rate to the statutory U.S. federal rate is as follows:

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

December 31,

2018

 

Federal statutory income tax rate

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

State taxes

 

 

4.3

 

 

 

11.0

 

 

 

5.6

 

Foreign tax rate differential

 

 

(7.9

)

 

 

(12.4

)

 

 

(3.8

)

Change in valuation allowance

 

 

(17.3

)

 

 

(30.5

)

 

 

(18.3

)

Stock-based compensation

 

 

6.7

 

 

 

7.7

 

 

 

(0.6

)

Research tax credit

 

 

3.8

 

 

 

3.3

 

 

 

1.3

 

Other

 

 

 

 

 

(0.1

)

 

 

(0.1

)

Sale of future royalties

 

 

(9.4

)

 

 

 

 

 

 

Section 162(m)

 

 

(1.2

)

 

 

 

 

 

 

Fair value adjustments

 

 

 

 

 

 

 

 

(2.4

)

Extinguishment of convertible note

 

 

 

 

 

 

 

 

(2.7

)

Provision for income taxes

 

 

0.0

%

 

 

0.0

%

 

 

0.0

%

Summary of Unrecognized Tax Benefits Amounts

The beginning and ending unrecognized tax benefits amounts are as follows (in thousands):

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

December 31,

2018

 

Unrecognized tax benefits at beginning of period

 

$

1,838

 

 

$

398

 

 

$

357

 

Increases related to prior year tax positions

 

 

 

 

 

 

 

 

-

 

Increases related to current year tax positions

 

 

2,812

 

 

 

1,440

 

 

 

41

 

Unrecognized tax benefits at end of period

 

$

4,650

 

 

$

1,838

 

 

$

398

 

XML 100 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Common Stock (Tables)
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Schedule of Common Stock Reserved for Future Issuances

 

The Company had reserved common stock for future issuances as follows:

 

 

 

December 31,

2020

 

 

December 31,

2019

 

Exercise of options outstanding and release of restricted shares

 

 

7,257,221

 

 

 

6,830,442

 

Exercise of common stock warrants outstanding

 

 

399,999

 

 

 

399,999

 

Issuance of common stock under the 2018 Equity Incentive Plan

 

 

2,742,183

 

 

 

2,118,877

 

Issuance of common stock under the 2018 Employee Share Purchase Plan

 

 

460,000

 

 

 

460,000

 

Total

 

 

10,859,403

 

 

 

9,809,318

 

XML 101 R33.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of Stock Options Activity Under 2018 Plan and 2015 Plan

Stock option activity under the 2018 Plan and 2015 Plan is summarized as follows:

 

 

 

Number

of

Options

 

 

Weighted

Average

Exercise

Price

 

 

Weighted

Average

Remaining

Contractual

Term

(in years)

 

 

Aggregate

Intrinsic

Value

(in thousands)

 

Outstanding at December 31, 2019

 

 

6,671,542

 

 

$

17.90

 

 

 

8.73

 

 

$

362,081

 

Granted

 

 

1,068,335

 

 

$

55.27

 

 

 

 

 

 

 

 

 

Exercised

 

 

(704,675

)

 

$

8.89

 

 

 

 

 

 

 

 

 

Forfeited or canceled

 

 

(137,926

)

 

$

25.07

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2020

 

 

6,897,276

 

 

$

24.52

 

 

 

8.07

 

 

$

841,704

 

Shares exercisable December 31, 2020

 

 

3,769,990

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested and expected to vest December 31, 2020

 

 

6,897,276

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value of Employee Stock Options Estimated Using Weighted-average Assumptions

The Company estimated the fair value of employee stock options using the Black-Scholes valuation model. The fair value of employee stock options was estimated using the following weighted-average assumptions:

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

 

Expected volatility

 

 

66

%

 

 

68

%

 

 

59

%

 

Risk-free interest rate

 

 

0.39

%

 

 

1.65

%

 

 

2.82

%

 

Dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

 

Expected term

 

 

6.00

 

 

 

5.78

 

 

 

6.06

 

 

Fair Value of Non-Employee Stock Options Estimated Using Weighted-average Assumptions The fair value of non-employee stock options was estimated using the following weighted-average assumptions:

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Expected volatility

 

 

67

%

 

 

73

%

 

 

68

%

Risk-free interest rate

 

 

0.36

%

 

 

1.61

%

 

 

2.71

%

Dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

Expected term

 

 

5.56

 

 

 

6.08

 

 

 

9.30

 

 

Summary of Restricted Shares

Restricted share activity, including restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and performance-based restricted stock units (“PSUs”), under the 2018 Plan and 2015 Plan is summarized as follows:

 

 

 

 

Number of

Restricted

Shares

 

 

Weighted

Average

Grant Date

Fair Value

 

Unvested at December 31, 2019

 

 

160,747

 

 

$

60.81

 

Granted

 

 

236,045

 

 

$

52.18

 

Vested

 

 

(23,848

)

 

$

9.21

 

Shares withheld related to net share settlement of RSUs

 

 

(7,999

)

 

$

9.90

 

Canceled

 

 

(5,000

)

 

$

72.46

 

Unvested at December 31, 2020

 

 

359,945

 

 

$

59.54

 

 

Fair Value of Performance Based Awards and RSUs Estimated Using Weighted-average Assumptions

The fair value of performance-based stock options was estimated using the following weighted-average assumptions:

 

 

 

 

 

Year Ended

December 31,

2019

 

Expected volatility

 

 

 

 

72

%

Risk-free interest rate

 

 

 

 

1.67

%

Dividend yield

 

 

 

 

0

%

Expected term

 

 

 

 

6.31

 

 

 

Summary of Stock-based Compensation Classified in Condensed Consolidated Statements of Operations and Comprehensive Loss

Stock-based compensation is classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

 

Research and development

 

$

16,957

 

 

$

3,496

 

 

$

1,535

 

 

General and administrative

 

 

13,711

 

 

 

2,614

 

 

 

1,073

 

 

Total stock-based compensation

 

$

30,668

 

 

$

6,110

 

 

$

2,608

 

 

XML 102 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Net Loss per Share Attributable to Common Stockholders (Tables)
12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share data):

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$

(133,096

)

 

$

(47,365

)

 

$

(41,443

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding

 

 

45,741,845

 

 

 

37,869,291

 

 

 

15,136,197

 

Less: weighted-average unvested restricted shares

   and shares subject to repurchase

 

 

 

 

 

(15,675

)

 

 

(159,682

)

Weighted-average shares outstanding used in

   computing net loss per share attributable to

   common stockholders, basic and diluted

 

 

45,741,845

 

 

 

37,853,616

 

 

 

14,976,515

 

Net loss per share attributable to common stockholders,

   basic and diluted

 

$

(2.91

)

 

$

(1.25

)

 

$

(2.77

)

 

Summary of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share

The following potentially dilutive securities, presented on an as-converted to common stock basis, were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive:

 

 

 

Year Ended

December 31,

2020

 

 

Year Ended

December 31,

2019

 

 

Year Ended

December 31,

2018

 

Exercise of options outstanding

 

 

6,897,276

 

 

 

6,671,542

 

 

 

5,135,267

 

Unvested restricted shares

 

 

359,945

 

 

 

160,747

 

 

 

50,450

 

Total

 

 

7,257,221

 

 

 

6,832,289

 

 

 

5,185,717

 

 

XML 103 R35.htm IDEA: XBRL DOCUMENT v3.20.4
Selected Quarterly Financial Data (Unaudited) (Tables)
12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information

The following table provides the selected quarterly financial information for the years, 2020 and 2019 (in thousands, except per share data):

 

 

 

Three Months Ended

 

 

 

March 31,

2020

 

 

June 30,

2020

 

 

September 30,

2020

 

 

December 31,

2020

 

Loss from operations

 

$

(25,723

)

 

$

(26,779

)

 

$

(36,663

)

 

$

(46,842

)

Net loss

 

$

(24,392

)

 

$

(25,999

)

 

$

(36,122

)

 

$

(46,583

)

Net loss per share attributable to common

   stockholders, basic and diluted

 

$

(0.54

)

 

$

(0.58

)

 

$

(0.80

)

 

$

(0.97

)

 

 

 

Three Months Ended

 

 

 

March 31,

2019

 

 

June 30,

2019

 

 

September 30,

2019

 

 

December 31,

2019

 

Loss from operations

 

$

(8,460

)

 

$

(11,814

)

 

$

(12,732

)

 

$

(16,184

)

Net loss

 

$

(7,984

)

 

$

(11,385

)

 

$

(12,380

)

 

$

(15,616

)

Net loss per share attributable to common

   stockholders, basic and diluted

 

$

(0.21

)

 

$

(0.31

)

 

$

(0.33

)

 

$

(0.40

)

 

XML 104 R36.htm IDEA: XBRL DOCUMENT v3.20.4
The Company - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Oct. 09, 2018
Nov. 30, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Line Items]            
Net proceeds from initial public offering           $ 83,500
Net proceeds from issuance of common stock       $ 612,016 $ 297,616 $ 83,755
Redeemable Convertible Preferred Stock            
Organization Consolidation And Presentation Of Financial Statements [Line Items]            
Conversion of redeemable convertible preferred stock into common stock, shares           (12,385,154)
Common Stock            
Organization Consolidation And Presentation Of Financial Statements [Line Items]            
Stock issued during period       5,972,222 6,900,000 9,400,000
Conversion of 2017 and 2018 convertible notes into common stock, shares           6,932,969
Initial Public Offering | Common Stock            
Organization Consolidation And Presentation Of Financial Statements [Line Items]            
Stock issued during period           9,400,000
Share issued price, per share           $ 10.00
Gross proceeds from initial public offering           $ 94,000
Conversion of redeemable convertible preferred stock into common stock, shares 12,385,154          
Initial Public Offering | Common Stock | 2017 Convertible Notes            
Organization Consolidation And Presentation Of Financial Statements [Line Items]            
Conversion of 2017 and 2018 convertible notes into common stock, shares 2,637,292          
Initial Public Offering | Common Stock | 2018 Convertible Notes            
Organization Consolidation And Presentation Of Financial Statements [Line Items]            
Conversion of 2017 and 2018 convertible notes into common stock, shares 4,295,677          
Initial Public Offering | Common Stock | Redeemable Convertible Preferred Stock | Warrants Exercised Into Convertible Preferred Shares Then Converted            
Organization Consolidation And Presentation Of Financial Statements [Line Items]            
Warrants exercised into common stock shares 100,000          
Initial Public Offering | Common Stock | Redeemable Convertible Preferred Stock | Warrant            
Organization Consolidation And Presentation Of Financial Statements [Line Items]            
Conversion of preferred stock warrants into common stock warrants, shares 500,000          
Follow-On Offering            
Organization Consolidation And Presentation Of Financial Statements [Line Items]            
Gross proceeds from issuance of common stock   $ 645,000 $ 317,400      
Net proceeds from issuance of common stock   $ 612,000 $ 297,600      
Follow-On Offering | Common Stock            
Organization Consolidation And Presentation Of Financial Statements [Line Items]            
Stock issued during period   5,972,222 6,900,000      
Share issued price, per share   $ 108.00 $ 46.00   $ 46.00  
XML 105 R37.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Additional Information (Details)
12 Months Ended
Dec. 01, 2019
USD ($)
Dec. 31, 2020
USD ($)
Segment
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jan. 01, 2019
USD ($)
Summary of Significant Accounting Policies [Line Items]          
Foreign currency transaction loss   $ (300,000)   $ (300,000)  
Number of reportable segments | Segment   1      
Number of operating segments | Segment   1      
Long-term restricted cash   $ 6,324,000 $ 140,000 $ 140,000  
Impairment of long-lived assets   0 0    
Unrecognized tax benefits, interest and penalties charged   0      
Operating lease right-of-use asset   73,672,000 1,790,000    
Operating lease liability   77,402,000      
Accounting Standards Update 2016-02          
Summary of Significant Accounting Policies [Line Items]          
Operating lease right-of-use asset         $ 2,200,000
Operating lease liability         2,300,000
Derecognition of noncurrent deferred liabilities         $ 200,000
ASU 2016-13          
Summary of Significant Accounting Policies [Line Items]          
Allowance for credit losses for available-for-sale debt securities   $ 0      
Baker Bros. Advisors LP | Funding Agreement          
Summary of Significant Accounting Policies [Line Items]          
Capped percentage of royalty on future net sales 4.50%        
Contractual obligation under funding agreement $ 225,000,000.0        
Laboratory Equipment          
Summary of Significant Accounting Policies [Line Items]          
Property and equipment estimated useful lives of assets   4 years      
Computer Equipment and Office Equipment          
Summary of Significant Accounting Policies [Line Items]          
Property and equipment estimated useful lives of assets   3 years      
Computer Software          
Summary of Significant Accounting Policies [Line Items]          
Property and equipment estimated useful lives of assets   5 years      
Deposited with Financial Institution          
Summary of Significant Accounting Policies [Line Items]          
Long-term restricted cash   $ 6,300,000 100,000    
Maximum          
Summary of Significant Accounting Policies [Line Items]          
Foreign currency transaction loss     $ (100,000)    
Maximum | Furniture and Fixtures          
Summary of Significant Accounting Policies [Line Items]          
Property and equipment estimated useful lives of assets   7 years      
Minimum | Baker Bros. Advisors LP | Funding Agreement          
Summary of Significant Accounting Policies [Line Items]          
Ownership percentage threshold 5.00%        
Minimum | Furniture and Fixtures          
Summary of Significant Accounting Policies [Line Items]          
Property and equipment estimated useful lives of assets   5 years      
XML 106 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Property Plant and Equipment [Line Items]    
Total property and equipment $ 7,306 $ 2,767
Less: Accumulated depreciation (2,170) (1,771)
Property and equipment, net 5,136 996
Leasehold Improvement    
Property Plant and Equipment [Line Items]    
Total property and equipment 1,285 1,265
Laboratory Equipment    
Property Plant and Equipment [Line Items]    
Total property and equipment 3,351 1,125
Furniture and Fixtures    
Property Plant and Equipment [Line Items]    
Total property and equipment 214 204
Computer Hardware    
Property Plant and Equipment [Line Items]    
Total property and equipment 31  
Computer Software    
Property Plant and Equipment [Line Items]    
Total property and equipment 89 79
Office Equipment    
Property Plant and Equipment [Line Items]    
Total property and equipment 107 $ 94
Construction in Progress    
Property Plant and Equipment [Line Items]    
Total property and equipment $ 2,229  
XML 107 R39.htm IDEA: XBRL DOCUMENT v3.20.4
Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Property Plant And Equipment [Abstract]      
Depreciation $ 477 $ 538 $ 490
XML 108 R40.htm IDEA: XBRL DOCUMENT v3.20.4
Accrued Liabilities and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Accounts Payable And Accrued Liabilities Current [Abstract]    
Accrued clinical trial and related costs $ 11,119 $ 4,056
Accrued research and development 3,082 838
Accrued salaries and benefits 5,094 3,108
Accrued legal fees 252 302
Accrued professional fees 253 195
Accrued other liabilities 602 159
Total accrued and other current liabilities $ 20,402 $ 8,658
XML 109 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements - Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total $ 942,063 $ 347,643
Money Market Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents 917,485 155,276
U.S. Treasury Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 10,006 50,185
Corporate Notes    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 14,572 51,662
Repurchase Agreement    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents   50,000
Commercial Paper    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents   5,987
Marketable securities   34,533
Quoted Price in Active Markets (Level 1)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total 917,485 205,276
Quoted Price in Active Markets (Level 1) | Money Market Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents 917,485 155,276
Quoted Price in Active Markets (Level 1) | U.S. Treasury Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 0 0
Quoted Price in Active Markets (Level 1) | Corporate Notes    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 0 0
Quoted Price in Active Markets (Level 1) | Repurchase Agreement    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents   50,000
Quoted Price in Active Markets (Level 1) | Commercial Paper    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents   0
Marketable securities   0
Significant Observable Inputs (Level 2)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total 24,578 142,367
Significant Observable Inputs (Level 2) | Money Market Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Significant Observable Inputs (Level 2) | U.S. Treasury Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 10,006 50,185
Significant Observable Inputs (Level 2) | Corporate Notes    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 14,572 51,662
Significant Observable Inputs (Level 2) | Repurchase Agreement    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents   0
Significant Observable Inputs (Level 2) | Commercial Paper    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents   5,987
Marketable securities   34,533
Significant Unobservable Inputs (Level 3)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total 0 0
Significant Unobservable Inputs (Level 3) | Money Market Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Significant Unobservable Inputs (Level 3) | U.S. Treasury Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities 0 0
Significant Unobservable Inputs (Level 3) | Corporate Notes    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Marketable securities $ 0 0
Significant Unobservable Inputs (Level 3) | Repurchase Agreement    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents   0
Significant Unobservable Inputs (Level 3) | Commercial Paper    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash equivalents   0
Marketable securities   $ 0
XML 110 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value Measurements - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Transfers of assets or liabilities between the fair value measurement levels $ 0 $ 0
Recurring    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Liability measured at fair value 0 0
Nonrecurring    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Liability measured at fair value $ 0 $ 0
XML 111 R43.htm IDEA: XBRL DOCUMENT v3.20.4
Marketable Securities - Summary of Marketable Securities Held (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Marketable Securities [Line Items]    
Amortized Cost, current $ 24,525 $ 124,678
Unrealized Gains, current 53 14
Unrealized Losses, current   (8)
Fair Value, current 24,578 124,684
Amortized Cost, noncurrent   11,692
Unrealized Gains, noncurrent   4
Fair Value, noncurrent   11,696
U.S. Treasury Securities    
Marketable Securities [Line Items]    
Amortized Cost, current 10,003 50,190
Unrealized Gains, current 3  
Unrealized Losses, current   (5)
Fair Value, current 10,006 50,185
Commercial Paper    
Marketable Securities [Line Items]    
Amortized Cost, current   34,532
Unrealized Gains, current   1
Fair Value, current   34,533
Corporate Notes    
Marketable Securities [Line Items]    
Amortized Cost, current 14,522 39,956
Unrealized Gains, current 50 13
Unrealized Losses, current   (3)
Fair Value, current $ 14,572 39,966
Amortized Cost, noncurrent   11,692
Unrealized Gains, noncurrent   4
Fair Value, noncurrent   $ 11,696
XML 112 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Marketable Securities - Additional Information (Details)
12 Months Ended
Dec. 31, 2020
USD ($)
Marketable Securities [Line Items]  
Realized gains or losses recognized on sale or maturity of available-for-sale debt securities $ 0
Marketable securities with unrealized losses $ 0
Maximum  
Marketable Securities [Line Items]  
Marketable securities, contractual maturities 1 year
XML 113 R45.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies - Additional Information (Details)
SFr in Thousands, ft² in Millions
1 Months Ended 12 Months Ended
Aug. 31, 2020
CHF (SFr)
Jun. 30, 2020
USD ($)
ft²
Building
Apr. 30, 2020
CHF (SFr)
Mar. 31, 2016
USD ($)
May 31, 2013
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jul. 01, 2020
USD ($)
Commitments And Contingencies Disclosure [Line Items]                  
Operating lease right-of-use asset           $ 73,672,000 $ 1,790,000    
Lease liabilities           77,402,000      
Current portion of tenant improvement allowance payable           20,402,000 8,658,000    
Other liabilities, non-current portion of tenant Improvement allowance payable           256,000 295,000    
Tenant Improvement Allowance Payable                  
Commitments And Contingencies Disclosure [Line Items]                  
Other liabilities, non-current portion of tenant Improvement allowance payable           300,000 300,000    
Purchase Commitments                  
Commitments And Contingencies Disclosure [Line Items]                  
Noncancellable purchase commitments, including potential cancellation fees           500,000 700,000    
Lonza | Service Agreements                  
Commitments And Contingencies Disclosure [Line Items]                  
Cancelable and/ or non-cancelable contractual obligations, total           $ 242,300,000 4,700,000    
Contractual obligation period           10 years      
Unrecorded unconditional purchase obligation, expenses recognized           $ 16,800,000 7,900,000 $ 2,800,000  
Unrecorded unconditional purchase obligation, cancellation fees           0      
Maximum | Tenant Improvement Allowance Payable                  
Commitments And Contingencies Disclosure [Line Items]                  
Current portion of tenant improvement allowance payable           100,000 $ 100,000    
Maximum | Cancellable Assignment and License Agreement                  
Commitments And Contingencies Disclosure [Line Items]                  
Milestone payments           33,200,000      
Clinical and Commercial Supply of Drug Substance | Manufacturing Agreement                  
Commitments And Contingencies Disclosure [Line Items]                  
Estimated capital contribution | SFr SFr 40,000                
Annual suite fees payment for 2021 | SFr 12,000                
Annual suite fees payment each year after 2021 | SFr SFr 16,000                
Manufacturing agreement initial term 8 years                
Clinical and Commercial Supply of Drug Substance | Maximum | Manufacturing Agreement                  
Commitments And Contingencies Disclosure [Line Items]                  
Manufacturing agreement term that can be extended 16 years                
Leasehold Improvements | California                  
Commitments And Contingencies Disclosure [Line Items]                  
Improvements allowance payable to be drawn       $ 400,000          
Interest rate       8.00%          
Lease term       Oct. 31, 2023          
Debt instrument term       10 years          
Lease Agreement on June 2020 | California                  
Commitments And Contingencies Disclosure [Line Items]                  
Number of buildings leased | Building   2              
Cash-collateralized letter of credit   $ 10,900,000             $ 6,200,000
Lease Agreement on June 2020 | 1200 Page Mill Road in Palo Alto | California                  
Commitments And Contingencies Disclosure [Line Items]                  
Lease area | ft²   82,662              
Initial lease term   6 years 6 months              
Monthly rent expense   $ 600,000              
Annual rent year-over-year increase percentage   3.00%              
Total rent abatement   $ 7,200,000              
Lessee operating lease option to extend   6.5 years              
Tenant improvement allowance   $ 1,200,000              
Lease Agreement on June 2020 | 1250 Page Mill Road in Palo Alto | California                  
Commitments And Contingencies Disclosure [Line Items]                  
Lease area | ft²   72,812              
Initial lease term   13 years              
Monthly rent expense   $ 500,000              
Annual rent year-over-year increase percentage   3.00%              
Total rent abatement   $ 6,300,000              
Lessee operating lease option to extend   5 years              
Tenant improvement allowance   $ 10,600,000              
Number of options to extend lease term   2              
Lease Agreement on April 2020 | Rottenstrasse 5 in Visp | Switzerland                  
Commitments And Contingencies Disclosure [Line Items]                  
Lease area | m²     1,000            
Initial lease term     5 years            
Monthly rent expense | SFr     SFr 32            
Automatic renewal interval     5 years            
Lease Agreement on April 2020 | Rottenstrasse 5 in Visp | Switzerland | Maximum                  
Commitments And Contingencies Disclosure [Line Items]                  
Lessee, operating lease, term of contract     15 years            
Lease Agreement on April and June 2020                  
Commitments And Contingencies Disclosure [Line Items]                  
Operating lease right-of-use asset           0      
Lease liabilities           $ 0      
Tenant Improvement Allowance Agreement | Leasehold Improvements | California                  
Commitments And Contingencies Disclosure [Line Items]                  
Improvements allowance payable to be drawn         $ 300,000        
Interest rate         8.00%        
Lease term         Oct. 31, 2018        
XML 114 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
Operating Lease  
2021 $ 4,288
2022 7,660
2023 14,598
2024 15,037
2025 15,475
Thereafter 71,462
Total undiscounted lease payments 128,520
Less: imputed interest (51,118)
Total operating lease liabilities $ 77,402
XML 115 R47.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies - Summary of Lessee, Weighted Average Remaining Lease Term and Weighted Average Discount Rates (Details)
Dec. 31, 2020
Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]    
Weighted-average remaining lease term (in years) 9 years 6 months 3 years 9 months 18 days
Weighted-average discount rate 6.70% 8.50%
XML 116 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2020
USD ($)
Current:  
Foreign $ 14
Total current 14
Deferred:  
Provision (Benefit) for income taxes $ 14
XML 117 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Components of Loss before Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
United States $ (17,273) $ 2,633 $ (17,273)
Foreign (115,809) (49,998) (24,170)
Total loss before income taxes $ (133,082) $ (47,365) $ (41,443)
XML 118 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Deferred tax assets:      
Net operating loss carryforwards $ 28,451 $ 18,523 $ 11,044
Intangible assets 12,088 12,112 7,588
Research and development tax credits 10,527 4,037 1,559
Stock-based compensation 8,405 1,539 394
Accruals 1,367 885 700
Operating lease liability 22,276 577 0
Property and equipment 127 143 109
Total deferred tax assets 83,241 37,816 21,394
Valuation allowance (62,005) (37,249) (21,394)
Net deferred tax assets 21,236 567 0
Deferred tax liabilities:      
Operating lease right-of-use asset (21,234) (534) 0
Capitalized legal fees (2) (33) 0
Total deferred tax liabilities $ (21,236) (567) 0
Total net deferred tax assets   $ 0 $ 0
XML 119 R51.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Taxes [Line Items]      
Increase in valuation allowance $ 24,800 $ 15,900 $ 8,200
Research and development credit carryforwards 10,527 $ 4,037 $ 1,559
Federal      
Income Taxes [Line Items]      
Net operating loss $ 50,100    
Net operating loss carryforwards expiration start year 2035    
Research and development credit carryforwards $ 10,200    
Tax credit carryforwards expiration start year 2035    
Number of periods open for examination 3 years    
Federal | Net Operating Loss Not Subject to Expiration      
Income Taxes [Line Items]      
Net operating loss $ 32,000    
State      
Income Taxes [Line Items]      
Net operating loss $ 171,000    
Net operating loss carryforwards expiration start year 2035    
Research and development credit carryforwards $ 4,900    
Number of periods open for examination 4 years    
California      
Income Taxes [Line Items]      
Tax credit carryforward, expiration year indefinitely    
XML 120 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Schedule of Reconciliation of Effective Tax Rate to Statutory U.S. Federal Rate (Details)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
Federal statutory income tax rate 21.00% 21.00% 21.00%
State taxes 4.30% 11.00% 5.60%
Foreign tax rate differential (7.90%) (12.40%) (3.80%)
Change in valuation allowance (17.30%) (30.50%) (18.30%)
Stock-based compensation 6.70% 7.70% (0.60%)
Research tax credit 3.80% 3.30% 1.30%
Other   (0.10%) (0.10%)
Sale of future royalties (9.40%)    
Section 162(m) (1.20%)    
Fair value adjustments     (2.40%)
Extinguishment of convertible note     (2.70%)
Provision for income taxes 0.00% 0.00% 0.00%
XML 121 R53.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Summary of Unrecognized Tax Benefits Amounts (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
Unrecognized tax benefits at beginning of period $ 1,838 $ 398 $ 357
Increases related to prior year tax positions 0 0 0
Increases related to current year tax positions 2,812 1,440 41
Unrecognized tax benefits at end of period $ 4,650 $ 1,838 $ 398
XML 122 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Preferred Stock - Additional Information (Details) - $ / shares
Dec. 31, 2020
Dec. 31, 2019
Class Of Stock [Line Items]    
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, par value $ 0.0001 $ 0.0001
Maximum    
Class Of Stock [Line Items]    
Preferred stock, shares authorized 10,000,000 10,000,000
XML 123 R55.htm IDEA: XBRL DOCUMENT v3.20.4
Common Stock - Additional Information (Details)
12 Months Ended
Dec. 31, 2020
Vote
$ / shares
shares
Dec. 31, 2019
Vote
$ / shares
shares
Equity [Abstract]    
Common stock, shares authorized | shares 490,000,000 490,000,000
Common stock, par value | $ / shares $ 0.0001 $ 0.0001
Common stock, number of vote per share | Vote 1 1
XML 124 R56.htm IDEA: XBRL DOCUMENT v3.20.4
Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details) - shares
Dec. 31, 2020
Dec. 31, 2019
Class Of Stock [Line Items]    
Common stock reserved for future issuances 10,859,403 9,809,318
Stock Options Outstanding and Release of Restricted Shares    
Class Of Stock [Line Items]    
Common stock reserved for future issuances 7,257,221 6,830,442
2018 Equity Incentive Plan    
Class Of Stock [Line Items]    
Common stock reserved for future issuances 2,742,183 2,118,877
2018 Employee Share Purchase Plan    
Class Of Stock [Line Items]    
Common stock reserved for future issuances 460,000 460,000
Warrant    
Class Of Stock [Line Items]    
Common stock reserved for future issuances 399,999 399,999
XML 125 R57.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Stock-based compensation expense recognized $ 30,668,000 $ 6,110,000 $ 2,608,000
Common stock, shares reserved for issuance 10,859,403 9,809,318  
Unrecognized stock-based compensation expense $ 91,400,000    
Unrecognized stock-based compensation weighted-average period expected for recognition 2 years 10 months 24 days    
Employee Stock Options      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Stock options, weighted-average grant date fair value $ 32.44 $ 34.11 $ 4.36
Dividends paid $ 0    
Expected dividend payment $ 0    
Dividend yield 0.00% 0.00% 0.00%
Total fair value of employee options vested $ 19,700,000 $ 4,600,000 $ 1,200,000
Stock-based compensation expense recognized $ 20,800,000 $ 5,700,000 $ 2,000,000.0
Non-employee Stock Options      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Dividend yield 0.00% 0.00% 0.00%
Stock options, granted 41,500 15,000 215,000
Options Granted to Non-employees      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Stock-based compensation expense recognized $ 700,000 $ 100,000 $ 400,000
Restricted Stock Awards (RSAs)      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Awards vesting period 4 years    
Stock-based compensation expense recognized   100,000 200,000
Stock-based compensation of total fair value vested   $ 100,000 200,000
Stock units, granted 236,045    
Awards vested 23,848    
Weighted-average grant date fair value $ 59.54 $ 60.81  
Restricted Stock Units (RSUs)      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Awards vesting period 4 years    
Stock-based compensation expense recognized $ 1,900,000 $ 300,000  
Stock-based compensation of total fair value vested $ 300,000 300,000  
Stock units, granted 236,045    
Restricted Stock Units (RSUs) | Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Stock-based compensation expense recognized     $ 100,000
Performance Based Equity Awards      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Stock-based compensation expense recognized $ 7,200,000 $ 100,000  
Stock options, granted 0    
Vesting period These performance-based equity awards will vest one-quarter upon the achievement of specific clinical development milestones. The remaining shares will then vest in three equal annual installments after that date.    
Awards vested 0 0  
Performance-based Stock Options      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Dividend yield   0.00%  
Weighted-average grant date fair value   $ 47.89  
Performance Based Restricted Stock Units      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Weighted-average grant date fair value   $ 73.51  
2018 Equity Incentive Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Number of shares increases annually 1,776,761    
Awards vesting period 4 years    
Number of shares available for grant 2,742,183    
2018 Equity Incentive Plan | Minimum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Number of shares increases annually 4,300,000    
Percentage of outstanding stock 4.00%    
2018 Equity Incentive Plan | Incentive Stock Options      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Common stock, shares reserved for issuance 4,300,000    
2018 Equity Incentive Plan | Incentive Stock Options | Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Options, periods granted 10 years    
2018 Equity Incentive Plan | ISO Granted to a Greater than 10% Stockholder | Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Options, periods granted 5 years    
Options exercise price, percentage of estimated fair value of shares on grant date 110.00%    
2018 Employee Share Purchase Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Common stock, shares reserved for issuance 460,000    
XML 126 R58.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Summary of Stock Options Activity Under 2018 Plan and 2015 Plan (Details) - 2018 Plan and 2015 Equity Incentive Plan - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Number of Options    
Beginning balance 6,671,542  
Granted 1,068,335  
Exercised (704,675)  
Forfeited or canceled (137,926)  
Ending balance 6,897,276 6,671,542
Shares exercisable 3,769,990  
Vested and expected to vest 6,897,276  
Weighted Average Exercise Price    
Beginning balance $ 17.90  
Granted 55.27  
Exercised 8.89  
Forfeited or canceled 25.07  
Ending balance $ 24.52 $ 17.90
Weighted Average Remaining Contractual Term (in years)    
Weighted Average Remaining Contractual Term (in years) 8 years 25 days 8 years 8 months 23 days
Aggregate Intrinsic Value    
Beginning balance $ 841,704 $ 362,081
XML 127 R59.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Fair Value of Employee Stock Options Estimated Using Weighted-average Assumptions (Details) - Employee Stock Options
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected volatility 66.00% 68.00% 59.00%
Risk-free interest rate 0.39% 1.65% 2.82%
Dividend yield 0.00% 0.00% 0.00%
Expected term 6 years 5 years 9 months 10 days 6 years 21 days
XML 128 R60.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Fair Value of Non-employee Stock Options Estimated Using Weighted-average Assumptions (Details) - Non-employee Stock Options
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected volatility 67.00% 73.00% 68.00%
Risk-free interest rate 0.36% 1.61% 2.71%
Dividend yield 0.00% 0.00% 0.00%
Expected term 5 years 6 months 21 days 6 years 29 days 9 years 3 months 18 days
XML 129 R61.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Summary of Restricted Shares (Details) - Restricted Stock Awards (RSAs)
12 Months Ended
Dec. 31, 2020
$ / shares
shares
Number of Restricted Shares  
Unvested, beginning balance | shares 160,747
Granted | shares 236,045
Vested | shares (23,848)
Shares withheld related to net share settlement of RSUs | shares (7,999)
Canceled | shares (5,000)
Unvested, ending balance | shares 359,945
Weighted Average Grant Date Fair Value  
Unvested, beginning balance | $ / shares $ 60.81
Granted | $ / shares 52.18
Vested | $ / shares 9.21
Shares withheld related to net share settlement of RSUs | $ / shares 9.90
Canceled | $ / shares 72.46
Unvested, ending balance | $ / shares $ 59.54
XML 130 R62.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Fair Value of Performance-based Stock Options Estimated Using Weighted-average Assumptions (Details) - Performance-based Stock Options
12 Months Ended
Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Expected volatility 72.00%
Risk-free interest rate 1.67%
Dividend yield 0.00%
Expected term 6 years 3 months 21 days
XML 131 R63.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Summary of Stock-based Compensation Classified in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]      
Total stock-based compensation $ 30,668 $ 6,110 $ 2,608
Research and Development      
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]      
Total stock-based compensation 16,957 3,496 1,535
General and Administrative      
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]      
Total stock-based compensation $ 13,711 $ 2,614 $ 1,073
XML 132 R64.htm IDEA: XBRL DOCUMENT v3.20.4
Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Numerator:                      
Net loss $ (46,583) $ (36,122) $ (25,999) $ (24,392) $ (15,616) $ (12,380) $ (11,385) $ (7,984) $ (133,096) $ (47,365) $ (41,443)
Denominator:                      
Weighted-average shares outstanding                 45,741,845 37,869,291 15,136,197
Less: weighted-average unvested restricted shares and shares subject to repurchase                 0 (15,675) (159,682)
Weighted-average common shares outstanding used in computing net loss per common share, basic and diluted                 45,741,845 37,853,616 14,976,515
Net loss per share attributable to common stockholders, basic and diluted $ (0.97) $ (0.80) $ (0.58) $ (0.54) $ (0.40) $ (0.33) $ (0.31) $ (0.21) $ (2.91) $ (1.25) $ (2.77)
XML 133 R65.htm IDEA: XBRL DOCUMENT v3.20.4
Net Loss per Share Attributable to Common Stockholders - Summary of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) - shares
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive securities excluded from the computation of diluted net loss per share 7,257,221 6,832,289 5,185,717
Employee Stock Options      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive securities excluded from the computation of diluted net loss per share 6,897,276 6,671,542 5,135,267
Unvested Restricted Shares      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive securities excluded from the computation of diluted net loss per share 359,945 160,747 50,450
XML 134 R66.htm IDEA: XBRL DOCUMENT v3.20.4
401(k) Plan - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Defined Contribution Plan Disclosure [Line Items]    
Plan name 401(k)  
Defined Contribution Plan, Plan Name [Extensible List] kod:RetirementAndSavingsPlanMember  
Employer matching contribution, percent of match 100.00%  
Expense related to matching contributions $ 0.6 $ 0.3
IRS    
Defined Contribution Plan Disclosure [Line Items]    
Defined contribution plan, employer matching contribution cap on employee contribution limit 50.00%  
XML 135 R67.htm IDEA: XBRL DOCUMENT v3.20.4
Liability Related to Sale of Future Royalties - Additional Information (Details) - USD ($)
12 Months Ended
Feb. 04, 2020
Dec. 01, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Feb. 29, 2020
Related Party Transaction [Line Items]            
Proceeds from sale of future royalties     $ 99,643,000 $ 0 $ 0  
Liability related to sale of future royalties     99,890,000      
Baker Bros. Advisors LP | Funding Agreement            
Related Party Transaction [Line Items]            
Capped percentage of royalty on future net sales   4.50%        
Contractual obligation under funding agreement   $ 225,000,000.0        
Percentage of repurchase of royalties   100.00%        
Proceeds from sale of future royalties $ 100,000,000.0          
Funds to be payable upon enrollment of patients           $ 125,000,000.0
Percentage of patients to be enrolled           50.00%
Liability related to sale of future royalties     100,000,000.0      
Interest expense, liability related to sale of future royalties     $ 0      
Baker Bros. Advisors LP | Funding Agreement | Minimum            
Related Party Transaction [Line Items]            
Ownership percentage   5.00%        
XML 136 R68.htm IDEA: XBRL DOCUMENT v3.20.4
Selected Quarterly Financial Data - Schedule of Quarterly Financial Information (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]                      
Loss from operations $ (46,842) $ (36,663) $ (26,779) $ (25,723) $ (16,184) $ (12,732) $ (11,814) $ (8,460) $ (136,007) $ (49,190) $ (26,374)
Net loss $ (46,583) $ (36,122) $ (25,999) $ (24,392) $ (15,616) $ (12,380) $ (11,385) $ (7,984) $ (133,096) $ (47,365) $ (41,443)
Net loss per share attributable to common stockholders, basic and diluted $ (0.97) $ (0.80) $ (0.58) $ (0.54) $ (0.40) $ (0.33) $ (0.31) $ (0.21) $ (2.91) $ (1.25) $ (2.77)
EXCEL 137 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 138 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 139 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 140 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 225 440 1 false 82 0 false 10 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Sheet http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 6 false false R7.htm 100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Sheet http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Statements 7 false false R8.htm 100070 - Statement - Consolidated Statements of Cash Flows Sheet http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical Consolidated Statements of Cash Flows (Parenthetical) Statements 9 false false R10.htm 100090 - Disclosure - The Company Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompany The Company Notes 10 false false R11.htm 100100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 100110 - Disclosure - Property and Equipment, Net Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 12 false false R13.htm 100120 - Disclosure - Accrued Liabilities and Other Current Liabilities Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities Accrued Liabilities and Other Current Liabilities Notes 13 false false R14.htm 100130 - Disclosure - Fair Value Measurements Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 100140 - Disclosure - Marketable Securities Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecurities Marketable Securities Notes 15 false false R16.htm 100150 - Disclosure - Commitments and Contingencies Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 100160 - Disclosure - Income Taxes Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 17 false false R18.htm 100170 - Disclosure - Preferred Stock Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStock Preferred Stock Notes 18 false false R19.htm 100180 - Disclosure - Common Stock Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStock Common Stock Notes 19 false false R20.htm 100190 - Disclosure - Stock-Based Compensation Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 20 false false R21.htm 100200 - Disclosure - Net Loss per Share Attributable to Common Stockholders Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders Net Loss per Share Attributable to Common Stockholders Notes 21 false false R22.htm 100210 - Disclosure - 401(k) Plan Sheet http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlan 401(k) Plan Notes 22 false false R23.htm 100220 - Disclosure - Liability Related to Sale of Future Royalties Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyalties Liability Related to Sale of Future Royalties Notes 23 false false R24.htm 100230 - Disclosure - Selected Quarterly Financial Data (Unaudited) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnaudited Selected Quarterly Financial Data (Unaudited) Notes 24 false false R25.htm 100240 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 25 false false R26.htm 100250 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet 26 false false R27.htm 100260 - Disclosure - Accrued Liabilities and Other Current Liabilities (Tables) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesTables Accrued Liabilities and Other Current Liabilities (Tables) Tables http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities 27 false false R28.htm 100270 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurements 28 false false R29.htm 100280 - Disclosure - Marketable Securities (Tables) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecurities 29 false false R30.htm 100290 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies 30 false false R31.htm 100300 - Disclosure - Income Taxes (Tables) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxes 31 false false R32.htm 100310 - Disclosure - Common Stock (Tables) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockTables Common Stock (Tables) Tables http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStock 32 false false R33.htm 100320 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensation 33 false false R34.htm 100330 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables Net Loss per Share Attributable to Common Stockholders (Tables) Tables http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders 34 false false R35.htm 100340 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables Selected Quarterly Financial Data (Unaudited) (Tables) Tables http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnaudited 35 false false R36.htm 100350 - Disclosure - The Company - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails The Company - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 37 false false R38.htm 100370 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Details 38 false false R39.htm 100380 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 39 false false R40.htm 100390 - Disclosure - Accrued Liabilities and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails Accrued Liabilities and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Details) Details 40 false false R41.htm 100400 - Disclosure - Fair Value Measurements - Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 41 false false R42.htm 100410 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 42 false false R43.htm 100420 - Disclosure - Marketable Securities - Summary of Marketable Securities Held (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails Marketable Securities - Summary of Marketable Securities Held (Details) Details 43 false false R44.htm 100430 - Disclosure - Marketable Securities - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails Marketable Securities - Additional Information (Details) Details 44 false false R45.htm 100440 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 45 false false R46.htm 100450 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Details) Details 46 false false R47.htm 100470 - Disclosure - Commitments and Contingencies - Summary of Lessee, Weighted Average Remaining Lease Term and Weighted Average Discount Rates (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRatesDetails Commitments and Contingencies - Summary of Lessee, Weighted Average Remaining Lease Term and Weighted Average Discount Rates (Details) Details 47 false false R48.htm 100480 - Disclosure - Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details) Details 48 false false R49.htm 100490 - Disclosure - Income Taxes - Components of Loss before Income Taxes (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails Income Taxes - Components of Loss before Income Taxes (Details) Details 49 false false R50.htm 100500 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails Income Taxes - Components of Deferred Tax Assets (Details) Details 50 false false R51.htm 100510 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 51 false false R52.htm 100520 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate to Statutory U.S. Federal Rate (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails Income Taxes - Schedule of Reconciliation of Effective Tax Rate to Statutory U.S. Federal Rate (Details) Details 52 false false R53.htm 100530 - Disclosure - Income Taxes - Summary of Unrecognized Tax Benefits Amounts (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfUnrecognizedTaxBenefitsAmountsDetails Income Taxes - Summary of Unrecognized Tax Benefits Amounts (Details) Details 53 false false R54.htm 100540 - Disclosure - Preferred Stock - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails Preferred Stock - Additional Information (Details) Details 54 false false R55.htm 100550 - Disclosure - Common Stock - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails Common Stock - Additional Information (Details) Details 55 false false R56.htm 100560 - Disclosure - Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details) Details 56 false false R57.htm 100570 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 57 false false R58.htm 100580 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity Under 2018 Plan and 2015 Plan (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails Stock-Based Compensation - Summary of Stock Options Activity Under 2018 Plan and 2015 Plan (Details) Details 58 false false R59.htm 100590 - Disclosure - Stock-Based Compensation - Fair Value of Employee Stock Options Estimated Using Weighted-average Assumptions (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails Stock-Based Compensation - Fair Value of Employee Stock Options Estimated Using Weighted-average Assumptions (Details) Details 59 false false R60.htm 100600 - Disclosure - Stock-Based Compensation - Fair Value of Non-employee Stock Options Estimated Using Weighted-average Assumptions (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails Stock-Based Compensation - Fair Value of Non-employee Stock Options Estimated Using Weighted-average Assumptions (Details) Details 60 false false R61.htm 100610 - Disclosure - Stock-Based Compensation - Summary of Restricted Shares (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails Stock-Based Compensation - Summary of Restricted Shares (Details) Details 61 false false R62.htm 100620 - Disclosure - Stock-Based Compensation - Fair Value of Performance-based Stock Options Estimated Using Weighted-average Assumptions (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails Stock-Based Compensation - Fair Value of Performance-based Stock Options Estimated Using Weighted-average Assumptions (Details) Details 62 false false R63.htm 100630 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Classified in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationClassifiedInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails Stock-Based Compensation - Summary of Stock-based Compensation Classified in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) Details 63 false false R64.htm 100640 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) Details 64 false false R65.htm 100650 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails Net Loss per Share Attributable to Common Stockholders - Summary of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) Details 65 false false R66.htm 100660 - Disclosure - 401(k) Plan - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails 401(k) Plan - Additional Information (Details) Details 66 false false R67.htm 100670 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails Liability Related to Sale of Future Royalties - Additional Information (Details) Details 67 false false R68.htm 100680 - Disclosure - Selected Quarterly Financial Data - Schedule of Quarterly Financial Information (Unaudited) (Details) Sheet http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataScheduleOfQuarterlyFinancialInformationUnauditedDetails Selected Quarterly Financial Data - Schedule of Quarterly Financial Information (Unaudited) (Details) Details 68 false false All Reports Book All Reports kod-10k_20201231.htm kod-20201231.xsd kod-20201231_cal.xml kod-20201231_def.xml kod-20201231_lab.xml kod-20201231_pre.xml kod-ex231_11.htm kod-ex311_10.htm kod-ex312_9.htm kod-ex321_6.htm kod-ex322_7.htm gexyhn0lyczh000001.jpg gexyhn0lyczh000002.jpg gexyhn0lyczh000003.jpg gexyhn0lyczh000004.jpg gexyhn0lyczh000005.jpg gexyhn0lyczh000006.jpg gexyhn0lyczh000007.jpg gexyhn0lyczh000008.jpg gexyhn0lyczh000009.jpg gexyhn0lyczh000010.jpg gexyhn0lyczh000011.jpg gexyhn0lyczh000012.jpg gexyhn0lyczh000013.jpg gexyhn0lyczh000014.jpg gexyhn0lyczh000015.jpg gexyhn0lyczh000016.jpg gexyhn0lyczh000017.jpg gexyhn0lyczh000018.jpg gexyhn0lyczh000019.jpg gexyhn0lyczh000020.jpg gexyhn0lyczh000021.jpg gexyhn0lyczh000022.jpg gexyhn0lyczh000023.jpg gexyhn0lyczh000024.jpg gexyhn0lyczh000025.jpg gexyhn0lyczh000026.jpg gexyhn0lyczh000027.jpg gexyhn0lyczh000028.jpg gexyhn0lyczh000029.jpg gexyhn0lyczh000030.jpg gexyhn0lyczh000031.jpg gexyhn0lyczh000032.jpg gexyhn0lyczh000033.jpg gexyhn0lyczh000034.jpg gexyhn0lyczh000035.jpg gexyhn0lyczh000036.jpg gexyhn0lyczh000037.jpg gexyhn0lyczh000038.jpg gexyhn0lyczh000039.jpg gexyhn0lyczh000040.jpg gexyhn0lyczh000041.jpg gexyhn0lyczh000042.jpg gexyhn0lyczh000043.jpg gexyhn0lyczh000044.jpg gexyhn0lyczh000045.jpg gexyhn0lyczh000046.jpg gexyhn0lyczh000047.jpg gexyhn0lyczh000048.jpg gexyhn0lyczh000049.jpg gexyhn0lyczh000050.jpg gexyhn0lyczh000051.jpg gexyhn0lyczh000052.jpg gexyhn0lyczh000053.jpg gexyhn0lyczh000054.jpg gexyhn0lyczh000055.jpg http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 true true JSON 143 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "kod-10k_20201231.htm": { "axisCustom": 0, "axisStandard": 29, "contextCount": 225, "dts": { "calculationLink": { "local": [ "kod-20201231_cal.xml" ] }, "definitionLink": { "local": [ "kod-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "kod-10k_20201231.htm" ] }, "labelLink": { "local": [ "kod-20201231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "kod-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "kod-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 595, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 19, "http://www.kodiak.com/20201231": 1, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 24 }, "keyCustom": 88, "keyStandard": 352, "memberCustom": 33, "memberStandard": 41, "nsprefix": "kod", "nsuri": "http://www.kodiak.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "kod:TheCompanyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - The Company", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompany", "shortName": "The Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "kod:TheCompanyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Property and Equipment, Net", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Accrued Liabilities and Other Current Liabilities", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities", "shortName": "Accrued Liabilities and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Fair Value Measurements", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Marketable Securities", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Commitments and Contingencies", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Income Taxes", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Preferred Stock", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStock", "shortName": "Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Common Stock", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Stock-Based Compensation", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Net Loss per Share Attributable to Common Stockholders", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders", "shortName": "Net Loss per Share Attributable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - 401(k) Plan", "role": "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlan", "shortName": "401(k) Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "kod:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Liability Related to Sale of Future Royalties", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyalties", "shortName": "Liability Related to Sale of Future Royalties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "kod:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Selected Quarterly Financial Data (Unaudited)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnaudited", "shortName": "Selected Quarterly Financial Data (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "kod:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Accrued Liabilities and Other Current Liabilities (Tables)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Liabilities and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "kod:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Marketable Securities (Tables)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Income Taxes (Tables)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "kod:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Common Stock (Tables)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "kod:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables", "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables", "shortName": "Selected Quarterly Financial Data (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "kod:TheCompanyTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20180101_20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - The Company - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "shortName": "The Company - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "kod:TheCompanyTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20180101_20181231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossRealized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossRealized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, Net - Summary of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "shortName": "Property and Equipment, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "kod:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "kod:AccruedClinicalTrialAndRelatedCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Accrued Liabilities and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails", "shortName": "Accrued Liabilities and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "kod:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "kod:AccruedClinicalTrialAndRelatedCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Fair Value Measurements - Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "kod:TransfersBetweenHierarchyLevels", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "kod:TransfersBetweenHierarchyLevels", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "kod:AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Marketable Securities - Summary of Marketable Securities Held (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails", "shortName": "Marketable Securities - Summary of Marketable Securities Held (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "kod:AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Marketable Securities - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "shortName": "Marketable Securities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapDebtInstrumentAxis_kodTenantImprovementAllowancePayableMember_20201231", "decimals": "-5", "lang": null, "name": "us-gaap:OtherLiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "shortName": "Commitments and Contingencies - Summary of Maturities of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Commitments and Contingencies - Summary of Lessee, Weighted Average Remaining Lease Term and Weighted Average Discount Rates (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRatesDetails", "shortName": "Commitments and Contingencies - Summary of Lessee, Weighted Average Remaining Lease Term and Weighted Average Discount Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails", "shortName": "Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Income Taxes - Components of Loss before Income Taxes (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails", "shortName": "Income Taxes - Components of Loss before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20180101_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "role": "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical", "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20180101_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails", "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate to Statutory U.S. Federal Rate (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails", "shortName": "Income Taxes - Schedule of Reconciliation of Effective Tax Rate to Statutory U.S. Federal Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Income Taxes - Summary of Unrecognized Tax Benefits Amounts (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfUnrecognizedTaxBenefitsAmountsDetails", "shortName": "Income Taxes - Summary of Unrecognized Tax Benefits Amounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20171231", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Preferred Stock - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "shortName": "Preferred Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PreferredStockTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_srtRangeAxis_srtMaximumMember_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Common Stock - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails", "shortName": "Common Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "INF", "lang": null, "name": "kod:CommonStockNumberOfVotesPerShare", "reportCount": 1, "unique": true, "unitRef": "U_kodVote", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "kod:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "shortName": "Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "kod:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_kodStockOptionsOutstandingAndReleaseOfRestrictedSharesMember_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201231", "decimals": "-5", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_kodTwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity Under 2018 Plan and 2015 Plan (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails", "shortName": "Stock-Based Compensation - Summary of Stock Options Activity Under 2018 Plan and 2015 Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_kodTwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember_20200101_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "kod:ScheduleOfShareBasedPaymentAwardEmployeeStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Stock-Based Compensation - Fair Value of Employee Stock Options Estimated Using Weighted-average Assumptions (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "shortName": "Stock-Based Compensation - Fair Value of Employee Stock Options Estimated Using Weighted-average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "kod:ScheduleOfShareBasedPaymentAwardEmployeeStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_kodNonEmployeeStockOptionMember_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Stock-Based Compensation - Fair Value of Non-employee Stock Options Estimated Using Weighted-average Assumptions (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "shortName": "Stock-Based Compensation - Fair Value of Non-employee Stock Options Estimated Using Weighted-average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_kodNonEmployeeStockOptionMember_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Stock-Based Compensation - Summary of Restricted Shares (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails", "shortName": "Stock-Based Compensation - Summary of Restricted Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "kod:ScheduleOfShareBasedPaymentAwardPerformanceBasedAwardsAndRSUsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_kodPerformanceBasedStockOptionsMember_20190101_20191231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Stock-Based Compensation - Fair Value of Performance-based Stock Options Estimated Using Weighted-average Assumptions (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "shortName": "Stock-Based Compensation - Fair Value of Performance-based Stock Options Estimated Using Weighted-average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "kod:ScheduleOfShareBasedPaymentAwardPerformanceBasedAwardsAndRSUsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapAwardTypeAxis_kodPerformanceBasedStockOptionsMember_20190101_20191231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Classified in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationClassifiedInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Classified in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201001_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "shortName": "Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails", "shortName": "Net Loss per Share Attributable to Common Stockholders - Summary of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - 401(k) Plan - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails", "shortName": "401(k) Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "kod:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "shortName": "Liability Related to Sale of Future Royalties - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "kod:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_us-gaapRelatedPartyTransactionAxis_kodBakerBrosAdvisorsLPMember_us-gaapTypeOfArrangementAxis_kodFundingAgreementMember_20191201", "decimals": "INF", "lang": null, "name": "kod:PercentageOfRepurchaseOfRoyalties", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201001_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Selected Quarterly Financial Data - Schedule of Quarterly Financial Information (Unaudited) (Details)", "role": "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataScheduleOfQuarterlyFinancialInformationUnauditedDetails", "shortName": "Selected Quarterly Financial Data - Schedule of Quarterly Financial Information (Unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20201001_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "kod:PaymentsOfOfferingCostsOnIssuanceOfCommonStockInConnectionWithInitialPublicOfferingOrFollowOnOffering", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "shortName": "Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "kod:PaymentsOfOfferingCostsOnIssuanceOfCommonStockInConnectionWithInitialPublicOfferingOrFollowOnOffering", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20180101_20181231", "decimals": "-3", "first": true, "lang": null, "name": "kod:ProceedsFromIssuanceOfConvertibleNotesToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kod-10k_20201231.htm", "contextRef": "C_0001468748_20180101_20181231", "decimals": "-3", "first": true, "lang": null, "name": "kod:ProceedsFromIssuanceOfConvertibleNotesToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } } }, "segmentCount": 82, "tag": { "country_CH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SWITZERLAND", "terseLabel": "Switzerland" } } }, "localname": "CH", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "verboseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "kod_AccruedClinicalTrialAndRelatedCostsCurrent": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued clinical trial and related costs current.", "label": "Accrued Clinical Trial And Related Costs Current", "terseLabel": "Accrued clinical trial and related costs" } } }, "localname": "AccruedClinicalTrialAndRelatedCostsCurrent", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "kod_AccruedLegalFeesCurrent": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued legal fees current.", "label": "Accrued Legal Fees Current", "terseLabel": "Accrued legal fees" } } }, "localname": "AccruedLegalFeesCurrent", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "kod_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development current.", "label": "Accrued Research And Development Current", "terseLabel": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "kod_AccruedResearchAndDevelopmentPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued research and development.", "label": "Accrued Research And Development Policy [Text Block]", "terseLabel": "Accrued Research And Development" } } }, "localname": "AccruedResearchAndDevelopmentPolicyTextBlock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "kod_AmortizationOfIssuanceCosts": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of issuance costs.", "label": "Amortization Of Issuance Costs", "terseLabel": "Amortization of issuance costs" } } }, "localname": "AmortizationOfIssuanceCosts", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "kod_AnnualRentYearOverYearIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual rent year over year increase percentage.", "label": "Annual Rent Year Over Year Increase Percentage", "terseLabel": "Annual rent year-over-year increase percentage" } } }, "localname": "AnnualRentYearOverYearIncreasePercentage", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "kod_AutomaticRenewalInterval": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Automatic renewal interval.", "label": "Automatic Renewal Interval", "terseLabel": "Automatic renewal interval" } } }, "localname": "AutomaticRenewalInterval", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "kod_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails": { "order": 10040.0, "parentTag": "kod_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available for sale debt securities accumulated gross unrealized gain before tax, current.", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current", "terseLabel": "Unrealized Gains, current" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "kod_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails": { "order": 10010.0, "parentTag": "kod_AvailableForSaleDebtSecuritiesAmortizedCostBasisNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available for sale debt securities accumulated gross unrealized gain before tax non current.", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Non Current", "terseLabel": "Unrealized Gains, noncurrent" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "kod_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails": { "order": 10050.0, "parentTag": "kod_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale debt securities accumulated gross unrealized loss before tax current.", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current", "negatedLabel": "Unrealized Losses, current" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "kod_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails": { "order": 10020.0, "parentTag": "kod_AvailableForSaleDebtSecuritiesAmortizedCostBasisNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale debt securities accumulated gross unrealized loss before tax non current.", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current", "negatedLabel": "Unrealized Losses, noncurrent" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "kod_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale debt securities amortized cost basis current.", "label": "Available For Sale Debt Securities Amortized Cost Basis Current", "totalLabel": "Amortized Cost, current" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "kod_AvailableForSaleDebtSecuritiesAmortizedCostBasisNoncurrent": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities amortized cost basis noncurrent.", "label": "Available For Sale Debt Securities Amortized Cost Basis Noncurrent", "totalLabel": "Amortized Cost, noncurrent" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasisNoncurrent", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "kod_BakerBrosAdvisorsLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Baker bros advisors LP.", "label": "Baker Bros Advisors L P [Member]", "terseLabel": "Baker Bros. Advisors LP" } } }, "localname": "BakerBrosAdvisorsLPMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_BuildingOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Building one.", "label": "Building One [Member]", "terseLabel": "1200 Page Mill Road in Palo Alto" } } }, "localname": "BuildingOneMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_BuildingTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Building two.", "label": "Building Two [Member]", "terseLabel": "1250 Page Mill Road in Palo Alto" } } }, "localname": "BuildingTwoMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_CappedPercentageOfRoyaltyOnFutureNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capped percentage of royalty on future net sales.", "label": "Capped Percentage Of Royalty On Future Net Sales", "positiveTerseLabel": "Capped percentage of royalty on future net sales", "terseLabel": "Capped percentage of royalty on future net sales" } } }, "localname": "CappedPercentageOfRoyaltyOnFutureNetSales", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "kod_CashCollateralizedLetterOfCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash-collateralized letter of credit.", "label": "Cash Collateralized Letter Of Credit", "terseLabel": "Cash-collateralized letter of credit" } } }, "localname": "CashCollateralizedLetterOfCredit", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_ChangeInFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of embedded derivative liability.", "label": "Change In Fair Value Of Embedded Derivative Liability", "terseLabel": "Change in fair value of derivative instrument" } } }, "localname": "ChangeInFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "kod_ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of redeemable convertible preferred stock warrant liability.", "label": "Change In Fair Value Of Redeemable Convertible Preferred Stock Warrant Liability", "terseLabel": "Change in fair value of redeemable convertible preferred stock warrant liability" } } }, "localname": "ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "kod_ClinicalAndCommercialSupplyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical and commercial supply.", "label": "Clinical And Commercial Supply [Member]", "terseLabel": "Clinical and Commercial Supply of Drug Substance" } } }, "localname": "ClinicalAndCommercialSupplyMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_CommitmentsAndContingenciesDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies disclosure.", "label": "Commitments And Contingencies Disclosure [Line Items]", "terseLabel": "Commitments And Contingencies Disclosure [Line Items]" } } }, "localname": "CommitmentsAndContingenciesDisclosureLineItems", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "kod_CommitmentsAndContingenciesDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies disclosure.", "label": "Commitments And Contingencies Disclosure [Table]", "terseLabel": "Commitments And Contingencies Disclosure [Table]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTable", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "kod_CommonStockIssuedUponConversionOfConvertibleNotesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued upon conversion of convertible notes, shares.", "label": "Common Stock Issued Upon Conversion Of Convertible Notes Shares", "terseLabel": "Conversion of 2017 and 2018 convertible notes into common stock, shares" } } }, "localname": "CommonStockIssuedUponConversionOfConvertibleNotesShares", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "kod_CommonStockIssuedUponConversionOfConvertibleNotesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued upon conversion of convertible notes, value.", "label": "Common Stock Issued Upon Conversion Of Convertible Notes Value", "terseLabel": "Conversion of 2017 and 2018 convertible notes into common stock" } } }, "localname": "CommonStockIssuedUponConversionOfConvertibleNotesValue", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "kod_CommonStockIssuedUponConversionOfPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued upon conversion of preferred stock, shares.", "label": "Common Stock Issued Upon Conversion Of Preferred Stock Shares", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock, shares" } } }, "localname": "CommonStockIssuedUponConversionOfPreferredStockShares", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "kod_CommonStockIssuedUponConversionOfPreferredStockValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issued upon conversion of preferred stock, value.", "label": "Common Stock Issued Upon Conversion Of Preferred Stock Value", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock" } } }, "localname": "CommonStockIssuedUponConversionOfPreferredStockValue", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "kod_CommonStockNumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock, number of votes per share.", "label": "Common Stock Number Of Votes Per Share", "terseLabel": "Common stock, number of vote per share" } } }, "localname": "CommonStockNumberOfVotesPerShare", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "kod_ComputerEquipmentAndOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer equipment and office equipment.", "label": "Computer Equipment And Office Equipment [Member]", "terseLabel": "Computer Equipment and Office Equipment" } } }, "localname": "ComputerEquipmentAndOfficeEquipmentMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_ComputerSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer software.", "label": "Computer Software [Member]", "terseLabel": "Computer Software" } } }, "localname": "ComputerSoftwareMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "kod_ContractualObligationDueInSecondYearAndAfter": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contractual obligation due in second year and after.", "label": "Contractual Obligation Due In Second Year And After", "terseLabel": "Annual suite fees payment each year after 2021" } } }, "localname": "ContractualObligationDueInSecondYearAndAfter", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_ContractualObligationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual obligation period.", "label": "Contractual Obligation Period", "terseLabel": "Contractual obligation period" } } }, "localname": "ContractualObligationPeriod", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "kod_ConversionOfRedeemableConvertiblePreferredStockWarrantIntoCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of redeemable convertible preferred stock warrant into common stock Warrants.", "label": "Conversion Of Redeemable Convertible Preferred Stock Warrant Into Common Stock Warrants", "terseLabel": "Conversion of redeemable convertible preferred stock warrants into common stock warrants" } } }, "localname": "ConversionOfRedeemableConvertiblePreferredStockWarrantIntoCommonStockWarrants", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "kod_ConversionOfRedeemableConvertiblePreferredStockWarrantsIntoCommonStockWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of redeemable convertible preferred stock warrants into common stock warrants shares.", "label": "Conversion Of Redeemable Convertible Preferred Stock Warrants Into Common Stock Warrants Shares", "verboseLabel": "Conversion of preferred stock warrants into common stock warrants, shares" } } }, "localname": "ConversionOfRedeemableConvertiblePreferredStockWarrantsIntoCommonStockWarrantsShares", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "kod_DeferredTaxAssetsTaxOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10120.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax operating lease liability.", "label": "Deferred Tax Assets Tax Operating Lease Liability", "terseLabel": "Operating lease liability" } } }, "localname": "DeferredTaxAssetsTaxOperatingLeaseLiability", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "kod_DeferredTaxLiabilitiesCapitalizedLegalFees": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10040.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities capitalized legal fees.", "label": "Deferred Tax Liabilities Capitalized Legal Fees", "negatedLabel": "Capitalized legal fees" } } }, "localname": "DeferredTaxLiabilitiesCapitalizedLegalFees", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "kod_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10030.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities operating lease right-of-use asset.", "label": "Deferred Tax Liabilities Operating Lease Right Of Use Asset", "negatedLabel": "Operating lease right-of-use asset" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "kod_DefinedContributionPlanEmployerMatchingContributionCapOnEmployeeContributionLimit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined contribution plan, employer matching contribution cap on employee contribution limit.", "label": "Defined Contribution Plan Employer Matching Contribution Cap On Employee Contribution Limit", "terseLabel": "Defined contribution plan, employer matching contribution cap on employee contribution limit" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionCapOnEmployeeContributionLimit", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "kod_DepositsOnPropertyAndEquipment": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deposits on property and equipment.", "label": "Deposits On Property And Equipment", "negatedLabel": "Deposits on property and equipment" } } }, "localname": "DepositsOnPropertyAndEquipment", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "kod_DerecognitionOfNoncurrentDeferredLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derecognition of noncurrent deferred liabilities.", "label": "Derecognition Of Noncurrent Deferred Liabilities", "terseLabel": "Derecognition of noncurrent deferred liabilities" } } }, "localname": "DerecognitionOfNoncurrentDeferredLiabilities", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_EffectiveIncomeTaxRateReconciliationExtinguishmentOfConvertibleNote": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10110.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation extinguishment of convertible note.", "label": "Effective Income Tax Rate Reconciliation Extinguishment Of Convertible Note", "terseLabel": "Extinguishment of convertible note" } } }, "localname": "EffectiveIncomeTaxRateReconciliationExtinguishmentOfConvertibleNote", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "kod_EffectiveIncomeTaxRateReconciliationFairValueAdjustments": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10100.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation fair value adjustments.", "label": "Effective Income Tax Rate Reconciliation Fair Value Adjustments", "terseLabel": "Fair value adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationFairValueAdjustments", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "kod_EffectiveIncomeTaxRateReconciliationSaleOfFutureRoyalties": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10080.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation, sale of future royalties.", "label": "Effective Income Tax Rate Reconciliation Sale Of Future Royalties", "terseLabel": "Sale of future royalties" } } }, "localname": "EffectiveIncomeTaxRateReconciliationSaleOfFutureRoyalties", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "kod_EstimatedCapitalContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated capital contributions.", "label": "Estimated Capital Contributions", "terseLabel": "Estimated capital contribution" } } }, "localname": "EstimatedCapitalContributions", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-On Offering.", "label": "Follow On Offering [Member]", "terseLabel": "Follow-On Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_FundingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding agreement.", "label": "Funding Agreement [Member]", "terseLabel": "Funding Agreement" } } }, "localname": "FundingAgreementMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_FundsPayableUponEnrollmentOfPatients": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Funds payable upon enrollment of patients.", "label": "Funds Payable Upon Enrollment Of Patients", "positiveTerseLabel": "Funds to be payable upon enrollment of patients" } } }, "localname": "FundsPayableUponEnrollmentOfPatients", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_GrossProceedsFromInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from initial public offering.", "label": "Gross Proceeds From Initial Public Offering", "terseLabel": "Gross proceeds from initial public offering" } } }, "localname": "GrossProceedsFromInitialPublicOffering", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_GrossProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issuance of common stock.", "label": "Gross Proceeds From Issuance Of Common Stock", "terseLabel": "Gross proceeds from issuance of common stock" } } }, "localname": "GrossProceedsFromIssuanceOfCommonStock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_IncentiveStockOptionsGrantedToGreaterThanTenPercentStockholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive stock options granted to a greater than 10% stockholder.", "label": "Incentive Stock Options Granted To Greater Than Ten Percent Stockholder [Member]", "terseLabel": "ISO Granted to a Greater than 10% Stockholder" } } }, "localname": "IncentiveStockOptionsGrantedToGreaterThanTenPercentStockholderMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive stock options.", "label": "Incentive Stock Options [Member]", "terseLabel": "Incentive Stock Options" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_IncomeTaxExaminationNumberOfPeriodsOpenForExamination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax examination, number of periods open for examination.", "label": "Income Tax Examination Number Of Periods Open For Examination", "terseLabel": "Number of periods open for examination" } } }, "localname": "IncomeTaxExaminationNumberOfPeriodsOpenForExamination", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "kod_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "kod_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "kod_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10320.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liability.", "label": "Increase Decrease In Operating Lease Liability", "terseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "kod_InterestExpenseLiabilityRelatedToSaleOfFutureRoyalties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest expense, liability related to sale of future royalties.", "label": "Interest Expense Liability Related To Sale Of Future Royalties", "terseLabel": "Interest expense, liability related to sale of future royalties" } } }, "localname": "InterestExpenseLiabilityRelatedToSaleOfFutureRoyalties", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_IssuanceOfCommonStockUponExerciseOfCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon exercise of common stock warrants.", "label": "Issuance Of Common Stock Upon Exercise Of Common Stock Warrants", "terseLabel": "Issuance of common stock upon exercise of common stock warrants" } } }, "localname": "IssuanceOfCommonStockUponExerciseOfCommonStockWarrants", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "kod_IssuanceOfCommonStockUponExerciseOfCommonStockWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon exercise of common stock warrants, shares.", "label": "Issuance Of Common Stock Upon Exercise Of Common Stock Warrants Shares", "terseLabel": "Issuance of common stock upon exercise of common stock warrants, shares" } } }, "localname": "IssuanceOfCommonStockUponExerciseOfCommonStockWarrantsShares", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "kod_IssuanceOfEmbeddedDerivative": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of embedded derivative in connection to convertible notes.", "label": "Issuance Of Embedded Derivative", "terseLabel": "Derivative instrument related to convertible notes" } } }, "localname": "IssuanceOfEmbeddedDerivative", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "kod_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_LeaseAgreementOnAprilAndJuneTwoThousandAndTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease agreement on April and June two thousand and twenty", "label": "Lease Agreement On April And June Two Thousand And Twenty [Member]", "terseLabel": "Lease Agreement on April and June 2020" } } }, "localname": "LeaseAgreementOnAprilAndJuneTwoThousandAndTwentyMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_LeaseAgreementOnAprilTwoThousandAndTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease agreement on April two thousand and twenty.", "label": "Lease Agreement On April Two Thousand And Twenty [Member]", "terseLabel": "Lease Agreement on April 2020" } } }, "localname": "LeaseAgreementOnAprilTwoThousandAndTwentyMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_LeaseAgreementOnJuneTwoThousandAndTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Agreement on June two thousand and twenty", "label": "Lease Agreement On June Two Thousand And Twenty [Member]", "terseLabel": "Lease Agreement on June 2020" } } }, "localname": "LeaseAgreementOnJuneTwoThousandAndTwentyMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_LesseeOperatingLeaseInitialTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease initial term of contract.", "label": "Lessee Operating Lease Initial Term Of Contract", "terseLabel": "Initial lease term" } } }, "localname": "LesseeOperatingLeaseInitialTermOfContract", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "kod_LesseeOperatingLeaseMonthlyRentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease monthly rent expense.", "label": "Lessee Operating Lease Monthly Rent Expense", "terseLabel": "Monthly rent expense" } } }, "localname": "LesseeOperatingLeaseMonthlyRentExpense", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_LesseeOperatingLeaseRentAbatement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease rent abatement.", "label": "Lessee Operating Lease Rent Abatement", "terseLabel": "Total rent abatement" } } }, "localname": "LesseeOperatingLeaseRentAbatement", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_LiabilityRelatedToSaleOfFutureRoyalties": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability related to sale of future royalties.", "label": "Liability Related To Sale Of Future Royalties", "positiveTerseLabel": "Liability related to sale of future royalties", "terseLabel": "Liability related to sale of future royalties" } } }, "localname": "LiabilityRelatedToSaleOfFutureRoyalties", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "kod_LiabilityRelatedToSaleOfFutureRoyaltiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability related to sale of future royalties.", "label": "Liability Related To Sale Of Future Royalties [Abstract]" } } }, "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesAbstract", "nsuri": "http://www.kodiak.com/20201231", "xbrltype": "stringItemType" }, "kod_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability related to sale of future royalties.", "label": "Liability Related To Sale Of Future Royalties Policy [Text Block]", "terseLabel": "Liability related to Sale of Future Royalties" } } }, "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "kod_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability related to sale of future royalties.", "label": "Liability Related To Sale Of Future Royalties [Text Block]", "terseLabel": "Liability related to Sale of Future Royalties" } } }, "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyalties" ], "xbrltype": "textBlockItemType" }, "kod_LonzaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lonza.", "label": "Lonza [Member]", "terseLabel": "Lonza" } } }, "localname": "LonzaMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_LossOnExtinguishmentOfDebtAttributableToRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss on extinguishment of debt attributable to related parties.", "label": "Loss On Extinguishment Of Debt Attributable To Related Parties", "terseLabel": "Loss on extinguishment of debt attributable to related parties" } } }, "localname": "LossOnExtinguishmentOfDebtAttributableToRelatedParties", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "kod_ManufacturingAgreementInitialTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing agreement initial term.", "label": "Manufacturing Agreement Initial Term", "terseLabel": "Manufacturing agreement initial term" } } }, "localname": "ManufacturingAgreementInitialTerm", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "kod_ManufacturingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing agreement.", "label": "Manufacturing Agreement [Member]", "terseLabel": "Manufacturing Agreement" } } }, "localname": "ManufacturingAgreementMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_ManufacturingAgreementTermThatCanBeExtended": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing agreement term that can be extended.", "label": "Manufacturing Agreement Term That Can Be Extended", "terseLabel": "Manufacturing agreement term that can be extended" } } }, "localname": "ManufacturingAgreementTermThatCanBeExtended", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "kod_NetOperatingLossNotSubjectToExpirationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss not subject to expiration.", "label": "Net Operating Loss Not Subject To Expiration [Member]", "terseLabel": "Net Operating Loss Not Subject to Expiration" } } }, "localname": "NetOperatingLossNotSubjectToExpirationMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_NonEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-employee stock option.", "label": "Non Employee Stock Option [Member]", "terseLabel": "Non-employee Stock Options" } } }, "localname": "NonEmployeeStockOptionMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "domainItemType" }, "kod_NoncancellablePurchaseCommitmentsIncludingPotentialCancellationFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncancellable purchase commitments, including potential cancellation fees.", "label": "Noncancellable Purchase Commitments Including Potential Cancellation Fees", "terseLabel": "Noncancellable purchase commitments, including potential cancellation fees" } } }, "localname": "NoncancellablePurchaseCommitmentsIncludingPotentialCancellationFees", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_NumberOfLeasedBuildings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of leased buildings.", "label": "Number Of Leased Buildings", "terseLabel": "Number of buildings leased" } } }, "localname": "NumberOfLeasedBuildings", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "kod_NumberOfOptionsToExtendLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options to extend lease term.", "label": "Number Of Options To Extend Lease Term", "terseLabel": "Number of options to extend lease term" } } }, "localname": "NumberOfOptionsToExtendLeaseTerm", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "kod_OfficeAndLaboratorySpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office and laboratory space.", "label": "Office And Laboratory Space [Member]", "terseLabel": "Rottenstrasse 5 in Visp" } } }, "localname": "OfficeAndLaboratorySpaceMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease right of use asset amortization.", "label": "Operating Lease Right Of Use Asset Amortization", "terseLabel": "Amortization of operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "kod_OperatingLossCarryforwardsExpirationStartYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards, expiration start year.", "label": "Operating Loss Carryforwards Expiration Start Year", "terseLabel": "Net operating loss carryforwards expiration start year" } } }, "localname": "OperatingLossCarryforwardsExpirationStartYear", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "kod_OptionsGrantedToNonEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options granted to non employees.", "label": "Options Granted To Non Employees [Member]", "terseLabel": "Options Granted to Non-employees" } } }, "localname": "OptionsGrantedToNonEmployeesMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "kod_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "kod_OtherNonOperatingIncomeExpenseAttributableToRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to non operating activities, classified as other attributable to related parties.", "label": "Other Non Operating Income Expense Attributable To Related Parties", "terseLabel": "Other income (expense) attributable to related parties" } } }, "localname": "OtherNonOperatingIncomeExpenseAttributableToRelatedParties", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "kod_PaymentsOfOfferingCostsOnIssuanceOfCommonStockInConnectionWithInitialPublicOfferingOrFollowOnOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of offering costs on issuance of common stock in connection with initial public offering or follow on offering.", "label": "Payments Of Offering Costs On Issuance Of Common Stock In Connection With Initial Public Offering Or Follow On Offering", "terseLabel": "Offering costs with respect to issuance of common stock in connection with initial public offering/follow-on offering" } } }, "localname": "PaymentsOfOfferingCostsOnIssuanceOfCommonStockInConnectionWithInitialPublicOfferingOrFollowOnOffering", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "kod_PercentageOfPatientsToBeEnrolled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of patients to be enrolled.", "label": "Percentage Of Patients To Be Enrolled", "positiveTerseLabel": "Percentage of patients to be enrolled" } } }, "localname": "PercentageOfPatientsToBeEnrolled", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "kod_PercentageOfRepurchaseOfRoyalties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of repurchase of royalties.", "label": "Percentage Of Repurchase Of Royalties", "positiveTerseLabel": "Percentage of repurchase of royalties" } } }, "localname": "PercentageOfRepurchaseOfRoyalties", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "kod_PerformanceBasedEquityAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance based equity awards.", "label": "Performance Based Equity Awards [Member]", "terseLabel": "Performance Based Equity Awards" } } }, "localname": "PerformanceBasedEquityAwardsMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_PerformanceBasedRestrictedStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance-based restricted stock unit.", "label": "Performance Based Restricted Stock Unit [Member]", "terseLabel": "Performance Based Restricted Stock Units" } } }, "localname": "PerformanceBasedRestrictedStockUnitMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_PerformanceBasedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance-based stock options.", "label": "Performance Based Stock Options [Member]", "terseLabel": "Performance-based Stock Options" } } }, "localname": "PerformanceBasedStockOptionsMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "domainItemType" }, "kod_PrincipalPaymentsOfTenantImprovementAllowancePayable": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Principal payments of tenant improvement allowance payable.", "label": "Principal Payments Of Tenant Improvement Allowance Payable", "negatedLabel": "Principal payments of tenant improvement allowance payable" } } }, "localname": "PrincipalPaymentsOfTenantImprovementAllowancePayable", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "kod_ProceedsFromIssuanceOfConvertibleNotesToRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of convertible notes to related parties.", "label": "Proceeds From Issuance Of Convertible Notes To Related Parties", "positiveTerseLabel": "Proceeds from issuance of convertible notes" } } }, "localname": "ProceedsFromIssuanceOfConvertibleNotesToRelatedParties", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "kod_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of future royalties, net of issuance costs.", "label": "Proceeds From Sale Of Future Royalties Net Of Issuance Costs", "terseLabel": "Proceeds from sale of future royalties, net of issuance costs", "verboseLabel": "Proceeds from sale of future royalties" } } }, "localname": "ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "kod_RelatedPartyTransactionOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party transaction ownership percentage.", "label": "Related Party Transaction Ownership Percentage", "positiveTerseLabel": "Ownership percentage" } } }, "localname": "RelatedPartyTransactionOwnershipPercentage", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "kod_RelatedPartyTransactionOwnershipPercentageThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party transaction ownership percentage threshold.", "label": "Related Party Transaction Ownership Percentage Threshold", "terseLabel": "Ownership percentage threshold" } } }, "localname": "RelatedPartyTransactionOwnershipPercentageThreshold", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "kod_RepurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repurchase agreement.", "label": "Repurchase Agreement [Member]", "terseLabel": "Repurchase Agreement" } } }, "localname": "RepurchaseAgreementMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "kod_ResearchAndDevelopmentCreditCarryforwardsExpirationStartYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development credit carryforwards expiration start year.", "label": "Research And Development Credit Carryforwards Expiration Start Year", "terseLabel": "Tax credit carryforwards expiration start year" } } }, "localname": "ResearchAndDevelopmentCreditCarryforwardsExpirationStartYear", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "kod_ResearchAndDevelopmentCreditCarryforwardsExpirationYearDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development credit carryforwards expiration year description.", "label": "Research And Development Credit Carryforwards Expiration Year Description", "terseLabel": "Tax credit carryforward, expiration year" } } }, "localname": "ResearchAndDevelopmentCreditCarryforwardsExpirationYearDescription", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "kod_RiskAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk and uncertainties.", "label": "Risk And Uncertainties Policy [Text Block]", "terseLabel": "Risk and Uncertainties" } } }, "localname": "RiskAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "kod_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of accrued liabilities and other current liabilities.", "label": "Schedule Of Accrued Liabilities And Other Current Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Liabilities and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "kod_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock reserved for future issuance.", "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]", "terseLabel": "Schedule of Common Stock Reserved for Future Issuances" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockTables" ], "xbrltype": "textBlockItemType" }, "kod_ScheduleOfShareBasedPaymentAwardEmployeeStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share-based payment award, employee stock options, valuation assumptions.", "label": "Schedule Of Share Based Payment Award Employee Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Fair Value of Employee Stock Options Estimated Using Weighted-average Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "kod_ScheduleOfShareBasedPaymentAwardNonEmployeeStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share-based payment award, non-employee stock options, valuation assumptions.", "label": "Schedule Of Share Based Payment Award Non Employee Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Fair Value of Non-Employee Stock Options Estimated Using Weighted-average Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardNonEmployeeStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "kod_ScheduleOfShareBasedPaymentAwardPerformanceBasedAwardsAndRSUsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share-based payment award, performance based awards and RSUs, valuation assumptions.", "label": "Schedule Of Share Based Payment Award Performance Based Awards And R S Us Valuation Assumptions Table [Text Block]", "terseLabel": "Fair Value of Performance Based Awards and RSUs Estimated Using Weighted-average Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardPerformanceBasedAwardsAndRSUsValuationAssumptionsTableTextBlock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "kod_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, award vesting description.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Description", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDescription", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "kod_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price must be equal to at least 110% of the fair market value of the common stock on the grant date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Exercise Price", "terseLabel": "Options exercise price, percentage of estimated fair value of shares on grant date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePrice", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "kod_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, options, aggregate intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "stringItemType" }, "kod_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options outstanding period increase decrease percentage.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Percentage", "terseLabel": "Percentage of outstanding stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreasePercentage", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "kod_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "stringItemType" }, "kod_SharesWithheldRelatedToNetShareSettlementOfRSUsWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares withheld related to net share settlement of RSUs weighted average grant date fair value", "label": "Shares Withheld Related To Net Share Settlement Of R S Us Weighted Average Grant Date Fair Value", "terseLabel": "Shares withheld related to net share settlement of RSUs" } } }, "localname": "SharesWithheldRelatedToNetShareSettlementOfRSUsWeightedAverageGrantDateFairValue", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "perShareItemType" }, "kod_StockOptionsOutstandingAndReleaseOfRestrictedSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options outstanding and release of restricted shares.", "label": "Stock Options Outstanding And Release Of Restricted Shares [Member]", "terseLabel": "Stock Options Outstanding and Release of Restricted Shares" } } }, "localname": "StockOptionsOutstandingAndReleaseOfRestrictedSharesMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" ], "xbrltype": "domainItemType" }, "kod_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "kod_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "kod_TenantImprovementAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance.", "label": "Tenant Improvement Allowance", "terseLabel": "Tenant improvement allowance" } } }, "localname": "TenantImprovementAllowance", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_TenantImprovementAllowanceAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance agreement.", "label": "Tenant Improvement Allowance Agreement [Member]", "terseLabel": "Tenant Improvement Allowance Agreement" } } }, "localname": "TenantImprovementAllowanceAgreementMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_TenantImprovementAllowancePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance payable.", "label": "Tenant Improvement Allowance Payable [Member]", "terseLabel": "Tenant Improvement Allowance Payable" } } }, "localname": "TenantImprovementAllowancePayableMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_TheCompanyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the company.", "label": "The Company [Text Block]", "terseLabel": "The Company" } } }, "localname": "TheCompanyTextBlock", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompany" ], "xbrltype": "textBlockItemType" }, "kod_TransfersBetweenHierarchyLevels": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transfers between hierarchy levels.", "label": "Transfers Between Hierarchy Levels", "terseLabel": "Transfers of assets or liabilities between the fair value measurement levels" } } }, "localname": "TransfersBetweenHierarchyLevels", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_TwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen and two thousand fifteen equity incentive plan.", "label": "Two Thousand Eighteen And Two Thousand Fifteen Equity Incentive Plan [Member]", "terseLabel": "2018 Plan and 2015 Equity Incentive Plan" } } }, "localname": "TwoThousandEighteenAndTwoThousandFifteenEquityIncentivePlanMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "domainItemType" }, "kod_TwoThousandEighteenConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 convertible notes.", "label": "Two Thousand Eighteen Convertible Notes [Member]", "terseLabel": "2018 Convertible Notes" } } }, "localname": "TwoThousandEighteenConvertibleNotesMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_TwoThousandEighteenEmployeeSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen employee share purchase plan.", "label": "Two Thousand Eighteen Employee Share Purchase Plan [Member]", "terseLabel": "2018 Employee Share Purchase Plan" } } }, "localname": "TwoThousandEighteenEmployeeSharePurchasePlanMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_TwoThousandEighteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen equity incentive plan.", "label": "Two Thousand Eighteen Equity Incentive Plan [Member]", "terseLabel": "2018 Equity Incentive Plan" } } }, "localname": "TwoThousandEighteenEquityIncentivePlanMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_TwoThousandSeventeenConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2017 convertible notes.", "label": "Two Thousand Seventeen Convertible Notes [Member]", "terseLabel": "2017 Convertible Notes" } } }, "localname": "TwoThousandSeventeenConvertibleNotesMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_UnpaidOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unpaid offering costs.", "label": "Unpaid Offering Costs", "terseLabel": "Unpaid offering costs" } } }, "localname": "UnpaidOfferingCosts", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "kod_UnrecordedMilestoneAndRoyaltyPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payments and royalties on net sales that are not estimable.", "label": "Unrecorded Milestone And Royalty Payments", "terseLabel": "Milestone payments" } } }, "localname": "UnrecordedMilestoneAndRoyaltyPayments", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_UnrecordedUnconditionalPurchaseObligationCancellationFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecorded unconditional purchase obligation cancellation fees.", "label": "Unrecorded Unconditional Purchase Obligation Cancellation Fees", "terseLabel": "Unrecorded unconditional purchase obligation, cancellation fees" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationCancellationFees", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "kod_VestingOfRestrictedStockUnitsNetOfTaxesWithheld": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Vesting of restricted stock units, net of taxes withheld.", "label": "Vesting Of Restricted Stock Units Net Of Taxes Withheld", "terseLabel": "Vesting of restricted stock units, net of taxes withheld" } } }, "localname": "VestingOfRestrictedStockUnitsNetOfTaxesWithheld", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "kod_VestingOfRestrictedStockUnitsNetOfTaxesWithheldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting of restricted stock units net of taxes withheld shares.", "label": "Vesting Of Restricted Stock Units Net Of Taxes Withheld Shares", "terseLabel": "Vesting of restricted stock units, net of taxes withheld, shares" } } }, "localname": "VestingOfRestrictedStockUnitsNetOfTaxesWithheldShares", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "kod_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares of common stock issued from warrants exercised.", "label": "Warrants Exercised", "verboseLabel": "Warrants exercised into common stock shares" } } }, "localname": "WarrantsExercised", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "kod_WarrantsExercisedIntoConvertiblePreferredSharesThenConvertedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants exercised into convertible preferred shares then Converted.", "label": "Warrants Exercised Into Convertible Preferred Shares Then Converted [Member]", "terseLabel": "Warrants Exercised Into Convertible Preferred Shares Then Converted" } } }, "localname": "WarrantsExercisedIntoConvertiblePreferredSharesThenConvertedMember", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "kod_WeightedAverageNumberOfSharesOutstandingAdjustment": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails": { "order": 10010.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesIssuedBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Weighted average number of shares outstanding adjustment.", "label": "Weighted Average Number Of Shares Outstanding Adjustment", "negatedLabel": "Less: weighted-average unvested restricted shares and shares subject to repurchase" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAdjustment", "nsuri": "http://www.kodiak.com/20201231", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "sharesItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r52", "r98" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r261", "r262", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r461", "r463" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r261", "r262", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r461", "r463" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r241", "r261", "r262", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r461", "r463" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r241", "r261", "r262", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r461", "r463" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r161", "r162", "r239", "r240", "r462", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r161", "r162", "r239", "r240", "r462", "r492", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA", "terseLabel": "California" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update201602 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update201613 [Member]", "terseLabel": "ASU 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]", "terseLabel": "Accrued Liabilities and Other Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable And Accrued Liabilities Current [Abstract]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r84" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Amortization (accretion) of premium (discount) on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued and other current liabilities", "totalLabel": "Total accrued and other current liabilities", "verboseLabel": "Current portion of tenant improvement allowance payable" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r8", "r41" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails": { "order": 10050.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r36", "r209" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r54", "r55", "r56", "r452", "r471", "r475" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r53", "r56", "r57", "r102", "r103", "r104", "r366", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r24" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r102", "r103", "r104", "r303", "r304", "r305" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r105", "r106", "r107", "r108", "r174", "r175", "r176", "r177", "r178", "r179", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r341", "r342", "r343", "r344", "r423", "r424", "r425", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r264", "r266", "r309", "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r266", "r295", "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense recognized", "verboseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationClassifiedInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r83", "r393" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization Of Financing Costs And Discounts", "terseLabel": "Non-cash interest expense and amortization of debt discount and issuance cost" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Anti-dilutive securities excluded from the computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area Of Land", "terseLabel": "Lease area" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r95", "r147", "r155", "r159", "r172", "r362", "r367", "r381", "r430", "r450" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r51", "r95", "r172", "r362", "r367", "r381" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r369" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r169" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "terseLabel": "Marketable securities with unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r164", "r167", "r193", "r436" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10020.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r166", "r193" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails": { "order": 10060.0, "parentTag": "kod_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available For Sale Securities Debt Securities Current", "terseLabel": "Fair Value, current" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r166", "r193" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails": { "order": 10030.0, "parentTag": "kod_AvailableForSaleDebtSecuritiesAmortizedCostBasisNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Available For Sale Securities Debt Securities Noncurrent", "terseLabel": "Fair Value, noncurrent" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r267", "r297" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Deposited with Financial Institution" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of the state of California.", "label": "California Franchise Tax Board [Member]", "terseLabel": "California" } } }, "localname": "CaliforniaFranchiseTaxBoardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r32", "r85" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10010.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r86", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r10", "r86", "r92", "r429" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r79", "r85", "r91" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, at end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash, at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r79", "r384" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing information:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r93", "r95", "r118", "r119", "r120", "r122", "r124", "r132", "r133", "r134", "r172", "r381" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r237", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r46", "r220", "r437", "r456" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r215", "r217", "r219", "r221" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock reserved for future issuances", "verboseLabel": "Common stock, shares reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.0001 par value, 490,000,000 shares authorized at December 31, 2020 and 2019; 51,112,302 and 44,413,404 shares issued and outstanding at December 31, 2020 and 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation And Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r60", "r62", "r63", "r68", "r440", "r458" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income Policy Policy [Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Hardware" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r137", "r447" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r92", "r364" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation Policy [Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Contractual obligation under funding agreement" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation Due In Next Twelve Months", "terseLabel": "Annual suite fees payment for 2021" } } }, "localname": "ContractualObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "auth_ref": [ "r88", "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "Information by description of stock conversions.", "label": "Conversion Of Stock By Unique Description [Axis]", "terseLabel": "Stock Conversion Description" } } }, "localname": "ConversionOfStockByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNameDomain": { "auth_ref": [ "r88", "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "The unique name of a noncash or part noncash stock conversion.", "label": "Conversion Of Stock Name [Domain]", "terseLabel": "Conversion of Stock, Name" } } }, "localname": "ConversionOfStockNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNoteSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest).", "label": "Corporate Note Securities [Member]", "terseLabel": "Corporate Notes" } } }, "localname": "CorporateNoteSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "auth_ref": [ "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r196", "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.", "label": "Credit Loss Financial Instrument Policy [Text Block]", "terseLabel": "Credit Losses \u2013 Available-for-Sale Debt Securities" } } }, "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r96", "r337", "r347" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails": { "order": 10060.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense Benefit", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r100", "r337" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails": { "order": 10080.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense Benefit", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r96", "r337", "r347", "r349" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails": { "order": 10010.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense Benefit", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense Benefit Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r96", "r337", "r347" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails": { "order": 10070.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State And Local Tax Expense Benefit", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r431", "r433", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r392", "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "verboseLabel": "Improvements allowance payable to be drawn" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "verboseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument Term", "terseLabel": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r88", "r89", "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction", "terseLabel": "Offering costs paid in restricted stock awards" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r168", "r193", "r198", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Allowance For Credit Loss", "terseLabel": "Allowance for credit losses for available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r170" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Realized Gain Loss", "terseLabel": "Realized gains or losses recognized on sale or maturity of available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Securities Available For Sale Term", "terseLabel": "Marketable securities, contractual maturities" } } }, "localname": "DebtSecuritiesAvailableForSaleTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r96", "r338", "r347" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails": { "order": 10030.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense Benefit", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r96", "r338", "r347" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails": { "order": 10050.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense Benefit", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r96", "r338", "r347", "r348", "r349" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails": { "order": 10020.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense Benefit", "totalLabel": "Total deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense Benefit Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r18", "r19", "r327", "r432", "r448" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Income Tax Liabilities", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r96", "r338", "r347" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails": { "order": 10040.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State And Local Income Tax Expense Benefit", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets Goodwill And Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r328" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10050.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r330" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Total net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r330" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r335", "r336" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10130.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets Property Plant And Equipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r333", "r335", "r336" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards Research", "terseLabel": "Research and development tax credits", "verboseLabel": "Research and development credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r335", "r336" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r335", "r336" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals", "terseLabel": "Accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r329" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": { "order": 10060.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities Net [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan Cost Recognized", "terseLabel": "Expense related to matching contributions" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]", "terseLabel": "Defined Contribution Plan Disclosure [Line Items]" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match", "terseLabel": "Employer matching contribution, percent of match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanPlanNameExtensibleList": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Indicates name of defined contribution plan designed to provide retirement benefits. Includes, but is not limited to, legal name of plan.", "label": "Defined Contribution Plan Plan Name Extensible List", "terseLabel": "Defined Contribution Plan, Plan Name [Extensible List]" } } }, "localname": "DefinedContributionPlanPlanNameExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]", "terseLabel": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r83", "r207" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of defined contribution pension and other postretirement plans.", "label": "Description Of Defined Contribution Pension And Other Postretirement Plans", "terseLabel": "Plan name" } } }, "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per common share, basic and diluted", "verboseLabel": "Net loss per share attributable to common stockholders, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataScheduleOfQuarterlyFinancialInformationUnauditedDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic And Diluted [Abstract]" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r92", "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r125", "r126", "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r317" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Provision for income taxes" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r317", "r351" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10010.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r317", "r351" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10040.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": { "auth_ref": [ "r317", "r351" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10090.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.", "label": "Effective Income Tax Rate Reconciliation Deductions", "terseLabel": "Section 162(m)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r317", "r351" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10030.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential", "terseLabel": "Foreign tax rate differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r317", "r351" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10050.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r317", "r351" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10070.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation Other Adjustments", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r317", "r351" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10020.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r317", "r351" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails": { "order": 10060.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation Tax Credits Research", "terseLabel": "Research tax credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateToStatutoryUSFederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued salaries and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationClassifiedInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Unrecognized stock-based compensation weighted-average period expected for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r102", "r103", "r104", "r106", "r113", "r115", "r131", "r177", "r229", "r236", "r303", "r304", "r305", "r343", "r344", "r385", "r386", "r387", "r388", "r389", "r390", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r369", "r370", "r371", "r377" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r369", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r257", "r370", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r369", "r370", "r372", "r373", "r378" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r242", "r244", "r249", "r257", "r370", "r411" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Quoted Price in Active Markets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r242", "r244", "r249", "r257", "r370", "r412" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Significant Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r257", "r370", "r413" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)", "verboseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value", "terseLabel": "Liability measured at fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r257", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r369", "r370", "r372", "r373", "r375", "r378" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value Measurements Nonrecurring [Member]", "verboseLabel": "Nonrecurring" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r376", "r378" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring", "verboseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r92", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r200", "r201", "r203", "r204", "r422", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r200", "r202" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r382", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain Loss Realized", "terseLabel": "Foreign currency transaction loss" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r83", "r224", "r225" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10080.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gains Losses On Extinguishment Of Debt", "negatedLabel": "Extinguishment of debt", "terseLabel": "Loss on extinguishment of debt (includes $1,587 attributable to related parties for the year ended December 31, 2018)" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10100.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationClassifiedInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r83", "r206", "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment Of Long Lived Assets Held For Use", "terseLabel": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r92", "r205", "r213" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r99", "r350" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails": { "order": 10010.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income Loss From Continuing Operations Before Income Taxes Domestic", "terseLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r66", "r147", "r154", "r157", "r158", "r160", "r427", "r438", "r443", "r459" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Total loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r99", "r350" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails": { "order": 10020.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income Loss From Continuing Operations Before Income Taxes Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationClassifiedInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationClassifiedInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority Name [Axis]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority Name [Domain]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r318", "r325", "r332", "r345", "r352", "r354", "r355", "r356" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r96", "r114", "r115", "r146", "r316", "r346", "r353", "r460" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "totalLabel": "Provision (Benefit) for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionBenefitForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r64", "r92", "r314", "r315", "r325", "r326", "r331", "r339", "r494" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r82" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10300.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r82" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10310.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r82" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10290.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase Decrease In Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r82" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10330.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase Decrease In Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r82" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expense and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r65", "r145", "r391", "r393", "r441" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10060.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense (includes $nil, $nil and $3,030 attributable to related parties for the years ended December 31, 2020, 2019 and 2018, respectively)" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense Related Party", "terseLabel": "Interest expense attributable to related parties" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r78", "r80", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service I R S [Member]", "terseLabel": "IRS" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r71", "r144" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10050.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r171", "r428", "r446", "r491" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Summary of Lessee, Weighted Average Remaining Lease Term and Weighted Average Discount Rates" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.", "label": "Lease Expiration Date1", "verboseLabel": "Lease term" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvement", "verboseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Summary of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r405" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r405" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10060.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r405" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r405" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r405" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r405" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r405" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r405" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Lessee operating lease option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Lessee, operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r95", "r156", "r172", "r363", "r367", "r368", "r381" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r95", "r172", "r381", "r435", "r454" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42", "r95", "r172", "r363", "r367", "r368", "r381" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Cancellable Assignment and License Agreement" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r44", "r223" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r3", "r40" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities Noncurrent", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Policy", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Text Block]", "terseLabel": "Summary of Marketable Securities Held" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r79" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r79" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r79", "r81", "r84" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r58", "r61", "r67", "r84", "r95", "r105", "r109", "r110", "r111", "r112", "r114", "r115", "r121", "r147", "r154", "r157", "r158", "r160", "r172", "r381", "r439", "r457" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataScheduleOfQuarterlyFinancialInformationUnauditedDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income Loss Available To Common Stockholders Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r88", "r89", "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash Or Part Noncash Acquisition Fixed Assets Acquired1", "terseLabel": "Purchase of property and equipment under accounts payable" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office Equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r147", "r154", "r157", "r158", "r160" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "terseLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataScheduleOfQuarterlyFinancialInformationUnauditedDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities Payments Due [Abstract]", "terseLabel": "Operating Lease" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r397" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "positiveTerseLabel": "Operating lease liability", "terseLabel": "Lease liabilities", "verboseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r397" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r397" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r396" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r403", "r406" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r402", "r406" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r333" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r41" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails": { "order": 10060.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Accrued other liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r360", "r361", "r365" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10030.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent", "terseLabel": "Change in unrealized gains related to available-for-sale debt securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r59", "r62", "r360", "r361", "r365" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent", "terseLabel": "Other comprehensive income", "totalLabel": "Total other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]", "terseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other liabilities", "verboseLabel": "Other liabilities, non-current portion of tenant Improvement allowance payable" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10070.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other income (expense), net (includes $49, $nil, and $2,736 expenses attributable to related parties for the years ended December 31, 2020, 2019, and 2018, respectively)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r77" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments Of Debt Issuance Costs", "negatedLabel": "Debt issuance cost" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments Of Dividends", "terseLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r76" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Payments for restricted stock units, net of taxes withheld" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r165" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments To Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r73" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r241", "r243", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r263" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "401(k) plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/Disclosure401KPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r267", "r297" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred Stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred Stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "Preferred Stock [Text Block]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2020 and 2019" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r30", "r31" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Prior Period Reclassification Adjustment Description", "terseLabel": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds From Issuance Initial Public Offering", "terseLabel": "Net proceeds from initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r74" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock in connection with offering, net of offering costs", "verboseLabel": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r75" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds From Notes Payable", "terseLabel": "Proceeds from issuance of convertible notes (includes $9,560 from related parties for the years ended December 31, 2018)" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r74", "r298" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock upon option exercise" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r36", "r210" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r214", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r35", "r208" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r210", "r455" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r34", "r92", "r210", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r11", "r210" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Summary of Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r208" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Property and equipment estimated useful lives of assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "auth_ref": [ "r17", "r434", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.", "label": "Purchase Commitment Excluding Longterm Commitment [Axis]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "auth_ref": [ "r17", "r434", "r451" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Purchase Commitment Excluding Longterm Commitment [Domain]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentMember": { "auth_ref": [ "r17", "r434", "r451" ], "lang": { "en-us": { "role": { "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments.", "label": "Purchase Commitment [Member]", "terseLabel": "Purchase Commitments" } } }, "localname": "PurchaseCommitmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Selected Quarterly Financial Data (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r251", "r407", "r408", "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.", "label": "Repayments Of Debt And Capital Lease Obligations", "negatedLabel": "Principal payments of capital lease" } } }, "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r312", "r507" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10090.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationClassifiedInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r92", "r312" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Axis]", "terseLabel": "Restricted Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r6", "r13", "r91", "r493" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash", "verboseLabel": "Long-term restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards (RSAs)", "verboseLabel": "Unvested Restricted Shares" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r236", "r306", "r453", "r470", "r475" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r102", "r103", "r104", "r106", "r113", "r115", "r177", "r303", "r304", "r305", "r343", "r344", "r466", "r468" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r401", "r406" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Operating lease right-of-use asset obtained in exchange for operating lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Summary of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]", "terseLabel": "Summary of Stock-based Compensation Classified in Condensed Consolidated Statements of Operations and Comprehensive Loss" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]", "terseLabel": "Schedule of Provision (Benefit) for Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Components of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of Reconciliation of Effective Tax Rate to Statutory U.S. Federal Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r266", "r294", "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationClassifiedInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]", "terseLabel": "Components of Loss before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r36", "r210" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Schedule Of Quarterly Financial Information Table [Text Block]", "terseLabel": "Schedule of Quarterly Financial Information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r97", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r267", "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r273", "r284", "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Options Activity Under 2018 Plan and 2015 Plan" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]", "terseLabel": "Summary of Restricted Shares" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r47", "r93", "r132", "r133", "r226", "r227", "r228", "r230", "r231", "r232", "r233", "r234", "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r324", "r340" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]", "terseLabel": "Summary of Unrecognized Tax Benefits Amounts" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r92", "r148", "r149", "r150", "r151", "r152", "r153", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ServiceAgreementsMember": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service.", "label": "Service Agreements [Member]", "terseLabel": "Service Agreements" } } }, "localname": "ServiceAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r82" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1", "terseLabel": "Awards vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Canceled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Canceled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Granted", "verboseLabel": "Stock units, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Unvested, ending balance", "periodStartLabel": "Unvested, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward", "terseLabel": "Number of Restricted Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested, ending balance", "periodStartLabel": "Unvested, beginning balance", "verboseLabel": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Vested", "terseLabel": "Awards vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value", "verboseLabel": "Stock-based compensation of total fair value vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments", "terseLabel": "Expected dividend payment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized", "verboseLabel": "Common stock, shares reserved for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Shares exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period", "negatedLabel": "Forfeited or canceled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price", "terseLabel": "Forfeited or canceled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Granted", "verboseLabel": "Stock options, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "verboseLabel": "Stock options, weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r275", "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease", "terseLabel": "Number of shares increases annually" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r265", "r270" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r92", "r267", "r271" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Options, periods granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r289", "r307" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfNonEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationFairValueOfPerformanceBasedStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted-average grant date fair value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1", "terseLabel": "Total fair value of employee options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Share issued price, per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Shares Paid For Tax Withholding For Share Based Compensation", "negatedLabel": "Shares withheld related to net share settlement of RSUs" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]", "terseLabel": "Computer Software" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r21", "r22", "r23", "r93", "r95", "r118", "r119", "r120", "r122", "r124", "r132", "r133", "r134", "r172", "r229", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r50", "r102", "r103", "r104", "r106", "r113", "r115", "r131", "r177", "r229", "r236", "r303", "r304", "r305", "r343", "r344", "r385", "r386", "r387", "r388", "r389", "r390", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r102", "r103", "r104", "r131", "r421" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r49", "r229", "r230", "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r22", "r23", "r229", "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock in connection with initial public offering/follow-on offering, net of offering costs, shares", "verboseLabel": "Stock issued during period" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r22", "r23", "r229", "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures", "terseLabel": "Issuance of restricted stock awards, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r229", "r236", "r277" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionsActivityUnder2018PlanAnd2015PlanDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r50", "r229", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r22", "r23", "r229", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock in connection with initial public offering/follow-on offering, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r229", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures", "terseLabel": "Issuance of restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r50", "r229", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r27", "r28", "r95", "r163", "r172", "r381" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r94", "r236", "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Carrying Amount Attributable To Parent", "periodEndLabel": "Redeemable convertible preferred stock, ending balance", "periodStartLabel": "Redeemable convertible preferred stock, beginning balance" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Outstanding", "periodEndLabel": "Redeemable convertible preferred stock, shares outstanding, ending balance", "periodStartLabel": "Redeemable convertible preferred stock, shares outstanding, beginning balance" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r105", "r106", "r107", "r108", "r174", "r175", "r176", "r177", "r178", "r179", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r341", "r342", "r343", "r344", "r423", "r424", "r425", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type Of Adoption [Member]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r242", "r257", "r444" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "U.S. Treasury Securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r313", "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits at end of period", "periodStartLabel": "Unrecognized tax benefits at beginning of period" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfUnrecognizedTaxBenefitsAmountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r319" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense", "terseLabel": "Unrecognized tax benefits, interest and penalties charged" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions", "terseLabel": "Increases related to current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfUnrecognizedTaxBenefitsAmountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions", "terseLabel": "Increases related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfUnrecognizedTaxBenefitsAmountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r216" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation Balance Sheet Amount", "terseLabel": "Cancelable and/ or non-cancelable contractual obligations, total" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount purchased during the period under an unrecorded unconditional purchase obligation (for example, under the take-or-pay or throughput contract).", "label": "Unrecorded Unconditional Purchase Obligation Purchases", "terseLabel": "Unrecorded unconditional purchase obligation, expenses recognized" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationPurchases", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r135", "r136", "r138", "r139", "r140", "r141", "r142" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance Deferred Tax Asset Change In Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant", "verboseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails", "http://www.kodiak.com/20201231/taxonomy/role/DisclosureTheCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails": { "order": 10020.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesIssuedBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average common shares outstanding used in computing net loss per common share, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://www.kodiak.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r116", "r117" ], "calculation": { "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number Of Shares Issued Basic", "totalLabel": "Weighted-average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.kodiak.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL82887624-210437" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "30", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647444&loc=SL120269210-210444" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "30", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647444&loc=SL120254536-210444" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121648281&loc=SL120267834-210445" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL120267845-210446" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919260-210447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919272-210447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL120267966-210447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL120267969-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121614247&loc=SL120267897-210452" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13A", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121565518&loc=SL120267917-210453" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121565518&loc=SL120269220-210453" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267853-210455" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3C", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267859-210455" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3D", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267862-210455" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r356": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r428": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=121551529&loc=d3e60009-112784" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r446": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r491": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r508": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r509": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r511": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r512": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r513": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r514": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r515": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r516": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 144 0001564590-21-009946-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-009946-xbrl.zip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�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®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�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�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

      !,#FX:CATV!CK,X=EZR-:*V4ITOL;RHU-5<1BWY+N()72[TQ MB.]('-6'O66MWL MO>C*.[ 3AFK/R!6"CH(@2F7V,<-9T3BHF.@]95/C:X*@#AN'WQG4G,.C;&*0J+KI89"QC+4#3G4)G/$84-!VA+S5$*(=F*[P$UQVJ\6AO=X M_3LK'-LU94ZG:BIORD/01 XQ]R/43T2(EOOIFNK:@TZ(P%:P0AZ70J-WPR1K M&%Q5X[A@O;WX1=W%Q?O0E0\*9!O*@F*$S_1.#2,@=VF+M,*NO/V)^45[]NY7 MAL?Q0]0O!>6S_[YQ:NE+R1^*.Y?)1S1#):<&K6+3F]$Z64$EEN,W "YA/6/,]_$&Z9A-UW2DPD9FN$8"Q1< M;9CJ 111HD.__UCWW+^VP9<1+1F8$AT/CR%F@8)ZEUO^,%I/ JZ ;[]S8=@= M6^FBOED4D!%,[9(5U+4T;"T.!I,C[KG%XC9Z4MC'OB]F1Z^APM-"JMT.'9 0"/LB M@!"TDY4:8*U=NZR';4L=-3@B7VU2GK"VW1E"8I(MBISYR&E#,ZN!K+_CC*A MKP7'+_K%;FP]P''418 \F*UNW=F54\2$7_WE&9:("YQ,]K74E:_U _T?L_&TF1;W2"?XQ40H.'EO.UY8*F4HMK&_3@7ZN8 **"%\*+;8G MBA:+NSS]\+Y4/G^JX,RE3YQL0B;2OFU7C)WX"U+CRU0+&5R)$"JB+ MFYI.,1*3@ IIK]V;5LN R1 *QT#_?6T?/MJ5]]ID!-,[28*Q)4;ON]>6.D%MCQ"G8UN1X8/=2<9^FCSJ;4@ESXC["]PRIL]-?O.WG(R';):2#XV$I M[!ZR-6^(.5#E"'9F@ (R!\1VVT <(.BY=OVN3\[FK/FC@FQ^2X"-M^F;-VD. M>%*1RU\_3<1WPC^JNBXQ/[[QZZ9;7PPO+?7 W8RA7?R1$Q.Y3\5T>?2E>F*3 M$,? ULV/5UX2:Y%@DH7#F8'835R/5I0?-Q@I]X% V'%:BXN*8/AK8*L[2<[ M\8\11W*D'2_ %>[$/W0K-U282Z10G0;/\/]P]M9Q52UA&^BF1$*Z4VEI*>F4 M5E) NKN[V8 "2H]_M.7KD?/?XW>]W_UNS9LW,6S/O M\TXM>WL\[ T3&6QW' 5 2Z^0U6#)C6\[Y*) Y.BKIPH)GX^Y.HTNWT$R*1 M"W1PGB2KF;#D+8_I;0BLT8^M4$"+:<9W_IS;>Y@0!%HK96E.C'_GFOR="SS2 M9%P[R2877E8S*"PK4Q>*Y"WTH/AJ7J;]+$$@VT=&%X:P$C 456^]U)C 4 #@ MG:: 7V'M'0K*K-)/B*& 7I,BN?Y).FQM45(DFB3JO.B'AH$.KT[(T*\19'GF MFL5Z:4JN2J\Q8*.;6-1-@IQP>S[PBP$4L,@QYF5W 28V/%*Y/\#T4&9U-MQ) M:FTKRD^(R2AX&GC0BI?2O#W0_(O-2M_?W!4]W'Z5:R!W"CC)45DW=6+;JF#[ MQ2\+I>&XR"8[\("82264+^D/>=:_\GJ%F;7GVNG?# Z>3\--&+4%U_,5#L5#*XQ7*&GYDS!X.P7538.(._$F! ]% M40+&+"/J\E;I#M]# (Y^:3%X-VK85H;I)3B@ MC1@RYPP%X'3)*Y72-H/FY;F*ATH:JN^'*A4[]B(3]V1_GF^SI6[^W+!YH_BJ M?\#E/);X&=T\NUOI'*F G9WTP4W-SLDZ6&3)0/LRT69"2L#;4H6>8Y9*)K/N M$0NEFG*S0!01>?GCH])U:6-)!T)*'.-@MW@6=6LIW=)=8 /$)\:.E0,>FT*: M?$?\NDO#03C\;%HL5DAJR#H=!A3DB/%?265$#SA??.UK3R;WQ6]3/.3YBJC: M:C3RK9\L3E) A\;/QJ*O4%D[P:8,SNM#-KA!:.6^CT2^WK=V4T$F&VV<6K)= MIS?LVSG4#YV[UZ29Q 8B$T(9\HA^'3C3VMF? 4X:WD1HPI"!WPRD'G/5JJHV MM^I##L&[>#M:0SS:Z%(,[VB^A^AE9WAP69+.CA=9\^.F\B+LTG9FM<)F@T&O M"@"9)FF!4HY=0E9H)3AZDH:^G-)DBHB)L@1=LT3/,@._(2"'NAG5\=T_.M%V$=B2S!B<^QNZB"W0T=,,;>1_-VTQBLNIS0A;'7\9,PI85U M*@IZ+X^:,GXO0#%C)'4)$#:21DX[!(4T:E9.L-J!+8H>5"IW&;_O\QG1U"5C M)8P4&_)6-B/DRH$"HE+USXL-D'NS%]62L5Q[7G MI8)-FD<=X7!HZ;[]N[&,P-T7(KV>33.V:]2VYL=2>%>X.YKV2]?R'\3W[,'U MV;G/,<_E:P#'M]LF09-- MOL+N@Z_1LJ3S" @5,B_%$3PCB,6=T^L#/;JK'#M?05K\99D*D#C0'-LP!!-Z M;J .:X'LD6G]6CU0/YYU^B;VG".?9TT]/##P>=UV:!EE<2)@4?$<3AYWV9 M'H6I]FA)QL&/V=R[[3L$#%%%C_&'EC$%<\D;/;G9;JA#J[YT(LT\.WQV&/*R M52!3@P\VGIC#_%:,5$#>9]<7@IZ:3544[E<-?ODDTS>\(G%U$E%K]" GGJ=%861TI5;IR_8 M1UJFJ.DF,6C'36V7Y-E6U6 M/^M1F"3>&W\.!4(7BRQ:];0T_!(FYT5<'@$ MK^H2"??C>!HY\AV7O^S*;SFS8F%1OM6KJ&PD347LGM%6VS.NZV=+).RL<"\*"V=+R<@>KR +&L'L[NEF ML;/<(?61'[T7#FWB93='C5"$5:.I M(@0, 2O31HML*96N9U'CXVZ -6D4U6:/0S\<(3USL(I.1@M=;:*" GI"\H%U MZ51JQ>@-&\PS1H9! 7KLP$UPD57O0?--*#_;K0=,+9\G MP 7)>S95J R?H]MJA("=)&^T5B?4G=X:^0?1,-!&VAYI-_S>+E40]1SPY1(D.\M,OA4/;.P25FC9X;]O; MUSKI!8^OGEEU91!(_)*CWJ).(WC Q5:VCI5FR"^+FH!*31T5]YS>CXQE)UH5UK]Z5HMH#%:>L-O]L 2.GVTQF7%<"Q9PPO@B MLS4D] 7.I^O^XU,<]B%?C_4O/BJ;>+(ZVTI=8O>51E$LD MPD<"G'*%((,?VD192?6!&D@ ;DN2[ BA#/"=/Y @81?K5NP'/S"WV:<&-S"/%/>BB,J7?#JE&%O@V8'X:D @4,!I[K%= M\\8X<'\?"M#RQYN:)@J7FD @91T!O6HE'GJR!;)DK;RV[K>O&,2:ND=HR=C; MQ9'IE$/>Q7"G6-2=VN +A2E&;%&]+RFIN+J$31O$N7;T8B=)UKS M5&&8D!6^SO?7WO8>\[.=O+DJN;V% G:4U^> P_E0P,("! S0_%S@6:U_O-U\ M?@X%%$FGND(!P@50 !!X-09G%EITYU.*WS4H(:4P5M_]]$X5HDB3"U500''[ M)8GBLUTF16>>WU.2E:HML-/4RPXETB9,\L4)P,PY/O4:Y2 M/IV<2+$IDA<@M9"7/1].X)@U3M?CS;[\ XV ]&\)%&*OOZO/R]JNBSQV2SCM MXA_IS9F6I4^Q7<9%FBY_VW5ZTMI-E#%8!P6DJT$!S+2JR%1[( M:^+H7!BX#"OC8Y[/!%D>?=,:2J6K"I:ZO'N5M%30G.REH-@]!]%1>],^T)4<6.\&G_).X,.1)958]<:;QW0V& MVMC1L)Q0A(8LNR9F>V*)J%C?E)>)Q=/G(8_]47_,4,#AH37D$@KX\N)5/JZL M\\;,^C;'9WD-=SC%\",74!UE+2ZV_91B*-397BGNF#"+G+#PI 4! MT=L\ZV'%I&"7^G'F KIW\AJILO_S(-)2)PFGEQ0-(*9/_VV >;/J?"O&Q;V- M@C.9;LN>@H?@X91,HF _45QWPS$,16[:$_YX<+@#R% M+[?%SHO^T"G"@B)];;B[(J6/]_ *:22(T\R328,% Z_9$OT7T(_^3C"7;NGD22 [+#]@K_?BMRH\:=^+%4=,([_*2)>>)'QOGY.%O?WW4R^V'GZ1]5KT92I1,.3 M9*H^OQ7Y+U,&J)56:';L6,,/W$,,?%*#;EPLQ)L=P=$B_B6,R1"79UWQL5O< MMA3_R!_[3T]EO46)^A9>L,R (ST:_1T;Z*?M M-2"9$]^(6S>GS (P33R'6:C^MK7F#AWP=/@T_QVS_VK)RG,K3R'I(JF.B;>Q MA+DDV3;'*6^.G\?2435OP+_VNW!I%4+6N\W^!SZ&/W'^NRJC[2U/=*VH!QVELH( MW.F.ED8"EJ9FJU!Y7XRHB)>!;_&F=(F?)T0MHN %_E"9][H PSL>*<"0S.[- MCK=T0^#&LR#S&)3[QJY.? A1:SI)GFRV3.1)2?U34OM7F^82Q"3]LABIU%J2 M6 _@NM2N]A^F$3Q<(?<^SZH$D18T3&?(13Q*(54->M8"J"=S'#XXH\_VT@HE M9J&MX4D48%D5,E%EO4_4P[?BS\NW]3)V6\V:U*+[O0$53\-SHK:8%L/;];;# M*5!3$V@CKLS+NG]07""7Y3,VN!:%?[__R6*\."8EF_/L6:=&$/H6=U7R_6L! MV?7,SN=^SUZ3&40EK0+9+<,0B)LKC(S)M]F&G=%;):1D^9C2]G:Z^$'@JDD> M?B^:>S(KTP"9]VM1V7A.5MI5;RMKP38V6DZ7R\M[8L[\$;E#_H@4[67"8*\* MF@EJ2YSY:]HK,ZV_7W8)&-I9ZE$GQ@)L4+RB8W\D*E3R< MQ%G8>&N0BS(A18H!7J9IW2)3>@5/"7'L_W!G@7K=]=G"Z1206MT*_(]KJOB] MN0D_9-G7M5* <0POI%\1K?W>BSE=3O)VD2A6>0FW:I2:[3Q0:&N!R-H.*^N M?SZ[J@[1GU(\K!EY M]KR($%[3*?-9+I-G.3AP.@@&E'6^_(GFQ+NR-.UA_BTBO%%)7GCP5DD MH9;[MD(*&"FT92#C^VR3*LCVF3$K%=DS'L;;\0"_EO/@]SI,MG9IJ9?&3H0&< MS&VM$AB)[<_KK7=YYM?&F&3\H_D1=/QR5N2OR>5,9 PMJ**+VS!DD"KF<$4!BZ!7%%(B\4YEF^<4#^MF$.WJTY(WC(\8Z*L;#;4J9ZF_SQ=N MMG_)(8ESU:B+>E[UP<[V\P?AU5QROS=F6;E%2_+>'A_#?6(^2E[!A28T(GE; M>49.?H%U?*-'7GWIM]:WUFH[K/:G4:<%[YB+QW'_VF]6*8O^X8'&*FKI+>.] M[#<]1)/TAUA00.>#?&!-,RQ\T)+F[KUY1GDHOMV\QP8)!CO.)GB%_&N *?>Y M&TR4:8T/G/-HP^Q&QE 27V_Y:'[,[TI-70B7S^P$X,J%X#:[QBU$=<@M$!)) MF,"75%>.?OK=6D*ARI>_1=JAGH9Q-8%ZE;YF8R2SMK&FUI(XP\-V%^)IP*RB MB7O]C;SN )-W-3(>AS8M\%*XGWN[9RI0)>C\08;_QD=DP?7/"214J!;1BEFL2U^,>".2C@4QS#3 MC2014!G+N37H.K52CZ9?WFN>PYR 7E5:O"7WT72N&BYR-@[D?$J<9_LU QL< M_R:"QIV-QD[#QJG Q$F1R7^*S&TE5,6V8Y*SK5P338:C3"J0WB<\UHD/$.[E M6I#GF-?N2%X?YIVG);1?2=3FMC/DY#P=9QQ*3)?N[4@SREX=/O#R^WQ'5Q\[ M$7NW\-3N:9[1U[X94D^V8IK0Y\GO@SK>W.[-(FP^[BV:*0>HZ//6AC_+5=!Q MA6O:VMI1$CH]^4IS2/0Q4O;&/Y9N73\ISTBLRPD#>21C_H1M=L%9'D$O/J$R)V$&TM9OL[(JD66E0]8=!2?P=8D3= M!G\ND9\+/P19#PISN/X=LJEU%&V$R )4/RYYGB//BQ[;/>&S9LU M4M,5"TOTF?>!?.ZJ.Q&]\/B [#(;H82WNZ-C-JFW4S2-(Q<+1^MQ72^3S64Z MK10>!5X>[WHC:JCES,<4P1%%?(^Z67D7+DM%T,,.)]'OT;BDN/[L"YQ(9+>S MQ\/X^?./)S,2+@:SWEQSO7U0/CU(?>G]A2M0[*BY;T@\=[A_(64W-\=U2MUW M6""U4YAJ@?N$Q+>K*\2&O3'U/?(N3JX9&3LM/LI&>"1?D2^GWN2^RZ[ZF2\_ M*;!B)D-;]+"'>)6]X$-W7;!1 _J!=='GX$F#BCW/YAM:/^;I:OF

      S(W X[K>4?Q@=\SEMF?LO'X\;=8N)U( M3@4HX$UUQVAJK4WE$QJLK+$RYFBY*(Z,_ X ;ZO!3"U90$OQ62AK/>IP;<12 MA+32N(NC:^X,,RXQ\4M&#GLE#]NBOHU14'R%)#[M#R> 7]QT6WWK1MDSGE+D M>K[;O%,*D2K\ O=+7YBAE=(3E:NO9*Z?/6B$$WQ*%MIQL#NC94VA.X9F-TCT M;HQU7EIV9"X:PR^^7_VU\UGTPC'_YC).SO>56 MXM#[*ZPZGP-J3KEI7U>^4-XH=T$4^3 MX.CA.$3"N MTJL.*PYVW#HJ%+]^_[N'MXKVQ)CE:R_[61(*AIB(5%3Q//](B MBL 4?;$'O%4KTRD)9B-YH0[A 7CZRP<1 38H)^KRV8]4LE_C$I(4+TGBJ7FDA M^T.9,0,X':D<0?>G5V\B]3UL8XQSR)QU(Y,=SXHXIIW'5XBO3KA[0QQ=:8VK M<8D9'6N=0AF**][^$$#0#H?]:<1IT=/"VN:)ZHEBFG+D+26P7%>&H?J[AU9! M^6:Y*2G8"']CPQ<_L6%=5;'J,MO-VY2ZCDW-/R*-Q#ZVZ.%I5>\^\ MEK[S+!^K&S),L?[!N=2A,DN'6 MQ,3%(E,.%5FAT9_YA-WW.8RA?%!-[29TF%("!:!@Q$$!(C"?XU-]H?SOI&KE M?JD>P6S6F;5WGF $LZ?ZD52OBSB[;DXI\L75\9[S=&&80'.Y9$[2LK9'7Q2? M=FR^&)&.@P?Y+2P>.8C>$CF^:#[O!P:Q_^RZWNZ8!&YC?A'!%5 M5K)/'D0-Y4?0&L4-@FM2B'F^7R;5S&P%[[[XQ6CG7XPR_)MOQI=F=7AS3\>Q MP@1. R?&"6BN.>$3B7L>PO,IJJ @@RX'9>KX^VG*]9XFT3ZL?)+PZAUYWT;< M_O?'"W]3E?Z#*LH[SR+ TF;WV5I[2Z3B?3KVK*;#;<6Q%%#%OZ3[KP1(UNVQ M II9!#\3)P2'G!X"Q(5*]Z;A581-3EM3@&!6PUG\ BTJB_)G6N[&\%H("5,6 V M%##:#!$2);#(7]C*@/C^J.S%I'] J@WH@^='M)=JNI.I5>LSCL1="A8+;J1V M.[;=50H6\./_9WX(@!<78)A)_[C6ME -I>G;QLQ&S]!QN/EU=O9_"QT$:\;(^HIZ.QCEDZOFIYYV%P-KB8$ZM'K?X@6=-.6Z_:B4F?6MWO5L M!]4HYK @P+<5.!C,E^R[>,$9,SPKT\ M^]1V[6GF(UGZ5;N4A_NCM_D \!W-!-J+]E[S4D8 -#/S6TM0]^[-4-1RV37T M$%?U;G)8("0U'.SNSYBS,S:HU)K:MAC3?RI.5ZB\QDA'JMKMXFX5SFDD+3ZW M':SZ;D[,E^$[OUM?5.UELEX>1-2F(#.=Y3D6&EY'D O3TM]J5(:D0@$P[WAQ M:F5TAP6Y9NO9IYZDSD.<*0#G"9.%'=(=+7M-9\KYOX?;7-E=E=K3W"0,L$F, MB%90OOI_C[B*_W/$3?^?.Q\)H( 8:$K(?(47"])?2E8KZJYU M8B6P4M:*=JNUO#[V]&8L<^#R^KQ\?!R"43X6AH*'X)4& MJ@]NR671I^\5D$Y;ZVN-W7G'8[?]8\%F-DIO=]**<+4%B@M2U4.S>FN6K/VI MW8Q2$ J-^MJWT'@I\B\KZ]U6ZA'GY',1C:K=7E+)0*0D^9DML^IK.:#Y3*J_ M\:R&FX90IW[YH4((,$LZKSUOIB@S7$EPB+H],E_"()@B)&6U*W&Y0 3+LFX< M%)2=&"5]C3@1YKDFC7N96IZD>K2(CNY^5GA= N_Q9JJ[T>4ZS]Y^C\WU?O3# MHVE)U,_T,:2H3XX=4'+ZL75!V87% >.OF= #,<3PP,,7E+(-7WP(L[:\ B1< MK0D3KDF=3GE;3[J8/N9Z)_RX2^RO37*)-\8[2VS7Z)UZL2T$?*59B9EX'RU)CLF-=)^/W'-+.6T#+W-UM%2V]683 MKK83[Q,*?14#;/SX&9P;>=2QR '1YCLS>KFT7K_!ZD6YC-[7B3DA+M:3.IQ] MZNZN$MSQ#M[3+< 4ZW-]B,7X6_3O\%68HBU.DN[ET@+"*@YAFZK/-U8T1^95-P)WLN M[$&_$6VY8=P,:71V*2./U]F[D=J.3JD0%?XK1Q XP66FZ9#0L67 P.3*->NH M&+BQ!=R?A$6 D?:/G-+PSBDXS%.50H>.^%9#^B, $FM1E?*5[WL1+_WT'(>% MK,UE[ GF-:UB%V2JJND0M7G#F< F1R\K<&-ECM'0*>6V!.O3S'?EH0"_[HLO M5+5"K(F06\S#3SUNO/:[;&]5M>;D;U/QZR^!%L&"U!S!IOI,):RAY!5?]I35 M6$\5<;<<(Z1NPDQB!3S6:[$_^M@E16-/L4(!IYY;8RM?O.CCG6% X4?=(1=? MUW2!PR-0P$()I)%L7GSM6'!?RIYDCL/*3#:#L->&-F)9-\.%I4D2\295VQZA MI-%MGM#Z[& \Y"PG_>ST+?.ZBYK3RNL/#7Y"5^/[C!L0/QB9P-/-H^+F7\*( M(V MJ]@SKGE@G^KOS-"]=^7@N]T=[_J3A^:K$SBCT)([?&C4U&AK4LE_4)@G?+\; M88*:-?RQ=]V?4U!]^E/UC*7A62KOLF>VVOO',8GQX9%9LJLK M0H,#9X%H.<&SG0AM(\\'^*A0"-_T\NZ_[EVN9ZK?M$$-F],;F2JE?=:I^M!5 M,*448N.0#+KB?LNZO 90$G(&O1\M36&_>7:5J=58.&V:%RMFSAMSE33I\VR7 MG/@ 8UP0AS$.:,Q3D">;-P-N22$2#/$VL]1U Z*@13MOO4Z7VS)*4[0^RW45 M\&1IH1\4S6+G3]L@4]'2*;JQ.?/*:FQ[W&HA7H,\^EJRK9MQ.J',E/S-FXA)F7DB[>R1BT8*:#X3UU;/K^I_[QD M)$.>&?C4$9PL1OUE.?-/4I/I_)_>/GY,@VK(R$Z,%$,Z;F,@P/EB,(OC3W:[25WM77*MA+T/:2V>FM\RT&82_,L<@ MW]A6UG9J.SR?V3) 4 MQ[G52T%"O&?C>O?+2#X6PV?2B5# M&9OOFG !?HN!UB(V2#HQ'%(9S#3Q<@-'Y'H\_S3.0<0+"M"JB>U)S1(?9R)S M5*XMH G(I\O3^V1E\3RHX/T%+#BBHLN#+ ,WK76U->@/U E&&$. NR(' M>+!^YMKCPS=&\W0:%.-S]7I;_6O;,6G$,STI"83 <.$]&3[]+#,HH,UQ>0M= M ZL]@]0ZPNH%!7Z,"081)U+,6]Z6F1YRW_S"?4--[;Q-X3\VL;%[B*PC1I', M-V++#9>OF#.8J]B@Q980T-KE1/S: -Z;9,L'?SFL&6N3)/B3!POYKCU=@-:7 M=%;)YX;O00J^EL(FQ2CTLS-'W%&P$:$2"FB!1?N=7U>M*8^A $LHP#\'"@@K MC*#OX)#.$3M+LF,5^6J[X9F(N)=*@V[BOFC@I=XR440R7AQ@;%/.2%PSS8$L M(A:-V>3+Z)ET27C2\;]6F_]B>08ID@=KCL!U.('Z,I&LE%I(M)MB.2NL0ZD^ M'JMO\3FUNR2 ;NNY9;2")S68;(!/XZ2?XH^"D,+$J2RP*,H9H ,]T[%3XJG: M3W/NN<0D(ZG(M3[\QMW&TC!2^3"P'_ES7^3//:BF"63!_Z*HT(G:):Z]?XK?P[.-), D!5#@U3UO3$)8T=( M##AQ@#%3JN\[9GG.7Q[6]77A.P->*3)UM.1?""$EV[YD0V8", M0@%PBE H71,(7#X-@<"GPYAS8C2CO3N]S","*V_=$I8[)HR(MPY(HMRU!JK M_;$/$21_:"8P!D2YS5\GUK@V8KZ_]!AFV[XD)\<0<%-VP_X_=YA.N&N\^)J-(:2 ;*>,CGO^7=[T>0UGO_<3%F[ N\X]CYY^1' MEZ4"RJ($OTY&]AP*!:WG+.W4"Z#XU+^#7V%5]4!'HUOJVU/2H,ZVCK%'L[)W M-!>*C+'/EB2"*VH:H46#Q*#%];3T9;AL.LY.NKO@<%NN-WA[O/?IJ,LO69:4 MMJ.J?_/"-D_P$-?_4*8PYQ ^Q18E(A$T&F,7$<)B]<%E * M]A5_U1%9]LE,N39I$:Y;QP28=PSBJ 7/]C&Z?D4&AN9"8]Q?]$5.=2QFBEBLB(\#;W\",@(L[^, M=Q4C-VYL+L&@"VE;;"A 1IG!3:2!)G%X?C:)"'%W=T?OM5I3W\+QN>-ER86J M'B8K3ZS\MQ@\G(&!CP !T..GCEE&<_C*#X^--:D;D[_ZFYJ:/GS]Y76H34_" M0>7H-DXG#GI%?7[N5>QC]'I)]6LFX/!<]WKSDO0W;8C?G@@W%(#Z8^;@FAH* M^)5!^4\&ZS\SH<.U50834,"6:EH?,HUCZUD>I \*^)LD):24-==42UB(J\IA M6:'/VJ'2K.0]N60!H]"' M,R935>/0#/G[%(%RNXF'.#B'M6KSM:V>\NO8"K+WY='@REJB'K6^(M2)"]Z* MYAUZHK5@"KR\KKF9O'E<+OXH(BOARB0"SLS,%$YT6[:3$#_20WR2?4>RD&VI M\_>GI;S(\)&1RS8MN79V7KQ\4C[&FJD&V'L2 MCTCQ!N.A@(V]E6/]@UR3$8,4 MBXWX\#CIQ1L''2G3($"@F0Z?^_& MQ!>W-L.=B0(K.&W$2E,^/LMKZKFC*L;J.[KXG7$/,=:WI!.KX\ITC.#,.3%2 M#$>;SR5F[9ULS#K%D62_+L$7HF ^]E:(G$IM,#%_U? M:F L6OUB"5&N:ZX)EW\8@3$;T>V/@M:]HK!<%N*-M!LQV,%$NS32\>7)O=5] M![7V? &RVR7BAY0ZKD68J K',]LTX-9W;+I4A#B7X;GXO$.*Q,/.D3<3:75> M.L^^ON"*[9I3$2W$7)3$MMQ!E,?C[,>S8L\-4)/^ B=Y@D;(D+]@\I,*AM^F M+&-<(K+2![Q:7^C+UJ]IELMPM5D>,C[+&\(ZD-F(RI*K*JD$9LVZG.H?_)C$ MLB\7^=GY?6-^R?@CNL6WRAU?C:%15E9U^60SF<]OGR;!%_-NQ7KY,CUZ9/GY MVJ?JJ@B\,^>Y?V;]4/Q)E(%2,<8B842+D_-H@&[(-_U?HB[PY6Y*1>UWSU4D MJ;!5 I@9;P)4%)=@HI&3 _VZ2XKS=9='?L*5 MW2=;IN=Q5NA?M\6H-.G-]"O(3 S2\%>/G#S(#K7*];Y)&I(?6\6F6CI0NSZJ MCOL"(*2YQI10G4XJ*9I8GH984MDL!9#74.<@>BD[E/5O)>)" 3867P6K(USV MV6;(YI"#5;!KU1 C/I6%PT7"K==[?:*(0^24Y7ING*#83$7%]'0LJ/>N^2^BMWN5+$PM9 M\>RHO_OGX@\C$Q:=] [%2ZQ3_7/<'S=3[Y#4BKQ-/Z*R:MZC_VOE-;%LLXEX M[.3D(#NRR->FD-D0D?@EEANF5[.S>X;>C*RMJ[.A(,Z#$KQR:B9,< ];96Q@!7RWXUDF7!P:&[T'%& =-ZQGK?J]"L;U/N'M <,U M2_/-=2<4X(.J(69)-@'.LJC+RFBW+9BQ'*2! BSB/V+Q)O=TZ>I@S=7NM!10 MD)9_N>',O V<5 U6.A(?:U)(E6DM: ?@".NUN$Q8@OLM00!,2I6DU#&YZ M-.\'*&Q/H,ET55=_85D,0EK+D$?U=!P:^13STMQ>Y/M&:!G"II)EAB*ANKT- M'!*%VJ-R)^>=6-DBRO(9F)4WZ)^W9/Q#Z6-=S'G.^1?WGN^G*@ID'BL.I34] MJ=_Q9T1[ZT*:6L-*<33&Q=:H9BJ*9C<7M[#OW)H_71TFR/1)/Y5%SF.QAM2# MIUAZ\-S/(-/YM"!EON23A]M]LW$M)I<415:1V43F*7H _U'KN_UJ/L]\6M? M=/&UK.$+PC&?\+;V[$\=/XO=5-4A7DUI76?'#3>FC*$^S*N\=-E5:2.= MX5V)G3>=#3>:EKG"NG]C-?R/ZA9&BR838W:N9KLK/=F4/^W+H3[[:$ X4/@ GR4B] *%R;&.\&6 M:;NC>I39M'#;[K7NT5!KZ:6J2-ZIK2QJFESF$.*=6Q'&L?\J']8AM,(X:Y$P M$%GW!GV'Z;EFCDY]Z?2KE;QN?."UM@(4\#&HY!:B?YC7]+O)W]*?P_0X@B'9 MZH1JMJ4G]L[HF=9/<*@=IFX*1DTA;$6>)5WWC2(::->ZPCZ8,>\J,8W>GQT MJU0SEF9XU\?DY!0QX9 B@!DCBD(M!=,F3*.D5U+\1'OWK!ZEA3J3&?D3DGE_ M54[@4D*J^_FSV"<^VADOEC'1%BS=CJ3)JE$_:3W?)3+P[!ZI%9)NTSJ2-N?" MQ+U\@',+(DV&B\(-=E<]"F$.>5#CHL>IVY7%$A%16'U^?@_-PY]#QL14C;C; MWEE9 M&UN]'>EGP-@.JY*V>[7HLLFY\#'O.<%'?U,#!< ]MPTA@:\#G7V1/)2(UEC; M$Y-,!4'5LFOQGR.^\1 FK])ZM-NAXP><+'^*6MJ]47I5H$_;6A4[LA3KN6;J MF3%/:Q,K,TOL"-F7^UY$J= 4Y0MNK[N,(KS:H.3 *>03>LNUI9".F;@^]^:8 M!IMN)_8IWRK#1MRN-"?&2^>KDM?%W(K8\KFROE0S#=&8CUEI%><8:V(<,C%3 MG2!JR5# ?9ZF=6R>RO)=,!97!,V;1:D>5?LY4R.U,,K4R!OCVFN6&H>@U5DI M\#(:$/SD:L(SD@9E[<9*M^^EO8P$J$;= M"F\0':.!4=7<6;">?V_!NFV>B2DW=D( 2",A& MXPQ&]8GDY=&_V:WX,A6.9!_N=)%'\V:0)A65^Y< MC1#KK?CWB#GI6;5OI:LVB 3(?+U7$Y]W2! Z:%\HDQ,;&Z@O14J4O>S"I"F/ MB5*"C8!*5_U0 %#[QL+)();YJQJDD["P^?RTN2NJ3'*'[?;6_C"/X5]S=[94 MZM6MBF)N%9'N$ M3IDF+VCN7'8;[HRW->^?IC[71HX,36NGOC.))'I?7QM?"MB9]^>DBE).?YFH MG/K"PGVF*-=_Z U(GH#&,2 :V4^VDR[ W-?2I<>@!CP:BQ3!LL=*8$3F>(2E M@,=&!O)8=$]!VT')J#5*_-+8X.<2\YQ&8TKLD?\P=2#OWA-Y"K MQSXQPK3,S8]XR6^]O2GEO,(DK$)+SA@:3:& YB((EV\HFR9P?P<8\2B!(1\* M, J;T+^^6EB1GOI\F@B!5%]\@;N[AO]F(@9EM\MT;?@&;+^7[I7^?Y1+JJ4] MUT0PTH-'"72MO$LFZB(?N45^-3"NO0X>78F43=CL.F(VC9D*8A9%/!ZE4;H7 M#W/.ORJT]/LE1']FY?]0WD>D?TUH+5ZI,=7S)@P9H=?>5^2HSIG(TF:HBC3] ML7/U!ZF#?R15D[^04$*I=(S%MFG,]LW;@V#4#EY*CH2')K9[THCC^[^:R[S& M$_ZG4)LNSZY+:>ST+-J;&NN>P;0>='OJ)C5W!X>B(2D,!48H(,0%!KM0@KKV M>9:7]H@US^-GO7"_@#@TQ$5C\EV9&B(WN*K+ $J?4P+2';UU=9,(??X=NY1WECM:P)B<44 2+ M :@TD7F'G)6KM>+K_M^W@"@NT]^\32GY>_'+->(O.(/-_1/.U.S)3YU 6A0 M0$]6!G RG/(*4&2U[L/E"KR0= &RV+CYAI+7)Q]'O"[!SX,"<$OV8%(^A\7T M008K>9\34DE>JMNY_GY)/-%<_^/?.HH0O%J?[L%52V7-VM^O@!T[UW7 6UAS M2])L2L,+V-PI_S":SC_K>(%:HKS6SI26YGV[.J&CLDZB,YDA/;&ELIS#O MV+K3R19:=&IK(CI)03).?'+=? _)'/,#)C@7MJ0PNREPX% M^(K\V)%PAWZ-V1>WN\@9[JS5'_W;=4E[;OA M%;V/L-)-8!7U4#S=&1(,;;I,TUE.Y?,L=&FY@7)1,#$?5]8[O/> "5XN%=Q0 M!OC37[^UTZ/^&O+6!:WQ<0X[6A#" %J]'='3YU&*6FM@$<"<#IKE&PG,>]:DBK.2)_D;'1;^QA DION MS8@Y+7+[8ER!8C[QQX@,[ [;E@YK3GEPI)_-'E,:AH":)X289MJ@'/(MD4I\ MWKJEL!4^Z)W8D%0G$2*%DVSQT"NN"_CDV'GV[]CRBZ91 /1SX7CZ*5N1C7F1 MZ_5TF"=T7%D:TY\^T*_*8[IT:@CF45A7C[9]%#R:T+H3S9^UJJ0_NC,6.;KA;%4>>Q7)0"PW.1PII1-6F=LL?N BF M#:I(,]:7SEHE@=3C@N)7!58XDLUVXE*"8]/A29'/U_#V>G6<))7BEF:JWB<=8AQ5S00H'Y:B5%6T'!?N(2; VV$[@K_KBZJ=!HXW \'R0;\,E=916F MN#P_T(G0_&I8;UT:..=$U$/F_ZUGT59X+G_Q0"C?0^/YEX_UWB[EH,<#!P^E M8Z)7TXU\/8L#6&Q,T%48M"T9W?P=I)5/YQX3(3C2=S#_>TEI2'X!UB' O9CI*=L@3_$ MN*IBV]A*$X:G!BR=_H$%@><]&=]YFH_W*6^/'J/?\8NY.M]FF+27[W>9 FX: M/6"#^,_R2DBAC,V_$LIGI/J7YU&02SPXHSRK"9%I+[7.I+A^2U74BZ&);0R! M\ "5WU3?H4:4.&'"*WD\,LLE(>Q1A&V'HUP'8J^933PQS0H"&=Q$T=89A_:< MONXL?\.YR@;35V/E-_HM)NENW,:_2&6X?E!R<]T-0\2A[G_YH__W>]%7GPO^ MNW'$?R\D:E]& MP#=?K0P\+?)U9>MV&E#Q1^K^5/=]XPJ7B3U[>;9$E@9EI#W4BEC@X:%&_G]J M$^9O?B5\_Q$BX%\B9:BH4D18.=@-@BJQ+CP+\.3!1:K4*H@#TA,+]7 MDWY%,M[MI->=<_'[[LPO2-;J3X/6Q)98B CU+PY?-U_#@QNF8''89^"">&W* MV#[;0YU:7&G"M%KRH2[: MJ? 85?OJVOB"EJ#,;/YI*<^^8R""7$.T$@6OX(:@AKU3U;E;^4S_PZ,U\8BJ M%SF(!HNO8T[QWWV^4)3^LC\-02DN9AW0$Q_T=!NM=-P0P"M;-,>7-W<4&HH, M-4^EO#E1O-Y4_D40/@_YEZO'(!O@\5>1_4_2O[(-ZB@E.7]Q\)M59D*)S>S? M+%#\+"89N'G,%IY^_/BO^P'YA*]]7WA.=M&K"^-.MT !'>NLP8WX4,#$TXEB M?52W7+A($94\ET9!62N$8N=0< C/B[E4 8$\9__ M*$87(;(D)#D/8COIER "N2H%2P0M!:PN7GF1K!8W\"W+,WD_K="-$?^*8&_I MIO3IN%U@]YEDG!,9EFB+ZB3WC(?_MK%D#3_OO>NU;^?.U0YSU>[]]7:.(,[P M20[MKF8[,%91:_54TG%G3<]E]>6,@L3M8#WOZ;X&P7=Y:D7TBQ3/6*:9BY1I M^G<2+/T),>IN;D;W+[4-4=D5%< /AH-N3*Z,NE)&N#<3X0T=J6PC\)BE$0*[ MD=(?KE:#9?)6>I@_:>: 5IQ$CQM0[.BEGE0GO<7 \E_B$WK7RE4!\]8MWG.2 M1B:AE.^UV5]%]>GR4>XB'3]%B/9VRRF)KB2U7V+#T;9*.)+,+U0W6M8$,9@P M558./^+MHG0J5<%\[KCS7!%I9^M!2&J^O-/$R+1.G;PO_3"C/:YA6?1]DY:M M(] ]RTGU>?Y060JT@G81**ZE]N)%V7U1O*Q_V&K=1\JHY3 MSQ]2W]-G(M5WQK?M6#6JR#S8#\.5?F5KMR*?$.A!P[&M*GO,_Q'W'E.T!!-Y M8[6#)4@ZPC;'V=C..-2ZEE;IF<@3YB1.DX/ZIQOF?#=,]F**>-*Y]5;'Q$59 MH693ZD_6>-^_'<-??4V!,N2)!Y:8[;9'O4@@ER*V*?D8C VD'4NE=V4N>4C# ML6)MRL%'[CVINO2!8T?FX#8KZW2L^FFH_S!S'%=JVFFKG>,F4WRI(IF\M[GP M9[N,ZM!;S:5W2\Q?*FV(>-B)U!9SN^FYA%P072LUX&@HA#4\,QI8!F*9[_&Z'3K TWDMMLG2\_60 M1;X_U:=XX2HH)8%HRX_ .B4C>7S)?DKK ZJ_G!M)9$NZC#P*/=9N9.J:##\< M=G9Y5BH>^K5!#'NECJ9'RL.88+0;.=H;=:(2"GC3Q^+6)A!'VQDHR^S<1/6B MA_Q,IL-)5C>=,0AB (-ES@7_>1SG[]\=:PC6C1_&"E3@-Y_9)*:;J)$V?#U. M:M_(1HNJCPSAV]5]8 (S-A'+LV&1@1J4]>0)3,YSZ\?;BUZK<9/$&\39;_JJ MISMO,('.B#SK_8H&%C(YJ>J= ]'8YHA:A*Q6F\@K0;I'+US4VCP/+YM96D4!K$]Z%\V)AO@&A;C0 MGC5J^Q^_E]5RJ>8PHXG>8"6EM9Y J@,;D MX.!42.3W40GQY.=NJO_3D1]#O9UAPV6N,A ^ 1VB>>V# 2>!\ES#V]%JXN\R MPUIS^4Y;"15SBH[,?L:*@.H8[7@3I,@G4 \UQ(@.\H23_DV MAI6 09T(,H98CX7C@.:5P"=T<5+$A,;@LL.PRW)^WPB1JFSH:YJ_4(C8=R2, M.<1BS5^'^H)^3"R7G!9)%^8-[^OOJ.%H(KCDIA;)W<(#4%)=ESZ/Y3C%>ZJ7HI/RNRP8)J$H_ M7P*V1=UY+E&6YMPCB_FN#.D<@0(V26%8UX_PAN%?*<931V'6E*/^+F'MQ_$.4V*^3?(-L!OPS4D=3:Y=UG M[]X9Z);S*5?Z9%R/R\K7"N\;3P#+7)JO[DT#%X)^;+6^FSCR;) MW'&;='?W M^G[%7.<78)_;BD>K;)[\I8+S'B7'FOCN>8GZEQ+Z,4&1'+W9[K5A1VNR_TWFGB*= M_:3RT@?)5>!@G.D!T:05M)@+C>R>$&?L'3W7?W:"B]FGA;MS.[F'XJF\F H! MTS[OP>3Z2C0L.&$:<_91+5ZRNTB:RI:/G &>GX%+"6G[Y]3L(_.T)VCWJX0L"Z8#] ITZ'PQG*>_J2(NW6D4\F@S[!$ MPUPSK:@X&64%&/UO.I@@.(,LV1XQ:V[/[9B(6WI/M[K$;JQD?12SVX4ZF(\( MJHUH&=\$!)G1;\*G=_ES^?R!DL&XC@1K$JWQVLZ/+W$G#< M"9Y_:Q95F/+BL=1W@&_.9"HF4TO%VH^SL/.\.BX45R]9:92'F\UWP.[Q#A+J/2ZM2OY(9+P5+>6;BZ#Z M)^'T-+PP%N!OJ9#!3M8,/(Q^:3RVX4"-UWP0MU7D-CXDX3LG@D87$'OI:)1V:5A#K:+]8 M9;P7*1&P[O.IAEP:N1%@>X<-Z3OLC;\7U,A.C;,1_']:N]*@)K(MW,! -F4 MH$'V12!L(YML"02150D@FR#()I-HV$4$! $91 $#"(1-( 8"B""/(1E6 1GV MG:"@$1@50?;5L!->G%'?FZKG5+U7[\?IJNZZY]SO]KW=WSFWJ_H[ $A&ZH'F6MY3WK M-B1U=\ ##I^S_!:V-#;C;ID&1T'\6'>?A#\OSI^3UC4C#UZU2$S^316$_C I M'J0%N[G&X+B1Z2B-[RWASIRV[' Q-<6)"_:*NP%WG+T"QFL%)+>R>W&M-NF< M9=A2=O_ D(]P<&KV=YZE4B$EY 3=[,AAV:Y^EY.0RXE)WC';=E0@YCM3^G@& MSP[[#IB\>."Q/M6K^H$*\^UNA(PEG0R#-P,1N2%BZ\.,R;"7^UO7_[''_\HM MX,^5 (]N\(!S MJWS5UDW36Q:)&/JDZ@$@"5V7",SB_>OWY66Q%BJ&I7*9,&"IO&:0U)SJ2"V. M4B1C.+R+7Y)=J[J!(-4"%$BJ-*#SB8T#?X*.Y5]I?^W1BL-I3F!$8Q $'"(R MBK^.*Y'OSJ(C/PF.1J[(1:YJY"3>3,M9"",*3.6O$(-^W.&:_WT+_(?$F_F, MZ]=6ZK6>8SPKW>ZQ09E3G5K@KGX:C0.@!B91]%#J(N'0#- MC[Z(]%E^BW'V\Q7TYJ'&#A=0=+BN:)Q7H?,L;A,WXI7](^E,F:&*8D=Q8!B/ M_ ;Q73G_A:.3UI2RI=CJG11%B88F]\5%2HW^UOFP8_MLUY?W.,7V+'[<@\)! M]!B=33HK+UTF-R, \VI90XQ[IJYA9/VJCEWN"]SO!-S T_<0"X9SX9_###3,2A;US=LULP55$/N;<3@#@R9-5UW8]+-+RJ M35AK('.)F1XT@XI_+Z&H6IB2ATUDU[]+:*E3F,MIJOKI#=>UAUQMDK[V@H*0 M'7N7A3J?\A[H,#Y0*:.;6='OO*D7S!/=+#M,(;]KJJI-[F =.U(S5]D)26JV MG?"^Y9?^++Q%TWM B]9!/.H>=*WCPCV?7]0%,T//_&P:_8.GKHD(9\4,*,!< MP[0]]<0N^N89N7JIE@=M->)N_BI8#&%,TZ>S7RW>+T6(L@DA5(:R>[K[:&=J\_%FD^M6$J)(3%/"%': XNFTGD84Y)7EE+A6K,12$@US).E M<9!WROH-QA4-#3B:,(7L; IA7B"NG'X;J$.3 I&#GI_>'V1#AH!)3#U=91?E MI8.S-;,.1;+'"=W1OVH=JC7?S^MU]VF!PCC+L#& M-$;4/&6\::??-?WBHM=ON>!Q7Q6*E>*3%I! ].OR&,!+:T>F&R)P5+XK5FSK M)\24!1LC&IBO#< Y]L.ZY5CR+8Q?=<#'&S/+N10:3_$M*K;N=12S%"'5GA=Q M7]QL$Q\R[+Q'-E]AGI1&^0$;M(VG6$970@ZWJ7Y59@1)6,I/IH-LB@51)X]- M V&3PK2VP_/,+G!?X[BICNKT9*;]=[/#G-J;P@X6)-_QZ'I&54S$\W@H.>EO MWQBT7.J 6-3;>E5NAN@K(Y93*-47D;^D"#I1N/06?Z]GT6W<_#A1;HW@,T%A M#MN(D.3L@N^7L(&*AU.WAS:$#'5Z?=S7'9::<)J\CSZ3R?O;$/[+*M)7'BX: M ;?2AJ]XO^YK,)$"R6E#.M;>%Q&B%$3T.FFD:GUQI(=KG0Y/+ORQ4_M0N^@( M&X2%[60(2+^_S!K!?6&(QP[,_R)ZZP"P07[5[_@;D_\Y;G. ]H26Q\@2QR+) M%ARQ8%):*\-( (EQX')R,G="B)2 @_%6S)1X687A-RDG4IJ&$BH!?O5HPE,8'QGAI\']9MS -53/F\ M02-1@E1L@B6L0D 0#Y)5;Y>NW"#^$&,FRXL "-@T*U;J>I_]K,>J3)52KUI? MX1OGB^0]_U:S#MRI2K&VXS0WU5LU%8:$I_P!DO[GR?UJK9PPFA7%Y'0Z/T/"4? MAC<%H823,94$[ T,2/+9@,2P1KV%20M5*2\5+;UJDBMZQGZA"=6:KVNZ!7&I MG0OM?#K[,95^U/84W76I/WEYVHVV;NM)J3.'=A>X/2X,I?57!Z-J5Z\:J R7 M^=+;I01[<:C[R=- Y[F(52:R/T@N)DGI&.(RX V/X0UR>$4]N?G!U# M"8P-G2X9KLF5'C;B/C[7LFE*SC^GL''*8(KU?#UB$@*[K>/VNK(_YRV;J M_]5*M/;7\\.:;"\? PN@XB^]N#Y_[G08YW7UQ,-(/"NQD(CWH%#. M4X!%1 %9\X86'D2A&UNR+P3%.A'8?H)&6@K1.23*W M##/9%HH'K'BU"^4YNO#:*$&1.>,%.:8$R X24Q;>'@GD%L&B696=%N?B$\5 M'D*(';S^)U!+ P04 " #'EH;C!L M>6-Z:# P,# T-"YJ<&>E>&58G,N:[4>P$)S@&J )[NX! @0($-PA"1"D:0C! MG:#!O4D@N'N0QMTEN#<67!MH@@:[V7//G3EGSYX]=^ZM[UF_JI[Z:E6]M=YW MU?W<_0^ 0%E!20% 04$!7O_^@/L%0 YXB(&!B8'^$!,3$POKX2,<8EP<;&P< M"J+'^,0TE'2T-)34U$] 7,Q/&#@8J:E9A%DY>'@%! 3HF$4E1?@DN/@%^/Z8 M! 4+"PL'&X<<%Y>[U^=T/H!&B$]'S MRF \UGB#R>!(S/?D%A47%5=0VLMJZ^H;&SJ[NGMZ]_8'!BG9^<7GUZP]>* JRO]I?\F+\#>O!VAHJ&B8?_!">>#V MQP!"-'1Z7@PB&0W,-XZ/&?@^/B26CK@%,%FHG;B$C!"WCS/Y!M>/^+W:WKH1GWLL?&Q5-[& M;HE7D;S]VO>'%XW5!'BCLL\0.CJ+?M//O?B&P,Z-]!J$NWOFITK^,",Y-6A<];$\R"(RL@10D$&C/:LT]5A= M$M>?<7$@!;\5OP?P_6QOX\6U))2V"^(_OV-QX\("X9QOU=S@NQ0+7GPZ16CI M)&N*^9QT$9]T?UIX^>*2'J#1'\-\(T_\"N5O@/HTA=W=U"97?UT&^DX$T"8U M3(+F1LZX8?%HA< ]Z((MP,MT]5,4RX)]D;1P;396%B9E5 M(3GKO$( =BC8F[ATT*J9Q@V-OZ#4S:/6DF%B:.I7I.4]^+L=/&D\>G1+/("P]2FD?BXD][_D"C&)'=2,G*4K- M4*TO4J2#F+XUU9+^]"E&S#S10S&ULN@5V2 T=FW!/LS:. M^3QWEBP&_Q/E]<.X%Z7T9AS4M8N%6J"W\)L]1/'@K+ MV#+_F);YPS.A_J(YMMGC[5?-RD++46Q&4D:T. M\5!;FDI<];;*YT!T=VFV3+ BY-D0VB9!BE? MFU5@! NJ';.9A>=N:_+G/)W/21Y\G17QWL IKJ/P#K4L5D M\L;U5TAN5.I6EP)8%6F#O5*D6,]G[==J%[ZTZ+T MR7J4#8F+E'(&$7BDHH \XOG3?0:>YF(3:\@#_PRK?FLG& M[C9""XH%DK-E"NH2&<-\[14'\2D BW18WPWO)61M ?^Q.N?QE#-+5 Y+HW^W M"LW0B5-3X&R![2GK:J%R8&IZV^SW4&8O.GE=R.PG@52JH0B5DIVL%/@L(H'C M"PK] -7 ;F0 VU)2,Q3*8S3DQ/D]+E,WW=@A-GH;P,EX8PI>CWE@Z\N.S!ON M)AIV<*"-H8N=U\*Y8.474V01'8S&(N^3FMZN&FG<[FNEJ*ZI::B?)A4I7_NY M^IW/GM?/NWRQV*_F&>U9 ;AL-WGV'G@+:XX&QU3GC6EOD&?0&],&4=.&-&^; MU,S 0B?/0HZW&@KV( 57G%))+@1Q(!PGG,H&^+C5%F[";"S;742V>_&*J5=M M^ C\JH9*_%W:ZI+]T]]2%J1@ZG_>?KH>#NR/ACOS5MP#;V@4N!$?U.R$9:)&[TLL)Z;;J-K 7KW3.87'25R(%;_<1>7# 4%!EEIT(IS')WKX'PMZ:!PPE$S M3*G*YR<8E]/\+LF(!064_YCY/74M[XR_)+/R](%@$Z%/O@G3=(DXPQ#=$I.2 M5HRIS%;Y+.OQ/:#<,.X-FM'3;;-T:6ITB0" */ZJ=6J4FO"34:P=^'+.JHIX MR].N5U&YXP[KS8WQ1Q_,^$LX'ODWB.+ND3F\_#J&V:9CT5:3\ K:P458OAIE M&?_$UT(7Q"KUI>.F9-"^F<+KC7E.+URJH,CF'IBW4+5Q\-;5/R/%OM[F?#(J MRX>%/?"@V-2=NX=PH%B%)G<"[)9"DJNH&?X>]640UECM#SDQ *47OW#_&6V/ MHQ=ZZ0SRY7?:-76N)Y75#^:8XS$P@9/W;$JQDXQQD\-CFWK2&W,58O6\];AE MZKPN[L4OGRG/2NB/^I66ES(?WXI0]+*@3A=C>XD;Z<:5E64%YXKG\O82-YR) M[&N-/T,GUO@/D,157.8H'/?5[>UW?8JB1R(B@QCM^U+6>*'U?@]EA& MR_^HU]<'%9M;+V%14.@"D=%?G?33\>Z!N)S>E7/BF'M :2T3KS><)1.?[#)M M[=;MCLCL %?XN4J]\WZ$T9$ Z8 E?6?ZXCHM;"<=#4DS&W[#ZE!B"FJB9>!0_?2SE\$=%JV\K"@FP[7.B)_I]&9+,7925R1 M]PG9P*C:XF1)0$!73]$] &U[$FSJ&?U5![Y;<#6W>_>D9M8SP<@0[-F3..Z! M,Z[XS2AIJ3XN5K\5E1IIRKTD3 M72:K3X,:D33!V0(1E+D,FYKR&_ZN9VP^CKWL6<<9X3=&EGGU,5UM#K4V:3-& MLA;/I!L?[D=J& 9+E\C+ET03(TVGE\6\V[Z?J2RYJ4T6G-@76&^TBYQ\C?;\ M@,&V5#8E7+LO@6,H-(*EV2+Y:=A]N77FCK6%S#,Z23(-#L0K_%2.BAO<= /$ MD#WVUG=2$]Z"^3WY0@F%5P06 K4KNP"OJ"AZ1'1K2,-V\I3VU'K9+[^7*H1D M&I.>@HLKR+3$?LZ*U],NXN^@A\OS.0$;V1"K1R]HZR7!^9,']T#UP<2<\:(Q M9/2(RV)YFUDBY82;[#+6/0UQ>,-=KB38;$&!X-'(2L+;@)2B4##NQID69, .==Y$:TB*T:W).;-F$EC1F?9,T=:0 MMW@?_$?P,S0V'BK@M&9N-2RY2GZ8F%C;&]*H_Q+ANP=GUW[+YVE%T7Y6JHYE MY!XZ".TUBAB6$KES_PXM[JCR?0,]2G<\M$9M+19+K\ZW'N]Z6N#G8)WP@B&J M();%31(8]80]4*(FS*WZ8J&#DLM&YGC6OFMJM=Z":HST"V>J@DUDIJI738+" MF%J25M5KU'LO^Q46-;1]L%TR\:XUD1@Q.2K4AM "L WHTP2#*HOF8 ['W"EJ M"_,-R%#X:Z6?#?PJ"J3!=A7(M&$R7GAA24$+V] 3>UI70>&B@F#45I5IIG&" M,'R+Q6C",5^H$Q$/T>>6B_7\J3;MG.9KD/1N\JS(#G%&PZ"MXN*S2VGX[7/? M[0158*33T3/:)7GWX*6"R.A4:^DUWQ3>IF:>)X^5W*BM'.9OVJ.KJ.GXJ6+H MN/;FQ80CF)NG#Z$_=<6"RT/M.2@V>.4$Q\.Z*E\F8 G3-[! 3T7 M"[V&M^L1#H=CH8Y9)O6C$^S/@EO'5ZJ4LSW?X+=5JI16U?*Y"I1 M"\*0-QFKZX*:FS#]"@$57.7U'C*9FI*!E[KO7M@[;7,GFJ!"Q3]@*#$?'OY> MZQ37:V&%*56*>JPM\CK<#J5V.Y=>KRG8%NWC<1A8G<[0UG 3=FVZN".T*]C_ MSMIWK"DH?(,F<]V!AD^).L$TXU]E\!^@QH\F.NSJ2<%K33'9RK&"0-P@'*[O MOU@HQNF]@8MVP&4DFV98OTTC?''O@4Y: 7!$FHFS96)I[&'H5L+G+BL,'0IZ MGV<5^MG^$FWMC::5;)=I9;-7DXVQ6#2K J3),!G<,5#@:>!9H3?, ,/ M<8@0]"/K\/%V.$S0DF$:"#/GHV.07C7%I';<-=ET7/Y+W11$7GPL:Y8K*=OP M!%4OK>JJ! SJQ**VHX<\_*5GLUK&-ZLXQEEJ5VI161?ANN!!SL^EGQ"/M:?F M1SF373:5:ERV([[C<11=YF)P]F+AY3'B[!J?16!70H4NN6G[%46@?>][3XOP MO1N>>,7,]GA]XSD>SKL8)P;QBN^>B?W;9>!Q0[7F/%4M+VXM034V-27;$?6> M%&W/Q/"<+D>SEY1/K[44"<5U3K0X1Y_Y-)0M,;!D34[33Y*I/NLCW2O,=)K% M[A/T#>_[ @-#W85[?#![>-U'5,V54EY N'%AF2Q]6W&MSQ[^N@?$3M5#I2@; M)B1P(07[L8I,+"ZP3%WR(VF. M*14R^#R)_IJRH"L5O^.#IE%%FXV[5*S:3NGJ&)*P5BPE:5I2-X^+B"*B= MN+P3 !$I:F38PM9' R'KZL1*I>6U'!?=<9^C:N^!1MZOAW2#M9Y$5J"Y5<@>FQ84@VE):Z8$(QRJ ME]2A\_Y2+V\**"05<-VYN\&J^)U2H/J))U$I&"G8E2GKUJ"/C MAKWZ FYT+-?Q\16+]/LV>FFR>0X'9%N:7#O**4\3;10THF/*"RI-M9=8"KWO MJ,X0%6=%8^/R)+V.A,,20KNM-IJ@$6%Q@/]RDKX%5N\3:]S%CA)?],0\IK,A MAM =;(Q$3]N,3(%]JOH2]@+>#WV&I[>U,N6YUM#VX/?"*.43ZRI-#.=,C(FB MJ,]#%'4T%4VZ@'0_MA)V>T^"SK$D3%$=997\MLW]L3.V+)]R&S&+(=R[(DL; M=MS!A$60G6(AVG2J3AKG6Z,B38/.CZ!/J7*T&SA?]1+=#SG;B')3P!^MT%(8 MGEZB^+S#HO<>NY0\>U?)7P\QS3PII M6\>LF5$-:MQH?9=*O'M>;[ 9K2[!L8 2!;A$9L3)4*"BS1PM'*(9/H>ZM=(W M3VKIQ4H.WQ81?9:O3JC>Q-,65GA"LX@SAED\[?JMQD=&$*,N[),JKIP]XGH&K4 VTT%IZM,T0L)IO2IJ]90TFXJ7?9LCUL]5!J MX]\[?;7"J&9NG''!Y9'W> H3S"OX9,=<^[4+5-V'%1712!IF\,UI9$2:P]]K MB63 6ZIAJKP&/-,*/?'2;DL2V#TR9Q6H[:(R^ B<+04\ Z&80( _N[H_0/*O M1K6)\D\UYC.:J+^0;'0^:_/ZX-4D.46&)$O)CH)Q65?43@FCK/V3RT'WW[4$ MHOP @2 EWXHG=GL'?VX LDKX>$DY>PS2@Y,%9R/Q^KWG[)D"]6 P5 Q!.WMX M,Z9:_2&_B70D#"U0OU8_KGDGH";W*WLA9%#Z@;3AZ/%(#DE!-_:0(V%T5W=L M:G^.?803W1!?C,E0R W[7 4;C&<<8M-V=EF=@:E+7#+@,'Y5L;5\ER91> M[ A\ZO9K*K5Y#Y;U[N_@ F(5):JVG2F0J_RLS,\#;G532%='7V MBA,#R5O=)S)7]9@[^0FKWX\D#*.OVX@7W^3TG=^V)>H=^97\L%HY+KA1/S"8O_)7D4U<]O0*JTZ5;_HUXS0PGPQ1&&=DG1H[Q*[\% MRB"]Y[<'!R?M"PNB^SV L^%1F( #KI&B8^D>P7P/HYW$N^!8S1QI;EY%2S EXT&.5_S M"S@PE"\6#G1!V#-&OA5,"NI>LMX##PWG3=(,/;U8_61TWB]PO3XK_9?<&V)%GY";A^MN?X]FN#'&4Z[T^GPAV7.H/E+ M9I79TJQYM]6%GI3GIGER=E_\")3*)XU593ZAN7C1;U'1?4.OX%>WTH; MYD+SSR%ZRJVU!'U%"U\DLE?]07:^BC=H=X([LKDMX:K+(^=M:BM?!BQ*G)A: M4ZG)>F0X/$-2RXQ FG 3A3+J+M4] 3 M)1 R*1REHH+2^<-_2#!#UN@(W)5'E0V<.VX_>G(N&N=\P6Z?-UZ/RE..&6D\ M>IC:PG!WW06/B06A+<.O*$YN"LP;]"16C>X!69(A78G6(_.=O9GSN8=:JJ9B M-VT_C/<+L\.[D9V_:Y0'_PWP)2X#?1MA:^Z:*S+UT^6Z FUQYE.Z_0I-G^F7 M/9B?'&.2DS!WJ5?)/:U^6TL9'))GA\1N\FIYOEP02RGL^%O@TBI3[0^$GM-2MS/)Q3=0<_O@?.?Q<' M3OEJ 6X3!BE8*N6>=<,MC@%8(FO^XGM_/(?]26I,HOZZ]OI+/E6"%:<>I8*$ M$\OOX^G.Z3:ERR]2%TX9LNTY&3N] M]=;95T)_FU'!(1^A/?+7;6"/+2+X%]E*@!\@=PK,\$;I<1."3^XM$TY(V)#T M-Z5T6O&KT#0$*:&\C<<-3B4': L.MYK]UGJ^M"*-/5-7X!S)/.TQ6-Q;"K+! M[^RXA#9H@S)LST>##8U=VW!*2YG2X2=D_!CNV.1+!@N,6\!%G_(ITCD+1X+I MO$;]D!O7")J=H3Y^=$G3*=8?OM.1%*(=V$&\MRU!SQ%KL+CCAF.XKI3E#H%!UOKMT8Y5YG9X:P4P7\ES_\$6A\DWL\>*!F/ M:KZ-F.!Y1(W'B\QS)K2KQ0QA&-V2VU'A9[][CHMJN%Q=T@K2Y8@^#-BWO@-)UMET,0(JT5?RA.55]..6&.WAZY/13KHG7(;[P2V+9A MC:R[#6:\!R;<"U$KL\-9@/\"J*.P%3SLCG+RS62$ZR@4C4 R6-APFG'"6P:W>^;D<^['K-BH>E\9 M\@'$B-.^OC0.DQ#9,N/Q>H@,V)T+,1W#P!KB>,DCG>:JG;LD;0/Y;:X5+_?> M*-L>TD0ZA%?:IJ@U.93J+RW*X2[*8O*\Z'=C!:$&CLB(_*(\5<>:7]&_?#=( MH^SQM)FU58L=^EI_VX8YG3^FL]"]KO-73-@J6'XZJ[:*25\!XE;O%L^""6?WJ]_BO\'"7N\%F3IJX(K9F=M*/%E73@XCZT8VQ,"A1GRV9' M?@Q0NB!Q:MK7WS&N9[X69J8,2!_3Z>WI(CHOW-B&\VK%GQQS!_ M=QWIA1N1J:&94=&+"@XN2JPD?"8WO)RYZ0R\2RO5XY9$*-Q3^>4$A56Z!T[\ M]^W+M!C0&";K>N_=,-(O]*QIB#VUC \;/.2!0XH03@:%-WTHQKKZIB>=ICV^ M@<1(/N[MZZ*TK,GI8O MM0B-JIK@]NQ]?MJ0@%"NJ$1](*5YA2I>'6 $K[NC5?3!JUQ_>,;^N=R!3$M= MR/KMR71,'"U/@\@ZS7Y3N7C'RHF ^\)=9]P]L"NAC3(W+D\,:/PU4+9-A4,I M9[\^U?MNB^-QE7!\*OC%AOQX._J&LR@L"7'F92.PNZ%U!X9JQ70*U>DT/I8%DPD%]Q M(LJH&%^=X30.3FZ[!\(P(UY/]0V9%R-@3:=*H;\*I$U?W0/M8*OGTV]F!=AI M-/'/]-Z#VJWR%1S/:*0?)6A/EIWY\*UU[CKA[.A43GD2'N+]=K!I5F3O/ 78 M6(:6YW=NI7_8&V4WF-!UGY^[CN9?AMPM+VA7.;#IICQ+=^\;8MLN?#,Z*S@. M-S4R6^#L2>MVZIS'!ME1J(E(A*OJLXVE"1]QBI]:G&K(,Q+\S1W\=_QI:W7F M_M.E!PZL_R90V6F>P9 E(4/S$[UV)#\0FT=U!"F MFDM.#M@-0J-T$=Z6( MD/(5D1*2>-56.&-=[&)!GW';BSIV7B ,9W.D='3*Z+;O

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

      3CQLIYNNQ M]4.3+6[S[2U^'9*XF'H5OJPX5N%DI&(MOU^K)H<%2PS3Z7].)8\GMGJ<13 < M'!KCZO),*=9,;M+&OR0"B[819#@5OP(ESCQ5=)*,M"@,5Y_\VJ&J18)Y>#@C M#I8,YAZ1XET>7VYA-Q!MAGU*7%$-8W/$;TA;0W/+.J:+DY 9X#]7,O_Q4@-O M1?3J\*!]HRCK5F;YU2C,KGBK;KG.->,$]KA"9@LZ\/02%.D^W9&@>T5O5975 M43J0Y<7FOI6D-*Z1:S&^1Y[K'(L39(]<= NA(YV?#(<9>(A1X.LR^Y.SAJ[( ME C8NS(<@7C)-&2P_@(8K[_\!U!+ P04 " #'EH;C!L>6-Z:# P,# U,BYJ<&>=F'585%OWQP_=( T##!U*=W<) MB AX 4D!D1B'%(9.26D%%*1;2AJ&5+J;D>[.D2%$A!_WOO?>-Y[[_-[8Y_G\ M<\Y^]EK???9:>^U]\_5F&;BCJ::A!J"AH0%/;Q_@9@Y0!G"QL7&PL7!Q<'#P M\'#Q"2F(" D("&G)R$DH&$",8 80/3T3&Q\G$PL/*ST]E_A='@%!$1$11DY) M60DA&3YA$:%?!T'#P\,C)""D(2*B$6*F9Q;ZK]M-.T"*"[2C03'06 !T4C0, M4K2;3H 1 -"PT'YKP.\-#1T#$PL;!Q*S">L>45JYC^%1L M(BOLR%^E_:;L/Q,6_#\I^U/8WW7- H08:+<_#X,4D ?.+[ER O%_9<6?-Z#W MS0W@5'<#7 H8NIOR=U5\)PLX.%NZ =3P@4-U1:W[4OC& %=.% "!=T#RT.?^2=PE-2EV3 ^2'+;:2_&9)B95)=N4NAJWU"+K'8B!IZ M]FCW#[?^'X1$E\CL6^FC:-UIV523H@IZ![[))6VY73D&R[Z8[)8TR$2]1,YIGNZ?%+IF0:>]PFO^628L8]''ZT,7B J6 MH#"++47<*#K[\=[/*8QM;KDCE>J6::BH1E*JCU%>)+:_7D7',W_*M%H4;;># M/RN2-R,\=P$OV_.(M*"QI:9&' ^7E2L;;7C)X*PD53YZHV&RU.#R1.<'1:J) MV9 +.2D8R60:_+6]QWJQ/"[\\J78]/',XBY5S(MQ+S)E22*0Y(":_,R(XFS9 MSB+^6,V,I:?E/K(/8ZP]KH@@;=?1TJJXUQ!_2EPNFSP(H"L9LW^K+%F M[XB> M'M^;3MO[5C]6='JNPJ?!N]V*UA VTMG[H>H9X^4*;'78;AG. (YH6?$%I_;D MA@8(TD"WOSKMQ**7X:N<(U^F[K;,R[%J4D?D0C;OQ<,:^X#'B1IW;UMA-9"+ M,<+ -0W2^R!XTF1!0P9=]/D"+BU:B'4;3:]D&:]P=YWAB3;A68J!#KU+?XX[ MH]1]/ ,Z#90,B+']\EG=6(=(O=[;8$^"YDQA/)]4B5RQ0]1;6:-2OS?!U9QG$S1=T =T0:7J9+ M/S*!](6B>)T35*G,6"R:]X7;*<<7%?A>;(0[)/8J'=(":U$G,\VD99]SMW>> MG\5Y00N'"H>K*@GJ=-9P&L%OT<88&>SE9X^-0/@&@@)GPWX"]\ VECZ<>V@I+I'=(L["3H8=QD3/[YDB]^,>%8@AH66R7&_V MJX ^ZQ:0D;2)APS1A2#H]$+H3J[@+\91R"7$U](M(NJ1)+>R, M@>F-EY?JA#E2Z)"K-RARTM*@RL7;X'T*&<8Q/ M]WZ2=#^R/\>#KN(>?HZ.2>P(=Y1"EP)M^#+F>2XI3CKRL8Y'YZA()^YN.7Q( M&/DQ;Y!0 5:WN^9P=-5Y/"31RK-8/#02ZL[0,NAX,7>F7U(@-0)=VY66P0?_SYJ M;D[[OOQ[LNIP%N?..L-15!=%X4-#@T\_:XK-J[,5.0U_WP?&[^U/5K0 MFM*B/7,2\H2D'2%[OV@W_-YH5)-M^9CI.ECJ>#*!&>HP9%K$KK6&7;(;0"HC M7_ NL/''HWCR-*NSA!F-N=2R1Z6 MM%+/3*VQ%_X(%^U=>J)[XM]ZW M4,EV67G06.K9]").!B0BD8WV.8\ %H:>MAD5U[;P$[A_6][N>+,'*+2E(VM^ M@&X]R!CSZE7(;*"V;'23$[D= O:EG^!B<3VQU4C_0]R7VI(>7\&2/7U?Y1F1 M-Q3)!AIN5$*OTQO7@LR[-*3?CQ8#TNH>R'@!YF MBL>(P!+[J>WU/!+>H_$\YL"[-#0<=7G04#?7H&O:%IWH>5!6#CVE*S$\R7U5 M*H1%2/M) UP[9JQ\YF.TOCAT#?WZ5WVIQ)Y\SF0_D#)94^H890<>8;M6W M/(2O_<2=H]I"Q.T3O9I.^6)2J6QZRX_(I>SL0HBQ8^DXD=P9=PA8_+NMM)OI M4K2O!6SEP$*[LAZ"FW@HR5#83$9IUM#^Q6T84A8\/ONU,GB1J][]VRA?P+U. M1+/ 97>)=;')KIO1@C%K=PR]PW>2Z'7&_.<'?M@&=;$MV"HLHSY.OJ?9!%2KM6+6+38TJA^?&X'8F*VPJ<\IHEI9Y* M-\ OTU=R*3R.T'WZ 7<_UGOO4XI>/SWX0(]:+=N5)RGC+^>$F\Q8P1.1Y>/: M0<%4"J$>&;CM>5AIF8QV'F,S#\Q7#LK'&/C(>+JS8\<:+K>BW:)VN<-:+B!0 MV ;_67Y_9WP/J5+4?*XC8=L"VVF/\2'0CC$>2!7%E87^)VLR.A\O2NYGK![B M^DWJ9 CL':7?:(,EWJH3Y&UZ@1-#& M=54I $,").1:)?.'WVT(C@4W??SGZN81CNMM@E(]T%D.5ALF\N-.\)YU\E,&%WE+$WY MHWVU"^WD:7CYV>L;K*$OR/P"?;L:]81\,,SB3<=GSRVB.#1$BW3JYWL8$JEV7BDX$Z(=EZ(H%-V MCDY*E?1Q"F\%!8]+L$]8-SRC$>I+'SKM4@PXGNB /7I17TWE].%[_)L/WJZ0 MBIRD^):WO!!ZLY0.!O1I#@V5D\H7X?:XK'-1%>47!&JUHT>&7MJ)(LEBL2J&:C0VEO'JXZ^9I01J$V5T;HN'<'WC2<>U%I]W:[$R(9A= MQ/LG'PP#;@#\/O(@N5!&,R M"D%R]%]Y8IBFW ,' 2N^7C;BP%38%?>>TR41Q.*"9NJKKFJ"?S]#W!W$RQB/ M@:X2:PA'B8AB)91;6IBR?:GFAVWJ44\0,?;2G=V]A%[A-WH04%TF28S(R^0S M"CL]]WAJ1N:G:8JH(?=T=8I$->=\NH'BM47QXXQB:_:2.7/SQ;DZT@ROZMJ^ M+T'F*2MI)FG\1/9GB*#D30FE7MHJM]./K5P3I]"'7$P3TQ,#&F0&]@M!\X5, MA!A=4..T$ AMD]'TFM,P*UN17.>$ENZ7U.@YE4E=56%7@K0!B*A!8T/4G1Z@ MM]WVI-S!(@*.*?7^DU#O,[*(^H\VPA]LY3).VXKLQ4!5+!:S/ M.M=DL@Y?-G?/[$KWQ_I5,2C<6%V:8 427<*J/@Y/WG2#&%HS;7W7FIWB%V\GMJV8JSH(' MH#:4DV(K$YND Z/DUR.BAM>44ZM&+1^\W\J9PA]X^^;G2/8+,H?+2NXH#%<8 M(U+40QXF90G]K#OD?DK9NN.&."YZN41ALGAAOF:6S!&\2"(!?_,F8B;HZFR* M0;W][-R0JE[L7%A=!A8_/["I.5S**DNI\65K]J/]XIUIZ,NF&&(_S7YM\-H( M,=7"J_;[1L=SE?$F$[4 Q-.DQQ,,;%K@8+NCH3RL40?W MXN%:QSDU-;6AP;<^-E*3>W,=&P6]G]$B1GC<^LK+_SQ62(R 9UL&9^GFRO*' MYL4?''\UHV=']+H*1SMB)*1F?D[ER[:4*RG:I4J>)G,@*RE+*K%AP<]VU='N M*>ZR]+T_66HSB6KA.'^ 8/OE[6 ]R!M,/!&3YRZ7&S5QX6T4HS50/YU; M_\; >E-R;I@"!8SB0']+0/]TWCHL";VHO0%8='ZVSMT VY\5&'JW[]KC*&HI M8%'H_@E]6XQBV))6FT4+U(^6<\QH&4&.5._P?H+DB_DX?((]R9>XZ"N.I@!8 MQQ+!KD4"YSW5'Q&6J3J/8*[0<8OC[M&>(DR)!R MAI2'7+@?1B3LNJ@QA[*8'JCB"V_?/27*:_5[2VXK]\QAYC)ZN# Z19N^'^W@L$!I[__V MJ/L')<7*9^E\A^C"FTI[WT-,@U5_EAP'^SS'BJCT'&E4"/C2E+KNRTYU1+*; M:KE'-(@,6'HB/UT;7&:J!50@&!I J5&3=C9W5KZM\?>OT+B0-J@L15YUF3C$T!AX*';0R]&F.45 M]%;P[1M$0V[[9=+^>>IBBIL?.)2?KD MM$R,("S2,RE2B7HAB-[/(8"X*VMN)V>NHWMDWT4,?[;A*=U\"&)/ 73:Z[EF M@'BY5$D$OJNB/IAXN"IM(3^@:B[!!BMOK3QM(YJ!+-Z6^)MBT4)A]>^ZGYB$ MZ<=FC>+0R$"+ASZ6#97-D]L[FQD;2WG10.(D79_AR-^E?^KGP/C:G^T3R/4B M@)K1$?+:2_W09*#[V/\&>( T^M5WHN98ROTQ<1OZ3= M .#O;64>IYV>AC_)5W%>OXA[8DY746Y(^Y.[/M]PM8$I)XI;,/0?@O(_!>RU MJJVG7&)A3U4_OJ#N(3@Q.=RJL/;[K!\Y2 MXAE;4$@(?42\D \8,'C17T[/MU*/%4R'5; GIHU^KE]?_D1#J*ZD<&3RMY#\ MKRN@7S&W6>/5TJ]&;F:RU]8+WLLCJI9S/&KFGH $7X04*T.+[&PXE&5;OL(4 MEH2*,1*Y?>5[(*;O7VB0BF72&,'WHK'AQ*&^*0Q(H<84)@0V1:L#R'F+.B[-?H6EX!,4\T:/HV M6V(;EJBO),>O3'B$FV/L7<"*B12,$K(PXJU%^-W)N Y]*^-]IVW00EN$B):9 M'J9=;H->?R)IHQ?K![][9OI&$R@3CN9)Q]SZH(?BC;M^.,7EBG)DVX_F>BBH M9VNPL F47QJZG'9SKL; ZJAW1FCN M'OQYB^U9B] WZ0AEJ%7A8::2-*A1ME-L5.:D/Z$SQ$U:##U.W_Q)EB\X8WA8 MI0WAF)V0U_\:3S.;AL%5:FI!>84K12=#.N#.;IPP,V[UR+N^&P""D4],T5B3 MLDQM"\V[2%%#@%4FW''YS/E;B^:#]N(T)^=EU;?,15=&0HS3\^V_?;)R6V)R,6.^T,K6QF[ 5<8#>WX;X6KORZE32.I^*BKQR7SIF0WB!8+< M'Q5-^.;(+/[6C;%,,HB9_-9JI'Y>XOGM($>G0]Q:":QMDU!H>O?&$QO\^Z>T M)1X( 7,3=1?H/2W"$-?[X?^7TNV253]VN)!BX M)WSY\[6S+ZP?3O Q@"%V*HYC6_:L$Z+DKRCT7S=AN9E'<96&_>OR^BN\.*HI MPE>)NK?SI*H=/*!6/_!8OF)L/D41($2M5V^ *[: &=Z- -L :Z]C:X\CZ<%% MP8-ZB0J]V?P02KIPY5@(=2=\9HS'P*6@S[N1_4O5Q^Z/0EI4RS[>J<#6#;"Z MO581)O]-E.8B=V\E[BK&+#G=!YQ?,+ND4IXPKU+U$;X2:/F!=,_ #N-53Q>C M!6' NH,@4AW1P?@=U 3GPA@HNU)$@KZ[5RE20QA615A.VXWS0\4W#8()ZP*L\A'-CKWX4H:- SR''=7EA?0.P MZL9%R;72W "]4PMCMVD]P LI_7"BW,GF!GAEU^-$KKGB.Q^?RPF^>BPE5XCD M-QDK/=6R7*D-/F1/HE+D>HK;.]+B >9$$A6&O=2H)6C(?_^8H5(E]/VP<)SE M(41SV*:ALCZ=W*H/U&"AH.:B0&_^EV9OO;GK_=MK ^VS-B2C#@+5 GI\O-,P M^2J,2I=OZFNC=!O^*6C#%IF>9\X!LC;J'V/OGZD]HM.#F7T61!1Z \-_-4M_ M,76Q]K?1O)E4UP-*MHY>)LD'O.+";Z>2L3,YQ5#,?F5=RZ<82J_)C@FG)Q/, MX+9@I/#S%;S=I4L"OBPRUR)Y0X<6\DN3D:HOCZ%)'M64GQ=B9T:\Y[.(R?_H M6/2'R)'6$/^N%PQ>Z@<[CDQ[>08]^%K(WC<-H6_0&K7\J;HN\TOD9 M-+!#39T\IKXU_[ !C^RPQ[]LGSL[[)<,FHT'!^Z$0M)@.XSP_U=BYA4\Z(-_X [K0:II+V:/+8QOE7O13FHWSJQ^8J) M3&%#789\.E!*\]_M6>NU_'@+^;6#WJJK]^L3A!;@N8(@CH 6@JJ+HA=9-K 'O!23#R MX@:P<:%HKO7RLW1VI^X+,3/N<<&EF"R7Z=G6\][?_9EUR MX ; Z^)[7ZX(@3ES3K':<*P^3V!E8X2W?9'_)Q*DRRDKAR( M9?2[SZOE,I1>XI&S!TY,(-,4Y"X_J?+F]Z(TI9 )^^5+!.3O<6[M"5-+4=76 ML'G/_L,,E:)50UHC0(.S%#7S^^:[+F.RLN!F-EEJ/OZMTWZZ9]!'.L^UJI<$ MJRY#85\64A8M$*-\L @LU!?X%4_^?A_S5HYN*@_Y"M1R>IJK"MF,2,75U+XG MKQ*/8O:#(TS^?>[Y5UP#R"K*:X[0+1:>/#PV956A4I%@%>*2S_X(RHQS*G,4 MU>!Y:0DKL">.6[3/6U80LX9X''!"C7(CEBQ%*\Q\N:N[1HWF%_-Q+X MS'1.&5-\)3=^*OVC) S>%DPW7O!M&J^NR]FP8"7Z; OS>:"PJ'Q$BHM8L=R; M/-Z-L!1T+1?AD8UJ*K/V>VL?B&L6./53SWO@^:=3!X,&'JDV+?US/)EPLVTM M,L$1S2%D>+"HF?(ODRF:$V=S2R8]Q!<5OD5]NM$#8"&7.?O-BCCLI:&*W>04 M7?DSM=R"N5D-&.8*FSYH>?F.-RJ+T +=<_SPI)O@[*>!]&NH^[/DZ9EG./NA M=/AY'CS-JW4K%S%%&FPPHAPUD:4#M0FPIKV5+V=&\"*;,'+8I93;^2=\&;R0FPF3+;-&%@+ MCZKM$XEQ\-.F4<>N2QX3K>WNUFU1&\Y\B9'IFYI,0@LQYKEF;TT=7+(7,\[6 ML/$Z1C+/"KR.=?EPMFL=\(7_M2Q51\;UXUV88T_,<^(53 MWL*"61_[9@Y32R.UN$&.Y<:##DQTP8DX8Z"PZ$JIJ3[E<5/56-=P7%X_2W.C M<.@;&%8=AV3WRKP!+%K&J7C>;I'5#'^$"NX.CW1Z-?=,_2G=NJE;H!\D>U(. M;"\5>CIYX.9'U+)6LC#3(?;5UJ:;@-#VTS")R(+%RO2;DGD+:3.+V8X 4(^[ M$Y3+:&-6("\:K K8]B'1M?GZKQ^+)D5BE9V,F[2K9K_?9UH,F)+/P04MQHKS2CQ#, MU6,Y#2'J]S<:D@[%;&B>+5N7N<'CHOE?'D4*[@J9#\))ZU]I..KTM[YXT>_? MB-XTUX9C7Q]7+I)H&E+:66EZX/(M4$ ,^7FKU2$V]WA-98JW?+G!IZK^T6>" MI'CT'$:X.CVC,=!YH5^\>QG:7?^SPHOG $Z;:RBC5L5QC+.LZOW+,WMSALJQ MBJ,*7L+L(TS+L7>4NJ #LUQZ%V,4\"^7 7\%VLW,_P%02P,$% @ W(IA M4A_YH'A;%0 JQ< !8 !G97AY:&XP;'EC>F@P,# P-3,N:G!GG9=W5%1; MEL9O59$%).=00 E%E@P2!NN\[M[K[N_@YW$?@7(-%3450 0" 3< M__D V!E "2# P\/'PR7 Q\@O(Z%3,#*PLS Q,3%"; M!67GXV!B@DMP\]T4$A459>62DI44EA$0$17^]1(0(2$A\35B.A(2.F$V)C;A M_W-@FP%R B /1 (!L0-@I=X#?'9/*N&PQ'<$'(IEGZGU MAW9@(C:/GQ$2T=#2T3/WCZ^??T!@^/,7$9%1T3&(I-?)*_Y"+_"<7& <'@H/_BPL$]ONU@1P'ETT(C^*V'OX#3TIVX3 "*L7$ M=V6?"3E$]'>H;1X/$=' 1+_=V/V%]CO9OP?V[/]%]E]@_\TU#1!#0#^+!R$' MY('CL[X)6((T:,7R[?T!*E:17E(/C]P=W_!-,^^).XE$:C$]@1'T5*"PW(W M6'_%X3UI^U%!#:![!6?>ZYD2B]"/^>(3+_.KA:'ADQFQ"EK_:<[[[1II+*K# M* 6B=P8 O@)ORDDP%F#O#9V8Q0)G-[_@&RH+FSZ,$$>8TDB.VKT9 %A6LM%- M%74V51,>VCW"=_3QH"%4()N8 8:5-!_!K5VI\9 GDY2/MV"2^X+B M=S*[2BH):)I"?ID+,+F^G(89U,CQ67P>;AU, <=!=O8*L24YWF].X4H KFUK MN;:[X]#O/4B0G?.%TU\4ROUH/?)+FATX'W?J>P2[%Q&?,S!^;W)?'Q.,YY ? M8W\KOKUB^LXS#BC!OBN2@'"N,L%@Z0/7APL^JY/8K6G^X@/Q>>\)1N"YD+0? M\3Y*O1DRG%POXGZCX]2MQ#;:=%[2-(R@CP#&Y, J]#6->!0+3(H/S714)1Q5 M=%!=BRIKJ(HCF:)[$/YE&!P7PNW$(J'IF#%V5]U36"L]'KKD.+,/2DQ;*M7X M,H+R;0S:Y2^<"49H_?:8\$'<:D*R$>LU4_-Z*X,D/A[#][$>O+R"<_8_,G>H MLVN?>#).Q*4?._!7[Y#.ZN+Y[]J_?FA\76*@JZP4,?-^UH. [KM#@ZKGXN4M M>.N=BKN:!5GDB?4TTQH(*>#P_4@]/W.];ZF?%W][?V-_@AI(,>T%RY3L::X< M126/P:R%Z]W+--N05?[JI82 PT$F70@6^,8[ O-BHL3S9,_O(XK ;:&07,59 M+#(]>:G5.+?,M]9"F:BE26*GQ/-B#6(3 \\"UUA'+NSQH2^#![% #HF/8<^%'!9( MM&O:W Z]I',$=R9@[!IV5$IQ8(0, MU9]DY2%6I<4M;J*\:XIUM&&C.$P9TL:))])&33MKM8@9M8S]P>DB!:C 0FNQ M.ZF#UF1/H)9@6#57FZKD M//V^\NV>N,.O$V\[E_A#KRC"O%:M1*]"2*H&RK8'D2/YCX;]YU<-=O&*<2^J M*$P6V0 5^KE]RHP0E%=^086Y'_N]8VO>T2-F)0O$0HN2T?,6.\?D+Y1[",_F M[BL4;?CA9GRH=DI0;K2M:L?DX*-@K0"WPJ"/SBPX%3M;9V)]'C,! 363:JZ- M\Z>Y._9E0=_$FQ 3*K4-FFAC>P,H-X0E;6@+6>ZV<2QZ3_7C>HA ^9B/W\B[ M9]_LM*8<+$AYLTH9OCP)$D-'<=4UZ.X,T'4SD8&7')L[9*4GE+R67.5U1[>^ M1QJ,BI[;2_ZFY?90%X"1J6U[\' I?S2A&D,Y9.L98@2+W;]1FEDHRSB@^N\4^!J1]@?TT0&+-<(V$91,5?O9EJLDG^@5PUX> M(6&!GGJ?E^RKT:1\=]SA\>^N.2![ XY;_Y%W*_\JDC3I-JGG[UL.1C^N;:OAKTXB-,[&\K++?VML>'%&F MUV!2&_0^NY,4$>*0%WE"6[+C !X- )X=\Y\J2MKD P8W)YW;EE)^6-3YZ2-])HI,5*<7/%@A"$D_3%6ZX1-:RG M)C8R>(TJO/ MGZ'AZPF'8T-&!1K"^I;@3K'%PJ"W[N#9&5-UKG0FGJ@>CTX<(_G6ML:D%F2W M2%??5@M)GS^N?V>^V(R5F6JPRXW*W#:WFQI2]TX3G$D$-5!#F)!^IQ6"BE>E M;(^"1;X8[#LJQ:ZNR*@VIPIDR;C;)SD>ZZJ2O];D*WS.XU7MT!AJ]F77<&X\ M?5'P$_\08K[M0]3-\X* SX,6D)BCGKT?]/Y@2_/VQ-G6CW3&^FQ$KP=:8A&A M9$*60H4,2<=5GW))^&+F)1J'&EM=!&(9S>:TH X(F)"=4!IY,VS7K)%LM[\H M4*BR,1KA[T=0CX+I+$!@%V,.B[21G$T[VV]QX]^CO::ZWH$/B6AQ,KL,&?E! ME:4ODD2K$#,;-!V:;<"K=:BLZBA1@K,;$6]0K),I8Z#J2XP8-Z?IP7GOC;@E M[P(ZH6TYBSU>\.*9ZDDT359J4NS-NK*R:NT7XDOCY5Q'BJY(#S@LWI$1KLT=6C"4'63>[ M ^P<4WVS;-KJTNFH^-<>!Y-XO_)OTD(-Y:2LK*\@)&\G#G.VIGDE\&9E#$]O MND_S+[YUUQ&"/-S/_=GM52X.T<3$=<1!(1:!-N4^T,4P]23FU,#)M-?_8VDV_$$!I:57?+52^6KI_9I22['P4Q M>C_CV^9IZ/U)]93#JU/NF)*Q EC0&7D0$ M;9!0'+AG6X8:6)B+5B?2:>3M]SG/C.(M[N!??&/38FM:LE:[CU )06V(ZCL. MY,J%5(F((L=-U"^+J;.]]ZX&VE8GI(I(?(_U6:#FO9HNT7P'#8U.JB!SS\L5 M@[TVKKM^8E-Z=RN+$BCV#<>_5R"4?#EB]*0+;S02\S*W?%B56284'M^\M(V92!*63 M-I\^/\"8SU,EA22SE_93:"]R0X2,+7:,_22+I^% =LSO@L3ONI;W%TV5SWP. M$&[& FO[)HRO\%3[I$ Z[H&3KNS,YJWCOGYLF$1#IDYP@ *9I&6D).O6N;%T MJ0[U507W6[VR$5@%)WSI24&+\[?@BEA\+6'O]/$FK M K,AE9X"[M]EY\S X$S[90YU^%WPNE"1]KO;:SK00WSJ0F71Z4EP5N/3.1,+ M\X]$PVU=A)C$F(P8A8#,B,K8EV#_@OGA(Y.52$,E!HVG3\L%H5X;(E9O+)!M MYO0"3WAOS*$O@DW4D+J)$SRA@\O:PT\T/SA/!(9.?46)(WU;ODMY50LJ"L4Y MB&)R^]XYAVSWG#IE M$*QZ='BH4X^L@S'>LN%2:8<[;XN]*!KIUT6=?^;$[^U>?[F\@MFI%& M%>;=QS<4XP\XJ/=7WI2X-#+O&HCKJ4?=;SB7?ZT 51G-:F$MF^U+H@Q[VBDY6/7-D%#TJ.:%2UZ:CE5V#(]6RR_?]!$D)X]VQ]B): 5N$!)J"ZN'HQZZ.P*_'A9%J"?*D58EN'L^FLN+? MK]+K@^33 >L(PPRZ%:77B4K<1S(3(CM8X(_3*#:>9?Y545K# MH:(?R"OS.W3G+%B@Q/GP\3QY.ENFW@C5U3J,UJCUZK<>"4 VK*LDKT!C4/&5 MGC(UQR]+\I=:#F$-[2I?.#R6OXH3&S/^\]S-(BWX1W5(3+:D-[$SN1\^JS^D MP&(9$!#Z;:JH9"L'G>(B-:.9;O^J9&VJ@I*)-%QL/:6?=T9EY-3*R3JSQ\98 MKNVHE/&D]]O,VW07G<;**L&CIU!['"].CYR9A,.%)U(DUY\]>L2)*U"$-I]5 MF7OHH7W[HOW18@,"J<\V4S8VI$P=_>"?W,O^IBF86HX3S.>.E:90,Q6P\2>X MT6=T8 +H'D&)^;_1V;]$9P7?V?"/U!$ZW>^44:AGL<@U]E]38PYI* 0/G(H& M%*-0POSQ7>:6>K8V_3B]S8G1JZ4X9V3.H:QKJ=N?^)K*TI&]TG._G*E5SE;QPFSD):XO6=:[ZZ5 L%%,LJM18&D]+YFNL*?P[9K1& M2I2?#ZD'T[FG*"CFS;_' FS;RH#@D7OU9J?4!>:)-=Y]K08+'%)C0_XI&BPK4NI"?\&C[DJ C"V8 +GME:U=C5 MZ.RW%B.V\1'T+*W0EWG. PU%\Y,+,K[%%+D-GVH\-C-%!-'NZ!*7G'LUMSN$ M1128I'92:H?HXK>C/QU:;S7+%]^V^ZIEK%-M'JN93L.=',L7KLWX^IQIURI, M&;S\\F'*5?]NYB4Q0^@5*/1P[8_)YLJ*Z<6"<]9>&(6^'\26 M&Q+SS)758S9[/][HI-:)[Q$R2QLUV#K2(OU21F1;H[--Q3][+F_M(UF#W/,> M@[:EB@/_U__PC^*Y5L?KX@( P 1P.Q9A'E]9 M2MR5N/E"<%6)ACVN:%PL1=/E=8RMH.-W[G,U8MIE^JYE MY(^'Q7=D-&4[RAR;/G,(5&._$-0>#N*@'UD,D38O%>-^VJY#QS"HQ-_%]J7 %]H_# MKGQL5MN'BX;:4I\,W0S(J=XG2B*\,WM+G%%JRQ%2D%UCSDJ;?HROBT9(&U3O M(;;@A%?%%F"1M+V CEM$Y3*FM-V,Z\=./C=5JM"N=?E& P12S6OJ.'&Z^$K* MC\]"8Y.+'8(5Y]7L36],L>"9\'7<; APK\M8$#.IF+ +OS,JB&+2>+2=&W4J MA.&CWI'L7MW-(I&>8V_52^4NP:28LI^_1TBOXC.K!#'46?CF+S&^#=AJ,U)A M1EM9;MU[:OEPFHZ:1ZV[2RPG9Q/)@(PZ-%=,C)6^_PS/NAX+S$NMJ00&PR%9 MOSS=!T%^:%-%RO"&$(RB9(H, ;FNS1,(!^=EYDT[>=#Q+0IU:/LB[:]LQVK_ M>FK_KD)K4Z4/9I<9'G>#ADXDETUN7BK\K'A;[4[\QXI$_JDW0T33G=*9 H") MT+4$U=N#DLUG1L%-S]TN3O)JJM5EUATD./IM9FP5JHUFND^#@96?=M-ML^7, M\$M4 (MN@B \P%K@^U+X9AQ$>3#BD4">DTE?R5YED>$NHOO3RW>_O$KG-UDI M3GO[##73BU:W'[\=;Q'6L52S5/]0/-%O@W,&Y;\!$S@X">^\&/B2S[):XK4@ MJJ= QDK4)EC9G._3\'IX%IG8J[8G!0OO$/^^NH%K4C9$7_EV1DOA':V?OG8+ MC20HTX,>&J2G#.A(1!9QU2,VE+U@;^;V/7L>71E<"BJ6#8M?)EHJMGPBZ<], M]GK9F0K/(N'Y%\-9'COU'U!+ P04 " #'EH;C!L>6-Z:# P,# U-"YJ<&>M6&=8E,N2_H8TY* DR4E DC(B2'*( M XA(SDA&PA D(X*#()*C" HB,"@@&KJZN[L9]QE("7$#<+"[_$-:$;HF)B M8NQ\DK*W(3(B-\4@OXR 2$A(R,G(&2DH&"&<+)R0?UMP+0 -,5 4L0'<0%X M-"!\&A"N V ' ! AZ#6)+FM;@;G<:2'/$K*(N17*6NETAK=Y;EI[!).0TC,P7F&Z MRLO'?TU [):XQ&U)*44E99B*JMI=73U] T,C8Q,;6[N']@Z.3IY>WCZ^?H_] M0YZ'O@@+CXA,?)GT*CGE]9M49/;[#SFY>1_S/Y575%95U]36M;5W='9U]_1^ M'AD=&Y^8_#J%6L L+BU_6UE=6]_9W=L_.#PZ_G'RBQ<(P ?]I_PE+YH+7G@$ M!/@$X%^\0'B^OQ1H" @Y18DNR6N#K=PO$=,J)&25M9)PW]39IK/V&":E MYQ%;N+KSB]IOS/XU8L'_)V9_)_9?O% .3[H(GGX- 4.#KA1P:18HHW;W&R M99&G?N(6R6**N.I)&M[3*R=W&P?(3,+O.61["^P4$*T3#SC@AU1-;!:+""\Q M7%;D@-L%HS^@OQ5("X5E-%&"!JTB)^MVHDS\/DTJI*@T*-DL>D+J8IJ/0I*T'2EAQR!YEA;I4;P%=?L2,\ M@9SE;39:'ICB]"BO0C2@J9;-(W*,TB4T(\>+-UT_(_K@*3/8@UNZT89MFYS- MJ).G8U!X%"5KTN;&6]$3/*E1X8-^\65U9:\PRH_!I&^KT?-[@S:SM470-M2+ M-+JN5L+AQEB'3>Y:#WW(E]YJ%FR[9=[!H%, $WTA-CB'D=Z!E3MU<<#[JYJS MY!7NA"#/8SWRM4UO:6GI\**5MSPC9QVM/(=8-?H"*['R;M89Y:)6R%Y,IK?D M/F.AL(K2V(>&2($0WZ9C<&7W> $\2_0 M]5CF-(Z$6"G\ S'0R/2,LK=K"K7J)T6.F=C<8%DGDV5O,K(""T+4UW#R4=AP M@3(S-:/KDJU/IZX;V;H.S]8N;%8I"D[]&D,Q0*R%0!/8S]&"IMYD7RJ$*5^Z M<557)E[JK9:=O$!G_8J=$+@4!QQ,4D!#*R5-C(NR7@R_D\RNUD])LVSU9W%/ MI,+/<=SQL]#CU"H7KK5YG:J]^S&12PX%X!//4%GX YL.Q=84[/H5L!@*[+K_D)E].1#6,*\85YKM9M*7+W&RF(^N\4*GUE_U9QQ,569/4G)<7 MR'9%/:;8=2=RBW7:[T_:E3V?AA^NP2N(.\3EY?!'9<99O2P<,*/8IP+I%!U] M;#*59M=]UE"Y4[,&S=^DT_MMG>[PC%8TZHS>KTUX?L2WW+9$V0[5[=2Q($?7 MD =HY)?*+-MJ42T)2 99JMFT2/='YQW?-HOL\?[9B[=6-L7?!EFJ'7 MSIB)Q6%A'S/O'CBQ!CWE&3T?ZVG0O$!5#GWZ4\>M:-1 ]U0VYB"T3B+6I9N9 M265/' M,-X( V*N21>O9!W>+EPNIC[6[@=\>?MYRZ'5I^"/H]K*=*_;LI/]+(%^(?>0H7I0QL#[?-^3 M!R_RPJLGRLR$[ 5XS.9'#9HR#<,Z3)2.]J94 DE2J^C "!95@+J9_UT-VT&SHZ.;C7/58>G[&[EH)4:\_( , MV[MG]TRIZ.3]1Z25XJ=A(T0)*SJ&-G0\>4ODD?5W&JW< @X_W07%D*FBDX*; MKX]ML5"9]%=NSZ0&-G; >0RU:E[_$,8KN+/;7]%L7J1OO:V@\7ZJ\[%'OS?+ MXX371!2HBB47EU=BW0?ILLV2WH%C53%Q MV#1N!<:NTCRM-D5>/1^>M^Q6#UQ^*X._PY"SQ (N]32;2_DC1%G(M(C&>?Q( M;;#W[1D4ZO2=4\0JNN?&,FQA:S:(79FNGYW:Z3K/Q'<[): 5K]%9-VTX086G3X>DD1 M]DV7GCJ'65Q7_D6J#1?V1HW++A9"GUER+09!^=V<][PE2BU,=X+K82C%9Q 3 M31]%]RBJR"0 ,CSK[EN 0@UR+,D3F'):.'M#8UPV,*]6LB0"*=T4CE/<7#"R M#NA7R=(1GJ1=[?G; %^T3:,;VJ_NY&3$D6.LPI20^"YL+\+VJ11;6[Z??6L3 M+1O'N/A:G$#]TV41;NO(QL.5V;KR>0196>^0LR<., LU:WS+FOBS-]K$X-YN M1IBA@4$162"L4H"MV,1QH#A*K@.*?5!GU,/QL5A868H4&U#F-DH6EKKXQMG&NE M^>*"RG.1.YMOAQ"35XSA#,;'2B)>D^6CWF]LPN/[*+XXS=.,?L/W5E]*VDR/ M3WU5&!O7SB8\O+*-CNKW=73D2Z)#SM+BW9[W-RC;$0GV7Z^R/T=%+LB(LJ7- M_S0-!'>@A'P^,=PQS^**X$B/.#^_H[L!+YNXW%['FWP2.IOAN/01< E]:GV? M2%"RL_,'Z:ZZQ^0I#XJ:D:DRX^R,KL=OI5/JQGD_:7)=D.DS3D'^JW(R<5G% M [+,L.2KB;)2_0DM=E:D\R''NCB@=#]A5*/B(N^"YW37*C:#[V8;:- A=^Z$ M6RF@TE,O90OP@MG&MH[5]J^?D!GC@+EA7825(W2?_/=?0@L>'#]1G?1"0UP@ M0XT+G&F]9C"I:S*^,CK,2AUN]N1FF8AM]_ M:]T^0\1XR9OEQ*9&@[(M,L]^V&Q_>&\?:0L;F-:\^=N\P(,Z90]%8]H MT_B[C=%(HV\1MA'CBU:O["3!._D67TWD&<^__!Y.W,)5>L/4V01V:M2#S5!$ M76Q]J6QY*FG#2[5T95KM>Z6%6%/3\F&;B,U3[*XC']HA;-R,IAK5G""A-\/[JU,%:875\]MZQVY)NE^X/I!<5EC[L4RXVCSD=TCQKXO#N MQ9F] Y?EFOLU]\Y^M(&(J8NF]5L<*'-30D!+U.T?'#068KC@JMC48048(Y$Y MXR:!N*9N?/=>+OKXB6;C8W.'.:\O70K%,&P/=5S.$%2 [!K\#B\]/48=RK7P M7/=FS)QW(J3%'5:+88Z1DB:H?F;^).^=N?9K 62P'PL.H/Y64;RO<><0*@+W MGJXE4&'#SX<1WLD&?GQ :E/4#O2#2D%6Y*[2@C_ ;-14O'NE% M4(OK+7E(ZU7T(%4Y59%:9?53VM/VJQ+?O%ZS,N51%/7:FITDKN'W3XH5 CB[K1:F]X=^]\E__&8TE" MZ7_$?,PZ9NCB4KT1CW7I*[4JB]Z1NS3A,A!A[\'+]T7MZJN'>]P!D!I& K;Q M#\J +=^+BJ_?@I54M"GGXJ&?E]4$C'PY$A%,*PV&<#>&F("K,H^47JH]X?U! M!SP\FUKW3]T4C-Y!G,:<4^* DBGHOG$FY4 D?R;ET[E6?];J\*5)3"6WEH^] MHP2+[0&FCI0_9_I)D+8R;1 _,A+XA9(G-O"\J5['QP2>TY_%&UPAQ,5XF#9V MJY]A!I?,K[NU!W>N[Q:CV]Y*[MV1 \)Q,!N5_!";X: MP5:&![A]1&M8EZU-JN9_(@%)RK=RSZ6NYV6^@6$?$])JR\O_GJ:_ I@$$X%, MZR T^2S=7"Z7VYM[25U(N7I:)I$3:>-Q=8(XB[Q:,LE+?S57Y']<=*+!VH& M&7! S]S\ULG92QR@G ILK/X^PW]&QPXT;+2#R0-YUV6K:+J_HM:BD38DZX3M MN<']-XM8*4&+$!0^=CIB2]7P0XVXN<)23JRU([\/1TW1^Q^9:\#FV E+$QI/%/J?BXI M\01)7"\'"S[SOM7)I'%"-_>[5Y>BHL:LAY5Y8>ZS[PG_A?L,/I7>:+&]VL2B M&?R)Y&YTL!BC;M=05Y6U,3J8H5:!Z0XLA_%[E_?[ M"V6[FP3[0N#,6Y-RP;>YY>H5\I@]WSX5 UW5&;^E*I:F7Y/^(*2G3" '\@4- MYB&MU[L%)[E%9AM[O7Q3#?^9.]7K,#9T7$TFZ4J'08$G+17M^N!RV%5Y&H:? MSTJ?+%8%?J?JQ &[$L?2Y\VV.‚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

      JN&NO]F)Y5(AV&]-<,IOW MA==0+CF*I/L+J%OX(]Y0EO:$5W<3TU42F<&I/=QB(2.Y,M5>D/9Q1B3]>C$W MM(4/H)Y8V0#8/+K!]&Q4"<..76=U22S8IU>R231 W7%ZF=S:>I?>:?M=Y:Y= MXL6JQ[K&Q:4(4!O3WC1%(%IM@=+&G3,7JZ8TMTPO2C?\'CG)%%J2LY2Y9WGEZYZ[A%F]AN]B?HF[F+.]0-E4;.JSJ4B5W.1- MV[E/H_+YBW?(Q5E\%B9OXD!!"]9U>-956^DP+B9NFPZ5Q?2*N=PQ%%T*,7/$ M@AJ87):J+J/+''ZM,Z#<)=?2)X"EF82^X:G45F,(\\UL'FG(L*+I*"D&**_2 MQGN8EIQV9F4[O2=23C\]*)3'66(Z0GC_>BV:U4]@^:Q: V#9S!S1:6"BCLE= MV(N,D0)[JNFT^',PS4"1+O'Q.ED%.0#]?I@YEE1JDFX8%HO:S%'DC(C)^(BO M(G-DWI-GD.^OSG,WW0,D5TPN.B-/SD@79H2E$9Z,S4F#?\@*]$'*.:+#"8>. M>V:56I);E*V;6/K@F9.CG V182(2WEP>6RK ZYK#N=7(G=>:F 2 *X['M##J MU]:;=)5&\[ENR5'9@&)Q"U4+EF=UP0*#E#9$#(3+WZJ6?!:WJTQ'1;"8*Q1J:;Z;9*K/?21\^]V5*HDGH:F[- M28$C>>U9DEF0W!HUU1FV^1O8_-^CWS%!WQ&/&'D:!B"]EP$FD$3&Y\_?CGAB MMZ#L_R? TYY+V\.FYKYK'_%TOM@A&#VYV[18Q+ K>VZN;*5YFHOR_C6Y M*,"L-MTQ@C=-CM7-E$F"NLE3>\L\=#6" M:?>=Y!??:;[52KN9^>4=KI#\E1Q!JUEI-WY[I^:9K"D)I2$_*#/!QC:>);Y; MVBIH79G<:VNC?1OH=9H:'QH0J])JZ8='\69C(38P%-S*_7%6.WLYG))??9@N MJH*N7FG55F,WC0F4!;?LV= >..UHYHW'8 5;DO7-R./0C<4YDAM.]3&TQ^\. MT[*N>%S8QA\9-FSCM<>MO#9>MCMD&Z\7+FSCCPF;5?V*EZ-T^>E3]=/E 2R\ MVA&?JFY<4!G'MKIQL%67ZK+W1=>F3F0WDW2X9?_M17B!87@&AAIYE<]"<=*] MN77%AE5$"QB8(%CZRPL#$X2^V+"*: %#Z0ABNXWSP4*CA]HX:X/ I2JHE9T0 MWA857V(-T&S9V?YK 0.[2/IBPRJB!0Q,$"S]Y86!"4)?;%A%M("A= 1QW<17QIAR%>!?I/VYN(,ZK_AG'1PR_Q45:CU6DW.C\PB=RJU:TS MHR\<%X85_7%V#F^1S8O^.'-_P50GHWX0J[^#L#@V(E,_>]]M-,QZM_6WW_/S M6'9-.>M[V6%@GMN&YUK[XKD=8AL6$%VKTV"BTTV< M=%7UTA%=,6D<>VBA=V(!CV]X":RK;F6-5#]\>1^VDZN>*"H>N'MSCM-6)#UB ML^LU6&*JT0"JVMK]L-CSW,SS;,]ZGLJX7DG;>N'W;]"PRH8N!XZTU,UJW=+F M;$W+WE?:2%JQEH()5A\LF&!/ "HFV$,1;&??!+M+^HK9;G298(]"TIA@=<;B MY-)<:NU*O:DW"G=!C+>E[27"PU'1$PM&3\T4+BH[FKKBE'*O6%@AM@F"&"M4V+S-?"= U?96&:+VV7I)U"Z*GOIJ.[D,BLT1^"[B.+0 M=6(A6Z5R6*QP#=!CV=G^:P$#.WO;.'NU66=O:N6P<=R:;MX.F1$MLU[C4FKM M)$E7+6>.8^DO+PS,<=MPW%P?\*TX;G$H(Q.O:' &@W;"HJLBEX[&.(/AI3M_ M!&,1QD_4\0,O=1F/8)"FX8N80W>%:X,>R\YO$J/W51PL>-$TK3H?46DG3;IJ.O,<2W]Y86">VX;GYAI[;\USSP4PNIQM MH9_ Z*K,I:,RSK9X601NP,C9,*1W45_K!N&:/^KU R(RCW6IE2^5L2C6\#,)ZX,%DS"3,)/P84AXKH_L&B2\ MRRTRS8[9:>VOA(DI^'3-/E.PCDE !RQV.H+XD*Y'+*7+@--CV?-."_N6NN(T M[V"R\W@TX'&2M18P,,4PQ3!.3#&G"!Y3C!8PE(YB2M*O)+N0O<#K[PC)MNO_ MV;5[KD(O M0PB,P'/^%*/ >E!N!-CVL\R7#0&V_3J@P @4C4#);/_)'6AK'H^XE.5AAC?= M%[_EH%#A02$]EIU#HEK P%W,],6&540+&)@@6/K+"P,3A+[8L(IH 4/I".+D MCI6M>J6M-P@7C@-K&4?&V'ZR>Y[0K\BJ=%J@Q[*7C .TK2XLMX>T>6%@;:XP M4%FX;]+ 71ZV7V/';#7T*1-D]=;02 8XB?A%.1)_RX@.ZV,*9SP[@T%[AJJ''LC,Q: $#.W_; M.'^-!="!@QNUJMFH[N\B3];S$]=S9CF6_O+"P"RW#WM]-9(=J*LTWD15O))A;]<&" MN?4$H&)N/12WMO?(K8O#.%,";=29/H]#CI@^=<;BY#)7CN!.!GEG)Z>K%(^$ MKJ'E->Z68@[1 *5-L[Z? MN+XSV['TEQ<&9KMMV,[:+]OM$O\PF]7]A3]8W4]74*(Y JGI,T+A MV;'H&W%@1&"M,/(QF,234!AA\&1[G&"BA7[HL>S,#EK P,[@-LY@VNGU9]!/ M3[Z>ODOS=Q?<@O&[&7PBT_<]L7R'"GYTNV:G6^7C,-VD2E>-9[YCZ2\O#,QW MB$VG9M4T!(=U1 L82L<0Y6@KHCDL-]1"=0^U*%RPI8^1XGIGAHKKG0\6AYAK MRD]&-).*NU/N1:992%.?BV6XUEE?&\#4J0\63)TG !53YZ&HH=HT#.$->88@LEKU-ZR-WHD6*Y92\WN MZO[=U;F["3*>ZN'NW&F9S>[^(C][,OCLOFIH-)B,]<&"R;@,6#(9%T;&PHQ?I@KN8O&3%>%8SYB/F*1U2TV'YGB/],W/CIK7[Q^-)I@Q[+SER@!0Q<5ZTO-JPB6L# !,'2 M7UX8F"#TQ8951 L82D<0)W<0;]4K;;U!^!:*@0A#T8?YP>;:-%ZME?[TXU8X31-A>K,5:"G+Z#-^S<[O EO8VR+]T_;FXAO(KS%AVR8LGS]]=.: M>5I+!SI7[[>'@1N+EK7+<K.W>6RR["6F<7G]6Y]S70)-$HG"Z;#,NS8^"@<,>J)T*A; MIH%K1!_"4?$)2N$>GQ[+SOL=+6#@D,!:Y_'=3,=./I#7 31=%8KIA*6_O# P MG:Q#)^TJTXEFH.FJ4*6CDY/+[](_YH2U88&_GV!T=^Z./OETO2+1W=J^1UEH M&+H[=P*0F8YV,>CNW#' MJ/=/ #=Z.X4@3;LN$SQY^5A/ K%;R.ILY3.1=+G1KI;B'C5<)N6:5DULUZMK2&EB,D6\YL["=H&BM>6A'<1.]S[LKW4UJ^^)J^\"\CII5=45!U8'+6!@-MN& MS5:%QIYGL^>N8F VTTY$=%5?9K.3R\W7'($+F#C:)-LSQK;;AT$:CCUV8]OC M@\'"E4&/96=NT (&=NVV<>WFC@FG!N\;V+MK_U):NXS'=ZA[#2S3:EIFM[;H M&$XW86.=UP(&9CR6_O+"P(RW#>/-I9KLR'@[7![0K-;-1EN?BRA9XS77^-+Q MWC.YL?27%P8FMVW(;2Z5?Y_D]EQ&A[6_$#ZK]XFK=^G(K9@,CES\@F^?S,8Y M^F+@.FY<5+2/KP4]ALCK:FSXPBF-H,I?.+437"?M5+[>W*N<*X#]+F+;]47_ MR@Y]0"/*V-6/TJQN$R4A"3I?\Q"MUK7,6FU_5W#OR9[S%=P+A:ZP^X299H_! M=C/-'@U43+,'H]FY[@8[TNR2>,U&-&LU.Z957]2WAFE6/Z%CFM4"!ET26EXZ M^E-K5^I-O:&Y"V+;DPW.%EYE652DE!7H&*+6:UQHS8[LD6"YY@7E[.GN_Y1R M[MJ-[-7"5V2'#U5MU&E5S79S?_[LGNP^^[,:V@[F9'VP8$XN Y;,R45QJAZHVG6FUWFY*,0+>9DG;'0+\VH'TQZGC!JE?+ (H-,GFOW7,^- M76P<[ON*VN4.4 Z^4#NXK_6#F9Z/@P]S_49WHF> M=PE$-3MFI]5B"W??=AL]GG)OM;;L0], ;O,E-J MC>/<&);86@<>)<+L>VKC1;9WT9L+"B0-A6$[V(O']I] .$O,4:30OBU;[@P MG?N06A2'L1$,C'@H(H&VD:B+JMP&KF_[CDLY3_"+$]4-@_S^T!3.BM[3W:3]&9\?MZ$]]>+'=3R6W7X!]!W[5_&K>. M*WP'WG+M.^NC?&23)=?A\N;K[P?]]N?IZ=_OCYMO5]XN[ M:_CKC\N;+]^^XYVF&76X394 ]>5F+$(;&5X&:'.U\0:6Q9_J$KY_[?I@+8)) M!/..3$/\<@1P%=U:1TL!"Y/\- +6C*,W&]]EMYO]5G1![*'H]8^S*CA^PO/0 MOP%CF/ZLV)E^SHWNK3V)@W>*G&&A/7L1+-= MJ76V/<_:0B:?=RRT[EK 4,5?+>RIWUIBLVK"):P, $ MP=)?7AB8(/3%AE5$"QB8(%CZRPL#$X2^V)1>198%_(H[+]D]YF?5*VV]6%-6V6>_LK_D:*_R)VUVF.Y9^ICNFN[7HSJK.]17=GNZL MKJ*[75H\M,UF59\.#ZSOFIM=9CN6?F8[9KLUV6ZNT^ .;-=)V*ZS_>:N8[:[ M=68[W01KCT'F_334WJD#P8E%GO\N?(%==3#P;/='KN]&,6:@/HBBFYYO7^!R MVLJCRT$9WS-R)%!5UZXW8@=H,P=HKI>CLJ;@_USD;.E+Q;=K';.%I35\M\@1 MR)L>=XLPS1:/!=/L"4#%-'LHFJWODV;W$5>W++/5:3#-'H6\,Z,@[&H.]-9N.+N>4?-GXJ6"9=YL.BR?[53F_JCGK5Z5-?I0C%1T^[[W>,JM5_2]B9%^J M>!O"W*P/%LS-9<"2N;DP;F[MQLW[.$QH=$UX#%/S44@84S-CP=1<'BR9F@NC MYO:.U+R' XA:RZRW]W?.S]2LQPD$-Z\^# )XB:@Q"(-1G-WIK/4G;GVG6 DT'CN<@X0D>"<%W0@P!WY]B19 M;_1#@ F3"9-Q8L)\8<*<:QVW*6$^$YS?C##W'*5GOF2^/-(5U]4.,U\>!T[, MEP?A2VNN]]S&?+DZ8KX97^XY=,Y\>0B^W"Y SIW>=UC_:[S*542QX9)2ZG?B MR=X+]P0K+PQ5;@2X^5&]-=<(\-I_ !N'S?^D[Y%8O<,WP#&[U9HV!_:L[IJK M.Y,=2W]Y86"RVX;LYIJ^;45V>VE#8S9;^VOVQNI^XNK.9,?27UX8F.RV(;NY MUFO;D=TSD>64T5J6/C7*K-'E2:P^HKBQ:MUBO'9]QYOT80RO?-GRNU2-ZF*BV^"\^.1?^;'<9/!R^ZJ)O5^N)$BQ.&5^J8_*]AQW'H]B:Q MW?.$$0=&*)??&,/ZNS J>)H1#X7Q).PP,@3,IU^FY?DH'#'JB="H6Z:!T4+\ MK]4EX4?),V'!HK%PL%69]\0)(L7SA1[+7GK:U@,&=L2W2N^8Z\XXP]$[U0Y, MST^:G+*AF[ P@['I+*7@ZPH#,]A6##;7!V\3!GLNF3]E,'UNOV$]9@)CRUEF MP=<5!B:PK0ALKEG<1@2VA]!HTVQ:7>8WW42)<^J+7?^;>"A"E5!OO%8')&], MPQ=Q]IAD\W.1M&?#SZ#_EM[R-?!GRFJ4[E]D8O9W0>; Q-VMO7.V G5.\TUU M]F/[I3H V +)[@L@N9>.8V:[WIK#.;VO89VCH3))PLPIV+*CH=)IR!Z/P3@? M[<02H4KFG.D* ^_!MLE'FV\*JK@\6,CE^_&\ZOJT &6UUERMF=18^LL+ Y/: M-J0VWQIR>U);^YRLUMI?J@?K]8GK-;,:2W]Y86!6V^JX;+Z!XPZTML_>5 VS MU>&Z6>U$; _':/NYX_OEKH[6/ZQ,=SJ NL,W8*TF;C3$VC\C&( &]G8[7FM4 MLX&OSU+YV:52L,0+X535_E8D[2!POFI!. BCF).>D$ MP&%.8BR8DTX$*N:D0QVAU.;N]/B[[?H1ADK%DF#IRYVB-,U&6Y]B)&9X&27:B\"S5W-PE8WF)NW*Z;U>Y\;5_!!+"^]2^5$2FL7(YYF7GY-+%D M7F9>SO#RW#4JZ_/R?B_V;IMUC4HAF):9EK6'@6GY=+!D6F9:SM#RW(4O&]#R M7FLT++/1J#,M'X6<:5ZY44*&3HX7C+$(06='(U#^: BS-HV>';D.79;1=[U) M+-/U-4O$*"%BNI[NYXEX(%S9H0^01=]$>(L?_X#F^<+O?Y3&>=L#BMK4X7I?JW0M[1,UV),JM%4ZDS&3 M\6EBR63,9+R$C.=N)-F%C%><2F3)V*IH=,<6DS&3L?8P,!F?#I9,QDS&2\AX M[G:5G@;KK]38R#-5R/7%0A68CS!XBRZ@^;0!S&; ?F<-U,2V]/!3'55 LS[1M-L-RRS MT^",U.,0P&(M##.W/E@P1P"R,S-6#!SEP=+9N[BF'ON*I!#,/?R(Y_5S&TUS&Z[938MWG,?AP#.6YAB M:DZ6VAIU1'2Z"-!-/G3*$8JA\"/W01@N58GI=[[/=Y?IFAU3*-,- MN'0/="2<2>CB?< FI;P' R.V?VEXN,Y7/&ES(,M7/!T-5%6^XFG7H_'%_1;K M9 MF]OO@F]DYW:Z\&#:G5'_SHQ\\5/Q!F5W'CYI:Z&KM6=B/AJHF)@/1$6B7A\VA]^,X8-WT=AWV-'3%_I5(92P-5K.):56 M\AHF#900%UT/GC>G*2YBW/I6HI?L5GK42YV,#<';T+P@))2&"G MD+VZAFA%<[IL;*!>-ZM-_1/ON4?=3G<'%L_2)VT.F+9/!TNF[=/5TRUH>^XV MWVUI^[EP_4:TW6B;]29WECT.J3MBUCXE&)BD3P=+)FDFZ0Q)S]WRNS5)+V_W MO@5)6V;C"&K:F:27W03\.R5CP&_[[L-F$\_-\[?<8'N!UW^7F4UK'.?(:8F> M._ H$3ZOZ(O>7% QP5 8MH-E!+;_Y.*MM4$,[P?9,FS?<&$Z]Z'M&2!LLK// M4$1XVZ]/9I.Z( U*.R?Y_8 )O36]A[MI^C,^/T0PI$5R]VT<=LU^$?0=^V?QJWC"M^! MMX"]KA@'4H7"9TNT=7GS]?;F\_7'B[NKCS]N[^#_OEQ]O;O]\?WJX]75EXL/ MGZ]^P$?^>84'=1E]N$VU !7FN^@+,4(+9<"G'D08N_CO;Z$8B#"DCP?.3[H* MFOXUA#F+,*+3\O8[X^H_$S=^,EY_% /7<>,WI[K@[U^[/AB78!+!2D2F(7XY M HB.[I.AQ<$[M-5/(^#;.)I;B@.;>\4N1#:*F^EV&4=X'K(OV,[T9\7K]'-N M=&_M21R\4\P."^W9XTB\3?[QSDB\U*KJ[SIW_OY"_D>]5K'VD1N^KDP^[X), ML>F,BTZ.>'D\JI6NAG \8S761VNOT,!(8"$ &]AO:+#C;%:JK?6JP4L#VY03 M]T!GQS+I#/N7:-8S?D[AN^J7V"WKL?+ZT18%P3;/GF5F*PR]6H:YZ"'EYBUV M-XX2MLM@- I\)B =M(7W3=I"DQJRV@L:,I7Q7VD_8[1*"=,%+!<>1ME>F78, MMML_O_8+-]0ZU0GI@0P;].."ID"#WJIT:BNNQ3RUY;]PG,EH0I?"E,A24]N$ M$LTWEZ["_*0=/OKP4VD,GWZ\T^2-Q+/\Q &0DMDC5@BV6\<($W4Z+I&'N2 # MK$2SE[ENA1,4.];;MX<;:#^-I#=P>,QA<_GS)?.TEW:8U<=&',D M@DT8FS#-39C,$F<3ED'M>J<;O-F"';$%*XV,'X5E>BX?KW26274@*]PT\3Z2 M39B>2\XF3'/4Z ?.DVAQ]LS_8=8=BQ\5$X M8M03H5&W3*-6M=K:WJ'G4JOA*'M]0<.:O;[@3HS&06B'3[)P1>8:W$SB*+9]1&;%'0;J$6FK MZ$O/CJ*; =7_7/QRH^0#TTZ9F?:1:4]%^O@7,M5X&4)[]C*$ZZ^?5EV"\-ZJ MF?5.T[2:C;U=?W!(V\.FI7 4F'>9=QDFYMU#\.[B6X,:M6=H]](.0[RX1*:Y M7,1QZ/8FU*7_+OA&N^C">1@O)5KK+J)FU:3=%I.Q5D*KJ;W9,@6?@3D\,-LT M3F9WZHG]EASX@'#VW02-Y.U\SL:K5->NU.N_C-!/(K0OQF&-/RG@SQQX%3,RQ M!^'8]DX"[)CM>H<)4C-IRA'D=@71!VLPL'M!M%6OM+5>_NLHFE!1=# M!<03>)@GZ*8Q 0=V]F:NTYJZI"#Y7T/\$J'C1K0.<@&",=J'PCHKL_^FU:J7 MS"IKBH)TSTKM?>T80&<%.6D%87)@V2\K"DP.3 ZZP*"E@G UK;; <#6MCKBP MV=(!!>;U;6IA.PM#[ACN$_V/DQ!6^IL(W: O2V3ICS@"@Y8*PN3 LE]6%)@<-@^S-:N' M#+-Q<.R8A:D$EZAJ7SB7K1D,112'KA.+OBJ;LQ_ML+]UU1QW/3BI B.B8'76#04D&8'%CVRXH"%XTQ.>@" M@Y8*PN3 LE]6%#BLQ.2@"PQ:*@B3 \M^65%@! M_R#""#-8J."J+\3([GD"$TO@#[$+_R[136WC4 Q$&*8%9ZX?![FKZ[0KT617 MA@MCRXH"NS(K[\M=EH=82_(0?P;]MYGL<#/XEIA$^LRM>MS: M>8>7GAU%-P.9PYB[KSZAFLLIT^3?M78NXAIW];ZW:F:]TS2M9H/+[C63X:VO ML6=2/2ES7C*QUQ0%)M4M+J%OUG?@5.HTHP^E4IN:YQDUT\JF636K5IMY53,Q MUI57N=Q10V"XW%%'7$IFL31%@5VB;,%>R[)<5!2[_ MW((K6SIRY45_I_L4UP_!MYA7-9-@36T+\RK+?EE1X,I9OE%+%QBT5! F!Y;] MLJ+ 4HF!UU@T%)!F!Q8]LN* I/#%A&Y]DM%Y/881^-45MWDCF]F+!X#+A5> M62K\:(?PD#C*U@R7:#GRBZ!=:P7V6[FA15E1^/_9^];FMI%DR[^"\,[LNB- M#=\/]]Z.D&5[1GO=EL*R>W8_38!$4<(8 C@ *%G]Z[>RJO#B2R1%BDGB?&BW M1)$@4"* G@=O,X%!I8*@DT?9+^J*( <0 Y<8&"I(" 'R'Y544#AX19I3OUR_[\\ MC6F-IGS_U(?FET$2%LKJS:M'581HRYO;6>X4S,Q)FQE0+&2_JBB@!A'[+RXP ML%00D -DOZHH(#@'5-- L4X+^AP1 7 M&%@J",@!LE]5%$ .( 'V+^9'=>C%JGT;[ MJ"]@%H6GL=H?3?BK]( M+G+,Q)2I <&F&+)?511 GINW5^TV7\2=?SC^5!R&.JD+:]YJM0&"9":*3(T$ M"!*R7U444&VW!4&VV!#DN?L*4P [=J_5!)DR$UNF!@5D"MFO*@JH3L01+!<8 M6"H(R &R7U44$(H$.7"!@:6"@!P@^U5% >2P11BNO=/5T'ZRMX9I5&W.^W='<>@V6X6W!B[Y"<>.[NOP*WW[+;G3[X MDYFD,K4AX$_(?E510 4NSE:YP,!204 .D/VJHH" (\B!"PPL%03D -FO*@H@ MARTB;_U=1]YV&"_;77]T:#ZOHEL,/MT> Z6@M:$3"Y>*;B0 (Q[%I"9?BVE70I.M6;7O& BGM ^T$K%/VDP[< MNV4MK2H:/&@6Z*AR4(".CAXIT!'HZ.BQX49'*\KOP%@LT%JO)@]@\20MN!?' M@A3<"[@71X\-!\+";O?@4(".CAXIT!'HZ.BQ 1T!"M#1*2"E:QA!1Z"C(\8& M= 0H0$>G@)0N[ ,=@8Z.&!O0$: '9T"4@C6K87>V\U+2AJS)25?1'(9C,)[ M\3F,=S4K_*M('"\0[D,'3\(2I[--LC]0I.S3H:\0$!I8:!'H!O0 F MT OHY=AA8*E!F&_(%AC,-^2("SR#HX )GL&+>B;^'$:^%U.SP[@426_-1M)5 M0\3X:IK$B1,0%#LZY9:OWH?!31*.?A0.N&=#\)=?/JT*O?_6ZMK]YL#N=WIH MB\A,^)C:#6RW0:J ":3ZBHV(VW.<2JQW%_IRD6/-D:]*JNI<.S^S!G,RDS"F MQ@',">8$3$M@*E>D@CEWPYR=5V/.<_>Y09E;=^UO#'IV9] !S3(31Z:6!#0+ MF@5,2S>HQ4I;T"S.@QG#P%*#0"^@%\"$^.=KEN=T7VT;MZ)V]N75/8U&W>YU M,8"-FT1N71X+DCTIZPV2/0J80++[")7V7L2Q+PIP]KMVO[6[JE?0XFG-)5V* MQ\NK7-F/(+V,XZFJ= W'4OGH<%X^I]1+:RJ=5X+F=!]=BY_^UQ(_133R8K4. M>@'""1F)@\UFA>O&:M4K;YI9H( Q\X?N40D%8:T@( ?(?E51 #F '+C P%)! M4&G+%AA4VG+$!6:+ PK@]6WJ9/L+P^T4[A/NAVDD5_I:1%[HZO)9]<EJ13[+"8PL%00D -DOZHH( @'513@H*%='Q<86"H(R &R7U44 M0 X@!RXPL%005!RR!085AQQQ@=GB@ )X?8N*PWXC#* GA]F]+!=C'\GD;[KL:%0K[O MDS!(V_>5_O!/$_HZ= 7A;PVT^V,FB$Q-!+:]D/VJH@!ZQ+:7"PPL%03D -FO M*@JH$ 0Y<(&!I8* '"#[544!%7$@!RXPL%00D -DOZHH(*P$L<>C[X6--+D8X'@L: MH5G!,7SIHTLYB).8!.0OFU82-YNE2N)KYXE2C>*K\96Y]@5=^BI8F.-T&5QD M DC%Q9?RRSS'OYX.?6^47N J^J2PN@K25_8^S+0QL'O]-O^B9#BY* 6O*@IP M0 Q<86"H(B@W9 H-B0XZXP&QQ0 &\ODVQ82>- MT)EBOW"__P'&P&!Q2P M#X;L5Q4%\.4JOES2&K>[)EW^X?A3<6"V5"UU\W,K<"(SZ6-J%\")D/VJHH"B MRRTXL7=(3CQW7S2/<:V4C^:@9W<;'1 H,U%E:D1 H)#]JJ* PE0^KL.O>TR8-9%P(R9@.VJY'9O M)= 5*+E5&EH;.K%PJ>1V(H+84=HN?M+/@EU9.IP2- .H*@IP2M M@PL,+!4$ MY #9KRH*( >0 Q<86"H("@G9 H-"0HZXP&QQ0 &\#E[G @-+!<&F#[)?511 M#B '+C"P5!"0 V2_JBB@?&R+');!; [+N?OO:9RH5L'?PG-W87V7:D>B#M$O M"F?H7\5_IEXL5_]&1 _>2.CDEZ]B%-X&ZBHJ#^:(*L^Z=J.QNV8FL#XG;7W MO)#]JJ* NC-LR[C P%)!0 Z0_:JB@)@=R($+#"P5!.0 V:\J"B"'S6-V@SJC MF!TB;56R&9@1^=H87"5W(E*E:I&XDUKK/0C+"^3O6Y>JH7[^I"JW*V^36* M/P;-5;C P%)!0 Z0_:JB '( .7"!@:6"H%2-+3 H5>.("\P6!Q3 Z^!U+C"P M5!!L^B#[544!Y !RX (#2P4!.4#VJXH"2M5 #EQ@8*D@( ?(?E510#75%CF1 MC=F<2)4X=5',F[I4:5.?PSC^(I*K\3?GYW48T>7/DR3RAM/$&?KB6WCM1'(] M=E6F/!I-[Z>^?*>[[(:V&":]NU1)F)*3-B6@4JK%R4[KE'/(Y-2[@4N:Z")EVW:MLS%DAI)V8G8)VRHW/@[BMK:571X$&S M0$>5@P)T=/1(@8Y 1T>/#3/#>@(4(".3@$I75$(.@(='3$VH"- 3HZ!:1T M#2/H"'1TQ-B C@ %Z.@4D$*P;BWTWFY>$]*:K0GY(I*\"&1'5?1?1>)X@7 _ M.E$@\8W7+IE78E=;WNATV4XA SBLD]1?P,@,4F%I[\/*Q( 5>WA"D;"F8VDWZCW7$V3.'$"@F)'I]SR MU?LPN$G"T8_" ?=L"/[RRZ=5H???VFV[W6C9[7H;;1&9"1]3NX'M-D@5,(%4 M7[&3<'>.4XGU[D)?+G*L.?)52;7<47AWQ]5@SI,V#F!.,"=@6@)3N2(5S+D; MYNR]&G.>2USIIAS_VO'FE@0T"YH% M3$LWJ,5*6]#L;FBV_WHTN]&$4(S".3+18VHU0*F@5,"$F.]KEB0-7HU35]0+ MO[RBJ='IVXU6 TS+3"*W+@D&R9Z4]0;)'@5,(-G=[UN;]?J+./9%0=U6NV.W M.@/P(C,AXC*,=2D>+R_M93]W]3*.IZJ\-QQ+[:.,!/F<4C&MJ?1>"9K3?70M M?OI?2_P4T3%;8%!>S!$7F"T.*(#7-R\.;M8;"^/M%.X3[H=I M)%?Z6D1>Z.J:8?7'*QWQ^FA"8>X>"YV:==/)4][HAF7$O7K;[NXP11O6XZ2M M!W;$D/VJH@#FQ(Z8"PPL%03D -FO*@JZ"K;2Y+!Y%E-SS5W5'XX_%?O<5)V[ MJVM@5VRPULZ;ZMK-=A_[+&9"R]2<@$HA^U5%05>Z5II*L<]B @-+!0$Y0/:K MB@*"<" '+C"P5!"0 V2_JBB '+8(PLU-]MYE$ ZALRH9@9.;)XBCXIK*Z"])6]DTFK:0_Z1S T XX\F@94%04X\IAMR 4&E@H" MWZ8RM;U19:J\=?6GF&])IVL]GD'YZ#S>" O;!D/VJH@"^Q#Z8"PPL%03D -FO*@JH1]TB%:ZS M22K3 !0:6"@)R@.Q7%060PQ:AM^ZN0V\(F%5+]3'L\K4Q^$/$B7QVJBR, MY(^1-TJ$:\I/2>'C"A9=)LY/^654A'HG?)==A3K<,O0%J"H*<,O0.8H+#"P5 M!.0 V:\J"B 'D ,7&%@J"&H*V0*#FD*.N,!L<4 !O+Y-36&OV/7+A/FNQE^S M()^*S7^G$-\7D5R-OU'0ZY\FYG5C+L>QO+#9M.6'T4B2F80RM1W8#T/VJXH" M>!/[82XPL%00D -DOZHHH+;PM[>;9SCU7["IXE%B&"NYJQ7SH]K]'K93S&3S M%W8 @"PA]E5% 76$V$EQ@8&E@H <(/M510%A-I #%QA8*@C( ;)?511 #MN$ MV0;[";,A.'8:$E4*CF%>Y6LOO]*^VM")A4OS*B];M1G^UZ?N_^>Q@E5 M2.B&V5_%*+P-U%54[VP> MI61K-=]NU>UNMX_>V\R$G*GY ?5"]JN* HK,L"_C @-+!0$Y0/:KB@*"=B ' M+C"P5!"0 V2_JBB '+8(VC48!>T0:JN4T<"8N]?&X"JY$Y$J5HO$G51;[T%8 M7B!_W[I8#=7R)U6G77F;Q (%.#)HI<(%!I8* G* [%<5!9 #R($+#"P5!,5J M;(%!L1I'7&"V.* 7@>O0 Q<86"H(R &R7U444*P& MNRJ4'DTFMY/??E.=]D-K3W_,N_LWT)C?V8"R]24@$8A M^U5% 0$X[+&XP,!204 .D/VJH@!RV&*/U7J]/19V0\6@ !T=/5*@(]#1T6/#C8Y6%,.!L5B@ MM5Z%',#B25IP+XX%*;@7<"^.'AL.A(7=[L&A !T=/5*@(]#1T6,#.@(4H*-3 M0$I7%(*.0$='C WH"%" CDX!*5W#"#H"'1TQ-J C0 $Z.@6D$*Q;"[VWF]>$ MM&=K0KZ()"\"V5$5_5>1.%X@W(].%$A\X[5+YI78U=:<0M1HM>SZH,MF#!'8 M>86H_@)B9H "4W,/8CX6I$#,^R+FSK;$#%8%JQYPV-^JFDTWG Y]837/*D.P M[QW?"4;"!RTY=Z_AQV?HU MI*"[PZ"U50TIP&+":O!-3@9*."A[;R[YQ?Z5^S4'#;C9[H/5C$-.MB^C!Z&!T,#H8O3J, MOCFA-UY$Z"^*CO>[=;O7:8"$MY&LQL'-ORF\_YL:EBU?=;V'S1Z^]*Q_+=WQ M4,K?KX6G[4Z2TCTLT>>1O)2(GE?H1=^\:AWUBM?3)=_ALGZ[$Y8S&DD/V F> MI#S*OR3R^Z5\64Y@>?)Q;B/'MZ3 )58XMI([$0M21V4>*;AEC;W "4:>?%.< MNM7QV=IK1"O2:$X6&4$^B]1HMLT#W47I$TV<6U$;1L+Y47/&\H'>.?ZC\Q2_ ML?ZV#^$HBN4"C=Q@6;9=@_\.7<_Y8=V,/!&,Y+=;J M\^6'\V\?/_SKYIO\W^\?OWR[^=?%^^=,D_!7P[9R$7UG$HMWZ0^_6H:1Z_+VWBQL\O)*/D&G=];L M;]M(;0MY>]XM.*0YYA!F;YRUM^YLMQ= UK$)ZV\)=@J-O!.Y$!*;YAL&6[U& MXZSWC"ZEBU89V/Z?<"+KH[PM=P=D=2P/7>P45:''/GQ/+&9=Y7C E([+FA M:MQA ZE5Y[&;]<8 I,8.%I#:<4$#4N,.&TBM.H\M2:T/4F,'R]*3R U;@.]O M6H".%I_H\JN#E3$=K%CC*+RWPHF(G(2.+NGX_L%+/!&S&^"@G9 3183IT QI MO*J45,45A;IRXBJ=%<45&B@(!Q3V0PU8=<@^?Q1 #FRA@8)P0 '[!DA^-24? MU, 6FJHKR&%&_KUZO(\+ %]$8OEAO'54;W\'5-BZ':;BLDKFAU^Q)*AYJ]8% MISIJ&(I^Y&T&P&^\5KU:8@]^XXC*%OPV-YEF?7YK# R_-08OY[=VSVYU^?2Q MAYZ#WD!OE15[T!M'5+:@M[FY+1O06S^EM_X.Z*UAM]M\&L)"SQ?06T420KFL M_;G[[VF'\J/:09;*X8)I;KQ2.Y_,G&\\F.:F&T<.I_U5IX<3QU@A$-:XP3 M?H= <+IP]%95%.!T;>%TSN>R9X#JX[)J'B MJN_@.LA^55$ UVW!=:W]<-WJ0/M:C18Z=KO?!/$QDS#D4Q\>@XL[)[@5U$-A M['@1+?A44+P]$JX0]\[0IZAS\""D'M//DTB,113-CRP\K54IA>#C)!S]L!Z= M2'XTL7S/&7J^ESSQ.\.#PX:3TZJB (=M"X>MG3IL/T+WG6:"R^"3Y($_B :N MQE\S$KC(.> ZI8 ;LHO_U&;QF059 M!.]A"4[;$H %(?M510$LN 4+=E^;!7<0UF_:O3J2Z[G)'I+K#X_!LK"^*R+O MP4F\!_I;G$13ZK3,[QP,W@M.'ZN* KR7+;R7WC/>R\?[H7!=X7[([-\11:RA M\:>M\6 [R'Y540#;;<%V_3VQ'8O(-#3^M#4>; ?9KRH*8+LMV&ZP+[;;002Z M80_ZNVM/!O7G%8%&8OGV&'S\2?/XIEY\1R'FM(4+O[,9N",X$:LJ"G!'\MTK M-VR@(1Q0 #M ]JN* M@![, %!IX: G: [%<5!;##YJ',]ER[Z;\[7A!_#N-8 MQ%=!.61R-?X@ALF+>E K&:FMWR.C-T R+3,90S+MX3%0R>VUH1,+5VKC/36I M?M'\09RMGM:I7M4M$@\4X)!LX9#,M6*^N7,B\9Y,W47!TNTJ1W:I\]&JV]TN M#E*Y"11770?/0?:KB@)X;@N>FVO#O 7/;9 =NY3GNG:CL;N*5:CZ::LZ: ZR M7U440'-;T-QIG,.Y:N!)1_OATA4)^98C*:1EW@BYGUJ?S%B6.!7KH'UQ(>JUYU6\4#!;#Y%H?( MI4D 5ZG%^TP&3R%Q-?X>BW,R=D7SN/\48;O7VMWV%9I_VIH/UH/L5Q4%L-X6 MK-?;/>NM'9=M]5H@-F82Q%6Y06R0_:JB &)[:7 6&L(K.(M4VMT%9[TXGCK! M2$B7+$Z0(7MPC>"QZE6W2SQ0 '-OL24MC7DIIPM=&EMW0:9N-QFP;31_XB8R M7+493 ;9KRH*8+(MF&RP"R9C,9T,ZGW:Z@UJ@^Q7%050V^;4UJGOA-K6[[D M:N,N0TCDQ@;'F!3LN-+2=P+=_,!?1$_([?"0I<#YQ;514%N!YLH8&" M<$ !Y #9KRH*( >VT$!!.* 7$MKLG;4ZK$&XCL3$ M\5Q+_*1FQT)%_<+D3D36:!I%\G9-.)!?C!PCMHKG@7M%-E%5,^XH>[39V-WT+J@[6LL=Y8)S MM:_5$GNN*(#EMF&YNV"YM0OU&SN<40EU!\L=Y8)SM:_5$GNN*(#EMF&Y MN<%=^V"Y'0SV:MB#P>X&>\$6[($"3R[9E'_466G@"R/+.!W&X1=0@#?"P1N9 MF\PU[XTHDY>UR7MY)'E-[Z/?:*-3'C,!VWH##LH[+6-;+;'GB@(H;QO*FYO3 MM0/*VZ!AP5+*:]N=!KJ>7SD1X+:TV<)V?H"WY'+7 \<,!5513@>&SA>/2>=SQ2JW>MC=[> \L=N]G< M76 96G_:6@_&@^Q7%04PWA:,U]\MX^TBKMRP.UTT?.;N!FY"_Y'$?"*1YF@JW 4M,PIM<_F=R< U MP4E855& :[+Y9KQ;7\LS(5/X.;=[:9E5/A@\_]O^TYX;MKP8SL>9B1Y7JP!& MA.Q7%04PXA:,N$8CJ1TRXFZRH@>M)@B1F>1Q-0H@1,A^55$ (6X1O>ZNT71J MEXRXV^!VH[Z[#ATP#VR"VTBC?L'Z9SII^:2^64C[B=^I#[P5G+55%05X*]MX M*ZWB"-H%55R9/T*_IT[)TXOZ/J[B2)V9+*$U)NQJ!<6>*PI@MVW8 MK;U[=GNNW_,\N[7Z2!CC)DM@-]C5"HH]5Q3 ;GDG"V[85%U##I-.7 JO6L,P M 3X^@W_1K MA^W;C;,Z[[#]%Y%8(^F@6M-8N)876&&63DT*]?"B4/YNX((CQ/IP.(>&UG0A MK\)3.@XHRY[2?N$\95=JBU2XN3ZBTC!?2+M\'84/GBO<]T_?I8$NY,2=9]9Y M)]G>:Q6@]5MVN[F[;B4[H@>X7*Q2Z$#:1V#I0=HG R5(^V"D/=<)=4>DO6X2 M^UJDW1K8G JX0-H@;>8H<+7T(.V3@1*D?2C2[LTU"=T5:>^TU&]YP8.(=W1V<6P]ZW@@ MPC4'8 VN?0V3!9!VX!0=Q.$!:PY:.0*00"O'BAQHY? 8@%9 M*P )M')"R%6;5DZN137OZ/#U-!K=45_J<&Q-(LJN3I[4($;QGZDWN9?WR^]T M"KW.T,FIJBC4T>MLBT/5N3E3U\X3V;;X6W@^DH8N$M?&]EW[\LO. _=C:O[V M/F.Q9?<;;39'J=#_ ZS>ZR@-A$I-WE60NAJO'#9N]'<7-H:^'WAS#9H[ M+0-;+;'GB@)H[J63H: AIZTA8 ?(?E51 #MLLPGJ[&@3M':HM5/?W01WS/3=Y-9OKV'7?M=N]5 4A,W 4-2$XQM!<6>*PJ@O&TH;VY@T*PK@O)>>-4)#>(VSV\W,P=<;9\<;E=^= MQ'AL.X_;8J(O&W[!1%\@5<=$W[U,].W-3:&[CL*1$&[\*0KO;^1^]3QPC9E] MNAH?)#[<&/3M1GO YL :K?'9&A"P+ALHP+K'CQ18=T^L.S=&;K>LNY,0==MN MU^L@W6,00) NH #IG@A2(-UC*,(!'QU!"^+7CI:W&V?U#FMDOHC$&M$,M8F9 M?6@-GZRWTUC^X 6_['2<&@;4LB$K#*@%E!OZ'?N%\Y0=DXVC ?UUY]->IM9Y MS?FT.PF^U]MVO\6GF3+\+K:F!83-!@H0=@6@!&$?*JV\/S?\8$>,_5P7Z(TF MRC=:77LPX--4$]3-,?,6V,O<(+1;HXFCJWW&P]$N!Z8,YF=S,5D M<85I3<>GTDX-5^RJ7NS' P64@H-> !/HY>2P [UP0 'T GH!3*"7D\.NZO2" M9M*O"D!:RZ?CEEX<3YU@)*A#R2B\OP\#^O'H)7?R+6,1 MR36SK4 D]('T!?G..$$/ZH-K$H]5K[H]XX%"'>Q$RZN>@_.@^Q7%05PWA:/-CT1\$>/M)!QMR]L"XS$3+:Y: M#\:#[%<5!3#>%HRW>L;1YHSW3+N'C-88S2R"7B,YF@4 Z?QM<@RM2,1)Y(T2 MX:9!9JG+<9;]G#@_Y;U09O2=\%U^!S5P1' \5E44X(ALTX%J?NZ3,8=?A>]( M,_@M_.;\_"<9O-"GA?\41C=W3B3>.](IN0CO)R*('?JNEP2A"P[*#G?=4/@C M;P0)GN.UZM42>ZXH@.>VX+G!W$2#O?#<<]V2"YV0F^ Y9E(%GH.%K:#8(-?2'?GLB[>.L%(W_JRI_^LJF7V&IG_;A_ MA.[2 H'L&[_0%WX+C0=Y[40O[A).%%LBH"F2'\1(W ]%9+4:MD4+OK5[A[R!TSJQKCIY\4 ! M[MVA!T9#0WAK"-@!LE]5%, .8 WJ<$ROY,?N!TX;ZLJ"G [ MMG [YD;MJ"W^?$!6]+;!ETK0&_(/M510'TMDW=S/RH@&WY;=T>%8WV M[D+#T.D]E,8@^?E5U[Z<_!Q+-:'$Y_$TF4;"BL(GQZ<@LK+"S(&=K?= MPG$V,TGC:@1 @)#]JJ( MR" +O[)$ 686>H_6FK/2@/LE]5%$!Y6U!>;Z^4 MMWX*,RB/NVPA:?G@X6DO&'D3Q[9=#>72J8:1+PI YU%FS GF)D7H M%PF+6D&QYXH">&T;7IOK_[\C7EN[$_(.!\M"PT%L1[G@7$UJM<2>*PH@MLV) MK56?:_B_*V);.X^Y#F;C)D<,\IA+46%K&$:NB-*UC4/? M+B"+H\>)".3;+.]^$H4/@EZV'-\/'U5>\T1WJ3G4P4O1(:D\?%P/75=#DZY; ME2P?5Z2T<[,3M. E1R@1OD,W=C9O'SKFS*RE[F-/4]-[#I]P-:.6[=VYP7M MR'2O;[>K9" .UAX?A'H$9AJ$>BQ(@5#W1:C-O1+JV@'S5A>$>@P2!D+E@ )7 M,PU"/1:D0*C[(M36?@EUW4!]?W>I52!4WL'[EYZCO';POMTXJW=8@_)%)-;( MB>\L4E*/!N\-GZRQ)Q5W)-?.(GUZ\*A(XU!'7_"&CN"(.X>&UG0AN<)=.@XH MR^[2?N$\97]J:-$N.KO_ ZH41MYV 2.I0Q<;8O& Z8U MG24X0ALY0KU91XB\(/KO8VX\OV9VD_YP'KCE%PKOO!:1%TJW29OC#T+__^// MD3\E5.4/=TYP*[XZB?@X'HM1LO_CBE;?[O71TYV;I'*U,J!@4#!@ @6_(@7/ M-:1C1,&[.("0'[0[&*O"3E*Y6AE0,"@8,(&"7Y&"YWKG<:+@'1PI]+MVOS, M S,35"XM[]')J(C*Q=HG"+;E)-90R.<*J$0B'%M/PHF0O<$ 1*Y'_J@6/1:D M4"VZ'V>K,=?/\47.EG2SM%OUP8LG8>SX?Y?R,9&?D+^35^4%4^%>342T5JOC M[;,L&PU[T$*6Y5'(++(L 05X^D20 D_OB:<;?'GZ!9&0OMT:M$'3QR"RH&E M 9H^$:1 TWNBZ29?FNYMGS-@=UI\YN2!I8^@ F+5(88;3H>^L)IGE2'L#0\Q MA'S]A<<7>VQV63WXN*8?;%ZM6,*NB@[97_BAN%W=Z79(PEDK.FLMML[:"VHL M!IVZW6O6V:27+'/7EM)(E378$./X(SEWV=N1[ZIVGO@JIA"//]Y1. MTO')9KVG3G19M%SJ?ZTD)$NE.,FA9Q\ZOAK]'=\)D1QLD@AJCWFM>MF#J;R? MR16F>6<3CN2Q8%?UPEH>*(!>0"^ "?1RL%, M@5<%@ YG5-1V-I3+[P!P/Y1?7-!AZ+LO0^;TCLZK9(W8GGI7FJDW/[">&WED MSJ1G3J+/DPLGBI[DPO_A^%.QMYSQ=MMN#;ILCIJA[;QM+K:VD'TP'9AN':9; M.-/F94SWPL3IWH!/XC2TG;?-!=-!]L%T8+IUF&[AZ)@7,MV+LH>;'3[9PU!V M7HG"Z#)?SA[>R3#:D^AR=PKA9O2X.Q8G$CWNCL[/F9O/4RZD^A(&HVE$MFE? MX>JNW6JB:^Q12!>ZQ@(*,.J)( 5&W0^C-N>&L&S%J(O#XH4VKNW==04#:9ZL M_H,TV4 !TCQ^I$":>R+-N8DHVY'FP@@[2//H!(A+GC8ZGV_7^=SR@GUTISB) M]FFG$))'\S1&:LDVY0#-TU[?D>([LP9MT*MACM A%5" Y$'R(/F]D3S?62=H M@UX-9 \2'YO),]XU@G:H%?!&G&I;EAJG$Z]60[74W!TQCEDC@A: MX3&&":WPCA>[JMCDY[$ O'% O8!> !/HY>2PJSJ]5*21 M-X\HV&'PCM]1%L*6Z ?%F1O0 :Z"T$!! M.*" 72%DOZHH@!S80@,%X8 "R &R7U440 YLH:FZ@B 9\54!4)/[)H[G4J*O MY06)H)X/_.+@8&NZ[Q M@,V8B0HR._ED M=KI>//+#>"KUS@K'\DU!S73W?9":*%=']?X=>X$3C.BW*N9_\M4;'JM>=>O% M P7X(&RA@8)P0 &;518P0!DXH "V8 L-%(0#"F +%C! &3B@ +9@"TW5%00Y MHJ\*@.D?&]Q:OG!B82D]KX7CVE3^XL2Q2*QPF#A>(%R:$"9^CNZ\[0\[WDB=^Y ^*E..W!<6T5W9G-CVO[<_-;Z6:NQM]C M<4YV_\J8_5(RO^,_4FE%4K7497 M1)8S&LD%3V)KXCPY0U_P.SI"]!<'=FS)'(?9G#:YK?KL)O=+&%"AP%5T[42) M^>5\)&U@[-$E/WD_A:NVO[%Z-1)N8S>]%OKUW>U?H>6G;6NQ?V4!0[64 93' M$97-*:^Q;\K;()[[IXA"5WY=81\."F0E7UQM+RB0!0S54@90($=4-J? YMXI M<'4;!U#@,+LBZ[:A_;PL]#[G)"E<[B@TU"QBJI0R@,XZH;$YG[9?0 MV=H-?-L=-#WD)BM<[2CHC 4,U5(&T!E'5#:GL\Z+Z&S=%K[-.L:K<),5Y"$? M&("K4I!7CVWS HOZ9T?>*!&N?.9P],-R'IW(W3H(C.1C'$,?+PHXAN:(RN9N MQMS8FP]BF%S&\=0)1D(Y&I?!:!I%POTP)9M8.J7V'-_\_HUN3W_IKAI0X%": MN[1QM<38=[. H5K* $+DB,KFA#@W.F>_A(A$Y1.2-JZ6&(3( H9J*0,(D2,J MFQ/B7'/"/1/BNJ'K00/\QTRXD*5\8 ^B,A[$"?15#7-B(3O4-0Z M"4GQ'H14RZ$OY*<2@13F@ZL(CU6OEJ'"(3E'5#;W30;%0_+4)[D:?[P?"M>5 M#DEF#OD'I:':IVU@L0=G 4.UE $\QQ&5C7FN7=\)S[&(-4.U3]O @N=8P% M M90#/<41E>/@UM8$F/^64!]@^:KK/6SV M\*5G_6OICH>A[_Y:>-JN?'OQ'I;H\4A>2D3/*_*B;UZUCGK%Z^F2[W!9O]T) MU5/Y?N($3Y3XK$+#EA/)EP/+DX]S&SF^-7&BA'HS)WA[K@HMC[U MJJHGWQ0G\@4*.\=G&T\EW'Y%-H:%OK+1G"RRMWQP:30[YH'NHO2))LZMJ TC MX?RH.6/Y0.\<_]%YBM]8?]N'/!8U88$1V&!9MB81:=F"]*F8W--_AZ[G_+!N M1IZ0_!1;E\%("CO=Z&][L@L'?V;%TE^NOGV\^=>WJW]]_W+^_7#QR\W^J>;J\^7'\Z_?7SSVQ=E0)+0NBA:B4^9E;C)K,1)+]CEEW]]^\?5 M]YN;?WW\OQ_O?4":53#:>P$;FS39%R4PVYK1,XL8SBR$M1$M=6>>HWW6[_YU MXSO?(2\%WDC3\ZVPAEXXD?)T M+WW&::)>-^1OQ1-!"NK]26Z %,L@?! ^,;[T*]5[E58GDG\2ZTX^5&T2">D& MT[U8\IK)G>/?2WETO9B&;\7EE7?%@[(+\70H[R.@[!#_R9+_D%?A)?+2Q7(A$?9<4?EH4NI](^AU.-+I3;Y$7$WZHQD+85N1XL:K8(A^'WA") M433UU+1@>8TX# +AGVV&_@9BK."D[_9&FXC'!LA?RNT3V<[KZ5!^B955J1VW M/%\&%FW4;)*Q3% D9;@*0T_N 25QK-A)_AQ&OJ>,8US82K;KK=FTI1NJV;M4 MU].)2M=R^4+W1GU4/I_ZTZJR6G.AC+H^_D=*UQ/=LGP\R63G/[TX?9-\]3X, MU%?^+N3N-_GETZJ=[&\#NUVO MV_+NY_:PFDEB4KF1NDM=S6A+;1_Y4]IF*BC4I)7'2.XMHUC%@'N_6N.I5%7Q M4T0C3T]ID6_T(DN:B$A2MA\F*MTDG-#WV):T$(XUD>PDE,F0UYQHR94?_,M: ML8&EX+;GP%7OT>A>TU=*<-5KS/!62GDX5ONE+\VV<+5E0:-%_^ MH$G)N;V-Q*V\=2L02;ZP1E132S26ZZ)>D+=A5"2F]"HM_&I+3#9YH0IDJF); MCT+"N 5@<^5Y);Q,@&Q3W#98QW[K;+Y!0+J.EMJ RL^ZTY&BVDDLQTTYS0W)F1V7?I=PKJ1CYH?)&C) HT2$OIYA])_TF M^>P1%9-K>RS?&5CA-"'/2%EA9RH?VE'NF?22S&<%E:)+&=V"$7M%Y2_HH[:: M=/,7ZCL(I*OQ=7I_ZCTWYG*L;$&C7N^G/PPV(<=&TV[U.W:C,S_&?"D[;K'@ M@_*"YVO[5;A"W%/$\B*7B/*"_].)I,Q1;G42%M8K?7E=/"Y\)XZOQN9C5Y$* M-!=7U/QE!H<41?/Q.1S6>( E5V0M%YUE+E.4/>\R'58-(1X-.JM5MRA7A8\$ M6[FY_:*,I=+QT?".NX: %,12+>O[I^^!]Y^I^"!W_I&G>$RMM+S^W.6U<"X0 M '6?DF2-19&/?FH"MIF]6297TLK$4[F?S:1 ^0FIVR#EY?Y>R-M*A)2B<2C= MB\?4/9^G&.W5R-OKS6=YOYP]&O6-V*. F@H%KFNO/H?!K?0I[JG&Y-O31*2B M]^TQ_&8"9#=RWR\ODLE6]AW':'&:=K?5LYN#YKI$I.Q$HH'N[P7H!A>@/Q)7 MG0C.;8EQQ^[V>FOC/"5G[)A2FCN5< M%60;T6*.)3G&[' MU#5@0UWK+VBCN6)!]T)=Z;>95*45F4OS.N[=!FJG&B3G(_7=9,U#:5$\$>\B MH4E]T@ND"3E/\MOXESL*DG_UZ\YX4!>#6KW;K-?:[5&[YG1[_5IW,!XZXV&O M/1"=8\V(:IY9-]-[>7=/9$P*RVSEZVRE"VVMS#?KS&G!>R?VXJOQ#&)/^M_7 M34.;]88.&9-0RT++?4UI3$&BXRW'[=S-)8X_FQ1NW3D/PAH*$=#IR<2)5*12 M721RR5[JB):3BZ'T)^1%)KY\D%L1B$CGC(TH15)_EJSZ=VFLY6^*V=4BGRLY M=:RW)BON^XWU]_/SZS0K;C/+U*W/6WHOC+1?^56,Z!!#1]3HM,3]]S16?E'A M"(5;TN7^Q7UV68Y;T"]$E#@>R:S$G;PS";SEW&LZ-#*XB>Q'V>ID?7GH'E*O M1?73DM;8?-&D8#%T6'9]T6W,BFZ>D2VO=@BCS$I,KW/K(JU&:6UV89N7%DZ] MM@"7RBC>+RM0TQ;]>4'6&T=1]+#-CC%.37>-A4!TLQ?S!Q" MS+[SXDZ^U5[XC:XGU2FQ'N]"HH;P,: #^=2/E@Z,73CC6$89])47SI-<>NLR M]G4>OM2Z"1VS/ C_R5YX4W^_'_YCX1_^<'S'TW]??,]22IZ]:REH=W.W?B/Y M\4\1T2V>6>=R=T[E65&:OEU>_+SE7M'V"-^[EVLIKZR9E5,ISD%^V<'^63SM< M(U;J.5U!QX->H,K1Y,9.O>'1B;?8J#7GZ/N3OI4+%WH1_EU;^L_RJKX*2 MX%=F4*QN'$3;+E4<6BONO^IG\T6EZ>[+MJ05HE64,KC%0\Z=X.SD(>,H^>H$ MM_I\5O[RN_/3NY_>%X*FRWM*+%N"^<:-^094BM86SSY'R--Z@J%^Q&Z9E5*"C<7 M=)=2)X684AM)I"AQ*UW,;2WH;+R[%HL1Q;P?Y491>L,KVPLLN>NYX\_TKJ_4 M*DE%V/M-2]@6=!68SS=,5U''UM+;LV)]?[9T&[S174JZ&9:2J)?52-'?W&AZ M&RLKM+14:W3GB7'A"^G1*,@G9>>'-%*1>/#$8USP"KU /RZ]1QGP N,/5M,_\?DK5W]W= M57\O=?E?7%V[8H6L]\N"FKNMO'ZN@OA$'GZ71=4GLB1;5$X?H",%,94Y:="& MLGCHL<%IPZKCBD[?'=&2>-OA: MLBF>+AG\/U./D@NT;ZD\#6FAR%N04I N':FB$\?3^XD.1DC?([&<\9@"(.3 M:']'Y"%5WB#Y!_:^(7KLEX M72]8JSR2GQ,1D-OBJD22PKV:JG(O-$$43[K;H[0[CG2$;D,5U+KZX_)#3>[F MI"_N"O*V4@U6=EP\A/Z#.+/.J41?+N+4EY[=R(2:EZ^>67,*DXPB\MUW*%"D M&\?K(-;8\2)J>C55UY+2_D-H)U5ZN=/(X%-PV&I#=7-"I5F8<:EVFI"\V$MU M1J-H*EUIM2@JTS_.UHR6;"JET:0,44\L$[)B17&EBZAU$B;\9 0SG3(G684A,4K M;WBL5&K5\=6+?YP'[O? " "M9N5WY+0H"NS2LARW);X,K-^5[.?I%@ M?UI<0&DBIJ29PZ=GS!5I2D";.15]2JW\S8NGMPK*Y$H4?U)\0EY3@B]E(7;&PA 7=P/'Z4% MLP(5#%&6W8M).A[DSM\089Q,W2>= 92[L3/=7>XDTR:2]\T#%N^47J;4+$>% M,:U[25K32/_IGD32,6)(NN\H0,.0_%+>&A*U4I]5-%RBUU]*.N*MSTLTNSDU/+NSK 4K#%A^M\ M.+LLQ@E(23\<%VR;E%#ELTESG*M+)$E*J\F,D=7)MK201EAJNOV2/JU3IV8: MZ*$GM_:CNT#NQ&_)$7&G<1(]G5GKG=J6#YD7/]0\ULHHJ8.V@O=E+,)<]%A9 M+:D4#UX4!FDX,9)VW4T=*7J2_!&41.9=GM032_51LJX<)YTN.-.$2@E?:2FR ME:*T!W7R\#)!V526RG8F-MZP,[JCNY,J("VQE-=XP27F M5'OF7#;'6JZ@7G8*^);4>^:BVH4WV50J^XHV7L'LB>\J*5(X1&(DR+ ON$E[ M'OM :G>&L5H+3Y+A0^H]*+F1EC$1F971FSII2J3,9")AFVT'MB45?=^=-8K,)(4]$]S$+K!]"J:'WX+FT&[&5 M_:7P/.USIV.2F4C>2VDK$Q;\-F-)M90K=\&37L&1&\OK% UC,G(',K479F=: M))\T[UHE!GP*0[UW^T"">>[2^;X"A60C3=7[].$\:UY'1Q5J#5660^"8_5Y1 MSN3>7V6IZM2L$FM)1\+1H@=J49WJ1J;'ZH^\\R;^F'D+^L6F@=MA%3RG[&ND6IS90 MI7 M+76)'^]$8-.%Y6?+WHI>;YWYF92W-!'%!Z1+I&0L_78->1I[7=B3];BTKNA6 M:A)2).71T,T2Q^8D1[DR(L[2#0+Y9=)6/E#NK,D]R#9@@= )B.%0BU8>4QEG MJ5GR]3!R1:IR'=LPC#-7MW 1!G3,HNT:A3 N:(^7T$^[ M"N%L=WZS96QGZRS&33)LBVNF^)JZY$KNI:2WJS:3GGR;IV.P!2__[F/-FY4_]:#U,18;\H; RQWWP]ZU\D!-[-IO=QHN_1%%BFZJ/&4!34Y\SZ??$N1I4J2Q^?0G,J?I_> MAU+ 6YJ206$3JNB12ZEB+PL>1BYSS51\EDX1LQW!XE4I[.G6W^'8,UN<81A0 MHLOBYU.WFB83)<7TGVSS,@TB4TACW] M)QE(6U7()]!S06@3G=K">(N[:";%Q@1=ZK,J)RNX)WP*0AJ)L:_"I8Y* MHY$+2ZN3Y:\E)?,SEV=1H.<\C"@>/'U&I++W5+F"/@20=VUN0 HC !4522,2#AV^1K=9-M"L MW[;E M"*'>E.7UC'FDXT%[]:;!+VW@E^T-I^ M$).0+8D7\J<'P:W-:+-0J15 M.Z"N_F;AIF[:PI"M=KB(62F:H;+/R5Z38TED$>N$>7(A@Q]Y=;VTMW2H+]T$ MN>U*$IT&9.+M>>199QEHMV&1>59>6^Z*A6-)[F+C3=E<_Z5/D@'_()*[&F=Q MJ\O\2*&J!I>6Q?HC)?\\HE=8FN,^*"ZT[KJA&3(J]?,B='.?,=+ID'[WDSKK+1YL MF1S0V8V%.N^2[CL]QE1?<"B21^I;42R!R'9TQB.BR*/U-AS&(GI0CIH73*8) M[2K*&6W_*Z9.&Z5+O9T&\Y\[LZYF7S-NMOI1W:7Y:C4":N1-]/P&E8Q!:66Z M6= H=>-5<8H*TV3U%PN?09_#TP$3)36D^=(D8CH]*9G)5#FSOL_?_MRM&D]X M9B6*J^ ,PVEB/,[=/6*Z.RDD#*4/K=(>*>VX6+N1.]II3Z7B-OW(TZ<^Y5). MFTP:#T8G>-2[E(C-Q""RU=1[[/R M)9J_SADK6V?$.+'UGVEHCMA-,"[-P5?P:5AU:$%EX.H:NH(2JSB0M@P%$%6 MZ\Q:G6!U? O>W'K!3=!%A?J*"*8+OQ@.6OS8D\]$<<%%2V_/XY<"IU,73>ZQ M!M4NYDOF5IS>5. (TF.=1R5]SR@MV&D MA0]P>C+26E=&%A&S#@ZE=)S7S&9[ D6):3VA+B#:!0\O4^ +8]#-D6ELW7J4 MX6DV+"IUR LH]8ZV1=K.FB8=H2/C%92W4J>D/FT(%M7;B]G!1A 7 M.R%'[DJJ3CU.%*F>NX6:^84E, OS"LWAD1DN-4H/W&=/B&W=,\ KE,+G=0UI MEU)M^.T\/#)QGK+>1:J@6\R4Y,]=HD1Y*NOWI[: !?CRLE;&\PJ?D&*HQ);YRADQECVY H&N9,L\HK>$TU6$:&Y/*HCZV/&%'NL-F MZQN)42B=S#\+44R=Z22MAZ!:VEANF^1BU\)Q3947%[H2J6?<3&N"A-F[ZG>D"Z&[-3Q,S MGYH""-1"@PHPLAV']-]4^(\"%^6#VRDU#/I3I/D)(^U12U894CA!32BF[Y_I M4:EO21]!JC"E?K>MFD;*._/IJ"PRZ3$JXF@KB=)A4.F24JE96)"-\KHX61Q% MA23TAK3PJD0M"*D%Q$P-N]HP4WGNR$SWEM\6J3RR2-RJ\\$_5,LD7VBA4=^M M?\QNP%$SFTW^35;PJJ2 OF)&"@IE>G/RD,;+"T)F-DAF$H JE4SS2\*AY&E- M$[K4+RPNBQ=GR[U99D=OKIOR=40WG3Q=^S2))W#IS%?5=QZ1M=^/?4]71B&7 M+8LM+Y8<]PZS]& B?3!=QZNSD57[!;4=CU4IY?1^JD^[73K*D&YF)IC.R/0K MTUI O5L*[_!4HPRYBR^GO^5*('4>@:5[ ] M^'$][Q:(L&LSY:HMRH24BROXLWWJE\B-> MN$@Z:W[Y*AE1C(HR3T9;??=Z"[=H+-SK+%PZ0RX<)X]24S_DA?A;2A0=%*VQ M5K'Y0K54ZD/YZ/GY!6JMSR]K+=#J$06;+]^G:22]O6DDY-L^R66A3E7;K1_5 MW 4^QDSQE9ORB\YL[[3!'J5/Z^\(Y5 ZG,3RIUXISQI4WRAFZ?0]1 >=/J:$.-"XG3DQ23]YQEN%)".SG# M@;J8F6KB>)%):5=)LSJ;NY 4N[6_-#=>X?*>OHP6ZRKZX,634*[BU?AS&-Q^ MIM/[<[5ZE?>=\E4BD:+5J:GEL?3Z'+?_5-PFITWS5:ZBKQ[1J)\Z2,F7@;J@ M4)N.M/$IV5C574MWXBV5K%!WHI'./C?G43,' OJ$Q)P&JCZ.NM\@[2VH%8C: MX'U-?S%9(H6\K*'IOA5YL3Y[6O0=Z2&+;K,E]^&F\$)^G@HBU''"V \?X\*V M)=T+186=K+Q.VN)%]^Z\+1F!68>.BT_R8Q=Z@'K=B;Y3*:-LWU; MJXS.K*GYA_#=3V$DV?00PSB6/,! MVF38S)HQOO&=<-SB-T1J)U?8U)6]56KHF13RF#;1TU)K[W-]!KY852OO!YK5 ML98J[7'K:M$3I!;)ZE15;5ATJU$OG,;%HA%U'I&^GMQYD:OSOLK*D;5?TP6" M% =6N82)*#:K7-R;,JL#N/AZ%6>% &G3YIDNE_KD9>&G?\\_K5H4T5:5-'!% M<__$>R@4?R\8':HD8>D%S%XS*D8 RRE":6Y09@7,. +ASO80G^ABX&BFM[-V MO>W2HXYHJF3)-!$U[<>>-INUR^VZ]6F;-5<)5 MGB=O5EHG;9;M7OJW2#72;TH[72;&6ICT7_/)W<4*I#-((;"U(2TZE0/ MP#"M/15"T@V>QK&ZT7(;\MS JR#:TCMULKQ!^9I4!3W*3'<6M-,@109IVH/0 MC-[(EUD_V:HA:.G"V=F,BR>1J*;.\LKRU=E2ZE0B5V8LI<*W/)*1-P0U&"0T M@O4VW6041F:49#>+SABAUMTTE7$0A=:J8>1)ZU?$:D$'35TE;>Y!0^ODF8)G MUG5Z;G3ON";/JF!Z]!$K?9K\@?R45V>4NP_IK2]X&AW T;J1<[,YY(IDTZ M^10_?'D)W:+TC)Y)SQ@(=]!OU<>U9K<[HO0,I]9WG'JMU:N/1-?M.*)SM%1_ MHUPZM9^O_9DUAA6BVF^UZG];;ZC[3EIQP*)S";$OHU&Z5AFS'= MH>D^2TU/\CD;)1+/#7IYX)"R77JBA7FG^C*3RO[M;G9 47JW=,+H^",3D<[/ M&-_[CGSPF]%=2./?\W1NE<)M9[GZ)LTZJXU3)EIWX:2CCD+14]'%>.O]4D[6 MT(NDZCA*8Y?>>N:=Z3VFCD@6&RO66-#CJ\^8#U&*?FU,9UJEY _MO[SU'G[) MKZ.ZF0O5[N6;N3%"5T71C256N1CEHU==_)6=+*CE4.Y)QN(J,V'AB:O*DA=Q M85B6G34E3DNNZ8'.5O;WM):JE_QO+-0!BG8A[H1TAT:2H5>.23[I1. !$H&1 M"(Q$X"HD J^5Q[NRG65]X X:O4&MT6T-:FVGV:[)C[CTSZ U=)JB5Q^_674G M>W)9V?EWRSHIO_9]7* MGJ7V6F878+:=5G[SSW2O?NTUUTN7KM>;7^R%E93*'2FZM*FC^NC,.D1NVC*L MM)'-8AIV(=N!:N@S4ST[=[30]TPWI%GFQA=FEZ;.F$YW'I?/EY,Y!SIWN,^L M<_(=BD)G%9:%&V9ZYNO_<:3)BIXL=>36&#"[R0T%R:11IYU=]LJJ*.K]ENE*MK"C-YBH\#'.Z%C6J,[3SQDV52S0;-"Y8*GQNH,=;+&Q:+- M>6G[EN[25 6EW&HZ<_LTL].>3LKS@'0W&!''68;72%DD+U9SR=03%V\Q"U3D MQ]>E+=7RR-MB4LN11'?T"]=,MNNI(FZAFSH++)4G(* MH[N?3-+W;!S&I@0="IV;?AM2/%6XFWK#B+&(S%SL_$N&(C\N4<&'M/&F&>2L M=X7%3C+R4MV?O/T[87,ITRYT\") MR30:2J=B[.D"$U600WJJFM#.CH%*S^N^7'TNG_8M/V;3G>Q42I3\6DU :6U* MEDR5!])$H _)Z-:C;&2Y[SP:8YM.7J+QOGI6(V6ZF6P:N3SSR6 TVBNB)-3S M0ER.#O,?E?G19E%CZJA>NLG"!9P&JCI!3QM3?1)\[X=0CICT >CX)\V>>\IN M,F\J?*(JF$]=HY5231)U3[4GPP$J"TXN1CI,KO >/=]7-9-Z*C&&\B1]RB-6 MP[0BX4O6HW0\YZ>ZW%3J#8&\MK2>T:Z?,_)4CJ0SJ7 MQ-2N*6HE!_Y>LV^2^+KEQ,(C;SWA1WEW89ZUF =S=40B<'QE868:2BK[:0J^ MU%SBHMV;[Z>=_SGS'B1NYIGE[86Y*_/"Y,3V+,E_#_*,3,EO[_5WQCGWIX^H MSMKTLYM)DM)(4T'A^80%%)-%7&81]OT1'*N!NFB MV*!9+Y3VD"KO)Y56QOHL6>Z4"JS+3Y<6.BA%5F=D8\7RZO5"5L+RQOIGUM5S M;TF[P<2%26SD5ZSH[4]QA7+G_ T36?O%!+G/J=/W51NX;^&-XU/_6N7K? V? MM")67O*S=2HRP8TJT1E;>K&L;+5.22G6&U?[YK>K8&% <_9(,4O'-J&A\O9= MN0M)K'K>>:Y'6X790Z2_WP__4<[D<]2L0N74I+E\VGMY+UVFR'H?A>3YN'+7 M'$9RP_+Y.O/+W[\_S]/H]&:':K^,PZI'W> 3"-Q6O--[]UYNC^K\LV>"I< M9-/(D'CJ%,1D.;'ZW1S/PP8:Z'2/EN$2Z2?5J%TM*6?'.F WZV)P4?.Y$G-Y10_=0A5;9 V[[W? MFI_L9E)'IXY_E;5IX O5\G[\S6;GK+ZT(S^UGTYC./I0P6C4G#%,MQ4>S3LJ MMJY0JB,W,6I+F7U,;\G2?L=VL;UJFH>J0F'3MMAH67,X_S MZ$KIGO67JX1$N9;J47,LH*+\DC6L_FA.G S5J-<30@XIB/YYYELT519 MA;[ZF&_VZLM2\M>YLU0TTOO09UZE\>W:A:$4TZ=L8T6$5(K& M%5F9H!CI+I04.\@ZW"P2IV6(EH&"I9 M3?ZF4ZZ\M';1-&74A8,ZW%#H_*ZP7Y"EZZF*^GP;2HZ%'CXU6"G8Z ME9V&J5'9T%@/D*>,%*O17IFAM733,-=:00\)IRW@@E$7E=\NF!'JG_6631%D MXU?KO#0@3^T>/M!6;J=S"@^X5_BT> C@W*"W0(!(BYA5>W^=)J!N M^4GIL)E[J$F6.GK)OU",UD3F3=O@O".$:A*A34,:WWZ4'Y'?:;DT"*,\,"UE M5FGSJ?UO?.PA<+E@%.//UJ4$Y]RIK#I>-R/;= Y&VJ;"G(>DH8^T-($*I"B= M>9C/B\M.1&;&P94;*:M#">7+E)&RE0^4'N:G3;B=I% JDDJ#BM:G?Y/;@X#& MQ*LC&C413YV>% ^2TS&"IH==*8R<7K-\M&:>SE2N>*4#XK3Y0-K=NKA"--8B M3IN#S/6T*Q3'%\][5#-ZW[3RR I;LHQZ_E3%0(K# MY3_0BZ8-5?;0^=.F'4=?\UF5*5M]WZ7U2#.^]&*<6;2QG4PC.@Y--^- WE'BT<_203/Y4>GA1OD%ZU&5=2>Z?43VL2!,TC'RV7.8XD<3 M:C.G(7KW,9.$NZASU[/(:6'5C05F,%P'E!+.QO'7SJJ\%=(4VE!D>47)8UA3 MKK-!TG M:U5!=?WE:*A9BU+8+[NZ]NMG&GUGR^WE*R[O6U=L4O+ZE$KSG%>I M7$=A$%+N6F&F[NZX=9&+T&]H%Z'?'?;=8Z]:=5JW=K(]J@VYG4!-NH]%I MMT>C?F=PK.3\5:C,0BX5Z,-,#M0B+:WFN5FA0IG>];[%3P\GKTE1IZ$9[VKULWKGM6.P M@?5)#"-5B"5M7=?.!"V5/5-'UJW5FVNTND@GJBCU??[MIBBQWV[^DDVKUB%9 M-231S#R>2,=3GH_Q=50/!_IKY:U_[2=>W7&NM, M^#;34 KK99>'AQI5,K,5C'S:T;&%5PY'+]+]6[D#S' @:%R@@*YDK]#]2DO.)=&%]7;4A42@: ?TT:QJRCGQ MFU^HU2.=:J39&A-JJTP]\HS"I6\UXZ7;]0UMR3X.NQC8WU(92$I!:H&:!2:> M*94MU/;<*QN@FO(EA70#56%(58&EL@5IX'3G=_F6FBGUR24^Z^]3<@!TV93> MS)@F9<61E87A\"536RBQS),5%@A.-JE 2?.#LO4JN=]L"HKKXWJNN@VAIO-F MVV]G](-V]:J%ZIRRF+,>91&$:CA:&+-D3FX*FI?W*IK]4C-6R4]W4@!CE80X,[PUGPY5N$555IX?"5%%P_RTJO(-"C\['R/[^+3T M#LVXS[0CMEP^53>:SIY**U&*S1*ITGGN[[&:O46WZA=>7W)32^Y%U7851=.? MF_9%':+2&5]T6*6B"5^F1/*OLR8B.R(WH86T0JO@.*E6 MC'/B1:]ND6(Y-X_F*BUT5&;\*WW/U?A[+%3+\.=3+<]S)OX41BLV]\79(/E[ MLA8;NL,&D5V]6MER]NMTH MQ%:2/_G.M&5G5B%:ZMVYS7*VZ\54[0_%[[P:?\F^\8/YPL_Y]S%?W_HJN9Q) M&YD5T90O9V.,9G:2+@G.&W=+JZ?"DM>.'UKG/O4&OY!^F;Q*X#EKM%35ICP( M\S)5XK51-I.B]-&L#%N;_6SJBUWRI\TM&Z]:%;5F>2*S*8R]92/$C[*^1NTD M)1D^LT-OM-)TXN=4A\5' MY'I_7-Y5#-9JF;ED;TL(F]MJRK58^"!*4)J_EFXQVQ.OFQ]N&B:J3:KZ5C/L M:6'/'U533?ZN;L<1^9Z(9JEV)DTMR/:?^073P4WIIO?Y/,FRVY7YN20BYHF- MVF5MJ')AT2_027FRSE<9 YYG6ZN"@4?Z9W,+/1>^IQS7/,4U2X*5-I928,_3 MK"?Y>YY4? AKW6@5AHWMI*AY-N^,FF:8NODTTEU M"$DN8Q906=!\J5E/HV[I;L<(#0E&R5 OZ)Q1'BY6V &>F@4^G][2[G=A-*^D M6_T-#/&'/#@I)>)>2$GY07:XG&1:>-?7/ ]9;YX_4=[A'RKOL&"BXYEPJJ#L MQ4 W'W=S@QH M.BM;XOG=5J.C,GS.5=*K8B3&/S?EV]4ZK F0;AD-I#J0-LU=M8W["Z/:NU#)&SU/)S MM ?5RBUM(+<4N:7(+:U";NGZJ:%++K2G!!+F?M6*&E6^WEYA+]O9J("7KBRW M%+>4AA;7_AZ&KA[^(@5==8&IJ>9*@>/7ODO7(1T4;;V]F0X3O>?MU&OMNMR- M7\B;"R6%9JY6(6^!?(1+ZE=[GYV#ZXETEV:HD"JNLR[\<*KG?$S5QPIEZ7(K MX236)555WYC^E&G%_.*6Q&R0TVY+>@YMCHW+2^.5EL:F3(/:=&(7VO5,)V.Y M.2S,S,M6;:36;)2M67'6SAGOE>'G#6[>[999\A!=9WF^D&1[Z_^)),LL.K'M M<-:D)^_0LVQ#/*@UFNMNB$M=5M.>YO0]:_$*'RS9Y*Q#.-W& MFU\*HU"R#!1*W#!77V@Q"HW[SN:>3+^@!Z?G6VGMR>BNC'H3;_J,%[.9Y/NR M)Z3X#?4T3#51_IR?Q*L-N$<' 69NK6K J,Z1U38B1T,RDM'9?-B-ZE?@W6<9 MO2IRYYDL&(I6/N6GC)Y*UKVG(F2W'%)2TQ'S-^9'MV##G8\64\25NW7QCY/5;);?GFLI(_9=+ESS1$++D M/' _II-+\_#-ZU;VK)\[O+X1V=9BM,ZL='V4V'W,Q[I2EGCJ92].]IZ;IKUT MJ5]W@=DE&9>66)27..LBF,:S0@HDZV%8A4V8M+0[V66I!>C.:)R\JNL]T/]T MDNB7]!UTNV>]_E]_-<^9KJ#RF"S]1AU^I-KY(/GUS7K1K^5 F%^S MNRTC0R\<,!Y6-+R)>QA &F?=K?'8U>H7S>\"CVX#<':*A+P5\I?^ZXVTMJ^& M2OK2^WQ1#5"ML\%JH/)>5J^C-(>'+7/R6@W[^0CAZ3PW\?2!S<9??Y6[AD2H M\REZA,?(F53+/,!0ROO>PY$=*B+F3!US!/P.D9G)I%GV5[J I&RG%WN# 91_F&6OF#GZ"S\$%)E7FZLW+_%4;A9:Y7J-JEFTPT3\_>L K_UYK>&W>S/3T3C)[$5LQE<33<8$](/ MQ@1CKL>8+;:,26,HMV?,+AB3G73BZ/C0"'S.NRUEF=K\8F'P8!""K"X,<&.V M<&/:AW!C?H1N;E"S-^QBR]^R6YW&SAP8F(P3-QD@3$A_=6$ 86Y!F!V&A/FB M'7^CN;L=/TP&LQT_COFW1>#3-)*V8&I:6XVE$E$G%'ZA,+@PB$!6%P:X,%NX M,.LW0]G]T45F5N7;/AFC^LS&/W=6FHTV#B>XR1]7TP!BA/17%P80XQ;$V.-* MC(LW^ 5BK(,8VLEWJ,DY\;LL^V%V* M.(P"LRW[2V,H.QB ?$JP7(1!G$13;0V\P)I$X6TDXH-5?[.8LLD&':Z1[_4& M:U;S<=]<(_D5;[9[=JG=Q4,%-GKC: E EJ!(X@2I?E2IWUP+^1:W; MFW:OBS0W=O*$,WV6L'P6C5<6I_%/+X"PB8 PQ[KJ\@X%);VI MO_"#<;VSFYT@>=*>UN:.UOH-]K^(O44O.G:CQ2<18IGSM-3L5\IZ')8)P,I\ ML K@Y7!RGMAY?5[!C_'RL]V2AB >#>5(BTIJ:"LDJG72+7X6^+(U9&ONM[# M;RF67Z;W(O)&FRU&Z=G_6GC6[B0IW<'65VV?];M_7:ANK[2*Y_ZRT@A+BI1U M[WA!(O\3+K5"2.Z$]5WJJOSM)G$2>6/TB9M'+_E31%(1W3.K&(NTQ,^)"&)A MR\^._"E)=RGOP@K'EA/'(HFE!9#B;8VU&KYP8A';UJ,36W_9V%ATYQJJ M%F_J&9>]WJ@W%OONGYYKM':VO?<&)A[7F#9 MUKYG!>06MSW7"V?]V^ZGM]U_P6U+^592^22<*+:$E")7BN!(E7U;K89M$93T M;V.@'I&^SK8B$4^$O-*#\)_.M 4I6XG_7?HU?^#6_)38\]%(FOPDOG:>R.S( M7Z.I<#][SM#SO<03L22G*WF+4>&E#UX\\L-X&HF+:42&^YMJ_5>013F/Y^?B7=]:+./,Y)B;:)T>-(#2.TW^] MD9PP$KY/KI&\H>QWXW2IWTOW\LZ9)N&OQNV2+H_O3&+Q+OWA5\NX9O6ZJ4"8 M.RYY)>?P12F>A4W&2/Y51+O8951V^__R;)+]X5&T["_;!NX4&WDK\%WLCQI21Z\E_:_$="U\^-PC@Y6$MR.X%]6%MN][97:85M)U9 QNTJWWIYCL2L7"BT9W: M=KOB0?@A6M;R4 D>RUYYR\0#!C@C6S@CG07.R%=C\*0?\B$W=WO><[?L>K_) M)N$;RLY,,#-V,+-F"M,^W@_\<,G(4Q,OU#N M[W#QA>D@]-H M=G+"585!8)#^ZL( MN.&V& 'Y$XL$5]XD\8 !7L467L5<]UIC[JX+UFYW.^06 N[<1(:K-H/+(/W5 MA0%YOS$Z/*:S._D9@5'$^=[J!U^_%"V_'C;09Z M2O!PC1)C>OC10(7IX7MR:5JS+HV:>C$_#V,7V_,NH_@_RRZK;.3HV%MI PNP M)Z ">^Z;/=L[9,]G P*=W?7_!'L>0Y3@I6&;55&""DZ _A;2 $G'Q I6CBL[ M5* -([N/(7:.D=V;8\FU52Q&=A_ ;>HL.4=YO4+T9MUN[S :L2.[SWZ:=Q5Y M )S,!PMP,C@9G+P73N[NAI-?4##?M[L=/@7SQT+)6H92$7JE^=]+(QQ_4Z.U MY:MFTO8>QGBG$F*FN\_]OD3'RS,*Z5O5K/OY^UIT(X=1XD:K:88NWD7I$TV< M6U$;1L+Y47/&\H'>.?ZC\Q2_L?[VS(._7Q8$W J9XBC %2MDO<_>L*,)@/\= MNI[SP[H9>2(8R:^Z#$9GST^F/)&'_Q(F\@N2T+H( T6,:M[>)R]P@A%-X;M) MY O4+C2NS)*\]0+K_[/WI4UN&TG:?Z6B=[RO%4'2!&^VQHIHM21/[]B20MV: MC?WD* +%)D8@0./H8W[]FUD 2(#@"5X%(#_8:EX JI[,?+*RLC+]B1-XW#:\ M&A,ON@"[[$W )LL0WTRXT2N8+/YF>5YR#78W:Y"R62D3M:#==B=3K^83-]U_ M<2L0'TQ/MQPO<(7W _QWG+T'UN6PTVMJ276Q0*X=8;@ X_O046]73%>@G#C MM.2$M]M@."%,S@C[0W"<#RGA;..\#C([,_?Z1!B!);Z,YS-\XWG"]V[LI(\3 MW<+X8G\3&!@&K^ ]]TSO 7GMLCAT&H/>3WO/_#$#Z!,!GIQE.<\P*TPRO<=F MV(S$!E<(/KQUIC-NO_[W?PW P7SKL3%"]R2AFYC"Q;+&K^@+,BYG7BIH(NK. MIM'D,^XG?PO^*V=N# <;(1XLI?AOKH^BV"O]#;AJY,S($4?NX*]731 "86$' M:QV>:OXZ\N]"1-_!29,-.Y57*N7.BMIJKP(%#CQ MO%))Y8KB--S-(:AVUKBBV%&5.35@((8AAB&B',*) M**=LV!'EJ $#48X:.!#E% (GHISB8D>4.8? MPF=CF-6+-66@P*9BTUXQ_ 5I3O^0UO03&M,_Y'')%3^?__F/ M^.2]S'-,7FO^E3M[%OB>_%Q;>\'$4!CO;F3E"0"BQ+.WNHM!IM.:WFYHF;%NZ1?W+<>VZ)^[F]^R!&_N+5$;)JOM\_1%9U<=D2GG*E MG%GE]491DT:$3M)?71B(T/,0>JODA*[ \=:UN;=:L]9L]HC>5=,B10T-R7\!;?OZ*630FHTLT[#D*+O+&4-]:]H#16E-<Q64*B!?(("UMO8E*=B M. %6,&\U*I6G\N#XW+I4'M<&9^T4:!1.253)J8NQP4E=2?6;P*ND\Z9J=YSS M($F.72#G@9R' M4S@/PTQ_OHLZ#RHGG[0P(C0@WZ$0BE!TWZ'45HJ7Z^: M(/#"LA @'+^.H)6ODX]RS4/?.=M!"Y,K,5GGKB._WC+(@%H-J,J9YD\F3.) MX$$E71+64X=/A7L,\UE9O^:HF!F0!PM,Z5 IY+ MI]_H[I@[6QW@D-R99'>6I'?&??9!Z)+;65NK,6#WX<7I^!PTJP@NNZ=L5IN* M5$2J6+14JUE6H-E?O7Q*AO5P2 9,#;FP#__FX2!$XM$3"ZJX=TIS^(:WI)S2FA6M8 MK@WS]__H=FNM?D^9D@UDV10G&.)UDG[B=>+UW7B]4V9>/WD5Y^V\KF[A13)E MBC,*!>G5P*%BZD#,KB(J^S-[M\S,?O*2RL3L)5 :51F%F%T-'"JF#L3L*J*R M/[/W"L'L%#HG0W3B' 6%C_:JGZ/P3Y)QA_=(74/_6R=V@W@Y*F*@L# MN4=YW*/^1=RC'XZQL*@WL4&M4J9"MUF#"3N:MT7&K=S&C:B=I+^Z,!"UYZ'V M08FIO=3)"F3.RFW.:$M#$1Q('52 @=@]#[L/2\SNI4Y8('-6;G-&[*X(#J0. M*L! [+X_NW>;S2*P.T71R1:=-F>!ZBH< ,*M,YT*5S>YQ69\)ESU,GEH4X,2 MJ"H+ SE&>1PC[9+IG N+^A4-:@GS%>BQYVOVAAQ%W9G=;=9(I.FJV@<(4%Q1$(2Z3PD268APIG M^J:@#NH**((:TUYY>Z0$#.0:*0L-:8@:,! _D/17%@;B!V6A(0U1 P:*M:J! M ZF#"C 082@+#6F(&C 08:B! ZF#"C 082@+#6D(G7 ].PC?&_<-YKMRN_8U ML7.DWHXJ!09I([NR,!!MY\FIR;0DNWGBIH5[Y)\<]YY;XGYN[SZ(D;]X=824 MFN_W#Y%575R63KNJH$MDTM2 @0B=I+^R,!"AYR'T3">RDA&ZTB=>FS5MT"5Z M5TV+%#5P%'=7! =2!Q5@(+[/P_>9UEHEXWLZ]DHFK; FC1A>$1Q('52 @1@^ M#\-G.FRIRO"T "=[=-H\!H7/OJJ?QW"L2MUTL(F2J@@&JL\TV"H/U9T=5JO5Z+ M?(I":%?1?8I2FSY%F8NK$$'(KRFL.R:U0&!QR M*XH/%;D5IW(K+ED-_*0=CVF\[+9+DV*4! MG =R'D[B/&0KJE[2>5 Y^43KM&KM7I^1.E5=/] MO8EL"=)+>A.ESC(A]Z&\#$7N@\+@D/M [@.Y#Z=P'UK9JJ='<1\N'SMH=_JU M7D>="B=%(?]0.&/9W"3&Y\@F^<7';"EXUS"?]AM\:JP_)<;6F_E+=PPEY',P M%:ZIY[]+IS$ YV'ME#;//*=_!]&QXX&\7Y<>=?7NQF/.F'T0NE0ZUM9JK-5L M-6O,GP@V!CU%'0D$?@G?L4P^,BW3?V6NL+@O#.8[S .MPR^, Q^4F;G.*[

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

      /3;NZ]?PMY$\^=A)O"^R2WK==&G)H=KD*D#N3!5 M2;VZP7.CC_+9WK]FK)G<,XF;1-T M^)/8I]BIZYLZS9?YJ@D"UY%NRS1;W R M/L,0TQ1N70\X[!V$<)J)%#]S+GCA=^*:Q#]?W=U_\:Y MX.#**!F![[BOZ2_54N6)\9/L.U(*O+E ?[O_[BUD.6I--YNY,*A0"*7'#%>> M"5>.'1\SO$34B7K^;C1($%$1;8C!SQ9-N/#K +@76'Y8!BG5N[,1VZ>DYB8L M32O%R-FO[JSDJ#6VE$U\@NB9^1,W+=E#"2&9P_%L6A8"XLKJS]RV ZE@D6J/ M31<,$>HU7$A@Y[@Q<#^WV*O@+A@$L*(VZJQIRRZ03/P%/X\U&*NR^?C#G[4W M>10U4V8NMZ)FR\9]!2='ZIH<]P<1_KM/HU\P1HM&O^HK9DT*Y\^M[4C, C?5 M(Z_;3S5O.S4&\"[.#7]4'0W4 YB4>@MF/S/K/\E:ZXD:Z^M:9,Z-A,47FB8- MYG0J##!0PD)2%;J0ET&]BZ!LOV%> !KI8-M@QJ=@&'R\GB%\X4Z!D0TV>@T) M.M,N,&16$==Q ]+64]7AI^A_C,1"G[D?J;.T"MQT&?A0/X2_:.R)'Z2&%IF0 M1RR_ /#WH6PR&9HXD.O!A]3]BVT'1^>11?"B,P>6[<8Z7 G3E<6S"P?T/9%\:#\QN8-ACZ TS<@[ C$Y?HN7TYJ1BC&[92 M+*25\;-F8KUMV)=9>LVC,$MM@X=JTV]S+IY[D1E__[!@)H>J8O[F$I",B'BJUM7W*=5;V< MP%VM7HTCA"ERAV6.'J'?,7:SS\HD7I1(-V;_Y4,ODSIYR>7#Q1<(6JW?[]5 M"=>NW.4:KM6,S3[P_#/^+\?,9S(E#HZP1'&56%# CY06^ P3?KS*&:O%/32O M2^<<9;0K7!HDN[E)?!IYHIPYP[ZG"?2&8++[8/3OR-7\)F;Q4!3-0-Z .H%>QHH,7 MN%TH)>&Z+QUXB9WQG[4W83AIA1L7!W26NWV!:X<._>)QC3ARL+C42@="+D8S M5^/ADM$'')*Q,(S':?VWWLKY,;WYPQJI_O1+OX+A)GX%5_?F$3K9UELV*?3C+UUC$><' M08HT 18;)D)6*;CMLJ4RUB0MS"W.^IA(]S^7K^EG4@Z27<3G5/.9G/=O*BM MUMK#2,TG;CRB&7\4]1$X]T4(.X>;A%FUBFE'?QGQP_W=FZ3JO_)M$'U3=#9>;U9 MKS)3\K.)QC#TE[UYG#!B]G!O+'H%D\7?'"4[93=KL)RZ$B6&A!MZR>25/9)# M-F67#+OMKM8:\GJ[J_-Z1^L;=6[TAW71ZVJ]WLCHMXW6'MDE2CGDV0W)BRP+ M)'G%(:;$*F=M9M(PDYET'_D-T8HQL^1,QO!NT.6 E=\#KL6.D9Q49(\QX3@P M'DW,ZE5IZ(ETHXP,=&.F,#),=D"G9NQ8L/KPKD^7IP97Q=0[3):4B^@P>?'7 MJR8@)RQL3J^#!SE_'24^RM>I9[GF@>^\C5(?P4;+%<-U_,=;%J5'-IM15W^:WE&[(RK--K(M[EX"85SG!509,J)DY1&@CA) M==C^5SX!)G]5QT[?/ F7/XHJ#3E.TZG2F&5*TL7)6*5Z1HH 0Z2M-!)$VJK# M1J1=B2%_D]O'9MC&O2J#OH6W,6LK""NK5678#\*=5FF\N+DI4W/?D(>F'CKD MH2F-!'EHJL-V\_CHBD?N5\I?N0/F-FW/U*LTZ']A"FZ5!IQ*2R+V5A A5:I% MKV6,**VBO$7Q$J>5, E_56*Q-E2O9I[TN,J+BJJE"G>H4T@E)17 24OZN?FA M2C@'5"ZRV>]E$TF/=U8T3+DY3AN.&SOY[B=S?/SNI;U:KZ_5NIV6,H4JJ7NI MXD:).)ND__0P_$T]!"0;$]FN(5O3-3KB%9[ M5^\&C7X[>892*11)F92 @:B$I)_6;15ED5W6;:FUVNK*N\=9J\VW[>56MC*K MLWI[4Z@TKK?9OGK7[K5JS4&VMIYZHE\QXW.L?>B392Z5?A\Z*I6K7M-Z\GXN M,NV5-T!JP$ N4)Y]XN/U#DH6$O?NHJKTO[F.YUW(^SFHMG"S-ZBUV]VC^3]D M?DIN?HA\2?H5#CT0[UXZ]+!VRWC_LO[>7ARLX+;Q!FIN7;WK=ANM/C&O:E*N M*@40\Y+T5Q<&HE]EH2$-40(&X@>2_NK"0/R@+#25UQ Z07M>!.*E?^Z]2\K< MHLPM@H%(^@30_)QC\[*7B9QBUX\[V:_M0^":<5O3L'U46=U]R MT!@,B795DW-528"XEZ2_NC 0 2L+#6F($C 0/Y#T5Q<&X@=EH:F\AESF0.41 MFB.7"99/CCL6((8&9Z M4$8++MT/@VA? 2XA%5'R7.BN?+X7,J7F],/V98]>UW\KNQ=NF[;5;335.3Y* M=DMY3B%^5P<+TA-UL2&2+Q9>I$OJ8D.6LJWFI3(T-G@*%81*W6R9KS% FKWP%V]"=T!BTP$7@AI5X(TB,#5P8+T1%UL MB,5W9_'M?77[6-4"LZ4NVE>7U$YYM2-Z4@<+TA-:7Q8;JOU[]0[+WJLWNXK< MN5?OH*/5^LT.K38+(?NJG#=?NPU6^C+883E8)L+8$4>9/.[./_6R*&0*TZZ; M_+2!KRI.F0U\VIP_QN;\T9VOCPO36[#-^78-IJ,V'#:5.6!&A7P4-TK$V23] MU86!"KTI"PUIB!(P$#^0]%<7!N('9:$A#5$"!N('DO[JPD#\H"PTE=<0ZE][ M7@3^)3PL",UM@XF7F=#_?WOOWIPXLJ0/?X+W.U3X7*)[?YA&W''O=(3MMF=\ MIMOVVNZ9G;\<0BJ,CH7$T<5N]M._F24)!.*.@)*4)W9[#.A2E9F5EZ>R,O&# M9[,W^%JRL[MDS24C>^%UE1QL(&N^Q?Y;JY+V_EN@2(-ZCT*-/MGX%9V9)554 M&%5$AIBDO[AL($,L+6MHA4C!!K(/)/W%90/9!VE90RM$"C:0?2#I+RX;R#Y( MRYJCK9" U!&EES'E$+MRGSP\7@#?ZL;;9I.?FNL_8G.K#;VI-^[GJ1&$>>L/ MN&-HV[^E7FXW_S%W%1R(-T]]SM[#@DVG:E"QB;W K1[358^SGFHXN&)\SNP> M\^!JU[.U5V8'*'5P*=<1^!6[>;BGIW3$_A_\T6;OJLO^OE.MJG;JT/JO..9% MS9/$CU]AZMY(M6JYGCPJ7-J5CDK^Z*AT M0CHJG7ETK)<5)4%'(9L[DK*:0U*V(U*VYY"R7JXE]VW8D#M,4*?$@$*X366\ M<7-4GJIJ,VV%3KXP5#GJRXO#7U#!&-')_E#+.'P(SP+RN$+;3*D>I*UJC?[Y MMS;PY[/+---VP<"&*FF(!>88\!(O-557'&!' PR:;!0]8B@(#&]E_*?&73?Z M/J$#PZ/'/'SLP#<]8V@:H.JZ(W&');;?\/Y(%]JQ4N6@#F.'E\NQZCUS; 5: M!J4ZG.=[S3-)H?KOVJ8>5_Z&!XZ-MHF[M8&=B$2'"=EAH=BRC4QL4S;C=P^R MX&!ZRCSANKF_*XD?YIC X'0Z?-+LP<"V0@$$UY$[Y@C9GS24: AU[G%G8%@3 M(>K:L$SQ0;KAP/*Q';C0\/I,=5T#90DDK^?8 P:S5P-%$J;6P(,LU63J<.BH M(*5PGRH6C,-9'_[J+2-;S)J@Y'*M9?67A=4T[71!_7.N-REJ^V?O:H M];GNF_RN-U_ESM&"+FK50&6[KC\(OGO"E?L$I+XPX<(E*G>./>>NI@XQNG) M66=XA3Q-^ AS\L @B(2N!+]YI!ZFA=YWH\5P84)X=0JLL4T8\%M$;C:P=6Z6 MA4U8ZXFXC"8#F3R_9YNF_8Z?$II]6X M:6*D!Z,;?PYC0_%Y:BQGJN_9G\/S\6 [377H\K/HC\\LC" KE1#92F0V[CW; M-!A!HPE.ZK;]L6*@ R:7<"<-U"&S.$-:_5=IYGG2%2P(8?[\9F]&QVO9FVVJGF$:WDB^?$&Q>O++ TK3)#8L84-%^-?%SF1> M59)@Z#M\*D6MEEJ*VCCK+)8;$6G-/\9*\T'U#IXI&358.:V>?&E270'IA/8? M\G& +"D)?G'90)9T"TM:SXQP/AOMZVG.X.&W)':S% M[(!JI)5P])4@!]D+9@)D90/YE%OXE,V]^I2H.:]!<=Z$>O/PNQSU*8^R4JZE MYU.20B&?,J,4EU6%%TSP964#6=(M+&DK#Y9TR2['M"55RLT&65+9A)8L*:GP M0@J^K&P@2[J%)6WGPI(NWN68MJ35GP53F5#>1*;N%*=@Z2,A,ISF,?XJA0OHQL$DN9IZ2_ M"RGXLK*!S.CF9K237@^)(YK1M4]PD!F53F+)C)+^+J3@R\H&,J-;F-'T6@@= MTXRN>WR#S*AT$DN[&L?7WW1ZXT@5JK!=#LG_T>5?#K(73/'+R@9R(\&-C+?[ M.W6Y=FK\/.T;.@SU+'0OC#>J;:IBB MX_2[Z/X>]("''PS+]7L]0S.P>WNL#[RN>BI3N[;OP=NYHQDN9T/5PX;RKF@N M/[1=F!XVV8;7!VVX1>/YH%M[T+:[R_OJFV$[P2P2X\/WCWNZXPRBQPU!+@JH4&;7,T,<^*9G#$T^.Q>W))[G"7GL.?8@F#\\ MTC/,8'311-P)0>Q><%?X#)C!"*;)PK[G,"J;#1T;]U)ADLS&KTUS>M!E%C-] M:R^]96WJC[OT)K7_UEB YP$7H_[VN@TCLFQ8+$!!%EL\, :T"^$B&@D&&, ( MS1X,;'R'K;V6(CK&7SM'P<\,@MD^2,@0V(0,!8:%O>W%TDMV)D$!1*[V86W! M A=WV^_6U$@2PT4!=_TAB%VPC&'*#A^HAC6Y2"@&PT(Z!](NI'7>E.9- GX- M92[^N& P0_C XS, H55!#,]Q,]#OPO28H[$R#FV=T.&&%S,M8NC'3K< MA;'#,X S< =2?TR>GN_YH/+FOR]8@T/? :T&#\1[462-WBA4KJC]<#3CEY:F MA *T@0MW.#Q0$B#PONLYHQ*\#N<+S]/Y&S?M(=(6O@5A%P3O@::T- /H8/*0 M-CA3V\.7P[?B=8[0V^,W!V.-J[_X2 9<=7T<1XS&<;K"6P1EA8+E__$-\)L$ MO^VDK@J48_3D=\,TA=HS+)_C]2"0R W49""9&G?=4!.I\66A#L#Y\G!:"X3( MX2^@^B(C-BT#R$&4W#C7NAQ(P6,FK9P+Y22J[^&!71:=V&68V;*FA^#,K]V7 ML+#"!//PZ!O3? <[:0$7)_X!7/BC_ A/=80DC=C_<<<&W]D?PB^&Z_H\M%)J M3#\(R[9"FH(U'7!26+LIJR+"66S M[T0S&L):/^T"C5]/U1Y,Z$PUW]61>\(^K9CXQ:* 9BOG.M[;; F%V,7X@I1: MFOUNZX;ZRAY128#J *'7RJO;(.9D\K>@X(79N@2[@>WMA"=_/38&CV##A!EV M"T.2#P8J*-MWP2R"<>4_-3[TF(M9@4&X 78K^(21R<>=8L#-M,%4X#NCI"99 MC[5&_5G7+.^YTZ@UE&I'/:TU-/6TKK3T4U5O=4YYLZ$TFUV]5=.K)V,[JI][ MLP_HM525P_].%:XII_6JWCKMU!N5TS9O:I5Z3:M6NY4-0 ;I#-W8"Q^?P][ MSD7."+BV;$E>JN':]:K2^O'X=2HQ-5%9/,PU=>]ZT6#=*(@:@7B"Z&%?;18UFV8UI<20VOBOTA'J Y/;V3M( MZ=\WUR'SJQ=U5PMA=U8( \%P_Q#3N+'N16PZEDSEL+)WVA@+6!,\]TZYE9 O M!NPWX8_2-F2;?U(_&V1; MRLD:61-Q@[ >5;/QQLU1F8D7G0;1O1:C@(BZ+1+:#*FA7JM(08>V% MW5BB#K==V(D6M,B14EOE@POHP9V2V_0:/H9D_17'XD8&Z5?'=C<.F5YM'=B64L2$ M3K=N>^$%8-654J.2%/S2-L1+K\?7(8FW1$^N(I[2*%7F$$\HS2WHEUX$?U#Z M+5:PJ^A7743 8$,ASZRSE6V-]^AW7?X?/[8SH^H!Q3"@ M/'_\(>9\6FDQWNL%DV;_4BU?=49,"2B#D*P1Y$-,4SSF%DY37NP76C8S;9! M)]BA%4&L7AIG4TS0D>D8UP)2;/(:>'@L)2;/6I_KOLGO>O-7W/Q%XF+T$2S: M"1;SA%MR3\#H"W")7I(8V M[U.HUB3]J&>#W_:.GP+)Y?IIM-^O3F9T-IL?MMG2VBA); E:/YD[O!K3UC") M4.Q_=FU'Y\XO)Q!O:MPT,:42YC3^'&;_B<]3 SY3?<_^'-R-.S&F.G3Y6?3' M9Q9EW%;"%,'$P>B])RZ&!Z%;Y6K['Y_#>49D%KM0++A0I K!O'%K>'$B\/0^ M["X)CC'%6#VP8CQN)NDX;;0N'S_B$<=N&:BI\@:&@M"NP(@ER/A5RJT5:RFB M6G'X]A?NC5RAE[5Z\SH_LXX MD'F3GF]DW@IHWI0.F3?Y^$+F+6.\(?,F/=_(O!71O+7)O,G'%_D[A050>U;'W>9*D,M MW\X3N32TX5=<-I!+LX5+DZ@B*UU-_!03VI-E$.63XH(I$TK#(_5=2,&7E0UD M1;>PHNG5M#Z>%5T[FYVLJ'0"2U:4U'=++KI+NZ5)>HOW&8BI$<,#Z%A/;1%B/%']'YG:DBJ$C,LS?31_4!9'%\D&C2KN#)< M]N&??VM7JY7/#X_GKOA3^?RQE+P:EW#\XA^QBW'-#[DCVK%;&@]MTXI'W$\] M OPM,$=HIX3]N3=5*[)&C>"3X3+7'P!3A&$#TQ,TD,8.T6DUA*[-> U[>VK1 M.DC7J]OVO$K!_RUL_!B0OUI6FD>DOC3Q8A8ZC+7+*UH;%:_!&/@7&*C8O2*U MV)H8]"+-.N9;'K.U6*%;AA7./LG,";).LK/M3S&"8JGI\S?NJ"^\2%,68!'[ M&E88+LJL,9N@/_&T$FCR4Z_;)=NKOOC2>!$Y5? MELAZWFGB#R%1YSI#E# A 9]:Y518E>^$BA7GUL36@CNU:Y=>8;BK__B&-[JQ M7,_Q\4OWSNMSYZFO6N%^W:T=:N4 $-ITXR_\I8*GHQ(:$*T2>SH8P1'K%7%>Z-T)ONC?6/7<,6T_9A5F2BKX* MCJC6FJ5*O4&%ZV439TDU#=E9DGZ9T08RL=*"">GU7M_0VAX:45A:7_U+ U1H M>FW92>-(!BU0^L2V'/A#P'_286SD\1"T66 VD-OSY<,6T$)Z%>Y7.CN!WI01 M6BBUZ^EY.J1I4A+GC])Q@$PL";[,H )95UE!A5JB%LJA[*QE$ MF](5CLV!X&@P>S>\?I^;6%O$5*.:5-P+JYZXW/-,H1N8W6-8HD0Z-(X\) )! M"\P&F""3XE*>:0S)(,$=L5HY"BQ* U;+K'^J'F\[ ,I2EI)PPUY]TO6J6)5 M<'TF!ZM:Z]8<*[:SM VJT#S""SG@5;068],ZD29-'W"W\\ZOOM$I-Y*==\DK*&[?]WCGEME%FV@%/VE%"F;DE<4'8R1C5$[-! M*[%%O:G;M?3.\XM_'CBH31?6\B-WW@R-![O;RKYQ[EC =.IR[4SWG7=0/"ZW M3K[T;-]A(ZXZ[JRDEQBH':V/G90#LH9C9VXP>.SA#*,OLP?0M$,#Z8LL6-0X M^H5;8 !,<\3ZZAMG;[8'6E$T;8;U;(!$Z4R8Z^#85M0+'8]LN3Z,(K!FS!^" MT7L1_;7P,MOWX,H7> %>B!R%AY;#MN-S1^/U58_I-DB1%TB . KF=_\=OJPW MWI\HLR>8-K)9M4;P(,U^L4#.W>!!8==J+28%C ==YO$9#/MC,VQP#Y<[*D[L MU#0LSN V(*@0NV54%<_ "X"LAA/*;#GC"S9.3QV\/^1!P$O\!BB&#."#H6F/ M. S$L 1F'/#!LT%!LA[V&'M#KR$XLW<>+&-@!,@TRA.23$@S$$Z'K^?#T$%; MIJAC>)N]JR[[NV68#,A@ B=+S.0NBKUJL;^OY7)-N5GS#^ 1M+J0I*5( M5QIOW!R5 PN_3#V-5=F.JV:LYE)>/@G\\MPT;0V3\.?@%CJQXT\W]VTP53X/Z.D)OJY MUJ@_ZYKE/?=:JLKA?Z<*UY33>E5OG7;JCU2KVF5:O=R@9HC5!NL@ ' M_XT-Q:-ARP-?_ #;B>@%CNY+MF,B/$$(H:QI!M$H+ H1D4-8"&I!M2S\CP'. M*D3.@R#$7HY8I%=N>?^(A6 C$.!(R 43=CA$!$#_)LQ1MB0I'EV_!/UZV.;9 M _4#EM;:1W>,U3*U>Y<,42QH8ZSBQR*L8FG0%85;G2#*VCB*J"MYBIPWX>YL M=%)+&Y2H'S!M^@BDW2 7DS:/8(3;#DN\B0V/PX*AU2$D>4DEW0J7H"W-V9*J[C/:""$-2 #]_5G\; 'X0SWXEFZV,W MBR';V26\D9TOCIX)/83@1ZE@A&_-CC6Q[A@NCA7HK4?=DZTCA MCV#S[2MW-<<8;E-"#,80XY!X2V 7@]WJA1H1/5]7./5C[@8&AHN[HPW(29 % MI#J%^,I![U]L*(I=8:UO\+=Q/4B4>*,'U-),PS)@H<#: ?FWA^("8!L\")[C M!AZ?PP)["> M#AI)L'R11>UR$$PQMO=H//@!9B->BP +QPUTPPHJ9':!E([=Q62+\E3\/YTA MIM3K1W#(;BU!?T.V+OK,/1;XD2NI-\M*)$Y*82)+X1.#).1 MUC!+TYB "/DA?L$13B>@=+F)]LD-3,0B[34#<'S$,H.]B+BBOY@ M@1G>M-)2;Q6W-1+(U7[BE136ZK3SW5JZ<;I+L-)(@#_')4F**213Z0;)S>4% M'F^MTY[R>+4^UWV3W_7F:ZW92073.;=TA!<0>PG4G^OZ@T"+/>%B>@+"70"9 M7Y>0<8YX@..L#G''S_'Y!OM%4CI4T]AGZZXWM$K'8A=4=^-E$O/!FE] M%YYKF$1^J@99Y.#?CFE^ELK6X/SM/WALF&TLDH_#?.U?3D#5:-PT,2,;AC?^ M'.9ZB\]3@SE3?<_^'&9[@V-CJD.7GT5_?&9A1GBE$M:O39QC/U!.>K-9;K6W M+5JS,&=CE[3T!%BPVU&,;!Z/"L6CW"3>R,J;>KE#O)&4-[1NUN<-# 4#&#PU M)<.YP=JJ937!!XK"MK]PR_@*(Z[5N6+YF75B=[Q(D\> 2;;#BD>M1"4)7V0I MZ[U0?X;^?'Z/NB-@(3;KWFP3@G'3\$;RU3 4_D=^>2!K@4_ADA>H-H"L?"#Q MIZZ;Q65#%;40%2U9MO,X]!T^M6V17F+E.$DR!M)'/L,?8Y?A0?72V/,0>VCA M?N8Z>Q[5\9;'J2A *TWU65(JH>3^X_@U9HOKVS\8[NMI#[.F#(SG,8_*@84J M7W$KTHOJOHT,;AZM!R?Y-9*1G=QZ.?A XD\(6W'9 M0&[]YFY]>M5RE\'VD=L@!6@O3R]8TBB$V1^?^.-\'#Q1+%]X2SX-(?4%Y@.) M/X%JQ64#N?33]3SQA/NI\?.T;^@PU+/0B6^=$P>3@_(G6,$G?@AZ_8H&BVIQ-.87F>FN#JZ["XK, M[*]#U_I1]IQ67?56N3VGD-VD'#16D5AUHGS]@HX+Z7V,+JJ'X,2,6*N]5&F);2[JP)+LXNM4>%\I:5M[H*BR' M-._:)<\/>AVQ>]_1^D!W=F^J5GIUN;:FY%X=ER7DN+'8N?_BNYZH.!/T^XHJ MZ*@ZJ >$)N [P9:(Y/-HR#[\\V_M:K7R^>KQ_E[\J7S^&!66[G(-5 /CO5Y0 M=82%->2Z6+L"Z[7HZH@-'0/KW=A!&Z?H4O'SN%K/BX'=H81V7JWG\+Z_E="K7$K(KAX5T1NO&^'EL_U9J4$ M@TDJ*'?%F,)[X($] M+NH?A57$0V;BA<+.J[[7MQU1**D[B@L@2I'2^NRRKHT-R^ ^W7! *FPG,%@X M3.R-H:,X_4NU?-49L;HHI:24MRJVEP/]&=2E"JIUQNTN"TL5Q>.4A45_DG7, MQH5_XL^\M%T/!#]IQ2 M;5:T=FD\TTQ&284J$=1HENMU^E4^?LAX.%^^\B9*N;&B- W5 M-RG&K./%,XLT;W1XJ+2)?'PARY8QWI!EDYYO9-F*-&\JVB4G7\BR98PW9-FD MYQM9MB+-&S?/R++)QQ>R;%GBC63'C4-Q9JYR7=@1RRA M_#)"UB-_!4O3_KM\'*@(U[K@*=H;-WE*9#>DU>3IQM+L 7^,=N&_A8D/,QUH MA5(]M_2O$Y4:OF&M5EBU9=D]T5'+VLD7I5GJ--(KH4)J).?:G(PH23\943*B MZQG1YMZ:1Z9F1)W(AK:W#T1+C5J#;*ALXBIKU8'"V=#CE%Q*X7!"GMCR*[>XHYIBKT/5!X85 M'C1\.UK[A-VW!_/$'UFUU7J)+618)&!59>T\)/)C-_-C$^VG#NC'AHH;W-CS M*;6]ERV56JFE)$L[4&J/C&*<]>0>X@59;V(56>^]6^]$SG54E.I MD_'.A!23\29>D/'.#:O(>._+>"=:2,AHO%/91*JT:F2\,R'%9+QEYL5QCM$L MVV[2;1\+@57+Q6'+DZA-Z2XH]7:LO?$E2Z> /)(WVRGB#1)UKA>UC'F%=(RE M39DZ#"O):9YRFANI.\WI["_5*J5FLRU-JM0B+W>A+2B42CFN>2!3+0\OR%23 MJ293O1]3G>CBDH*I3F,SJ5E2%'EZF9*EEMCZ5.]/]* MPU*GL'-4+34K%%-G0^JDW3DB2_W_S>^DF5IWRE4]8S+:\_) M-0-[]+GLQM(2S4QS.WE8F_ "4"27\?YLUX:E6AKV1!SG5;F%(LLZHG82&P:7JF.!1ZD"WI7*/$G?LB^ MA1NTJES?\=E:_U7+\"B/?<.N@LC(H$'LN0>FM^L'??[$8A!]184WT8?Q<<=E MRXA>KR2J3$T:4WM8H+6J-0JU1"MT:A=I9RL@7LFP9XPU9-NGY1I:M M2/.F=I9R\H4L6\9X0Y9->KZ192O2O*F=I9Q\D>6L]T+=&6+'^# MD2\U5K@T!*1@@UD,B1A!*T'*=A )D->WA1^B1RU\]CWLRL*,FYF9^NM4JV97K]Y,K-D9LG,2J/ RVQN8 MV>75%#_(Q>9V829I:3@PQ+_*[?L@6%16K <[)!W-S)>MIC<&EGY M-.W;;,^K7#LVLC*O\%O^FUJ7[8VNR\;*^E@JZJXG>A6X-Z[KM!"C:0)=S*$M;W8@F7Y @OMX2U M5JG=[)2J'84LH6S2)>O*)TLH"2-H/4C!!K*$6UG"1,O ="SAXC3>Y990:924 M6K.D=%ID"663+EEJ]Z;0Y"UGH/8W[KIGR=[/&W'+O(;I_W&9N0WOMKZ MJ[_VW<]["F>TH["_W''UE6WCR+8KBK5SZEYC2EI=[F:0$@C<,=5 M&&1Y9>8.6=X9WM8>3>_66QA*H]1LI;>13^97RI(F9'F+J<[) M\F:&561Y]V=YV_NTO-MOF71*S7:53&\FQ"Z%,B=4W#QMIJQQ*(#Y+M>9815I MYT2S!T/?P\E;4?7W(7<"XLS6@2\8769+WI=8%S?%Q6:3;IB^%[09IK*!LK)2 MQFR"^#'&N1X;U17,""^3QU+WQ\]<>^E;..F=33*:8GZZR&HZM_2O@?HNS)D7 M*DLHKX8A6RXS=\B6%X&79,N/9LO;B<8X>[#E.YW::=1*384:YF1# ,F6$W?( MEA>9EV3+CV?+$\UW]F'+M]Y$JYI[1+M,1.+O%&)TWO6*'9)WFA:W:>.7K>4'-%=TK@F[:D6 M.J6)5E57JF,!R]Q[[@A'-*5=H>JD=]67:CG%.B_[RM8B+U/61&DRSV2><[7( MR#R3>5Y@GA,52WN+F62E7Y3_'1.:9S+/$C"'SG!]>DGDF\[S /"?* MJ.YDGA?OW4Q'SZWT:L.1>3[T6:=/8A\ OM6-M\TF/C7/?\3&WAQZ,R8GD(Y; M?\ =0XOV*L./$_FM5Q);DH]:G^N^R>]ZYY9G"(C>>../7/,=PS.X>_53,WV= MZ]>./;@4IV-4E+^[WJS@/\%@+TQ;>]T,,.*NI@Y1Z3@^WU NXN2IE]O-?\SE M[C)!2)'S3WW.>K9IVN]X>FAH>S J0S7-$8MHRMPQ44ML"(H%G2"=@0I2X?]< M6*#6&W?PJYDM([&% O>\@ND$VDAL>FO<-%'?P!C'GT--)CY/C>5,]3W['$9NN!=L4;K7)5KA("F76V4TMKV[H8Y_[X$1*Y"ZMY1ZN8*F]@*$ ) M2_@U$B1%*6M7#"@.W_[BJL.N8%SZK-+.\ZR_XDY(*NWM][>=+_P02H\Y/B,* MW]!,#C94J)7A-@>,$ZT,=]S#/Q\ NY<5[0W?L^-K+D;S'W#^TW"C5UP-AJ8] MXOP1-Z?OA$[_+KR^Y:=.;FZOEYYZ;I;:G5:IVDJO@ GIIISK)K+5DC""UH,4 M;"!;O96M;A;35B\Y@K+:5C=;2JE1EZ?0/^DFR743V6I)&$'K00HVD*W>RE:W M"FJK%Y]'666K&R6EUBA5F_(<5"'=E/+VQ-ZV=G._/?'#>N,NGJ$ />,YAH9_ M!EI'OGJ1Y$%)PHC":RDYV$ >U%8>5#N_'M3#6(D+'RJ-78E:HU/J2-0@A;22 MY%J)K+0DC*#U( 4;R$IO9:43C [4N>;$\UCUY4 M=.M.,N1/';^H*#6(RS(ODY5%J4'"8$DVT[<(=M> M9%Z2;3^>;4\TZ3J ;=_I;$:[46HI\IS-R(IM#X0NDKD#=9)8N%%RC$8B:S86 MJ342QYOON>6"C)U;^IW7Y\Z][7H.]PR'#V 4%]SB/<-SOQJN9MJN?^CV(F:FW6,V-V(D?O@W)C,>"-4A)-1%#I MJ=:(J;H]Q$,O:C31B22(SO"N^H;JD UQ_IK]!L)EO3#5-!D/CZNY988=5L+; MQ74J-EMQ)U=@1Y.!^LJQ9\FI>.P09.[44W\*B1*=3T1E,'^(E^+X!NI/8^ / M@D>)-B*JT,3,Y1[KCL0U-^B=6JK)'O@;MWS.'KGS9F@\&-"B!='N)#I%?059 M=8QA8 &^@OA;7+^,#6SI@D')<#=:&E\"6LVNX(!V[ZH+4^58.1)I$?1TX=B( M)B2G [3QM#ZR8>C8;P:.#"Y#WG:"F4>\?3> 38+NXSNFR6WWV"H3.P0%,&5@ M$]ID'KU@(N%I1N=[^.II>CH86MSUQ(\[@>*@9' EGE9AM5:2N07_P#E&>Y[_5M\&U& MMS"<>!Y'M$C"-1(ND9N'Q[5/1\1(/"=[0U 85R.H.>/-T'W5'%,T3F]FXHR" M]0RB#2X+#]H9P5"8XYNH1Z[##DU M9:IA@Z9 ?%Q9I76_V3E6UJ9UV>@U=[56:NMI5-O"-E*I,SE&]S,9D MCJ\_I#0JA8#6;$SL%+RGA8' H7VI_\;ZV]%$+A:EIIU\N4.G$:^=OF-Z'K&Z MR4+)1;IM[*/!*@>/G+E^UX585G5&['<;_OO*'C6#6QK,]-=!]SZ;Q#TPD@MP>9P+QW;/=7"/;,?]=C]]_]-HB%T5'0??A)2)[KP.2'8>42QV M-D&I5I:;QL66,>3C/__6!EW\V0VZ^I484-/U0:QPS03\ -;@MUI?=7$IP:T" MT\$+') 0[%2H,E ]0_AU8UY5XKRZ% ^9<.2N%RS3T9T5+-M;[N$Z7N;8'ID9 M:W&E7I['%R>8*S9X[ 5*"ELRNCA?Y-GOCS>GML:]A#VQR!14)B_=M_ 7K@O8XZ')70-><_@:4P.]'"<6-[W4FV!A6&&FX' M9^NN:QHO KR2EU6+O8%JM5%.^I21/Q"$,Q&W0+D-# LF@*X[T VYHP>D5CVQ M=F#=1 M%%ZT[7V! @AMA\,C_@^XI+">0"^8)&X%/&6O*X*JA:HP=R9#])> 2 M2 ?$M"JL+?1-U(*">TLQ U$T7#!S#![ MS-9@]0]5M .CV:%&LRTQ&^\.U+C7!V/TT@]:D ;:(J(A/ ;?Y<9$'X)(W=?P M42) <*=C2"0I/B>HW5T"41;UO(.(W!-#&MI@<)CN"V0@FN>R:=HQ>FVNQVIQ M/3:EP<8/C;29(;/^VBJ4]<;K >8&-!?-8E'T4;.H8^,!3(4@;WMQ9ZJ04]<' MHX3WE9@0_N &-[AC6L[#<93'[DZFH3)< 8A^(I46";(()L$E^S?$*Z)E+W<\ MU4"0#"X,PDUTW&Q-\YW *V/7O.OXZ+YA*#&]SL9J:POS4)]:$8ZM<:Z[N+,Q M-^8!RW[7NW'1]= X1GA2KA&(N:J5^OB/Q18$ELH2"S++/3O&A'HIQ@>'#X!Y M>,D6#&C$&8!3L&$IBB$1 MZ:MKPV[#<(ZH7_#SPQ]WH+I E.%VM.TOCCJ8BZ2LE?,Q1AV2^GL>#G&<;6*E M7@O-3=^)9C0$ 3CM.EQ]/55[,*$SU7Q71[#P/JV8^,)@?JNMO 0P,Y]"[&(1 M/3@"^$'%X8D M'X1ZL'T7?!(7W7B-#[V@U%VP(0?!0_ )B*5^W,A]VTT;3&UR@XH*X=0@]HGC MNWN!5'.",\ZXDIBZH8>[,N"+@LAOX=5L ZC+:5V7[TBL\"##D!E#(I698\ [ M!""TN(;IJB8ZU;"0./<$I@1&V@A=;;@4?.WR.G PN\/K$S%[&.J)1'@J9KF\ #DFB:)B@.)MG#@F:[AXK^(DEC!((*Q>8@SW/3$\-[[W)IZ*VY9 MN\GI3[8,YX *!L1CMF]B(4_=UV9'%C%&]28Q;9F=BR WL<-82KX:20Z.[ (J MYR3H76?WM;3,.U^@1]IQ/7(32M%5L&^;:;6R]G&]4Y=KF/KW#GK9Y=;)%\M. MZIOQ^HJVM-\#-#/ MGA+M%NXP)]( _L<'<>...1J[EC=6P'8@\&'3YM9V. ^Q,]PH3YFW.1( -FX= M0_C(32YJ,H\I'?/BOX*CRC[XENKK!ESS,::$%_&P7DF<_7G4^F Q4.%QE\K# M3 I0R'$V/[B9"6G.]J3"L@)-[%7MP8T&G\.TZ[%YZFQ MG*F^9W\.$Z]A[J8Z=/E9],=G%ITOJ(2URQ+U6?9>,R<80;U2KE;EZ]:>Q5,H M*75_+M,_9^!-S 45!N_G"CU$PFJ335:\P[KS3TQ5!S&/?7!W6;?X<>^ MRZXP%CEZ>W5JFTX&)P.<(N,C-6_&QJ B*_:MM -I?M+\^>'KOWR+LUJ%%#\I?E+\15KXI-#SR=='/O3" M#6[2Z@?7ZNLZCJ3]2?M+QQ32_IGG:SR[B90_*?]C\R7%;9>]%3<,=V+R6U3R MF^VZK.?8 V8/N2,25+;N!;^_$I/"1.>7";)6]ES#Q!:J NO?Y6.1LI8C5.RZ MJA\V3^).E(RZ"[2C]1*4($.UN6Y69*4V60I21+29:2+"592K*42J*LX1:6LA59RLZNEK+6+#6;%%-*)UAD*WE$IE4;N!C2UEO5EJUZMD*643K(^I;!WO+4HE#M-"EV@ZED[2[;H?&"K&KGN<873^HDHX],^W!P+8V+LR>(2($1C_X MEXG&W]ATG3MN273'T40M>]TP?6_[$L>4Z):[1+="*6I9\]C((UOMD04M685V M=Z>\L]:L=W:E.MA?U[WGSB->?H'J[]S2OP;*;]M=Y>K$7?M2*3?JE)8FFR!1 M C?9M4(*/MDU&;FRHUU+-(';T:XMVDN>L6MMLFNR"1+9-;)KA11\LFLR>MFN=%MDUV01IWG[P)[$5"=^&_9NI.71>>W5FT;)3?TYJ#DW-H:DYM%34 MI^;0V>44&1^I>4,]A3+/U^_%; ZM=,@$%UFQ;Z4=2/.3YL\/7XO9')H4_]%U MAYR*OS@+GQ1Z/OE:X.;0$FAUZ@]*VC^S3"'MGWF^%K;$EJ3Y*%=$IJ3Y)"ON54CN7.C;R43GB^&_[8N6IXNU1OTK$"Z>2* MCA60H21#288R-VS;PE#NW,<+[&,],I0[%Q]7E%);H8(IT@D664JRE&0IR5+F MAFU;6,I$"ZHM+&4KLI0[%S%7JJ56C3I>2B=89"G)4I*E)$N9&[9M82D3K:PV MMY3AH7;X8^=BZ$JSI+0III1.L*@WM!S%T.7K"D ."S5CD-@?H:XK!V:"N6]NYLK=T@"R>;2)&% M(PM72,$G"R\G3 M=JU&=DTZ02*[1G:MD()/=DU&KNQHUQ+EG7:T:XMVD&?L6HWLFFR"1':-[%HA M!9_LFHQBXXC8DJ]'DZH[T0S&JHO_+3KK[<^?Y\K?SVU^O'I]O;I^_WCR>__IP=?7] MZO;I\?G/FZ??GL\O+T^^X)6L4V;AI>SFEIW??F53ES.\G,'E=S]NG\[QB[O; MZ./-[:_BANN;V_/;RYOS;WCKY;>[QQ\/5X\+1!(IUEPI*?5RNWE48;F%W\JI MK*JX&.QS]1[C/8<7Z_/GR[O;IX>[;X_/]P]WEU=?4=0B23X'40Y_%7(YN6*C MF3<7Z4L,##:C-LYPSDUU&EVE)W4 NOZL6J*P!#.N??VN#=_7995?@K?BB M$CZS>\SV'?;5<#73=GV'LTMXC&.;KDAEN7=LC>OPM;L3/8+%F28!=EJJ?W(V M4 W+@_]G2)1JY;,^(8 6)\!P3("2N%+YS%07_,2>87&=P?T/O@EC56KJJ=+X MP#^*FY2&'GX"QX\[S.MS=O53ZZO6"V?GFE>";U2/80J5SM'-A$=Y-N.6>+_X MS;""9$7DD'^WPH>UX;G#C.V<]P^3,!HOE=P>&MV , MS'#9!^4CW*QA=1^]%$S5=?%/UQ\ -X$WNIA/\ +X\&YX_?"E'O (4\$,6W>9 M.P3'N6=,AO1X=3F6-D=0")^#4PK^^E %2FF:/_!-U0O?@MEC$ QHX@N8*LKE M8"R\)7BT9OKH^XI?A@Y\-H:JR?A/KOF>\<9#AD7? XM4^!/^LGL]0Q-)6D 5 M&+-K6R*-#<>#SW,-$#O583W?$LX]7 A,5H= $7@'HYJF_2ZF;8Y$H.#B ME4";%]41HQJS:2)+99:G97-NC18N#K@*F.6!0\3Z0*9W;IH3V<9K@^8;*%R: M:N&=;X8.4FH!,<&9 HZ()$+5!;(!US@J)E7K&_P-28LBA4]#ZH8C8';WWUQ# MM@=CF4@*LSC*,0P?G@U,- VXQ(#U\6]??Q$7@)#R4 6&#]=LUSOM<@O6M0?C M,8,V(7UCB.,8VJYKX.@63+[,[F9$%=>)>.Y0=3P#Q3&N;.>);BBBJT2X% T< MEP@\G_=Z 1$LF#$^'[^\M =#U1J-%^!JW8;B#C?'^R>Q:J5:*3,(I^%5_A!& M[_I:?TPWVRKM.A<<#*YH,1707!&37ZR8P,3(ML8TWKD3HPE#'3M?NDS^QLV9 M60<>SWCJ&ZU<$,R^X$M9-MKWUZ16+QA#D!Z0\6.AP.^,N@@D&* '0$8&&"5P&\5D'98^& MP8C(I<7)-9%U)R(7^[#$;^A-^0V]17[#QS+[,?[!]6&!O DK))2EI>]3[4P; M8UQ)PE68KX3PXO4)$ZS"_\;F>Y$L32^426.WZ27ZWY_PGB^8>0TCL0//0W,, M>+&A,I=[R$>@2'<4J45PASPN;,LC\MIV\/UWSHMJ&?\7J/Q(ASZ!VM AL _N M<@65)][B["(1ZZ@JOGX15HY=.^J O]O.:^0U?JA6E-K'2*&*P1IN2,? :,3( M.Z,9-Z/G.Q TI@-WI.XB/9BA=8YC&7(Q('37#!0?>.WW;=_FEC?;+9=^^W9VC4PD>[$+C#7R. M'S XW!(2_B[H.V_LP1M.^/C0[0Y^N/'X@+6#-0+2>VY9_M@DH$Q? ]F94CG] M/3_6\\LW" Z\2#D$.N9JEG%1S)PG;_^":RH(,D[/L/H<>SG/#K0UT,?FS,Y\1OIE<-!&8]WT.? M,(I%,:J&R!L/H: 2+^Q6A#<].7E_:;#H$@\L'@U\\WST\W]Q>WSU\ M/W^ZN;N-$/"+,KM[^NWJ@<5^R_:J_),+&Z#Y#MHLD&&,AH1>"'Z\(->N1#+P!#VKBLE$: "0[$LF0?<*6.@X$5CPQ#@(_L MO6]H_0C[*MKJXZ.'W3#@15K(]J)]O2K4V;WW#$=V^N78E>"IC*"N ]1MEXR)BPS4&^K MZ04W#@TT;,(C'''5"=X+4_JN.C#=0"O!O^^&+&SW.'L$F@YUV@VO8!U"J9N!/F*,2B[TR MN/DJ9,;X'3BW/PPD\)BL,%+[A>,[)M9_^NZI!T^1-"87ABLTK) O((^([R%6 MY$&L@%1&$[&:(<*+\AW7AV6!#PJ>[L69*1:(D#,S>!GP6^R& "-5D\]EC)@: M@B2A8Q4DYX3>SP#Q03P./8-!LCXW]2@ '[^^'!Z@?A*^F7AZ>-MDA!,$9"GO M85AF8) ,RQ>&-_ /!83C#X4'"*89Y=+->"B+U(*+^(N-*&EX.;8HZW M?!!=1W%R."C:+B+Z/0P8-!YYX,O?'NQXN6+C2D_6S;W0-C]7+K0,S+:^) M+(V#)K+LB=;2^UM?[L\?GMC-S/%Q=/MT]/#Y?_>_5Y8^G MFS^NGJ]O+J_@B\N[A_N[T(54*F4VOK3$QM>RN^O@:I%9(>YX.'^Z8K_>_7'U M@.D_5]G7QW.WZ86Y0VN.:)FP3]U@RTJ-P'^QG85[ 8;PN, C_#EB8R DW.-L"C GD<<5N;!?(Q=6_'II.T.! ME;!?,>#$:).'=X^MD6%IT54A@KD4GIRR40LWZ3=4[<==KDILD5[>?;^_NGV, MQWF*4HZMS/@%A5V$?KK^>[/ M6U#]O]W#J_N7V^N+J]NH[$L5IFT:5L?"E8#!9>S<35-R)%-/A=6)'O MY[?GOXHT4_'QX>H;6)2O[/'I[O+WW^Z^?;UZ@$N>GN!R$NMUQ/H1I-HQP&F_ M>[= *8<)+Y=A-'@A$F($MA?\+@1].GV Q'\B_K6QK O!!.6*4OWX'(KI\_UY M)/ZU\EC0IRZ=DFIT)O]B3P_GH*DOQ26E,-LZ<+;8S>W7*]#C7Z^*[$MM).\/ M/(AF[T42('N*A;LDS-/"7'^^?[BYO;RY/__V/,G>?[Z^NGH$+?_PQTUT'$"I ME]GXTGBB/UXJ!#:X/.L)_@>347A\#]-@0RCG?#BT#GP> M'V9Z?GP"PXW>Z?/CY6^1>FQ@Y!5<6HH=?!I?R^#:JZ\_OF5=/WY0/[( H\9, M>;&K;6M^F-GA\ FZB_MQXQRB8-/X+.-35S[.XVP:#)7FO.V32).W1 -H83\F M&__Q%)X5C [-7I!(EO$-&3S$DN/U? Z.C*OUN2XRE<.-G/4DP!:)MD(&@@-* MH:<4=Y] )+@A-DWA*7A*0Q,Y^B);BKMHY,:NT\J79EV0:A_')B)O7E:+O*Q# M;#Q-H?E'&\75_X9;!'(,1ZPH@9*,Q[7/J@=AT8F@''X73U4ZOYQ43IC&31.+ M(E0NE:8X^^M1M-)(%(Z386I; M"JYG5F9\ZV,F"=E:66SMPM6ZAODMW'+].DFK)1N_K:B.C4$E9M=QE'-EB^0O M)G^X%Y>*X.U(^%P+9J-(\(2[)>^R[#73=FSQRK?QBOWTZ=[0^UO'^Q/47U?FDJY[ZJ3+NTR3^ M;#3KC4Y%:5>JG5:]]NG5UD_YSYKR7*O4RGUOL.X*$0/6L>*]R$$]$\G($(YS M3'<-2SOA49D''A;#Q).0P6$<'IR]B;;AP[,YO]NZH;Z.BPKA!>7Q2E-W6FW[ M]YAP9"<(GDA$P-\HGI?FI"@[4'%$I1BR7?I">J7!( M\IGO/^))'4C*%)*TL^=-.-T^G5:B[C%^CQ[L]1(B YHP[C8B YC7 T M4YX3 L@<9$7X*-"3:6PA81;+P<-JY3_C'!QEF&C95. M3:DVE':U7:DKG4]Z YC64G3^LZZD!1N+JONBE[SHIBDZ>,7SCPDC)HQXE?Y] M/%4^G4L#[<@D(P02C\&_6NVT6FU5:RT2%$*)EPA*.DX;H<1YEI'.IVJ=0&+9 MH5("B>6?.X'$F0#9""3.%7T))":0..,.2.9\QL4@,>46$TB<2Y!X7F[Q,BSX MQH(W>;8CFA(KK<],<,EEYR\.%QW/2BQHAO;(AQ['\OJ!A+1+#(*Q1@D;KZE! M&G()VT5@*K(ZL*V7L!T;=HT%BGCB!T_TM0U?*+[IV6(P+K/@(>("AQL6 = $ M0*\%0#-I8".9A(00:$*@"8'>$(&F/&5"H F!SCX.2PBT_',G!#H3"!XAT+FB M+R'0A$!GW ')G,^X&(%N$ )-"'0.$.AFIUI5X@AT(_4T95-U77;!'ONJP]F? MJH-X3)X1MOSXM<496;SAKG)%J,GOVH[>?3C&< M["Q@783RR3]W0ODR@9(0RI+7>K5.9U7-L*8:Y6*AUV)RH7 M!,W1[AV[9W@NN[$\[G#78_>F2CFHA"BO@RA+@P'))"&$)Q.>3'CRIGBR/)4K M"$^64TBHC&T&0%6"D^6?.\')F8#C"$[.%7T)3B8X.0\.B-Q.8IIP"GX\J]'N#GQM'A)\IXUD6SS=S$ !!S@0Y$^0L M8Q"2.4%!_TX:$2'(64XA(<@Y \ K0<[RSYT@YTQ =@0YYXJ^!#D3Y)P'!T1N M)S%-R+E)D#-!SGG(>$XV^6NF6#.CS:[^XQO>B"#D8WNRF0OIJ9$?@<@$(LL9 M5F1.4-!CDT9$"$264TBHD5\6L%1"D>6?.Z'(F4#A"$7.%7T)1284.0\.B-Q> M8IHH"G>6?.\'.F8#M"';.%7T)=B;8.0\.B-Q>8IJP&G1^XZSF&YO$(:OYA&5X,?W[BSL 5?UW:EF[@$]U5]Q$X+:6#G#FH@,!I M J<)G)8S6LF7F"8XW2%PFL#I?(+3G70K:PR&ICWB/(2;[WT8F^H2F$Q@,H')DCKE MF9,1 I,)3%X73.Y((R($)LLI) 0F9P%2)3!9_KD3F)P),([ Y%S1E\!D I/S MX(#([26F"28K%4*3"4W.)YH,XKU=KO.CWW4UQUA508/@99E.^>60*$?^(OA>N.Z&W\8FF<[[!Y>Y]A>GR!H@J ) M@I;.D\^7F"H$724(FB#HG$+0U0TAZ/,!AT\ZVR\4_2^[;[$+VWGAKDVY MT 1$$Q MGS^?.1DA()J Z+6!Z*HT,D) M)Q20D!T%N!8 J+EGSL!T9D \@B( MSA5]"8@F(#H/#HC<7F*J0'2-@&@"HG,*1->DRH7^E^K:%KOJP]LTRH0F )H M:/G\^,S)" '0!$"O#4#7I)$1 J#EE))5 #3\HW9-#O_5C;HG!"-J?88-D M[L3II50G!$M25,YH3*FW2>L$^2 MJ$L81<@8P2?6M1UP;W\YJ9PPC9LF\%2#N&+\.8PSQ.>IL9^IOF=_#NY&(3'5 MHV#>@P@MM3=#6!&U-2.?,9TY&:&N"MB;6 MWIJH2R,CM#4AIY10;GP6L%A"H>6?.Z'0F4#Q"(7.%7T)A284.@\.B-Q>8JHH M=(-0:$*A)B:C%)T#%!QW)ZX)F3$8*."3I> M&SIN2",C!!W+*24$'6B-H.-@8X*.\^" R.TEI@H= M-PDZ)N@XI]!Q"9DQ%" MC@DY7ALY;DHC(X0XG=;-]17]J@9W-* 6#>65BXEOOUUT/U-E+ZX4%_A M*1>.[9;9N?YFN+;CEMBW^S@F'1_S$3422Q.QR!6L18"%,$7MT]^E ;5DDA!" MR",) 1U]6FLWV_)T(Y1)3@@@CP/DTH@(X>.2"DGU4Q7Q\0[AXQ*CQ(2/RS]W MPLW M&\UZHU.I5BJU=KO3^O1JZZ<"VWY6:K7.A@#W-ZZZ? )O,Q@X4^#1[%Y]X>R[ M89I #U4OL0O?, 447BNQ[DB UDM*.2N5QNPCV+UC#[GCC4KLV[?+"$?_EV]Q MAL!Y%28TDX$M]*>DGBSART=$A4[_AU A@I@S!C'+)2D$,A/(3"#S^GN:GY3* MIRD7A6(\Z9@T&^/-VQ$X/G\HQJ,8;^L8KXHQ7GM.C+=D66R4#KAYK)@(]&*Q M8OV0L6)>I&9#MDJ]X4-A,H7)LHD(!DFLR>$P2)-U(Z_SM. MIT#NMN3I_W3P8?NY*X?/;,Y:ZC@=?:"C#P9 8\&5JJ>[W V5%_X1X+Z".K+&F<(ZI.5,P3T23L9 OJ.[V-+#G?MU0.5 M?.Y4XX2 /@+ZB+X$\Q',=VQ;1# ?_EM3)J=:MX+Z\@GS21'N9='_.G9J7TU1 MGF%E;U;K6MP]O?MI\E'TE&JE4BT3 MRD@H8]8X0RBCM),AG%'>R1#.>'PG7W*LC1(*Y9\[H8R90&D(97!!,H4S5@EGE)^WQ?3GCH]:5I\WK8,82,,DS#,/+@@ M&<(PJ_-S)6>ARG_^K5VMUG<[04UP)\&=^84[J\IS\U YFDJ;_2@_EB_+8R12 MJ34J*^'*3J5)<*6T#G;6@!>9.$-PI;23(;A2WLD07'G\6$%RT([@2OGG3G!E M)L >@BMS!J817$EP91Y1\#E9W4W"Y^1UHPB?(]X0/B>%MSPO5-4%L!+%)([LK M(+:OO&=8!B%L1_<)LX85R,090MBDG0PA;/).AA V0M@(82.$C1 V0MBR3U]" MV')'84+8"&%+(FS?SB\(82.$31K978&P?5.[W"1PC<"UC'*&P#5I)T/@FKR3 M(7"-P#4"UPA<(W"-P+7LTY? M=Q1F, U M>2X-K]PQ6!:P2N22.[*\"U>X>[ M,&@Z(GI\KS!K:(%,G"&,3=K)$,8F[V1DQ]@^>6K7Y/"M;KSAY_ _XEO6M1V= M.[^<5$Z8QDT3?"X-3/SX>IF9VIOF=_#NY&JICJT.5GT1^?622VE9 P M2[WL_3C3N_'DD(JYV(YJ=OS1_-EVY['ELV73,LFCCL^EF99C2X#1) M*=/H-"5"-WXB-4JI,A)N>0CO)(&]E0ZAVS#',]5\5T?N"?LDB=8D)S8?L-H4)"S-J)1*?3GX'-"^P-[[W@F0 M>T#YTG[C#KL'1\4 M?G!LLF0+[J6]_N-K7=KKSYB/5ZC]Y(QYA87B3<;\R/$80R\P'..C;1HZF[&K MX6_*9, K9^0(D]VIEMN@YJ>F](\E";B!?QN-+$#3D3:A%[JESYN2GQM<7!N\;'C_%=R/&\^ZHP[F,1Z+,A_ZEP9OD1%K_BZW.\MV9X*F-=Z,5BB">SOK< MX>^&UR^/)SA_?XF6 RV'DR__+[_+X<;2#4WUX"+X67WAF!L'FT;AOI#+:M6R(K:-X(\J4QW.= XK4&>">C _W[$,%^X2GY7/XEK+ M]F8O0Y,670*39$/?&=HN3,#NL4>NX0@")T]IXU<># ^^]AW#,S@.1^NKU@MG MY[CB>TSIU.KB33@@?)MGLRYGAJ79\%A'Q:VO[H@YO =&U-+P%[A"M48,!@(K M%Y_QNZT;ZBM[U R\ O?)M#(#WYT[:[R]AGIGC4&6V'N?PW4.Z"X=] J'N7.\ M5R1'B"?H,%IA[.$6PW&X.^3!AAY\QA&_<(L[JAF;')X4F9H=J+P7'_<#I_;V M\&;7U_KAG$N,_]3X4- *W\OQ" I\ZJN>^.SP%\-%(?08#D$(AFF.XD1UF>%- MO;D\NWA6I,"L3GB9%PB$RZ=KF_K&^F)+Y< ,_9>3FZ>K[\]*\_GZ[@'^6_G] M^?'']^_G#W^!28)?F-(L,_R)*973WUGX6QBCS)MQ<^6$ [U_1)5X"[^59Z>P M3=[2/#8>*2.C4=E;DM+VLYP):5?3>K-!'&O%/-[\>GO^]./AZO'DR^3O;*^) M>]]Q?=2*H=YT^']\PQ%>:-QZ,478!*7Q0?^XI@4KS>K=/EA>W0>=JZF^"TK< MZQLN_ [*-[)P+D@&_ "O0^/@":'^VCTQ/-4W^O;#I!( M3ZSNK>1K"313W*W'>J-SL8V]%;K+#Z-#S^N6D>B(!"QJU M;4$4#0]=-3MJ(M!&1?:]DKY9K M1/8C*'ZEK!2,[HM4_=Z9,*77V?2FK!O;E&5B9D/5 6K.<&:+\#)#O/JJ>OR, M?5<=K<^4$JM6JLK&T$2;$BEPA5X7X91D3XN07WP9Y1=X(YZ/;XCL0.!3A0/KP"V0[$"Q\$) ( M7B>2J%S#"]@/L^"NJSJC,,M)!^D/& &OZ-I^D* Z=#B,&QFA!@,1ER/%0,;$ MZ,3KH\1BE#'.!KCL@D,"OJGC&.&YP9HHB:Q;3&=5/:,WPF&%]7%Z8)?PHUA% M^(*5A"DQ(6ANF!9L.!/1%.F^DT]PZ4 =A1(/4X 1X>@PX2L^>QC6F^%X?I0: MO"AO*R,Z:U42W9K9E^%N Z'HAQ& M$1*CY)C!2I64849MK4765\.'G>0>4AQF88[]V^CCRP7,R['?$V<(9G:Q)SHK M3RR/D&<1RPF\F8VA9A:BS&Q?J8/!H T/"*[M2(0-IOSAWC$LS1A"Z)R8ZOJ5 M?_/FDZZ] JJ)XHGYSOM*)-$>RBG-MF)9F0*QF=LDQ1K)N)NWL!1=]H@T<52QH MN38L%9QZ\.ES'[1,IHK3/](2B;UDC;' MOQH.1XB6H@6*%G(:+=!.#+)S6JV7V'V?=F*R)K#99H%4XY72N.=3S"EV*$SL M<-E7'1->>J%:FF/W/(H>Y%(P%#U0]$#1 T4/VR2(;JW8)538&?>H:,=!)O_U MV$8]GS).44-AHH8+U74-D]V4V5>U;XQ4"ALDTS 4-E#80&$#A0T;LS.AV6G? M(8LRFVT62#5>*>U[/L6<(HC"1! /AM97'9T]EMDW_C:B^$$N_4+Q \4/%#]0 M_+ Q.V?T.AT?/_X,*'B0S(T]MG'/IYA3\%"('BA\VCQ\2JKW$_D4A1-9D-MLLD&J\4MKW?(HYA1"%"2&>5&-D M6.POU7JAV$$NW4*Q \4.%#M0[+ Q.V,ZG;*6Y)'6=%M'+NHMM;^&E/,GN1;Q M\95*=3*$V*"V'T7:RT9IA.6QN[8^$@SK>P,3_OC_ 5!+ P04 " #=BF%2 M<2%W!P\: 2,@$ $ &MO9"TR,#(P,3(S,2YX0%&53 M6>8A(Q/H1E\^ (T&"/[TMY>E;3Q1UV,._[)WM'^X9U!N.A;C\R][OCG?1B/C_/+JQAB;@CW1<^:9MN/Y+GWW\/4[X^^G]]?&@[F@2V*< M.Z:_I%P8(V,AQ.KDX.#Y^7G?FC'N.;8OH"EOWW26!\9H%#$^3XZ.3X_'_XZ3\.#T\.#Q4&OP4Z&,I_ M)\:'_K:^XX[/["$ M>R#6*WH E490B[K,W OI+,IB(DG@47-_[CP=0,$!2'H(EAR]/XJJUV@CS1_P M@(^]F&I&O*FDB$H*6O'$RBV6"DN X.C'#($KRIJ)BXK:869),\PLJ/[-L5+* MP]^,?).PQ,I'QTE5Y&:)-'.4YOCP\,-!4*C(7BAU@0!@LCDAJT);8D&1PP@S MO6(E91$:\U.:!"NQ8B^#^.\/H$L*0"R-ZIN.SX6[+FXD+"R0S&;\6T4K6#PE M7MS*2Z[^\WM9^^CSY\\'LC06R'==&)'*) I+"T2B+^:BF A+4@1$")=-?4$O M'7=Y3F?$M\&-/O^G3VPV8]2"0=&F.**E*BC%@KAS*F[(DGHK8M+:R/*L(BN MS8X._O[U.AA.]V",, PY2K#ERG&%$0P6UXXIA\P*N^-?H\C%(WPT.CH&E?>! MV9[!"\4MP\?!AF)$&&@E1@*@UF)$717;_U#6F5]5=HC]&">XJ9:CJ M!),=XN,SXO/H8RU\%D_( MFXJSJ2S-Y,AY)AXBY:^FOLD-L.VL8;ON 7%-U[$IS(ZFN'A9V803X#)LUK%>,S)WP$#S$0/4'5)L#,8!"^3^@29A)!K^6B!8L> M[Z]T"X!@M$V3-EM)Q2)%0EETQCB3"ASB?\9(S<-$31G8UD\'68HL,]^CUBW_ M6?Y>N=0#)M(V"G58I8K2)+;IVRT($\G*Z<*GD2\R+HKL=$]GAEQ/GH2S?_6J M\V#E.BOJ"@9 41:MDL'"I;,O>^#,4>3%/T#!?7!;5"/'/^T[Z?.,34(9(PZ" M"61QEE22#O.^-X@=-X,X_K+G01^RZ387X =O8E/P?5.;IN%2;-+SN([6HF^C MMTVF3?4&$FJ7JWR-Q3W5%@:5IMIFQZ%BI>^46HUUCP?VNL.X("\.=Y;K0,)H MO(W^'7/K@H-?L[8?.C?T(D/(+7,]9TYN%W!+%R5G1(;LV /"TJ%I[BP1F6= X_0@3$? M S<8$E9&R,L(F W>V]Q[=\2%X@45#.S3R)5I2IU?CQOXU7B7XOW=X.=6?HX? M>K>S6YB,I&(>#*MGSA)T75#NL2=Z[7C:+MR DPX'[RMQD#1D.#,C:4H.WZG& M#&QM ,:6@=%H=&C+5@>9'[J$S#"V= ZA>VI1NB13FT*-)PQZX2<$GC/JNEC3 M,;\!".2_"\>VJ.M=_-.'0 S7("8336"U:5,ZJ'UH +5$%D,1QHBE,:08$H:J M0/].5H[WGT8@E_$NE&S X9OCL/58UVF[.H1^?#.$#B-GYX@](][BTG:>&P5@ M"9$.*Y\:8 6Y&I+MX-?N_-IZ3"GAH//XCZT\/O3LQJFM^+3G9$$QR"1\K::R MBHIUOOLL4UY2+*@14@\NJ>^2!W^Y).[Z=O; YIS!Y$6X&)ORZ!#C\SOH M#B:C7J&[:I)J7'ETF'-ER!C[G<+:2'@;$?/!T_4]?18*H9H985CVPT5 MA:XMJZOSY5'.EQ&G(*<<\?K> &Z#\^H[#[#O^M2Z9F3*;(8[)>":6YB$W#-Y MJ$XH)84>;<1 Y^;CG)M#]H;"17I<\LK*ASV0\YER5L MC(3/X+#Z#H/@<JOLY]'W+N4[B%R5B%W^#&^FZ\XE"- M3LA+B=O47 M^T8MUSGFQ\*QS>QJOS=%@IP3:QL0&Y5[N%)"NJLY7^32*9#22G R5U>"W M^GZ#M:W36% MSL7Y/$[%?H?Q+N Z>'1+&Q\5;F[!1N?[?'*H\2;(@(BN=D,J7%]57^?C?)*I M9&=D\&1'6R05CJRHKO-C/B=5N%TR>+';?9,*9^JI=#[-YZXJ]U &WVZVF5+A MRWPMC>_>Y[-1ZL;*X*K-4OB:;I>NI7-5/OVD9@4'5W66UZ_P6B6!SH'YE%-9 MCG]PYO:3_15>;L=)Y_Y\"JI=XG\ Q_9RD%5=OQ$''1@*4E)-\I$#!C8Z]#ZV M+"D2L95;%]X O,TG^@[<[3T,W1D(' M;'4HR>>S&J2K!Q!U":*2I'0,@I+R*@!MR%('GJ+36.6)\!2T*C/F WHZ0T_C M,:<-'QU.\HFX:IP,H\K;;*7@]>&6CR<GU6M=A,)\X;+YQ,S(B&7$( M:['Q,P"XHYV?> :+2W]EU"6NN5A?.N[8\ZC,,"O&#ZFML8A);OD];@*X$-.< M$H]5 OGUI= ^H=\-K5LERHU\2J58F$-&&.-0%R)8!6SD<0&$2HM#,>QV(:4 M>T!W9^AN/&DWYZ)#5SX!7(ZN8;K>[NYH/,P4%?Y*;:L*&ALQU*$DGV4NWF%- MC4#%5;#9 3)=0:;Q"-*8B0X:^0QT&32&X>-5MN4;0Z(M+QTR\NGHZBW\ 2&O MA!!E6A!A]XRO*>3S:YCT:-Z##5\-7:[(042:+ !=MZ"[IK#DI;]3_,@F+,F?P =S>D^7!)0(<3&A[A+H M,W6P&=P,N2=B\W&P6RETH,VG[!N -A#U>R,2Q @E,6)Q0_RBP))9KF8DM"&E M'@;4#<_G)3G3.]=Y8OA!VU/*053\\*12KPJD&[#3H2V?^$^=^$OG4^,FC7=A MH]_)Q%3ZD. F(T @_O_#@]N4,3C0*<43$R;(Z4V'QU$\GGY#$22EN00A$>8 MIK*Q 1C; L9Y>*4&% 19X1:@*.6A <0'S2GA+""B=K XRF$/6-@,"XU3!75I M=;[/9YTSOA\R 5L.(^ZIZ4#D9S.IV^WL8C:CIF!/6 ]#MHF#5^3Z^!74QX=+ M:D%49^/SQ@'&I@WIH)1/35>$'FEA\$DLCAQ7L&'YAGXDDO&X_[!OA&(%Q0,& M-\1@M"!ZY"ZX8\[9GW+V"&-!;[S$=4/M2+89-QV:\MGL+)J259+:HD1/U*81 M-CI 9?/+Q%J<:ZI-K@-#/H&=_5[ ,%%UG@H_M$K4O'#>[*N?(\'[^.IDW&;<95!Y+BC+ "$C7F2!5%;>1] M/\7EF_V<,\\,RJ-<< MC1TWK,-G_2M'TR<-<24>BI?!:BRA(46,=YI&)-QI4J0<$+L5Q-XX_,U VU'; M&MQ^+/A,35W<@H0C.F"W3]B-IV (MX7+\ UH^29\"RAJ6>F0E4]UUYNQD_:" MM_@'@&QG<+NCKHRV80$FJ[WZ"->E #HP-K@M)#O,*6*.IK+Z,-;U ^NOGT+^@>6[^J!\WNBW!3$E]L,P%7Y\SVP6$-655UC+>72MO2=98ID!:# ML\,NL1W!=+TBOP_4NEU'%;UGZ!D;?+FC\1Y! M+4(=LO*;1\H7/X:-@$X]7?/#'HV!T 5?'4[RNT>-/B8R(*G;Q5?E37W)/G.^ M7#%]?-=>Y5)J*RWIT%:PL:2].S"]SUU4+04[]:;!_P<0_.G@Q;-.R&K%P CR M6?B$0)'B(S\#4N#R4< !4_C%^ NM@5''IN-C!S^E4*.]KFZ:_].4(\(L+ M\0 >1",V'D/[A3 >G-"?D)?P9IH]@Y,E_;+7+4\!BG[9>YFZ-CN!F ?L.W1FSF&=?C&G1J<:6 MM;^R%9BI=O6^6* &G.2U3S>PPHC>Y0Q.B%Z\8%(HLYH)U;Z#D5&QRB8<.C:4 MY0>IJ*U8"L%^RR]>4$6?>0LLQ!=&IJ*.E=I2[Y*%E-4NG@*CUN/*P53H$ZP< MY2(V?9HUV B*#-226+6/)Y^]CG6Z,X/%H>^*"S67$CY5L-,IT]Z8LT:?BXY;ILZ$(F@N7JAK,B]=D#5< M6^J_OH72@]-F/'9QC%(ZSXTCJ-=LE"JAWB78--:QX7161MY#L/Q&/0Q;4J=& M9 > I:1W0R&.D>\3_<[$8D%M*S)!8[)=@D=#Y=+@:$G<0VCS1X_*2PK&2P<0\&?4>+#^KT^P0V90!;^=10.,'&_BK%E5 ME1U2]8K#0 .N.Z?!OU>\^):Q&/T-"';(#.=TY7@,IY.BCPE$NNMJ]4;A&I,' M:&!2:GEXV* PDRE#D4+LMR+MC6WT8+B#4,!D*P@7XIAC0CDF#98KUWF2E<<8 M."!#J(.M)[9I0]L;X]0 SB-?$6:E@K!(^<*B7=(MB27S,WH^'5!49Y>T5?NQ M&D6GUZ9E2>VVU+VQD'X@2#YK-J$OXM2&>#?2OK H4(W#RL-?GHCH^9NOTVIN M7>5T;$ZWVP88ARP;ZI^0I=;H L? +:L>_%VA^3WSOD&,\@B =P5A'.65WT++ M([I6U9XZ./RN#5Y)@%\'P8/&](G:CHS+2O1M1M-3Q6M"M,0$;:E[:HQV7V.2 M7PK-F:8;7KTW5)V[1'0&:L.C]X:1:5?Y*DT8R(^?B6L5O;^+*:#@@HWDK3"= MR;KEOJ/&+'D?NCM[;M# CIHT^P*F?(CCU?W#8X>&W;B9GII7GG!+K6N*M@TB M*]6MO4,+GEMW3GB8U4Q>^T-?FJ6BXQ#160DK.'A3L)LD]S1A61UNE$,X M^I4NI]2-+-4%I]2X8SGX!8"WAM+DV9DL'-\CW'J ]0<7-)8[3J*D#=&$HM\* M7\CWZAOHJR/HH;K9+>:T;F6E/50DU_]*.V;'AQ7JGX#N_.BA5W),,'O<9QN\ M>WC@(Q_Q%)V]*(^/BFOO4'R4W +!YIS-F D.&YORZS#0>66>A-%\(-28K'\1 M3ST54J%-(Y(^QS#79.H &\==QWN]Z5&\HD(/!_+@E6SJQK)B/FL&_J$EZC4@ MZ*&ZI^0;=4]A+!I;3\QS7._Z+JU>184>JG/I@+SO$?D MV<3;9PZ1PX*M$K4F"YCJ\&.F#6F7%N@D #NGX2<&@M7LC?0U' M2:,GYVV:T'0<1VSSQ;MH1'UP9N(90KOB\39;VL-.'&Z.G-F,P_QN3UQ&;,P# M!I"5)T"RKYLVH-@ACU;N)A:;0%-W]Y2_IG-B7U):XO)\\0ZI>$]7/OB*>+1D MYJVHT,-^*^<1&$.]4RJ>*>6_,NHB%M?7B,1X -96Z\W:;?.7YX,#O<$0A-=] MY5#_C)WJW3\!JF_C6@N5;5\L^EHW6W1GTE*V M?3&I'J0W/LX^^+%FW*(]]9F-*\-X:"\M5C5D7- Y==]\]11\Q3G]HD&XVXK? M;9;'3M-']^H3J/I&TO92X:\@\L)>WT.]\'Z-*FV+:O=FMJXQQ$*P1&R4_G\A M2+Y]HB[^&[U\DBQYXXY>NW[_<@-%[D--QM-PH[?*SYF*.^3B\OJ! X^)Z%Q%&"2U=OAY2.YI?PT-7$N7@1E%L2LS@$ M9^>A\GI]G)!P XL)>0A#WN$MMS0HQPT-]6K%S#Y04ZK^;0/5TB"U"]2$HM>; M0%1=VM_R__(Y54XF@&Z39RA89W:&&E+U,%40A8:W/).F+"CHL?A@]6+QE8(> MBI\%T'CE,KLY[K1D/50]V&($29/MU8<5,3,HU-7JH6)?"?=G4-5WRS?RJNOT M4*DHH1]\TF*)1X&(_>"O5G8&FC4J]E"]P@X%*K2;!NI2]]$0#O^39+13'_50 MY/)E1$GG:T"P4^J&[YO75393O8>JCGWAX)W,)JR"Z3->&PW+I2=BQUF!TO)> M9GWB#T^=D143Q)9)*KP>%%=&D4Z:2GU9(M:Z#5)R\(E].[79/+A2WJ=7_(&: M#K+(@XHSP4QJL M_).#Q8U(>JDT;BB8C@L"/G*$9_@-@[MPISB!\!D"Q0[N@\J3]L4RS4"BZ!<&A<'F07C>JMHBQ10[9(C@DP/RTM1< MQKVXK']Y=47.5/8\_[S/.7*\]RWN7X[GW3CBP9_^@YH"MW56+&@BO?QL1M/# M-6A*^C/BNNN9X\H7XA/Q'Z#[R(WI.&O9C$AU^EQN;+]U=%-R>%7VUKI&V(S' M7\(F*/A6)N+%[)D M7'*,SDX$ZV",;?FEXRH5KJN5=X*'YJ5GM?1 7-CB@=W6.%#HL20/54UU'VT #)K5/X*ASE7G C#MZ/,)F%T]A$ 8$MQ6F%:Q37,;3 M!=E[X%^]V?[M3VQJ@O%\[M(YS/Y7>%B)>\P,LE(=6UK;3$\M&W_M+[Z('>^R MP9('*D1 >OVA\ M;P^S\1F71TFR #AJZBA.'4?F:4.9,D _KC,\IS/&J:4>H,0),(QLW:]$F(MH MF [+S\CJ-@Y]U8)KMF3JT8.N&?=O*5S_6JID5ZL^19?Z=G)_U9UZ[UA\UTMT M!YGZ721]Q=XIA]?&>>%Q;_EE:^XZMAW,#G> %77;J5[='3H_HCHL4F#BG-) ML>0XJKY>[_PJS[O#;!3> %#S>R])-J<==6^.VBGGRWXZ0/MXY@*"[Y__#U!+ M P04 " #=BF%2MUW6]P(3 !!*0$ % &MO9"TR,#(P,3(S,5]C86PN M>&UL[5W?<]LV$GZ_F?L?=.[+=>YD2W*3-)ZF'<6R4\\XEL=VVMY3!R8A"PU% MJ"!I2_WK;P%1HBB1(@!2("$W#ZTED8O]/OQ:["Z 'WZ:3;S6,V8!H?Z'H^YQ MYZB%?8>ZQ'_Z7DY=D?$#Z@7A5!8 M<.S0R4FKW5Z*/F<8\1]: Q3BEOAWUNIU>MUVY[3=Z3[TNF>]T[/>V^/OWW7? MG';>_:?3.>MTU@3\LD#16OMWUGISW#GN'K]YUUU[\!8Y7]$3;ET-UAX<]=ZX M[]^]Z;Q_VQU]YWR'OG^'WNH^/.%70.9W.&7D:AZU_.]\*%0&O[V// MP_/6)?&1[Q#DM>Z72/_;NO*=XU;?\UIW_+6@=8<#S)ZQ>QQ+]8"W,V])'E2) M'XB/'X[6V)L],N^8LJ>37J=S>K)\^BA^?+;U_,NI>+K[_OW[$_'KZM& 9#T( M8KLGOWV^OG?&>(+:4%4A(.$%!.0L$%]>4T?4D81>K=PG^*?V\K$V_ZK=[;5/ MN\>SP#T"-EJM!1^,>O@.CUI"][-P/L4?C@(RF7I<)?'=F.'1AZ.OU 4IO4ZW MMY#QS0.&AZ 170O,7,R7NZN4RO *05]%"UR^><*?.TF_>I*AC:RX$,VH3R?S MA=S[$(3R#G%.>0\@+GQT/R*/$WP_QC@,"C#=@93?Y:6DV5K'X2#/B3Q1BQQD MZGD\"['O8G/5"AS%(=CSHIX'%AHL6,4/ HF@V,0T\(3469)]@+@^4W M@B,8'.+6\TW\]>^W#$\1<2]F4^P'N.^[PW",63\(H/SSB#'0+\V4QQLV9/7R/G8B1D& =/#O%F,!QCH(QT,C_=_%G1)Z1 M!T4'_? <,3:'J><7Y$58!9&D0!/8UMK&#?4=]=K)$6!$]REF,#3X3]<8QF8Q M60U'7Z#)OO4:5;Z,NL8M/1Q%DDR@T9Y':I@Q%D6J*UG'>'--T"/Q2#C7H+9(DA&N M'8=%V%T6KCR?0 9$HP-O>N45=B LZ1LAO%EMD.7_R^ M:HQWF"\MW =Z#^;)<'09A;!XOJ-SY/%29#14$E=C!];DO5B8"4SE^F]='?<. M9D7B8_<",1\H#* ;1I-(M) !'A&'*)H+Q=(,#4?+3*<-C6(:19WSE MPT(47],@ %-L.'I ,\5Q2DVT$;RN2_C2''FWL."\\L_1E(3( ]TFU+\/J?-5 M":*$-"/+O:1 ]97=UKMF%@]XA*'WNGI*9[YN0F]1WIAZ+F8!7ZB$6\S'M18Z?. FBR41(:Y,03Y;OCQB=J.@8JT%S*H4R>/C#4;?3Z7:. M.YVCUI01"HO/^8>CWE$K"D!1.EV,M$>M%\S='2*8TK$5_QUL9#V5 MD'!J'PERL#-GL03W=X>*>]OD2$"_.530,K9B0L/;@Z5!=560\"%!;Z'=)X>^*(:44&"A%;@1"*2;OV2@M-#( MRT=9%#A.8%MHQ^7#SH_[)X MM-CR >].UTA 6VBVY8,N2+=9H>Y9:*WM0)V= M*)6@M= TR\XM67=.R&6Z)218:*<5DK S@3&!;J&=5@A=*A M-J'S)T3\@#=>' S]BQE7("+!F',W' WPHU(&BX0P8QEI8)W0):4+'[)&HRJ2 M9 +-E1]B!BL*#?6W7C6C[S,4R>M\0=92"37%\V08[<=)[$&K)Z^_;JS=9P1/ M^L^(>-QP&U$6H'7[K>_^$2UX7@97;BD3ME<(*]C'2)A[#_06::5S[E.5.OE< M#T;MF2_IHDSP 8KH]8B-%PVE-VURJ9.PN%-,_2L7&90TMQZLSK!1A%ZZ@UF= M@%/52"9!:&4CO-7)/ME#99;W,+M#6ACO*82<;]19G>HC@7O#"M=*Z6E;@[=H MT61U]DXA>HDUL-5Y._E.#BKMC+$ZD4>*@$+?6NEDGKJ]Q3P8^&%V3V*/>[@TLGF68J/JZ4BVK-D;64[I*0TX+JP=3FF3U??ZR$NM!%X'H*@@B?OC1.0WD-"X4H:'2SOR0]<)D%500:.KD!2PL MKQ1Q_(@ZT56A5J&Z)R2:!,G*3^U4#,T2C&SZ'".&/T(]B# PM&+IJBR2\/JB M?IG=YWR,_"<8,BX182*_9CBZF#QBU^4;(!AY%N:TLAVA*K4:Q>^PB_%$)#93 M:*C0EN'/]$ZO7Q%CR ^K *15FI$1(]6-XT,;_2&0+U^1B'W*L^'HZRT-!4\&L*-8$9S M,9L]T+[S9T08+HU33J#&@ >-EP8$EL;^,@]X/058=B KDE(+Z;F)S:68WR%5 M@_Y;1F#(F_(]I//81?& 81@,KR931I^%VZ+O>?2%F[,*BS%]V6;RQJ8KE;B- M(=)SQ>Y981T/'SWRM,C44TLBDY>J557IL69KCYL(C&FM7K1$F^Q3"T*5L4F) M,3T)W= 0Z_@U\F68K(G5-LL'-/N5A&.^%QE,IDO*RB]J],LP;DAP.W@H7.S! MQ0PSAP2)WUC9<,@69AK3LEL,1YJ'5TD(,V2<5*#.EFCI<>V-[4'H7(%@2Z2_6GKS% MC%!WTUMZ,7.\R!5Q1DG+XD5@1=I-M.,9Z@K)>]2(5$): M6@<-'D2;T@ES:IU-V'2V=GF?,X8FF9BVUBF&EO,DD]&@=;2AY;PH9J-HG8MX M*!2I)R99?9ZB1J!(8FN[C0&+Y8B03PVU^JQ&/9*JS!VV^O#' M2NG;F4MN]?&0Y;JBRJ9HE1,DFS[52])3Z!'2/5+27DIT]_XDE!V042TQ&"EL M#DLH.AS7M01#._?W)9R\.LM9=Y=F0MD!N:NU.QYMPI&!]'RQ'6YNX5_2< MOAJ[>R<[2KOZ$_)>E=6M-+,7]GS633YHT[ M)NXYGVP^'.7\/N"7J7E2)]54759MY]A4!L3,40+)Y7:)]PK^]A9K -]=M]XJ MV95779F&=GED%_^)*>[?+9)4*QIQ7TP%6(2<^L=P*9PR]^C$=6-UJJPJ&=5U M4*U4V'8M$UR^$1C?,[+VR[TSQF[$,R!4WM*:"XVKU8!ITQQF4T>9[[AI4'[, M+9)DZN@A*!ZZ_ @'@>BXEU@+39$DG:.H8F[PD[)6.U\W0>P%]#-59;<*J,%/0KJWB5?VWUZ\\$,SX>SB]I'$6#D7$->?RVVP^3 ME!+_CN?W,>(_?40!T5N]U:9> U9QYK&;,+Z6=ZSPW42I.U9X+HW>^7#R,NL[ M'V'%?5*_*A 5A!HQH44[*XEIAY &3 >%" N/"\A\V6XK6H44^5Y9VIHV-EMF MY:ZO1N2L'W_&GJLU\5514@/FL%(P&C0=Z7@(5$7K.&LVRDA+7@M#B"C,%Y]A MY)&_P&:%3Q_Y-6?X 7)&(,(]T.,PO=&^(N>@FX;V!T?[A!7O/^#.,S6.ED*1^&4UB8!^(FQ#' M4L9/JZA9JT-_)BA;C0)6>@J,,[68(:QT#9CF:F% 6)VI9XPJ85U:N:8W2=7& M^N/U+N=[]:[G>VD;Y: 6]#TCVZORCB"0-_UR1=1NRW[QW?C4)7X6C ./]B?\ M4V6&;7X!M6/_VX[7'^CSJ_75&O'%1Y4T/GMO<LEU)J=9$H(TGC"R7N M0Q3RT\JN*=^-5P&J(H$&L5UB&">J094OR@2>Y>%R<8M9=0!]6+(23:)+M9P* M,*)NWX%<(HDF4!3 0Q)_>NP,XO04?G*L-K> M5N"AL(]9[1.7'8PR""D:2ZWV?Y?@16X>M=KE7:;5%%A25ONW):?"[5$VWVZV M^DY(;3Z*5D=6WP6IWTIR5\):USS6[>KA]Q)0'XNKT9($U@I]/*H%-,NY(ZV] M,:N8:\%OCEH$4"+B/R47B6]I%S=6=<-9KQ1S:P,E_0;P1Q 29\\T),4TE(>+ M6<@0C%+$1VQ^!4.CV$4!;T+[!_V>KOP0,X"P9Y[DU:A_FC#!,JVHU1W 8K#) M1*]&.2M#.NL3V7(9 #\LSJRHL#CT#&TV=L5*DBRA(>C7+S8#_>+54)!] M\QG?+%8Q-QKEU\7<.7PFX3EB; YSRPMB;K \2;,L*3M%UX+W$Z7N"_'X@:DP M$2/_B5\XN;P^J038G7)K09J,3V!.I*J@%-!=8FO!R4^U6G2SY8WII?!EB:NG MI:K>M)$GH=P4NGY2)IJ2,-Y4O#Q156,&+918F<([+RDLIWF!Z%J"Q:E+EDI$ MBE-R:FG[BO>R9+]?B^9KW)4%L2FJ_M6P+-J,V$ZZ:JSV"91@(;N+E;\OI@ET M[!R&:(FQ]+""Q6_=261@(U@:?99EJA8 ;-W3DV+R[ MR-BU#+$Z ER"DYUKT-)A8$M)*?)")+PH7)E\&+R4=UFMR.M:>*%RI>1E^D(3 M>@[!S-VB1]DSGO!A<3JD1G.1N2NRV_2[D#/W%MUAA_H.5*\H>3BZ&(TPORB: M/W>'0OQ >;I6!*O>^9?[.).-?U_=%JV*-&A6_*\Z>.JNM%4)*WVXO+0>%S/> MO2,2C'DK'H[.J?\,#9S;&S YN>(A ,5%Y:JY#U5'3_+<3BZC$+H5'=TCCQ9CVC) II2>8N+KM2: M;3GY34&^,O:U(IBZ)30%_0WE%-;.Q[!2A@[5E;&:>KA MJ@DI+*X^7K)R.,O#SY9:_QI9@P-:<55;'5KU7W3USQ-&1UG'+_ M!"H9.U:'-_?/I:JM;77 =/]T9BWJK-Y8B=F_'X:,/$;B=MX' M"F; A!O\U/DZIAY $MO*X-=%)(G?CN3 2F! O"C$KJ(HK0!>8]1M0+2O?BX, M^$1^%9T#NWWH8.@)WT231\R&(Z'F, J#$/DN],4-/"K^$=T2-$)/NXH*ULI* MQF'9F)..9!,NK9UZ705!A%U!;%45EI99_SRDC)_JUZ?5?BL=HLKVX/WM=X]_ MX/]YA/7TC_\'4$L#!!0 ( -V*85(GJ9(U)C( #:M P 4 :V]D+3(P M,C Q,C,Q7V1E9BYX;6SM75MSXSAV?D]5_H/3^Y)4TFW+;O>M=G9+OLTZ<5LN M69Y)GKIH$K*X31$:D+2M^?4!2)&@)%X $ 1 FO/0TRV)A^=\ X.S@U__?OK MTCMX!BAPH?_+N]&'HW<'P+>AX_I/O[R+@O=68+ONN[__[5__Y:__]O[]P<75 M]>W!V [=9W#A!K8'@PB!?[___A\'_WLVO3FXK;X>'+R\L'9^[Z ?2B$+\L^&##Y>'!^_GQZ\I]'1]^.CG($?DND.,C]]^W@],/1 MA]&'T\^CW _O+/NG]00.KB]R/YP?GSI?/Y\>??TTFG^T/UI?/@/GZ&1D'7]R M'A_!UHO.X6J-W*=%>/#O]G_$+&)Y?1]X'E@?7+F^Y=NNY1WP90\%AQ,00#0,W ^;*AZ&+=O7@H>'A(_B/_YR[L<>J^/R/L T=/A\='1 MR6'ZZW>;GY-OG3![(/_CT\/DR^RG>Z1?3N+?CKY^_7H8?YO]-'"+?HB)C@[_ M]_O-O;T 2^L]'M40"TUX"=QO0?SA#;3CX600X:#T%^1?[].?O2RDV*$7G) M*2'_%\OSWAUL"#],K_>1=?WPT'&7AYO?',8/'+;,%7XA\,DT?^^ N15Y(1^/ M!8\KY!@N+=<79GCS=.O\QN]YOP3+1X XF=U^M&U.%Y@$LJ-'\#Y#B8_?0@)Y MKEE9_@D=S-;QT>@X69M_F0'\(ZS';V)=LLL0$0T_XEH_XTT@??(P9FK[T2)N M6,F%UBOTX7*=T+T/,5&R)YU#L@FY#OZGDWT83.93X "LN!X]@'^!M\30Q7^] MP_(!A,@OH?US["?_7T#/P;O-Y1^1&ZXOP-RUW; &D2GFX8-8DE06#]I%"R>>[G,K>(SG/+9AGBQK%7-\ M"+PP2#^)AP<;%IOMY"^;CW_<@A!OUW );F 0; /JD3T-HO1#SWH$7FPE%3UX MJ(#72;@ Z!PN5P@LR/I]!I0#S,YD/K->[R BPST.0^0^1B'!?@;O+(0'A$>Z MQJ]2@Y]L^ME1M:WOT",T3L"8=(@T6)S90I MP/,L<$-PCPTSUP9W +G0F0(;/B7+Y3?+BP /8.WSH@+1>"E>!T$$G(L(X5-! MPDS,.![WE_@KKF7"2E&C=#&^,H7;)5@MV][>@3_X@2?($OHY^@\KZ"=*E.S; MDWE.H=["$ 0)H"S,-R*O0A3FM=>$NH @A#XY]Q":V4O)ZRY?L5WE!MM?_&XA M9&%MP#R.S;NN_1 VD$_R2[6K^)*%=I%5PS'(>^;R(G[,)P$%4AX[EG!<%D'K_W8A.P8A>FZ.DN%@%SQMK D\"Z.-ERJ^@2@ATEW?E^G6'BT!8 MQQ834BK+C!@+0LQOGE3*[0W6[-?XKV)PYY[>YIJF 8R1O4790G9*=9,FPICY ME#PS1W!9SCHP]'1NX,5/NXA/&]^>8PTLO)O3+NP \+9/CR^9[#^*#X2_O0K3O@Y4+1F%2324X MVS.R")CB94-Q^EB/4YLB%V2550IB0SNR5/Y=>]I"7*7W8TH\)J7LAM;%;[ MYV@J[A=CU#731E7J5X!U[@\JLFX5QK=#B4F8P6;3O'PKW%U;:Y?9LTB% M-U]WLYKD^SYB*J7N52Q+RGIO?B;SR5$_968)TE 0CGL"0N5(ZSY,25W#?&'3 M#(2/G_H-0F7 /$/AM#?SO7'J1(;)IYXO#YX,FPR4SUW?'822KC+QOW1]G31( MFDM!&!UU?0Y(2H;, -%^V),Q*P2S8S,0CKL^*\03G2D&75MF M!8N=E:L5S03_VO55P+2-%DK>]1V!Q@#;K@E/,3L9]06SQHT',DAZX]G;Z321 M"@#8 37.$Y5VB:\229,1 3*"C\%>$I+85/'FIOO1^#R$$N M*#G)\<<59I<1"5HJ)$ M^>6AIJZB,9DB=RBQ,N//>,"O(**]_E9CPZ+"J70%/0^^3/QTF-EK,JJ>%F!D M]@)G"Q@%EN]^2M'RBATF7M5A2^[;^>M=RE^7H95DA@^!=91K(WP42.=M<#A6P RWJ2F M@HV:+;%FOK66 O.KDDP_Y%"U6/98.%L_^.X?$;@ @8W?,$Q1W'A8NZB\GT0PYEZZ.(!>X%44YDZ-U@9A>$H0?"4)5N M9E5ZG^JZK^\F_',F]Y 2O"T/Y,RSR7R&E7A@V;'[GWOBL%#KHU3*NAY$CX'K MN!9:YWCB7AGE1 2.@1/T9/GNGW&\B+;6)S:P[^ -,\!++O[G9)Y=/T.[[C,W M/)#U)M4"WO#T2)#Y-J4]%5J "7W.*E-F,PWHO>)WYUP:0'9(F> M%URW. M49G413.!\^*:?Y"N22*$_(F;5'K=>T,+TM>EV=)F->9O"'RNQ*I<:"JUN1.^ MG<@.;_IZAM17W;I?&U+EE0L4'-T&MFIP>&I4:"\DW3X)75.(H_*(@F5NI79[ M4ZII7R6#NV2W!UI!J2$%1+?]JF<6M5$]2C%]:S:#G XMNH-7ANR1Q:7FM,W5 M6S6SN$!B-K=4=;2XCY9+"ZWQZ<1]\MVY:V/-,;9MTCV9V-88)ML%@;QN%_+> MI[\3A@19%.1_DA,W[=HW?L;O);O*%43D6#HFYTPR9?&_S_'&XH9)$Y8\:-6I MH6+T!9(J+P"B_8$F\UOHXY>2GC@7FTWQQK4>78_YMG1^FBK2=2V MP,)=X?.Q3?:!)S##5 )R7P#K/!(BK:B:,428FQ\0=H(JH'[P-[KD3^#,K-H%\!X0ZTB?A'FPY@G"RU?2$HVK(46CUR@I85FN+!<1PVDR)V[? M&_<9./&J#?X!/ =O! ]\$C,25-3?!:NE<'WGD;W>=TAVW(IPACF81]Z-.^>2 MC(F#T";!"?QZ-OY[?#7_$)C9A_4V!Y1'WQ2,5#5864U-"_)Y>N M6,@)'E;X2 GPKO=I=")T330+0>VR'1U+EHT25"$;"3Y.YF,G.7#SBU+\?%5W0"BX.:.;Z54$%!C 1>>X/DKOVL(]4<659.\A G>J5Y)1HE='"$_OFH+ M*Y K]S6^=(M?$U514=). ,[#%PN!"_ ,/+CBVQ$9B(@UFUU%(4#9Z1E#,YG/ M71MDG_"I(@Z" NS>6(\0D3>O!=FK(*#5!R+6&I&)7#_E4J5!2UDY6XNT@V0B MIT*N,\O_.7.76(VL8."& MJTC()ZGQO&D?R/8/EL><3.+/Y4I"]9D_<,2*@U MZ<5XY#>&Q-\B@$* PAP"^%^[TN./?GQW?7<9+=F'M>"AUGBS7@5XVWZH+=ZF MY.S&Q]G6(V;R);C>V#EC73([#P@8?&QY(EQ]K;A(ML;R#6^G*FZRREM2B0H. M!<;E#329$IGZ<&_-=:5S5+%N@86ZK2.MH%A%ZD9OI[)M"19NV,8T<&H@T;9Y M1!OR:"Z::U-YR+!Q*5"Z2W_8*H@V[27M3!5(9L#7AXZW=M"?5FK ME&,[K'?&&-,N38768G*N441TUV^RJ2<>!R0+%B5-#[17ZC"IF_; R$%Q;'Y5 M/(^_'=9&/JCDNO><5B3G"$E1),S?0CB18(@?4NG-/88TE+XJ!$S%[T++S<86 M?D5(GS9<[,8>R9+F4"][P:YXTHE=4:;X.>$_FK\/LF7KP-HL*2IS%_J -5SZ M)8EK% .S/85L"7PY>042$"D6NNT )@70%A1Y(,PW"41S6&%UNC&%X V8!9PY MX;2-6C=\?6*Y]/NZEJFR2]LLS]S@A&8:"$EB*@N[]H744RFN9 MN](Z40((3-7IM.^?N=NE)#P8^Q#0;D^Z[R]:GSDE;64H F9W$6TX)X3:!5%L>K_SU/1^RI#0?F&.8B1RO;PH!KW==_D; MM%%0>G^*$VN[EP'$[NM2U8DRM3;SAB;9&E.H2KX7ZD(IYUWZ.U VE$-GZ>$M M7S? :CJ*FN)$RRC>MR_ "FLE=]/)$X]^K#9\9[R$*-PTF2UEF$=J>>_46F8: M-Q.6,MH;2HHZ)P8ABF+#[)I ^X0M,8&BPVHZ2EIRBM;"UQ!H4*J?)O"(U>7O M/JUF.NPD8(G,A!(2;Z'[1"];(<1&.3F=72]7"#XGX29^5"O)]+/UP=#XH%$3 M%GL!G(A<*E4.-6LY*3]-K2.W?RAJ,G WFDI-!<2$(D-%2]@8/"7=*S$57@_" M!1?:;SE%/5FE%UCG9* *Z;9ZV$)#G7LVP.C4W-MO2 M;+G-1V0Y+&0N MN+AYVAF'V2,3?TH"<.3^TS,K< .A4)0V]O1'K]2+KB),%'.8<4*EY8K[E!-1 M$NK:B2;3./-VU)E+)&::2KSYA:TI&HX:!U%%$8LEN5C7\NXLK+J%XA5%!(1N M7EM%> 7C4[7@-0H5!-1 B5;D5!S?$$OGJ@BDE8247%-V/T.QQEPW$:2*B@HI MOD,?K+];Z"<(2?/@8 /1,U.:UCT^H^&OH MVWC?B^W1LW7\^+EG!0%_D*8]'@8$F_&@JM5PQG^>!=Z86 41I3+$R 8WI"&( MP.5;E61TR2%PT58E&5URC.3(,=(B1_YLLG\D:: TV B_'5DU:+U]5N*)UD % M5E+4-I;9?M1@(5;2TR79%0)_1*2(5<[:LX+: 0^V,IFX>K-W-\-(_IHO&HXJ MS69.?W6V-C4\VK\(B^K]BZ*A.^#&E)#5'ACY) 5S>W2(&#LU..Q;H<8T;3=. MJU0>2\Q)]>!6+"P'N+II5'4>I=#H;N7 JV7:1":/B[F-"IIY-XJP*?)%=2E) MIA4D]IN''>O>D34AL=]+[$3SAFS'-C<%>%4E/YC3=MXLS&HR7VB#X@X=8EN$K2;I MB;8K'5;F3@%+4B*[__NAHN]_2[8WO""ZI;3PF"7#CDM,G):=#MDS8TH6 M1P?Z"\D$HL@&[5+''74*7NXYQIR[U#5BS'1:%@B?J7+7),&KY-*FU ^7=1(H M^I)Y M=HVTZC\#&71T>EF:,="I;CVGT%R M%S/IN7B.9\,3/ADD;?/XI6&AUD>I5!7F;G/"&[,H>EI)RY^"8PEWR*&"B"X9 MA$("-82TN/C9A(-,@\'E#NVN"[Y^3L/JA6=.\1];!GV%ZBF5M$Q5FM.)G2EZ M($OT;KF%.?90W@SK#O1A%Y.^+HNU TW8105G2Q+O0#MVYLVPT4F1ILV;GP^I^PU3L-^I2FCRWL7/U/086>M=213OUBEP *%UH5\^S+%#0NWCBXDSM=)M+U1FQ/@:>%@ MR&)%40!TKSKE .P;RA2,'CE4)!^=!(H95'D.2%#+#9-N ;YSCK=-%^L!WY;J M0&CX$OU^!%$!%)B1DW !4*[>1"SWOHJ*DN1DV\:66+YN1B0-N9R(JN/\=7QY M<1Q@%3B^[SZM@NL;8 7@\G7EHF3F8FTVXN&[^'GU>%]C@Q^!()QB!NY#HI/O ML-V-O[">N$Z%/%352WEEV6"\A!'?PBBG(9">378YF^QHSG?7P]! 'V"=.(5K MRPO7=]8ZUI*LR=B,Q 38)!K,\FW@Q?OWW:9E6TZ17_NV%SE8C]]!O%.$KN6= M;WY/YO$58+M(5=JK&HW$@X\/O.D^E#(P>?3(&2)&U6]M)/N-PJ M(M0%!I$8$\BRP\CR%/,2IJY#+$R$NKYG[I/BW R?PB2NF9Q*?8("2R3[Y8?S!ZR7PC-1U--$5(91[?XA#A[ =XS^(Y_L^#:&WBH"@S-91"Z2V)LGELK M-\36 GF=^QC%?1-8QZ*&B)JS!5[O8%L9D/DZF:< \ITTZJF)E!M&(22G=GL* M?/!"CO$A:5OAL>)<_KS(HK2"Q3DDEA26,G$E@1#_'.8M?W5I+P-_GM)Q& MUR505=N\_7[>VN:BIY7YQA?087X1R&GHDN'S=N+%OH/^$#Q-+^A6_1A(B_S;E5J6DN5CC MU>$"Q%7(?(_/ZFY.SPEHFE(22KI?D_P'<.,^ ^<:GT3\)Q?;5YLK?:Q_0A3? MS"-F,W"3?EORJEJ5%6R=K2ECW#WN>S%SA; MP"BP? =_,GO!/UASSGA!ZB*>9?P#U[:\.'\M;61Q'ZU6'B?/#(2D! M]BWX2=W+&[!&?-[^5P4U:A;RDB\ADGF.-=QG%J1,!<#^\ 2?#VVRJZ!UPM?F'[ML;3[^B0=>B!:WZ\LF]-?6T=%UK;9TGXIOE$6#G(0KA >X=&7^&_OR=_RLPY_ M]N-\S#3?TI^V-?OODZ*V7P%\0M9J039E/C.O@D#W>&[3%(U3?W=?RZ-W*@@( MK*XTVH-G/M_Z*7BPP>LG/J>B*7A0B5\+P17 !X$[S\(&AN^0^W57:1,T 0\> M"SFMTLJP_$UL? M5+58KM5&-5)3W4DEU]UIEZG!LAS!N]$:@F,+A6)FC#'M)!0L?B:#U)Q>NTRK M@<=F9X$B?^:@4)C;:D3D3 9+3X^9Q*?FMR)I(''NN$XEUMQDOL7U7^,PR2#0 MWNRV>N=G]T6=S-B(IW?=&G\V>G/S= M]T:?S56Z8MWW1I\UZT\%!\"2[! *@>X+,9B.?-5),K!!B@^]]D&W75B_EXJF M1D&6W"X*A+F*JX%1P9!R1^^U,-^L:FA=,N1'TKLK^FV,%*>YTHLJ=-_<47] MKDSRA0+9R%1XW:J@UBB3*GM>YL]50;Y.L#J+3]MX.X:C4R8$ZZ$1@3 MJ6]APZ:L:HW2J*4X'&^:A[2;$%*35!E0>J R',!H7BE3CM*: .1##@ZE+2B:_;D^7@KVXJ-M-*O_)L3FAAJK-MJ+?3ZFD MQ4;ZR;'N&<^T9383."^N;K=%_0*O;4A5J]]V^H!1X74?R,J%;YX87-JQ+1/_ M1'<\HRWQBUKF95)_U*W2VAQTCDZ'%!#=CAO5@!2UJ:1HZ#Y>MHD&>W]1BD=? ME01C5]@,B-.^Z@UJ$=>W\*5HZ([UM#DMJEHS4P3ZK#;K>V9G.'SJ,P[UCBS7<5U!1*%I*\&1JI%:JZOHD#T=4\I!B)W M&UD&@7;O;-L0-+ITCL+4UXVW=(M)[Q_,(#CIJR+EGBFY"R,I.GVV01K<(YH! MU&NGJ)0;9#.H=)<&*YI+E3<&9V!\ZJLA6QR-RU_N3#'HNR> Y])NBHJYN22R M_"-%5[-3^?MNO6[/BIUSG?;:L=9CK;:-(N"D1CM^\#Q":"N$\M'@4G1)!YAP M 5 . K+1[J/ O!#^>K@# G[YS^2;^ LBU!3,#\C_'Z;7&0 O+R\?L$"N]?.# M#9>'::.UP]!ZA3Y+N'2S"S7D$P=E)SZ=J?0[1,EC((+=?+)"YI MX3;%1'\($TU&-7"7*]H];G<.$/&W?@YV[F#>F@9MH<#?V"ZC?/EJ+5T_II9& M6)*#2X"/OOX51+D?; -3WM].D+A ?[XI" !>2@N\."[ ,_!@G&:7!$+.+836 M&*H7"SD!W02(N^\"!#9R5SPRR7B3&@'QAH_B8'J+HN7>H>;RO#G .LO!4RK) MJ,5_*> O%81%<&'2(DW*,R<2# )9H\9)5,4PE;/$,R)55%1(\9OE13%Z68A] M=XZ<+TC9]K6?'C/89>.GK4+B<\MS,<:^:UTAS-/"#8CR/H,8<_YK.AB("2RA M6Q!NS8M;&-Y'C_\$=D@2 =+YSM= F8^FDMM$BG2/V%U>M:3Z)8^JELJ%;'#? M^5).1,F-?\0C0!HT82:]_XZ0&SBNS;=\F$DIL0ZPL1F$KGV>-&/BEZ*$@ K> M,U-Y'(6+^.S%OS3*:71= E6K>O_]O$NZC(+ 5I<[]'&U0M]_KMG+]]T*[ SD MGE7>O+Q2!%B&U1MH1%XZL6#]/.Y:L_&:%5TI<6<;C3<7NEM-QFNW'EB[QQO3 M35RRN+6&62;XJ OUI"RJJ\*JIL+JCGFP::_Z4T:=W,6EI$?:\[78^@5*%#\G MO,&96KP'9BCBP:! F)L>(:+K&#Q.F>C:&QY5Q_OJ;%=Q/Z(YMT3(0:#*2TRO M".CV: NX^3/1/YFK['B&F3L\0P'0O=4W'_MF@;D,B<]FYYVVA,1>])7BH?L( MVQP/P0@[A<"XA(\[M%GI]R&T?\K+^>"GJS_M@X-G)9>LYKFYL] $)3F%Q @A M%?KW"PLQ>2EY*:JY0C;/2_SB8&-S_DF'DU^J?4IM7MA]JB[>B&P=J.-MZI%6^>*[6SCV@)'QH+X 3>6 RCR?ZV3KN;,<&9P^64W)H5 I%QV8[*K7^RR M&Y.]^6*7W6AWTS/X[)AU4)VE1(76O=):$[K#("+.R4#HZ";M=?I/=,U%46$047XV7522I5G*')>Q MQ$]<('TE=R7.)6E: (!_B4<=K@&(7Y<6EI+.O'S)HB*4)0GP1X17_[5/ZO?< M9TFLE],48#H>U4U?KDD4!B%^$VFGX3M3X,4]V^9XF$/DVEC=)IGB6D^Z-26@F=]_7V9K^9E.B.XZ#FN0/TA4:BT(&02PWMIWW#\B) MO5]5TB+E@#-7<>=!%;S^'E]U%[*O^I('5?":Z$8R'Z"_?V\! \\E!)2E=L<7 M,6SS$/#.D1I"@Y]I\#,-?B9)?B;&-=<1_Q.?*H*U:K,+7BJVK0.6;FO&^*W: MFMH[)@?U<>CN3<.6CUEL:L'V[4ASW'],:UX+3GF4S$]L;/7$ QL?ERF4YJ;. MJ822SW="T3-_K]*%7IW3S)Q<=8G.?P'O)\W69D[?4Q4'2+;\O:DC+6=+G+Y^ M3[\ [RI\&NFJ2ZYZ+5[[M]!_QML"2!9X,(-Q'W7Z_3D,PEL8_A\(I\"&3SX) MUB7)AGCZ;CXBOQMQ.4L4\;*=.396T M V 0=X.;+2Q_,V;9F/\.XOW9&3\#9#V!7\GIE+1+O+)<% >HI7K5E?"K;&0> MZR5]W)6T??P5<=7M^?];+.9UUJO;A#F^RY-(0%:4N?@/P@ ^+@HTR9/_WFY/ MKWC!!&9-KUV>NHWP]F*);1;#MJQJ#HU&OW#&_(I@P!=*;./U2@+L7BS8QD6V M)T%V42='Y)V18A=,E^UYG4UIKL-?>SP8O:XR1L?X&+%,1"%C3]RQ%^ZSZP#? M(:W;E:PR=F8ZCRF]',$07"E#2DK=-F^;S-/W>E*B?#?C [X2*])_X"[-\7W_*,$6') M:-W#*I#*_9&!&:,Q378K4-GE-Q--:W$\QR63$D!O3@NQPI MZYP$);";C[XUX[.(D@0&$^=8$D]LQF 1)14KOV @^G] W\A0PTA#;(TEJ'! M1,D??X S@[R3W,S\MI9IB%^QX1@F(9H9\#?F>?S+!?0<@/@6N9QWR1)2 N]#X6P7 M"F?5%']VLD1=DK-<>%+IF ZRN%55NYR^E7?V;C^GN I56%DTJ5EM^E(CU'@9 MCSJT+%0+Q=(U]DKM^D-);HKO0T&B]NO M8LR]+WK56%DGVQ/==V3([F3[T=S%(]CW]:.Y+0T$>_-^--^2:EO!,816Z!U& M USUP;0,K2_F*@"5:+%$12EFPPRKB7!G4'TU5QMKAFHWH2&%;#3TY&%.:,DP M.QDP8\U2RC#[.!PR.3/0,NA.S=\TV^LS-.J#@246.6@SG32#]Y/N%G^=@Y<] M]YF";.X5C^V K#QUGT*M.Y*C=3[+*1VA8.KVGW=JWNX4*64H?AY4K-0R-PKL M6U.K[9=?4FS?VM+75C.<0=X'YY@0Y(6EZQDL7P?UV6IO PKTH$Y;:\Y!01[L M4]G-9"BV/? Q"6'+VK@H1>I8>S98YY9Z5;>K#-8.7(AI&*P-^[-ER&M/E>@? M\KN="#.L/[TUY=%.[\P,SR_#W&V[26N&=1\BQ%K,+YZFPRG:)T?#S-;98CL; M!^WW..D:AP87>YSTX8H=(= 474>0 7W\5F>GZLLU*.(=N;/F/EHN+;3>7.&S MF3EC.W2?,=,//I8&D_U"T@;&OH/_>DK^*O%.&QGO-_7.FT:RF5RUNA\^OO9# MY/J!:RMO(%K!A(;^?..G)P2>L(VPS3. EL?<$T\U>QJF)"-SJJ?;;PY1.1! Z'>XJX+J"?.Y&0GBD/[,T@^RHF;I%6IQ)J=IRX@O)D? M)!5-/90%+^\"9K5&DE$6FR),B2N#N'*!N7.V^J_R?LB(R;'T"]6 M:[_8H>7FT')S:+G),U>&EIOM->FP8=M!.3W@9T)\'H!75=!Q]&:!NY@*CW;D&))5Z7+.Z M..V65I^ +P@79$ ?#T#K"''1QFP]QE^59<<S LN1P@N@]!=DJX]#\'^XLYUE))8T-@.1Z:6.$J6UN2JM*I.9&1/&"DI M/F/@PNCL"_9^;@J2,]B9Z1RF4S?X>84 V58 -OA#K9@6,],Y3-.I\1OT,!D/ M;XM&S-1==E3@6G$3$3L:%42,F!M#+N602SGD4@ZYE$,NY9!+.>12#KF4;+F4 M#-;-D">IQ!#.8!X-;==;.\51D(=.E*VY'^A%\KIWHV%^[NPRT"Q^N9K(%!-PXC! M'OS9@S][\&F=9GV'J<[F6OY-/E;57KF6*TUCN'1-P=%,,L>BUWX$ MO[OA8@$\9PH\*Z[/OP5A_,T]",/DB(.GQ/V#'-C:>:_1)W[.>RX[,CNYF>[V M&%56AILZ1MQ,=WN,>&[5-&%X>/A]*R.CNI]T6ZQW>[PVID?^\F43QJ* +64X M!W>62R[CG%FOL>4"/5+=BC\H%I<;,&[ZW9YANW=[FS"]=GGJ-L+;F[\9"._R MU&V$LZU!X<41_$SU!&-S#0/E^W[./T,<.?Q5D24$C)@I0P;)D$$R9) ,&21# M!LF003)DD P9)'P5D266S9 ^HMH.SA#_J'L)]QCQO1LE3C\-8+?LLLBP_C2D M2+7M@*-8O^E,*6[7\)NX84;3'"V(0=!;9MY:GU9CPV_TUA2&0]DP)*V%K;-Q M&)G;8[>KX\"=W4$'8S@%:4^'HM<-G;ZQP6@G!9!>'S1H?+V9J'0DF/U2QO0Z MP\#OM:@CU1Y8?QUJE MX?4L5I)1ZV?,&F "].S:H,042A0:_AOIU&7#)]_]$]LL<=[).0S"H('/42H# M2B\);<2PD#-2^JNU>";; K#032EU>KTYEV4;V@$RZD$3G9E@;D5>6(P:R]Y0 M+SO=SZC\NK/UF)RY,L7OEH^6S<2!G(9FESRNW @P'B*HF\/\!$L%NQKKN5+ MP:G*.W0+0G*\QQ+',HS#$+F/44@VB!G$PBRA'_L62,$10$'FA&9 M)/? CK T+@@N7VTO"(($))=C&/P7.SMN$7$,F<:S?+V0$&BJ<0IA? MAYW?2POYKO]$<5G"R ]Y3'M)+QQZ 3$>WD0NQ&(@HB2AJ7"JB*5UU=/JFT2J M7$4-%_39NI@ =Q);FVRH=54U%*6!CTK.FSLPZX2\4O+>J<4=)1VR0C^4G"GT MYAQ04M<\5*06N^:Y4K%5U6*_O4-WS/EE&(+=\I\Q6W^0R03ODN-,1/2Z?F,= M\)6UN>5*.D@;[$/[>#3Z'Y+1.W8<-^'@VH\3>&.?JXB/BX>B?A\4$[<*;.T+ M(F^/B+^4,.P\+].(25I;<$F6>.!B>_O&#;A< MGYR$U<@:V,A=;9S1!?PE-N'8=^*^%7=XA2(0NB@^8A'&N0[0,MZF)OLI! BK MVREX!GZ41KJNI_?\+M1:4NJRN6;6ZS@*%_'F+N9RK*;3%TG4YMCM\B"68E=, M1:.VY'9"5M/1* FUQX2H>,UVS:?&H,5J M)>^L.TR>\-WR9#%MPY##"NJ2+ZNIPFQN W>I>K:5[:7LR-2E8LQ6@.$Y2V=@ M'9O?6ED,K)8<,Q0XW5NTIEFVZZBC@!A7I7OC6H])WX&T#^J]1>*M5Q%IN3F% M:\N+ U#27,P27ZC? RU#&'XG;MK%8)/GR\@$JZ=6E+J -UHRYVVRNMD&QN??9Z @P=Q7Y3G!GK@7'Z!@X:[H6UGYY*&HP@45;[28A\CR)H^>^[2Y M9YP0'00&H Q3F8,;_VH48 M?_3CN_7J+J,ENQ>_X*'6>,,;.C]OVP^UQ=N4='+AXVSKD5;Y8G68[SP@N WA MH\+X"8'X-,[78+7L:279LKD^:F/?N<6F&OTDI_@X>L8*DU8A+VD'-YGG6..- MJI00$)@T9]9/@,X0Q$;RLQM %-S<\A?#5VQ[&JS=?XV)6JE?""4&$@W Z(XI,"V!:CL1-K!R*1#F M7\XG>CJ U0<;"H'F6+ZZU;%SQC0G'%FY&HJ/TK#@($\%,C=,7^:P@(4N$QJZ M,K>:I$ZB;0<5E[<<*.*W6WNL MQ\GCOWVSSXZC;!7'WX LCY)UA' "_^V;5YA]\S___?_^O_[U_SD^!F<7E]=@ MLO@?'QR7ITQ1&]!?@+,HA8/_W$_CXX>/)\8=/ MQQ].[C^>_/3QTT\??__NAS]\_/[C]Y_^WP\??OKP02#P9SXL(/S?3^#[=Q_> MG;S[_@\GPA_>1*M?HT<(+L^$/]Q\_'[]XQ^^__#C[T\VOUO]+OKA#W#]X=-) M]/'WZX<'V&!TBG>O:?SXE(-O5]\Q$X?3Q_<H);J-C M A6Q@A5ED,4_9>S#*[QB&"G(!3K_@O[KN/RS8_K1\^I'/\DHY:_[H@_9/%VAXA6WEN+>@USM]*V";H6^ :F,5Z?)XZ5+"?K M1_B[/$H=:[V+L.L!W)/Y#;H5_9"DR3DH[^>)WF;!5L\ MJ*7WO=;Q*UXS_$\^%NB3#_ZZ>(YB(@V"%SB]BQ \@P_Y'5SMTSB/8;98D>!T MC^A<\L<49]F7A(2>*/X'^6<4)Y_A!J?P/GHYW:,W_UX)" @SD!$1P9K("+)*2!#54H)'*B;85W*"1R(H>&"2@CQZ.0(K M+NR[:,PIA3_ S3Q4-&5L65DM-(OF06MC2(N#%;#O*_,\K@EY+V_S=]A"+7,NY4 MA >@RP.S>S)(59R;WS:3A/BBMC@$I^>EQEBH9=RDB%(4B+5VZ,,8%X;.F MO"Y0]*AJC:TOF6FO0<2]/5;D :4_O4'*%8T[=1&,4I&>/EW.D-5I(;TGT)TJ M6U^V<_$&,8^3)^<#""-V-S*]V?9#@0>U%)S:VU.LLL9=&O9%G*TBQ%E?D,\R M7>.6$+#3] %!CT;.>96:9]S",?1N:+"2QH*$H6WT6@BX-_S_@E%J8?;"UUUH MNR+GW^0IJS -_A 2J;FW=!6@^CM,747S+@S]/HUHAL7=Z_8!(U7S;GW)3*L- M(NY-N2 /./WIS5>N:-RIBV"4BO3TZ>Z&[!8^QO1H(\FOHZUR."W_KLW]6).6 M&Z4^P_0!MR_(:D: 9GMQP$,Z"DWGR%S9T]ZE-@77N$9U]O]?0@E-C10YGHSN("U;15X@8(!OUNUM^+F($TU/"[!&GFND9 MK:_:3(0-4MY2,Q@74+*9WKC[$, #Z@E,V\A(T6[-^'J_?8"IO@V7W[-5*:?C MU7H!YQ&2Z;:T?F"WHE9"TO"AQ0XJUYVYWD;F.=SF]AN)Q$;-7<0 M]6;5A!]H,@S,QH>@PLK:"Q869(N(.\=8K-=D!%GQGZLX@2=Z3B$E8*-Y"4%O MSE P.2I_H,]Y(%@F 03BP_!@):T%"062H= X61$XS\E/R[3>_PU,3)]\>L. MM%V3\V_VE!? *:#< C-Y"2@R@V]K*T Y,;.5+\<4KUS6[_+R29AF=ZD^#E. M5IK'GUTT'"B]1=._Z3.&U/9+EH'9?Q=0,B>0*B]44.3NP.%8JL#AW"=N<)9' MZ/_$NU.\-O.(%@4'JF]0].\-G!T@_ !E&)@OR &2>8)$;6&"(?<"91B<','3 M :8PTK'ZYG<,CWD%&AZ.UYD^"?E #%FJ9=REB5 TBO24Z<(]:3(.@+$(YLRE4^NX3RLA:1CI*]==!'&9K'"ZPRD[MF$QS"G> M)WGZJA]*#)"R6<9Z27L++AI3PS3LP)#1].@Y%3MZ+TU67\XP'&_IA0FKJBY42-J.H8N&RU3A M19+L(W0+B6>:91D M,5UBS$SZ\/N6CQ9;]'R^"*U8!6?>G:BTGXI*M14B FU3UU"^"W,OGM6_GGQ\ MN(]SI+P5./R>F7+;=#PDPE.R &_ R<=O'[X#)U' 0QH*3>/(3-GN-I1_ M@0C]1X*_)GC6L ML++Z@L4%'4 "_D,/$H>5 ODNED=#]'%7'N7J3U'[:5C5#932]%<^L'@/4/$# MG&$H7C$ $U957:B0($LTW#G$GS':)WF4\G1]34\X^+*-OEO$O-E^Q8<_( C& MYKN0P(-*"D[KR%#A[LSZ;ALA]'F?Q0G,-(VZ]54;Y39(>3-HQ@64;$(Q9SD" M>$ ]@6D;&2G:G1F?;V'Z2!:$/Z;X:_YTBK>[*-%\/]=!PD;14I+>S+OD!C@[ M4/ +Q<[[(<**>@L4#F2'A,/Y_(EL&XSLO_E-J_E%H.1O,J=,0K-QJ?9QOV[" MTC0R4;(+\[U<;=+%?AT3$UWD.;FE&#U[]>O<4D9$L]SGK/D66$\W3EUY* M5AO^'LK^3F(84\"X'@'.%PB,IW<1#0"QGCK#!@MUXJ0%DSL?NMD_H'AU@7"D MF1S6^**-T@5"WAR"\P",22C&+],\[E5,4%I&!@I6Z11Q%4KZY?39'^7*_I)>](L/OXK2^BE.! 9RH:--YBGQ.BT6]"C MIV^?.O3=7E*7#,%R(_2T+'D&T[[!"%!LHM@QS'*193#/3 RP_4US4VM2\E"# MG]$/PVHZ](W[M1&6;I&H5B6_]&BZQ8VEN04?$+!5=HN@OPJ&$6/W4TB&W87& M@7U+E12DYIO67NI^,JL_C;*G1;*F_SG_^SY^)E%-0AP\/XW2])5L__XQ]G[R$T*=U&\/G_9P22#Q(V7^1-,&ZNRCJ\HD3-'2(&\>]\IF +( MN69L;<*4<=G^L@CHPO G'42Q@6IG@!YJ E&4VQ_C;8^SH-N1 MP^ \0H7#W-.?@_2-02]P:N_^+'M2^Y4MD]=$]VXB*Y&2VZ6\IOR;CZ\D< V$ M6&WEA0U-;Z!5,QO9<6YAEJ?Q*H=L>V;F,MTTS!'IHNG>36I.;',?AH,,PH)5 M514J!.A ^VRO/IDCW*1X!]/\]88H)B=1&3TTV-&;E6NHN=OHHV,3J';3];&_ MX-S8O@*6K(Y B=.7M"""^NH+V1H4 L5QHGM'2I>X+H/&B\NLR3"1/1=UQ6, M,G@;/S[ER\T7LHNBD:".SPP0,D>FE[![KZG8 43Y@90R/,:;XSWY!]MSA.$\ M:L!A+3T)JX\-8 <:+9@A\H3OQ?GS\>%!]V& 6>G40L !#1M"#I[ CCY"V MX?U08"4-!:EV)&J\V*1/%F5Q_OH'3/9''KZ.E$*RX99V#\Z0W!P>>3@U&MD* MRWP^LO,F,13+?7[":$WF)QI.Y:\F^1_J-,WUK\K#0[7CFC/;$F0"[__Q3S]\ M//G#O[!MPM0UHXP1QJ9:G@N:Z!!(NG\0V0+.=[IT%$$XBTRL/BI.T!HM)PO5 M/ -)S%) 2.Y)CE.T?*,A\9;)D[46JQ6MX)S=1*_T^-CDLJZ#@D5$(*7H(>NV MX -VG%$8WC" "%;34YC:1RW%%SRFNI]>K=(]7!^ZO:;Y=Q&QPD!.U(L34%:2 M7 ]AH0C&,P;PPLHJ#!8;U(1%LEA,>B!;O5HR<)4A2JY.^]J4_9_)EJX2R$9% M$;+.LUBY L.&I^,TMGY,.(WWV"TN;E<5;\M)9TI4<$N(VMKA?M'PO%H$NTH8 M7D ,$W,^&7F]F.A:+MC=-WW67#H,JVF))^ZTJX_I\$KB\%9C'/P&UQ.5ZPZ% M88W^VEYV JOTU'Y>PT3M$19,P3T&E"U[P\U'>#L\0G\7M<+4;7%;VT'%\NY0 M2M77O6UPL8("/.T;W!Z%A0M%XRY7C"0FN] 5A#",EAW%:K[BX^!L7:9Q>4#L M,!+V%0*/_=X9;[=QOF7/3Y/U*4YHN "3E:;U]I*Q>"?;3=;#'5/-C#]L%MF! M;Z]Q#L$?O@O#Y%5@PQIZ#!@B=(@.>\7%0:>HEB%40]4O M17/P7;ME7Z3E)QS#28\G_>[''E?J]Y1_ =^?')V384M\S@Q<=(LM/O1O< 6%!$11J^AD$=Q M?G49J0J"D3A#Z#FW@5:U93&*9F\ZA_B+I?]UQS M)F'XH@9P6%^%X8-4.%G)#I3\@(C8V1!B(QTZVATVNCW/\G79%/JSJAY4>D\6 MW9\H^CY)#.Q%HN'=:@\7>\,)SVAOXG2 M9Q/=K=!ZX=1S7 M$Z9@F0+.EI\< L*8]_B:U/5XE[%%=7AM[G*'E%Q!UJ8\@HL='.J'Z&J=V'6Z MF%R38>/4X5)%>[R% D*CN=$EN[BQ=:&2BEM8.%6?KG/7HT!\/%IDF)G)/+^/&V2\WDC<#V2CKXR;,D?.V21L-*EDL1TO[HH.FSV>:H MEXP3F/QOBYJN%.B>2 4ON2NYW@UYQT;F.E/O@PX&K;\)ZB3A$ I?VQ^IBX2T M]QG"I\\UW.QZO&+1XQ*3['<.!FNXV>FGXQ ,K]L.I0U4#;Y$U3)PES,#I(.L6A2)JJ>Z2'U@U]"!JLJ*\Q>IY752>* MCFY&[<][B#BHOM$FZK-J2MF0, Q#&@9'5@Y%KJ]@@4!M#$HVT[V&NX49)##1 MKK]G\!DBS%J4%'+I.,8 (:OF1MV$O3298NQ8\LJZ9AB&FZC!A;6T%S0TJ(4* MS5 1>)4>-++7_!$FQ(41$6:QWL9)3'V7/JXR\)M!4N;P#)!V[SL%0^8Z48-E M&-ZC"AO6U&'@$*$F.M2%FMPF\J*#U=8J$'.Z[OO*CL1S";^4PB[GX9;G,&LJ M^ZZ?WAA9N/AU!\JNR7FH?4>?]U#3*BT=)Z%9N 0,F8VWM12@X@_L7'AC-?H1 MS3/,6!4<+L-E0JR"?*)W1M-%P^:01D[3O>67E(-ZPC@("U955:@05 =E)9/2 M"4HVHSL"9VNP$SCXJHW.&Z0L5?TC5W4"'^D-?-O>BT &?$L,'^W7, /_G,3H MB/TOVPG\\Z>C#Y\^@"C/T_AASQMJY[@JCKJ+4O;V8(-3D#]!\$HV>AF R9J] M:&N5M#AB]2S*PA8_- M;!%(#KCPA69%WX\^L.GWU?;#I?N>!2V M/RJ:4+OL[ "@89L+$BU%Y%4NCQ.=FT5QDM'P%&;+Y/R%"K2/LR>Z;B\W9_!! M*UY4(&9Q,#-$W-/>"2?$145NM&CXFO 3/?ODZ/L?_J#EP7('/ODA$!=5MPNL M#5'P-E >SU%N@+,#RP0T&=)Z&93ER Y[#7.SPXO6%\U!:!!R?RQ'2Y&@WOWR MF'X@5S?NU490JD6U5J<[C"B+8Y2IR9^C+%[1.ZH8[7.][,-!4N;:'R#M?GTI M31WL>-DEEGQ%.1^!!\J;WWAR[F&X@RJ06%.K@8-6.%%5XZ5*=@>,';\#'<+) MBV?]!<:/3X3MXIF$DX_P>D^#B>6&"2?DAUDXG"D'P&P'F:#6I:#"AD %P(&BKRZ4*08_*I M0Z4@W0UOU+40-C;W^"8R;2_NC*7E7M]>!%]G2.$67W1M+NW3'5>8O!'3:)P7 MJ11N!(5H0)2-M@'CTDV7T-BEUL5S%",JY :GM!G;'5SM4UYB:?VW/;\[4E"[ MB_G'F2CNC<^1:!X>BSR1,=$I"NR3%$:(U5)_9$]J!3_F,A_S'KNL;.S MK!I&U1PR[RL^&L),Y]I@%69 I^B_<>,\E8O9[L(NO>C9O@A7/#H (1 MUM!9P' @&1*%&QE4H/\5KYG=GWPLK)YV7R[O\I?2N_SF1%'T2K[AU[,J#F'+ M01\<.XYN<%OCU9Y&1BQ[^)M_7VSQGE^#MS->Q,@_(7-@G>00T0R4(MY?H2C+ MXDU,FR9EQ<(Z<'7^;EI?=618V V<_4]SI5Y!%RGYC;D+CS"E;N8-9MR\>,) M@DCX1FUI%]@>D3'>F;>R,04QM(K#]Y)QEBLJDO68%%\F"0_8:!@QD@J W5&5LE5-4(T M)&X6(!HQ\Q(?B@6URCZQ>R(,6%724//>R>O9!Q ?VAD%ML;#8*NCR4VY-[(Y M[5&LV&'[7$=&S.KXSL^&#WH?VX%A9,$UW5NXAG!+)WS^:1Z3'YO,_A*E:43? M] 6O@6-1U(Z*$Y4:@2CWY_ 6FJSAK_D+7@TRIF[F*&3__1J.[5L:!K:'9#1KUHO;[7B,:=D>HWA+^PXHG'=B,E;6[CNX M%Y:4:YS#S&UXWT'=4X OY39EB"_&. F5:$9!?K]AJ(;Y/9",8*\2MN"V5_B_.D) M(J67:$9DS6Q8DXT7VRUDX/O+4HHRXJ!RB!G3, -?"V$"L%E3\+&%]OW;J-ZL M:TA\%'OU..,.6JW<:,.9;^V,PLR"U>=:-XD05:W_Y8:)U>AA;O*@3Y&@^7V[ M$@.G=W!U:P?Z:E/@6;1>#Z[C@QZHV$BWHQKG/3T;-++"XIL.S(U1!4C0ZU#'[A#,8VZ\5Z'=,#@0C=1/'Z,CF-=G$>(7T3'R!D MCD$O8?>F7[,#E-_Q90(*CF$X@AI@6$M_08.#I+B &I?)7&>UVF_W+*.WZ^FS M@1NI$[5 396)!_>J68/N1]J!N)HVP-A8Q[,!$^G@.)5KWL*BO)^9YMQ*'*K^ MH97LVQ;[R@-JOPWK[\$ #VLG/'TC4=6U>4]S0J60IV\2!RD3M5F9%9GX:%9= MO0@1>(.*>4C>HP\P-M;Q;,!$.CA.'HY=D>CPDOQH%H<)WW:P]E?4O%Z;4RZ ML0GM[OP0"UGHU=)2>'H_O$=75KFRY.UD$S>2[V :8S(C1&E>V,UG^!@G"2^V MCNACA9']]!YN=SB-TE<^3)[N)=2 U_':85KFMC1$VQ<^MTKO)X\D'1>.P$.% M[<,0MF-.!\J08UWUAPYO,7%4S,H$ \Y.;'TPK1>>1FGZ2J3@9>QL*^4:$'<& MY#"SJ1UW'DZJ81'=7JL*QNS0[_+KDC\HZD$&4?#6:HEUNJ:.MHA^;OM8N5Z& MX6M**Z#S)<_O&C?YDB:\YSK;IX3_#3,+]AR1_6ZYHY?;6?D65ZOCEP%QFVV, M)C,/-1&5WW?SCS&7*!#W,K8$; W"[%"O]K841LX>\AULP?A[8)K ME*[9F\(+G&Y@G.\57ZFZX^5G 5#A[7=V.'C!&E$9PIX!]$U$,0!0AV/NYJ : M'M02%;,&DZEL82&(%<;DP2>XD68/'6:>5I-@YX\911*.)Q)=8&9O&.FH,F8!Y S?@+G8_(F/\RT9A=5@9Q@;G:5!FV'NPL MH)@@P@@A6-S3436J;J+I:O.AP,A/J#G(V,?32(."P@>%A(..*#2-1W%;HHC5 MK U%=4,B&!&91\2$M5HBZYETPK8*[AW&V?HRH590J1#AV6]A)%2(EE6T4Q>' MEA<_XW=8PW3L631H9=C9 A,DC$B#F^48H88R)T^;T=D&&S,ZQG 9=6BA-F^; M43Z]&"GP"*XKB+53E<7A)3U!RE^]1;VA Y6Q7;'26XM"$D %!(V%[B^N-#9E M4PVSFVH_EC.E'E!+!6Q>$1RTHWH!6W)C':+L?CST< MNM>@CQ]._@"B9$U_^.&PR/T4&Q^/>M#;^H@K#)-D://C2P/CG(]HF\)X!R,^ M%6)K$\&=O5_#K^PWSL[8!8)^CD@K!B.NAC%K\)' %4WB8G=)Y".R"8D0V.T? M4+PBWR Q)1'T_08CA+\>,R_A'U4W4>4'A%863KE:'=M0/$)O030+.U ]$B=L M^:\#\6(^H[ATXP.*GLX;9;&].*6[BV4B/1N_I$=> MQ3Z&9G9>\EW,#=O$E 26Z07;Q"R3\A.5>'!$8'1#>?.6W B9FJ;+#)+0W!'10(Y=V+'D],7Z MXF!&RBZ"^VJZ6&Y I7,F-%@FH/.J\I+=0Y1JIL*#0GK Q:^)+5/ 1T )+@8D1B%]6%RA4WP];D3KC[Z53.1*,NMR'" M@6=V>*V=1P10*60 :XACR\+N,33H&2UA?[Y]@.LU7)\1;WPF<#Y#%V[12]69 M^?=P&=7,82$'6%>"A&[+*K!WV^R@X@ULQH]/^7+S)8.+ M+(,YV542Q_@'QT'1+#4(FEFD,@,OQEAQ!XBR!RGE3ZUQ3_X141% ),@0@!GJ M(XR-%&U@?"*1Y:8,=ECTHVINO23,#*R'I!>3$OE12ZIB:Q9Z!V!!*C!A1=T9 M6,EELDJI!9Y!_M_+I&F9VBNG!D$S"U)FX,6>2NYD72Q^($LG;LU;(2V4^@!C M(ST;V-X9W.$LICO(FY2J,']=)&MZ]+K;*A;[5:%B9F7]5+V85LF2GCSM"J8L M11"6; ,P)T7,L+H6#0R'$%M!N,XNB%AW$2+1V\6>UN*XQ:\1HD];V$68T9)G M1-KP\$J?E9]#U4(.0%$&&9&$+I0;)@M(2V&JY)W@5E ;:\"64!@9;YRLXAV] M$"_/T^YA0A_X;(G7/[/>#@MZI$19D;^AVVAUZS6A;6J^^KP\V6\A"-@)UP,Y MDP7$M3 @*J6A?TC%"<)X+:P!VR)A8+Y?DET4KQLGP*K6*?VJF?%)2'FQ+<+1> M=@1@/$IH8E4-]YN3X[Y:R\UIE#U=D+DL6SQD>1JMM)J"]--QT/-)0M=3]R=Z M:458 <8+_%)R"ZWY5A]@LC9YDVCP.2:6_OGU2P;7PKYW0=SZ MF;V=-S$^$^KF)JG/S<.3-VJ@&V:@;&]1GY-$%?6RO\_FAC.KL209R M*0#X_ JH"/0.O3[-KZ50FJC\OQ2@J;DD9$:PD5UZCSUZOQ_^CK*T')E6^9Y=\SQURDXWYZ$*F'X=]2?>,^?82D M6Z2C5C_+=...\R).R.:S/+Y8).NS.%O19'RM=[KJ-"WF-D4>'EZPX.28K7YQ M0CZ&65Z^D&-W1U'K_GL-'W*P+J1A?]$XSP_#B;2- )L",1? RP5*1).6H2_9 M%EFMA#&H.-M7"@DH.[.QK72.O.6HQU ON0/:@$DC7XE$O<%-UM/[>?,VN=3'=0L.RT>D#1C:F1>>,!#S[5 M#R.8&,"FW>RV0V-AXE#>"E 6X//!V_2Q8_?5*H7LX7DC-JH"$A*=D'5F&^^W MV259>HJ=ME8D;\C!(LPSXNACHFO$?M]&I5S?T2EOQT4 WY:1_7U MI-H+'IX^AZK@NAF":SQ72O=DIJYW1^4:7Y^2U+^S]C0M7HZ1UN#MQ4\I?TD< M*VQ, W9>$R,9\FUM0.9N$ ,S S,0@:D0Y0J'AZKF$E[MA4;-O*X:"W,;E-II M!3_R5;B?GV2[XFR&'VDR'W'>YNXW@SG:<>:=<)(UFDPG?INFXY$Z5,=X MI>3('W$>H<(?KU4>AX3AHP80&ST^&^_1V;2/S<+P4'[M[NOU:"]UYQ#WC0NF<_%<560'W;@09W/#V45AZZ$".(955E9Y1XO5G_?QRDLZUG=$"WGNF7+ M3*B:HZS.Q9^6U+PB\/W3F/4L;7"9X=PZ<%E+53*'E#^;,TL): IOB$XM/K& MS<\1PSB;3H^'@;MRQ_GP"KXM3@:_>Q,G#'8G"^.=*$Q[DA"&OU;/][T<#?92 M=PYQ#S?_1X.;J@["3!Q7!?EA!Q[4^?Q05G'HNNI%$$>#0L B[81G&DQW$',3 M6DF)NW?49FUYG<:&9 M2?E.E2%6, 05QXF.>&\AHJ>9]_@^>J'M4Y\PHOV^+W!J7RC%G(?]2:(N3R]G MP^49XP:GM&EPGL:KO*IMM4_BO&[5DDNA,Y ""((!( @(I#B/.CM>T$8+!6YQN&FYF;9'FN,MNJTD$^#9. M5FB_)C_]\X]'W__^ _].6B"]BU*VYZ%30/X$P2N,T@S A%?W6M'&%"GX='($ M/GXX^>&[0/Q^"/^.I?H0DU"QEB[,C,U$CW?J=D"T^)IV.S0E,O:3J(2LG]O] MASS$6J>9?UD=O>CX]V+ M3GL?.K*74MGH_]/DXF<2[K'#L?)LDOZ"K"C-#X2_O(%IC-?M=Y_G+_0$A(R* M_, *]-V2J?M\LX%ZR1%C2V9N6N-*ZF?&BT5"_A#['T$D4 O+?T>CX/9GXM_S,8##A^/5,$ Y#D ' M OA(YC0U7R;%2,[B;(>S"/TQQ?M=V=\FR>-D#]?%VUO-+?*X+KR!"=K4DEU-ST:6\%NR6J=3 M0?2?T$75VRHW)E@B"3P,2>D7(' =LJ6"[PE[DT4KZ^A9MN3UE=M M*MHU2'EZ#L7JWM.,L+(/N:*)[\ M6+^K3-:2*PBZ;4 XVZ?0--RUXV47D]CP]KQ*K2N&[,HXJ5MP5P^(27!2W[:% MMY8Y,R3L&K2Y&XT8P[*5L!!'?(=,C$/ZB+&6:;HUL]7>;OF01W%"[SC+L^P+ M+!1C;11(ULJ0LF%CD6-CSM9_3>O#UH4 %P+2"S587B;05;[=]E"Q'O9H.5<. MK @[A&W&%E.F:1VV?RQEH4D U4T3??,12AWQ8NI;IC=1FA?_8(61LIBNA1?Q M"USS%C%%N:3UB586CPEYB]P/?78>$HL'ZRF"?;*F[9.";/1B8Q'8 10S1+], M 2K"B&4*J 156"'( )@01=,E4(EAG:WX):&;RV7Q -]3QCQGHO7,?TK144/J MDL$D*>P'SS4N$]8K9GVVIS(U##>.4/'O^S1*LFBE^_[6 3-S'[1F[B&&:]@K M/X4AL=K!R]SH:Y2N [G/<&.8F*0O&P"I4" 2P1:4SH1JOI($,N^ MP4U5 ^1\^P#7:Z(18K+/)$!\]O#,M:9-_( XP9[%).7357[=UWSM.H,!EL=_ M0G63DA6H>2G/^T1H-IF??"RF\O:C+;%L2Z4M]I;T'A?OO6_X(V"5N=N&NKX_ MFG-S@]4:KYC-\;(!_W[_!$%Q.,?NE11>7Q,C;3VU?C?MQ.W /+ ],/,S!58" MFSCFO=DS?*?O,,<>.VH-5U*>J1XN?Z9^CZMB$H4H6I%L5H:R&5R]>\3/[]

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end

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

      ^UX$<.*FGOW^NJX)[HJQ2BTT^OJQ%@PV3B2375Y4[D]10G!,O?G2VUV#P&;]XR M!HGG@;.;+HC3[1&1U=?-L=*]R01E]GP\VS1!\:!UT(J.J_*Q8Y?0QHXA#"@? M^641&].BR&1#.T88,).K*0@#BAO<$^\S,:BM^A!\!Q<)A0%2,*!3\3XS__*# M 0QH+@,=*6L*MBMEUAAKF9-L'"LH1\<\LJ(8E"/WF!3VJS2K+,36%7*9_AU>')]*'>,V^%<:Z$Q7W]&-[DU&9)3^'$ZA82@)5YK,D:#H&T: M'OYU>*UY;$.O"PTZAZ0N=L[VQ[%&_I=S.\Q]FUD*VL6WCR,Z![*#&E[!_2#= M-J&ZPI&AFO9FOL\"M_JT\"GU8X:V$ZBC93]/#/=YI-[3 _FV\G!OFFI1*H7^ MF(V!="CX,03T<&YHCB0@0 7J:.\_F,^E%F%Y?^JB+STJ AL[+.>7VM&K MA*6_N7I!J3NJ4B)A+XQ9.7T_=:T\/+]#U1HYZP&;=!@@KN2X5FGP\QQ@WWP8 M[AI[G(12UVT]ZU\C?$W ?C[U)<$S"=M?>+>4.=F23.)XDD_ M?HQOE(!WFQ\+'3UJ"$!;6:!C=^/FL5TG4!W/O@R\B[>W^E&!6',;R!:(9 :)*@5*KF7@I0;]YXQ#1VL(;<>B)9I7 M"S*G7I2*10$ MG,0,%W^.-AJ>UXA/A $&0KH'9QB4#SY6Y)5J4V9'JE8D8^U$Q^T%UE2Q#-=) MTVZL4^M7X<2>)-Q!I[O=#QA24-CNI[=0VDU]%>0]([R9S:OUCO:]\V\[ M941P]B*A[E@W&R%EH)\O3GJ.1\DC>!C=E](?H5?I5LDGPZ E;EI\.,K?1IK- MT=^>4ET,2(D!$E5R5UO"!W$\O3! $/GN1%'A+\3R]+:/]3K"XV?>H=X7ZG4J M:[D(3LBI#XI'1'"8WN##\TA2O DU8WQ,_/2!(.IXA3R2SE# :?_\7;%L2;*@ MYYRR%=2@+./2;<6<[/V(U8KM@5:JW_T4_-24Q+CIJ@S*>#F7R8@#KBD+BV96 M*TBC:FYC2XKX6Y>PSBP%M33";]_EI@VPJ10.Y\LL>5P%B;MU4]Y"&IV#,A6E MU+5S[D-R!;U1V*-+][&PE %5+Z/$!V-A4&<2C6TF!+Q6.3$BG0C^2IY]^PC: M1']T'VPU]Q -]=6R^I >KFL4#)B7RB]("W5#9A*([]9#+W0BYCJ#SD]J1+S' MFJ78;WDI8@)_*4F^4>_%W*J)%!5>F?7-?!.1I"8:^[CTC&6&MR@HR"8CKMQ M06H^F,9'7Y(3ND?VFZIS&7(8P+^JF\OZ5R7^O#3[F[;_VBL%Y?PW=8O_9I&? MMV $?S/>?9(9>JAY&:TC>, U9SEFR7,W6ONJNNX]+W(H%KF:FAC7K(O(1(\B MG1AJ<%YZ"@J OW<_4.&GU;\F4C9F#CP.8<]^\ )7K-P9WC ;.E:R+I:[?M C'@VCP].<>3? M>)YMBE8A*-<$_K'H[IYL5D^2D6S\-Q=&LJAEL-V!"'G4(D?CAT6O:R.3#3(_ M7S\'KO B^7KCKU)]OA]]W)X4:KKFS.],GK?-\E1]G<2JD. Y6(QM6$3B?6N7 M5+NG.'OY9K)?CE#UXCK!CGG_)9NL6I%=-V_OH,.0H(6E')IYM-KA@E9![AK< M>OL&%0N'C._1W5Z#B0\W6_/J K@&:I"\*78_+Z*3O+K&\6A-L8EQT;?AKW5< M,)\R?X0!?@>J]PIP;KYHO8>-LU\?3J@%AKPYS-JC'FG8:MY,@SJZC8"&Q&YW M!T$K_!/-FXG%=X>@+O"E[)GMU>;]N<63ZJC0.U-Y:#<*+'Z2]O/!OZN1W]@5 M\_Z)NO#?4LA5P2I2%"0;_ )U9]^42"2Z/=4;;-B$XC5J0=UF8< 2\L_EG_XP M7"A36:A6\M26C_UJJSF1TE'O9 3$=Y+\MZ*D_V'\]5?YZ_5_.(\HUUU5%N08 MRU[HRE\9Z/V!P2$&:%4NB&L(QT(56S0KUKK(*!"MK2.L0&1H8++\/BMZ7%9# MO4Z;;PZ7;E5H_?(F!KPJL-)O_\!R$^M2%\H* Y*]V*&WSV$ @<0M.X@0!@PU MQ< ;S(8$)2^XR2VM^Q%]9OFTG_5BMX+4-O%D>WMS3;H8J7Y,D_X#\RHE/(H M%Y%'H+^**; % ^Y9.IV _DS[Y]I,!Y"EJXM1&'#0?H]MO&1S/%RI)*Y^$6[K M-Z--W8/MP\9;+1@@=*UW=VD+98J!$C5_ 6TN2=]#(HQ[C*1PQI?ZORMC\R\B M!OS=]/^/L?K/:F.0ZH_* /_9@N,[ =6^IZ!?_1;\J\=XWCL1VE)G\\G!/9>E M3S DO,/N>V&VB*V7$D&TJDI4*B3+49&'6_R=4RNH=?'HP["_3AB M3",IO,KDJQ12+;WT= W/_JSZO^-ZG2A_?B@$_G-P)_Q1_?3_ADN_FFNY?C4( M_IL ;WK_YSG\T:1"V2_AI?4OZ./L'^BCS_[3^X$EBW\ M?8S^(;=+%F M6*W97585T?Z#M#_JAGU6!-Y97?\D_)1@0D!X9C:IO%":17P0LH3]M(9._-%[ MY!4%W?0-[6(HY;K"AZI\*&GW UZ2M+#W0&;16!2CVD'QN*)B\9)>3L8Y@IMP ML/":TY3P[K7M'6>31_?@+QG[7I MP\V M2/"M/-^-TMC=$Z2?38;/0LQXD=X^V[DJIL=0QCFNH135E:G'ZFU^O4C M8\+[B0S4;E'O]G2_'5G@>4"&L.9>]NA:LRW2TM8@QOI&SA6^HYM0 M*8J+RT@@^;(LA[Y]/3-QQFJ\2:H;;F%#)XE)J32(3[F M:WH.M2N*1/MG^8: M*7+SQCPNKR[>(QK]L*=1W",4:_U A^BC8ZYCKZ?ILE;_%^4)6ZNOUCTQ:Q$B M&?[H=D/?A?7>9*^ND5*UWY=LKJH[DJ'Y%L8UM4&\\%>B7_1Q^6^74@MJY_+3 M8<"G4NW<5TH#9FE!/SC^_/[3/VW"74'\P\_VZN4N3SY":XN/<_/(_K*9OPF6 M_/?T.C3U+F+U9=,G?';JMKZ\1JE.MYA;ZKJA.W@VX<=0[MV*T%:-)&N%-2[/K.]D> MH4S,'R=+EQ).R==(VMZO?L&^#AHP(,6X>TVXJY%'QD4R0%Y'2$=Q@%W+9LXY M\76 RT+;IL!Y7A/UD6KDBK605N&;'6ZCP$QINR>!QFA3!A'/286:A7ZE._1' MNBY_I6\1/-Q'SJX3P[S$*89X_D#JJR=_P;[>9?2\$\6]/C+[(1BDA)4: M3I;XS_7)O*90!9;="383;E1#J/1R9Y#'4^>O;#N@<$?6FT%G'O$@K,5>A.J( M!IL\CC[UY5!+9BA!=S ,V-)JOJ_N)"ZGIKB4"ZQ&*\.K2P*/G]\R@TGNS5D- MN@?\X)_KH?ZIJ]+UZZ+^)OPZU3\6/J?@5BY=M[) *F7NU>8ER[]P-(?I0+_D:6>@NYE MC'39:,:XT!1Z3_YC241[]O:M^ M6A)/N,*)%%L3'<)J=)L@OWM5S+^EL^2_Z&PG>6_OT:M-"L4>L36O=+=$YRN- MKMO-__,GB'M]'\ M;ZCJ[#XD_S*/5H@U+L2Y6D>S1SN-* +^??PJ8%R-?N0[-9H, QY2!MPEQ('/ M.P.F,T"L;$+#25K/+U[=9[M?O&/Z]97I/[;YCB!UARII\Z?EJ?"!QN"1;R[: M8?'XN \-$S"3*F7[NTD1?VB&M(P_"AKLS$]TTIL^YWT-UMO M@/^QK?.,IAP_V[!:KTVP1%BFD"Z0.B')NQ.0; J63OI/53A[5.BH]E3&W'K! M\6U075Q=@7ZGN_Y/ J" Q0F-57'"IH!MN:[:0"2:!#Z7.JL >*-[2&6[(I8$GF_\X M PZ#;"XC[\]1>EB@9:OD6QFJ/^UJYJY1=M$/)?_C*!"]JX?(W<%Y"L( WS+0 M$9?7GW8MLL,\B).%_J00 MYS]1.-;>$BYH"VWEX!;C?B*!Z7_:W541"/B?KMWDOZ?";HBWN?2//3D%NG!$ M#_5IHH0!+3/"EW%"?]JM5.KQ_E^6A9N\[@!\.CTP<.!_NMMO1)8A(W3ZS6=? M14/$<.\W'4IFJ&U$^?89%RP6RM%_.CT46@' M^0?FES64UXEP8OB*P-_>I?G+W9J>S%5CJ@Z4; 412E/C92I<,/Q]$47ME6M. M+Q=$H$[[:5&.HZZ'PK-EH#)L^1. _E'*X7!3JTXZ-S0SNUWP;$[.R1:!+0R1 MXTJZY&,-%40@9*85TL@3!!PO7:I<)SB/S(F!LBML,1/*>UG0C50K9I&C'=I* M= -2Z2<+^@_[($;-6&X62V:EX];I"SC\E!L.3ZIO$\%SQ$BTQ;CLJ]<+PUW MXF<>A3RK-\)F>9MR3O-!8K(LH,U:?MM^>R]GNXWA-+>BWXVZVMA%[2NY0(! MDLUUE>>3$I=MG'OD'V ,4IY:8J>8"JN^?>E:-R>;114(1%.0@BQ73 M4 H+'$OL-^Q6FGV""DY/!]"\4JHCU\ML!GDNJ'SV=$/$ #>=XG9!]]F.E]P> MB!$8K%QS+M+.5^&FN,9EL@^!X-" \%>>3.-ZX=Z+DD:.U/;FFN,E"#/>N/T7U@DS/7V2%+G14'?D>Y]U.M^JCX?6> M;:LN7[KD:GE%7_,G"NQP+/4['KTMZT?P7<%.V+?N] $^=F"O[)3&%^6B%M)58>W1-6L[5 MH++$0Y1ODH/VG&&+M6?%4FD^ DU+*]9W?G6<91/Z(06K@28)U)^LRRK\G8W2 MV;^__/ T,3!+\Y8N:7%.OBIB?Q#RO"IN<28+M_2)E%]S UP+<*V]XM2 MRBKB=C94@E#D>VF"WQ.(]-+5%G]*/I81X(3P6'<+/K*P$47YV@R?%7!=5:R%LU,6=(4;.)B M2KQV3;J]V]%L6O3D"(4BP\\;K#LG9L8@TXF*:Q\R\]TUOWN1ZM ND%LK"Z_O M.0UVU@7S;FC[_%@#\VHC?)B]";ID89&M1JU41OSJ>NNDD4S 6O%@BJ4>XS2^KE,@M;BHE<6 MMY&GC_-K;U.T),EUH0@H&LXESS6=N ['&:DO+08Q?4RY$XMN66HFSBCL)2LMS0K/5+2_6;TN?U4!X)"7S"8X/JA^=Z@=OG,] M<+.4SY.9U6V@+!;B+Y]KT[#)V\F^,'=]3-5@L7V]1KKI]V2R,%I]I;;B65X" MLE[4T1E!E]FBL(<.?%O5^;5S>MZ"): MT"N',7IB6RVL;_=BAQ!,22[."C"H5^:V;5<(^<(BH3B7FR\%$MR@)EY0;6^N M&+IJLN:7_@>AF/DI&O.]UCGF,>]WC\RK"<\OT&JDDD2ML'L<>@ \I<5;U8KR M";:8&^YDR?+Z&X+.^RQKB%YF]$"5^N3I@_?JJL\_WPK;92YJ;*L&.GDYY%Y^ MX_8:T:)B6^1H?V\R^.(>?$R"_(\EBG1D3'-FQ+)U=,EZ#6-D0C6&(Z-?AY?[ MT<\%3\Q^HSQ*=5N=:]X+>3DE>3BQD6^9]:9D<5Z4Z9/:BY[09_WA2>ZJM-U? MSGH%Y%;YF>,M/SLN",N=4)O1OH[ "H]]\8*F_!RZSTN0[[8L^([;2]$:JZ,X M2\/BA&7*KK!I6Z$+CE-(?-YWGEPYI@F^(5EGBIWUS$A:QE2., 9'&ND"O31* M#2-\-[*;*S*KN5BTR8#8TTZ AP_S6\:V6MQ@H4N6A/M(__O/O83( S1^AG9" M'R/?+.'M+;T=M2GD\JC=9S_0;2U\GM>+OL.KE(3U8I/Z8YR& 'R.1F^&WI;[ MJ,9.%:F]>5D_:_4W@HXW2$]K$;#%);BJ]# FNUA1Z+*.![)WY'*U!V@\Y_N6 M/VUYZTUE4M5CN?I#&6BS O(7=OA8)JMG=>:=(S7==OIKH=LG?(AG+R!U5*B7 MH:L=/&.]=MFLQ5$M+&$+F=^??G@6Y72ZCT(0\]S7YGL33=R4QHU 7>-W-31H M:Q M?;T-]X ]>X"(&/L7UC#$3Q3>R^(?TS[@A KC6E87T:]JTK$1%Y@Z@D1[+U\84>H+F:L2RV0G+;&?I:#!@#E"L@F,/MM'1]N^25Z,QSO8 MF?'S790K1,C8(1UK\+>AEHQ<"VA]-352TT_":.TXK^P2X"\CY8Q'XN6@@WR^ MV(0J*GCZ(36K0@D.R>Y XUVQE6UA(9&'8(>N!3GPX'S0;2.1,M^2H9%IX,M3 M5<-0/_3D$RBWY%!ZQ>&\(/3O% M44*"AY,-J,V'M;U@1LH0<3[B,W4R/T('?/=P7)R@^* &@MU\QWUMQWK#48Z)E[T/'T@-Y5 %<,'E M4E9F2Q)_J?%1%-D%1O>9SL[ M\+$Z"?3J2HE,M52^IB8D<,ZG<)#8!VM7P[XS3?MM,>V6ZW]EA/@Q4+<;2AGBO;=)WF;L"]@X[+OVGJ9@$$Q89400K]9(D9HP^6*Z/P"E M9LWOG$_&"+W^PCB+_.U)*B.ENXU@.0S8[33NJ*-H^%8=K3??-E;?U0TGKD9/ M(8ENMW>I/'C->MML'K%J;HK38**8VA<9TK^$G GH?5$?VPBDD\4.8U.U#X4+@O@2RG/[V*(0-9]9EVA?3WNV^('WC9$F0)*FYP3&R MS$GO(T5-YR+PE';NJWQH^2!R;8Y0?)QA MG^!$[SMM''AK!F\SIUC1P/0H4>>;B_^6W>Y'22=IFF]I$1"N<(>O)L#1TA54 M)0SIBZG=>4?M^VW"NS:=)3:)?K!7.EA4:8 PD*\BHB^YV=CP&\KF!OSVX$&7 M#WMWGH;D(.&*D+:]+!PR,?4) ;G[8N*3'-V1/I)S&# M!SPOT6.!A),?&#@S9DIZ**MA P(C%<%0DQ^^\\D*]6 S9>(H.B M9]E\9FD[S,F5KS/U]NC9^\DYD&$ I8"7( .\3*4T@3E!41H&F?5[K?UD]U!! MDS:%BHBOQO*&VE:W!;#O)/7-TAD- M\6N>S&NGR#4]=PSP[YP2>>>?+'1( :&NO#28('AINF)C@HOIM5B6>2..EMXN M)!#I0#0&IA+#B495E[%7:(?UVP>N^\)"KMENUQ17$>O[P%,JQH^UN@%CU0N[ M>R*D"CO1BGTCW>^#>SZ)4Z?(OY?B^J@ZUD.C^ZI+&#R5J5A=-O*CB*Y2JI3K ML^)K#2>$'-\HVSQ'@R&@B1\NBY]H-GGAN?:B+[HX5)^+MWA!.Y(-,O2Q! MGS'VINH/#(60^**!7TZ_@$;!Y3KES6I$:QB339&(K7_R:AY2D*F9*-S[/$_[ MKA8>_ZW?PIA0\IV=,COKJ1'XPQ0,PO$]0_59B>DB=>-/'&HYPGWQ;*79[?@1W/-:"L\3>%S/ MSPH.KP4["V18)WG*WT8\L^(5YK2UM;I6PGL[3-XS(O.AE)#61/B)(<*-70*4 M"RZ;LE1_-[FB*]L&4M""+115MG/.B68_Q0E9I=3 :*5P.%TM-):R31,@>]00 MRD@P,7(1H5)/?@_\)R1F*J2HJZLBMJ37)=:C3]Z3Z0M[(.?,2]['A=:-:KNY M;66[3_W0P+ CU(G&Y3PB$-T%IR38N*_JY44!8V&#@$C8T$;M^V266H/U@(%] M>PE!IM[JX1\#\^).G\M0,O6X0M+AS]:\'>$\+6;=AJZ-!-@.FF=]\S7N: MJ_M\O%_=;%\V(ATOG,0CP[FK(]F(.1'S#J5WF@PJG\X?$0_*\EX[[HJ0&JJ7 MF'"EV6V+<>Y[\S_;-W]%F>D(O#@@?E5P;8?7Y<*U,6!6Q MB34\2Z_5:3:/533Z^IE?4O4]?O4QF/RT=UNYD-51ZQ5A MJH4+=AL5K]8+Y'(/>^%7"G/S9A=$A!=?N XYZ,1P>44TIM=P=H^3VW=%R.CE M*_#I9^H3NZNW0$S^E5_PJ1H2%:H)9MTWG1>3]8[RH@_2$S7>/K.M M,?@>&_D(5W89N=8 I)G+W10VY6WW82]^#PG)KH:)]U'DD($ZIO#U*5PM9JJI M'4,H66R&0P2!%GUHI4F.QM:Y,VO= @D9G#U9"37\Z8/B7_]=285;[@IA$09, MW>>381FMO+J(\FT7BY1R+C: 0FK6O+ U ?Q1]UCX(Y_A]H[FF6/"7 [)]WC, M1:PFYCY/3M,C^K:74$MAU*LIHFRGSH%1V[ S&J,7JS3)#KKMAUVO8U:R _HX MK*N"0D*_UR)XB2+558ML];ASM!9^U96@M9P/H+3D3W[A23PN(&99)&6;:;XM M%&]GASUNPAB)>CO]:,VPV5#W!BN02RM$Y_2SD_1]$=6+95$&_V2U2*+2Q/55 M2YW$!__ET;AM_QDE^N1'H/H$0]\="WZJ@&N>Y%5^,,'+"U.%A-KWHQ^IOG.\ MY[PS*U0DH%MC$.M4/UY"ZR<*$#83U%V\FD2H=1NA5*J@6)-LN!G);_!^%82;AHZ*>G28/K(S;*Q]ES RW*LX=WADLA11OB\!4X_QKQEB?9"&:[Z7:V%25"H!M C34W8O* M!<&!%8(\/.4X>M_\/IB^8YRNI52'1UX2S'>NQ<(Q?WZ1)'08FFIK-:JIP=U; M&\7Q0'!DQ7505B[308SNC-NERC_6^[&K+&1_<9+5?B:K)K(OQ/M=S"!/9#!\ M^/ J-WNPDY>:Z.%M7=%78X)=S?^GF"O]9CM1PS\UJJW8]THIB49I%34DMF!( MI:JT#(K2""J42Z/VK;:B*#'VB(XNJ7UI&NNH)17+B"6ML;266(**6T4M1:[[ MH1_FG/ER/]V_X'W>Y[SG?9YSWJ66P.)G+"9$L?(/SR+84ZU[PL<_X[Z,3%OI M.0N:/)@-'EZ[MAL=',*&?V_;K<&N%M9KOP@3-#-T]]CD66<]A[1]1-7T'QE%%9,N'TMS51*^ M\G2H6G3QK%QV>1NWKQA"WI%S&_&DW#9:.5Q<174I!":-,5"AO&\P.PZ=A?,. MA>"09OMG$LW:8N4#^ A1JH.JW8D/TGBUD%Z9[7_[BX2\'BOJV11$THUD/SPP M9]Y[\#AL;:S6S&6V;VN"AJE;M4*_".WOFEC8K6/^;.%?':>=!._R4/%[3H*S M1UNG44.1#I>2(R]%E"V'Q_H*E!F-NCI*31GVM6SM_87]0C=M&8I4 M&=U++!FOD5\+DT7?M+BK?QT5X?[;[(DJF?=%'M&7U[^'XFTHS$K*KK\_M#$. ML1"$ 9V'W(G\-+81:XBH9C5R@>1FP\/7IVBL(,(Q?\+4VC=/J>6^&DR7&T M)?A8 -)@W5G<++OS2\_)*S>C\4Z_HO^/6?UF@"ZA,MXIP,C]N$+?FA_@L M Y]/3G9=0"LZO_N:!WTM08\Q!GB_EN>N>^OF:DS7]RF";+1'2"=N:H6Q,Y ' MO]:<2WDY<*;9"@=^>R0O=B[^:CM;9/4L+VKG=+]7&K)@0U^\18:!'KRNG7 M7J_;'$KV^SG#J.7CCS"+D/Q/!6%\\]ALXOS&H#;/-<4^M$9ONF-9'QO1*[A+:JJ":SL+X'(=%5566DQ M45S U9I]OT_I1ZHNL4>7:/]0T MIM(7!9,E,HRX@'$@TS"TPGG3,FS4Y%Q(4L-LK\FV71R2[Z?O]L5M)7Z^M;0$ M+?\N*>@^30IF>-^XG&W"+)CW2LB&B(T'L^&#T40;/F^E(0Y'="X7J5SD4X>/ M-H$G\&C%/]9GT=HKH5-(H?MAPL+'=R*YQ^TWA M5=E%2HLS6K>].@$$@&?"UYE$_&=CV0;;Y:IO39[U300-FL'#:+2,Q$V>P7*5 MWO:9C='RBVWIB[0:;' 6U#6@8')>( V?Q BC6Z]748C")FXMQJJ%-3L[)5ZNR0YR,@?-\S)8 M44WE8O\]7VP(RPYE5JE7RVS?B\ A M$Z560AU*FI708R:P, 8J $]ZJ_D4M*LT9+'KS YV-R#?H0>>&OO&V1S0L](W M#2' L@]L(Y?9.M*R]Q[L%;8&Z1\G(=*@K3Z26IQ8?JIWD5E=8^$MC_3^_NV> MK"34"4C\1W%CV0L3 A0?T'.K9JTX4\D E*7'S'UITHY\S@7\DLX%YKMSIF;1 MG\7(!CK\VQD=)9V4F-K-KR^!N72BFH?TR1$2._ M8H0'/ST%*@1+#WI"KBJ[M9Y&=;3??@;=2*LV/%_A-[OS242AT,;6" .'#QKM M]+"HGB.<_[@-B\C?28M;5=NU@ILQ)?PRVKN%*@=SVW0-2Z$IX>"% M5AR"O4G5;4SN%C45/]]SL@>!=/UC>7AY[\SJ4MU/!#.;&35P(G)HL:I8V!IG M1D*!5:XE&0+M^XEZTZCZ-P7*2;H.YA-"&TR$X1(/=L3/'51>0^D>GNFAW8// M+=/E<\2]]2*2NTS13_31>!(:MG'!]WHJ0#;*\PU4S/J0D-BPYG V/E8+J7A# M4*S=>?>8^$+.9#J;+'_82?%^"NIXBF.Y:=,&%!<*B 1Z':RI;'&$<[?QSO'5$B'1Q14:T M R2^5\$T[!UNV%CV[9B]#- ]#_*0E2,&P4C/B+;=Z1XP D;./^NV,QNNF.&\ M^V%/A1>^%&P4P8!X9DT&>MX7LG8E-2%>7GI$H=TLG5X8Y V\ MSCTD=W<0I$SE0OKF0_@5KL4&FDU(%O\YTA\@CPJ9:L(FP '.)D/M*.G!/(L& MPH1(#^BC(T78# MP!/-6F,&ORNQ\'UI[&5;4^9< M JU6).'.$1V8'??<.;/Z9@1))R;'@>](!CCP+5F#T70)GMPI!::+2J@ WW*> M@3R""]#-8?N09J_5QY&8%!GLT,:3EQ'V51(\Z,T*](5%BG=*TAW>ZCD&<&/0 M-16IFF$E;)V+"FZ0*[36()+0@$(7$.BD;7/[#0H,=1!=:P7C0>_VMR[ M(Z1Z2[L%IXYM-'+O( IK=(5.*?$@;\2WBPP M%9LS^PW3!QI)PAI;0;)\)]?X)6(\]LVYP.\55[A QRTNP/K<4%I3O"69 ?D. M8UTZ$'1"'IX:Y +25[Y9T]SV3E-B]B5+#M5;PE7847D?I>!/5DN2WV[^[,T% M=M20^[<5QI&B,4L^PUS@BWW,3C-GZ5GQ-[< 1Q:R/EKIR-=^>,8%9BJYP'K0 M/T3-"!F/ZL F'_;N/.8"O]@_X0)QK[G N^&#['7IPZ0J!2[ =Z1]CZNG4A'3 MGMM\/P#J_1U@T#\"U%[Z_P'\WQC4?7!%0Z M4J[)@1 0EM/_E^DY&+1SU15+*JF6/.L&Z"-<&@)>%OS27ETG[X&^[X M?P!02P,$% @ W(IA4B=<2HN.W0 5?4 !8 !G97AY:&XP;'EC>F@P M,# P,30N:G!GS+MU5%S=MCU8!!(2(! ([DYP=TL@>' IG."6PMV*0( $#1[< MW8-[<)>@P=VM\ **HNNS>[_[WGWO]_IU]QA]&.>/,^K4W'.N-==:>X]!/?QZ M6 6\D)>6DP8@(2$!WB/^ \+ $G TR=/4)\\?HJ*BOKLV5,T#-SG&.CH&$0X M+[%PR8@IR,F(24DI:=D8**E9:$A)7_$SLG!P\O#P4# (B@IPB;!Q\W#]!H+T M[-DS#'0,PN?/";FH2*FX_F]?#S\ V$^1?!_E(R-1 QYA(R%C(SUT R@ *3' M2+]?@#\OI$?(*(^?H#Y]AH:.>*'V!> 1$C+R(Q3DQX]14!"?^B(^!Z!@/\:A MXGSSY*6J,2JU(R[7Q^BLIS0251UX:C\AM-PF3@'/T/ )"(F(Z>@97C$R\?#R M\0L("DF^E9*6D9635]?0U )JZ^B:FIE;6%I9VSB[N+JY>WAZ!7X*"@[Y_"4T M)C8N/B'Q6U)R=DYN7GY!85'Q]^J:VKKZAL:FSJ[NGMZ^_H'!B75]?0F]O?="$!D)'^NOZM+FR$KDB=-/-'Q:GC6ZT]^D M_:[L?R8LX'^E[!_"_JEK'H"!C(1('C(V0!RPL7)OZJO(E_H ."#9MZZ]E!E\ MS(JK0L5HE?TQB(Z5#D#/^+1 18J29D$A]%B,#*KW[E0D.7E?@1/_-$=F:Z"^ M_'#G#$^FHPVSX52K\,=QF.+'=K X?+#]B&*BTG6-@/:6I/AE3)B!DC::/E!Q M'9WUB3WVPFX;OIR9Q3>)6:YA';*!7H)?7M?E&6J0ZZX' +HR?EK9TLJB$6%7 M_\_CSL 5]'$_B]CN'KJPV7)P9]42)DMFL+"HIZ M$5P0GY11^1A^3.\ [AOU%LWG;8_DUH&^+$:2#XNQ"H\+D]J05\C8_(5EY[E9L# ,-@UY ^5DKEFLN,$(UAA*E^:6.V?@IH;@L986G!*]Q/ MGN]O"GA]+HDF]_$%>G0SF9*W*LM;&MR%19J0U-P)/3O/;^07$VZI:';'T/+$ M3K=EXF;;G^OX32J?\U<.]W<84G>LQ)9L=G@)%S^_&=02_+%YF=^P$>HE26-G M+F-NF*?Q5:QF@S0;BZ>/(_9C9C2G=:@A3L( <6B$%8?_4(EKB MH?0 T)T5FWB<.DJ4_=4?6X,\L$)=>ZJPJ-P"I)12>!B)Y*%ZH-+_5.2Z0JL* M4M^U@C/XH4;1\(QY/;>7EF$;1HAQCU1N_Q82T-XM .,O8P9I.6S3,S>@L)1B M9:U.W';3IN]W>7CVE->/;W0Y*H3/9L&D(6Q):RG,)".T[TQBM$+MN12A'\Q\ MA7CM/(37\K\40TUZ[]0)*&P:M;ZB?"M<2!>X-3TO\BADLLF9BZNL)9-1M(NB M!JRG"I2OK.T$\8R]M)DO:\NFYUP F)YMSON=DMY>E#VI@:J5#]J[D@8&#F? M%/6Z>Q021F))>5(URJ.WMY,&Q%EM/:)=C,MJ_,BL\ZI>-:,'L^@U;%I4XQ$S MW.]_QX:Q<("99KBVJ\*SU[D=R3QR'(L" UX#8CP F+6SX,[:4V'K!X -'^?] MR / DBN*G^+X]L[BB](+:)YQ[\N,SG+'S,EJ)6R ]SV6S6Q85^*$AYV![UN) M3D&1;!U(SW=4Y';ZHEJRN6>"'\+C<6M4=5_@JDH]PH^I+?,1+C3T\#O7#W_+ M B+Y$#X6H$R&ZI>=4@3U5IFH"7LNO_NVTBC\!_)6?Z^3C!WGS92WK.$LSY5S M[:'YSZ^/961MRA6#Z/V5;=[,I,F:UGM-<*\ZRCH\4;0]$".9XB'Q)JKXQ,1N M>DZMX5.WB-Q_-*7F))=[&Q!F75/'*3%@S'6=;1! M)ZF301QL3%*YP9TQ&:'6^51/LZRM,M__ZN/QGQ)D<;*1>A+C3E;*]VY3(U0@ ML]Q:4_;1I]J77I@]A'G9I=& O.Q0 *.--[-@+?J=-[/K<]'N ($. 2(&/+&J MW,5=K]PFU[6H(VQ3<,*"?W__SFG1-G!K7PQH9Q>$Q@Q\#;E\ 'QAIZV=G*&A M5;TI-_/-9'M] )W1(33APL04R)+C'YI&#I,_,7Z5'9HMD1 J#V"T?I7Y*!1Q M)\2$CW-IB\]0Y.&^@5?>O\KM#1:_[;U-!@D^ &;XIR:M/^LROLI\(X6K@B0W MD1#ZA"@SV1IW@E'?FKP(8H3E6E;NU?."X=1F[VA%8I9'U*@#3M+"-Z';4ST< MOLHIJG1$0QGG(!Q\A6Z\L=+#5M5W3@F;MJ-.E[BC7AXZV1TM5'6 M3[-^]ZD7GKS;]3N#&Y4S#Q=)N#(I*0SV%2BU,$Y\,DKKIPY4F72M"5Y^IJY> MF['UY44U2ZCSN.O>#;!080.,?F#.ZF.YML=JOZ%2/O9,V'D,Q7C*O:_5&-K< M?4LW^_GB 8 #]9(#JGV<&B&MC-@2DO"-_+I28P9)'<+;T4FE\.]RLS9N;I*\-8[)F!&VEF_CY1>R> M\]:(M&&7BSJNK975+&=Z3CAKK[%XH136OP1+<;Y^UYD%2$^XC:0 MO81-G D,_%X'P$&DD]SFI(CG>AJW >0JR-J8-M^6Y9E[KP;65TRL*;5PIKM( MA1)XDEH:NZ_4A=$$69$/W 0XR*2 M"+=>O05-Y:4>"LO^S?#P<,O0 >^[/1HS[X-\+4*J?).GMQ:M+^$X]H^A&5)5 M(=WCBSK+ .#G9AX+?2\. M@,2N=1'H"]:WQL_M](V3>@$"AP#"1TU:IQD!O M+P@8S)LV!6M]5[[Z-?^=$ MI2E 0>X?%3U(DW94!;E8[3I]6HSQ5:>"%OG< B,OFN_X-)N#IP1,N ,;JZ)O MIMO1;0B2*[JB\ U6] <<'=8-QJ@&'@ : E?DG2UW/>F48%S;:^(4:9,(?]D< M!CH5E[%V=>C,2A!,,]]:#&76):61CL"]&?:U*@&5,XA(M+',7*J84VM6>7B0 M-[:"P9<7%DF1/5OH0_!AJ.+JOAM\)^KYF8)AS:"@"XQK[4<8JR64&I/9^ 5? MG(WKAL;-.3)-"A0:%D\?G8 OIZF8QM#I3 B9_9+L\:DR,#&B2>CP0^!ER0, M2T3=>X-@FJ?,9'GZ$.;_LX?TC29NZH<^Q\FS#X%IP.I'!-^^;[K.(U M1"84)IKO(:/RL[:OX=$Q<+%*NN_5(*KJ.,36YYU>?FGM^$Z7'%/D2>. !T^_ MB'6VI\[SJ_Y;+\N,2=[]^9!$Q%9D0V$N8L54^/2@[IW?MU(2+&P?0 M6#K-U]DGU*>"@W]0F4Q[U=?!%OG-J=W)YY)U1?/0'.Y$["*0?Y:FBBCJHZI4 M2RTE.=X,?)3PXBG[.Z6A2>?,%N.C&'+]1\8%, D M;[)^@)T+=C>BG/91=]O+/.&!&R/<"J=7K87*M"MS3<%$:+T*=H2],H8I12[* M9-9??21G:A?VZ/$353U50.'5[_%Z9>P>&[.(*O""<-K')+,%0MW5VNKK!_0S M5G=@X<37=SD/ $F;XMN,S@[FXY_VUW;";=?ZYS#7#,AUCY=1L&N$EJ^\G)9P M_"-V-JZYFR\[9$+37>R="6XF3>G:,1XQ=7&ZQ0O*^;W8,2[9L0;N@CJ\BN+O M3OVG:X0E6%EW=$!9WZ+',;%H+T> I_3M_%]J!WCU/M,$R&&K9..\GN='M)2>D,4+!:Q28DI\:IHY1PI7?.W5GY*_= M +\5%S&5RJJ]-CU:;J[ @;*8V\*,?Q8T;%6-YZBXC2 -[(Q+,E<)X3U(;"7F?ZZ MLTX(V,T_858[Q7Z(AS+T./LXKHB44<0!T\DOOH2O>56N1>8!\.QM1&'K#L[] MIYZSF\SWI!>'PANM;[*@5Q,@(Z.&&5UOR6+I(KR>RL69_4S_G';)U-M9'M]B M8*BWK1] M>1#-"VW@9A?G67H;C3X M@6%%/=L%P87[GOK0W$ZA]82,BRS^V@Y#OBM61R% MS1/=AZ6]_25"BTJ@ZK(4V#446+JZZQ2TY@<"\#)5W0\@CMO7+P'WE6M++SR$7M- M&9EY;,C%.,@=-+U48[1C8OQ*:73PMOVL430A;4U1K^-V[$NB]!U+PBF/Q.R( M*;$LZN"^QT&CQUZ/ [%6!EM)\;PUY"M=8[PIAA?&I;C_=BM%]U'!+L(@+*4U MO^Q8UZ?LD!\W(O;R^\],1J+TV[&'CUJ9W!>NJ^"5,*T+K0'(0N M8&ZN"JA;\'G4N[&889SN6;K$T) 9KGQQD;< MB[_)P/NRJIV7]WAPQK[ +I%]UVT9Z[3V:#O"-),O=0]=#N01$S,2\$3;CW)U MN\2#IG,&>,M6X$L7KEM78,L9*DR0,?0.PZ?O8)1[3\YTG0(-*C1X">.YKI^/ MG_"T9AT$:1/4&V<8^:#EY"Q[J-:4@&OT;83XJM#-3T#HXFEP"F7=-MW4BH2K M23A6$NG432)O104,B\KG3?XO(QLOBR3SM;LR+.V&>-,$(DQCRE0[]73'?>:R M!\ G!=G)6F\0AH?8B4J=0XECB3!'%_:4:>5).%!P/8KLC7>IE?->&,M>+H>C M:/_\>3W1J- CU&TOS;L5'*C2G5JB3HKJK$)_$HB5+)I_@\*#''7\ 1#$*%W/ MXN+K?2PP&!I7:Q3< \:",BO$]@EMQ[NGY$W.NI95#U2/C5%RDJ= *)Z4O:7PP@GP2\6<0?Q2+:Y=:H\48142DECA] MVO!>O+Q;4/U*:48/T2]'%:0FMF9J2T3Y\-&N<5 6P9]<&2" 64=?!O\+5L<6 M<=?L%D@GG[X-*PT1WFDZ /[M%DBP=F1TA]J-KYN1N!WFR=6/B^I[WY:$I MU/+=1+DK2&I69IIWR$H[3'8]RH:_(-F)P\LOO[8%M+: KOQ$]P#Y+3%;[BRY M^GQN[>,A[F^?(W4T<$*G>P,*EY;WO*8'\:2:I_<]&EX6\WE\]BNWVHT.4 M+'-7LFNL@92E.0<_(Q?^^Q:,'6@DO\MEZ4KM58D,PM180^IO]YB4-=W:2>YO M"6I;:3K3<2O4H4*E(J%UW$O5:*,]Y4LJA[VNG H;NH__8(+R;?2HV)TBL<*0F:&W:5., MZE1S-.N#]@+>VS"/CGG4 CMG38DT*8%ZW[2!"K643W&@IOJ;Y';,FN?JZNKR)03"=[/VK&2\:ZVM\#J+,1FX"=T(!UALG M(6>M%B+1R$#(K-K4Y:O"*BQ.,(7=7 MS\+G,8N+]&.L'-*HR*DO;[:S[9R+V/2.8XZV]7&IE$1FYNI7^JORK?Q(JJ". MUA4'=3$*(I,)4E_ZK:65I@[\,;F4\VVT>5:>]V09> RI3CA:\F0+/^?BI_*X M<>IKI'VY"RBUQ_<(49KR$+^97KBG[6:P/ZLAZQ=:4Z$ MNO.":([$^'<=;?Z.^X_Q2V,7L% M2M]^7)V]IEW\Z'\C?^^.-5BHYR&QT 6GF#RF@XST?78EJ<&1+^Z6>;1*ZKB2 ML:/CU?X9)DK0-;FV]'3I),9AHN9TM6%4X>5D*CMYO",,F'EPZY;L"E+0G&1G MR<&63_"N4\HA3WO6MY8\%I/=+#?7+KQ0D%0@RF\VWV2HU6Y$0[*.%5)Z\5SW M9RFU!^L)*VS-;H>>?HQY;,JOMG^FXG,MLX$R,,:6\)BZ6K6.MB$IU\==T,0Q M0WY@Q M7(YXGKW%GQM&5)+)S8L(D=&KX5?[FI,^P U@(B(Z#QIBYJ5[DKVZM MR/=U #1VHGQ7H[8 +A.79WS^M.\ZXI)G'O@ T%XY(9;/ELK-#D7!594"_'Y_ M4HL-M3A,?F?]1#"O![?Q,M,XE%,A6J^)/_"RU6MJ27N^8BX0]%*!,D+[%N.R M*&[CL:<+R BICDH\Z7 X<2T)3 M_'Y$TR 12?P0D:>\1/)!7\Q0S)O,+O P2XE_)A0-B*I&!R@!1M@3G,]?,-N) M/SWX#@TPP$$7YX(#,(IC&+5[D8;X'(1"J\JA# ;CA])9GE;YLSD** &O"U;( MF$3SA.=O$P_W=:\$.PE$U.S0;,[32): M/W7XZ&HCI:A9,-Y3K-,6[6D>9:>E=WO33_\4 M=_15P3CBSES+ZGS2@8R1AQWYX/:RL*6JFL*"P6:()X#7&3[J-7DU7GM(3[6&6NNO9=!FYDMN_@DY7J MYG2=SSIE*6PNJ?QW,3FAD_$V#L /JGF"S;0.X7[JJ@6\$]!M$A(PD0W^/*C& M[:KNL.KI!B$1P$X\W3J9(:#VY,4\[W*:Q?.FNA4^G4?,%&_2:[QESQB'WMP) M.@O(:#EOI^;Z.RXWWTMV.5A1H.N"9!0C>)M35NC(I>XW3=W?0!GW#C1\E'.4 M$HG90JS7\KY/)9/6QS/U7S, [#ZX[/8ECPI\KB_(6-6O/%,P8N_>X%9 I%>O<](F@_*A)@*>:9V48DFB MRA,5\QWEMKLRWY/=;-5Q8^D%;@K);(':$'C1VMW%]RD0L> F49CU(NW16?1L M^O1W,2)HY;QO#H)_/3C&PHB;XGBGHA:S%$=QR$$C?T%>F#0S;]]660IR7%*Q M.&!?H$M$3)6D\UDJZG[=RY=IN7KUWK9K7,:Q<+ZP_NN13O97(,$>0]G@A%H>(TR;9:JDC4E6C&6CVSY:)H;I*(H@ MXNO@2_!S$4GUVK,)HTLGFA#I*Q3WJYS?%PTH$#.TM3*? *I:0DYZ^.NL7M%L8)8U52S*.>P?S%1X$/R+6Z6)5VX#$/N\_ MO74HXXXL]BZ\+DJ@CC/9\@V-)"_-S0&-D@<:H!ABS!XG["MXXSG:.X%RM;?4 MOW")J8Y1FCG+MSV;W9S)FZ"NUK%;T_24D$63?MJ_N(1T57PU]0!(>GEH V86 M')S_*6)<[N'UI'ZRPDVOVHZC_^.L6"9Y1I"P 22X<6T7QU=BG+4Y+=LJ56@' M$?&ZG0F>>_$ULK8C6L-M,9II"GJ6N:B3+!HLD9/-E(WGITV15#$:]*_0@)JNWHY M?:RG-07"\>7%_B1[R$F;&9DS[CP;NN-CQ'?ON@8B'U-(1OJN#=+F2CB(D2'J M>)3/F[TO9)NEEO-J4I-"'1D7:)IE -53_FG,;:U8=@!\^=C;4@L=9P?JT2$J M_E(1&I%E?8OU>2-,R8B)U&;MI]U:Y?3=S5?E]3_@ MZ+$]P!':K8U)8X'DM^\)ZY#0N _2:W7!J/O7AJ_:)FKNQ7>"AG!UD+2_GC5G M"(QRGB@O3*HYVAM[HT4RR=DYNVAMUZ\]M^\:S[T-RM1S%WY;U> ZED639])' M,D0M17P<_8NI\%CN!UZN)1&;5>O3.#H":U;IB=E2A;4EBDZW*[=Z/\(,'9, M10DH#=W<,2ZVJVRM%)68%$P9.WKU M*QRRFVJ@H/6";S+WZ6%QF$3Y*BU7HUYW&F[M6"*J;O1S^8=G27%?S#189 P: M1:+\XC-F&,%<[/N7X/@DG(/D\'E:(9Y$HLDUW[VG4H1VGJ-<7NFU:;JZ6A^+ M#X GY@5S+?78IY1WV2*D/MT0P9+DV4#7%:P%UNG[3/S-HW.3KT)%%P)[BDJI MYH/)S2^#Y&22\B1)? M#E8MO9O BE]!4@5."N[,UXH806[W#[3JZR#'L2A:$+TH/K5.3I9/=Y>42#=H$3Y'R5 [2HB^DNNRT?MCO$-/;']9DK!T!87HD*\)KB*U+ M/L0)BXPS<5BOGLNOCM^^RBZ45)3NS./I+3*GYO%Q5$?6O&V?R"=C,NFC9:3. M80_UQ"/2M5LMU:N]0R20F)&5A/5"E_&SM6!T6WZH]=BWQ6N>S-M)"2O=5]E) M5%*L= !6.EP59-E:2$)DLR)R%5\%J9H8WDC[9JZ!U MM$)BJE;;U0@;&N%B,75A>Y-.\O%E%,HZAT[D6G[[(165_AB3\*TQ[>F M:@X$M]%N04-<)98B1PQUB]"V%Y 5%0^>(Z#^-.\< MWJ7"GEVHI97S6;DO8%63123^[7A['?@S09D,'D30Q^G#^<=,;:5N:+F#U[@I: MRYN*W BR[2P7-0:R-[1L,N/5?IH_I"ILQO/.9 K?A?G)-0.B5EZF'L/&=A1! M1BJ^5#SU+7%[IW47]1OO/\1F#">#M7S=)H_?WANSUL^>6+J21N7"GC5%S[6, MJ$$*6>0$%I'N7\S*;#SE*0D#8\[QQ9XTL?F1*>DM1YG'? M6U9D8%UWZW+MU!K1.,Q!"I(<4QZ&N[HKG;I_=@FCJ/JU?_UBP2W\A<0#H#FZ M;TU>VY/?=>E[SN=0+6\=FEF>YIYI/R9DYX(A:\\":SH2 PVD&)<_4 N4F >/7/4.#&2-.MRY#.W8 M=T*$!T3E1,]/=*L])KMGU08M9LI31J*&7/O1@).$/11:\:FF(,W \ZFN(J< MQI3"I=K[^ZT#',-U8.(Y[6PN]%II:AMR'52S1#SO^>%Y Z5>$54NE6.JK]S M)>]6*F9\M?7ZV L=Z_:YF?G:82W_]])EUS*9HJ]OB7>+E!1[^K)&E'+58A+5 M)V%&*+.Z[1]A_$[;.I*T]0R"2S6O&%9RIH7O1FR,PH2"RW*TG[_A*0QJ&4]Z ME);GY+:3NB/P0V0V=6!=T<9 B57Q4G#^%O=L(S6Z$9B.2KYS7@BZ+%.:5?>5 M7X9[5.2:C''Q$0T<9.C/<'8.,%O7;X]LA8:YSX('R*/!^=9>&4&N42]VJ_;G M'T^]KQWFXNZ-3<\U%=D1E7&>R&LDUH9JKD'I)B\5AA@=S U8_'V6G=NG[,;6 MF<=XP7BVR2,-@:I3!0WAI#=F0?JWJTC)%;G0%+UQ4X^+$7EOJ\6M:%GF#/T7 MTM8B/#<@O_:9'.UOSH9+K/R8]LTQ>QY3;1^4GYI0QQWV*OOJJD^]=Y27%GW5+W41K'D MN6;%,68FB4,CFWO@Y<75GF[4!OM+ T7:&%MWJ=RH(>.ON!7YG*&)02GZ17%5 M*LI).<60M..L BOBB*,'0,CF5,US0S5SOF/T(MK L\!4MQW"$O)7XQ='7&-= MUWR)0(C5=;W@@H(VYYF&,@JCZ0L\\TE>HK*?HSJX ;FWJYL6 MV5.7($F=!@+B^,UZ-:0:(JPE8GH&Z[9&N%$?*A(:+*+[V&V:))4UH*TE[R[!HO\7NZ2%1\UM3, MF4Y/HN4W74V+TZ555Z";'F6#C^:EPD:^.HZ9XV78%MAZ23>N@2BZ$Z/3! MT MLFNXGIR-@;J(*#C[U(1F&7(]8K7'IR??35G4R6'^*49IN8LLOO$9AD,/0H_?!5NE$_M0" M:X0L;_8&EM(W3_7JL"P]3^WUI]>9QJWKJ&BCO8@X \CYQ,V$ MEE9B(QH6^4TGW8UF"G5L;B/3[)T?IVU62KDT6VJ('SQYNG,NGB8S3;]A,3/# M?N"@UJ3LG1X(N59I:&@]%0]EIW>W.OI"EQ*>6DGAK_)8:JV[H18J6;[<&3/@ MZ,T9_C2N"CF( 7E_ND//9CXH+:@GHG8Q6G?Q 5#^1;;K-!*,5E4 C=69*,VO MKIJB#Y[7/XEPD*%!)=J#:L5VR=5-UQLY41-^SHT]A%^Y$P!GR4F@HOF2(.8N MUV+YX=$"C!=;D5B&'Z5]]UQRO%:>5&3(X0SYLOXD4,1F91OV]X4?BS^R'3VY M+).XG9^?/S[66:LUJ)3>-.'TYQ ',#89?78%X6C%OFM+GLXX^23"/T7^7"'S MQN?$L?@@97!&%)/9.^+EZF@6?FD%:?UYU'>]H>M@^0W F1#^ ^!R2ARGJL": MG&@\,:I:]R92%$)P!\ SO+LUXB.6@7H, M[TU+BCPCJ*MEF1XT0VWF,MH99(_+Y5NLD%KHWB^P4\ZA7(^WG5#O/*??YVPK M\E69:%".!&0.LU56.]5J+M7S35&99DC'/(W!T]L'$,&LI[M&U>*3:P+B/7HY MVTZ%17',)^'$'@7 S]]Z+KLD 6-2#,@4UW.PDI&F=&7#W.FZZ=HG$XD*MHW/ M ^I.[3/B^)PSAJ?EY^,94.EOJXEK-:;4=J,D(?# =?!3CPIE;UN!"IQ+34.K MN!83ZB[WL8\UJY:\8:?XS-H^SH6LI664PKKO&D'E,C0,DY'"+J5WR@0>P9T_ MM.?WKSGU/@:]_G%$[I\NLZ8]W/.MFM/"-$9N@#X[C;$X?0+D-EFDR=0Q>>70 M#I;\V48FPUH0U*):W$4:\Z[RAI/ZD1PH%X+:J)LHI] -Y?;B^11_DKZ7<#*( M.H+>@'QR[0A]J<\7NTYF)'DNG01FK4P\*5X-ONXX.5&<=%T"RC3$^(K!;3WI M!+\6K8TUB!"/>G@.*NG:92Q:8[PU)>PS2+Z[39OB4,[V(9ZBGN[JH;MX .PF MG-VO#:ZN_N& 6>RU(JJP'J%WB2A/M8ZY-B^0'0I=14W59@IT+IGGRLU4@[C( M<;TQ PHORZQ_VG"I+4MK,C/*LPG3+(9!8XS"OHT,>[&\V-RAQI?(B :M1.%U M_/*8M\>RG<\5>HMO;^I>R.,_^.G(X-<&RGO3Y,[$GG3*%$7X:*Q6DZU!LSS^ M9D66J"S,EOA[P:?O-F[S*Q!%F_7CR:#K=ACRE!^EQ]F6?46- K:Q8\&(W8O1 M1K>;$('WCCT.AB15\(E3OB3+\-+Z5R3WXT[@U[8L&"YX)H-7!TK-"LV"R^B? MS[^_W>?B ,O/X.()V;U8''1=D@]U_G5I;9FH#UW!(#=- 7$^TT0-HA)\ /1] MP^K,@92=V[3C^$B6*]/PMH9ST7J*, 7ZHZ[FPGFW9^:/2RP+E0OU5D;P-F_. M+=3XQ924P"^8A!5-52L#]M$5!HQ#=TU<)>&53H*(_8ZV",W6]\/$FY12W>WF MXY4;\L"UF_(=J,XZ>BNC0:UP6+UU2^K-QV=JCI%^>_8S.9.LQSSLG[P6]M=E M$V[JYO5&OG9_!5"2)XG BVXNPCV,^5N]22"J/6!D;5\ FU[C-LZ=I.6V9W%U&@:R$9$9'YP<. MI^%NN -6[^Q,^VKU3R.J?($=AD2+8+>JF]3S:> -,S#%\, KLL 9]_HZ9E'Q MZ2-^'_/7@H0PZUFOF3SO0IE" R-%UDWM.4[[) <1(6U S8TH0L%';1J8;;OPX/B@MZ'ZD?_.GM=? M:A%-#YVC+N%M; ^5I MD!HTW]1'E9#.HK.'^TB)'@*_VTRF?,OA[*-$0ROJE5&"4L2K?9]Q%>7:MRTA MF0,=TZ/(45,D?7=RAIZK54YNU:5H%WR)XKU9^D*C1':K*LY453;PA]7OZ\,H<MK06XO1+R %#QX*4O6'^N;A!-H=Z>O%FP"!30O$7JX960 MS[;>@[]M.G69MS4Z?T5L7#!)&*5[:$E,C,JS'][V7!;3,S?IG0./':ZZCD\TZC4[>$*5-*$6\W:<$S%-)-7TN=1)1+2KR;$H MKL6ZL55TW^&(BFR6$ENYMX0]"641SI!$G&U:(>G.]U_LQYK!$120"A^&!\!K M!?!(>V^3#?..:)GR-MCS(KTWXZRB81N\9@A5AOLG/ !2_M.[KZYJQ9/NUPZM M'P!,=Y&6<+R3(/'=9_8W]="?#P"TZT[P!4H]; %FFY\=9:M^D[%,_N\A6_X& MN0ZG65S4W7-3M!>IK$H-,'7*C2B8*$\MUD@.B)T='BVU5@],"9WL;_T[OM4# M(,A[3?SVD1X8#?WU0T'#P _BZ$"NJYQDP",X("Q;![Q2N/_GS>BME1C6&D4T@)EO5G>UNP MA7J:[9TFL6S$9IORR0&)R5R0"&;3/@.TLY/3FS+Z%=U:07)+I@QCKGBZ0?$+ MD:?K27 $ XPYXREX'&T%?FM_6JY\=)UQ?B-^?R^^(9^8>-:4Z\[/-NR0968B ME]N0QF^GX[L![ZJK-W*<1I1! R38^3[(_@'@RP^=0#PW0B*=[T/^>)YE9)W) MPJC 302B[;I5;*.2(:"D?7[>_N_S_;+*+N\AF.-[*[P'[ MLTC._U$D_^W7F>^Z[E!'_E?L96XG_JB1_U[\ -W6161AO7."Z<>["4'8ODRB M^A=:3X9&J4AEUC!Y:9+),MUUK>DI\^N8,X$"BXUK,D&HZ]K+64^ MU.+;J/_T]%_&_*V_;=.!M)YJ65LT:2\0TJNO1*=[;,QD_CU"18[L-#59=.?T M@K1FY:E&_8CN8>BA\%=>V&',*\\> .,XOUM+\C]:ZR^0C-\S<_H ^&<#4?^W M$Z01JW[Y 3"VU7=_CS#]W^$> +K LR&$/?^S.?Y_@M#R[Q'*[[JX1)HPL&BJ MJU@33&.G9NV0A3T&(U/M:MIV^)B9(LG1E,8V5?[N$1XP8AK__AS00>;-OXAB#JOL9^ MB[3P!]%_:7)[NSD(HA;D@[]CBO\=D_U?,)/_PB3^'5,<$T8+WOZ]5B? G4V0 MJ']"[K_*.[*$#8O&BV\9.0[_L=YO@?E'4\7^O:G^UIH,I'"]=1X W%CFRC? M1:<5A.]I$($1!M_MM?>FBI%!9<'#F'])*GT )(5\+X"5' MF0('I+Q$H=+^U M9IG_P--OIN!^ZYM3AFM>D?3#F]M^; M]_GOO7OE;[U;68I\!CS\YWL_$,5-"=[\6W'^:^9S?D_\GT2S('>=H4Y-K V( M46M5GO#W&*YFAS)SO\X.?07X[2XG67>'!7P 'ZPB]@GTSZ"")':#"^&ZC?.1@"")T)N>$AW-V)M'9RN%W0]O/)W].<.? M=\%O4!,&)W$)Y@ M\(<)4C/GXG!5]E.[44:-%AP(F'\W]P6^G,[Y^%-\$QNQD3-"^&"75:ND):I3 MERRBM+!*Q"$! U+R4D_ZN7%-4#H"Z_35QHR&:C*J9"KD38SE=, M,RSX)3HQ[\NFMKZ,GX:!#X"G";$/ )%5[Z!6O_W;F=P#(%T-O-(E<]L:>MSV M ( BW5=(5L/;+#-4_TMH'O!?P!1_X#IZ:<[/V7 J4HD!J=^$;\GN1=X7+Z47 M/-)5W$D=/>-N-&?=#N! ZFLO<_TO5C?0<"IUI>[C.VX9OW%781 M[*\E(3P"Y5A:GBT3="@!K6]:V]E:#QA/Z+S/G;6%#3@6ZH^0N\G1<&V:!MBT M>F'!J'6586>Q<#BB/EY.B/^.,\MS1JJ?NSD_.PN+_+Q=0QVGYD7N*_6O[_ZU MYM0_(RU^Y$66<7DNQ'U9[PZ&7+!8XSB)VLY]X8][D9@& ^FS6' ML #W6&'%FW_)P]\6F#X$NEX_ 'Y@_0$J$-9^Z99Q>2R>5%R[&[7FR_:&T"KW MAL $#D&B3_D5X3='7=7/F_-\2BM+%FT,XE_^?:.O_D#[QJQ1R[ MO4G_0ZK7?Y+Z$UYATES1#@> ;< *NH_XHJ\W]&G:[AM],ZZ2;VO%/G*71U,[[Z<.-]H\TR5_A.-4IL7,O[%'ZK9N^7[4J[0NLVO[_;](P7R^3F0J*4ED6UN^2J^Q,9M9 M'I34=W$F1S$276?NV]=SU/" HRBC-^-HH_]E%G?*8DSV!T_B?>9J14:#>,TR M5O^;*M3Y1V59_R_*\/^K\O:\]&(( F\:U=_6PS]99_QC!5NUT5$2=,WZ>A3I MQA\,HIX5ZDR#!\;,0O'$M659/5%]ZMWJJ@'>":^R0V^1!]!>9?O_/[J%535Y M49(5&*F#D$4"+1F0WNPK3\2Z 8F!;MP5;.DW47/;''JOG69)84>3Z/N",(\> M[8DU/LB 2/',7=N%#!(NY@9D7U$!]+Z_WX(S/NQ>P[%\2OT@RFA+H:B+=QC= M'M?&IY=D#K[O[]Q_DFJ*%Q!F>+RWX;WNC%?CJ8%"NOAR@3R$ MPK#6K^=Q1)B"H-6;FV6^']ICV1\78-=%H-)A.]IO)4+/JX((M6<71._W1:67 M;>N#"3?">TF&W6/C-_P;3E+AA%D2"BO>@3%^)Y)\VPIAO014CB0^7^<;Q-O) MG&0.]@[T\/$? !8ULM?"[ET;S.G+7?-AMNHD1'G&M(<<>J2OX/NW6#M:Q463 MU=O>L8)+3F4!H:_*PCM#__RIVI\WQLJ+14-=#W?5QLGQUDVM44BA09\#*B'9 M6+W7)A!(#)H?R-R?M-7J[#FNT/(.%% I_?8>_''NW3=#U*%QD]9'WZ)ER(^B MLX\%0<5/E(LR,='.^[SBI =E63(YEM[.JO*4OASY/%3'^SC5./1%'U+4< Y( MIM#C0*-R(F(CC((S:'@ *Z'KVE&N\M'PJMF=V1E'09D7NA0):(DX+80Y^MHO MCH>3;^EGUKQ3HVH/P!%.W-PTS6M@,[-]O):%%(#$^!AUGL$H+E)FL)A+]+&E MWHJ^U;RD4=[(UF+[/,$IDJL[3?DOK=7,#O&+D3>7!S.M3ZDKEE3$ B*^A(/T M+05Z X;/5Y'I1,D#2SE.(QOI9G-'(YU?XWRQ2A+\%WL"&[DL:5M*$IL="67 MY["6U<3H2I%^-G$ [A!1!52OLJLY/2,+R-(B6$V MCHHJ'N[J8!\S5S/TJ;*^H<$[3H9S\>DGQ5J.18IE/ :&QV"T^@V2'3F7^Z:8 M^5[( -7'"MVA$7$VM)& O$2&31'2G5HW9@S9C_@\FLA($OZ<;Z-EF()B>%Q1 M*;D"7B%_G( 9.#]_ -R"+BQ&30%&M86ALIIE(C_T4(DLU42YOS(U>31K3^=- MS,_;DGANQDO,X73LL%I-!(L@NC?+ZSV8X*A'A;25B<])!(G J ;I1AZ?GE6> MUF.W:BK%O;/O42:"%$$ IXAUVS2%3H+YVN]A'F;QE+5? XC>F,DXPP\2$6M\<4F,Y^P" 5,+('@"2;(A)_Q%=YF^PL_VD MJC*5!EWSW(@3WG]'2B#G%]O:_QND9Q%\3]'J/)$H["2O$O M#(TH_V>D7EVA-WA+^X+_3J,&_#=8GX]2Y!WN6%9C%8CSZ]]H_&O\*[Z^^D/= ME5+:!L7S_>LB\X(#-WZ@TC/M[&_ M^,;@H;[!N*H4WN-_< MZ98CG4\6@13NJ9:"8S8KI9\@1[E>8U??8GSAIN^HV42J:.@[H;U.&J;EHH7( MAHC>C48\D^\2P;1^H3OD9"+1*1#" $A7-NZC_Q[;\X6^VK: KLE">]V3:!M- MHS_7/S,JI:#PH-?6[6R:_4,Y*QT+33I?1&@J*4='WXZ.9><5_15ZYC6@N^I) MN, "8YB8CIU0^%4/ /13"A;>70 ]9M)DK)'8$S6D8EZE"RS1U(Q)5 MUS6RF0S>[%T@B>[I5E7BN0DK[_GVHNU'.?=!ACROXB-6H$I-J_="/VWM6!R5 M*]JS?0>-\TCN/:F08)JZ,PL/V'>\R$6S*H%+6G@<4@4B+D_P1EL= M0>5\*??)9JSH0TARB2XIK\7=LP.4D!@*]T*KL_8G;,87DT )ST [' UR(MVT M *69'Z/<@7THV"K+'G;H0[--,6>7VL%GT^8WQA:*0;'A@?5B7;3KI;M-(EYT M_M7!Z^M6P.-GH6F!X^\Q7R%+!SAP2_')SFC/\QOTKY8@+Q(#$(=\SO.\AM#! M'\/K>ZQE80-5EBSA=]6!09VIY,Y]9?;67I^\RA-MP3C?\[I-7I=-6=::8J%8 M05JB+!AJHM/(R%$[/A=2@OI%OQRDUS::6F)FF#Y.:SH*1L'.9&!XY,^B09#H M\&M>SED8%,D9^S'&%T V((*D/FU[@&X@/[5@^+I:0M8D8I)RDV+47S#OM)$Y MGXAG@\0P-L[3W_S^)+'&\9QC7X;4G7<6R$WQL>9;3N2KY&V!Q) W##A1W,-( M#;LDDWB3"'>U42$:0F5.'?7C^ *G1D\T:D!NS##NJA_9@4WUI2*CJ_9;95=7 MNP9S^^J!>J_*#E3* $YHY!121@$TB_>YEX&0@ DZT2NS\][U020!?:=V?A7G M7L?076;BR2X^?*&89;VD."J6K_;W\X(J0?Z_&Y/9PA^MH^&4QP$:[^(:RAV1 M_B&*0P+]D?2XS,B/G>C9\)E+4R,/BRZ5J8C-;:,,RY2G'V08WQVQ<*9S>6&_ MQOS).S6SU8[]^F<7Z%6D(*(&R]2R C_^(CW=%RSS&ISP$2VPBEU2,'X6=O38 MG>TP"(T#<$&QH5L# (K>-Q>E+"QH_MR(43!3_W;1A 2!IHH'@? M)Q3QZ0J(IDNTP=F BHIB6F:BL+I E&/,.GV@0,.98,^!&J^CJ4."3")?' G8 M>TV&X<121?O9J3SKXQ7/OI3*9[S7:#D S,X$?ZZ6-V5@8^L#%Q,=?GF:H8$J M L&M2$Q4\I#"T@4P05B$16_7(9W8-*[3(\0NRXM@=-$IAY!!U%MKM""OKUCF MJ:=%L"P=3@\+"S+-^_"SI[NRF^ZE!_9/K>L2^28Z9]$2X'HL8A:J:;C%51N" M@'3H5>;S6\3&6O#>LN=9SO[7>=$&%_.(S:^#N/XGE2"C#;NI&P=P:O+;&OZ'%?IY_( M"DI26QRJCW^'S]%:9.R1TQ%D;4L(5RG81LF4Y;<@>*B5,R):0LF:9LB_9MZQC[$N6L0YFSOS>4_?>=._]?#Z/ M[^/W!YWW-._7/%_[\W7FG".FBG^HDVQ)=[WD&FF("AT6PZPM^ &>G9F<-HH* M0<]KCX#14Q9>MNX(+3^[+*MQF-G,1C-$A9&[[^R[-[>5;V^3'C<>>[!XHE/: M8[UP-7L*/3V46&9K89WY0,OHW#"T]9)WM$%43\-RY['>LZ?"][&?Y;]Q8W]H MFW[[2I!SL,H-$_\#AS3.60?G'D![LXK!?9_WZ\]K%.]J-;M4@H$F'$B.&HIV M9CD+@^+?4V9V80K-0U@72J?E:RH=C\]>Q!)LW[4R40>MF=(<>LF>R< M;NERPB4WOE8EZV523OA@UPVW?25(RUV+XA.)S?ZRSQ4TDWN,W&1*F=7HSSM( M&3P8U#7==T$SF]ECX$[:)Z:R<6<]#Q:W+]9+E$Z+UEIEN>^YD+7E2>5)89G;\E[6G$NOJHO03G%I:LO<+SL& M58XN<&C=?S@QK2;\WLSTNS/LA[K6E"'^IHW3^KBQZ&)6MN#S&11]%;==KRE= MM.V7<2$3G*\+T>KXE3.P]SNQZ?0DDT*5P-LO'\RJ]!5!FL3[46-BGC9I?1,V M-R6Z./:J;2]:%_)*3#B]XVA$QE8&7+%Q(2DP\\IJ_W6KZM9ZQO)9MO@T=9&+ M^W@>3SHRY.5)I1_O/\S$8;EF=S^]/G&BVZ?B>VX&T;2H:5O;N61.4Y:PV2FS MK4E1/'EE,2QZS=G+1H/M47(6A3M:+M5QFD??9A'8Y,60FB&IA MFO_I6=+3MP/LYA'WNQ.]KA,7M]U1O;&^RT#T3N#'T85]+K%>Q[O?-E0;\+4M M;7>VO31V.>;0>3N4A\C1K$W+/&\36?68V;((7HR>:IEJ2<7XKKWQS_5?U>&S M#W%,A&$+#9=L--OL%M.R7,V/^]X.Y9W;M&ITX?U8&_-1^1[EA.P/)%<;6/&C M\>1)G_J8OH#^,_SL@C>@PH.[TP_0/1MXX*1_![W;,AQ9P6%7P _N!D1=!N]L_]UES&.0NWS:]<$58L.B5\P%&__!O*\.Q M.? YHG[>ZVX-FR1K)OM=Z44I*K;IP85/GEPX(5L[,!A7J=_KJCII9(F?RYRQ MFY6Z^>$EWY[N_AKY?3.S=&2"CKQGHNG#*H82FX#T+H6;F1IQ8H&')W-CP]R% M]SY0>'MW:T^^EY.AGI:&W9&&E8$J\C-%2:1 DPK%=Y>D9#Y#=L$U.JWHJ:=@ M1A1-FPP82R=RE5V-#Q ^5!H@_)AH7VYBO]VF+LFT9SN7C?C)MNTGLEM?GA#Q MG&-P+)_; KDL&L3:X/7T1K83> ?7'%Q&5^##O[OH45P;; M?8KFR.VX7,8S2OK:&DWOVO/EHN6N/6V?.>598 M#YJS>/89ADLD[ _)?[V[>]GHP,?GAI<5'K_QX1] ]-@37 \_RXQA993?2E=W M)7E"Q[17-+WP:_5,BL3I7=%Z/+?.V@J>7\[-4;UYR)G^&V+1Q.[,W[9\D'XY_=S2U:U_LF<$[7)T]XQ7 ML*U?P+.S43C\&H^AK&KBS7W"F=B)U%2 H#^+"IT.ID*(XI^01C>^T"FY_$IS M3= 5NS**(29,G\ N7IZA0K-?<4-7(MO!=@$"7_?:,]3J"DGWI#U)4SITC=6> M"A%GD2-/W!8,P9BC2EI .EC,>WLMD6/Q_7#^)=PY1-38R?2M'&#L-#L M;KCY3!$5PDE0H6"4?C(9^^CAI"X\AB=FG M3:@0%>*E0H-6\&_P1ADKP$[ACXWD^4BRE7>K%152V;V D.L0*2]C[#S"S)2J M186PL,^9)"KTZ(>HTW^)LOSKE;^%V[Q1ULA"/ M.+!U)8$*L3Y;:1W]B4I^ ZH1I-DJ'Z[X4CC161L9VA&S'/@_28+#6N'_-R/A M_LM(('!JJ%" ZOI_&FFDHB))DVPJG#4[HMXX=6FCCK_)05?_Z?S+?VY$_R9F M[,[3"(,%,I9K&WHX>I$3Z]*$.>1"$N].>+#387('E3(_UU[4^:)4%)Z M)D>/.1'H?;F;9S*.K[+SW2G":25-1%%G^C:Z'D5^@35_]!TW[Z2.L!2#W3O_ MW/U&2:'C.!4Z%#P'$ "4C6:[EYZR#-FT\SON4%)#%#4BSI88UF"XKE3#G]A6 MR=V1.9]70I&+:/-'B![P1!0\%VN#6A3$4Z$A/%D#]=OJ:B.SR7&CD@-F"5N[ ME4.N,"4;VU47M01S[A(D-DGF7[+YPB:GGS( M4>[9GWIN,30MP3^6L;#HI[05>6?[7)_OP) ,.6YNE[47 I$1R0AX:<26>2H$ MZL7PV)E_%I9_59H.@2[X[B$0Q MG/Q"'"!S!>!.@)JXT9V: &L0%:I.\/H9:\'+DB/OL'-8L^_P)\\".8K-Z;K2 MM=C7/-.>%NZ'XC:]L@FY._0\_AM-))J 7L>MRMG\],1??DSXW:T)R!XO5\1W M'4];!?R^2D3J:+KN_L9$4Y7P3\5:F'B!%XYB>#WL?D8S0R<\3KN!^>]V- MS_3J-Z+S>-E>,H:LA_I>@ED]9K*)@B='P_\J@9]POY;GJ="V$X6AJ_O%8> = MH4(3V2O]#9S\SY+',=6?DP54?#F3%YYT1&[>[NCLOK8X=5H+>), M9N@J:Z8?KAY :U+P2!M"5(1_NC1C%+,DCDPD:B[9++)%YH*ZK$2%V)THYDS@ MR*"_0:BGB9T@<.$?/+&?T!PD+A0=A";D[]U.TY-;R8 M5_"+JNN%#GWWDML<%S57*LX;O?!Q1P67L)FZC55TWGUC7.1BPZQF/Y*]I>;@ M&0LY5#]%N%/(QX\,6\-+<[@U4:'X[G:6PUY,+%3(UQ7D8EPX$YD>#:PSU["" M6Y10ID+WP 04D.D1G];]5>Z0FP!9LGB6LNL)/' 06#B%MJOXURZ//E8/(S]^ M3?I_O/YO::$VQX;]!["_OYZ [.M?07S/H>?V@$30F[VC-7UK?Y@"RV\OZ\)E M\OU4J*F& =F,0H2*9QY^KN?M4*YA^8(FQ,RBQV\\I$*;@!G9U'Z#FM9UQ^RN MJ$-FT2N/Q_HML( DK9X+Y0XD/]D](ZFE,<3$9%(O)3'94<4(#GY-U/^AC@5(I5 UF28CQ@O?>B^];3[@.;-+HFBQ9O]]?(Y. 3'C MX99@2ILKT=0K@#W*D"!W_>UMAZE&AJ98![7L%XYGYS5)%A[XM7T'J-!GD+L5 M>AZX>S(N8?Q^Y9=/3&@K> $VQ[*EL7\E\T86T3O"XZU&\JM' 81;>\^&]-:] M:/_"^Y+QLT(T5V$Z7!6-7EIA0(*,V<[W:@?D- _B_P_S:B]_% X7>/"[04-_ M1V/PMI<4M=9HDI>+5=?]F%^TOE_$XNN, U9*E6&M:*7AU!CGVQ/])\.ON3$& M<&Q_=6XH4N3[3$7_1Y*Z^Z MG6=,&T,SLGO0#/WU;\M<%>.GZXO3CKDW#)SV+!J(9YYV^BVIK>-*FKS>*"3LV)%_B>KC(I>U:O;\QRX M#AR/?3TH+3<5-9(MGV:(R4M=R\;^N1DM^R\6=.W_^J];]/'4OR:2LG$)7OE9(BO&(J5:33:-$?'4A\-F^] M];J!9XO_KD=YG"/^$Z'60U>)J*#7[9LU4J2_:IE-/&Y^Q:8LU!O:O^O^9YVF MD)=CTC9?>,4ZG3&L78:3KAG3BC[E*RZA-X>Z1[*W725[B[6=%Z0KB4C MG"'OFE.V2J7Z?J:&M]:I!UO;144'8U88PV2YMU&A);W *64/ZR;VG>&[+XS1 M[V_G<;X:JKK=B;]?^]DNXOSH/0G/8 ODGK$]90XWI!;V#H3:3@W0AU$;CN\6A>8- M4*&O*Y2GM-9\&/SPW\%<)ZI1=IP4H*R'@F!]8R+.LA"ZW=(/NSJ*_8M6\].1!\&HL[04# M>< R(\D(&&-6:B^C""',H>C"\O/(["XHBZ.')N'*D8!,SCCN;Z M"HI6-/]AM;08 %0-@9VIT#I!<./QL!>. ;GV/9&,6Q7!K?+%G;@B.$L09

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�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gexyhn0lyczh000046.jpg GRAPHIC begin 644 gexyhn0lyczh000046.jpg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end GRAPHIC 13 gexyhn0lyczh000020.jpg GRAPHIC begin 644 gexyhn0lyczh000020.jpg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gexyhn0lyczh000016.jpg GRAPHIC begin 644 gexyhn0lyczh000016.jpg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ⅅ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